<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24012374</PMID><DateCompleted><Year>2013</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>10</Issue><PubDate><Year>2013</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.</ArticleTitle><Pagination><StartPage>957</StartPage><EndPage>965</EndPage><MedlinePgn>957-65</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(13)70194-7</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(13)70194-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">New research criteria for preclinical Alzheimer's disease have been proposed, which include stages for cognitively normal individuals with abnormal amyloid markers (stage 1), abnormal amyloid and neuronal injury markers (stage 2), or abnormal amyloid and neuronal injury markers and subtle cognitive changes (stage 3). We aimed to investigate the prevalence and long-term outcome of preclinical Alzheimer's disease according to these criteria.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were cognitively normal (clinical dementia rating [CDR]=0) community-dwelling volunteers aged at least 65 years who were enrolled between 1998 and 2011 at the Washington University School of Medicine (MO, USA). CSF amyloid-&#x3b2;1-42 and tau concentrations and a memory composite score were used to classify participants as normal (both markers normal), preclinical Alzheimer's disease stage 1-3, or suspected non-Alzheimer pathophysiology (SNAP, abnormal injury marker without abnormal amyloid marker). The primary outcome was the proportion of participants in each preclinical AD stage. Secondary outcomes included progression to CDR at least 0&#xb7;5, symptomatic Alzheimer's disease (score of at least 0&#xb7;5 for memory and at least one other domain and cognitive impairments deemed to be due to Alzheimer's disease), and mortality. We undertook survival analyses using subdistribution and standard Cox hazards models and linear mixed models.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Of 311 participants, 129 (41%) were classed as normal, 47 (15%) as stage 1, 36 (12%) as stage 2, 13 (4%) as stage 3, 72 (23%) as SNAP, and 14 (5%) remained unclassified. The 5-year progression rate to CDR at least 0&#xb7;5, symptomatic Alzheimer's disease was 2% for participants classed as normal, 11% for stage 1, 26% for stage 2, 56% for stage 3, and 5% for SNAP. Compared with individuals classed as normal, participants with preclinical Alzheimer's disease had an increased risk of death after adjusting for covariates (hazard ratio 6&#xb7;2, 95% CI 1&#xb7;1-35&#xb7;0; p=0&#xb7;040).</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Preclinical Alzheimer's disease is common in cognitively normal elderly people and is associated with future cognitive decline and mortality. Thus, preclinical Alzheimer's disease could be an important target for therapeutic intervention.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Institute of Aging of the National Institutes of Health (P01-AG003991, P50-AG05681, P01-AG02676), Internationale Stichting Alzheimer Onderzoek, the Center for Translational Molecular Medicine project LeARN, the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, and the Charles and Joanne Knight Alzheimer Research Initiative.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vos</LastName><ForeName>Stephanie Jb</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, Netherlands. Electronic address: s.vos@maastrichtuniversity.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter Jelle</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Jasielec</LastName><ForeName>Mateusz S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Hassenstab</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK094982</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19-AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG02676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2013 Oct;12(10):933-5. doi: 10.1016/S1474-4422(13)70217-5.</RefSource><PMID Version="1">24012373</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2013 Dec;12(12):1134. doi: 10.1016/S1474-4422(13)70222-9.</RefSource><PMID Version="1">24025450</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="Y">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflicts of interest</b>. Ms. Stephanie Vos receives research support from the Center for Translational Molecular Medicine, project LeARN (grant 02N-01) and received funds from Internationale Stichting Alzheimer Onderzoek (ISAO) to perform this study. No conflict of interest exists. Dr. Xiong reports no disclosures. Dr. Visser has served as an advisory board member of Bristol-Myers Squibb. He receives/received research grants from Bristol-Myers Squibb, the European Union&#x2019;s 6th and 7th Framework programme, Life Sciences, Genomics and Biotechnology for Health and Innovative Medicines Initiative Joint Undertaking under grant agreement n&#xb0; 115372, resources of which are composed of financial contribution from the European Union's 7th Framework programme and EFPIA companies (PJV), Diagenic, Norway, and Innogenetics, Belgium. No conflict of interest exists. Mr. Mateusz Jasielec reports no disclosures. Dr. Hassenstab reports no disclosures. Dr. Grant reports no disclosures. Dr. Cairns reports no disclosures. Dr. Morris has participated or is currently participating in clinical trials of anti-dementia drugs sponsored by the following companies: Janssen Immunotherapy, and Pfizer. Dr. Morris has served as a consultant for the following companies: Eisai, Esteve, Janssen Alzheimer Immunotherapy Program, Glaxo-Smith-Kline, Novartis, and Pfizer. He receives research support from Eli Lilly/Avid Radiopharmaceuticals and is funded by NIH grants # P50AG005681; P01AG003991; P01AG026276 and U19AG032438. Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. No conflict of interest exists. Dr. Holtzman reports consulting for Bristol-Myers-Squibb, AstraZeneca, and Genentech, and is on the scientific advisory board of C2N Diagnostics. His research grant support is from the NIH, Ellison Medical Foundation, Cure Alzheimer&#x2019;s Fund, Pfizer, Astra Zeneca, C2N Diagnostics and Integrated Diagnostics. No conflict of interest exists. Dr. Fagan serves as an advisory board member for Roche and Eli Lilly. No conflict of interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24012374</ArticleId><ArticleId IdType="mid">NIHMS539923</ArticleId><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(13)70194-7</ArticleId><ArticleId IdType="pii">S1474-4422(13)70194-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Price J, Morris JC. Tangles and plaques in non demented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45:358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette C, Welsh-Bohmer K, Murray M, Saunders A, Mash D, Mcintyre L. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1274.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clincial and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimer&#x2019;s &amp; Dementia. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease: relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>Villareal DT, Grant E, Miller JP, Strorandt M, McKeel DW, Morris JC. Clinical outcomes of possible versus probable Alzheimer&#x2019;s disease. Neurology. 2003;61:661&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12963758</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Langford ZD, Galvin JE. Cognitive profiles in dementia: Alzheimer disease versus nondemented aging. Neurology. 2008;71:1783&#x2013;1889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676971</ArticleId><ArticleId IdType="pubmed">19029518</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, Miller JP, Baty J, Rubin EH, Morris JC, Figiel G. Mild senile dementia of the Alzheimer type. 4. Evaluation of intervention. Ann Neurol. 1992;31:242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">1637132</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, EM S. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work-Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Grant EA, Miller JP, Morris JC. Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology. 2006;67:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondi MW, Jak AJ, Delano-Wood L, Jacobson MW, Delis DC, Salmon DP. Neuropsychological contributions to the early identification of Alzheimer&#x2019;s disease. Neuropsychol Rev. 2008;18:73&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882236</ArticleId><ArticleId IdType="pubmed">18347989</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Buschke H, Crystal H, Bang S. Screening for dementia by memory testing. Neurology. 1988;38:900&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368071</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Manual: Wechsler Memory Scale-Revised. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer's disease. Arch Neurol. 2009;66:1254&#x2013;1559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and Alzheimer&#x2019;s Association workgroup. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Taylor-Reinwald L, Morris JC the Alzheimer'sDisease Neuroimaging Initiative. Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimer&#x2019;s Dement. 2010;6:274&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893399</ArticleId><ArticleId IdType="pubmed">20451876</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR. Human apoeE isoforms differentially regulate brain amyloid-&#xdf; peptide clearance. Sci Transl Med. 2011</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine J, Gray R. A proportional hazards model for the sub distribution of a competing risk. J Amer Statist Assoc. 1999;94:496&#x2013;509.</Citation></Reference><Reference><Citation>Diggle PJ, Heagerty P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. 2nd ed. New York: Oxford University Press; 2002.</Citation></Reference><Reference><Citation>Akaike Hirotugu. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716&#x2013;823.</Citation></Reference><Reference><Citation>L&#xf6;nnroos E, Kyyr&#xf6;nen P, Bell JS, van der Cammen TJ, Hartikainen S. Risk of death among persons with Alzheimer&#x2019;s disease: a national register-based nested case-control study. J Alzheimers Dis. 2013;33:157&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">22914589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology. 2010;74:1531&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">20458070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopponen M, Raiha I, Isoaho R, Vahlberg T, Puolijoki H, Kivela SL. Dementia associates with under medication of cardiovascular diseases in the elderly: a population-based study. Dement Geriatr Cogn Disord. 2006;22:132&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadley VG, Okonkwo O, Crowe M, et al. Mild cognitive impairment and everyday function: an investigation of driving performance. J Geriatr Psychiatry Neurol. 2009;22:87&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832580</ArticleId><ArticleId IdType="pubmed">19196629</ArticleId></ArticleIdList></Reference><Reference><Citation>Simic G, Stanic G, Mladinov M, Jovanov-Milosevic N, Kostovic I, Hof PR. Does Alzheimer&#x2019;s disease begin in the brainstem? Neuropathol Appl Neurobiol. 2009;35:532&#x2013;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787819</ArticleId><ArticleId IdType="pubmed">19682326</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Holland D, et al. Apolipoprotein E &#x3b5;4 does not modulate amyloid-&#x3b2;-associated neurodegeneration in preclinical Alzheimer disease. Am J Neuroradiol. 2013;34:505&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041629</ArticleId><ArticleId IdType="pubmed">22976236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, et al. Visinin-like protein 1: Diagnostic and prognostic biomarker in Alzheimer's disease. Ann Neurol. 2011;70:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez GM, et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer&#x2019;s disease: a retrospective cohort study. Lancet Neurol. 2011;10:213&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">23814339</PMID><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1550-9109</ISSN><JournalIssue CitedMedium="Internet"><Volume>36</Volume><Issue>7</Issue><PubDate><Year>2013</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Sleep</Title><ISOAbbreviation>Sleep</ISOAbbreviation></Journal><ArticleTitle>Sleep Fragmentation and the Risk of Incident Alzheimer's Disease and Cognitive Decline in Older Persons.</ArticleTitle><Pagination><StartPage>1027</StartPage><EndPage>1032</EndPage><MedlinePgn>1027-1032</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cross-sectional studies suggest that sleep fragmentation is associated with cognitive performance in older adults. We tested the hypothesis that sleep fragmentation is associated with incident Alzheimer's disease (AD) and the rate of cognitive decline in older adults.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Community-based.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">737 community dwelling older adults without dementia.</AbstractText><AbstractText Label="MEASUREMENTS AND RESULTS" NlmCategory="RESULTS">Sleep fragmentation was quantified from up to 10 consecutive days of actigraphy. Subjects underwent annual evaluation for AD with 19 neuropsychological tests. Over a follow-up period of up to 6 years (mean 3.3 years), 97 individuals developed AD. In a Cox proportional hazards model controlling for age, sex, and education, a higher level of sleep fragmentation was associated with an increased risk of AD (HR = 1.22, 95%CI 1.03-1.44, P = 0.02 per 1SD increase in sleep fragmentation). An individual with high sleep fragmentation (90<sup>th</sup> percentile) had a 1.5-fold risk of developing AD as compared with someone with low sleep fragmentation (10<sup>th</sup> percentile). The association of sleep fragmentation with incident AD did not vary along demographic lines and was unchanged after controlling for potential confounders including total daily rest time, chronic medical conditions, and the use of common medications which can affect sleep. In a linear mixed effect analysis, a 0.01 unit increase in sleep fragmentation was associated with a 22% increase in the annual rate of cognitive decline relative to the average rate of decline in the cohort (Estimate = -0.016, SE = 0.007, P = 0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Sleep fragmentation in older adults is associated with incident AD and the rate of cognitive decline.</AbstractText><AbstractText Label="CITATION" NlmCategory="BACKGROUND">Lim ASP; Kowgier M; Yu L; Buchman AS; Bennett DA. Sleep fragmentation and the risk of incident alzheimer's disease and cognitive decline in older persons. <i>SLEEP</i> 2013;36(7):1027-1032.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Andrew S P</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowgier</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Buchman</LastName><ForeName>Aron S</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG024480</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034374</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sleep</MedlineTA><NlmUniqueID>7809084</NlmUniqueID><ISSNLinking>0161-8105</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Actigraphy</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">cognitive decline</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">sleep fragmentation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23814339</ArticleId><ArticleId IdType="pmc">PMC3669060</ArticleId><ArticleId IdType="doi">10.5665/sleep.2802</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148:427&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2670458</ArticleId><ArticleId IdType="pubmed">18347351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dramatic Changes in U.S. Aging. 2006.  (Accessed at  http://www.census.gov/newsroom/releases/archives/aging_population/cv06_36.html.)</Citation></Reference><Reference><Citation>Pallier PN, Maywood ES, Zheng Z, et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci. 2007;27:7869&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672877</ArticleId><ArticleId IdType="pubmed">17634381</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, Lim MM, Bateman RJ, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326:1005&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet MH. The effect of sleep fragmentation on sleep and performance in younger and older subjects. Neurobiol Aging. 1989;10:21&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2755554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartar JL, Ward CP, McKenna JT, et al. Hippocampal synaptic plasticity and spatial learning are impaired in a rat model of sleep fragmentation. Eur J Neurosci. 2006;23:2739&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607950</ArticleId><ArticleId IdType="pubmed">16817877</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartar JL, McKenna JT, Ward CP, McCarley RW, Strecker RE, Brown RE. Sleep fragmentation reduces hippocampal CA1 pyramidal cell excitability and response to adenosine. Neurosci Lett. 2010;469:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2815010</ArticleId><ArticleId IdType="pubmed">19914331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet MH. Performance and sleepiness as a function of frequency and placement of sleep disruption. Psychophysiology. 1986;23:263&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">3749406</ArticleId></ArticleIdList></Reference><Reference><Citation>Oosterman JM, van Someren EJ, Vogels RL, Van Harten B, Scherder EJ. Fragmentation of the rest-activity rhythm correlates with age-related cognitive deficits. J Sleep Res. 2009;18:129&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">19250179</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell T, Yaffe K, Ancoli-Israel S, et al. Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci. 2006;61:405&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611709</ArticleId></ArticleIdList></Reference><Reference><Citation>Blackwell T, Yaffe K, Ancoli-Israel S, et al. Association of sleep characteristics and cognition in older community-dwelling men: the MrOS sleep study. Sleep. 2011;34:1347&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174836</ArticleId><ArticleId IdType="pubmed">21966066</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Yu L, Costa MD, et al. Quantification of the fragmentation of rest-activity patterns in elderly individuals using a state transition analysis. Sleep. 2011;34:1569&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3198212</ArticleId><ArticleId IdType="pubmed">22043128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AS, Yu L, Costa MD, et al. Increased fragmentation of rest-activity patterns is associated with a characteristic pattern of cognitive impairment in older individuals. Sleep. 2012;35:633&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321422</ArticleId><ArticleId IdType="pubmed">22547889</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman RG, Scott MA, Ayappa I, Walsleben JA, Rapoport DM. Sleep continuity measured by survival curve analysis. Sleep. 2006;29:1625&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">17252894</ArticleId></ArticleIdList></Reference><Reference><Citation>Swihart BJ, Caffo B, Bandeen-Roche K, Punjabi NM. Characterizing sleep structure using the hypnogram. J Clin Sleep Med. 2008;4:349&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2542492</ArticleId><ArticleId IdType="pubmed">18763427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bianchi MT, Cash SS, Mietus J, Peng CK, Thomas R. Obstructive sleep apnea alters sleep stage transition dynamics. PLoS One. 2010;5:e11356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2893208</ArticleId><ArticleId IdType="pubmed">20596541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bien-ias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25:163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Rolls A, Colas D, Adamantidis A, et al. Optogenetic disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci U S A. 2011;108:13305&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3156195</ArticleId><ArticleId IdType="pubmed">21788501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc. 2005;11:400&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16209420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27:169&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT) Mov Disord. 1992;7:2&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1557062</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team. R: A language and environment for statistical computing. Vienne, Austria: R Foundation for Statistical Computing; 2008.</Citation></Reference><Reference><Citation>Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. Neurology. 2012;78:1323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3335448</ArticleId><ArticleId IdType="pubmed">22517108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850264</ArticleId><ArticleId IdType="pubmed">16360788</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep. 1995;18:425&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">7481413</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushey D, Tononi G, Cirelli C. Sleep and synaptic homeostasis: structural evidence in Drosophila. Science. 2011;332:1576&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128387</ArticleId><ArticleId IdType="pubmed">21700878</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirelli C, Faraguna U, Tononi G. Changes in brain gene expression after long-term sleep deprivation. J Neurochem. 2006;98:1632&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16923172</ArticleId></ArticleIdList></Reference><Reference><Citation>Roman V, Van der Borght K, Leemburg SA, Van der Zee EA, Meerlo P. Sleep restriction by forced activity reduces hippocampal cell proliferation. Brain Res. 2005;1065:53&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16309630</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrigoni E, Lu J, Vetrivelan R, Saper CB. Long-term synaptic plasticity is impaired in rats with lesions of the ventrolateral preoptic nucleus. Eur J Neurosci. 2009;30:2112&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819366</ArticleId><ArticleId IdType="pubmed">20128848</ArticleId></ArticleIdList></Reference><Reference><Citation>de Souza L, Smaili SS, Ureshino RP, et al. Effect of chronic sleep restriction and aging on calcium signaling and apoptosis in the hippocampus of young and aged animals. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22343009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cole RJ, Kripke DF, Gruen W, Mullaney DJ, Gillin JC. Automatic sleep/ wake identification from wrist activity. Sleep. 1992;15:461&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">1455130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep. 2005;28:499&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">16171294</ArticleId></ArticleIdList></Reference><Reference><Citation>Iber C, Ancoli-Israel S, Chesson A, Quan SF. 1 ed. Westchester, IL: American Academy of sleep Medicine; 2007. The AASM manual for the scoring of sleep and associated events: rules, terminology, and technical specification.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">23900711</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>126</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series.</ArticleTitle><Pagination><StartPage>365</StartPage><EndPage>384</EndPage><MedlinePgn>365-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-013-1157-y</ELocationID><Abstract><AbstractText>Neurodegenerative diseases are characterised by neuronal loss and cerebral deposition of proteins with altered physicochemical properties. The major proteins are amyloid-&#x3b2; (A&#x3b2;), tau, &#x3b1;-synuclein, and TDP-43. Although neuropathological studies on elderly individuals have emphasised the importance of mixed pathologies, there have been few observations on the full spectrum of proteinopathies in the ageing brain. During a community-based study we performed comprehensive mapping of neurodegeneration-related proteins and vascular pathology in the brains of 233 individuals (age at death 77-87; 73 examined clinically in detail). While all brains (from individuals with and without dementia) showed some degree of neurofibrillary degeneration, A&#x3b2; deposits were observed only in 160 (68.7 %). Further pathologies included &#x3b1;-synucleinopathies (24.9 %), non-Alzheimer tauopathies (23.2 %; including novel forms), TDP-43 proteinopathy (13.3 %), vascular lesions (48.9 %), and others (15.1 %; inflammation, metabolic encephalopathy, and tumours). TDP-43 proteinopathy correlated with hippocampal sclerosis (p &lt; 0.001) and Alzheimer-related pathology (CERAD score and Braak and Braak stages, p = 0.001). The presence of one specific variable (cerebral amyloid angiopathy, A&#x3b2; parenchymal deposits, TDP-43 proteinopathy, &#x3b1;-synucleinopathy, vascular lesions, non-Alzheimer type tauopathy) did not increase the probability of the co-occurrence of others (p = 0.24). The number of observed pathologies correlated with AD-neuropathologic change (p &lt; 0.0001). In addition to AD-neuropathologic change, tauopathies associated well with dementia, while TDP-43 pathology and &#x3b1;-synucleinopathy showed strong effects but lost significance when evaluated together with AD-neuropathologic change. Non-AD neurodegenerative pathologies and their combinations have been underestimated, but are frequent in reality as demonstrated here. This should be considered in diagnostic evaluation of biomarkers, and for better clinical stratification of patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Institute of Neurology, Medical University Vienna, AKH 4J, W&#xe4;hringer G&#xfc;rtel 18-20, 1097, Vienna, Austria. gabor.kovacs@meduniwien.ac.at</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milenkovic</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>W&#xf6;hrer</LastName><ForeName>Adelheid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>H&#xf6;ftberger</LastName><ForeName>Romana</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Gelpi</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Haberler</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>H&#xf6;nigschnabl</LastName><ForeName>Selma</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Reiner-Concin</LastName><ForeName>Angelika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heinzl</LastName><ForeName>Harald</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jungwirth</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Krampla</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Budka</LastName><ForeName>Herbert</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23900711</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1157-y</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24116116</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>10</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Characterization of novel CSF Tau and ptau biomarkers for Alzheimer's disease.</ArticleTitle><Pagination><StartPage>e76523</StartPage><MedlinePgn>e76523</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e76523</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0076523</ELocationID><Abstract><AbstractText>Cerebral spinal fluid (CSF) A&#x3b2;42, tau and p181tau are widely accepted biomarkers of Alzheimer's disease (AD). Numerous studies show that CSF tau and p181tau levels are elevated in mild-to-moderate AD compared to age-matched controls. In addition, these increases might predict preclinical AD in cognitively normal elderly. Despite their importance as biomarkers, the molecular nature of CSF tau and ptau is not known. In the current study, reverse-phase high performance liquid chromatography was used to enrich and concentrate tau prior to western-blot analysis. Multiple N-terminal and mid-domain fragments of tau were detected in pooled CSF with apparent sizes ranging from &lt;20 kDa to ~40 kDa. The pattern of tau fragments in AD and control samples were similar. In contrast, full-length tau and C-terminal-containing fragments were not detected. To quantify levels, five tau ELISAs and three ptau ELISAs were developed to detect different overlapping regions of the protein. The discriminatory potential of each assay was determined using 20 AD and 20 age-matched control CSF samples. Of the tau ELISAs, the two assays specific for tau containing N-terminal sequences, amino acids 9-198 (numbering based on tau 441) and 9-163, exhibited the most significant differences between AD and control samples. In contrast, CSF tau was not detected with an ELISA specific for a more C-terminal region (amino acids 159-335). Significant discrimination was also observed with ptau assays measuring amino acids 159-p181 and 159-p231. Interestingly, the discriminatory potential of p181 was reduced when measured in the context of tau species containing amino acids 9-p181. Taken together, these results demonstrate that tau in CSF occurs as a series of fragments and that discrimination of AD from control is dependent on the subset of tau species measured. These assays provide novel tools to investigate CSF tau and ptau as biomarkers for other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meredith</LastName><ForeName>Jere E</ForeName><Initials>JE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Research and Development, Bristol-Myers Squibb, Wallingford, Connecticut, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sankaranarayanan</LastName><ForeName>Sethu</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Guss</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Lanzetti</LastName><ForeName>Anthony J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Berisha</LastName><ForeName>Flora</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Neely</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Slemmon</LastName><ForeName>J Randall</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ahlijanian</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Albright</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056148" MajorTopicYN="N">Chromatography, Reverse-Phase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008970" MajorTopicYN="N">Molecular Weight</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors JM, SS, VG, AL, FB, RN, JRS, HS, MA and CA are/were employees of Bristol-Myers Squibb. KB has served on Advisory Boards for Innogenetics (Ghent, Belgium) and Roche (Basel, Switzerland). This work is included in US Patent Application: [PLEASE PROVIDE NAME] and number 61/671,397 (SS, JM, VG). There are no further patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24116116</ArticleId><ArticleId IdType="pmc">PMC3792042</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0076523</ArticleId><ArticleId IdType="pii">PONE-D-13-19450</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Zetterberg H, Blennow K (2012) Cerebrospinal Fluid Biomarkers for Alzheimer&#x2019;s Disease: More to Come?
J Alzheimers Dis
33: S361-S369. PubMed: 22710917.</Citation><ArticleIdList><ArticleId IdType="pubmed">22710917</ArticleId></ArticleIdList></Reference><Reference><Citation>
Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer&#x2019;s disease. Lancet
368: 387-403. doi:10.1016/S0140-6736(06)69113-7. PubMed: 16876668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69113-7</ArticleId><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS
et al. (2009) Cerebrospinal fluid biomarker signature in Alzheimer&#x2019;s Disease Neuroimaging Initiative subjects. Ann Neurol
65: 403-413. doi:10.1002/ana.21610. PubMed: 19296504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K
et al. (2006) Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol
5: 228-234. doi:10.1016/S1474-4422(06)70355-6. PubMed: 16488378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(06)70355-6</ArticleId><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L
et al. (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA
302: 385-393. doi:10.1001/jama.2009.1064. PubMed: 19622817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1064</ArticleId><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I
et al. (2002) Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer&#x2019;s disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol
160: 1269-1278. doi:10.1016/S0002-9440(10)62554-0. PubMed: 11943712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)62554-0</ArticleId><ArticleId IdType="pmc">PMC1867203</ArticleId><ArticleId IdType="pubmed">11943712</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ishiguro K, Ohno H, Arai H, Yamaguchi H, Urakami K
et al. (1999) Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer&#x2019;s disease. Neurosci Lett
270: 91-94. doi:10.1016/S0304-3940(99)00476-0. PubMed: 10462105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(99)00476-0</ArticleId><ArticleId IdType="pubmed">10462105</ArticleId></ArticleIdList></Reference><Reference><Citation>
Singer D, Soininen H, Alafuzoff I, Hoffmann R (2009) Immuno-PCR-based quantification of multiple phosphorylated tau-epitopes linked to Alzheimer&#x2019;s disease. Anal Bioanal Chem
395: 2263-2267. doi:10.1007/s00216-009-3208-8. PubMed: 19821112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-009-3208-8</ArticleId><ArticleId IdType="pubmed">19821112</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kohnken R, Buerger K, Zinkowski R, Miller C, Kerkman D
et al. (2000) Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer&#x2019;s disease patients. Neurosci Lett
287: 187-190. doi:10.1016/S0304-3940(00)01178-2. PubMed: 10863026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01178-2</ArticleId><ArticleId IdType="pubmed">10863026</ArticleId></ArticleIdList></Reference><Reference><Citation>
Buerger K, Zinkowski R, Teipel SJ, Tapiola T, Arai H
et al. (2002) Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol
59: 1267-1272. doi:10.1001/archneur.59.8.1267. PubMed: 12164722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.8.1267</ArticleId><ArticleId IdType="pubmed">12164722</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A
et al. (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry
61: 95-102. doi:10.1001/archpsyc.61.1.95. PubMed: 14706948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archpsyc.61.1.95</ArticleId><ArticleId IdType="pubmed">14706948</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A
et al. (2012) Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med
367: 795-804. doi:10.1056/NEJMoa1202753. PubMed: 22784036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1202753</ArticleId><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K
et al. (2012) Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry
69: 98-106. doi:10.1001/archgenpsychiatry.2011.155. PubMed: 22213792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.155</ArticleId><ArticleId IdType="pubmed">22213792</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mattsson N, Ros&#xe9;n E, Hansson O, Andreasen N, Parnetti L
et al. (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology
78: 468-476. doi:10.1212/WNL.0b013e3182477eed. PubMed: 22302554.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182477eed</ArticleId><ArticleId IdType="pmc">PMC3280049</ArticleId><ArticleId IdType="pubmed">22302554</ArticleId></ArticleIdList></Reference><Reference><Citation>
Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO
et al. (2009) Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol
8: 619-627. doi:10.1016/S1474-4422(09)70139-5. PubMed: 19523877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70139-5</ArticleId><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS
et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol
59: 512-519. doi:10.1002/ana.20730. PubMed: 16372280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20730</ArticleId><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>
Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P
et al. (2009) Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol
66: 382-389. doi:10.1001/archneurol.2008.596. PubMed: 19273758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.596</ArticleId><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO. Mol Med 1: 371-380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>
Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G
et al. (2008) PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging
29: 1456-1465. doi:10.1016/j.neurobiolaging.2007.03.029. PubMed: 17499392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.029</ArticleId><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>
Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology
60: 652-656. doi:10.1212/01.WNL.0000046581.81650.D0. PubMed: 12601108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000046581.81650.D0</ArticleId><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hesse C, Rosengren L, Vanmechelen E, Vanderstichele H, Jensen C
et al. (2000) Cerebrospinal fluid markers for Alzheimer&#x2019;s disease evaluated after acute ischemic stroke. J Alzheimers Dis
2: 199-206. PubMed: 12214084.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214084</ArticleId></ArticleIdList></Reference><Reference><Citation>
Zemlan FP, Rosenberg WS, Luebbe PA, Campbell TA, Dean GE
et al. (1999) Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem
72: 741-750. doi:10.1046/j.1471-4159.1999.0720741.x. PubMed: 9930748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1999.0720741.x</ArticleId><ArticleId IdType="pubmed">9930748</ArticleId></ArticleIdList></Reference><Reference><Citation>
Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E
et al. (2003) Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology
60: 1457-1461. doi:10.1212/01.WNL.0000063313.57292.00. PubMed: 12743231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000063313.57292.00</ArticleId><ArticleId IdType="pubmed">12743231</ArticleId></ArticleIdList></Reference><Reference><Citation>
Bahl JM, Heegaard NH, Falkenhorst G, Laursen H, H&#xf8;genhaven H
et al. (2009) The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer&#x2019;s disease. Neurobiol Aging
30: 1834-1841. doi:10.1016/j.neurobiolaging.2008.01.013. PubMed: 18339451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.01.013</ArticleId><ArticleId IdType="pubmed">18339451</ArticleId></ArticleIdList></Reference><Reference><Citation>
Itoh N, Arai H, Urakami K, Ishiguro K, Ohno H
et al. (2001) Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer&#x2019;s disease. Ann Neurol
50: 150-156. doi:10.1002/ana.1054. PubMed: 11506396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.1054</ArticleId><ArticleId IdType="pubmed">11506396</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kim W, Lee S, Hall GF (2010) Secretion of human tau fragments resembling CSF-tau in Alzheimer&#x2019;s disease is modulated by the presence of the exon 2 insert. FEBS Lett
584: 3085-3088. doi:10.1016/j.febslet.2010.05.042. PubMed: 20553717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2010.05.042</ArticleId><ArticleId IdType="pubmed">20553717</ArticleId></ArticleIdList></Reference><Reference><Citation>
Saman S, Kim W, Raya M, Visnick Y, Miro S
et al. (2012) Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem
287: 3842-3849. doi:10.1074/jbc.M111.277061. PubMed: 22057275.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.277061</ArticleId><ArticleId IdType="pmc">PMC3281682</ArticleId><ArticleId IdType="pubmed">22057275</ArticleId></ArticleIdList></Reference><Reference><Citation>
Plouffe V, Mohamed NV, Rivest-McGraw J, Bertrand J, Lauzon M
et al. (2012) Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLOS ONE
7: e36873. doi:10.1371/journal.pone.0036873. PubMed: 22615831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0036873</ArticleId><ArticleId IdType="pmc">PMC3352936</ArticleId><ArticleId IdType="pubmed">22615831</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sim&#xf3;n D, Garc&#xed;a-Garc&#xed;a E, Royo F, Falc&#xf3;n-P&#xe9;rez JM, Avila J (2012) Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett
586: 47-54. doi:10.1016/j.febslet.2011.11.022. PubMed: 22138183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2011.11.022</ArticleId><ArticleId IdType="pubmed">22138183</ArticleId></ArticleIdList></Reference><Reference><Citation>
Chai X, Dage JL, Citron M (2012) Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis
48: 356-366. doi:10.1016/j.nbd.2012.05.021. PubMed: 22668776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.05.021</ArticleId><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pooler AM, Phillips EC, Lau DH, Noble W, Hanger DP (2013) Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep
14: 389-394. doi:10.1038/embor.2013.15. PubMed: 23412472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol
22: 521-526. doi:10.1002/ana.410220412. PubMed: 3435070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410220412</ArticleId><ArticleId IdType="pubmed">3435070</ArticleId></ArticleIdList></Reference><Reference><Citation>
Johnson GV, Seubert P, Cox TM, Motter R, Brown JP
et al. (1997) The tau protein in human cerebrospinal fluid in Alzheimer&#x2019;s disease consists of proteolytically derived fragments. J Neurochem
68: 430-433. PubMed: 8978756.</Citation><ArticleIdList><ArticleId IdType="pubmed">8978756</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sj&#xf6;gren M, Davidsson P, Tullberg M, Minthon L, Wallin A
et al. (2001) Both total and phosphorylated tau are increased in Alzheimer&#x2019;s disease. J Neurol Neurosurg, Psychiatry
70: 624-630. doi:10.1136/jnnp.70.5.624. PubMed: 11309456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.70.5.624</ArticleId><ArticleId IdType="pmc">PMC1737352</ArticleId><ArticleId IdType="pubmed">11309456</ArticleId></ArticleIdList></Reference><Reference><Citation>
Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M
et al. (2009) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging
30: 34-40. doi:10.1016/j.neurobiolaging.2007.05.009. PubMed: 17709155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.05.009</ArticleId><ArticleId IdType="pubmed">17709155</ArticleId></ArticleIdList></Reference><Reference><Citation>
Borroni B, Malinverno M, Gardoni F, Alberici A, Parnetti L
et al. (2008) Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology
71: 1796-1803. doi:10.1212/01.wnl.0000335941.68602.39. PubMed: 18971445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000335941.68602.39</ArticleId><ArticleId IdType="pubmed">18971445</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hanisch K, Soininen H, Alafuzoff I, Hoffmann R (2010) Analysis of human tau in cerebrospinal fluid. J Proteome Res
9: 1476-1482. doi:10.1021/pr901002t. PubMed: 20067323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr901002t</ArticleId><ArticleId IdType="pubmed">20067323</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B
et al. (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett
285: 49-52. doi:10.1016/S0304-3940(00)01036-3. PubMed: 10788705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(00)01036-3</ArticleId><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>
Blennow K, Wallin A, Agren H, Spenger C, Siegfried J
et al. (1995) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
Mol Chem Neuropathol
26: 231-245. doi:10.1007/BF02815140. PubMed: 8748926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02815140</ArticleId><ArticleId IdType="pubmed">8748926</ArticleId></ArticleIdList></Reference><Reference><Citation>
Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M
et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer&#x2019;s disease. Neurology
45: 788-793. doi:10.1212/WNL.45.4.788. PubMed: 7723971.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.45.4.788</ArticleId><ArticleId IdType="pubmed">7723971</ArticleId></ArticleIdList></Reference><Reference><Citation>
Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T
et al. (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer&#x2019;s disease. Ann Neurol
38: 649-652. doi:10.1002/ana.410380414. PubMed: 7574462.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380414</ArticleId><ArticleId IdType="pubmed">7574462</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kuiperij HB, Verbeek MM (2012) Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?
Neurobiol Aging
33: 204: e217-e208. PubMed: 20947213.</Citation><ArticleIdList><ArticleId IdType="pubmed">20947213</ArticleId></ArticleIdList></Reference><Reference><Citation>
Barten DM, Cadelina GW, Hoque N, DeCarr LB, Guss VL
et al. (2011) Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J Alzheimers Dis
24
Suppl 2: 127-141. PubMed: 21422517.</Citation><ArticleIdList><ArticleId IdType="pubmed">21422517</ArticleId></ArticleIdList></Reference><Reference><Citation>
Luk C, Compta Y, Magdalinou N, Mart&#xed; MJ, Hondhamuni G
et al. (2012) Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. J Neurochem
123: 396-405. doi:10.1111/j.1471-4159.2012.07911.x. PubMed: 22862741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2012.07911.x</ArticleId><ArticleId IdType="pubmed">22862741</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y
et al. (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett
186: 181-183. doi:10.1016/0304-3940(95)11291-4. PubMed: 7777192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(95)11291-4</ArticleId><ArticleId IdType="pubmed">7777192</ArticleId></ArticleIdList></Reference><Reference><Citation>
Hanger DP, Wray S (2010) Tau cleavage and tau aggregation in neurodegenerative disease. Biochem Soc Trans
38: 1016-1020. doi:10.1042/BST0381016. PubMed: 20658996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0381016</ArticleId><ArticleId IdType="pubmed">20658996</ArticleId></ArticleIdList></Reference><Reference><Citation>
Wang Y, Garg S, Mandelkow EM, Mandelkow E (2010) Proteolytic processing of tau. Biochem Soc Trans
38: 955-961. doi:10.1042/BST0380955. PubMed: 20658984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0380955</ArticleId><ArticleId IdType="pubmed">20658984</ArticleId></ArticleIdList></Reference><Reference><Citation>
Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y (2011) Cleavage of Tau by calpain in Alzheimer&#x2019;s disease: the quest for the toxic 17 kD fragment. Neurobiol Aging
32: 1-14. doi:10.1016/j.neurobiolaging.2011.09.005. PubMed: 20961659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.09.005</ArticleId><ArticleId IdType="pubmed">20961659</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mercken M, Vandermeeren M, L&#xfc;bke U, Six J, Boons J
et al. (1992) Affinity purification of human tau proteins and the construction of a sensitive sandwich enzyme-linked immunosorbent assay for human tau detection. J Neurochem
58: 548-553. doi:10.1111/j.1471-4159.1992.tb09754.x. PubMed: 1729400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1992.tb09754.x</ArticleId><ArticleId IdType="pubmed">1729400</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ditto NT, Kline TR, Alfinito PD, Slemmon JR (2009) Enrichment and analysis of Alzheimer&#x2019;s Abeta1-42 peptide in human plasma and whole blood. J Neurosci Methods
182: 260-265. doi:10.1016/j.jneumeth.2009.05.025. PubMed: 19520113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2009.05.025</ArticleId><ArticleId IdType="pubmed">19520113</ArticleId></ArticleIdList></Reference><Reference><Citation>
Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N
et al. (2012) Measurement of Abeta1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem
120: 325-333. doi:10.1111/j.1471-4159.2011.07553.x. PubMed: 22023354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07553.x</ArticleId><ArticleId IdType="pubmed">22023354</ArticleId></ArticleIdList></Reference><Reference><Citation>
Carmel G, Mager EM, Binder LI, Kuret J (1996) The structural basis of monoclonal antibody Alz50&#x2019;s selectivity for Alzheimer&#x2019;s disease pathology. J Biol Chem
271: 32789-32795. doi:10.1074/jbc.271.51.32789. PubMed: 8955115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.51.32789</ArticleId><ArticleId IdType="pubmed">8955115</ArticleId></ArticleIdList></Reference><Reference><Citation>
Porzig R, Singer D, Hoffmann R (2007) Epitope mapping of mAbs AT8 and Tau5 directed against hyperphosphorylated regions of the human tau protein. Biochem Biophys Res Commun
358: 644-649. doi:10.1016/j.bbrc.2007.04.187. PubMed: 17499212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2007.04.187</ArticleId><ArticleId IdType="pubmed">17499212</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ghoshal N, Garc&#xed;a-Sierra F, Wuu J, Leurgans S, Bennett DA
et al. (2002) Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer&#x2019;s disease. Exp Neurol
177: 475-493. doi:10.1006/exnr.2002.8014. PubMed: 12429193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.2002.8014</ArticleId><ArticleId IdType="pubmed">12429193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann R, Lee VM, Leight S, Varga I, Otvos L Jr. (1997) Unique Alzheimer&#x2019;s disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry 36: 8114-8124. doi:10.1021/bi970380 + PubMed; : 9201960</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi970380</ArticleId><ArticleId IdType="pubmed">9201960</ArticleId></ArticleIdList></Reference><Reference><Citation>
Goedert M, Jakes R, Crowther RA, Cohen P, Vanmechelen E
et al. (1994) Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer&#x2019;s disease: identification of phosphorylation sites in tau protein. Biochem J
301(3): 871-877. PubMed: 7519852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1137067</ArticleId><ArticleId IdType="pubmed">7519852</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24075978</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo.</ArticleTitle><Pagination><StartPage>402</StartPage><EndPage>414</EndPage><MedlinePgn>402-414</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2013.07.046</ELocationID><Abstract><AbstractText>Tau aggregation occurs in neurodegenerative diseases including Alzheimer's disease and many other disorders collectively termed tauopathies. trans-cellular propagation of tau pathology, mediated by extracellular tau aggregates, may underlie pathogenesis of these conditions. P301S tau transgenic mice express mutant human tau protein and develop progressive tau pathology. Using a cell-based biosensor assay, we screened anti-tau monoclonal antibodies for their ability to block seeding activity present in P301S brain lysates. We infused three effective antibodies or controls into the lateral ventricle of P301S mice for 3 months. The antibodies markedly reduced hyperphosphorylated, aggregated, and insoluble tau. They also blocked development of tau seeding activity detected in brain lysates using the biosensor assay, reduced microglial activation, and improved cognitive deficits. These data imply a central role for extracellular tau aggregates in the development of pathology. They also suggest that immunotherapy specifically designed to block trans-cellular aggregate propagation will be a productive treatment strategy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yanamandra</LastName><ForeName>Kiran</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kfoury</LastName><ForeName>Najla</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Shengmei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maloney</LastName><ForeName>Susan E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Charles F and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2013 Oct 16;80(2):254-6. doi: 10.1016/j.neuron.2013.10.009.</RefSource><PMID Version="1">24139027</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Drug Discov. 2013 Dec;12(12):904. doi: 10.1038/nrd4179.</RefSource><PMID Version="1">24232374</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057967" MajorTopicYN="N">Infusions, Intraventricular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24075978</ArticleId><ArticleId IdType="mid">NIHMS548975</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andoh T, Kuraishi Y. Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I. FASEB J. 2004;18:182&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pubmed">14630707</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631&#x2013;639.</Citation><ArticleIdList><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454&#x2013;13469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752153</ArticleId><ArticleId IdType="pubmed">23015436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. 1993;162:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8121624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Basak JM, Verghese PB, Yoon H, Kim J, Holtzman DM. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J Biol Chem. 2012;287:13959&#x2013;13971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3340151</ArticleId><ArticleId IdType="pubmed">22383525</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Ittner A, Ke YD, Gotz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118:658&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci. 2010;30:16559&#x2013;16566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135981</ArticleId><ArticleId IdType="pubmed">21147995</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer's disease. Neurobiol Aging. 1997;18:S85&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330992</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, et al. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, Hyman BT. Caspase activation precedes and leads to tangles. Nature. 2010;464:1201&#x2013;1204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3091360</ArticleId><ArticleId IdType="pubmed">20357768</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850&#x2013;8855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141&#x2013;1154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC275678</ArticleId><ArticleId IdType="pubmed">1421571</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ. Core features of frontotemporal dementia recapitulated in progranulin knockout mice. Neurobiol Dis. 2012;45:395&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3225509</ArticleId><ArticleId IdType="pubmed">21933710</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Jakes R, Vanmechelen E. Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995;189:167&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7624036</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Lee VM. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem. 2011;286:15317&#x2013;15331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann R, Lindquist S. Screening for amyloid aggregation by Semi-Denaturing Detergent-Agarose Gel Electrophoresis. J Vis Exp. 2008</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2723713</ArticleId><ArticleId IdType="pubmed">19066511</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy. J Neurosci. 2013;33:1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeganathan S, von Bergen M, Mandelkow EM, Mandelkow E. The natively unfolded character of tau and its aggregation to Alzheimer-like paired helical filaments. Biochemistry. 2008;47:10526&#x2013;10539.</Citation><ArticleIdList><ArticleId IdType="pubmed">18783251</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci. 1999;19:7486&#x2013;7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287:19440&#x2013;19451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis. 2010;19:647&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryndushkin DS, Alexandrov IM, Ter-Avanesyan MD, Kushnirov VV. Yeast [PSI+] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104. J Biol Chem. 2003;278:49636&#x2013;49643.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507919</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Macauley SL, Pekny M, Sands MS. The role of attenuated astrocyte activation in infantile neuronal ceroid lipofuscinosis. J Neurosci. 2011;31:15575&#x2013;15585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3218425</ArticleId><ArticleId IdType="pubmed">22031903</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci U S A. 2010;107:19985&#x2013;19990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2993423</ArticleId><ArticleId IdType="pubmed">21045130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012;2:a006247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3385935</ArticleId><ArticleId IdType="pubmed">22762014</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>McEwan WA, Tam JC, Watkinson RE, Bidgood SR, Mallery DL, James LC. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013;14:327&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3672961</ArticleId><ArticleId IdType="pubmed">23455675</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed HA, Mosier DR, Zou LL, Siklos L, Alexianu ME, Engelhardt JI, Beers DR, Le WD, Appel SH. Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res. 2002;69:110&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">12111822</ArticleId></ArticleIdList></Reference><Reference><Citation>Otvos L, Jr., Feiner L, Lang E, Szendrei GI, Goedert M, Lee VM. Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res. 1994;39:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">7534834</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741&#x2013;10749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol. 2001;19:275&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">11244038</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006;63:1459&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030663</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem. 2012;287:20522&#x2013;20533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370237</ArticleId><ArticleId IdType="pubmed">22496370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato C, Turkoz M, Dearborn JT, Wozniak DF, Kopan R, Hass MR. Loss of RBPj in postnatal excitatory neurons does not cause neurodegeneration or memory impairments in aged mice. PLoS One. 2012;7:e48180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3482205</ArticleId><ArticleId IdType="pubmed">23110206</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res. 2009;6:446&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891148</ArticleId><ArticleId IdType="pubmed">19874269</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron. 2008;60:534&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692134</ArticleId><ArticleId IdType="pubmed">19038212</ArticleId></ArticleIdList></Reference><Reference><Citation>Strazielle N, Ghersi-Egea JF. Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. Mol Pharm. 2013;10:1473&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">23298398</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Witman GB, Cleveland DW, Weingarten MD, Kirschner MW. Tubulin requires tau for growth onto microtubule initiating sites. Proc Natl Acad Sci U S A. 1976;73:4070&#x2013;4074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC431332</ArticleId><ArticleId IdType="pubmed">1069293</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF, Xiao M, Xu L, Yamada KA, Ornitz DM. Impaired spatial learning and defective theta burst induced LTP in mice lacking fibroblast growth factor 14. Neurobiol Dis. 2007;26:14&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2267915</ArticleId><ArticleId IdType="pubmed">17236779</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow EM, Diamond MI, Lee VM, Holtzman DM. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci. 2011;31:13110&#x2013;13117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB, 3rd, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci. 2012;32:3601&#x2013;3611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3321513</ArticleId><ArticleId IdType="pubmed">22423084</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24240737</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Staging TDP-43 pathology in Alzheimer's disease.</ArticleTitle><Pagination><StartPage>441</StartPage><EndPage>450</EndPage><MedlinePgn>441-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-013-1211-9</ELocationID><Abstract><AbstractText>TDP-43 immunoreactivity occurs in 19-57 % of Alzheimer's disease (AD) cases. Two patterns of TDP-43 deposition in AD have been described involving hippocampus (limbic) or hippocampus and neocortex (diffuse), although focal amygdala involvement has been observed. In 195 AD cases with TDP-43, we investigated regional TDP-43 immunoreactivity with the aim of developing a TDP-43 in AD staging scheme. TDP-43 immunoreactivity was assessed in amygdala, entorhinal cortex, subiculum, hippocampal dentate gyrus, occipitotemporal, inferior temporal and frontal cortices, and basal ganglia. Clinical, neuroimaging, genetic and pathological characteristics were assessed across stages. Five stages were identified: stage I showed scant-sparse TDP-43 in the amygdala only (17 %); stage II showed moderate-frequent amygdala TDP-43 with spread into entorhinal and subiculum (25 %); stage III showed further spread into dentate gyrus and occipitotemporal cortex (31 %); stage IV showed further spread into inferior temporal cortex (20 %); and stage V showed involvement of frontal cortex and basal ganglia (7 %). Cognition and medial temporal volumes differed across all stages and progression across stages correlated with worsening cognition and medial temporal volume loss. Compared to 147 AD patients without TDP-43, only the Boston Naming Test showed abnormalities in stage I. The findings demonstrate that TDP-43 deposition in AD progresses in a stereotypic manner that can be divided into five distinct topographic stages which are supported by correlations with clinical and neuroimaging features. Given these findings, we recommend sequential regional TDP-43 screening in AD beginning with the amygdala.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Josephs</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Division of Behavioral Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, 55905, USA, josephs.keith@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Melissa E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Whitwell</LastName><ForeName>Jennifer L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Parisi</LastName><ForeName>Joseph E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-AG037491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037491</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21-AG038736</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG038736</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>. The authors declare that they have no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24240737</ArticleId><ArticleId IdType="mid">NIHMS541112</ArticleId><ArticleId IdType="pmc">PMC3944799</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1211-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Mackenzie IR, Hasegawa M, et al. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta neuropathologica. 2009;117:125&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">19139911</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Mishra M, Hatanpaa KJ, et al. TDP-43 pathology in primary progressive aphasia and frontotemporal dementia with pathologic Alzheimer disease. Acta neuropathologica. 2010;120:43&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2903745</ArticleId><ArticleId IdType="pubmed">20361198</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Wu JY, Deng HX, et al. Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta neuropathologica. 2013;125:463&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593646</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathologica. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994;53:125&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">7823614</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson YS, Raby S, Foulds PG, et al. TDP-43 pathological changes in early onset familial and sporadic Alzheimer's disease, late onset Alzheimer's disease and Down's syndrome: association with age hippocampal sclerosis and clinical phenotype. Acta neuropathologica. 2011;122:703&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">21968532</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Davies P, Bevona C, et al. Hippocampal sclerosis: a common pathological feature of dementia in very old (&gt; or = 80 years of age) humans. Acta neuropathologica. 1994;88:212&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">7810292</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Baker M, Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neuro-degenerative diseases. 2010;7:170&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859236</ArticleId><ArticleId IdType="pubmed">20197700</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, et al. Pathological 43-kDa transactivation response DNA-binding protein in older adults with and without severe mental illness. Arch Neurol. 2010;67:1238&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain research. 2007;1184:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu WT, Josephs KA, Knopman DS, et al. Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. Acta neuropathologica. 2008;116:215&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3404722</ArticleId><ArticleId IdType="pubmed">18592255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain : a journal of neurology. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Tsuboi Y, Cookson N, Watt H, Dickson DW. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. Arch Neurol. 2004;61:1579&#x2013;1584.</Citation><ArticleIdList><ArticleId IdType="pubmed">15477512</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, et al. Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008;70:1850&#x2013;1857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Stroh A, Dugger B, Dickson DW. Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta neuropathologica. 2009</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044602</ArticleId><ArticleId IdType="pubmed">19455346</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology. Neuropathology : official journal of the Japanese Society of Neuropathology. 2009;29:566&#x2013;573.</Citation><ArticleIdList><ArticleId IdType="pubmed">19422539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Veterans Administration Medical Center, City; 1978.</Citation></Reference><Reference><Citation>King A, Sweeney F, Bodi I, Troakes C, Maekawa S, Al-Sarraj S. Abnormal TDP-43 expression is identified in the neocortex in cases of dementia pugilistica, but is mainly confined to the limbic system when identified in high and moderate stages of Alzheimer's disease. Neuropathology : official journal of the Japanese Society of Neuropathology. 2010;30:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102526</ArticleId></ArticleIdList></Reference><Reference><Citation>King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain research. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta neuropathologica. 2008;116:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Baborie A, Pickering-Brown S, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta neuropathologica. 2006;112:539&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668618</ArticleId><ArticleId IdType="pubmed">17021754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta neuropathologica. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattis S. Dementia Rating Scale. Psychological Assessment Resources, City; 1988.</Citation></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain : a journal of neurology. 2011;134:1506&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer disease and associated disorders. 2011;25:364&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107353</ArticleId><ArticleId IdType="pubmed">21346515</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Corrada MM, et al. Neocortical and hippocampal amyloidbeta and tau measures associate with dementia in the oldest-old. Brain : a journal of neurology. 2011;134:3708&#x2013;3715.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3235569</ArticleId><ArticleId IdType="pubmed">22120149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE transactions on medical imaging. 1998;17:87&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">9617910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. Journal of neuropathology and experimental neurology. 2008;67:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Jr, Przybelski SA, et al. Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiol Aging. 2011;32:1531&#x2013;1541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888989</ArticleId><ArticleId IdType="pubmed">19914744</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet neurology. 2012;11:868&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3490201</ArticleId><ArticleId IdType="pubmed">22951070</ArticleId></ArticleIdList></Reference><Reference><Citation>WorkingGroup. Consensus recommendation for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for Neuropathologic Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18(Supp 1):S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O, Davidson Y, Bigio EH, et al. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta neuropathologica. 2010;120:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901929</ArticleId><ArticleId IdType="pubmed">20512649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106:7607&#x2013;7612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24217017</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports.</ArticleTitle><Pagination><StartPage>83</StartPage><EndPage>87</EndPage><MedlinePgn>83-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.4749</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Recent advances in stem cell technologies have rekindled an interest in the use of cell replacement strategies for patients with Parkinson disease. This study reports the very long-term clinical outcomes of fetal cell transplantation in 2 patients with Parkinson disease. Such long-term follow-up data can usefully inform on the potential efficacy of this approach, as well as the design of trials for its further evaluation.</AbstractText><AbstractText Label="OBSERVATIONS" NlmCategory="METHODS">Two patients received intrastriatal grafts of human fetal ventral mesencephalic tissue, rich in dopaminergic neuroblasts, as restorative treatment for their Parkinson disease. To evaluate the very long-term efficacy of the grafts, clinical assessments were performed 18 and 15 years posttransplantation. Motor improvements gained gradually over the first postoperative years were sustained up to 18 years posttransplantation, while both patients have discontinued, and remained free of any, pharmacological dopaminergic therapy.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The results from these 2 cases indicate that dopaminergic cell transplantation can offer very long-term symptomatic relief in patients with Parkinson disease and provide proof-of-concept support for future clinical trials using fetal or stem cell therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kefalopoulou</LastName><ForeName>Zinovia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politis</LastName><ForeName>Marios</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hammersmith Hospital, Imperial College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccini</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hammersmith Hospital, Imperial College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mencacci</LastName><ForeName>Niccolo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Reta Lila Weston Laboratories and Department of Molecular Neuroscience, UCL Institute of Neurology, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jahanshahi</LastName><ForeName>Marjan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Widner</LastName><ForeName>H&#xe5;kan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Clinical Sciences, University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rehncrona</LastName><ForeName>Stig</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Clinical Sciences, University Hospital, Lund, Sweden5Division of Neurosurgery, Department of Clinical Sciences, University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brundin</LastName><ForeName>Patrik</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Neuronal Survival Unit, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bj&#xf6;rklund</LastName><ForeName>Anders</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuronal Survival Unit, Wallenberg Neuroscience Center, Lund University, Lund, Sweden7Neurobiology Unit, Wallenberg Neuroscience Center, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindvall</LastName><ForeName>Olle</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Clinical Sciences, University Hospital, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limousin</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Niall</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089698</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100810</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_U120036861</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2014 Feb 12;311(6):617-8. doi: 10.1001/jama.2013.285516.</RefSource><PMID Version="1">24519302</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS60983</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24217017</ArticleId><ArticleId IdType="mid">EMS60983</ArticleId><ArticleId IdType="pmc">PMC4235249</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.4749</ArticleId><ArticleId IdType="pii">1765680</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders: time for clinical translation? J Clin Invest. 2010;120(1):29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798697</ArticleId><ArticleId IdType="pubmed">20051634</ArticleId></ArticleIdList></Reference><Reference><Citation>Barker RA, Barrett J, Mason SL, Bj&#xf6;rklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson&#x2019;s disease. Lancet Neurol. 2013;12(1):84&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">23237903</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson&#x2019;s disease: effects of the second graft. Brain. 1999;122(pt 6):1121&#x2013;1132.</Citation><ArticleIdList><ArticleId IdType="pubmed">10356064</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson&#x2019;s disease. Brain. 2000;123(pt 7):1380&#x2013;1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">10869050</ArticleId></ArticleIdList></Reference><Reference><Citation>Langston JW, Widner H, Goetz CG, et al. Core assessment program for intracerebral transplantations (CAPIT) Mov Disord. 1992;7(1):2&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">1557062</ArticleId></ArticleIdList></Reference><Reference><Citation>Politis M, Wu K, Loane C, et al. Serotonergic neurons mediate dyskinesia side effects in Parkinson&#x2019;s patients with neural transplants. Sci Transl Med. 2010;2(38):38ra46.</Citation><ArticleIdList><ArticleId IdType="pubmed">20592420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagell P, Piccini P, Bj&#xf6;rklund A, et al. Dyskinesias following neural transplantation in Parkinson&#x2019;s disease. Nat Neurosci. 2002;5(7):627&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">12042822</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans JR, Mason SL, Williams-Gray CH, et al. The natural history of treated Parkinson&#x2019;s disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry. 2011;82(10):1112&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">21593513</ArticleId></ArticleIdList></Reference><Reference><Citation>Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson&#x2019;s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307261</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini P, Pavese N, Hagell P, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson&#x2019;s disease. Brain. 2005;128(pt 12):2977&#x2013;2986.</Citation><ArticleIdList><ArticleId IdType="pubmed">16246865</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson&#x2019;s disease. N Engl J Med. 2001;344(10):710&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">11236774</ArticleId></ArticleIdList></Reference><Reference><Citation>Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson&#x2019;s disease. Ann Neurol. 2003;54(3):403&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindvall O, Bj&#xf6;rklund A. Cell therapy in Parkinson&#x2019;s disease. NeuroRx. 2004;1(4):382&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534947</ArticleId><ArticleId IdType="pubmed">15717042</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccini P, Brooks DJ, Bj&#xf6;rklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson&#x2019;s patient. Nat Neurosci. 1999;2(12):1137&#x2013;1140.</Citation><ArticleIdList><ArticleId IdType="pubmed">10570493</ArticleId></ArticleIdList></Reference><Reference><Citation>Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson&#x2019;s disease: high striatal serotonin/dopamine transporter ratio. Mov Disord. 2011;26(11):1997&#x2013;2003.</Citation><ArticleIdList><ArticleId IdType="pubmed">21611977</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff-Radford J, Foote KD, Rodriguez RL, et al. Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. Arch Neurol. 2006;63(8):1181&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908749</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzog J, Pogarell O, Pinsker MO, et al. Deep brain stimulation in Parkinson&#x2019;s disease following fetal nigral transplantation. Mov Disord. 2008;23(9):1293&#x2013;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">18536037</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat Med. 2008;14(5):501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat Med. 2008;14(5):504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Kordower JH. Neuropathology in transplants in Parkinson&#x2019;s disease: implications for disease pathogenesis and the future of cell therapy. Prog Brain Res. 2012;200:221&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">23195421</ArticleId></ArticleIdList></Reference><Reference><Citation>Politis M, Wu K, Loane C, et al. Serotonin neuron loss and nonmotor symptoms continue in Parkinson&#x2019;s patients treated with dopamine grafts. Sci Transl Med. 2012;4(128):28ra41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22491951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">24279935</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0197-4580</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>1980</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>Positron emission tomography in the study of aging and senile dementia.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>131</EndPage><MedlinePgn>127-31</MedlinePgn></Pagination><Abstract><AbstractText>(18)F-2-deoxy-2-fluoro-D-glucose ((18)FDG) is a positron emitting tracer for rate of glucose utilization in brain. When used in conjunction with positron emission tomography (PET), the PET-FDG technique permits in vivo quantitation of regional brain metabolism in man. We have applied this technique to the study of regional brain function in normal aging and senile dementia. Preliminary results for 7 patients with senile dementia of the Alzheimer's type (SDAT) and 3 elderly normal subjects indicated a large, statistically significant (p &lt; 0.01) diminution in rate of glucose utilization in SDAT. Furthermore, the degree of diminution in metabolic activity in SDAT was highly correlated with objective measures of degree of cognitive impairment. These results demonstrate the feasibility and potential utility of the PET-FDG technique for studying regional brain function in normal aging and dementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>S H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>New York University Medical Center USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Leon</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>A P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Farkas</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Christman</LastName><ForeName>D R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Reisberg</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Author><Author ValidYN="Y"><LastName>Macgregor</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Rampal</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>1980</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24279935</ArticleId><ArticleId IdType="doi">10.1016/0197-4580(80)90005-6</ArticleId><ArticleId IdType="pii">0197-4580(80)90005-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24331439</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5 Suppl</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>Imatinib treatment and A&#x3b2;42 in humans.</ArticleTitle><Pagination><StartPage>S374</StartPage><EndPage>S380</EndPage><MedlinePgn>S374-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2013.08.283</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(13)02839-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The first-line treatment in chronic myeloid leukemia (CML), imatinib, has been shown to decrease the production of amyloid-&#x3b2; (A&#x3b2;) in vitro and in animal studies. However, whether imatinib has this effect in humans is not known.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Plasma levels of A&#x3b2;42 were analyzed in sequential samples from CML patients treated with imatinib (n=51). The effect of imatinib on A&#x3b2; production was also investigated in human embryonic kidney 293 (HEK293) cells overexpressing the amyloid precursor protein (APP) with the Swedish mutation, in mouse primary cortical neurons and in human Down syndrome embryonic stem-cell-derived cortical neurons.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve months of imatinib treatment did not lower plasma A&#x3b2;42 levels in CML patients, and imatinib treatment did not lead to less A&#x3b2;42 production in any of the in vitro models whereas &#x3b2;- and &#x3b3;-secretase inhibitors did.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These data question the previously described role of imatinib in inhibiting amyloidogenic APP processing and as a drug candidate for AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Bob</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden. Electronic address: bob.olsson@medic.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legros</LastName><ForeName>Laurence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service d'H&#xe9;matologie Clinique, H&#xf4;pital de l'Archet, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilhot</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM CIC 0802, CHU de Poitiers, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Str&#xf6;mberg</LastName><ForeName>Kia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AstraZeneca R&amp;D, S&#xf6;dert&#xe4;lje, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>Frederick J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Quanterix Corporation, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden; UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>079249</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>092096</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101052</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001549">Benzamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015464" MajorTopicYN="N">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="N">Pyrimidines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">A&#x3b2;42</Keyword><Keyword MajorTopicYN="N">CML</Keyword><Keyword MajorTopicYN="N">Imatinib</Keyword><Keyword MajorTopicYN="N">Plasma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24331439</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2013.08.283</ArticleId><ArticleId IdType="pii">S1552-5260(13)02839-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24371306</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>07</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Head trauma and in vivo measures of amyloid and neurodegeneration in a population-based study.</ArticleTitle><Pagination><StartPage>70</StartPage><EndPage>76</EndPage><MedlinePgn>70-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/01.wnl.0000438229.56094.54</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We determined whether head trauma was associated with amyloid deposition and neurodegeneration among individuals who were cognitively normal (CN) or had mild cognitive impairment (MCI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants included 448 CN individuals and 141 individuals with MCI from the Mayo Clinic Study of Aging who underwent Pittsburgh compound B (PiB)-PET, fluorodeoxyglucose-PET, and MRI. Head trauma was defined as a self-reported brain injury with at least momentary loss of consciousness or memory. Regression models examined whether head trauma was associated with each neuroimaging variable (assessed as continuous and dichotomous measures) in both CN and MCI participants, controlling for age and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 448 CN individuals, 74 (17%) self-reported a head trauma. There was no difference in any neuroimaging measure between CN subjects with and without head trauma. Of 141 participants with MCI, 25 (18%) self-reported a head trauma. MCI participants with a head trauma had higher amyloid levels (by an average 0.36 standardized uptake value ratio units, p = 0.002).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among individuals with MCI, but not CN individuals, self-reported head trauma with at least momentary loss of consciousness or memory was associated with greater amyloid deposition, suggesting that head trauma may be associated with Alzheimer disease-related neuropathology. Differences between CN individuals and individuals with MCI raise questions about the relevance of head injury-PET abnormality findings in those with MCI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>From the Divisions of Epidemiology (M.M.Mielke, R.O.R., R.C.P., Y.E.G.) and Biomedical Statistics and Informatics (H.J.W., S.D.W.), Department of Health Sciences Research; Departments of Neurology (R.S., D.S.K., R.O.R, R.C.P.), Psychiatry and Psychology (M.M.Machulda), and Radiology (P.V., V.J.L, C.R.J.), Mayo Clinic, Rochester, MN; and Departments of Psychiatry, Psychology, and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savica</LastName><ForeName>Rodolfo</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Wiste</LastName><ForeName>Heather J</ForeName><Initials>HJ</Initials></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials></Author><Author ValidYN="Y"><LastName>Machulda</LastName><ForeName>Mary M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Geda</LastName><ForeName>Yonas E</ForeName><Initials>YE</Initials></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 MH068351</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG034676</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG028573</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG037526</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>12</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006259" MajorTopicYN="N">Craniocerebral Trauma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>1</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24371306</ArticleId><ArticleId IdType="pmc">PMC3873622</ArticleId><ArticleId IdType="doi">10.1212/01.wnl.0000438229.56094.54</ArticleId><ArticleId IdType="pii">01.wnl.0000438229.56094.54</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Graves AB, White E, Koepsell TD, et al. The association between head trauma and Alzheimer's disease. Am J Epidemiol 1990;131:491&#x2013;501</Citation><ArticleIdList><ArticleId IdType="pubmed">2405648</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortimer JA, van Duijn CM, Chandra V, et al. Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(suppl 2):S28&#x2013;S35</Citation><ArticleIdList><ArticleId IdType="pubmed">1833351</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Meara ES, Kukull WA, Sheppard L, et al. Head injury and risk of Alzheimer's disease by apolipoprotein E genotype. Am J Epidemiol 1997;146:373&#x2013;384</Citation><ArticleIdList><ArticleId IdType="pubmed">9290497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemetz PN, Leibson C, Naessens JM, et al. Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 1999;149:32&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">9883791</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Havlik RJ, Steffens DC, et al. Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology 2000;55:1158&#x2013;1166</Citation><ArticleIdList><ArticleId IdType="pubmed">11071494</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Cupples LA, Kurz A, et al. Head injury and the risk of AD in the MIRAGE study. Neurology 2000;54:1316&#x2013;1323</Citation><ArticleIdList><ArticleId IdType="pubmed">10746604</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HK, Lin SH, Sung PS, et al. Population based study on patients with traumatic brain injury suggests increased risk of dementia. J Neurol Neurosurg Psychiatry 2012;83:1080&#x2013;1085</Citation><ArticleIdList><ArticleId IdType="pubmed">22842203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta KM, Ott A, Kalmijn S, et al. Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. Neurology 1999;53:1959&#x2013;1962</Citation><ArticleIdList><ArticleId IdType="pubmed">10599765</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">9921852</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzman R, Aronson M, Fuld P, et al. Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol 1989;25:317&#x2013;324</Citation><ArticleIdList><ArticleId IdType="pubmed">2712531</ArticleId></ArticleIdList></Reference><Reference><Citation>Dams-O'Connor K, Gibbons LE, Bowen JD, McCurry SM, Larson EB, Crane PK. Risk for late-life re-injury, dementia and death among individuals with traumatic brain injury: a population-based study. J Neurol Neurosurg Psychiatry 2013;84:177&#x2013;182</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752841</ArticleId><ArticleId IdType="pubmed">23172868</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Parisi JE, Wold LE, Josephs KA, Ahlskog JE. High school football and risk of neurodegeneration: a community-based study. Mayo Clin Proc 2012;87:335&#x2013;340</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3538465</ArticleId><ArticleId IdType="pubmed">22469346</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Graham DI. beta A4 amyloid protein deposition in brain after head trauma. Lancet 1991;338:1422&#x2013;1423</Citation><ArticleIdList><ArticleId IdType="pubmed">1683421</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 1994;57:419&#x2013;425</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072869</ArticleId><ArticleId IdType="pubmed">8163989</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Widespread tau and amyloid-beta pathology many years after a single traumatic brain injury in humans. Brain Pathol 2012;22:142&#x2013;149</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979351</ArticleId><ArticleId IdType="pubmed">21714827</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz G, Beer R, Kampfl A, et al. Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 2003;60:1457&#x2013;1461</Citation><ArticleIdList><ArticleId IdType="pubmed">12743231</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnoni S, Esparza TJ, Conte V, et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain 2012;135:1268&#x2013;1280</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3326246</ArticleId><ArticleId IdType="pubmed">22116192</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58&#x2013;69</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology 2010;75:889&#x2013;897</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Rey A. L'examen Clinique en Psychologie. Paris: Presses Universitaires de France; 1964</Citation></Reference><Reference><Citation>Wechsler D. Manual for the Wechsler Memory Scale-revised. San Antonio: The Psychological Corporation; 1987</Citation></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S. The Boston Naming Test. Philadelphia: Lea &amp; Febiger; 1983</Citation></Reference><Reference><Citation>Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests. New York: Oxford University Press; 2006</Citation></Reference><Reference><Citation>Reitan R. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 1958;8:271&#x2013;276</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale-Revised [Manual]. San Antonio: Psychological Corporation; 1981</Citation></Reference><Reference><Citation>Ivnik RJ, Malec JF, Smith GE, et al. Mayo's Older Americans Normative Studies: WAIS-R, WMS-R and AVLT norms for ages 56 through 97. Clin Neuropsychol 1992;6(suppl 1):1&#x2013;104</Citation></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183&#x2013;194</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed Washington, DC: American Psychiatric Association; 1994</Citation></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008;131:665&#x2013;680</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012;71:765&#x2013;775</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010;75:230&#x2013;238</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906178</ArticleId><ArticleId IdType="pubmed">20592257</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai H, Pierce JE, Raghupathi R, et al. Twofold overexpression of human beta-amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain injury. J Comp Neurol 1998;392:428&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pubmed">9514508</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Nakamura M, McIntosh TK, et al. Brain trauma induces massive hippocampal neuron death linked to a surge in beta-amyloid levels in mice overexpressing mutant amyloid precursor protein. Am J Pathol 1998;153:1005&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853010</ArticleId><ArticleId IdType="pubmed">9736050</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa Y, Nakamura M, McIntosh TK, et al. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging. J Comp Neurol 1999;411:390&#x2013;398</Citation><ArticleIdList><ArticleId IdType="pubmed">10413774</ArticleId></ArticleIdList></Reference><Reference><Citation>Loane DJ, Pocivavsek A, Moussa CE, et al. Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury. Nat Med 2009;15:377&#x2013;379</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2844765</ArticleId><ArticleId IdType="pubmed">19287391</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Pierce JE, et al. Progressive atrophy and neuron death for one year following brain trauma in the rat. J Neurotrauma 1997;14:715&#x2013;727</Citation><ArticleIdList><ArticleId IdType="pubmed">9383090</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen XH, Siman R, Iwata A, Meaney DF, Trojanowski JQ, Smith DH. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol 2004;165:357&#x2013;371</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1618579</ArticleId><ArticleId IdType="pubmed">15277212</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson VE, Stewart W, Smith DH. Traumatic brain injury and amyloid-beta pathology: a link to Alzheimer's disease? Nat Rev Neurosci 2010;11:361&#x2013;370</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979339</ArticleId><ArticleId IdType="pubmed">20216546</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DH, Chen XH, Xu BN, McIntosh TK, Gennarelli TA, Meaney DF. Characterization of diffuse axonal pathology and selective hippocampal damage following inertial brain trauma in the pig. J Neuropathol Exp Neurol 1997;56:822&#x2013;834</Citation><ArticleIdList><ArticleId IdType="pubmed">9210879</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G. Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging 2011;32:1341&#x2013;1371</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128664</ArticleId><ArticleId IdType="pubmed">19775776</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24378564</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Lower motor neuron involvement in TAR DNA-binding protein of 43 kDa-related frontotemporal lobar degeneration and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>172</StartPage><EndPage>179</EndPage><MedlinePgn>172-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.5489</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">TAR DNA-binding protein of 43 kDa (TDP-43) plays a major role in the pathogenesis of frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Although a pathological continuity between FTLD and ALS has been suggested, the neuropathological changes of the lower motor neuron (LMN) systems have not been assessed in TDP-43-associated FTLD (FTLD-TDP), to our knowledge.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate a pathological continuity between FTLD-TDP and ALS by comparing their respective neuropathological changes in the motor neuron system.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">A retrospective clinical medical record review and a semiquantitative neuropathological evaluation of the cranial motor nerve nuclei and spinal cord were conducted at autopsy. We included 43 patients with sporadic FTLD-TDP, type A, B, or C, from 269 consecutively autopsied patients with TDP-43 proteinopathy. Patients were categorized as having FTLD without ALS, FTLD-ALS (onset of FTLD symptoms/signs preceded those of ALS), or ALS-FTLD (onset of ALS symptoms/signs preceded those of FTLD).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Neuronal TDP-43 pathological changes and neuronal loss.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-three patients were included in the clinical analysis, and 29 from whom spinal cords were obtained were included in the neuropathological analysis. Survival time was significantly shorter in the FTLD-ALS and ALS-FTLD groups than in the FTLD without ALS group (P&#x2009;&lt;&#x2009;.001). At neuropathological examination, 89% of patients in the FTLD without ALS group showed aggregations of TDP-43 in the spinal motor neurons. The LMN loss was most severe in ALS-FTLD, followed by FTLD-ALS and FTLD without ALS. All the patients with type A or C FTLD-TDP were included in the FTLD without ALS group, and all those with type B pathological changes were in the FTLD-ALS or the ALS-FTLD group. Lower motor neuron loss and TDP-43-positive skeinlike inclusions were observed in all pathological subtypes.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The LMN systems of FTLD-TDP frequently exhibit neuropathological changes corresponding to ALS. Thus, a pathological continuity between FTLD-TDP and ALS is supported at the level of the LMN system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riku</LastName><ForeName>Yuichi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Hirohisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Mari</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatsumi</LastName><ForeName>Shinsui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mimuro</LastName><ForeName>Maya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasaki</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iguchi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masuda</LastName><ForeName>Michihito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senda</LastName><ForeName>Jo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishigaki</LastName><ForeName>Shinsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udagawa</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24378564</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.5489</ArticleId><ArticleId IdType="pii">1791530</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24381967</PMID><DateCompleted><Year>2014</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>311</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>44</EndPage><MedlinePgn>33-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2013.282834</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine if vitamin E (alpha tocopherol), memantine, or both slow progression of mild to moderate AD in patients taking an acetylcholinesterase inhibitor.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Double-blind, placebo-controlled, parallel-group, randomized clinical trial involving 613 patients with mild to moderate AD initiated in August 2007 and concluded in September 2012 at 14 Veterans Affairs medical centers.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants received either 2000 IU/d of alpha tocopherol (n&#x2009;=&#x2009;152), 20 mg/d of memantine (n&#x2009;=&#x2009;155), the combination (n&#x2009;=&#x2009;154), or placebo (n&#x2009;=&#x2009;152).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) Inventory score (range, 0-78). Secondary outcomes included cognitive, neuropsychiatric, functional, and caregiver measures.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data from 561 participants were analyzed (alpha tocopherol&#x2009;=&#x2009;140, memantine&#x2009;=&#x2009;142, combination&#x2009;=&#x2009;139, placebo&#x2009;=&#x2009;140), with 52 excluded because of a lack of any follow-up data. Over the mean (SD) follow-up of 2.27 (1.22) years, ADCS-ADL Inventory scores declined by 3.15 units (95% CI, 0.92 to 5.39; adjusted P&#x2009;=&#x2009;.03) less in the alpha tocopherol group compared with the placebo group. In the memantine group, these scores declined 1.98 units less (95% CI, -0.24 to 4.20; adjusted P&#x2009;=&#x2009;.40) than the placebo group's decline. This change in the alpha tocopherol group translates into a delay in clinical progression of 19% per year compared with placebo or a delay of approximately 6.2 months over the follow-up period. Caregiver time increased least in the alpha tocopherol group. All-cause mortality and safety analyses showed a difference only on the serious adverse event of "infections or infestations," with greater frequencies in the memantine (31 events in 23 participants) and combination groups (44 events in 31 participants) compared with placebo (13 events in 11 participants).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among patients with mild to moderate AD, 2000 IU/d of alpha tocopherol compared with placebo resulted in slower functional decline. There were no significant differences in the groups receiving memantine alone or memantine plus alpha tocopherol. These findings suggest benefit of alpha tocopherol in mild to moderate AD by slowing functional decline and decreasing caregiver burden.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00235716.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dysken</LastName><ForeName>Maurice W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Minneapolis VA Health Care System, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>James J. Peters VA Medical Research Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asthana</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>William S. Middleton Memorial Veterans Hospital, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vertrees</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallaki</LastName><ForeName>Muralidhar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio6Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Llorente</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Washington DC VA Medical Center, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Love</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Minneapolis VA Health Care System, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Gerard D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>University of Pennsylvania School of Medicine, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarten</LastName><ForeName>J Riley</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Minneapolis VA Health Care System, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malphurs</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Miami VA Healthcare System, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Miami VA Healthcare System, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Peijun</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio6Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loreck</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>VA Maryland Healthcare System, Baltimore11University of Maryland Medical School, Department of Psychiatry, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trapp</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>VA North Texas Health Care System, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakshi</LastName><ForeName>Rajbir S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>VA North Texas Health Care System, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Ralph H. Johnson VA Medical Center, Charleston, South Carolina14Department of Health Studies, Medical University of South Carolina, Charleston15Roper St Francis Healthcare, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>Judith L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>VA Ann Arbor Healthcare System, Ann Arbor, Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal-Cardona</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VA Caribbean Healthcare System, San Juan, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arroyo</LastName><ForeName>Lillian M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>VA Caribbean Healthcare System, San Juan, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>Angel R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Bay Pines VA Healthcare System, Bay Pines, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zachariah</LastName><ForeName>Sally</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bay Pines VA Healthcare System, Bay Pines, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowall</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chopra</LastName><ForeName>Mohit P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>VA Boston Healthcare System, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System, Seattle, Washington21Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thielke</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System, Seattle, Washington21Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turvey</LastName><ForeName>Carolyn L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Iowa City VA Medical Center, Iowa City, Iowa23University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woodman</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Iowa City VA Medical Center, Iowa City, Iowa23University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monnell</LastName><ForeName>Kimberly A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>W. G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>W. G. (Bill) Hefner VA Medical Center, Salisbury, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomaska</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Minneapolis VA Health Care System, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Minneapolis VA Health Care System, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peduzzi</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven26Yale University School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarino</LastName><ForeName>Peter D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Cooperative Studies Program Coordinating Center, VA Connecticut Healthcare System, West Haven26Yale University School of Public Health, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00235716</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG013846</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005138</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002800">Cholinesterase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>1406-18-4</RegistryNumber><NameOfSubstance UI="D014810">Vitamin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber><NameOfSubstance UI="D008559">Memantine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA. 2014 Mar 19;311(11):1161</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2014 Jan 1;311(1):29-30. doi: 10.1001/jama.2013.282835.</RefSource><PMID Version="1">24381966</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2014 Aug;19(4):140. doi: 10.1136/eb-2014-101741.</RefSource><PMID Version="1">24639394</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002800" MajorTopicYN="N">Cholinesterase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008559" MajorTopicYN="N">Memantine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014810" MajorTopicYN="N">Vitamin E</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24381967</ArticleId><ArticleId IdType="mid">NIHMS557752</ArticleId><ArticleId IdType="pmc">PMC4109898</ArticleId><ArticleId IdType="doi">10.1001/jama.2013.282834</ArticleId><ArticleId IdType="pii">1810379</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: the Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336(17):1216&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">9110909</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Thomas RG, Grundman M, et al. Alzheimer's Disease Cooperative Study Group. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379&#x2013;2388.</Citation><ArticleIdList><ArticleId IdType="pubmed">15829527</ArticleId></ArticleIdList></Reference><Reference><Citation>Reisberg B, Doody R, St&#xf6;ffler A, Schmitt F, Ferris S, M&#xf6;bius HJ Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348(14):1333&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pubmed">12672860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I Memantine Study Group. Memantine treatment in patients with moderate-to-severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">14734594</ArticleId></ArticleIdList></Reference><Reference><Citation>Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14(8):704&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861375</ArticleId></ArticleIdList></Reference><Reference><Citation>Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">18288936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2008;13(1):97&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">18334761</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">21482915</ArticleId></ArticleIdList></Reference><Reference><Citation>Dysken MW, Guarino PD, Vertrees JE, et al. Vitamin E and memantine in Alzheimer's disease: clinical trial methods and baseline data. Alzheimers Dement. doi: 10.1016/j.jalz.2013.01.014. published online April 11, 2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.01.014</ArticleId><ArticleId IdType="pmc">PMC4128187</ArticleId><ArticleId IdType="pubmed">23583234</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman DD, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(2 suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Oremus M, Perrault A, Demers L, Wolfson C. Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales. J Geriatr Psychiatry Neurol. 2000;13(4):197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128059</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull. 1983;19(3):448&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">6635122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141(11):1356&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis KL, Marin DB, Kane R, et al. The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry. 1997;12(10):978&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pubmed">9395929</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49(5):M216&#x2013;M222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA. 2005;293(11):1338&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pubmed">15769967</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800&#x2013;802.</Citation></Reference><Reference><Citation>Kalbfleish JD, Prentice PL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley &amp; Sons; 1980.</Citation></Reference><Reference><Citation>Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics. 1992;48(3):951&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">1420849</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rigler SK, Studenski S, Wallace D, Reker DM, Duncan PW. Co-morbidity adjustment for functional outcomes in community-dwelling older adults. Clin Rehabil. 2002;16(4):420&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061477</ArticleId></ArticleIdList></Reference><Reference><Citation>Studenski SA, Lai SM, Duncan PW, Rigler SK. The impact of self-reported cumulative comorbidity on stroke recovery. Age Ageing. 2004;33(2):195&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">14960439</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Karlawish J. Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials. Alzheimers Res Ther. 2010;2(6):34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3031880</ArticleId><ArticleId IdType="pubmed">21172069</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142(1):37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15537682</ArticleId></ArticleIdList></Reference><Reference><Citation>Dysken MW, Kirk LN, Kuskowski M. Changes in vitamin E prescribing for Alzheimer patients. Am J Geriatr Psychiatry. 2009;17(7):621&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pubmed">19546657</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer LA, Cupples LA, Haines JL, et al. APOE and Alzheimer Disease Meta Analysis Consortium. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis. JAMA. 1997;278(16):1349&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pubmed">9343467</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun G, Naj AC, Beecham GW, et al. Alzheimer's Disease Genetics Consortium. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol. 2010;67(12):1473&#x2013;1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048805</ArticleId><ArticleId IdType="pubmed">20697030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD: the Galantamine USA-10 Study Group. Neurology. 2000;54(12):2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20(2-3):120&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">15990426</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu CW, Scarmeas N, Torgan R, et al. Clinical characteristics and longitudinal changes of informal cost of Alzheimer's disease in the community. J Am Geriatr Soc. 2006;54(10):1596&#x2013;1602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229197</ArticleId><ArticleId IdType="pubmed">17038080</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu CW, Scarmeas N, Torgan R, et al. Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease. Neurology. 2006;67(6):998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914696</ArticleId></ArticleIdList></Reference><Reference><Citation>Potkin SG. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Int Psychogeriatr. 2002;14(suppl 1):7&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">12636178</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M. Nursing home placement is related to dementia progression: experience from a clinical trial: Alzheimer's Disease Cooperative Study. Neurology. 1999;52(4):714&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pubmed">10078715</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith GE, Kokmen E, O'Brien PC. Risk factors for nursing home placement in a population-based dementia cohort. J Am Geriatr Soc. 2000;48(5):519&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">10811545</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23(1):44&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951873</ArticleId><ArticleId IdType="pubmed">20214847</ArticleId></ArticleIdList></Reference><Reference><Citation>Semla T. Updated criteria for use: memantine to treat dementia. VHA Pharmacy Benefits Management Service and the Medical Advisory Panel.  [Accessed September 15, 2013];  http://www.pbm.va.gov/PBM/clinicalguidance/criteriaforuse.asp.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24378367</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>The role of clusterin in amyloid-&#x3b2;-associated neurodegeneration.</ArticleTitle><Pagination><StartPage>180</StartPage><EndPage>187</EndPage><MedlinePgn>180-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.4560</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To elucidate the relationship between clusterin, amyloid-&#x3b2; (A&#x3b2;), phosphorylated tau (p-tau), and the rate of brain atrophy over time among nondemented older individuals.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This longitudinal cohort included cognitively normal older participants and individuals with mild cognitive impairment assessed with baseline lumbar puncture and longitudinal structural magnetic resonance imaging. We examined 241 nondemented older individuals from research centers across the United States and Canada (91 participants with a Clinical Dementia Rating score of 0 and 150 individuals with a Clinical Dementia Rating score of 0.5).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Using linear mixed-effects models, we investigated interactions between cerebrospinal fluid (CSF) clusterin, CSF A&#x3b2;1-42, and CSF p-tau at threonine 181 (p-tau181p) on the atrophy rate of the entorhinal cortex and hippocampus.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Across all participants, we found a significant interaction between CSF clusterin and CSF A&#x3b2;1-42 on the entorhinal cortex atrophy rate but not on the hippocampal atrophy rate. Cerebrospinal fluid clusterin was associated with the entorhinal cortex atrophy rate among CSF A&#x3b2;1-42-positive individuals but not among CSF A&#x3b2;1-42-negative individuals. In secondary analyses, we found significant interactions between CSF A&#x3b2;1-42 and CSF clusterin, as well as CSF A&#x3b2;1-42 and CSF p-tau181p, on the entorhinal cortex atrophy rate. We found similar results in subgroup analyses within the mild cognitive impairment and cognitively normal cohorts.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In nondemented older individuals, A&#x3b2;-associated volume loss occurs in the presence of elevated clusterin. The effect of clusterin on A&#x3b2;-associated brain atrophy is not confounded or explained by p-tau. These findings implicate a potentially important role for clusterin in the earliest stages of the Alzheimer disease neurodegenerative process and suggest independent effects of clusterin and p-tau on A&#x3b2;-associated volume loss.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Desikan</LastName><ForeName>Rahul S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Wesley K</ForeName><Initials>WK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holland</LastName><ForeName>Dominic</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Neuroradiology Section, Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brewer</LastName><ForeName>James B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla3Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at G&#xf6;teburg University, M&#xf6;lndal, Gotheburg, Sweden6University College London Institute of Neurology, Queen Square, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, The Sahlgrenska Academy at G&#xf6;teburg University, M&#xf6;lndal, Gotheburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California, San Diego, La Jolla7Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Linda K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dale</LastName><ForeName>Anders M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of California, San Diego, La Jolla2Department of Psychiatry, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01AG029218</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U19 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K02 NS067427</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG029218</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 EB005970</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051152">Clusterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Feb;10(2):60. doi: 10.1038/nrneurol.2014.1.</RefSource><PMID Version="1">24445801</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051152" MajorTopicYN="N">Clusterin</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Disclosure Statement</b>: Dr. Anders M. Dale is a founder and holds equity in CorTechs Labs, Inc, and also serves on the Scientific Advisory Board. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Dr. Linda K. McEvoy's spouse is CEO of CorTechs Labs, Inc. Dr. James B. Brewer holds stock options in CorTechs Labs, Inc and serves on the advisory board and receives financial support from the Eli Lilly Biomarker Unit (Amyvid). Dr. Brewer also receives research support from General Electric and Janssen Alzheimer Immunotherapy. Dr. Kaj Blennow has served on the advisory boards for Innogenetics, Lilly, Pfizer and Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24378367</ArticleId><ArticleId IdType="mid">NIHMS591828</ArticleId><ArticleId IdType="pmc">PMC4118752</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.4560</ArticleId><ArticleId IdType="pii">1791527</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>May PC, Johnson SA, Poirier J, Lampert-Etchells M, Finch CE. Altered gene expression in Alzheimer's disease brain tissue. Can J Neurol Sci. 1989;16:473&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">2680007</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579:337&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">1378350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidstr&#xf6;m AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (apolipoprotein J) protein levels are increased in hippocampus and frontal cortex in Alzheimer's disease. Exp Neurol. 1998;154:511&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9878186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilselid AM, Davidsson P, N&#xe4;gga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: Analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48:718&#x2013;728.</Citation><ArticleIdList><ArticleId IdType="pubmed">16490286</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JT, Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Mol Neurobiol. 2012 Apr;45(2):314&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">22274961</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305:1322&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pubmed">21467285</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, Wahlund LO, Westman E, Kinsey A, G&#xfc;ntert A, Proitsi P, Powell J, Causevic M, Killick R, Lunnon K, Lynham S, Broadstock M, Choudhry F, Howlett DR, Williams RJ, Sharp SI, Mitchelmore C, Tunnard C, Leung R, Foy C, O'Brien D, Breen G, Furney SJ, Ward M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Hodges A, Murphy DG, Parkins S, Richardson JC, Resnick SM, Ferrucci L, Wong DF, Zhou Y, Muehlboeck S, Evans A, Francis PT, Spenger C, Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010 Jul;67(7):739&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111021</ArticleId><ArticleId IdType="pubmed">20603455</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman SH, Kandel R, Cruz L, Rozkalne A, Newell K, Frosch MP, Hedley-Whyte ET, Locascio JJ, Lipsitz LA, Hyman BT. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol. 2008 Dec;67:1205&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734185</ArticleId><ArticleId IdType="pubmed">19018241</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobinski M, de Leon MJ, Wegiel J, Desanti S, Convit A, Louis LA, Rusinek H, Wisniewski HM. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience. 2000;95(3):721&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10670438</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3426814</ArticleId><ArticleId IdType="pubmed">22951438</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM Alzheimer's Disease Neuroimaging Initiative. Amyloid-&#x3b2; associated volume loss occurs only in the presence of p-tau. Ann Neurol. 2011 Oct;70:657&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368003</ArticleId><ArticleId IdType="pubmed">22002658</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM Alzheimer's Disease Neuroimaging Initiative. Amyloid-&#x3b2;--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012 Jun;69(6):709&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM for the Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E {varepsilon}4 Does Not Modulate Amyloid-&#x3b2;-Associated Neurodegeneration in Preclinical Alzheimer Disease. AJNR Am J Neuroradiol. 2013 Mar;34(3):505&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4041629</ArticleId><ArticleId IdType="pubmed">22976236</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC. Toward a multifactorial model of Alzheimer disease. Neurobiol Aging. 2012 Oct;33(10):2262&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334456</ArticleId><ArticleId IdType="pubmed">22261556</ArticleId></ArticleIdList></Reference><Reference><Citation>Stricker NH, Dodge HH, Dowling NM, Han SD, Erosheva EA, Jagust WJ Alzheimer's Disease Neuroimaging Initiative. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav. 2012 Dec;6(4):599&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656503</ArticleId><ArticleId IdType="pubmed">22614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Biomarkers Consortium Data Primer &#x2013; ADNI, Version. 2011 Dec 28;</Citation></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 Apr;65(4):403&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fennema-Notestine C, Hagler DJ, Jr, McEvoy LK, Fleisher AS, Wu EH, Karow DS, Dale AM Alzheimer's Disease Neuroimaging Initiative. Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp. 2009;30:3238&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951116</ArticleId><ArticleId IdType="pubmed">19277975</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, S&#xe9;gonne F, Fischl B, Quinn BT, Dickerson BC, Blacker D, Buckner RL, Dale AM, Maguire RP, Hyman BT, Albert MS, Killiany RJ. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 2006;31:968&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">16530430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Killiany R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, Dale AM. Nonlinear registration of longitudinal images and measurement of change in regions of interest. Medical Image Analysis. 2011;15:489&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3115407</ArticleId><ArticleId IdType="pubmed">21388857</ArticleId></ArticleIdList></Reference><Reference><Citation>Holland D, McEvoy LK, Dale AM Alzheimer's Disease Neuroimaging Initiative. Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp. 2012 Nov;33:2586&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3782292</ArticleId><ArticleId IdType="pubmed">21830259</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuutinen T, Suuronen T, Kauppinen A, Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res Rev. 2009 Oct;61(2):89&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">19651157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, An Y, Kinsey A, Koka D, Saleem M, G&#xfc;ntert A, Kraut M, Ferrucci L, Davatzikos C, Lovestone S, Resnick SM. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage. 2012 Jan 2;59(1):212&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3425349</ArticleId><ArticleId IdType="pubmed">21824521</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick R, Ribe EM, Al-Shawi R, Malik B, Hooper C, Fernandes C, Dobson R, Nolan PM, Lourdusamy A, Furney S, Lin K, Breen G, Wroe R, To AW, Leroy K, Causevic M, Usardi A, Robinson M, Noble W, Williamson R, Lunnon K, Kellie S, Reynolds CH, Bazenet C, Hodges A, Brion JP, Stephenson J, Paul Simons J, Lovestone S. Clusterin regulates &#x3b2;-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry. 2012 Nov 20;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3873038</ArticleId><ArticleId IdType="pubmed">23164821</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, O'dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99:10843&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125060</ArticleId><ArticleId IdType="pubmed">12145324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24390130</PMID><DateCompleted><Year>2015</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Familial Alzheimer's mutations within APPTM increase A&#x3b2;42 production by enhancing accessibility of &#x3b5;-cleavage site.</ArticleTitle><Pagination><StartPage>3037</StartPage><MedlinePgn>3037</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms4037</ELocationID><Abstract><AbstractText>The high A&#x3b2;42/A&#x3b2;40 production ratio is a hallmark of familial Alzheimer's disease, which can be caused by mutations in the amyloid precursor protein (APP). The C-terminus of A&#x3b2; is generated by &#x3b3;-secretase cleavage within the transmembrane domain of APP (APPTM), a process that is primed by an initial &#x3b5;-cleavage at either T48 or L49, resulting in subsequent production of A&#x3b2;42 or A&#x3b2;40, respectively. Here we solve the dimer structures of wild-type APPTM (AAPTM WT) and mutant APPTM (FAD mutants V44M) with solution NMR. The right-handed APPTM helical dimer is mediated by GXXXA motif. From the NMR structural and dynamic data, we show that the V44M and V44A mutations can selectively expose the T48 site by weakening helical hydrogen bonds and increasing hydrogen-deuterium exchange rate (kex). We propose a structural model in which FAD mutations (V44M and V44A) can open the T48 site &#x3b3;-secretase for the initial &#x3b5;-cleavage, and consequently shift cleavage preference towards A&#x3b2;42.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamache</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenman</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Maria M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yue-Ming</ForeName><Initials>YM</Initials><AffiliationInfo><Affiliation>Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Chunyu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, 110 8th Street, Troy, New York 12180, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM067545</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>7YNJ3PO35Z</RegistryNumber><NameOfSubstance UI="D006859">Hydrogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>AR09D82C7G</RegistryNumber><NameOfSubstance UI="D003903">Deuterium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003903" MajorTopicYN="N">Deuterium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006859" MajorTopicYN="N">Hydrogen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests:</b> The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24390130</ArticleId><ArticleId IdType="mid">NIHMS587861</ArticleId><ArticleId IdType="pmc">PMC4082030</ArticleId><ArticleId IdType="doi">10.1038/ncomms4037</ArticleId><ArticleId IdType="pii">ncomms4037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Selkoe DJ. Toward a comprehensive theory for Alzheimer&#x2019;s disease. Hypothesis: Alzheimer&#x2019;s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci. 2000;924:17&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">11193794</ArticleId></ArticleIdList></Reference><Reference><Citation>Annaert W, De Strooper B. A cell biological perspective on Alzheimer&#x2019;s disease. Annu Rev Cell Dev Biol. 2002;18:25&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142279</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, et al. Assembly and aggregation properties of synthetic Alzheimer&#x2019;s A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide(1-42) through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156:519&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2173346</ArticleId><ArticleId IdType="pubmed">11815632</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C, et al. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001;10:1665&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. An increased percentage of long amyloid-beta protein secreted by familial amyloid-beta protein-precursor (Beta-App(717)) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha S, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature. 1999;402:537&#x2013;540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10591214</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R, et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol. 2002;3:673&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">12209127</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraering PC, et al. Purification and characterization of the human gamma-secretase complex. Biochemistry. 2004;43:9774&#x2013;9789.</Citation><ArticleIdList><ArticleId IdType="pubmed">15274632</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C. Take five--BACE and the gamma-secretase quartet conduct Alzheimer&#x2019;s amyloid beta-peptide generation. EMBO J. 2004;23:483&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1271800</ArticleId><ArticleId IdType="pubmed">14749724</ArticleId></ArticleIdList></Reference><Reference><Citation>Takami M, et al. Gamma-secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci. 2009;29:13042&#x2013;13052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665297</ArticleId><ArticleId IdType="pubmed">19828817</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama K, et al. Familial Alzheimer&#x2019;s disease-linked mutations at Val717 of amyloid precursor protein are specific for the increased secretion of A beta 42(43) Biochem Biophys Res Commun. 1996;227:730&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">8886002</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nat Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler SF, et al. Mechanism of the cleavage specificity of Alzheimer&#x2019;s disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc Natl Acad Sci USA. 1999;96:3053&#x2013;3058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15893</ArticleId><ArticleId IdType="pubmed">10077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S, et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer&#x2019;s disease. Hum Mol Genet. 2000;9:2589&#x2013;2598.</Citation><ArticleIdList><ArticleId IdType="pubmed">11063718</ArticleId></ArticleIdList></Reference><Reference><Citation>Hecimovic S, et al. Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol Dis. 2004;17:205&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">15474359</ArticleId></ArticleIdList></Reference><Reference><Citation>Ancolio K, et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --&gt; Met betaAPP-770 mutation responsible for probable early-onset Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 1999;96:4119&#x2013;4124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC22430</ArticleId><ArticleId IdType="pubmed">10097173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin YI, et al. Gamma-secretase substrate concentration modulates the A beta 42/A beta 40 ratio. J Biol Chem. 2007;282:23639&#x2013;23644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett PJ, et al. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 2012;336:1168&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528355</ArticleId><ArticleId IdType="pubmed">22654059</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, et al. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor? Biochemistry. 2008;47:9428&#x2013;9446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572687</ArticleId><ArticleId IdType="pubmed">18702528</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J Biol Chem. 2008;283:7733&#x2013;7744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702479</ArticleId><ArticleId IdType="pubmed">18201969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorman PM, et al. Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer&#x2019;s disease mutants. BMC Neurosci. 2008;9:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2266763</ArticleId><ArticleId IdType="pubmed">18234110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, et al. A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc Natl Acad Sci USA. 2009;106:1421&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635791</ArticleId><ArticleId IdType="pubmed">19164538</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadezhdin KD, Bocharova OV, Bocharov EV, Arseniev AS. Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment. FEBS Lett. 2012;586:1687&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">22584060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu JX, Yau WM, Tycko R. Evidence from solid-state NMR for nonhelical conformations in the transmembrane domain of the amyloid precursor protein. Biophys J. 2011;100:711&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030151</ArticleId><ArticleId IdType="pubmed">21281586</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyashita N, Straub JE, Thirumalai D, Sugita Y. Transmembrane structures of amyloid precursor protein dimer predicted by replica-exchange molecular dynamics simulations. J Am Chem Soc. 2009;131:3438&#x2013;3439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2727648</ArticleId><ArticleId IdType="pubmed">19275251</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Molecular determinants and thermodynamics of the amyloid precursor protein transmembrane domain implicated in Alzheimer&#x2019;s disease. J Mol Biol. 2011;408:879&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082318</ArticleId><ArticleId IdType="pubmed">21440556</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen W, Gamache E, Richardson D, Du ZM, Wang CY. Expression, purification, and reconstitution of the transmembrane domain of the human amyloid precursor protein for NMR studies. Protein Expr Purif. 2012;81:11&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907289</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie KR, Prestegard JH, Engelman DM. A transmembrane helix dimer: structure and implications. Science. 1997;276:131&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">9082985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimitrov M, et al. Alzheimer&#x2019;s disease mutations in APP but not gamma-secretase modulators affect epsilon-cleavage-dependent AICD production. Nat Commun. 2013;4:2246.</Citation><ArticleIdList><ArticleId IdType="pubmed">23907250</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavez-Gutierrez L, et al. The mechanism of gamma-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Ran Y, Felsenstein KM. Shifting a complex debate on gamma-secretase cleavage and Alzheimer&#x2019;s disease. EMBO J. 2012;31:2237&#x2013;2239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364746</ArticleId><ArticleId IdType="pubmed">22505028</ArticleId></ArticleIdList></Reference><Reference><Citation>Botev A, et al. The amyloid precursor protein C-terminal fragment C100 occurs in monomeric and dimeric stable conformations and binds gamma-secretase modulators. Biochemistry. 2011;50:828&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">21186781</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J Biol Chem. 2010;285:21636&#x2013;21643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898405</ArticleId><ArticleId IdType="pubmed">20452985</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, et al. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaglio F, et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995;6:277&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">8520220</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntert P. Automated NMR structure calculation with CYANA. Methods Mol Biol. 2004;278:353&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pubmed">15318003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwieters CD, Kuszewski JJ, Tjandra N, Clore GM. The Xplor-NIH NMR molecular structure determination package. J Magn Res. 2003;160:66&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12565051</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou JJ, Gaemers S, Howder B, Louis JM, Bax A. A simple apparatus for generating stretched polyacrylamide gels, yielding uniform alignment of proteins and detergent micelles. J Biomol NMR. 2001;21:377&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">11824758</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorieau J, Yao L, Bax A. Liquid crystalline phase of G-tetrad DNA for NMR study of detergent-solubilized proteins. J Am Chem Soc. 2008;130:7536&#x2013;7537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652356</ArticleId><ArticleId IdType="pubmed">18498162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya A, Tejero R, Montelione GT. Evaluating protein structures determined by structural genomics consortia. Proteins. 2007;66:778&#x2013;795.</Citation><ArticleIdList><ArticleId IdType="pubmed">17186527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24403142</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies.</ArticleTitle><Pagination><StartPage>418</StartPage><EndPage>433</EndPage><MedlinePgn>418-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2712-13.2014</ELocationID><Abstract><AbstractText>By combining experimental neuron models and mathematical tools, we developed a "systems" approach to deconvolve cellular mechanisms of neurodegeneration underlying the most common known cause of Parkinson's disease (PD), mutations in leucine-rich repeat kinase 2 (LRRK2). Neurons ectopically expressing mutant LRRK2 formed inclusion bodies (IBs), retracted neurites, accumulated synuclein, and died prematurely, recapitulating key features of PD. Degeneration was predicted from the levels of diffuse mutant LRRK2 that each neuron contained, but IB formation was neither necessary nor sufficient for death. Genetic or pharmacological blockade of its kinase activity destabilized LRRK2 and lowered its levels enough to account for the moderate reduction in LRRK2 toxicity that ensued. By contrast, targeting synuclein, including neurons made from PD patient-derived induced pluripotent cells, dramatically reduced LRRK2-dependent neurodegeneration and LRRK2 levels. These findings suggest that LRRK2 levels are more important than kinase activity per se in predicting toxicity and implicate synuclein as a major mediator of LRRK2-induced neurodegeneration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Skibinski</LastName><ForeName>Gaia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, the Taube-Koret Center for Neurodegenerative Disease Research, and the Hellman Family Foundation Program in Alzheimer's Disease Research, San Francisco, California 94158, Departments of Neurology, Physiology, and Graduate Programs in Neuroscience and Biomedical Sciences, University of California, San Francisco, California 94158, and Laboratory of Neurogenetics, National Institutes of Health, Bethesda, Maryland 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Finkbeiner</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2P01 AG0224074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS039074</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS078370</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS083390</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS069496</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>1K08NS062954-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>3R01 NS039074</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS069496</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2R01 NS04549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS062954</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C06 RR018928</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051843">Synucleins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004789" MajorTopicYN="N">Enzyme Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051843" MajorTopicYN="N">Synucleins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LRRK2</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">mechanisms</Keyword><Keyword MajorTopicYN="N">single cell</Keyword><Keyword MajorTopicYN="N">synuclein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24403142</ArticleId><ArticleId IdType="pmc">PMC3870929</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2712-13.2014</ArticleId><ArticleId IdType="pii">34/2/418</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeliovich A, Schmitz Y, Fari&#xf1;as I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking&#x3b1;-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25:239&#x2013;252. doi: 10.1016/S0896-6273(00)80886-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80886-7</ArticleId><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Alegre-Abarrategui J, Christian H, Lufino MM, Mutihac R, Venda LL, Ansorge O, Wade-Martins R. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet. 2009;18:4022&#x2013;4034. doi: 10.1093/hmg/ddp346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp346</ArticleId><ArticleId IdType="pmc">PMC2758136</ArticleId><ArticleId IdType="pubmed">19640926</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PK, Gill RD. Cox's regression model for counting processes, a large sample study. Ann Statistics. 1982;10:1100&#x2013;1120. doi: 10.1214/aos/1176345976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aos/1176345976</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres-Mateos E, Mejias R, Sasaki M, Li X, Lin BM, Biskup S, Zhang L, Banerjee R, Thomas B, Yang L, Liu G, Beal MF, Huso DL, Dawson TM, Dawson VL. Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) J Neurosci. 2009;29:15846&#x2013;15850. doi: 10.1523/JNEUROSCI.4357-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4357-09.2009</ArticleId><ArticleId IdType="pmc">PMC2846613</ArticleId><ArticleId IdType="pubmed">20016100</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar S, Peters O, Millership S, Ninkina N, Doig N, Connor-Robson N, Threlfell S, Kooner G, Deacon RM, Bannerman DM, Bolam JP, Chandra SS, Cragg SJ, Wade-Martins R, Buchman VL. Functional alterations to the nigrostriatal system in mice lacking all three members of the synuclein family. J Neurosci. 2011;31:7264&#x2013;7274. doi: 10.1523/JNEUROSCI.6194-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6194-10.2011</ArticleId><ArticleId IdType="pmc">PMC3154647</ArticleId><ArticleId IdType="pubmed">21593311</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Finkbeiner S. Automated microscope system for determining factors that predict neuronal fate. Proc Natl Acad Sci U S A. 2005;102:3840&#x2013;3845. doi: 10.1073/pnas.0409777102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409777102</ArticleId><ArticleId IdType="pmc">PMC553329</ArticleId><ArticleId IdType="pubmed">15738408</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805&#x2013;810. doi: 10.1038/nature02998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02998</ArticleId><ArticleId IdType="pubmed">15483602</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010;30:639&#x2013;649. doi: 10.1523/JNEUROSCI.4988-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4988-09.2010</ArticleId><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilican B, Serio A, Barmada SJ, Nishimura AL, Sullivan GJ, Carrasco M, Phatnani HP, Puddifoot CA, Story D, Fletcher J, Park IH, Friedman BA, Daley GQ, Wyllie DJ, Hardingham GE, Wilmut I, Finkbeiner S, Maniatis T, Shaw CE, Chandran S. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012;109:5803&#x2013;5808. doi: 10.1073/pnas.1202922109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202922109</ArticleId><ArticleId IdType="pmc">PMC3326463</ArticleId><ArticleId IdType="pubmed">22451909</ArticleId></ArticleIdList></Reference><Reference><Citation>Biskup S, West AB. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta. 2009;1792:625&#x2013;633. doi: 10.1016/j.bbadis.2008.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.09.015</ArticleId><ArticleId IdType="pmc">PMC2745057</ArticleId><ArticleId IdType="pubmed">18973807</ArticleId></ArticleIdList></Reference><Reference><Citation>Botta-Orfila T, Ezquerra M, Pastor P, Fern&#xe1;ndez-Santiago R, Pont-Sunyer C, Compta Y, Lorenzo-Betancor O, Samaranch L, Mart&#xed; MJ, Valldeoriola F, Calopa M, Fern&#xe1;ndez M, Aguilar M, de Fabregas O, Hern&#xe1;ndez-Vara J, Tolosa E. Age at onset in LRRK2-associated PD is modified by SNCA variants. J Mol Neurosci. 2012;48:245&#x2013;247. doi: 10.1007/s12031-012-9820-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-012-9820-7</ArticleId><ArticleId IdType="pubmed">22669510</ArticleId></ArticleIdList></Reference><Reference><Citation>Byers B, Cord B, Nguyen HN, Sch&#xfc;le B, Fenno L, Lee PC, Deisseroth K, Langston JW, Pera RR, Palmer TD. SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate &#x3b1;-synuclein and are susceptible to oxidative stress. PloS One. 2011;6:e26159. doi: 10.1371/journal.pone.0026159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026159</ArticleId><ArticleId IdType="pmc">PMC3217921</ArticleId><ArticleId IdType="pubmed">22110584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, Orrison B, Chen A, Ellis CE, Paylor R, Lu B, Nussbaum RL. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking &#x3b1;-synuclein. J Neurosci. 2002;22:8797&#x2013;8807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757677</ArticleId><ArticleId IdType="pubmed">12388586</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra S, Fornai F, Kwon HB, Yazdani U, Atasoy D, Liu X, Hammer RE, Battaglia G, German DC, Castillo PE, S&#xfc;dhof TC. Double-knock-out mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A. 2004;101:14966&#x2013;14971. doi: 10.1073/pnas.0406283101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0406283101</ArticleId><ArticleId IdType="pmc">PMC522043</ArticleId><ArticleId IdType="pubmed">15465911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333&#x2013;366. doi: 10.1146/annurev.biochem.75.101304.123901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.75.101304.123901</ArticleId><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, Louis ED, Cote LJ, Andrews H, Fahn S, Waters C, Ford B, Frucht S, Ottman R, Marder K. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology. 2006;67:1786&#x2013;1791. doi: 10.1212/01.wnl.0000244345.49809.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000244345.49809.36</ArticleId><ArticleId IdType="pubmed">17050822</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant &#x3b1;-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292&#x2013;1295. doi: 10.1126/science.1101738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1101738</ArticleId><ArticleId IdType="pubmed">15333840</ArticleId></ArticleIdList></Reference><Reference><Citation>Daher JP, Pletnikova O, Biskup S, Musso A, Gellhaar S, Galter D, Troncoso JC, Lee MK, Dawson TM, Dawson VL, Moore DJ. Neurodegenerative phenotypes in an A53T &#x3b1;-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet. 2012;21:2420&#x2013;2431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349422</ArticleId><ArticleId IdType="pubmed">22357653</ArticleId></ArticleIdList></Reference><Reference><Citation>Daub A, Sharma P, Finkbeiner S. High-content screening of primary neurons: ready for prime time. Curr Opin Neurobiol. 2009;19:537&#x2013;543. doi: 10.1016/j.conb.2009.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2009.10.002</ArticleId><ArticleId IdType="pmc">PMC2787795</ArticleId><ArticleId IdType="pubmed">19889533</ArticleId></ArticleIdList></Reference><Reference><Citation>Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, Hen R. Resistance of &#x3b1;-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A. 2002;99:14524&#x2013;14529. doi: 10.1073/pnas.172514599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.172514599</ArticleId><ArticleId IdType="pmc">PMC137916</ArticleId><ArticleId IdType="pubmed">12376616</ArticleId></ArticleIdList></Reference><Reference><Citation>Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74:994&#x2013;997. doi: 10.1038/ki.2008.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.328</ArticleId><ArticleId IdType="pubmed">18633346</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, Gray NS. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011;7:203&#x2013;205. doi: 10.1038/nchembio.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.538</ArticleId><ArticleId IdType="pmc">PMC3287420</ArticleId><ArticleId IdType="pubmed">21378983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko N, Deak M, Hentati F, Reith AD, Prescott AR, Alessi DR, Nichols RJ. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 2010;430:405&#x2013;413. doi: 10.1042/BJ20100784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20100784</ArticleId><ArticleId IdType="pmc">PMC3631100</ArticleId><ArticleId IdType="pubmed">20659021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496&#x2013;509. doi: 10.1080/01621459.1999.10474144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkbeiner S, Tavazoie SF, Maloratsky A, Jacobs KM, Harris KM, Greenberg ME. CREB: a major mediator of neuronal neurotrophin responses. Neuron. 1997;19:1031&#x2013;1047. doi: 10.1016/S0896-6273(00)80395-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80395-5</ArticleId><ArticleId IdType="pubmed">9390517</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics. 2000;56:971&#x2013;983. doi: 10.1111/j.0006-341X.2000.0971.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0006-341X.2000.0971.x</ArticleId><ArticleId IdType="pubmed">11129494</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornai F, Schl&#xfc;ter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, S&#xfc;dhof TC. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and &#x3b1;-synuclein. Proc Natl Acad Sci U S A. 2005;102:3413&#x2013;3418. doi: 10.1073/pnas.0409713102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409713102</ArticleId><ArticleId IdType="pmc">PMC552938</ArticleId><ArticleId IdType="pubmed">15716361</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Jostins L, Latiano A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118&#x2013;1125. doi: 10.1038/ng.717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.717</ArticleId><ArticleId IdType="pmc">PMC3299551</ArticleId><ArticleId IdType="pubmed">21102463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T. Genetic variability in the SNCA gene influences &#x3b1;-synuclein levels in the blood and brain. FASEB J. 2008;22:1327&#x2013;1334. doi: 10.1096/fj.07-9348com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-9348com</ArticleId><ArticleId IdType="pubmed">18162487</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471&#x2013;1474. doi: 10.1126/science.1124514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1124514</ArticleId><ArticleId IdType="pubmed">16469881</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Suaga P, Luzon-Toro B, Churamani D, Zhang L, Bloor-Young D, Patel S, Woodman PG, Churchill GC, Hilfiker S. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2011;21:511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259011</ArticleId><ArticleId IdType="pubmed">22012985</ArticleId></ArticleIdList></Reference><Reference><Citation>Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Disease. 2006;23:329&#x2013;341. doi: 10.1016/j.nbd.2006.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.04.001</ArticleId><ArticleId IdType="pubmed">16750377</ArticleId></ArticleIdList></Reference><Reference><Citation>Greggio E, Bisaglia M, Civiero L, Bubacco L. Leucine-rich repeat kinase 2 and &#x3b1;-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener. 2011;6:6. doi: 10.1186/1750-1326-6-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-6</ArticleId><ArticleId IdType="pmc">PMC3035023</ArticleId><ArticleId IdType="pubmed">21244648</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Kasturi P, Bracher A, Loew C, Zheng M, Villella A, Garza D, Hartl FU, Raychaudhuri S. Firefly luciferase mutants as sensors of proteome stress. Nat Methods. 2011;8:879&#x2013;884. doi: 10.1038/nmeth.1697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1697</ArticleId><ArticleId IdType="pubmed">21892152</ArticleId></ArticleIdList></Reference><Reference><Citation>Haugarvoll K, Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, et al. Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. Neurology. 2008;70:1456&#x2013;1460. doi: 10.1212/01.wnl.0000304044.22253.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000304044.22253.03</ArticleId><ArticleId IdType="pmc">PMC3906630</ArticleId><ArticleId IdType="pubmed">18337586</ArticleId></ArticleIdList></Reference><Reference><Citation>HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell. 2012;11:264&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3804072</ArticleId><ArticleId IdType="pubmed">22748968</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 2008;7:583&#x2013;590. doi: 10.1016/S1474-4422(08)70117-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(08)70117-0</ArticleId><ArticleId IdType="pmc">PMC2832754</ArticleId><ArticleId IdType="pubmed">18539534</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzig MC, Kolly C, Persohn E, Theil D, Schweizer T, Hafner T, Stemmelen C, Troxler TJ, Schmid P, Danner S, Schnell CR, Mueller M, Kinzel B, Grevot A, Bolognani F, Stirn M, Kuhn RR, Kaupmann K, van der Putten PH, Rovelli G, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet. 2011;20:4209&#x2013;4223. doi: 10.1093/hmg/ddr348.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr348</ArticleId><ArticleId IdType="pmc">PMC3188995</ArticleId><ArticleId IdType="pubmed">21828077</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Biskup S, West AB, Trinkaus D, Dawson VL, Faull RL, Waldvogel HJ, Arai H, Dawson TM, Moore DJ, Emson PC. Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res. 2007;1155:208&#x2013;219. doi: 10.1016/j.brainres.2007.04.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2007.04.034</ArticleId><ArticleId IdType="pubmed">17512502</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinkle KM, Yue M, Behrouz B, D&#xe4;chsel JC, Lincoln SJ, Bowles EE, Beevers JE, Dugger B, Winner B, Prots I, Kent CB, Nishioka K, Lin WL, Dickson DW, Janus CJ, Farrer MJ, Melrose HL. LRRK2 knock-out mice have an intact dopaminergic system but display alterations in exploratory and motor coordination behaviors. Mol Neurodegener. 2012;7:25. doi: 10.1186/1750-1326-7-25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-25</ArticleId><ArticleId IdType="pmc">PMC3441373</ArticleId><ArticleId IdType="pubmed">22647713</ArticleId></ArticleIdList></Reference><Reference><Citation>Jager KJ, van Dijk PC, Zoccali C, Dekker FW. The analysis of survival data: the Kaplan-Meier method. Kidney Int. 2008;74:560&#x2013;565. doi: 10.1038/ki.2008.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2008.217</ArticleId><ArticleId IdType="pubmed">18596735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kay DM, Zabetian CP, Factor SA, Nutt JG, Samii A, Griffith A, Bird TD, Kramer P, Higgins DS, Payami H. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord. 2006;21:519&#x2013;523. doi: 10.1002/mds.20751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20751</ArticleId><ArticleId IdType="pubmed">16250030</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazantsev A, Preisinger E, Dranovsky A, Goldgaber D, Housman D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc Natl Acad Sci U S A. 1999;96:11404&#x2013;11409. doi: 10.1073/pnas.96.20.11404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.20.11404</ArticleId><ArticleId IdType="pmc">PMC18046</ArticleId><ArticleId IdType="pubmed">10500189</ArticleId></ArticleIdList></Reference><Reference><Citation>Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, Ellisman M, Dauer WT. LRRK2 Parkinson disease mutations enhance its microtubule association. Hum Mol Genet. 2012;21:890&#x2013;899. doi: 10.1093/hmg/ddr526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddr526</ArticleId><ArticleId IdType="pmc">PMC3263991</ArticleId><ArticleId IdType="pubmed">22080837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, Bailey R, Smith WW, Liu Z, Shin JH, Lee YI, Zhang YJ, Jiang H, Ross CA, Moore DJ, Patterson C, Petrucelli L, Dawson TM, Dawson VL. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A. 2009;106:2897&#x2013;2902. doi: 10.1073/pnas.0810123106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0810123106</ArticleId><ArticleId IdType="pmc">PMC2650345</ArticleId><ArticleId IdType="pubmed">19196961</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokhan VS, Afanasyeva MA, Van'kin GI. &#x3b1;-Synuclein knockout mice have cognitive impairments. Behav Brain Res. 2012;231:226&#x2013;230. doi: 10.1016/j.bbr.2012.03.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2012.03.026</ArticleId><ArticleId IdType="pubmed">22469626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of &#x3b1;-synuclein correlates with striatal dopamine deficit. Mov Disord. 2008;23:1608&#x2013;1612. doi: 10.1002/mds.22207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22207</ArticleId><ArticleId IdType="pubmed">18649394</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010;16:998&#x2013;1000. doi: 10.1038/nm.2199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2199</ArticleId><ArticleId IdType="pmc">PMC2935926</ArticleId><ArticleId IdType="pubmed">20729864</ArticleId></ArticleIdList></Reference><Reference><Citation>LePage KT, Dickey RW, Gerwick WH, Jester EL, Murray TF. On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies. Crit Rev Neurobiol. 2005;17:27&#x2013;50. doi: 10.1615/CritRevNeurobiol.v17.i1.20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1615/CritRevNeurobiol.v17.i1.20</ArticleId><ArticleId IdType="pubmed">16307526</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis PA, Manzoni C. LRRK2 and human disease: a complicated question or a question of complexes? Sci Signal. 2012;5:pe2. doi: 10.1126/scisignal.2002680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2002680</ArticleId><ArticleId IdType="pubmed">22253261</ArticleId></ArticleIdList></Reference><Reference><Citation>Li LH, Qin HZ, Wang JL, Wang J, Wang XL, Gao GD. Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Int Med Res. 2009;37:455&#x2013;463. doi: 10.1177/147323000903700221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/147323000903700221</ArticleId><ArticleId IdType="pubmed">19383240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, Chen ZZ, Gallant PE, Tao-Cheng JH, Rudow G, Troncoso JC, Liu Z, Li Z, Cai H. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant &#x3b1;-synuclein. Neuron. 2009;64:807&#x2013;827. doi: 10.1016/j.neuron.2009.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.11.006</ArticleId><ArticleId IdType="pmc">PMC2807409</ArticleId><ArticleId IdType="pubmed">20064389</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GH, Liu GH, Qu J, Suzuki K, Nivet E, Li M, Montserrat N, Yi F, Xu X, Ruiz S, Zhang W, Wagner U, Kim A, Ren B, Li Y, Goebl A, Kim J, Soligalla RD, Dubova I, Thompson J, et al. Progressive degeneration of human neural stem cells caused by pathogenic LRRK2. Nature. 2012;491:603&#x2013;607. doi: 10.1038/nature11557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11557</ArticleId><ArticleId IdType="pmc">PMC3504651</ArticleId><ArticleId IdType="pubmed">23075850</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52:587&#x2013;593. doi: 10.1016/j.neuron.2006.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.10.008</ArticleId><ArticleId IdType="pubmed">17114044</ArticleId></ArticleIdList></Reference><Reference><Citation>Mena MA, Khan U, Togasaki DM, Sulzer D, Epstein CJ, Przedborski S. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and l-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem. 1997;69:21&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202290</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Arrasate M, Shaby BA, Mitra S, Masliah E, Finkbeiner S. Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis. J Neurosci. 2010;30:10541&#x2013;10550. doi: 10.1523/JNEUROSCI.0146-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0146-10.2010</ArticleId><ArticleId IdType="pmc">PMC3078518</ArticleId><ArticleId IdType="pubmed">20685997</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Miller J, Arrasate M, Brooks E, Libeu CP, Legleiter J, Hatters D, Curtis J, Cheung K, Krishnan P, Mitra S, Widjaja K, Shaby BA, Lotz GP, Newhouse Y, Mitchell EJ, Osmand A, Gray M, Thulasiramin V, Saudou F, et al. Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol. 2011;7:925&#x2013;934. doi: 10.1038/nchembio.694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.694</ArticleId><ArticleId IdType="pmc">PMC3271120</ArticleId><ArticleId IdType="pubmed">22037470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein &#x3b1;-synuclein. J Biol Chem. 2011;286:20710&#x2013;20726. doi: 10.1074/jbc.M110.213538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.213538</ArticleId><ArticleId IdType="pmc">PMC3121472</ArticleId><ArticleId IdType="pubmed">21489994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HN, Byers B, Cord B, Shcheglovitov A, Byrne J, Gujar P, Kee K, Sch&#xfc;le B, Dolmetsch RE, Langston W, Palmer TD, Pera RR. LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell. 2011;8:267&#x2013;280. doi: 10.1016/j.stem.2011.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2011.01.013</ArticleId><ArticleId IdType="pmc">PMC3578553</ArticleId><ArticleId IdType="pubmed">21362567</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols RJ, Dzamko N, Morrice NA, Campbell DG, Deak M, Ordureau A, Macartney T, Tong Y, Shen J, Prescott AR, Alessi DR. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010;430:393&#x2013;404. doi: 10.1042/BJ20100483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20100483</ArticleId><ArticleId IdType="pmc">PMC2932554</ArticleId><ArticleId IdType="pubmed">20642453</ArticleId></ArticleIdList></Reference><Reference><Citation>Orenstein SJ, Kuo SH, Tasset I, Arias E, Koga H, Fernandez-Carasa I, Cortes E, Honig LS, Dauer W, Consiglio A, Raya A, Sulzer D, Cuervo AM. Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci. 2013;16:394&#x2013;406. doi: 10.1038/nn.3350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3350</ArticleId><ArticleId IdType="pmc">PMC3609872</ArticleId><ArticleId IdType="pubmed">23455607</ArticleId></ArticleIdList></Reference><Reference><Citation>Pais&#xe1;n-Ru&#xed;z C, Jain S, Evans EW, Gilks WP, Sim&#xf3;n J, van der Brug M, L&#xf3;pez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Mart&#xed;-Mass&#xf3; JF, P&#xe9;rez-Tur J, Wood NW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600. doi: 10.1016/j.neuron.2004.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.10.023</ArticleId><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Park CH, Minn YK, Lee JY, Choi DH, Chang MY, Shim JW, Ko JY, Koh HC, Kang MJ, Kang JS, Rhie DJ, Lee YS, Son H, Moon SY, Kim KS, Lee SH. In vitro and in vivo analyses of human embryonic stem cell-derived dopamine neurons. J Neurochem. 2005;92:1265&#x2013;1276. doi: 10.1111/j.1471-4159.2004.03006.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.03006.x</ArticleId><ArticleId IdType="pubmed">15715675</ArticleId></ArticleIdList></Reference><Reference><Citation>Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW, Daley GQ. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141&#x2013;146. doi: 10.1038/nature06534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06534</ArticleId><ArticleId IdType="pubmed">18157115</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastrana E. A handle on neurodegenerative disease complexity. Nat Methods. 2012;9:21. doi: 10.1038/nchembio.1130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1130</ArticleId><ArticleId IdType="pubmed">22312633</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinhardt P, Schmid B, Burbulla LF, Sch&#xf6;ndorf DC, Wagner L, Glatza M, H&#xf6;ing S, Hargus G, Heck SA, Dhingra A, Wu G, M&#xfc;ller S, Brockmann K, Kluba T, Maisel M, Kr&#xfc;ger R, Berg D, Tsytsyura Y, Thiel CS, Psathaki OE, et al. Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell. 2013;12:354&#x2013;367. doi: 10.1016/j.stem.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2013.01.008</ArticleId><ArticleId IdType="pubmed">23472874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Danes A, Richaud-Patin Y, Carballo-Carbajal I, Jimenez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, Lopez-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBO Mol Med. 2012;4:380&#x2013;395. doi: 10.1002/emmm.201200215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201200215</ArticleId><ArticleId IdType="pmc">PMC3403296</ArticleId><ArticleId IdType="pubmed">22407749</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009;41:1303&#x2013;1307. doi: 10.1038/ng.485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.485</ArticleId><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95:55&#x2013;66. doi: 10.1016/S0092-8674(00)81782-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81782-1</ArticleId><ArticleId IdType="pubmed">9778247</ArticleId></ArticleIdList></Reference><Reference><Citation>Scrucca L, Santucci A, Aversa F. Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant. 2010;45:1388&#x2013;1395. doi: 10.1038/bmt.2009.359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bmt.2009.359</ArticleId><ArticleId IdType="pubmed">20062101</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, et al. &#x3b1;-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841. doi: 10.1126/science.1090278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090278</ArticleId><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinski G, Finkbeiner S. Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease. FEBS Lett. 2013;587:1139&#x2013;1146. doi: 10.1016/j.febslet.2013.02.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2013.02.043</ArticleId><ArticleId IdType="pubmed">23458259</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A. 2005;102:18676&#x2013;18681. doi: 10.1073/pnas.0508052102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508052102</ArticleId><ArticleId IdType="pmc">PMC1317945</ArticleId><ArticleId IdType="pubmed">16352719</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:1231&#x2013;1233. doi: 10.1038/nn1776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1776</ArticleId><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. Aggregated and monomeric &#x3b1;-synuclein bind to the S6&#x2032; proteasomal protein and inhibit proteasomal function. J Biol Chem. 2003;278:11753&#x2013;11759. doi: 10.1074/jbc.M208641200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M208641200</ArticleId><ArticleId IdType="pubmed">12551928</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, Giaime E, Yamaguchi H, Ichimura T, Liu Y, Si H, Cai H, Bonventre JV, Shen J. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener. 2012;7:2. doi: 10.1186/1750-1326-7-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-2</ArticleId><ArticleId IdType="pmc">PMC3296570</ArticleId><ArticleId IdType="pubmed">22230652</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsvetkov AS, Miller J, Arrasate M, Wong JS, Pleiss MA, Finkbeiner S. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci U S A. 2010;107:16982&#x2013;16987. doi: 10.1073/pnas.1004498107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1004498107</ArticleId><ArticleId IdType="pmc">PMC2947884</ArticleId><ArticleId IdType="pubmed">20833817</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Xie C, Greggio E, Parisiadou L, Shim H, Sun L, Chandran J, Lin X, Lai C, Yang WJ, Moore DJ, Dawson TM, Dawson VL, Chiosis G, Cookson MR, Cai H. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci. 2008;28:3384&#x2013;3391. doi: 10.1523/JNEUROSCI.0185-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0185-08.2008</ArticleId><ArticleId IdType="pmc">PMC2564280</ArticleId><ArticleId IdType="pubmed">18367605</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X. LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet. 2012;21:1931&#x2013;1944. doi: 10.1093/hmg/dds003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds003</ArticleId><ArticleId IdType="pmc">PMC3315202</ArticleId><ArticleId IdType="pubmed">22228096</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005;102:16842&#x2013;16847. doi: 10.1073/pnas.0507360102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0507360102</ArticleId><ArticleId IdType="pmc">PMC1283829</ArticleId><ArticleId IdType="pubmed">16269541</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, Dawson TM. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet. 2007;16:223&#x2013;232. doi: 10.1093/hmg/ddl471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl471</ArticleId><ArticleId IdType="pubmed">17200152</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi J, Liu Y, Liu H, Chen H, Emborg ME, Zhang SC. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells. 2012;30:1655&#x2013;1663. doi: 10.1002/stem.1152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1152</ArticleId><ArticleId IdType="pmc">PMC3405174</ArticleId><ArticleId IdType="pubmed">22696177</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, M&#xfc;ller-Myhsok B, Dickson DW, Meitinger T, Strom TM, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607. doi: 10.1016/j.neuron.2004.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.11.005</ArticleId><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24407427</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD).</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>439</EndPage><MedlinePgn>423-439</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-013-1238-y</ELocationID><Abstract><AbstractText>We examined regional distribution patterns of phosphorylated 43-kDa TAR DNA-binding protein (pTDP-43) intraneuronal inclusions in frontotemporal lobar degeneration (FTLD). Immunohistochemistry was performed on 70 &#x3bc;m sections from FTLD-TDP autopsy cases (n = 39) presenting with behavioral variant frontotemporal dementia. Two main types of cortical pTDP-43 pathology emerged, characterized by either predominantly perikaryal pTDP-43 inclusions (cytoplasmic type, cFTLD) or long aggregates in dendrites (neuritic type, nFTLD). Cortical involvement in nFTLD was extensive and frequently reached occipital areas, whereas cases with cFTLD often involved bulbar somatomotor neurons and the spinal cord. We observed four patterns indicative of potentially sequential dissemination of pTDP-43: cases with the lowest burden of pathology (pattern I) were characterized by widespread pTDP-43 lesions in the orbital gyri, gyrus rectus, and amygdala. With increasing burden of pathology (pattern II) pTDP-43 lesions emerged in the middle frontal and anterior cingulate gyrus as well as in anteromedial temporal lobe areas, the superior and medial temporal gyri, striatum, red nucleus, thalamus, and precerebellar nuclei. More advanced cases showed a third pattern (III) with involvement of the motor cortex, bulbar somatomotor neurons, and the spinal cord anterior horn, whereas cases with the highest burden of pathology (pattern IV) were characterized by pTDP-43 lesions in the visual cortex. We interpret the four neuropathological patterns in bvFTD to be consistent with the hypothesis that pTDP-43 pathology can spread sequentially and may propagate along axonal pathways.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Brettschneider</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Del Tredici</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy Section, Department of Neurology, Center for Biomedical research, University of Ulm, Helmholtzstrasse 8/1, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Irwin</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, 3 W Gates, 3400 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo</LastName><ForeName>Jon B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Lubin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy Section, Department of Neurology, Center for Biomedical research, University of Ulm, Helmholtzstrasse 8/1, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Deerlin</LastName><ForeName>Vivianna M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Ulm, Oberer Eselsberg 45, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Virginia M-Y</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braak</LastName><ForeName>Heiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Clinical Neuroanatomy Section, Department of Neurology, Center for Biomedical research, University of Ulm, Helmholtzstrasse 8/1, 89081 Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Center for Neurodegenerative Disease research (CNDR), Perelman School of Medicine at the University of Pennsylvania, 3rd Floor Maloney Building, 3600 Spruce Street, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG039510</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG033101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG039510</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS044266</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 NS088341</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS044266</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG017586</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32-AG000255</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032953</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG033101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Acta Neuropathol. 2015 Jun;129(6):929. doi: 10.1007/s00401-015-1428-x.</RefSource><PMID Version="1">25931052</PMID><Note>Lee, Edward B [added]</Note></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005820" MajorTopicYN="N">Genetic Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24407427</ArticleId><ArticleId IdType="mid">NIHMS555831</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590050</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA, Carter D, Cairns NJ. A quantitative study of the neuropathology of 32 sporadic and familial cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) Neuropathol Appl Neurobiol. 2012;38:25&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3206199</ArticleId><ArticleId IdType="pubmed">21696412</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbas H. Specialized elements of orbitofrontal cortex in primates. Ann N Y Acad Sci. 2007;1121:10&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698996</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbas H, De Olmos J. Projections from the amygdala to basoventral and mediodorsal prefrontal regions in the rhesus monkey. J Comp Neurol. 1990;300:549&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">2273093</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbas H, Henion TH, Dermon CR. Diverse thalamic projections to the prefrontal cortex in the rhesus monkey. J Comp Neurol. 1991;313:65&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">1761756</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbas H, Pandya DN. Architecture and intrinsic connections of the prefrontal cortex in the rhesus monkey. J Comp Neurol. 1989;286:353&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">2768563</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes J, Whitwell JL, Frost C, et al. Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. Arch Neurol. 2006;63:1434&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">17030660</ArticleId></ArticleIdList></Reference><Reference><Citation>Basar K, Sesia T, Groenewegen H, et al. Nucleus accumbens and impulsivity. Prog Neurobiol. 2010;92:533&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831892</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3906709</ArticleId><ArticleId IdType="pubmed">16906426</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Brettschneider J, Ludolph A, et al. Amyotrophic lateral sclerosis: a model of corticofugal axonal spread. Nat Rev Neurol. 2013;9:708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943211</ArticleId><ArticleId IdType="pubmed">24217521</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K, R&#xfc;b U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, R&#xfc;b U, Del Tredici K. Involvement of precerebellar nuclei in multiple system atrophy. Neuropathol Appl Neurobiol. 2003;29:60&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">12581341</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Libon DJ, Toledo JB, et al. Microglial activation and TDP-43 pathology correlate with executive dysfunction in amyotrophic lateral sclerosis. Acta Neuropathol. 2012;123:395&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3595560</ArticleId><ArticleId IdType="pubmed">22210083</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Van Deerlin VM, Robinson JL, et al. Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. Acta Neuropathol. 2012;123:825&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3521561</ArticleId><ArticleId IdType="pubmed">22426854</ArticleId></ArticleIdList></Reference><Reference><Citation>Broe M, Hodges JR, Schofield E, et al. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology. 2003;60:1005&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">12654969</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the consortium for frontotemporal lobar degeneration. Acta Neuropathol. 2007;114:5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Colby DW, Prusiner SB. De novo generation of prion strains. Nat rev Microbiol. 2011;9:771&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924856</ArticleId><ArticleId IdType="pubmed">21947062</ArticleId></ArticleIdList></Reference><Reference><Citation>De Leon MJ, Convit A, George AE, et al. In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer's disease. Ann N Y Acad Sci. 1996;777:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8624070</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150&#x2013;1157.</Citation><ArticleIdList><ArticleId IdType="pubmed">19909913</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, et al. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol. 2002;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang PC, Stepniewska I, Kaas JH. Ipsilateral cortical connections of motor, premotor, frontal eye, and posterior parietal fields in a prosimian primate, Otolemur garnetti. J Comp Neurol. 2005;490:305&#x2013;333.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082679</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldengut S, Del Tredici K, Braak H. Paraffin sections of 70&#x2013;100mum: a novel technique and its benefits for studying the nervous system. J Neurosci Methods. 2013;215:241&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">23537935</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein Se, Mchugh Pr. &#x201c;Mini-mental state&#x201d;. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629792</ArticleId><ArticleId IdType="pubmed">16718704</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, Kaneko K, Watanabe S, et al. A seeding reaction recapitulates intracellular formation of Sarkosyl-insoluble transactivation response element (TAR) DNA-binding protein-43 inclusions. J Biol Chem. 2011;286:18664&#x2013;18672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3099683</ArticleId><ArticleId IdType="pubmed">21454603</ArticleId></ArticleIdList></Reference><Reference><Citation>Gambetti P, Cali I, Notari S, et al. Molecular biology and pathology of prion strains in sporadic human prion diseases. Acta Neuropathol. 2011;121:79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077936</ArticleId><ArticleId IdType="pubmed">21058033</ArticleId></ArticleIdList></Reference><Reference><Citation>Garibotto V, Borroni B, Agosti C, et al. Subcortical and deep cortical atrophy in frontotemporal lobar degeneration. Neurobiol Aging. 2011;32:875&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">19501427</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, et al. Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol. 2008;65:636&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez-lage M, Robinson J, et al. Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol. 2009;66:180&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghashghaei HT, Hilgetag CC, Barbas H. Sequence of information processing for emotions based on the anatomic dialogue between prefrontal cortex and amygdala. NeuroImage. 2007;34:905&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045074</ArticleId><ArticleId IdType="pubmed">17126037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannakopoulos P, Hof PR, Bouras C. Dementia lacking distinctive histopathology: clinicopathological evaluation of 32 cases. Acta Neuropathol. 1995;89:346&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">7610766</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon E, Rohrer JD, Kim LG, et al. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology. 2010;74:666&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830919</ArticleId><ArticleId IdType="pubmed">20177120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M. Primary progressive aphasia: clinicopatho-logical correlations, nature reviews. Neurology. 2010;6:88&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3637977</ArticleId><ArticleId IdType="pubmed">20139998</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Jl, Covell DJ, Daniels JP, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell. 2013;154:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Haber SN. The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat. 2003;26:317&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pubmed">14729134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornberger M, Geng J, Hodges JR. Convergent grey and white matter evidence of orbitofrontal cortex changes related to disinhibition in behavioural variant frontotemporal dementia. Brain J Neurol. 2011;134:2502&#x2013;2512.</Citation><ArticleIdList><ArticleId IdType="pubmed">21785117</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornberger M, Savage S, Hsieh S, et al. Orbitofrontal dysfunction discriminates behavioral variant frontotemporal dementia from Alzheimer's disease. Dement geriatr Cogn Disord. 2010;30:547&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">21252550</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730601</ArticleId><ArticleId IdType="pubmed">9305341</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, et al. Staging TDP-43 pathology in Alzheimer's disease. Acta neuropathologica. 2013 Epub ahead of print.</Citation></Reference><Reference><Citation>Josephs KA, Stroh A, Dugger B, et al. Evaluation of sub-cortical pathology and clinical correlations in FTlD-U sub-types. Acta Neuropathol. 2009;118:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044602</ArticleId><ArticleId IdType="pubmed">19455346</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Murray ME, et al. Corticospinal tract degeneration associated with TDP-43 type C pathology and semantic dementia. Brain J Neurol. 2013;136:455&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572926</ArticleId><ArticleId IdType="pubmed">23358603</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanouchi T, Ohkubo T, Yokota T. Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation? J Neurol Neurosurg Psychiatry. 2012;83:739&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3368493</ArticleId><ArticleId IdType="pubmed">22544947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan E, Goodglass H, Weintraub S, editors. Boston naming test. Lippincott Williams and Wilins; Philadelphia: 2001.</Citation></Reference><Reference><Citation>Kersaitis C, Halliday GM, Kril JJ. Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol. 2004;108:515&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">15368070</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Kril JJ, Halliday GM. Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement geriatr Cogn Disord. 2004;17:311&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">15178943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kril JJ, Halliday GM. Pathological staging of frontotemporal lobar degeneration. J Mol Neurosci. 2011;45:379&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">21552993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kril JJ, Macdonald V, Patel S, et al. Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci. 2005;232:83&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">15850587</ArticleId></ArticleIdList></Reference><Reference><Citation>Krueger CE, Dean DL, Rosen HJ, et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord. 2010;24:43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2837112</ArticleId><ArticleId IdType="pubmed">19571735</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumfor F, Irish M, Hodges JR, et al. The orbitofrontal cortex is involved in emotional enhancement of memory: evidence from the dementias. Brain. 2013;136:2992&#x2013;3003.</Citation><ArticleIdList><ArticleId IdType="pubmed">23838694</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Lee VM, Trojanowski JQ. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat rev Neurosci. 2012;13:38&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285250</ArticleId><ArticleId IdType="pubmed">22127299</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak M. Neuropsychological assessment. Oxford University Press; New York: 1983.</Citation></Reference><Reference><Citation>Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010;67:826&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">20625088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillo P, Mioshi E, Burrell JR, et al. Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum. PLoS ONE. 2012;7:e43993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3430626</ArticleId><ArticleId IdType="pubmed">22952843</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Miller BL, Kramer JH, et al. Behavioral disorders in the frontal and temporal variants of frontotemporal dementia. Neurology. 2004;62:742&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367136</ArticleId><ArticleId IdType="pubmed">15007124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Anderson T, Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077&#x2013;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu MT, Preston JB, Strick PL. Interconnections between the prefrontal cortex and the premotor areas in the frontal lobe. J Comp Neurol. 1994;341:375&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515081</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209:975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 2009;117:15&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2710877</ArticleId><ArticleId IdType="pubmed">19015862</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DM, South PW. The topographic distribution of brain atrophy in frontal lobe dementia. Acta Neuropathol. 1993;85:334&#x2013;340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8460535</ArticleId></ArticleIdList></Reference><Reference><Citation>Mckhann GM, Albert MS, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pubmed">11708987</ArticleId></ArticleIdList></Reference><Reference><Citation>Mioshi E, Hsieh S, Savage S, et al. Clinical staging and disease progression in frontotemporal dementia. Neurology. 2010;74:1591&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">20479357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL, Nicot S, Bencsik A, et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2011;33:2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-ruiz MA, Hartikainen P, Koikkalainen J, et al. Structural MRI in frontotemporal dementia: comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry. PLoS ONE. 2012;7:e52531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527560</ArticleId><ArticleId IdType="pubmed">23285078</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Tan CF, Toyoshima Y, et al. Sporadic amyotrophic lateral sclerosis: widespread multisystem degeneration with TDP-43 pathology in a patient after long-term survival on a respirator. Neuropathology. 2009;29:689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">19170893</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Callaghan C, Bertoux M, Hornberger M. Beyond and below the cortex: the contribution of striatal dysfunction to cognition and behaviour in neurodegeneration. J Neurol Neurosurg Psychiatry. 2013 Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain J Neurol. 2004;127:2657&#x2013;2671.</Citation><ArticleIdList><ArticleId IdType="pubmed">15509623</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry RJ, Graham A, Williams G, et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord. 2006;22:278&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914925</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol. 2007;6:994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Piguet O, Hornberger M, Mioshi E, et al. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol. 2011;10:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">21147039</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med. 2012;209:889&#x2013;893.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348110</ArticleId><ArticleId IdType="pubmed">22566400</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. The seeds of neurode-generation: prion-like spreading in ALS. Cell. 2011;147:498&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220614</ArticleId><ArticleId IdType="pubmed">22036560</ArticleId></ArticleIdList></Reference><Reference><Citation>Porrino LJ, Crane AM, Goldman-Rakic PS. Direct and indirect pathways from the amygdala to the frontal lobe in rhesus monkeys. J Comp Neurol. 1981;198:121&#x2013;136.</Citation><ArticleIdList><ArticleId IdType="pubmed">6164704</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Seeley WW, Kim EJ, et al. Distinct MRI atrophy patterns in autopsy-proven Alzheimer's disease and frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2007;22:474&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2443731</ArticleId><ArticleId IdType="pubmed">18166607</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. Nat rev Neurosci. 2010;11:760&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124757</ArticleId><ArticleId IdType="pubmed">20944662</ArticleId></ArticleIdList></Reference><Reference><Citation>Rempel-Clower Nl, Barbas H. The laminar pattern of connections between prefrontal and anterior temporal cortices in the rhesus monkey is related to cortical structure and function. Cereb Cortex. 2000;10:851&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">10982746</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleo-tide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockland KS, Pandya DN. Laminar origins and terminations of cortical connections of the occipital lobe in the rhesus monkey. Brain Res. 1979;179:3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">116716</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Geser F, Zhou J, et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology. 2010;75:2204&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3013589</ArticleId><ArticleId IdType="pubmed">21172843</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain. 2003;126:2016&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">12876142</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, Cohen FE, Prusiner SB. Quantitative traits of prion strains are enciphered in the conformation of the prion protein. Archiv Virol. 2000:227&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">11214926</ArticleId></ArticleIdList></Reference><Reference><Citation>Seelaar H, Rohrer JD, Pijnenburg YA, et al. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry. 2011;82:476&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">20971753</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135:693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Thompson JC, Stopford CL, et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain. 2011;134:2478&#x2013;2492.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840888</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartaglia MC, Zhang Y, Racine C, et al. Executive dys-function in frontotemporal dementia is related to abnormalities in frontal white matter tracts. J Neurol. 2012;259:1071&#x2013;1080.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3590313</ArticleId><ArticleId IdType="pubmed">22037958</ArticleId></ArticleIdList></Reference><Reference><Citation>The Lund and Manchester Groups Clinical and neuro-pathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57:416&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1072868</ArticleId><ArticleId IdType="pubmed">8163988</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Van Deerlin VM, Lee EB, et al. A platform for discovery: the University of Pennsylvania integrated neurodegenerative disease biobank. Alzheimers Dement. 2013 doi:10.1016/j.jalz.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3933464</ArticleId><ArticleId IdType="pubmed">23978324</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Pol LA, Hensel A, Van Der Flier WM, et al. Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2006;77:439&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077497</ArticleId><ArticleId IdType="pubmed">16306153</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72:57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GD, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Jack CR, Jr, Parisi Je, et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci. 2011;45:372&#x2013;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3401589</ArticleId><ArticleId IdType="pubmed">21556732</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Sampson EL, Watt HC, et al. A volumetric magnetic resonance imaging study of the amygdala in fronto-temporal lobar degeneration and Alzheimer's disease. Dement Geriatr Cogn Disord. 2005;20:238&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">16088140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CW, Bichot NP, Kaas JH. Converging evidence from microstimulation, architecture, and connections for multiple motor areas in the frontal and cingulate cortex of prosimian primates. J Comp Neurol. 2000;423:140&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pubmed">10861543</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie SX, Baek Y, Grossman M, et al. Building an integrated neurodegenerative disease database at an academic health center. Alzheimers Dement. 2011;7:e84&#x2013;e93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145967</ArticleId><ArticleId IdType="pubmed">21784346</ArticleId></ArticleIdList></Reference><Reference><Citation>Yakovlev PI. Motility, behavior and the brain; stereodynamic organization and neural coordinates of behavior. J Nerv Ment Dis. 1948;107:313&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">18913439</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CE, Bird TD, Bekris LM, et al. The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol. 2010;67:161&#x2013;170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901991</ArticleId><ArticleId IdType="pubmed">20142524</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24411731</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>01</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle.</ArticleTitle><Pagination><StartPage>49</StartPage><EndPage>60</EndPage><MedlinePgn>49-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2013.10.061</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(13)01035-0</ELocationID><Abstract><AbstractText>Although biotherapeutics have vast potential for treating brain disorders, their use has been limited due to low exposure across the blood-brain barrier (BBB). We report that by manipulating the binding mode of an antibody fragment to the transferrin receptor (TfR), we have developed a Brain Shuttle module, which can be engineered into a standard therapeutic antibody for successful BBB transcytosis. Brain Shuttle version of an anti-A&#x3b2; antibody, which uses a monovalent binding mode to the TfR, increases &#x3b2;-Amyloid target engagement in a mouse model of Alzheimer's disease by 55-fold compared to the parent antibody. We provide in vitro and in vivo evidence that the monovalent binding mode facilitates transcellular transport, whereas a bivalent binding mode leads to lysosome sorting. Enhanced target engagement of the Brain Shuttle module translates into a significant improvement in amyloid reduction. These findings have major implications for the development of biologics-based treatment of brain disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Niewoehner</LastName><ForeName>Jens</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bohrmann</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collin</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urich</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sade</LastName><ForeName>Hadassah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rueger</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stracke</LastName><ForeName>Jan Olaf</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wilma</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tissot</LastName><ForeName>Alain C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Large Molecule Research, F. Hoffmann-La Roche, Penzberg 82377, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loetscher</LastName><ForeName>Hansruedi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghosh</LastName><ForeName>Anirvan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland. Electronic address: anirvan.ghosh@roche.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freskg&#xe5;rd</LastName><ForeName>Per-Ola</ForeName><Initials>PO</Initials><AffiliationInfo><Affiliation>Pharma Research and Early Development, Neuroscience Discovery and Translation Area, F. Hoffmann-La Roche, Basel 4070, Switzerland. Electronic address: per-ola.freskgard@roche.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018942">Macrolides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057127">Single-Chain Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>88899-55-2</RegistryNumber><NameOfSubstance UI="C040929">bafilomycin A1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2014 Jan 8;81(1):1-3. doi: 10.1016/j.neuron.2013.12.023.</RefSource><PMID Version="1">24411725</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002461" MajorTopicYN="N">Cell Line, Transformed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018448" MajorTopicYN="N">Models, Immunological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057127" MajorTopicYN="N">Single-Chain Antibodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013347" MajorTopicYN="N">Subcellular Fractions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="N">Transcytosis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24411731</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2013.10.061</ArticleId><ArticleId IdType="pii">S0896-6273(13)01035-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24412048</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>383</Volume><Issue>9923</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.</ArticleTitle><Pagination><StartPage>1138</StartPage><EndPage>1146</EndPage><MedlinePgn>1138-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(13)61939-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0140-6736(13)61939-X</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Parkinson's disease is typically treated with oral dopamine replacement therapies; however, long-term treatment leads to motor complications and, occasionally, impulse control disorders caused by intermittent stimulation of dopamine receptors and off-target effects, respectively. We aimed to assess the safety, tolerability, and efficacy of bilateral, intrastriatal delivery of ProSavin, a lentiviral vector-based gene therapy aimed at restoring local and continuous dopamine production in patients with advanced Parkinson's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We undertook a phase 1/2 open-label trial with 12-month follow-up at two study sites (France and UK) to assess the safety and efficacy of ProSavin after bilateral injection into the putamen of patients with Parkinson's disease. All patients were then enrolled in a separate open-label follow-up study of long-term safety. Three doses were assessed in separate cohorts: low dose (1&#xb7;9&#xd7;10(7) transducing units [TU]); mid dose (4&#xb7;0&#xd7;10(7) TU); and high dose (1&#xd7;10(8) TU). Inclusion criteria were age 48-65 years, disease duration 5 years or longer, motor fluctuations, and 50% or higher motor response to oral dopaminergic therapy. The primary endpoints of the phase 1/2 study were the number and severity of adverse events associated with ProSavin and motor responses as assessed with Unified Parkinson's Disease Rating Scale (UPDRS) part III (off medication) scores, at 6 months after vector administration. Both trials are registered at ClinicalTrials.gov, NCT00627588 and NCT01856439.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">15 patients received ProSavin and were followed up (three at low dose, six mid dose, six high dose). During the first 12 months of follow-up, 54 drug-related adverse events were reported (51 mild, three moderate). Most common were increased on-medication dyskinesias (20 events, 11 patients) and on-off phenomena (12 events, nine patients). No serious adverse events related to the study drug or surgical procedure were reported. A significant improvement in mean UPDRS part III motor scores off medication was recorded in all patients at 6 months (mean score 38 [SD 9] vs 26 [8], n=15, p=0&#xb7;0001) and 12 months (38 vs 27 [8]; n=15, p=0&#xb7;0001) compared with baseline.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">ProSavin was safe and well tolerated in patients with advanced Parkinson's disease. Improvement in motor behaviour was observed in all patients.</AbstractText><AbstractText Label="FUNDING" NlmCategory="BACKGROUND">Oxford BioMedica.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palfi</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France. Electronic address: stephane.palfi@hmn.aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gurruchaga</LastName><ForeName>Jean Marc</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ralph</LastName><ForeName>G Scott</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lepetit</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavisse</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buttery</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskin</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeley</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwamuro</LastName><ForeName>Hirokazu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefaucheur</LastName><ForeName>Jean Pascal</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thiriez</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fenelon</LastName><ForeName>Gilles</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France; INSERM U955, E01, Institut de Recherche Biom&#xe9;dicale, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucas</LastName><ForeName>Cherry</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brugi&#xe8;res</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabriel</LastName><ForeName>Inanna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abhay</LastName><ForeName>Kou</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drouot</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kas</LastName><ForeName>Aurelie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghaleh</LastName><ForeName>Bijan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Corvoisier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolphin</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Breen</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guzman</LastName><ForeName>Natalie Valle</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazarakis</LastName><ForeName>Nicholas D</ForeName><Initials>ND</Initials><AffiliationInfo><Affiliation>Gene Therapy, Centre of Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Faculty of Medicine, Hammersmith Hospital Campus, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radcliffe</LastName><ForeName>Pippa A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrop</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kingsman</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>CIC9302 and UMR 825, INSERM and Department of Pharmacology and Neurosciences, University Hospital and University of Toulouse III, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naylor</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair and Addenbrooke's Hospital, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hantraye</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Remy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France; CEA, DSV I(2)BM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cesaro</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, UF Neurochirurgie Fonctionnelle, Neurologie, Neurophysiologie, Anesth&#xe9;sie, Centre d'Investigation Clinique 006, Plateforme de Ressources Biologiques, Cr&#xe9;teil, France; Universit&#xe9; Paris 12, Facult&#xe9; de M&#xe9;decine, Cr&#xe9;teil, France; INSERM U955, E01, Institut de Recherche Biom&#xe9;dicale, Cr&#xe9;teil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitrophanous</LastName><ForeName>Kyriacos A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Oxford BioMedica, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00627588</AccessionNumber><AccessionNumber>NCT01856439</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>G108/507</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.16</RegistryNumber><NameOfSubstance UI="D006136">GTP Cyclohydrolase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 4.1.1.-</RegistryNumber><NameOfSubstance UI="D004296">Dopa Decarboxylase</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2014 Mar 29;383(9923):1107-9. doi: 10.1016/S0140-6736(13)62108-X.</RefSource><PMID Version="1">24412047</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Apr;10(4):186-7. doi: 10.1038/nrneurol.2014.45.</RefSource><PMID Version="1">24662536</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004296" MajorTopicYN="N">Dopa Decarboxylase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006136" MajorTopicYN="N">GTP Cyclohydrolase</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005822" MajorTopicYN="N">Genetic Vectors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004860" MajorTopicYN="N">Infectious Anemia Virus, Equine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015552" MajorTopicYN="N">Injections, Intralesional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011699" MajorTopicYN="N">Putamen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24412048</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(13)61939-X</ArticleId><ArticleId IdType="pii">S0140-6736(13)61939-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24425039</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA).</ArticleTitle><Pagination><StartPage>315</StartPage><EndPage>323</EndPage><MedlinePgn>315-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.5570</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Late-onset Alzheimer disease (LOAD), defined as onset of symptoms after age 65 years, is the most common form of dementia. Few reports investigate incidence rates in large family-based studies in which the participants were selected for family history of LOAD.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the incidence rates of dementia and LOAD in unaffected members in the National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA) family studies.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Families with 2 or more affected siblings who had a clinical or pathological diagnosis of LOAD were recruited as a part of the NIA-LOAD/NCRAD Family Study. A cohort of Caribbean Hispanics with familial LOAD was recruited in a different study at the Taub Institute for Research on Alzheimer's Disease and the Aging Brain in New York and from clinics in the Dominican Republic as part of the EFIGA study.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Age-specific incidence rates of LOAD were estimated in the unaffected family members in the NIA-LOAD/NCRAD and EFIGA data sets. We restricted analyses to families with follow-up and complete phenotype information, including 396 NIA-LOAD/NCRAD and 242 EFIGA families. Among the 943 at-risk family members in the NIA-LOAD/NCRAD families, 126 (13.4%) developed dementia, of whom 109 (86.5%) met criteria for LOAD. Among 683 at-risk family members in the EFIGA families, 174 (25.5%) developed dementia during the study period, of whom 145 (83.3%) had LOAD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The annual incidence rates of dementia and LOAD in the NIA-LOAD/NCRAD families per person-year were 0.03 and 0.03, respectively, in participants aged 65 to 74 years; 0.07 and 0.06, respectively, in those aged 75 to 84 years; and 0.08 and 0.07, respectively, in those 85 years or older. Incidence rates in the EFIGA families were slightly higher, at 0.03 and 0.02, 0.06 and 0.05, 0.10 and 0.08, and 0.10 and 0.07, respectively, in the same age groups. Contrasting these results with the population-based estimates, the incidence was increased by 3-fold for NIA-LOAD/NCRAD families (standardized incidence ratio, 3.44) and 2-fold among the EFIGA compared with the NIA-LOAD/NCRAD families (1.71).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">The incidence rates for familial dementia and LOAD in the NIA-LOAD/NCRAD and EFIGA families are significantly higher than population-based estimates. The incidence rates in all groups increase with age. The higher incidence of LOAD can be explained by segregation of Alzheimer disease-related genes in these families or shared environmental risks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vardarajan</LastName><ForeName>Badri N</ForeName><Initials>BN</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York2Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faber</LastName><ForeName>Kelley M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bird</LastName><ForeName>Thomas D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Washington, Seattle5Department of Medicine, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurotherapeutics, The University of Texas Southwestern Medical Center, Dallas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>Neill R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Genetics, Knight Alzheimer's Disease Research Center, Washington University, St Louis, Missouri11Hope Center for Neurological Disorders, Washington University, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University Center for Alzheimer's Disease and Related Disorders, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweet</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania14Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania15Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lantigua</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York16Department of Medicine, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medrano</LastName><ForeName>Martin Z</ForeName><Initials>MZ</Initials><AffiliationInfo><Affiliation>Universidad Tecnol&#xf3;gica de Santiago, Santiago, Dominican Republic18currently with Department of Geriatrics, Pontificia Universidad Cat&#xf3;lica Madre y Maestra, Santiago, Dominican Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ottman</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York3Department of Medical and Molecular Genetics, Indiana University, Indianapolis19Department of Epidemiology, Columbia University, New York, New York20.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaid</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foroud</LastName><ForeName>Tatiana M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Medical and Molecular Genetics, Indiana University, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, New York2Gertrude H. Sergievsky Center, Columbia University College of Physicians and Surgeons, New York, New York22Department of Neurolo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NIA-LOAD/NCRAD Family Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032306</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027224</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG041797</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG056270</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001108</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG015473</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG026395</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536595">Alzheimer disease type 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004293" MajorTopicYN="N" Type="Geographic">Dominican Republic</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054561" MajorTopicYN="N">National Institute on Aging (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009518" MajorTopicYN="N" Type="Geographic">New York</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Boeve was an investigator for clinical trials sponsored by Cephalon, Inc, Allon Pharmaceuticals, and GE Healthcare; receives royalties from the publication of a book titled <i>Behavioral Neurology of Dementia</i> (Cambridge Medicine; 2009); has received honoraria from the American Academy of Neurology; serves on the Scientific Advisory Board of the Tau Consortium; and receives research support from the National Institute on Aging (NIA) (P50 AG016574, U01 AG006786, RO1 AG032306, RO1 AG041797) and the Mangurian Foundation. Dr Rosenberg has received clinical trial grants from Janssen and Pfizer Inc; holds a US patent for &#x201c;Amyloid &#x3b2; Gene Vaccines&#x201d;; and serves on the editorial board of the <i>Journal of the Neurological Sciences</i>. Dr Farlow has received grant and research support from Accera, Biogen, Eisai Med Res, Eli Lilly &amp; Company, Genentech, MedAvante/AstraZeneca, and Navidea; serves on the speaker&#x2019;s bureau at Eisai Med Res, Pfizer Inc, Forest, Novartis, and Eli Lilly &amp; Company; serves on the consultant/advisory boards at Accera, Alltech, Avanir, Eisai Med Res, Inc, Helicon, Medavante, Medivation, Inc, Merck and Co, Inc, Novartis, Pfizer Inc, Prana Biotech, QR Pharma, Roche, Sanofi-Aventis, Schering-Plough, Toyama Pharm, Eli Lilly &amp; Company, UCB Pharma and Elan. Dr Sweet is a consultant for Eli Lilly &amp; Company. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24425039</ArticleId><ArticleId IdType="mid">NIHMS570093</ArticleId><ArticleId IdType="pmc">PMC4000602</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.5570</ArticleId><ArticleId IdType="pii">1813792</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jorm AF, Korten AE, Henderson AS. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand. 1987;76(5):465&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pubmed">3324647</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261(5123):921&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, et al. NIA-LOAD/NCRAD Family Study Consortium. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer&#x2019;s disease families [published correction appears in PLoS One. 2012;7(5). doi:10.1371/annotation/c92e16da-7733-421d-b063-1db19488daa6] PLoS One. 2012;7(2):e31039. doi: 10.1371/journal.pone.0031039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031039</ArticleId><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobbs FB, Damon BL.  Sixty-five Plus in the United States. Washington, DC: US Bureau of the Census; 1996. pp. 23&#x2013;190.  http://books.google.com/books?uid=114584440181414684107&amp;source=gbs_lp_bookshelf_list.</Citation></Reference><Reference><Citation>Gurland BJ, Wilder DE, Lantigua R, et al. Rates of dementia in three ethnoracial groups. Int J Geriatr Psychiatry. 1999;14(6):481&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">10398359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Cross P, Andrews H, et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology. 2001;56(1):49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">11148235</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang MX, Stern Y, Marder K, et al. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics. JAMA. 1998;279(10):751&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">9508150</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982 Jun;140:566&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">7104545</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer&#x2019;s disease. Neurology. 1991;41(4):479&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">2011243</ArticleId></ArticleIdList></Reference><Reference><Citation>Maestre G, Ottman R, Stern Y, et al. Apolipoprotein E and Alzheimer&#x2019;s disease: ethnic variation in genotypic risks. Ann Neurol. 1995;37(2):254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">7847867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31(3):545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow NE, Day NE. Statistical methods in cancer research: volume II&#x2014;the design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">3329634</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Petersen RC, Cha RH, Edland SD, Rocca WA. Incidence and causes of nondegenerative nonvascular dementia: a population-based study. Arch Neurol. 2006;63(2):218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">16476810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson EB, Hilferty MM. The distribution of chi-square. Proc Natl Acad Sci U S A. 1931;17(12):684&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1076144</ArticleId><ArticleId IdType="pubmed">16577411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012;33(9):1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer&#x2019;s disease in a general population: the Framingham Study. Neurology. 1993;43(3 pt 1):515&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">8450993</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Scherr PA, Beckett LA, et al. Age-specific incidence of Alzheimer&#x2019;s disease in a community population. JAMA. 1995;273(17):1354&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">7715060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokmen E, Chandra V, Schoenberg BS. Trends in incidence of dementing illness in Rochester, Minnesota, in three quinquennial periods: 1960&#x2013;1974. Neurology. 1988;38(6):975&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">3368079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshitake T, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer&#x2019;s disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783883</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagnell O, Franck A, Gr&#xe4;sbeck A, et al. Senile dementia of the Alzheimer type in the Lundby Study, I: a prospective, epidemiological study of incidence and risk during the 15 years 1957&#x2013;1972. Eur Arch Psychiatry Clin Neurosci. 1991;241(3):159&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">1790161</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Newman TT, Breitner JC. APOE and AD concordance in twin pairs as predictors of AD in first-degree relatives. Neurology. 2000;54(3):593&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pubmed">10680788</ArticleId></ArticleIdList></Reference><Reference><Citation>Green RC, Cupples LA, Go R, et al. MIRAGE Study Group. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA. 2002;287(3):329&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pubmed">11790212</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrada M, Brookmeyer R, Kawas C. Sources of variability in prevalence rates of Alzheimer&#x2019;s disease. Int J Epidemiol. 1995;24(5):1000&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">8557432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Cheng R, Barral S, et al. Identification of novel loci for Alzheimer disease and replication of CLU, PICALM, and BIN1 in Caribbean Hispanic individuals. Arch Neurol. 2011;68(3):320&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268783</ArticleId><ArticleId IdType="pubmed">21059989</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryc K, Velez C, Karafet T, et al. Colloquium paper: genome-wide patterns of population structure and admixture among Hispanic/Latino populations. Proc Natl Acad Sci U S A. 2010;107(suppl 2):8954&#x2013;8961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024022</ArticleId><ArticleId IdType="pubmed">20445096</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer&#x2019;s disease. JAMA. 1994;271(13):1004&#x2013;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">8139057</ArticleId></ArticleIdList></Reference><Reference><Citation>Teresi JA, Golden RR, Cross P, Gurland B, Kleinman M, Wilder D. Item bias in cognitive screening measures: comparisons of elderly white, Afro-American, Hispanic and high and low education subgroups. J Clin Epidemiol. 1995;48(4):473&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">7722601</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall KS, Gao S, Unverzagt FW, Hendrie HC. Low education and childhood rural residence: risk for Alzheimer&#x2019;s disease in African Americans. Neurology. 2000;54(1):95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">10636132</ArticleId></ArticleIdList></Reference><Reference><Citation>Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo JM, Dartigues JF. Are sex and educational level independent predictors of dementia and Alzheimer&#x2019;s disease? incidence data from the PAQUID project. J Neurol Neurosurg Psychiatry. 1999;66(2):177&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1736218</ArticleId><ArticleId IdType="pubmed">10071096</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu HC, Chou P, Lin KN, et al. Assessing cognitive abilities and dementia in a predominantly illiterate population of older individuals in Kinmen. Psychol Med. 1994;24(3):763&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991758</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachman DL, Wolf PA, Linn R, et al. Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology. 1992;42(1):115&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">1734291</ArticleId></ArticleIdList></Reference><Reference><Citation>Canadian study of health and aging: study methods and prevalence of dementia. CMAJ. 1994;150(6):899&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1486712</ArticleId><ArticleId IdType="pubmed">8131123</ArticleId></ArticleIdList></Reference><Reference><Citation>Corso EA, Campo G, Triglio A, Napoli A, Reggio A, Lanaia F. Prevalence of moderate and severe Alzheimer dementia and multi-infarct dementia in the population of southeastern Sicily. Ital J Neurol Sci. 1992;13(3):215&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">1624277</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowirrat A, Treves TA, Friedland RP, Korczyn AD. Prevalence of Alzheimer&#x2019;s type dementia in an elderly Arab population. Eur J Neurol. 2001;8(2):119&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">11284991</ArticleId></ArticleIdList></Reference><Reference><Citation>Manubens JM, Mart&#xed;nez-Lage JM, Lacruz F, et al. Prevalence of Alzheimer&#x2019;s disease and other dementing disorders in Pamplona, Spain. Neuroepidemiology. 1995;14(4):155&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">7643949</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez Pousa S, Llin&#xe1;s Regla J, Vilalta Franch J, Lozano Fern&#xe1;ndez de Pinedo L. The prevalence of dementia in Girona. Neurologia. 1995;10(5):189&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">7619535</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyohara Y, Yoshitake T, Kato I, et al. Changing patterns in the prevalence of dementia in a Japanese community: the Hisayama Study. Gerontology. 1994;40(suppl 2):29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">7926864</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo JI, Lee JH, Yoo KY, Kim CY, Kim YI, Shin YS. Prevalence estimation of dementia in a rural area of Korea. J Am Geriatr Soc. 1998;46(8):983&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">9706887</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson LV. Incidence of severe dementia in an urban sample followed from 70 to 79 years of age. Acta Psychiatr Scand. 1984;70(5):478&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">6334976</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarvik LF, Ruth V, Matsuyama SS. Organic brain syndrome and aging: a six-year follow-up of surviving twins. Arch Gen Psychiatry. 1980;37(3):280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7362417</ArticleId></ArticleIdList></Reference><Reference><Citation>Brayne C, Gill C, Huppert FA, et al. Incidence of clinically diagnosed subtypes of dementia in an elderly population: Cambridge Project for Later Life. Br J Psychiatry. 1995;167(2):255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">7582679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24441681</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency.</ArticleTitle><Pagination><StartPage>223</StartPage><EndPage>231</EndPage><MedlinePgn>223-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3618</ELocationID><Abstract><AbstractText>Amyloid-induced microglial activation and neuroinflammation impair central synapses and memory function, although the mechanism remains unclear. Neuroligin 1 (NLGN1), a postsynaptic protein found in central excitatory synapses, governs excitatory synaptic efficacy and plasticity in the brain. Here we found, in rodents, that amyloid fibril-induced neuroinflammation enhanced the interaction between histone deacetylase 2 and methyl-CpG-binding protein 2, leading to suppressed histone H3 acetylation and enhanced cytosine methylation in the Nlgn1 promoter region and decreased NLGN1 expression, underlying amyloid-induced memory deficiency. Manipulation of microglia-associated neuroinflammation modulated the epigenetic modification of the Nlgn1 promoter, hippocampal glutamatergic transmission and memory function. These findings link neuroinflammation, synaptic efficacy and memory, thus providing insight into the pathogenesis of amyloid-associated diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bie</LastName><ForeName>Bihua</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>1] Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jijun J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naguib</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Anesthesiology, Anesthesiology Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR000439</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015816">Cell Adhesion Molecules, Neuronal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051783">Methyl-CpG-Binding Protein 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C093438">neuroligin 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="C533424">Hdac2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.1.98</RegistryNumber><NameOfSubstance UI="D056464">Histone Deacetylase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Mar;10(3):122. doi: 10.1038/nrneurol.2014.19.</RefSource><PMID Version="1">24492351</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="Y">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015816" MajorTopicYN="N">Cell Adhesion Molecules, Neuronal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019175" MajorTopicYN="N">DNA Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018691" MajorTopicYN="N">Excitatory Amino Acid Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056464" MajorTopicYN="N">Histone Deacetylase 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008564" MajorTopicYN="N">Membrane Potentials</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="Y">Memory Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051783" MajorTopicYN="N">Methyl-CpG-Binding Protein 2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24441681</ArticleId><ArticleId IdType="doi">10.1038/nn.3618</ArticleId><ArticleId IdType="pii">nn.3618</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Pharmacol Exp Ther. 2009 Apr;329(1):290-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19168708</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1998 Jun;19(2):187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">9620779</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2002 Jul 19;297(5580):353-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Mar 13;104(11):4676-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17360583</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 May 12;70(3):468-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21555073</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2012 Aug;72(2):269-77</Citation><ArticleIdList><ArticleId IdType="pubmed">22926857</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 2010 Dec;31(12):605-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20980063</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2011 Oct;44(1):142-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21757005</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharmacol. 2011 Feb 25;653(1-3):26-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21147092</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2012 Oct 18;76(2):410-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23083742</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1997 Nov 1;17(21):8187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9334394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 1999 Oct-Nov;9(7):722-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10554995</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4882-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19225110</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2006 Sep;12(9):1005-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16960575</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1998 May 28;393(6683):386-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9620804</ArticleId></ArticleIdList></Reference><Reference><Citation>Learn Mem. 2004 Jul-Aug;11(4):447-52</Citation><ArticleIdList><ArticleId IdType="pubmed">15286183</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 6;72(1):3-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21982363</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2010 Feb 26;37(4):457-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20188665</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011 Apr 29;6(4):e19430</Citation><ArticleIdList><ArticleId IdType="pubmed">21559374</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 Oct 6;72(1):72-85</Citation><ArticleIdList><ArticleId IdType="pubmed">21982370</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2009 Nov;12(11):1361-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2011 Oct 09;17(11):1448-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21983856</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2011 May 12;70(3):379-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21555066</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2013 Jan;38(1):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22781840</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 1998 Dec 28;143(7):2009-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9864371</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Apr 29;280(17):17312-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15723836</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Stem Cell. 2009 Dec 4;5(6):624-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19951690</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2003 Sep;12(3):723-34</Citation><ArticleIdList><ArticleId IdType="pubmed">14527417</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2011 Sep 27;50(38):8127-37</Citation><ArticleIdList><ArticleId IdType="pubmed">21838267</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2006 Oct 19;52(2):255-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17046689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Apr 21;30(16):5617-28</Citation><ArticleIdList><ArticleId IdType="pubmed">20410114</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Biol. 2012 Jul;32(14):2894-903</Citation><ArticleIdList><ArticleId IdType="pubmed">22615490</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2010 Sep 1;169(3):1296-306</Citation><ArticleIdList><ArticleId IdType="pubmed">20538041</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci Res. 2010 Feb 15;88(3):469-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19774677</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Cell Dev Biol. 2011;27:631-52</Citation><ArticleIdList><ArticleId IdType="pubmed">21721946</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Struct Biol. 2011 Dec;21(6):735-43</Citation><ArticleIdList><ArticleId IdType="pubmed">21872466</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Neurosci. 2006 Jan;29(1):21-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16337696</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Oct 15;28(42):10576-86</Citation><ArticleIdList><ArticleId IdType="pubmed">18923034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 May 7;459(7243):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19424149</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Feb 2;31(5):1688-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21289177</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Feb 29;483(7388):222-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22388814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Jul 17;14(8):1001-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21765426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2005 Apr 13;25(15):3824-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15829634</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Oct 16;455(7215):903-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18923512</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Pharmacol. 2012 Feb 10;3:14</Citation><ArticleIdList><ArticleId IdType="pubmed">22363284</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2013 Mar;34(3):791-804</Citation><ArticleIdList><ArticleId IdType="pubmed">22795792</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 May 5;160(2):348-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19258026</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Neurosci. 2004 Nov;27(3):306-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15519245</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Oct;9(10):953-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15098004</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Nov 11;468(7321):253-62</Citation><ArticleIdList><ArticleId IdType="pubmed">21068834</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Cell Biol. 2011 Feb;89(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21326358</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2012;35:49-71</Citation><ArticleIdList><ArticleId IdType="pubmed">22540979</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2010 Feb 10;30(6):2115-29</Citation><ArticleIdList><ArticleId IdType="pubmed">20147539</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Jun 1;31(22):7951-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21632916</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Feb 25;307(5713):1324-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15681343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2011 Dec 7;31(49):17800-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22159096</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Sep 27;14(10):1227-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21952260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 15;13(2):159-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2012 Dec;37(13):2780-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22871918</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2003 Feb 14;278(7):4806-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12473678</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24448836</PMID><DateCompleted><Year>2014</Year><Month>03</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>Predicting Alzheimer disease with &#x3b2;-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing.</ArticleTitle><Pagination><StartPage>905</StartPage><EndPage>913</EndPage><MedlinePgn>905-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.24040</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Biomarkers for Alzheimer disease (AD) can detect the disease pathology in asymptomatic subjects and individuals with mild cognitive impairment (MCI), but their cognitive prognosis remains uncertain. We aimed to determine the prognostic value of &#x3b2;-amyloid imaging, alone and in combination with memory performance, hippocampal atrophy, and apolipoprotein E &#x3b5;4 status in nondemented, older individuals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 183 healthy individuals (age = 72.0 &#xb1; 7.26 years) and 87 participants with MCI (age = 73.7 &#xb1; 8.27) in the Australian Imaging, Biomarkers, and Lifestyle study of ageing were studied. Clinical reclassification was performed after 3 years, blind to biomarker findings. &#x3b2;-Amyloid imaging was considered positive if the (11) C-Pittsburgh compound B cortical to reference ratio was &#x2265;1.5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Thirteen percent of healthy persons progressed (15 to MCI, 8 to dementia), and 59% of the MCI cohort progressed to probable AD. Multivariate analysis showed &#x3b2;-amyloid imaging as the single variable most strongly associated with progression. Of combinations, subtle memory impairment (Z score = -0.5 to -1.5) with a positive amyloid scan was most strongly associated with progression in healthy individuals (odds ratio [OR] = 16, 95% confidence interval [CI] = 3.7-68; positive predictive value [PPV] = 50%, 95% CI = 19-81; negative predictive value [NPV] = 94%, 95% CI = 88-98). Almost all amnestic MCI subjects (Z score &#x2264; -1.5) with a positive amyloid scan developed AD (OR = &#x221e;; PPV = 86%, 95% CI = 72-95; NPV = 100%, 95% CI = 80-100). Hippocampal atrophy and &#x3b5;4 status did not add further predictive value.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Subtle memory impairment with a positive &#x3b2;-amyloid scan identifies healthy individuals at high risk for MCI or AD. Clearly amnestic patients with a positive amyloid scan have prodromal AD and a poor prognosis for dementia within 3 years.</AbstractText><CopyrightInformation>&#xa9; 2013 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher C</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Austin Health, Department of Nuclear Medicine and Centre for Positron Emission Tomography, Heidelberg, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourgeat</LastName><ForeName>Pierrick</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Ellis</LastName><ForeName>Kathryn A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Belinda</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Yen Ying</ForeName><Initials>YY</Initials></Author><Author ValidYN="Y"><LastName>Mulligan</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Gareth</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Maruff</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Woodward</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Robins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tochon-Danguy</LastName><ForeName>Henri</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>O'Keefe</LastName><ForeName>Graeme</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pike</LastName><ForeName>Kerryn E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Szoeke</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Salvado</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Macaulay</LastName><ForeName>S Lance</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>O'Meara</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Head</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cobiac</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Greg</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Ames</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Villemagne</LastName><ForeName>Victor L</ForeName><Initials>VL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24448836</ArticleId><ArticleId IdType="doi">10.1002/ana.24040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24450891</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>370</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.</ArticleTitle><Pagination><StartPage>322</StartPage><EndPage>333</EndPage><MedlinePgn>322-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1304839</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) &#x3b5;4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE &#x3b5;4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE &#x3b5;4 allele carriers but not in noncarriers.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE &#x3b5;4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From Butler Hospital, Providence, RI (S.S.); Brigham and Women's Hospital, Boston (R.S.); University College London, Institute of Neurology, London (N.C.F.); University of G&#xf6;teborg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden (K.B.); University of Pittsburgh, Pittsburgh (W.K.); Veterans Affairs Medical Center, Seattle (M.R.); Cleo Roberts Center for Clinical Research/Sun Health Research Institute, Sun City, AZ (M.S.); Columbia University (L.S.H.) and New York University Langone Medical Center (S.F.), New York; University of Rochester School of Medicine and Dentistry, Rochester, NY (A.P.P.); Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA (M.R., N.K., B.N., V.G., M.M., D.W., Y.L., I.C.T., E.L., E.Y., H.R.B.); Janssen Research and Development, Titusville, NJ (J.L.); Global R&amp;D Partners and the University of California, San Diego - both in San Diego (M.G.); and Pfizer, Collegeville, PA (R.B.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Raskind</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Honig</LastName><ForeName>Lawrence S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Ferris</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Reichert</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>Nzeera</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Nejadnik</LastName><ForeName>Bijan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Guenzler</LastName><ForeName>Volkmar</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Miloslavsky</LastName><ForeName>Maja</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Lull</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tudor</LastName><ForeName>Iulia Cristina</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Enchi</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Yuen</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Brashear</LastName><ForeName>H Robert</ForeName><Initials>HR</Initials></Author><Author ValidYN="Y"><CollectiveName>Bapineuzumab 301 and 302 Clinical Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00574132</AccessionNumber><AccessionNumber>NCT00575055</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MR/K013041/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG008051</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L501517/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080820</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>IK2 BX001820</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>G0902227</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50 AG005136</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>NC11WKO35D</RegistryNumber><NameOfSubstance UI="C545458">bapineuzumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.</RefSource><PMID Version="1">24450897</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892.</RefSource><PMID Version="1">24570189</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.</RefSource><PMID Version="1">24716688</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.</RefSource><PMID Version="1">24724181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004487" MajorTopicYN="N">Edema</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weisman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diamond</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casher</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rhodes</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olivia</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Years</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenzweig</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boruta</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blue-Schaller</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGowan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wurziger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yalkinoglu</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wurziger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirsch</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spirling</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohnesorge</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kluge</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCartney</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stubbs</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweeney</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santangelo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiCarli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingram</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jutras</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shay</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGlew</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warner-Coviello</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nandan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rees</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iqbal</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naqvi</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stair</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacob</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malik</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghumman</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naqvi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gulati</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thaker</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spano</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dietrich</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henning</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hessel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Permann</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaefer</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstrong</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schleining</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>English</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wodushek</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernhardt</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Denny</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermann-Gertz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eggers</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittlitz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dittrich</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germander</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jahn-Gertz</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zahrend</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kollewe</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grotius</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nevin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cioppa</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clemins</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roe</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regan</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forchetti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaishnavi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanfilippo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leahy</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilat</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Layne</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiss</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubox</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stelton</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merideth</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGregor</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlinder</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badal</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kay</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>R</ForeName><Initials>R</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Okolisan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frech</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerio</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmichael</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blair</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdoom</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempsey</LastName><ForeName>G M</ForeName><Initials>GM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempsey</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winterkorn</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munoz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riddle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seaman</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazis</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strange</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durden</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spear</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ettigi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atri</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnhardt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saiyed</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koduru</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilliam</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petree</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walthour</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hegab</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hines</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nazmy</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilliam</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartsook</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damski</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herskowitz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gran</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortiz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lino</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herskowitz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Creel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ocana</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zacharis</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brownstone</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garmany</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nystrom</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brucher</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharp</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zacharias</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shioshita</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemme-Raup</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teague</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asheim</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shua-Haim</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clayton</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shua-Haim</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poole</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahuja</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheshun</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shua-Haim</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pabon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehra</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porras</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryant</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartolome</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharif</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kortman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovacs</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chini</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markind</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Culligan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonwetsch</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richter</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peters</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neumann</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girgenti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glicklich</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosales</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelikan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torabi</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gereg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lasher</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauro</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Onofrio</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bobulinski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pennarola</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cappillino</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zagar</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siegel</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palmer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAllister</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czapka</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bebon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadimi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cretella</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottschalk</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gross</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reis</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Del Vecchio-Scully</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toothaker</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Termine</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dankwah-Quansah</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kingson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castaneda</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miner</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castelot</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Twyman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chumley</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cecil</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinley</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heckler</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yearsley</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodgers</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shirley</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coates</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adkisson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCreary</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knox</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stobbs</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alva</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alva</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellogg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lykke</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabe</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shih</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuller</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voss</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malone</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuller</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weaver</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittelsrud</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erpenbach</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Syverson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinker</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFollette</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheth</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ageton</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurd</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ehli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodd</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarate-Rowell</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibraheem</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Razinia</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valdes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodero</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safranko</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yoo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cascione</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sergay</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vila</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunamker</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kilian</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andia</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scalf</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donharl</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branscum</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tariot</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yaari</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chavira</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dennis-Busier</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seward</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weir</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monarrez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Branch</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langbaum</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohammand</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullen</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodwin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleisher</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jakimovich</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costanzo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drimer-Kagan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holt</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>High</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saunders</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richter</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vadovicky</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salomon</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frantz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minero</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langlois</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chana</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Media-Rodriguez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeFranc</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luk</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez-Lujan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holladay</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cottam</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shill</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Connor</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allinich</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sala</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Covert</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ceimo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molnar</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malek-Ahmadi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karoll</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rangel</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delco</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohl</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montalvo</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chong</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doody</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rountree</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipscomb</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chowdhury</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bishop</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorton</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powers</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villaneuva-Meyer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Awosika-Olumo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawson</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heggins</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bronson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wideman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karagol</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capriles</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monk</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hittle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Severa</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kersten</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Douglas</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liggett</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knapp</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gransberry</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verdon</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Audet</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauwens</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aspinwall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goetting</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouma</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rauch</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packard</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kothi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timpe</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNett</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moorman</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skaf</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mehta</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hotchkiss</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fields</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taborn</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cutler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moorman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jawahir</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berker</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stern</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kopits</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barest</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nadgir</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandell</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gokce</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mwicigi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossi</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Callaghan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sakai</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hong</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raghavan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joshi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGowan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiCarli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qui</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>McElveen</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberston</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Byerly</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roman</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woods</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dowell</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roby</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuentes</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohler-Sampson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marino</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foil</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morran</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noorani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brody</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berger</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hackebeil</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbati</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bouchard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kung</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauceri</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinoza</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuquay-Scolari</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tobin</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wahlestedt</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rentz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGinnis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atri</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Searl</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperling</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frishe</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vitolo</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amariglio</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Carli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vander Vliet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horkey</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larvie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donovan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorius</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boot</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapir</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roy</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seiden</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caso</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piloto</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilera</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosche</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rex</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grnja</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berrios</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guzman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Habib</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gravelle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latour</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>De hartog</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yamin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loy-English</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salloway</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lederer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fennelly</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackham</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Primack</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monast</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kechichian</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sofios</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santoro</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mello</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maxwell</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rickler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tirpaeck</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerue</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piryatinsky</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Carli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsland</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Read</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mikos</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medeiros</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinney</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahl</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thurstin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>May</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeves</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garner</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steele</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tolbert</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindbergh</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redwine</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savage</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maiorca</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKenna</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vickeri</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherif</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khalafallah</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicz</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saillard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gee</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gvozdjan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clark</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pesce</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kofalt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tape</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstone</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oladapo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franklin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soufer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabideau</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berardi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koliani</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeLuca</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lebowitz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levinson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubenstein</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edelsohn</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnaudo</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carunchio</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fink</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paradise</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenberg</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yu</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killar</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mueller</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenbaum</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leschek-Gelman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesem</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clay</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timmons</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katic</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Claghorn</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalimuddin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Libo-On</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malit</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernick</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sholar</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramani</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munic-Miller</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vranesh</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Venkatesh</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kluge</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geiser</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newland</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koneru</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viens</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keene</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mather</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macpherson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartmann</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michie</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biton</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sillivan</LastName><ForeName>J Retherford</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landers</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollis-Holderfield</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hemphill</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biton</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSantis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Annas</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunze</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lail</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherr</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campopiano</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobkin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard-Aasen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Champ</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dutka</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Celanovic</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minkel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belt</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flamm</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasdan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clegg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duncan</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moutz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gautier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Champ</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravella</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulford</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Usher</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warach</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cass</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joslin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Balenger</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conroy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gruber</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keefe</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gajaraj</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Omidvar</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goenjian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walling</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mori</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arceo</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segui</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabral</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iler</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonomo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freinhar</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemp</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Issa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bui</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marlotte</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Britton</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lachica</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Webb</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guinto</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaky</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Te</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanimura</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fukuma</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lloyd</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wise</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lam</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Botros</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosas</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyd</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gladding</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norris</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parikh</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stephens</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waight</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ho</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorine</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramezan-Arab</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yang</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kashani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spoor</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayele</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honig</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicki</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dominguez-Rivera</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tejeda</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ichise</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordillo</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mules</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rocha</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinerman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noble</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curtis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dever</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Creamer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mele</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heurich</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romm</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonough</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schubert</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairbank</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonyea</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryant</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMahon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniels</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foust</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanton</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Afolabi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romm</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davila</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardcastle</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoeckendorf</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagenseller</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joseph</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brudon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasca</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ball</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Licht</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakst</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaudhary</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barie</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da Pena</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cantu-Reyna</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Paur</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yagi</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bujarski</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clough</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexandre</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bingham</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nixon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurlbut-Styke</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torok</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lonquist</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mungari</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strasser</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramierz</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Earl</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engstrom</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scholl</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesselyong</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grove</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drotning</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edgelman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scriviano</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turknett</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarbrough</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas-Seaton</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vedanarayanan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Previto-Craft</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruflodt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krendel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiff</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssami</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Townsend</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazeale</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohajermilani</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cutsuries</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Micheli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruflodt</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flemister</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiting</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gbadebo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caltabiano</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazelrig</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stein</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toups</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coney</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stenstrom</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saroukhanians</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maack</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chee</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crain</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirkland</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chuck</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Englander</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tedesco</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christiansen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stacey</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Converse</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bermak</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eicher-Raymond</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kron</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisch</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tatum</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Florer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morimoto</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Germain</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girard</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boismenu</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doucet</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pare</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergeron</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanasse</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeGrace</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marks</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corwin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cunio</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricks</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brogna</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schober</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferraro</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Carli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madore</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birbiglia</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsons</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kearney</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelissier</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orzechowski</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nair</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desautels</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azzoug</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacher</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dastoor</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thavundayil</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bossy</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anton</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dai</LastName><ForeName>X</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sully</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niazi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Legare</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadulina</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papazova</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subramanian</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radulescu</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lippa</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gliebus</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosso</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silversteen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hepler</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irwin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koenigsberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulandaivel</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kazmi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paylor</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durmala</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kharkar</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalanuria</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ambady</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eppig</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieves</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mbeo</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kabasakalian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spruill</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beyer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellegers</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Husn</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gersing</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aiello</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burks</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lateef</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gang</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wrubel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jehle</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macarewich</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nielsen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wexler</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lockhart</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barber</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wesson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nolan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrisler</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prausnitz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaietta</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macmillan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vyas</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murillo</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallace</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadam</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swami</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooke</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolsterman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kadari</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vashist</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modarresifar</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheini</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massey</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidic</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitdenhowen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliot</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelletier</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siatczynski</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodwin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hapner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiedler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quakenbush</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naeem</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Igleburger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aubert</LastName><ForeName>F</ForeName><Initials>F</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Briggs</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Page</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grantham</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lomax</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillippi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talor</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piacente</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pakutinski</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levey</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lah</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tune</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stout</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cellar</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meng</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ollivierre</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masterson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wingo</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strozier</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson-Hazan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hales</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stennett</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zanders</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozarsky</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huh</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perkins</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Button</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boorse</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Button</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>DePalma</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Senzon</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Staunton</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goodman</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rieben</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rampersad</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lowenstein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saffioti</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Metz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berko</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upadhyay</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batwin</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fogel</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keilson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casale</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerbers</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bustos-Wyss</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gupta</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curfman</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sible</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elias</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobsiger</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Frazine</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cecil</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grumley</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pittard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stricklin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallace</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Massey</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunning</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wentworth</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sowash</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dome</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>E</ForeName><Initials>E</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Adamson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moller</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adamson</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCoy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grubbs</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Middleton</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibata</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kolawole</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Browning</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schultz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berokowitz</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gebrou</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawrence</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aisen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tornatore</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duarte</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janicic-Kahric</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zielinska</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sita</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevenson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redington</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Apter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Southwick</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blyskal</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doring</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Procaccini</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergner</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aamir</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shim-Chim</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gajian</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schafer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raymond</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tabachnik</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siddique</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrington-Dix</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kogan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacFadden</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shechet</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soika</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selivra</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott-Igoe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shamel</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostertag</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davillo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfson</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnhart</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castro</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dean</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinehart</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cermin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarbrough</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas-Seaton</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vedanarayanan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Previto-Craft</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruflodt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krendel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiff</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssami</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Townsend</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazeale</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohajermilani</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cutsuries</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Micheli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruflodt</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flemister</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiting</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gbadebo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caltabiano</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazelrig</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Archer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aultman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burks</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crimmins</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dickson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helveston</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lynn</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maksi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIlwain</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinard</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starrett</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Szatmary</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Warren</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shatz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lemere</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holmes</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pabla</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eilya</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerghet</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reuther</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozak</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mussomeli</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barricks</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fenton</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamann</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumble</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carothers</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trncic</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saber</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlos</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kloos</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallace</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nambron</LastName></Investigator><Investigator ValidYN="Y"><LastName>Subasic</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiStefano</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carpenter</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chong</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chrvala</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stankovic</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawenski</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bessette</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferries</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burk</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robillard</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bocti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charette</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chayer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Comeau</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demers</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lachance</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lachapelle</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lepine</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trouve</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reid</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAvoy</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peltsch</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanstone</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breen</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chesney</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowes</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohlenberg</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stec</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strehlow</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daniels</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobratz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koplin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doria</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winter</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koplin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hake</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rexroth</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Havison</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fleming</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donadio</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turchi</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lim</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Hook</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klank</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cavanaugh</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zauber</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chehrenama</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stark</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khosla</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shadley</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullins</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergsrud</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullins</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alway</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrison</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>McCarroll</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poss</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garza</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeatts</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hendrix</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Jesus</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyes</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansalone</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crenshaw</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lester</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damon</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiwach</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sureddi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaels</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siwach</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buckner</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shiwach</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jon-Ubabuco</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marchand</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peters</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawyer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galindo</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heritage</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rana</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marek</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fussell</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uy</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stottle</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gazda</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neiman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Delden</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleinguenther</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ales</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoyler</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smitley</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mapa</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lester</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mappes</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luncefold</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dib</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garza</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villasenor</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krumbholz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munoz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davtian</LastName><ForeName>Ar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davtian</LastName><ForeName>As</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tananyan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilavian</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Santos-Alonso</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romero</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lasky</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kochumian</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booker</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kessel</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burr</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booker</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrus</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrison</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sonnier</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bushnell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pilcher</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rovner</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carsello</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liang</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maloney</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McElwaine</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadaka</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sailor</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaffer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tisera</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kornsey</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldenstein</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cardona</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomson</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michaelson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barron</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Manna</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calideen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benedict-Somich</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andew</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardila</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bondurant</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chanti-Ketteri</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Everidge</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrison</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luhn</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malek-Ahmadi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCasland</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Ramos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savage</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sneed</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tetan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ventura</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whelan</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owens</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergey</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brasic</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dieter</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gogel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guevara</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marano</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ye</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watkins</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wittmer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Standfield</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chamberlain</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordineer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingram</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knowles</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Downer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edington</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartoli</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsay</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chertkow</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaitekunas</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelner</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitehead</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosein</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kape</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Babins</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marques</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergman</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yadalam</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woodard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novak</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrett</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardiner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laughlin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Victory</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doucet</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saucier</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashworth</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Applebaum</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCabe</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Acuna</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Copeland</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biunno</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dahmes</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traylor</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigler</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemery</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jubelin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talwar</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Minagar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elliott</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shneyder</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reddy</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Booth</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jinkins</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinkston</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khandelwal</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bridges</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiegel</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lafitte</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lafitte</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bezucha</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chalamidas</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGee</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golas</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rujescu</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clauss</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genius</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dammer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bitzer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buschert</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoessler</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benninghoff</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Autenrieth</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Randhawa</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arledge</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aven</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bow</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferguson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Green</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heinzig</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howorth</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imes</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawson-Allen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narula</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringrose</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robert</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skaggs</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tirado</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dinnerstein</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannon</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howard</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaminow</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beaulieu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henninger</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margolin</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margolin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ossinalde</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agustin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morino</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamel</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norwood</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basi</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graff-Radford</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ertekin-Taner</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kistler</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fletcher</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pao</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molano</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haukom</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neil</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maroney-Smith</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCormick</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schriever</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tangalos</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swenson-Dravis</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxter</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albers</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellison</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harper</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forester</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wodward</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Carli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malloy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jordan-Arthur</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antuono</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franczak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravanelli-Meyer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antuono</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koschnitzke</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krouwer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sugden</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banks</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Novic</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadedorn</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Templin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klink</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nygro</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilks</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zapata</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alonso</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bedoya</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cymberknopf</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torres</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du Preez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swart</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicic</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kubanska</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shillington</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynoso</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Outram</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loring</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matheson-MacLean</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benoit</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hattrick</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shillington</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacLeod</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hibbert</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barkhuizen</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIntosh</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kooy</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fowler</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindsay</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belik</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gates</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pretorius</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bredenkamp</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thebaud</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romain</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greco</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ball</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liss</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canedo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaplan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidhpura</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madril</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Price</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Appledorn</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toffler</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pitman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herbst</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frost</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couturier</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfe</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brawman-Mintzer</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faison</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hatchell</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craig</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flynn-Longmire</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucas</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown-Jenkins</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broadway</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porter</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dempsey</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cherry</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirbach</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lange</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerenzia</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stuckey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravenel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weichsel</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashby</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DesMarteau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacDonnell</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rumboldt</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>E</ForeName><Initials>E</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Pursley</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safrit</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Speakman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holycross</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunsicker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snider</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snider</LastName><ForeName>S Ennis</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynham</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Modlin</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mills</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dal-Bianco</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wieszmuellner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werner</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rapf</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehrner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Assem-Hilger</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moser</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peuhringer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sieczkowski</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Imre</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ratzinger</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolinar</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lechner</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reinhart</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Homayoon</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrovic</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leitner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pichler</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Radl</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dandapani</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gulk</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anthony</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beckner</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunter</LastName><ForeName>W</ForeName><Initials>W</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuczinski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainwater</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wallinger</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasile</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferguson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farmer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lefebvre</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cameron</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shafer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zarrella</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hensely-Oaten</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCoeur</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agronin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adorno</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bishop</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riveros</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newton</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cole</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colina</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Philord</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mestre</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silverman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Centeno</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miloslavich</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barnett</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryant</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alalu</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarado</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiner</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohrman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pardo</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pino</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rey</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas-Vasquez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berriors</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Amador</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arguelles</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramires</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheldon</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padilla</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racher</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beltran</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reyno-Ramos</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosales</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capdevilla</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suarez</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bello</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hurtado</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Acosta</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bozoki</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goudreau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flatley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doerr</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGhee-Helmy</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leiter</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillespie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snider</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wehner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spallinger</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaps</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doneson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mann</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Mello</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leipprandt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bielski</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schramm</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Defever</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rice</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinheiro</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrison</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frank</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee-Livingston</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapper</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klapper</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gossen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parks</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greaves</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waldman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winegarner</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feaster</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Shea</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowee</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dall</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kreshel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karr</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Town</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cannon</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemble</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cone</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schell</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>English</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilbert</LastName><ForeName>R</ForeName><Initials>R</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Court</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilhite</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Serbanescu</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallagher</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shindell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schimming</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marzloff</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vigario</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lundquist</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corn</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karani</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charney</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mirigliani</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivas</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neugroschi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tipiani</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Romirowsky</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomara</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liption</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De la Pena</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernando</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarreal</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmeltz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belzer</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zillka</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blumenthal</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adolphson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bayer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beck</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowardin</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dietze</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haire</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herstein</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoffnung</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madhavan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melgoza</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oborny</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orr</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padala</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phillips</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scholl</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweeny</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taghavi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tefft</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spikol</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Varrato</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isayev</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbour</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castaldo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liew</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ottinger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenny</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kanchana</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knapp</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swiatek</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McElhenney</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clauser</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walicki</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galuska</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cain</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerrone</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dondero</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nabhan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malhotra</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malhotra</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faust</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masters</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagner</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirkland</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hellgren</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorfman</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eldeo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyce</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoopingarner</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cobb</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackford</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyce</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gehret</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nussbaum</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyal</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swank</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaidi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curry</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norwood</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biber</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilpatrick</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stein</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Carli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanton</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scinto</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scofield</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrios</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atkinson</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oster</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devine</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoukimas</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rimmer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cincotta</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMillian</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burkholder</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrefsky</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bavis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berke</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhagat</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casanova</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al Jaberi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadeghian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stalker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakore</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hagen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Concialdi</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duszynaki</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gednetz</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruppenthal</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tramontano</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redling</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilder-Willis</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sangama</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinrichs</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tennyson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genkin</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonk</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glassmoyer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendez</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capstraw</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noye</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernardo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammond</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdloff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarras</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenzweig</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearlman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Todd</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weitz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flaten</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holub</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xynellis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markert</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torpey</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Sr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Olin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohn</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gatus</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irwin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Magliulo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McAteer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brann</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upright</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sellman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Button</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairbank</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collins</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellsworth</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kudrow</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarema</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arreloa</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Latorre</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasquez</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valdez</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hung</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbon</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honeycutt</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isa</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieves-Quinones</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera-Castelao</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leli</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petit</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holley</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Honeycutt</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waldman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mossa</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciabarra</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slaven</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armstrong</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fani</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ornelas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittur</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowley</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chapman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graziano</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poiesz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shrestha</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sprague</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stratton</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Verman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhagavatula</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blumner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goriganti</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vertino</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schad</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pulvino</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stein</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Segal</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rucker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandidge</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradley</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Landy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasu</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerard</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanza</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michalak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morran</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hansen</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corsoe</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicula</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sindilar</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlesinger</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chauhan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parameswaran</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jagani</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dos Santos</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marinoff</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wace</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaikh</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rasile</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mistry</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chaudhary</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saha</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maheswaran</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wainberg</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wace</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strilchuk</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstick</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flexman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiemerslage</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armantrout</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pence</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>McOwen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Decker</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weller</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritter</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kussman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kusko</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chueh</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schermerhorn</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drancea</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scarpino</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Badrtalei</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ortiz</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hasso</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hess</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brokenbourgh</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaerf</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keown</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouaou</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaerf</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bannester</LastName><ForeName>C</ForeName><Initials>C</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Black</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Driscoll</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mowzoon</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carracino</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polley</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edgecomb</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mather</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roby</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Votolato</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylvester</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harvey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramarz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holt</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nasreddine</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berger</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clement</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fillatrault</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boulanger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Amour</LastName><ForeName>C Pinard</ForeName><Initials>CP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laure</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robidoux</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Collin</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gimard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laprade</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milot</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trepanier</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laperle</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robillard-Roy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lafreniere</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Melo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gauthier</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Primeau</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blaquiere</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ostiguy</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bashara</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bednar</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Axt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hess</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciliberti</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parise</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willis</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shreefter</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallagher</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macchi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noto</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mansen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleiner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kloman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamoureaux</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clionsky</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marshall</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kittler</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandey</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majchrowski</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vittone</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsey-Rosenheim</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalinowsky</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plager</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCauley</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reynolds</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leland</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weslowski</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nash</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schindler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turknett</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yarbrough</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas-Seaton</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vedanarayanan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruflodt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craft</LastName><ForeName>L Previto</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Townsend</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Houssami</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brazeale</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rozin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krendel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiff</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mohajermilani</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cutsuries</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michelli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meltzer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brufoldt</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flemister</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whiting</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gbadebo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caltabiano</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hazelrig</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudd</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shubin</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dow</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edge-Booth</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNamara</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Philpott</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plemons</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sider</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gywnn</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freschi</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walton</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinow</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burks</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>2nd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Lees</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmechel</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jolly</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howard</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Washburn</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Synn</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whisnant</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colvin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bucher</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weldman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chua</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Putty</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scully</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vance</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laguna</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Putty</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caffrey</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dalby</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saul</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schroeder</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesulam</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borosh</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regalado</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipowski</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gliebus</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilpin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weaver</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gitelman</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottfried</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Musil</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agugliaro</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baquiran</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blinkoff</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Epstein</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferris</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Golomb</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ku-Pang</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lew</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monteiro</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moutoussis</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pogorelec</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sierra</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sollins</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torossian</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wisniewski</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yunger</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zichlin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zweig</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gurnani</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinn</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaye</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silbert</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wild</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sommer</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erten-Lyons</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lear</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Larsen</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buracchio</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanko</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salazar</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loree</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mikszewski</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mai</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nattrass</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vogt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hadford</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Birk</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuchman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>York</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Punchowski</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanford</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pratt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schleyer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skiles</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuchman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCallister</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carta-Sanchez</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rahe</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iwasz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foley</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Breuer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferazzoli</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forde</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Percicles</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tannazzo</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chintakayala</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhutaney</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waites</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andreoli</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quadri</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seide</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borrie</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>AlAama</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Best</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burham</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mardin</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poirier</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>To</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truemner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viger</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huege</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCoubrey</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rockwell</LastName><ForeName>K</ForeName><Initials>K</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Janis</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunez-Lopez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Combs</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubroff</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brookstein</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivera-Colon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rehrig</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newberg</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rooney</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rousseau</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alsina</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arana</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berreiro</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrasco</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cesar</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cunningham</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isla</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mejia</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskooilar</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilcox</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Francisco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guevarra</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tong</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiser</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thach</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manuputty</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grosz</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiser</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskooilar</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilcox</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrissey</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stotts</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flowers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panlilio</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oskooilar</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilcox</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Francisco</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guevarra</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tong</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heiser</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cabrera</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thach</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manuputty</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kwentus</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nhema</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chandler</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagwell</LastName><ForeName>R</ForeName><Initials>R</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Couey</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cipriani</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drain</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kessel</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Layne</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moreno</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sununu</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tirana</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Villena</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wingkun</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winner</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolfson</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zuniga</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pernsteiner</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mega</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huddleston</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curtis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timmins</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernards</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moses</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smoot</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Migaki</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edmondson</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siaroff</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cave</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackey</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burkley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlini</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Narus</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dibb</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hehn</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaasko</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milhoun</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicols</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duffy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heath</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nieto</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>George-Strader</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espasadin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jamieson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jack</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeLaney</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harkleroad</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rogers</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Killen</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Gandara</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedraza</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pantuso</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herr</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilgoren</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komlos</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranjan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sedenik</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sofianos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manuel</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campbell</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couture</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Broadway</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carnes</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Naslund</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hales</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabr</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glenn</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hull</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Konanc</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrell</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freedman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yerramsetty</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tim</LastName><ForeName>R Chan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perkins</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starnes</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butler</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Downs</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conder</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farley</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garriss</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strickland</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yelton</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chakraburtty</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrus</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teague</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerden</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smela</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dasharathy</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aven</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>M McCall</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holland</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cox</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greyson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waugh</LastName><ForeName>K Reid</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandle</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grandle</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corbin</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frotmann</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nardandrea</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clevinger</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riddle</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Culp-Papierniak</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yordan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patterson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Craggs</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sloan</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phanumas</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Pena</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De La Pena</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shrestha</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rai</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thapamagar</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cunningham</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dedovic</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neupane</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haupt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malla</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subedi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ott</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Astphan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxerman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bricusse</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daiello</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erbozhurt</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faucher</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaynor</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knott</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazar</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oden</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querfurth</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizvi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremont</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoukides</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cimini</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cerullo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rainville</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teixeira</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoukides</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nolan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritzau</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodgers</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Keegan</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luis</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hawkins</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parrish</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rickard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moritz</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordano</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burke</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lincoln</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stilson</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arthur</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillett</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rindfleisch</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grantham</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koepf</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lund</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reed</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bakski</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mc Mearty</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ventura</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kluge</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geiser</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newland</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koneru</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Viens</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keene</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morgan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mather</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macpherson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartmann</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michie</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bettinger</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boutwell</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weinstein</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Old</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arkin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobbie</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grau</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Summers</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smithson</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartzman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peters</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rymer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McIntire</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mullen</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milburn</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossberg</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tait</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chibnall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malmstrom</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morefield</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Filla-Taylor</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redden</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eller</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz-Flores</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holzemer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manepalli</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feen</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piriyawat</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fann</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herr</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bassil</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thaipisuttikul</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singh</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engelmann</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gabriel</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kavanagh-Hale</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yee</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ludwig</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marcal</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tindle</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aissi</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gok</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Borden</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishioka</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Targan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Itzcovich-Schuster</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malamed</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schreiber</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ettlinger</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grosz</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resille</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matsoyan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuster</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rose</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labunsky</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svidler</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Neal</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hosseini</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ossinalde</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haider</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winston</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitehead</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eisenberg</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McColl</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burt</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLendon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woodard</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peppard</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burt</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLendon</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woodard</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peppard</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plopper</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ayers</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berkowitz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buda</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cary</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coughlin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dang</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobrina</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geriak</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hessling</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Highum</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>LoCascio</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morache</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolas</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pirlliman</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tecca</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woods</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferencz</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miskin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandler</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiPaolo</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Escandon</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandler</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ala</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elble</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lokaitis</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Popovich</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richey</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zec</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kohlrus</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fritz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vatakis</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fink</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shylman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuryev-Golger</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Starosta</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mogilyansky</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutkin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montoya</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fowler</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stengel</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thursby</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holt</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shahzad</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henegar</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livingston</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutzmer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wightman</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flanagan</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melchionna</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorrell</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panasci</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallaher</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGovern</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lapponese</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenstein</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stedman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herrero</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pea</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dagon</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drum</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallery</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pea</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackmer</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rossignol</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eubanks</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carulli</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pea</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maloney</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheppf</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Urive</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altemose</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blazek</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carver</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pasternak</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kertesz</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finger</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morlog</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pantazopoulos</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jesso</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Losk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ottum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adamoski</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nelson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crider</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conrad</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horton</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergthold</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wellnitz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plank</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marambe</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yeo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasquez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Dio</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lash</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tearney</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Passaro</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cutie</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Di Mattia</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Triana</LastName><ForeName>S</ForeName><Initials>S</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Copil</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwartz</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maniar</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dokson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Padilla</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seliger</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Camacho</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Castleberry</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wetherill</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galindo</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaspar</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Puyot</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Au</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kile</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Au</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olsen-Wilson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donnel</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benabides</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolnak</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ishaque</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkin</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Packard</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vassilenko</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tunell</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenfield</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chafetz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benfield-Phillips</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blansit</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hastings</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Leary</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Q</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marotta</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poisinelli</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allan</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gandell</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pitcher</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tersigni</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Accarrino</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dopslaff</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Attardo</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornejo</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sacareni</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sedran</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ng</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ronchi</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsui</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacolor</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ervin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradshaw</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brouillette</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ervin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wyatt</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bedford</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jokerst</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biggs</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sachedina</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marquez</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tyson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sandefur</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hager</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Irwin</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacPhall</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eldridge</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Box</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacques</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendland</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalafer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pressman</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummins</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkening</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dobi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geiger</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lombardo</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solomon</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Catapano-Friedman</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stitelman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazzola</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Little</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Budson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgher</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michalcuzk</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paro</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hearst</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redlich</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burgher</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richards</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markowitz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dufort</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reif</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flether</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desai</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacMillan</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doyle</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaccarelli</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donovan</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aponte</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dioguardi</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadlon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothschild</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bradley</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ponugoti</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodala</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donne</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilder-Willis</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gomez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ornstein</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koempel</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kundla</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gartner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharre</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agrawal</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>deRoche</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferguson</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grothause</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Himes</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Icenhour</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kataki</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keddie</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostyk</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovesci</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoicea</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vrettos</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wessner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobatz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blumenfeld</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heinen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schim</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chippendale</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neill-Conover</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadoff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soto</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frishberg</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahagian</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tenorio</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinkle</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brower</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hubbard</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roger</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jerez</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hensgen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bumby</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobatz</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blumenfield</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heinen</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schim</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chippendale</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neill-Conover</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadoff</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soto</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frishberg</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahagian</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tenorio</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinkle</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oh</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brower</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banker</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lerner</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foxhall</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogrocki</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>L</ForeName><Initials>L</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banchy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sami</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahern</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hishaw</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merski</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carmody</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norris</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Godard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Skiver</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sinnard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baldwin</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menchola</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hemmer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seal</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furet</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cohen</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hogan</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muller</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Megarry</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeCarli</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seavey</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweeney</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levallois</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Campos</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barjas-Ochoa</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Butler</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conover</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grill</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ringman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beigi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lu</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quach</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tingus</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pazienza</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benitez</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yi</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rushing</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bardens</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barsuglia</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Medina</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becker</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boxer</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Matthews</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicolson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barton</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fine</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sha</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vossel</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaMarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valcour</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tartaglia</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>De May</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adams</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perry</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haws</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenbloom</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racine</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerchner</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ho</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thibodeau</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arnold</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zizak</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mozer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lubega</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brewer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lehmer</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderswag</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontaine</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peavy</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buchsbaum</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gigliotti</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gonzales</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinoza</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoh</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sun</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Da Pena</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Espinoza</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sherzai</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caccavale</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tam</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Preda</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potkin</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faziola</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kemp</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsey</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pellicer</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plon</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upton</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hannaford</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Highurn</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Milne</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mastrianni</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grant</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freed</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Semmes</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nader</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Austria</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Couldry</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaus</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swerdlow</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Curtis</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Switzer</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bothwell</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laubinger</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arthur</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corey</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahan</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaeffer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skea</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jicha</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howe</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kennedy</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmitt</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cambi</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caban-Holt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holbrook</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fee</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tandy</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sitzlar</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lightner</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nichols</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Everman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Freeman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newsham</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vanderpool</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carr</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smart</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markesbery</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wethington</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dudderar</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fishman</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powell</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barry</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nickerson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderson</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chopra</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheinthal</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forsberg</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palli</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fogle</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elahi</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruchinskas</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiVito</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maslowski</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbas</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heidebrink</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giordani</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lord</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothley</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woon</LastName><ForeName>F</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Votruba</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cline</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hammers</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powells</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Michalski</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coulas</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franti</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McFadden</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bachert</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edmonds</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prestopnik</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adair</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Greinel</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wroblewski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jung</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knoefel</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barrow</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harmon</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aragon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knebl</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heffeman</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hooper</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alvarez</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harty</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davanloo</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patki</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>O</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sweet</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macedonia</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aizenstein</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baumgartner</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarles</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothfus</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doyle</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mountz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heyman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zachariah</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ruszhiewicz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klunk</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDade</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rickard</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenberg</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolk</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salem-Spencer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cole</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bean</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowalski</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stear</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosman</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ciancaglinia</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ardila</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baxter</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casady</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chanti-Ketteri</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chichkova</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fargher</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luhn</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Major</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malek-Ahmadi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutolo</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raj</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sneed</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teten</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ventura</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whelan</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Auchus</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brint</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hennessey</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hickerson</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wahba</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dale</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figures</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kearns</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cucio-Brint</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haykal</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Womack</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Svetlik</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miles</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Acevedo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Phan</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diaz-Arrastia</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lake</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lug</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harrah</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chansard</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koch</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogunnaike</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giesecke</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noe</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitten</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khan</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isah</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eschweiler</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuder-Buletta</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trunk</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niebler</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waechter</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Von Ulardt</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zwarg</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bosch</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ethofer</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riepe</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wigand</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palm</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schiffczyk</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walter-Nebenprufer</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalkan</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altintas</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>von Arnim</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baslic</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gualazzini</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Polivka</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schuck</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donniacuo</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pohler</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfluger</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zamrini</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesley</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kay</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mesley</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plante</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duff</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redd</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Floore</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bersick</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dennett</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dekosky</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geldmacher</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Solorzano</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manning</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Webber</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zieman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damgaard</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ducharme</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermott</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christoper</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson-Heisterman</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Opie</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wooten</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rinehardt</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leone</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pendelbury</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyd</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daley</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumas</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edgren</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrag</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamill</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingvoldstad</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jafree</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kenney</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lenox</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucy</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsh-Reed</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moustakas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oesterle</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peyser</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savage</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shang</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waterman</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Asthana</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gleason</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlsson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barczi</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnston</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sivesind</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zugin</LastName><ForeName>Z</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markgraf</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christian</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mueller</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blazel</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harding</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sachs</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wroblewski</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gassman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hart</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calder</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Storey</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Beesley</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Finkle</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wymer</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadekoski</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edmunds</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Penc</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raskind</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burges</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conybeare</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eliza</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoff</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchings</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawrence</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leverenz</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Li</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCraw</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connell</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>U</ForeName><Initials>U</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peskind</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ritcher</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohde</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shen</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stout</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tsuang</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petrie</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trader</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wang</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trader</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holt</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Qasabian</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gamalyan</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Iskin</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Castro</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guillen</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bagramyan</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dougherty</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibson</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shumate</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fisher</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oglesby</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vine</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>George</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nichols</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Enyeart</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sorenson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gowdy</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewandowski</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wheeler</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schowengerdt</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hom</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carr</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nobbe</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snider</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghoshal</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fierberg</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eastep</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gier</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dreyfus</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coats</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oliver</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarawneh</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aeschleman</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galvin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Overkamp</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wier</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sundermann</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tornabene</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaster</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Timiras</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savina</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horner</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roozen</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akers</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keren</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wherrett</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNeill</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fiss</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sukhai</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghazanfari</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anor</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacLennan</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ip</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arone</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fischler</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dyck</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tampi</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aziz</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whang</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reech</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benincasa</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiemers</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacAvoy</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frye</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vinci</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barcelos</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corsi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishimura</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oellette</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan-Parsch</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayeri</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shamsi</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ricitelli</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azar</LastName><ForeName>B</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beltran</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chivukulu</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Correa</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiznia</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheng</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vallabhaneni</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henry</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Werdiger</LastName><ForeName>N</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleves-Bayon</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiechers</LastName><ForeName>I</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paturzo</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nygaard</LastName><ForeName>H</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bowen</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brisibe</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laborde-Lahoz</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wagner</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nespoli</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Asis</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Good</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24450891</ArticleId><ArticleId IdType="mid">NIHMS593138</ArticleId><ArticleId IdType="pmc">PMC4159618</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1304839</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;6. [Erratum, Science 2002;297:2209.]</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804. [Erratum, N Engl J Med 2012;367:780.]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Schneider LS, Koo EH. Anti-a&#x3b2; therapeutics in Alzheimer&#x2019;s disease: the need for a paradigm shift. Neuron. 2011;69:203&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058906</ArticleId><ArticleId IdType="pubmed">21262461</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer&#x2019;s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100:2023&#x2013;8. [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC149952</ArticleId><ArticleId IdType="pubmed">12566568</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer&#x2019;s disease. J Neurosci. 2005;25:9096&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer&#x2019;s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zago W, Buttini M, Comery TA, et al. Neutralization of soluble, synaptotoxic amyloid &#x3b2; species by antibodies is epitope specific. J Neurosci. 2012;32:2696&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6621896</ArticleId><ArticleId IdType="pubmed">22357853</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1002&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">22473769</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4063417</ArticleId><ArticleId IdType="pubmed">22305802</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer&#x2019;s Association Research Roundtable Work-group. Alzheimers Dement. 2011;7:367&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3693547</ArticleId><ArticleId IdType="pubmed">21784348</ArticleId></ArticleIdList></Reference><Reference><Citation>Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2790221</ArticleId><ArticleId IdType="pubmed">19923550</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A. Pathological verification of ischemic score in differentiation of dementias. Ann Neurol. 1980;7:486&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7396427</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer&#x2019;s disease. Am J Psychiatry. 1984;141:1356&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">6496779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauthier S, G&#xe9;linas I, Gauthier L. Functional disability in Alzheimer&#x2019;s disease. Int Psychogeriatr. 1997;9(Suppl 1):163&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9447439</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, Minassian SL, Jenkins L, Black RS, Koller M, Grundman M. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846273</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer&#x2019;s disease. J Gerontol. 1994;49:M216&#x2013;M222.</Citation><ArticleIdList><ArticleId IdType="pubmed">8056940</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanmechelen E, Vanderstichele H, Davidsson P, et al. Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett. 2000;285:49&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">10788705</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">10714659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zago W, Schroeter S, Guido T, et al. Vascular alterations in PDAPP mice after anti-A&#x3b2; immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimers Dement. 2013 Apr 11; (Epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pubmed">23583235</ArticleId></ArticleIdList></Reference><Reference><Citation>Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer&#x2019;s disease. N Engl J Med. 2014;370:311&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24450890</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>370</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>23</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.</ArticleTitle><Pagination><StartPage>311</StartPage><EndPage>321</EndPage><MedlinePgn>311-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1312889</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doody</LastName><ForeName>Rachelle S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>From the Alzheimer's Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston (R.S.D.); Alzheimer's Disease Cooperative Study, Department of Family and Preventive Medicine (R.G.T., R.R., X.S.), and the Department of Neurosciences (R.G.T., R.R., P.S.A., R.M.), University of California at San Diego, San Diego; Indiana Alzheimer Disease Center, Indiana University (M.F.), and Eli Lilly (E.S., H.L.-S., R.M.) - both in Indianapolis; the Department of Neuropathology, School of Medicine, and the Department of Neuropathology and Neuroscience, School of Pharmacological Science, University of Tokyo, Tokyo (T.I.); Gerontopole, Unit&#xe9; Mixte de Recherche 1027, Centre Hospitalier Universitaire Toulouse, Toulouse, France (B.V.); the Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia (S.J.); and the Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, NY (K.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials></Author><Author ValidYN="Y"><LastName>Farlow</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Iwatsubo</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Joffe</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kieburtz</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Siemers</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Liu-Seifert</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mohs</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><CollectiveName>Alzheimer's Disease Cooperative Study Steering Committee</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Solanezumab Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00904683</AccessionNumber><AccessionNumber>NCT00905372</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Jan 23;370(4):377-8. doi: 10.1056/NEJMe1313943.</RefSource><PMID Version="1">24450897</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Dtsch Med Wochenschr. 2014 Mar;139(10):468. doi: 10.1055/s-0033-1353892.</RefSource><PMID Version="1">24570189</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Apr 10;370(15):1460. doi: 10.1056/NEJMc1402193.</RefSource><PMID Version="1">24716687</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2014 Apr 10;370(15):1459. doi: 10.1056/NEJMc1402193.</RefSource><PMID Version="1">24716688</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2016 Nov 09;539(7628):156-158. doi: 10.1038/539156a.</RefSource><PMID Version="1">27830826</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017211" MajorTopicYN="N">Treatment Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24450890</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1312889</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24464041</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Tau promotes neurodegeneration through global chromatin relaxation.</ArticleTitle><Pagination><StartPage>357</StartPage><EndPage>366</EndPage><MedlinePgn>357-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3639</ELocationID><Abstract><AbstractText>The microtubule-associated protein tau is involved in a number of neurodegenerative disorders, including Alzheimer's disease. Previous studies have linked oxidative stress and subsequent DNA damage to neuronal death in Alzheimer's disease and related tauopathies. Given that DNA damage can substantially alter chromatin structure, we examined epigenetic changes in tau-induced neurodegeneration. We found widespread loss of heterochromatin in tau transgenic Drosophila and mice and in human Alzheimer's disease. Notably, genetic rescue of tau-induced heterochromatin loss substantially reduced neurodegeneration in Drosophila. We identified oxidative stress and subsequent DNA damage as a mechanistic link between transgenic tau expression and heterochromatin relaxation, and found that heterochromatin loss permitted aberrant gene expression in tauopathies. Furthermore, large-scale analyses from the brains of individuals with Alzheimer's disease revealed a widespread transcriptional increase in genes that were heterochromatically silenced in controls. Our results establish heterochromatin loss as a toxic effector of tau-induced neurodegeneration and identify chromatin structure as a potential therapeutic target in Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frost</LastName><ForeName>Bess</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hemberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Program in Neurobiology, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jada</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience and Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feany</LastName><ForeName>Mel B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE53719</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG033518</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 CA095616</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R21NS070250</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 NS050606</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 HD018655</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG33518</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS070250</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM084947</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044113</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG039193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32AG039193</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006570">Heterochromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Neurosci. 2014 Mar;17(3):334-5. doi: 10.1038/nn.3659.</RefSource><PMID Version="1">24569826</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006570" MajorTopicYN="N">Heterochromatin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24464041</ArticleId><ArticleId IdType="mid">NIHMS560028</ArticleId><ArticleId IdType="pmc">PMC4012297</ArticleId><ArticleId IdType="doi">10.1038/nn.3639</ArticleId><ArticleId IdType="pii">nn.3639</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Crowther RA, Kamphorst W, Heutink P, van Swieten JC. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau. Am J Pathol. 1998;153:1359&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853390</ArticleId><ArticleId IdType="pubmed">9811325</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med. 2012;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3543098</ArticleId><ArticleId IdType="pubmed">23125202</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruman, et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron. 2004;41:549&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">14980204</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, et al. TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol. 2006;16:230&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">16461276</ArticleId></ArticleIdList></Reference><Reference><Citation>Khurana V, et al. A neuroprotective role for the DNA damage checkpoint in tauopathy. Aging Cell. 2012;11:360&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">22181010</ArticleId></ArticleIdList></Reference><Reference><Citation>Blard O, et al. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum Mol Genet. 2007;16:555&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">17309878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambegaokar SS, Jackson GR. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet. 2011;20:4947&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221533</ArticleId><ArticleId IdType="pubmed">21949350</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith KT, Workman JL. Chromatin proteins: key responders to stress. PLoS Biol. 2012;10:e1001371.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409139</ArticleId><ArticleId IdType="pubmed">22859908</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon N. Heterochromatin structure and function. Biol Cell. 2004;96:631&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15519697</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng JC, Karpen GH. Heterochromatic genome stability requires regulators of histone H3 K9 methylation. PLoS Genet. 2009;5:e1000435.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2654965</ArticleId><ArticleId IdType="pubmed">19325889</ArticleId></ArticleIdList></Reference><Reference><Citation>De Lucia F, Ni JQ, Vaillant C, Sun FL. HP1 modulates the transcription of cell-cycle regulators in Drosophila melanogaster. Nucleic Acids Res. 2005;33:2852&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1131934</ArticleId><ArticleId IdType="pubmed">15905474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB. Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest. 2007;117:236&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1697799</ArticleId><ArticleId IdType="pubmed">17173140</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell. 2007;18:5060&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2096612</ArticleId><ArticleId IdType="pubmed">17928404</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, et al. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2007;9:139&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu BY, Ma J, Eissenberg JC. Developmental regulation of heterochromatin-mediated gene silencing in Drosophila. Development. 1998;125:2223&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9584122</ArticleId></ArticleIdList></Reference><Reference><Citation>Paredes S, Maggert KA. Ribosomal DNA contributes to global chromatin regulation. Proc Natl Acad Sci U S A. 2009;106:17829&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764911</ArticleId><ArticleId IdType="pubmed">19822756</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DW, Kondo S, Krzyzanowska A, Hiromi Y, Truman JW. Local caspase activity directs engulfment of dendrites during pruning. Nat Neurosci. 2006;9:1234&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980964</ArticleId></ArticleIdList></Reference><Reference><Citation>Beisel C, Imhof A, Greene J, Kremmer E, Sauer F. Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature. 2002;419:857&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">12397363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukiyama T, Wu C. Purification and properties of an ATP-dependent nucleosome remodeling factor. Cell. 1995;83:1011&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8521501</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley K, et al. Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 1998;18:8126&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6792852</ArticleId><ArticleId IdType="pubmed">9763459</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullaart E, Boerrigter ME, Ravid R, Swaab DF, Vijg J. Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging. 1990;11:169&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">2362649</ArticleId></ArticleIdList></Reference><Reference><Citation>Missirlis F, et al. Mitochondrial and cytoplasmic thioredoxin reductase variants encoded by a single Drosophila gene are both essential for viability. J Biol Chem. 2002;277:11521&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796729</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X, Sehgal A. Sod2[Delta02] and Sod2[Delta12] 2009</Citation></Reference><Reference><Citation>Hittelman WN, Pollard M. Visualization of chromatin events associated with repair of ultraviolet light-induced damage by premature chromosome condensation. Carcinogenesis. 1984;5:1277&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">6488448</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubbi CP, Milner J. p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J. 2003;22:975&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145442</ArticleId><ArticleId IdType="pubmed">12574133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent WJ, et al. The human genome browser at UCSC. Genome Res. 2002;12:996&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC186604</ArticleId><ArticleId IdType="pubmed">12045153</ArticleId></ArticleIdList></Reference><Reference><Citation>Celniker SE, et al. Unlocking the secrets of the genome. Nature. 2009;459:927&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843545</ArticleId><ArticleId IdType="pubmed">19536255</ArticleId></ArticleIdList></Reference><Reference><Citation>Brennecke J, et al. Discrete small RNA-generating loci as master regulators of transposon activity in Drosophila. Cell. 2007;128:1089&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">17346786</ArticleId></ArticleIdList></Reference><Reference><Citation>Aravin A, et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature. 2006;442:203&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751777</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature. 2006;442:199&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pubmed">16751776</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Edwards TN, Meinertzhagen IA. The functional organisation of glia in the adult brain of Drosophila and other insects. Prog Neurobiol. 2010;90:471&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2847375</ArticleId><ArticleId IdType="pubmed">20109517</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. The NIH Roadmap Epigenomics Mapping Consortium. Nat Biotechnol. 2010;28:1045&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3607281</ArticleId><ArticleId IdType="pubmed">20944595</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst J, Kellis M. ChromHMM: automating chromatin-state discovery and characterization. Nat Methods. 2012;9:215&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577932</ArticleId><ArticleId IdType="pubmed">22373907</ArticleId></ArticleIdList></Reference><Reference><Citation>Blalock EM, et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A. 2004;101:2173&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC357071</ArticleId><ArticleId IdType="pubmed">14769913</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell. 2013;152:642&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3563935</ArticleId><ArticleId IdType="pubmed">23333102</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Gene expression profiling in human neurodegenerative disease. Nat Rev Neurol. 2012;8:518&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22890216</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Gotz J. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12:65&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284:12845&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBoff B, Gotz J, Feany MB. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron. 2012;75:618&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428596</ArticleId><ArticleId IdType="pubmed">22920254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch-Presegue L, et al. Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol Cell. 2011;42:210&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">21504832</ArticleId></ArticleIdList></Reference><Reference><Citation>Krylova SM, et al. Tau protein binds single-stranded DNA sequence specifically--the proof obtained in vitro with non-equilibrium capillary electrophoresis of equilibrium mixtures. FEBS Lett. 2005;579:1371&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">15733843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoberg MK, Shestakova E, Mansuroglu Z, Maccioni RB, Bonnefoy E. Tau protein binds to pericentromeric DNA: a putative role for nuclear tau in nucleolar organization. J Cell Sci. 2006;119:2025&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">16638814</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, et al. Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxidation. PLoS One. 2008;3:e2600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2432501</ArticleId><ArticleId IdType="pubmed">18596978</ArticleId></ArticleIdList></Reference><Reference><Citation>Faghihi MA, et al. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med. 2008;14:723&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2826895</ArticleId><ArticleId IdType="pubmed">18587408</ArticleId></ArticleIdList></Reference><Reference><Citation>Juliano C, Wang J, Lin H. Uniting germline and stem cells: the function of Piwi proteins and the piRNA pathway in diverse organisms. Annu Rev Genet. 2011;45:447&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832951</ArticleId><ArticleId IdType="pubmed">21942366</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz YB, et al. Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet. 2006;38:700&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16732288</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelbart ME, Larschan E, Peng S, Park PJ, Kuroda MI. Drosophila MSL complex globally acetylates H4K16 on the male X chromosome for dosage compensation. Nat Struct Mol Biol. 2009;16:825&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722042</ArticleId><ArticleId IdType="pubmed">19648925</ArticleId></ArticleIdList></Reference><Reference><Citation>Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690996</ArticleId><ArticleId IdType="pubmed">19261174</ArticleId></ArticleIdList></Reference><Reference><Citation>Penna I, et al. Selection of candidate housekeeping genes for normalization in human postmortem brain samples. Int J Mol Sci. 2011;12:5461&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189726</ArticleId><ArticleId IdType="pubmed">22016602</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Matevossian A, Huang HS, Straubhaar J, Akbarian S. Isolation of neuronal chromatin from brain tissue. BMC Neurosci. 2008;9:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377267</ArticleId><ArticleId IdType="pubmed">18442397</ArticleId></ArticleIdList></Reference><Reference><Citation>Berzsenyi MD, et al. Down-regulation of intra-hepatic T-cell signaling associated with GB virus C in a HCV/HIV co-infected group with reduced liver disease. J Hepatol. 2011;55:536&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">21266183</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes OC, et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging. 2007;28:1795&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">16979800</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimand J, Kull M, Peterson H, Hansen J, Vilo J. g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 2007;35:W193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933153</ArticleId><ArticleId IdType="pubmed">17478515</ArticleId></ArticleIdList></Reference><Reference><Citation>Martens GA, et al. Clusters of conserved beta cell marker genes for assessment of beta cell phenotype. PLoS One. 2011;6:e24134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3166300</ArticleId><ArticleId IdType="pubmed">21912665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24462250</PMID><DateCompleted><Year>2015</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-4186</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>04</Day></PubDate></JournalIssue><Title>Structure (London, England : 1993)</Title><ISOAbbreviation>Structure</ISOAbbreviation></Journal><ArticleTitle>Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased A&#x3b2; production.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>396</EndPage><MedlinePgn>387-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.str.2013.12.012</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0969-2126(14)00003-3</ELocationID><Abstract><AbstractText>Proteolysis of the &#x3b2; C-terminal fragment (&#x3b2;-CTF) of the amyloid precursor protein generates the A&#x3b2; peptides associated with Alzheimer's disease. Familial mutations in the &#x3b2;-CTF, such as the A21G Flemish mutation, can increase A&#x3b2; secretion. We establish how the Flemish mutation alters the structure of C55, the first 55 residues of the &#x3b2;-CTF, using FTIR and solid-state NMR spectroscopy. We show that the A21G mutation reduces &#x3b2; sheet structure of C55 from Leu17 to Ala21, an inhibitory region near the site of the mutation, and increases &#x3b1;-helical structure from Gly25 to Gly29, in a region near the membrane surface and thought to interact with cholesterol. Cholesterol also increases A&#x3b2; peptide secretion, and we show that the incorporation of cholesterol into model membranes enhances the structural changes induced by the Flemish mutant, suggesting a common link between familial mutations and the cellular environment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Tzu-Chun</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794-5215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794-5215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kienlen-Campard</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El Haylani</LastName><ForeName>Laetitia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Decock</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Hees</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research and de Duve Institute, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Ziao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794-5215, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Octave</LastName><ForeName>Jean-Noel</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Constantinescu</LastName><ForeName>Stefan N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Ludwig Institute for Cancer Research and de Duve Institute, Universit&#xe9; catholique de Louvain, Brussels 1200, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Steven O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY 11794-5215, USA. Electronic address: steven.o.smith@stonybrook.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027317</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG027317</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Structure</MedlineTA><NlmUniqueID>101087697</NlmUniqueID><ISSNLinking>0969-2126</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008051">Lipid Bilayers</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Structure. 2014 Mar 4;22(3):361-2. doi: 10.1016/j.str.2014.02.008.</RefSource><PMID Version="1">24607141</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016466" MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003412" MajorTopicYN="N">Cricetulus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008051" MajorTopicYN="N">Lipid Bilayers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="N">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017550" MajorTopicYN="N">Spectroscopy, Fourier Transform Infrared</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24462250</ArticleId><ArticleId IdType="mid">NIHMS560544</ArticleId><ArticleId IdType="pmc">PMC3952111</ArticleId><ArticleId IdType="doi">10.1016/j.str.2013.12.012</ArticleId><ArticleId IdType="pii">S0969-2126(14)00003-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Balbach JJ, Ishii Y, Antzutkin ON, Leapman RD, Rizzo NW, Dyda F, Reed J, Tycko R. Amyloid fibril formation by A&#x3b2;16-22, a seven-residue fragment of the Alzheimer&#x2019;s &#x3b2;-amyloid peptide, and structural characterization by solid state NMR. Biochemistry. 2000;39:13748&#x2013;13759.</Citation><ArticleIdList><ArticleId IdType="pubmed">11076514</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett PJ, Song Y, Van Horn WD, Hustedt EJ, Schafer JM, Hadziselimovic A, Beel AJ, Sanders CR. The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science. 2012;336:1168&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528355</ArticleId><ArticleId IdType="pubmed">22654059</ArticleId></ArticleIdList></Reference><Reference><Citation>Beel AJ, Mobley CK, Kim HJ, Tian F, Hadziselimovic A, Jap B, Prestegard JH, Sanders CR. Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): Does APP function as a cholesterol sensor? Biochemistry. 2008;47:9428&#x2013;9446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2572687</ArticleId><ArticleId IdType="pubmed">18702528</ArticleId></ArticleIdList></Reference><Reference><Citation>Betts V, Leissring MA, Dolios G, Wang R, Selkoe DJ, Walsh DM. Aggregation and catabolism of disease-associated intra-A&#x3b2; mutations: reduced proteolysis of A&#x3b2;A21G by neprilysin. Neurobiol. Disease. 2008;31:442&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3160758</ArticleId><ArticleId IdType="pubmed">18602473</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer&#x2019;s A4/&#x3b2; amyloid peptide analogs. J. Biol. Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon RO, Attema B, Devries GH. Lipid composition of neuronal cell bodies and neurites from cultured dorsal root ganglia. J. Neurochem. 1995;64:424&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">7798942</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C, Zehr C, Yager D, Prada CM, Younkin S, Hendriks L, Van Broeckhoven C, Eckman CB. Flemish and Dutch mutations in amyloid &#x3b2; precursor protein have different effects on amyloid &#x3b2; secretion. Neurobiol. Disease. 1998;5:281&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">9848098</ArticleId></ArticleIdList></Reference><Reference><Citation>Funamoto S, Morshima-Kawashima M, Tanimura Y, Hirotani N, Saido TC, Ihara Y. Truncated carboxyl-terminal fragments of &#x3b2;-amyloid precursor protein are processed to amyloid &#x3b2;-proteins 40 and 42. Biochemistry. 2004;43:13532&#x2013;13540.</Citation><ArticleIdList><ArticleId IdType="pubmed">15491160</ArticleId></ArticleIdList></Reference><Reference><Citation>Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol. 2001;49:697&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">11409420</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin JJ, et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the &#x3b2;-amyloid precursor protein gene. Nat. Genet. 1992;1:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303239</ArticleId></ArticleIdList></Reference><Reference><Citation>Inouye H, Gleason KA, Zhang D, Decatur SM, Kirschner DA. Differential effects of Phe19 and Phe20 on fibril formation by amyloidogenic peptide A&#x3b2; 16-22 (Ac-KLVFFAE-NH2) Proteins. 2010;78:2306&#x2013;2321.</Citation><ArticleIdList><ArticleId IdType="pubmed">20544966</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, Pulst SM, Anderson L, O&#x2019;Dahl S, Nemens E, White JA, et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am. J. Hum. Genet. 1992;51:998&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1682859</ArticleId><ArticleId IdType="pubmed">1415269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kienlen-Campard P, Tasiaux B, Van Hees J, Li M, Huysseune S, Sato T, Fei JZ, Aimoto S, Courtoy PJ, Smith SO, et al. Amyloidogenic processing but not amyloid precursor protein (APP) intracellular C-terminal domain production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. J. Biol. Chem. 2008;283:7733&#x2013;7744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702479</ArticleId><ArticleId IdType="pubmed">18201969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissien A. Midlife vascular risk factors and Alzheimer&#x2019;s disease in later life: longitudinal, population based study. Br. Med. J. 2001;322:1447&#x2013;1451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC32306</ArticleId><ArticleId IdType="pubmed">11408299</ArticleId></ArticleIdList></Reference><Reference><Citation>Kukar TL, Ladd TB, Robertson P, Pintchovski SA, Moore B, Bann MA, Ren Z, Jansen-West K, Malphrus K, Eggert S, et al. Lysine 624 of the amyloid precursor protein (APP) is a critical determinant of amyloid &#x3b2; peptide length: Support for a sequential model of &#x3b3;-secretase intramembrane proteolysis and regulation by the amyloid &#x3b2; precursor protein (APP) juxtamembrane region. J. Biol. Chem. 2011;286:39804&#x2013;39812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220543</ArticleId><ArticleId IdType="pubmed">21868378</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmon MA, Flanagan JM, Treutlein HR, Zhang J, Engelman DM. Sequence specificity in the dimerization of transmembrane &#x3b1;-helices. Biochemistry. 1992;31:12719&#x2013;12725.</Citation><ArticleIdList><ArticleId IdType="pubmed">1463743</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B. Mutation of the Alzheimer&#x2019;s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science. 1990;248:1124&#x2013;1126.</Citation><ArticleIdList><ArticleId IdType="pubmed">2111584</ArticleId></ArticleIdList></Reference><Reference><Citation>London E. How principles of domain formation in model membranes may explain ambiguities concerning lipid raft formation in cells. Biochim. Biophys. Acta. 2005;1746:203&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">16225940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Z, Van Horn WD, Chen J, Mathew S, Zent R, Sanders CR. Bicelles at low concentrations. Mol. Pharm. 2012;9:752&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319193</ArticleId><ArticleId IdType="pubmed">22221179</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor DL, Kim PS. Measurement of the &#x3b2;-sheet-forming propensities of amino acids. Nature. 1994;367:660&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">8107853</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter L-M, Botev A, Richter L, Hildebrand PW, Althoff V, Weise C, Kaden D, Multhaup G. Aberrant amyloid precursor protein (APP) processing in hereditary forms of Alzheimer disease caused by APP familial Alzheimer disease mutations can be rescued by mutations in the APP GxxxG motif. J. Biol. Chem. 2010;285:21636&#x2013;21643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898405</ArticleId><ArticleId IdType="pubmed">20452985</ArticleId></ArticleIdList></Reference><Reference><Citation>Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, Pipkorn R, Schaefer M, Langosch D, Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of A&#x3b2;42. EMBO J. 2007;26:1702&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1829382</ArticleId><ArticleId IdType="pubmed">17332749</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadezhdin KD, Bocharova OV, Bocharov EV, Arseniev AS. Dimeric structure of transmembrane domain of amyloid precursor protein in micellar environment. FEBS Lett. 2012;586:1687&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">22584060</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul C, Wang JP, Wimley WC, Hochstrasser RM, Axelsen PH. Vibrational coupling, isotopic editing, and &#x3b2;-sheet structure in a membrane-bound polypeptide. J. Am. Chem. Soc. 2004;126:5843&#x2013;5850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2982945</ArticleId><ArticleId IdType="pubmed">15125676</ArticleId></ArticleIdList></Reference><Reference><Citation>Petty SA, Decatur SM. Experimental evidence for the reorganization of &#x3b2;-strands within aggregates of the A&#x3b2;(16-22) peptide. J. Am. Chem. Soc. 2005;127:13488&#x2013;13489.</Citation><ArticleIdList><ArticleId IdType="pubmed">16190699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z, Schenk D, Basi GS, Shapiro IP. Amyloid &#x3b2;-protein precursor juxtamembrane domain regulates specificity of &#x3b3;-secretase-dependent cleavages. J. Biol. Chem. 2007;282:35350&#x2013;35360.</Citation><ArticleIdList><ArticleId IdType="pubmed">17890228</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T, Tang TC, Reubins G, Fei JZ, Fujimoto T, Kienlen-Campard P, Constantinescu SN, Octave JN, Aimoto S, Smith SO. A helix-to-coil transition at the &#x3b5;-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. Proc. Natl. Acad. Sci. USA. 2009;106:1421&#x2013;1426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635791</ArticleId><ArticleId IdType="pubmed">19164538</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer disease: Mechanistic understanding predicts novel therapies. Ann. Internal Med. 2004;140:627&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pubmed">15096334</ArticleId></ArticleIdList></Reference><Reference><Citation>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of &#x3b2;-amyloid in hippocampal neurons. Proceedings of the National Academy of Sciences of the United States of America. 1998;95:6460&#x2013;6464.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27798</ArticleId><ArticleId IdType="pubmed">9600988</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith SO, Eilers M, Song D, Crocker E, Ying WW, Groesbeek M, Metz G, Ziliox M, Aimoto S. Implications of threonine hydrogen bonding in the glycophorin A transmembrane helix dimer. Biophys. J. 2002;82:2476&#x2013;2486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302037</ArticleId><ArticleId IdType="pubmed">11964235</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Y, Hustedt EJ, Brandon S, Sanders CR. Competition between homodimerization and cholesterol binding to the c99 domain of the amyloid precursor protein. Biochemistry. 2013;52:5051&#x2013;5064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3758481</ArticleId><ArticleId IdType="pubmed">23865807</ArticleId></ArticleIdList></Reference><Reference><Citation>Takegoshi K, Nakamura S, Terao T. 13C-1H dipolar-assisted rotational resonance in magic-angle spinning NMR. Chem. Phys. Lett. 2001;344:631&#x2013;637.</Citation></Reference><Reference><Citation>Tian Y, Bassit B, Chau DM, Li YM. An APP inhibitory domain containing the Flemish mutation residue modulates &#x3b3;-secretase activity for A&#x3b2; production. Nat. Struct. Mol. Biol. 2010;17:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">20062056</ArticleId></ArticleIdList></Reference><Reference><Citation>Umeda T, Tomiyama T, Kitajima E, Idomoto T, Nomura S, Lambert MP, Klein WL, Mori H. Hypercholesterolemia accelerates intraneuronal accumulation of A beta oligomers resulting in memory impairment in Alzheimer&#x2019;s disease model mice. Life Sci. 2012;91:1169&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">22273754</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE. Cholesterol-dependent &#x3b3;-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Disease. 2002;9:11&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">11848681</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li Y-M. &#x3b3;-secretase substrate concentration modulates the A&#x3b2;42/A&#x3b2;40 ratio. J. Biol. Chem. 2007;282:23639&#x2013;23644.</Citation><ArticleIdList><ArticleId IdType="pubmed">17556361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24470444</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>211</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.</ArticleTitle><Pagination><StartPage>233</StartPage><EndPage>244</EndPage><MedlinePgn>233-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20131660</ELocationID><Abstract><AbstractText>Antibodies to transferrin receptor (TfR) have potential use for therapeutic entry into the brain. We have shown that bispecific antibodies against TfR and &#x3b2;-secretase (BACE1 [&#x3b2;-amyloid cleaving enzyme-1]) traverse the blood-brain barrier (BBB) and effectively reduce brain amyloid &#x3b2; levels. We found that optimizing anti-TfR affinity improves brain exposure and BACE1 inhibition. Here we probe the cellular basis of this improvement and explore whether TfR antibody affinity alters the intracellular trafficking of TfR. Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affinity binding to TfR caused a dose-dependent reduction of brain TfR levels. In vitro live imaging and colocalization experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR to lysosomes and thus induced the degradation of TfR, an observation which was further confirmed in vivo. Importantly, high-affinity anti-TfR dosing induced reductions in brain TfR levels, which significantly decreased brain exposure to a second dose of low-affinity anti-TfR bispecific. Thus, high-affinity anti-TfR alters TfR trafficking, which dramatically impacts the capacity for TfR to mediate BBB transcytosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bien-Ly</LastName><ForeName>Nga</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, 2 Development Sciences, 3 Biomedical Imaging Group, 4 Antibody Engineering Group, 5 Biochemical and Cellular Pharmacology Group, and 6 Molecular Oncology Group, Genentech Inc., South San Francisco, CA 94080.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Y Joy</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Bumbaca</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Elstrott</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boswell</LastName><ForeName>C Andrew</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yin</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Luk</LastName><ForeName>Wilman</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Weimer</LastName><ForeName>Robby M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Inhee</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ryan J</ForeName><Initials>RJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018033">Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011990">Receptors, Transferrin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C480029">Tfrc protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018033" MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000915" MajorTopicYN="N">Antibody Affinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001812" MajorTopicYN="N">Blood-Brain Barrier</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011990" MajorTopicYN="N">Receptors, Transferrin</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057900" MajorTopicYN="N">Transcytosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24470444</ArticleId><ArticleId IdType="pmc">PMC3920563</ArticleId><ArticleId IdType="doi">10.1084/jem.20131660</ArticleId><ArticleId IdType="pii">jem.20131660</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Atwal J.K., Chen Y., Chiu C., Mortensen D.L., Meilandt W.J., Liu Y., Heise C.E., Hoyte K., Luk W., Lu Y., et al. 2011. A therapeutic antibody targeting BACE1 inhibits amyloid-&#x3b2; production in vivo. Sci. Transl. Med. 3:84ra43 10.1126/scitranslmed.3002254</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002254</ArticleId><ArticleId IdType="pubmed">21613622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N., Gillespie A.K., Walker D., Yoon S.Y., Huang Y. 2012. Reducing human apolipoprotein E levels attenuates age-dependent A&#x3b2; accumulation in mutant human amyloid precursor protein transgenic mice. J. Neurosci. 32:4803&#x2013;4811 10.1523/JNEUROSCI.0033-12.2012</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0033-12.2012</ArticleId><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Boswell C.A., Bumbaca D., Fielder P.J., Khawli L.A. 2012. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 14:612&#x2013;618 10.1208/s12248-012-9374-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-012-9374-1</ArticleId><ArticleId IdType="pmc">PMC3385837</ArticleId><ArticleId IdType="pubmed">22648903</ArticleId></ArticleIdList></Reference><Reference><Citation>Chizzonite R., Truitt T., Podlaski F.J., Wolitzky A.G., Quinn P.M., Nunes P., Stern A.S., Gately M.K. 1991. IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts. J. Immunol. 147:1548&#x2013;1556</Citation><ArticleIdList><ArticleId IdType="pubmed">1715362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung I., Akita R., Vandlen R., Toomre D., Schlessinger J., Mellman I. 2010. Spatial control of EGF receptor activation by reversible dimerization on living cells. Nature. 464:783&#x2013;787 10.1038/nature08827</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08827</ArticleId><ArticleId IdType="pubmed">20208517</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch J.A., Yu Y.J., Zhang Y., Tarrant J.M., Fuji R.N., Meilandt W.J., Solanoy H., Tong R.K., Hoyte K., Luk W., et al. 2013. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 5:183ra57 10.1126/scitranslmed.3005338</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005338</ArticleId><ArticleId IdType="pubmed">23636093</ArticleId></ArticleIdList></Reference><Reference><Citation>Dautry-Varsat A., Ciechanover A., Lodish H.F. 1983. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc. Natl. Acad. Sci. USA. 80:2258&#x2013;2262 10.1073/pnas.80.8.2258</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.80.8.2258</ArticleId><ArticleId IdType="pmc">PMC393798</ArticleId><ArticleId IdType="pubmed">6300903</ArticleId></ArticleIdList></Reference><Reference><Citation>Duf&#xe8;s C., Al Robaian M., Somani S. 2013. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther. Deliv. 4:629&#x2013;640 10.4155/tde.13.21</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde.13.21</ArticleId><ArticleId IdType="pubmed">23647279</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. 1987. Receptor-mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:299&#x2013;304 10.1002/jnr.490180206</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490180206</ArticleId><ArticleId IdType="pubmed">3694713</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosk S., Vermehren C., Storm G., Moos T. 2004. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24:1193&#x2013;1204 10.1097/01.WCB.0000135592.28823.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.WCB.0000135592.28823.47</ArticleId><ArticleId IdType="pubmed">15545912</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmaat A., Bonhoeffer T., Chow D.K., Chuckowree J., De Paola V., Hofer S.B., H&#xfc;bener M., Keck T., Knott G., Lee W.C., et al. 2009. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat. Protoc. 4:1128&#x2013;1144 10.1038/nprot.2009.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.89</ArticleId><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., Mason D.Y. 1984. Transferrin receptor on endothelium of brain capillaries. Nature. 312:162&#x2013;163 10.1038/312162a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/312162a0</ArticleId><ArticleId IdType="pubmed">6095085</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones A.R., Shusta E.V. 2007. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24:1759&#x2013;1771 10.1007/s11095-007-9379-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-007-9379-0</ArticleId><ArticleId IdType="pmc">PMC2685177</ArticleId><ArticleId IdType="pubmed">17619996</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissel K., Hamm S., Schulz M., Vecchi A., Garlanda C., Engelhardt B. 1998. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem. Cell Biol. 110:63&#x2013;72 10.1007/s004180050266</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004180050266</ArticleId><ArticleId IdType="pubmed">9681691</ArticleId></ArticleIdList></Reference><Reference><Citation>Manich G., Cabez&#xf3;n I., del Valle J., Duran-Vilaregut J., Camins A., Pall&#xe0;s M., Pelegr&#xed; C., Vilaplana J. 2013. Study of the transcytosis of an anti-transferrin receptor antibody with a Fab&#x2019; cargo across the blood-brain barrier in mice. Eur. J. Pharm. Sci. 49:556&#x2013;564 10.1016/j.ejps.2013.05.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2013.05.027</ArticleId><ArticleId IdType="pubmed">23748097</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsui T., Itoh T., Fukuda M. 2011. Small GTPase Rab12 regulates constitutive degradation of transferrin receptor. Traffic. 12:1432&#x2013;1443 10.1111/j.1600-0854.2011.01240.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0854.2011.01240.x</ArticleId><ArticleId IdType="pubmed">21718402</ArticleId></ArticleIdList></Reference><Reference><Citation>Moos T., Morgan E.H. 2001. Restricted transport of anti-transferrin receptor antibody (OX26) through the blood-brain barrier in the rat. J. Neurochem. 79:119&#x2013;129 10.1046/j.1471-4159.2001.00541.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00541.x</ArticleId><ArticleId IdType="pubmed">11595764</ArticleId></ArticleIdList></Reference><Reference><Citation>Paris-Robidas S., Emond V., Tremblay C., Soulet D., Calon F. 2011. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol. Pharmacol. 80:32&#x2013;39 10.1124/mol.111.071027</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.111.071027</ArticleId><ArticleId IdType="pubmed">21454448</ArticleId></ArticleIdList></Reference><Reference><Citation>Predescu S.A., Predescu D.N., Malik A.B. 2007. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am. J. Physiol. Lung Cell. Mol. Physiol. 293:L823&#x2013;L842 10.1152/ajplung.00436.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00436.2006</ArticleId><ArticleId IdType="pubmed">17644753</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts R.L., Fine R.E., Sandra A. 1993. Receptor-mediated endocytosis of transferrin at the blood-brain barrier. J. Cell Sci. 104:521&#x2013;532</Citation><ArticleIdList><ArticleId IdType="pubmed">8505377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin L.L., Staddon J.M. 1999. The cell biology of the blood-brain barrier. Annu. Rev. Neurosci. 22:11&#x2013;28 10.1146/annurev.neuro.22.1.11</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.22.1.11</ArticleId><ArticleId IdType="pubmed">10202530</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheff D., Pelletier L., O&#x2019;Connell C.B., Warren G., Mellman I. 2002. Transferrin receptor recycling in the absence of perinuclear recycling endosomes. J. Cell Biol. 156:797&#x2013;804 10.1083/jcb.20111048</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.20111048</ArticleId><ArticleId IdType="pmc">PMC2173326</ArticleId><ArticleId IdType="pubmed">11877458</ArticleId></ArticleIdList></Reference><Reference><Citation>Traer C.J., Rutherford A.C., Palmer K.J., Wassmer T., Oakley J., Attar N., Carlton J.G., Kremerskothen J., Stephens D.J., Cullen P.J. 2007. SNX4 coordinates endosomal sorting of TfnR with dynein-mediated transport into the endocytic recycling compartment. Nat. Cell Biol. 9:1370&#x2013;1380 10.1038/ncb1656</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1656</ArticleId><ArticleId IdType="pubmed">17994011</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y.J., Watts R.J. 2013. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 10:459&#x2013;472 10.1007/s13311-013-0187-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-013-0187-4</ArticleId><ArticleId IdType="pmc">PMC3701773</ArticleId><ArticleId IdType="pubmed">23549647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., Dennis M.S. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3:84ra44 10.1126/scitranslmed.3002230</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002230</ArticleId><ArticleId IdType="pubmed">21613623</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24473795</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Elevated serum pesticide levels and risk for Alzheimer disease.</ArticleTitle><Pagination><StartPage>284</StartPage><EndPage>290</EndPage><MedlinePgn>284-90</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.6030</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The causes of late-onset Alzheimer disease (AD) are not yet understood but likely include a combination of genetic, environmental, and lifestyle factors. Limited epidemiological studies suggest that occupational pesticide exposures are associated with AD. Previously, we reported that serum levels of dichlorodiphenyldichloroethylene (DDE), the metabolite of the pesticide dichlorodiphenyltrichloroethane (DDT), were elevated in a small number of patients with AD (n=20).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the association between serum levels of DDE and AD and whether the apolipoprotein E (APOE) genotype modifies the association.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A case-control study consisting of existing samples from patients with AD and control participants from the Emory University Alzheimer's Disease Research Center and the University of Texas Southwestern Medical School's Alzheimer's Disease Center. Serum levels of DDE were measured in 79 control and 86 AD cases.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Serum DDE levels, AD diagnosis, severity of AD measured by the Mini-Mental State Examination score, and interaction with APOE4 status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Levels of DDE were 3.8-fold higher in the serum of those with AD (mean [SEM], 2.64 [0.35] ng/mg cholesterol) when compared with control participants (mean [SEM], 0.69 [0.1] ng/mg cholesterol; P &lt;&#x2009;.001). The highest tertile of DDE levels was associated with an odds ratio of 4.18 for increased risk for AD (95% CI, 2.54-5.82; P &lt;&#x2009;.001) and lower Mini-Mental State Examination scores (-1.605; range, -3.095 to -0.114; P &lt;&#x2009;.0001). The Mini-Mental State Examination scores in the highest tertile of DDE were -1.753 points lower in the subpopulation carrying an APOE &#x3b5;4 allele compared with those carrying an APOE &#x3b5;3 allele (P interaction =&#x2009;.04). Serum levels of DDE were highly correlated with brain levels of DDE (&#x3c1; = 0.95). Exposure of human neuroblastoma cells to DDT or DDE increased levels of amyloid precursor protein.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Elevated serum DDE levels are associated with an increased risk for AD and carriers of an APOE4 &#x3b5;4 allele may be more susceptible to the effects of DDE. Both DDT and DDE increase amyloid precursor protein levels, providing mechanistic plausibility for the association of DDE exposure with AD. Identifying people who have elevated levels of DDE and carry an APOE &#x3b5;4 allele may lead to early identification of some cases of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey2Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy</LastName><ForeName>Ananya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shalat</LastName><ForeName>Stuart L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey2Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Stein</LastName><ForeName>Richard T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hossain</LastName><ForeName>Muhammad M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Environmental and Occupational Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, New Jersey2Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buckley</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Environmental and Occupational Health Sciences Institute, Rutgers University, Piscataway, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gearing</LastName><ForeName>Marla</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Levey</LastName><ForeName>Allan I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Department of Neurology and Alzheimer's Disease, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>German</LastName><ForeName>Dwight C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 ES007148</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS072097</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32ES07148</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01ES015991</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG025688</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21NS072097</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS079249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES005022</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES015991</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30ES005022</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053318">Apolipoprotein E3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007306">Insecticides</NameOfSubstance></Chemical><Chemical><RegistryNumber>4M7FS82U08</RegistryNumber><NameOfSubstance UI="D003633">Dichlorodiphenyl Dichloroethylene</NameOfSubstance></Chemical><Chemical><RegistryNumber>CIW5S16655</RegistryNumber><NameOfSubstance UI="D003634">DDT</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Mar;71(3):273-5. doi: 10.1001/jamaneurol.2013.6031.</RefSource><PMID Version="1">24473699</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Mar;10(3):125. doi: 10.1038/nrneurol.2014.25.</RefSource><PMID Version="1">24535461</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Aug;71(8):1055-6. doi: 10.1001/jamaneurol.2014.432.</RefSource><PMID Version="1">25111212</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Aug;71(8):1056. doi: 10.1001/jamaneurol.2014.1548.</RefSource><PMID Version="1">25111214</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Sep;71(9):1189-90. doi: 10.1001/jamaneurol.2014.795.</RefSource><PMID Version="1">25200541</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Sep;71(9):1190. doi: 10.1001/jamaneurol.2014.1814.</RefSource><PMID Version="1">25200543</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053318" MajorTopicYN="N">Apolipoprotein E3</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003634" MajorTopicYN="N">DDT</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003633" MajorTopicYN="N">Dichlorodiphenyl Dichloroethylene</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007306" MajorTopicYN="N">Insecticides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24473795</ArticleId><ArticleId IdType="mid">NIHMS612018</ArticleId><ArticleId IdType="pmc">PMC4132934</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.6030</ArticleId><ArticleId IdType="pii">1816015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer&#x2019;s disease. Alzheimers Dement. 2007;3(3):186&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pubmed">19595937</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen NL. Reaching the limits of genome-wide significance in Alzheimer disease: back to the environment. JAMA. 2010;303(18):1864&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pubmed">20460629</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellenberg GD, Montine TJ. The genetics and neuropathology of Alzheimer&#x2019;s disease. Acta Neuropathol. 2012;124(3):305&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708460</ArticleId><ArticleId IdType="pubmed">22618995</ArticleId></ArticleIdList></Reference><Reference><Citation>Santib&#xe1;&#xf1;ez M, Bolumar F, Garc&#xed;a AM. Occupational risk factors in Alzheimer&#x2019;s disease: a review assessing the quality of published epidemiological studies. Occup Environ Med. 2007;64(11):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2078415</ArticleId><ArticleId IdType="pubmed">17525096</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Norton MC, Darcey D, et al. Cache County Study Investigators. Occupational exposure to pesticides increases the risk of incident AD: the Cache County Study. Neurology. 2010;74(19):1524&#x2013;1530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875926</ArticleId><ArticleId IdType="pubmed">20458069</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson JR, Shalat SL, Buckley B, et al. Elevated serum pesticide levels and risk of Parkinson disease. Arch Neurol. 2009;66(7):870&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383784</ArticleId><ArticleId IdType="pubmed">19597089</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson JR, Roy A, Shalat SL, et al. &#x3b2;-Hexachlorocyclohexane levels in serum and risk of Parkinson&#x2019;s disease. Neurotoxicology. 2011;32(5):640&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176949</ArticleId><ArticleId IdType="pubmed">21620887</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect. 2004;112(17):1691&#x2013;1696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1253661</ArticleId><ArticleId IdType="pubmed">15579415</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149(3):708&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A, Hardy J. Twenty years of Alzheimer&#x2019;s disease-causing mutations. J Neurochem. 2012;120(suppl 1):3&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22122678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreiss K, Zack MM, Kimbrough RD, Needham LL, Smrek AL, Jones BT. Cross-sectional study of a community with exceptional exposure to DDT. JAMA. 1981;245(19):1926&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">6971946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffney SH, Curriero FC, Strickland PT, Glass GE, Helzlsouer KJ, Breysse PN. Influence of geographic location in modeling blood pesticide levels in a community surrounding a US Environmental Protection Agency superfund site. Environ Health Perspect. 2005;113(12):1712&#x2013;1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1314910</ArticleId><ArticleId IdType="pubmed">16330352</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency for Toxic Substances and Disease Registry. Toxicological Profile for DDT, DDE, DDD. Atlanta, GA: US Department of Health and Human Services, Public Health Service; 2002.</Citation></Reference><Reference><Citation>Eskenazi B, Chevrier J, Rosas LG, et al. The Pine River statement: human health consequences of DDT use. Environ Health Perspect. 2009;117(9):1359&#x2013;1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737010</ArticleId><ArticleId IdType="pubmed">19750098</ArticleId></ArticleIdList></Reference><Reference><Citation>Rehwagen C. WHO recommends DDT to control malaria. BMJ. 2006;333(7569):622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570869</ArticleId><ArticleId IdType="pubmed">16990319</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention.  [Accessed May 31, 2013];Fourth National Report on Human Exposure to Environmental Chemicals. 2009   http://www.cdc.gov/exposurereport/pdf/FourthReport.pdf.</Citation></Reference><Reference><Citation>Food and Drug Administration.  [Accessed May 31, 2013];Pesticide Monitoring Program. 2008   http://www.fda.gov/Food/FoodborneIllnessContaminants/Pesticides/ucm228867.htm.</Citation></Reference><Reference><Citation>Botella B, Crespo J, Rivas A, Cerrillo I, Olea-Serrano MF, Olea N. Exposure of women to organochlorine pesticides in Southern Spain. Environ Res. 2004;96(1):34&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">15261782</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatnagar VK, Kashyap R, Zaidi SS, Kulkarni PK, Saiyed HN. Levels of DDT, HCH, and HCB residues in human blood in Ahmedabad, India. Bull Environ Contam Toxicol. 2004;72(2):261&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">15106760</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusiecki JA, Matthews A, Sturgeon S, et al. A correlation study of organochlorine levels in serum, breast adipose tissue, and gluteal adipose tissue among breast cancer cases in India. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1113&#x2013;1124.</Citation><ArticleIdList><ArticleId IdType="pubmed">15894661</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaines TB. Acute toxicity of pesticides. Toxicol Appl Pharmacol. 1969;14(3):515&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">5787520</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan DP, Roan CC. Absorption, storage, and metabolic conversion of ingested DDT and DDT metabolites in man. Arch Environ Health. 1971;22(3):301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">5541487</ArticleId></ArticleIdList></Reference><Reference><Citation>Cueto C, Jr, Durham WF, Hayes WJ., Jr The effect of known repeated oral doses of chlorophenothane (DDT) in man. J Am Med Assoc. 1956;162(9):890&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pubmed">13366680</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1-trichloroethane (DDT) Lancet. 2005;366(9487):763&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">16125595</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra UK, Nag D, Murti CR. A study of cognitive functions in DDT sprayers. Ind Health. 1984;22(3):199&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">6501005</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wendel de Joode B, Wesseling C, Kromhout H, Monge P, Garc&#xed;a M, Mergler D. Chronic nervous-system effects of long-term occupational exposure to DDT. Lancet. 2001;357(9261):1014&#x2013;1016.</Citation><ArticleIdList><ArticleId IdType="pubmed">11293598</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming L, Mann JB, Bean J, Briggle T, Sanchez-Ramos JR. Parkinson&#x2019;s disease and brain levels of organochlorine pesticides. Ann Neurol. 1994;36(1):100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">7517654</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Chhillar N, Banerjee B, Bala K, Basu M, Mustafa M. Organochlorine pesticide levels and risk of Alzheimer&#x2019;s disease in north Indian population. Hum Exp Toxicol. 2013;32(1):24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22899726</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldi I, Lebailly P, Mohammed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol. 2003;157(5):409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615605</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(2):107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24473151</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Postmortem examination of patient H.M.'s brain based on histological sectioning and digital 3D reconstruction.</ArticleTitle><Pagination><StartPage>3122</StartPage><MedlinePgn>3122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms4122</ELocationID><Abstract><AbstractText>Modern scientific knowledge of how memory functions are organized in the human brain originated from the case of Henry G. Molaison (H.M.), an epileptic patient whose amnesia ensued unexpectedly following a bilateral surgical ablation of medial temporal lobe structures, including the hippocampus. The neuroanatomical extent of the 1953 operation could not be assessed definitively during H.M.'s life. Here we describe the results of a procedure designed to reconstruct a microscopic anatomical model of the whole brain and conduct detailed 3D measurements in the medial temporal lobe region. This approach, combined with cellular-level imaging of stained histological slices, demonstrates a significant amount of residual hippocampal tissue with distinctive cytoarchitecture. Our study also reveals diffuse pathology in the deep white matter and a small, circumscribed lesion in the left orbitofrontal cortex. The findings constitute new evidence that may help elucidate the consequences of H.M.'s operation in the context of the brain's overall pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Annese</LastName><ForeName>Jacopo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schenker-Ahmed</LastName><ForeName>Natalie M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartsch</LastName><ForeName>Hauke</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maechler</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheh</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Natasha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayano</LastName><ForeName>Junya</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghatan</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bresler</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Brain Observatory, San Diego, California 92101, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frosch</LastName><ForeName>Matthew P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital and Harvard Medical School, Massachusetts 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klaming</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] The Brain Observatory, San Diego, California 92101, USA [2] Department of Radiology, University of California San Diego, San Diego, California 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corkin</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Massachusetts 02139, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ARRA R01 EY018359-02S1</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084756</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY018359</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01MH084756</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01EY018359-02</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D057666">Research Support, American Recovery and Reinvestment Act</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="Y">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004210" MajorTopicYN="N">Dissection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="Y">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013194" MajorTopicYN="N">Staining and Labeling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24473151</ArticleId><ArticleId IdType="pmc">PMC3916843</ArticleId><ArticleId IdType="doi">10.1038/ncomms4122</ArticleId><ArticleId IdType="pii">ncomms4122</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Scoville W. B. &amp; Milner B. Loss of recent memory after bilateral hippocampal lesions. J. Neurol. Neurosurg. Psychiatr. 296, 1&#x2013;22 (1957).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC497229</ArticleId><ArticleId IdType="pubmed">13406589</ArticleId></ArticleIdList></Reference><Reference><Citation>Corkin S. Lasting consequences of bilateral medial temporal lobectomy: clinical course and experimental findings in H.M. Sem. Neurol. 4, 249&#x2013;259 (1984).</Citation></Reference><Reference><Citation>Corkin S. Tactually-guided maze learning in man: Effects of unilateral cortical excisions and bilateral hippocampal lesions. Neuropsychologia 3, 339&#x2013;351 (1965).</Citation></Reference><Reference><Citation>Corkin S. Acquisition of motor skill after bilateral medial temporal-lobe excision. Neuropsychologia 6, 255&#x2013;265 (1968).</Citation></Reference><Reference><Citation>Woodruff-Pak D. S. Delay and trace paradigms. Behav. Neurosci. 107, 911&#x2013;925 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8136067</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner B., Corkin S. &amp; Teuber H.-L. Further analysis of the hippocampal amnesiac syndrome: 14-year follow-up study of H.M. Neuropsychologia 6, 215&#x2013;234 (1968).</Citation></Reference><Reference><Citation>Keane M. M., Gabrieli J. D. E., Mapstone H. C., Johnson K. A. &amp; Corkin S. Double dissociation of memory capacities after bilateral occipital-lobe or medial temporal-lobe lesions. Brain 118, 1129&#x2013;1148 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7496775</ArticleId></ArticleIdList></Reference><Reference><Citation>Milner B. Memory and the medial temporal regions of the brain. InBiology of Memory (eds Pribram K. H., Broadbent D. E. )29&#x2013;50Academic Press (1970).</Citation></Reference><Reference><Citation>Milner B. The medial temporal lobe amnesic syndrome. Psychiatr. Clin. N. Am. 28, 599&#x2013;611 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16122569</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen N. J. &amp; Squire L. R. Preserved learning and retention of pattern analyzing skill in amnesia: dissociation of knowing how and knowing that. Science 210, 207&#x2013;209 (1980).</Citation><ArticleIdList><ArticleId IdType="pubmed">7414331</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinvorth S., Levine B. &amp; Corkin S. Medial temporal lobe structures are needed to re-experience remote autobiographical memories: evidence from H.M. and W.R. Neuropsychologia 43, 479&#x2013;496 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15716139</ArticleId></ArticleIdList></Reference><Reference><Citation>Squire L. R. &amp; Wixted J. T. The cognitive neuroscience of human memory since H.M. Ann. Rev. Neurosci. 34, 259&#x2013;288 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192650</ArticleId><ArticleId IdType="pubmed">21456960</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulving E. Episodic and semantic memory. In:Organization of Memory (eds Tulving E., Donaldson W. )381&#x2013;402Academic Press (1972).</Citation></Reference><Reference><Citation>Gabrieli J. D. E., Cohen N. J. &amp; Corkin S. The impaired learning of semantic knowledge following bilateral medial temporal-lobe resection. Brain Cogn. 7, 157&#x2013;177 (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3377896</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kane G., Kensinger E. A. &amp; Corkin S. Evidence for semantic learning in profound amnesia: an investigation with patient H.M. Hippocampus 14, 417&#x2013;425 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15224979</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville W. B. The limbic lobe in man. J. Neurosurg. 11, 64&#x2013;66 (1954).</Citation><ArticleIdList><ArticleId IdType="pubmed">13131095</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville W. B., Dunsmore R. H., Liberson W. T., Henry C. E. &amp; Pepe A. Observations on medial temporal lobotomy and uncotomy in the treatment of psychotic states. Res. Pub. Assoc. Res. Nerv. Ment. Dis. 31, 347&#x2013;373 (1953).</Citation><ArticleIdList><ArticleId IdType="pubmed">13038115</ArticleId></ArticleIdList></Reference><Reference><Citation>Scoville W. B. Amnesia after bilateral mesial temporal-lobe excision: Introduction to case H.M. Neuropsychologia 6, 211&#x2013;213 (1968).</Citation></Reference><Reference><Citation>Corkin S., Amaral D. G., Gonz&#xe1;lez R., Johnson K. &amp; Hyman B. T. H.M.&#x2019;s medial temporal lobe lesion: findings from magnetic resonance imaging. J. Neurosci. 17, 3964&#x2013;3979 (1997).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573687</ArticleId><ArticleId IdType="pubmed">9133414</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat D. H. et al. Neuroimaging H.M.: a 10-year follow-up examination. Hippocampus 16, 936&#x2013;945 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17016801</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Kouwe A. et al. Technical description of post-mortem magnetic resonance neuroimaging of H.M. Program No. 714.17. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online.</Citation></Reference><Reference><Citation>Annese J. Deconstructing Henry: the neuroanatomy and neuroinformatics of the brain of the amnesic patient H.M. Program No. 397.18. 2010 Neuroscience Meeting Planner. San Diego, CA: Society for Neuroscience, 2010. Online.</Citation></Reference><Reference><Citation>Talairach J. &amp; Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain Thieme Medical Publishers (1988).</Citation></Reference><Reference><Citation>Wilson B. A., Baddeley A. D. &amp; Kapur N. Dense amnesia in a professional musician following herpes simplex virus encephalitis. J. Clin. Exp. Neuropsychol. 17, 668&#x2013;681 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8557808</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanacci L., Buffalo E. A., Schmolck H. &amp; Squire L. R. Profound amnesia after damage to the medial temporal lobe: a neuroanatomical and neuropsychological profile of patient E.P. J. Neurosci. 20, 7024&#x2013;7036 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772843</ArticleId><ArticleId IdType="pubmed">10995848</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R., Annese J., Amaral D. G. &amp; Squire L. R. Human amnesia and the medial temporal lobe illuminated by neuropsychological and neurohistological findings for patient E.P. Proc. Natl Acad. Sci. USA 110, E1953&#x2013;E1962 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3666743</ArticleId><ArticleId IdType="pubmed">23620517</ArticleId></ArticleIdList></Reference><Reference><Citation>Damasio A. R., Eslinger P., Damasio H., van Hoesen G. W. &amp; Cornell S. Multimodal amnesic syndrome following bilateral and basal forebrain damage. Arch. Neurol. 42, 252&#x2013;259 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3977656</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese J. The importance of combining MRI and large-scale digital histology in neuroimaging studies of brain connectivity and disease. Front. Neuroinform. 6, 1&#x2013;5 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3334523</ArticleId><ArticleId IdType="pubmed">22536182</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchen L. Famous brain set to go under the knife. Nature 462, 403 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19940891</ArticleId></ArticleIdList></Reference><Reference><Citation>Insausti R. et al. MR volumetric analysis of the human entorhinal, perirhinal, and temporopolar cortices. Am. J. Neuroradiol. 19, 659&#x2013;671 (1998).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8337393</ArticleId><ArticleId IdType="pubmed">9576651</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marcos F. A., Ghizoni E., Kobayashi E., Li L. M. &amp; Cendes F. Cerebellar volume and long-term use of phenytoin. Seizure 12, 312&#x2013;315 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12810345</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghatak N. R., Santoso R. A. &amp; McKinney W. M. Cerebellar degeneration following long-term phenytoin therapy. Neurology 26, 818&#x2013;820 (1976).</Citation><ArticleIdList><ArticleId IdType="pubmed">821007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X. et al. Transcriptional profiling reveals strict boundaries between hippocampal subregions. J. Comp. Neurol. 441, 187&#x2013;196 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11745644</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson C. et al. Genomic anatomy of the hippocampus. Neuron 60, 1010&#x2013;1021 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19109908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanselow M. &amp; Dong H. Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65, 7&#x2013;19 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2822727</ArticleId><ArticleId IdType="pubmed">20152109</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S., Nava A., DeLaPaz R., Mayeux R. &amp; Stern Y. Circuit mechanisms underlying memory encoding and retrieval in the long axis of the hippocampal formation. Nat. Neurosci. 4, 442&#x2013;449 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11276237</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavenex P. &amp; Amaral D. Hippocampal-neocortical interaction: a hierarchy of associativity. Hippocampus 10, 420&#x2013;430 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10985281</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebben N., Corkin S., Eichenbaum H. &amp; Shedlack K. Diminished ability to interpret and report internal states after bilateral medial temporal resection: case H.M. Behav. Neurosci. 99, 1031&#x2013;1039 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">3843537</ArticleId></ArticleIdList></Reference><Reference><Citation>Corkin S. What&#x2019;s new with the amnesic patient H.M.? Nat. Rev. Neurosci. 3, 153&#x2013;160 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11836523</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese J., Pitiot A., Dinov I. &amp; Toga A. A myeloarchitectonic method for the structural classification of cortical areas. NeuroImage 21, 15&#x2013;26 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">14741638</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese J., Gazzaniga M. &amp; Toga A. Localization of the human cortical visual area MT based on computer-aided histological analysis. J. Neurosci. 15, 1044&#x2013;1053 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15590914</ArticleId></ArticleIdList></Reference><Reference><Citation>Duvernoy H. M. The Human Hippocampus: Functional Anatomy, Vascularization and Serial Sections with MRI, Third Edn Springer (2005).</Citation></Reference><Reference><Citation>West M. J. &amp; Gundersen H. J. Unbiased stereological estimation of the number of neurons in the human hippocampus. J. Comp. Neurol. 296, 1&#x2013;22 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2358525</ArticleId></ArticleIdList></Reference><Reference><Citation>Annese J. From the jar to the world wide web: designing a public digital library for the human brain. Interdiscipl. Sci. Rev. 38, 222&#x2013;231 (2013).</Citation></Reference><Reference><Citation>Insausti R. &amp; Amaral D. G. Hippocampal formation. InThe Human Nervous System 2nd edn (eds Paxinos G., Mai J. K. )871&#x2013;914Academic Press (2004).</Citation></Reference><Reference><Citation>Gallyas F. Silver staining of myelin by means of physical development. Neurol. Res. 1, 203&#x2013;209 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">95356</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24477113</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>25</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Prevalence of cortical superficial siderosis in a memory clinic population.</ArticleTitle><Pagination><StartPage>698</StartPage><EndPage>704</EndPage><MedlinePgn>698-704</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000150</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine prevalence, topography, and severity of cortical superficial siderosis (SS), a recently recognized manifestation of cerebral amyloid angiopathy, and its possible association with Alzheimer disease (AD) in a memory clinic patient cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included 809 patients (56% men, aged 66 &#xb1; 10 years) from the Amsterdam Dementia Cohort between November 2010 and November 2012 scanned on a 3-tesla MRI system. We analyzed prevalence and topography of cortical SS according to demographic, clinical, and MRI data. Agreement for SS detection between 2 neuroradiologists was calculated by using Cohen &#x3ba;.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Agreement for detection of SS was excellent (unweighted &#x3ba; of 0.81). In 17 patients (2.1%), cortical SS was found without a known cause. The prevalence of idiopathic SS differed according to diagnostic groups (p &lt; 0.001): nearly 5% (95% confidence interval [CI] 2.8%-8.2%) in patients with AD (n = 168) vs 2% (95% CI 0.7%-6.0%) in patients with mild cognitive impairment (n = 143) and 2.5% (95% CI 0.7%-8.7%) in other types of dementia (n = 80). By contrast, SS was not found in patients with subjective complaints (n = 168) or in those with other disorders (n = 157). Presence of SS was associated with APOE &#x3b5;4, microbleeds, and white matter hyperintensities (all p &lt; 0.05) independent of diagnosis.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The prevalence of cortical SS in a memory clinic setting is higher than reported in the general population but lower than reported in cerebral amyloid angiopathy. The relatively high prevalence of SS in AD suggests that SS is a relevant radiologic manifestation of amyloid pathology in AD. Presence of SS does not seem to predict severity of AD. Further longitudinal research is needed to investigate clinical relevance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zonneveld</LastName><ForeName>Hazel I</ForeName><Initials>HI</Initials><AffiliationInfo><Affiliation>From the Alzheimer Center and the Neuroscience Campus Amsterdam, and Departments of Radiology and Nuclear Medicine (H.I.Z., M.P.W., F.B.), Neurology (J.D.C.G., N.D.P., P.S., W.M.v.d.F.), Epidemiology and Biostatistics (W.M.v.d.F.), Physics and Medical Technology (J.P.A.K.), and Internal Medicine (M.M.), VU University Medical Center, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goos</LastName><ForeName>Jeroen D C</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Wattjes</LastName><ForeName>Mike P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Prins</LastName><ForeName>Niels D</ForeName><Initials>ND</Initials></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>van der Flier</LastName><ForeName>Wiesje M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Kuijer</LastName><ForeName>Joost P A</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Muller</LastName><ForeName>Majon</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barkhof</LastName><ForeName>Frederik</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016657" MajorTopicYN="N">Cerebral Amyloid Angiopathy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012806" MajorTopicYN="N">Siderosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24477113</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000150</ArticleId><ArticleId IdType="pii">WNL.0000000000000150</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24482835</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>505</Volume><Issue>7485</Issue><PubDate><Year>2014</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Policy: NIH plans to enhance reproducibility.</ArticleTitle><Pagination><StartPage>612</StartPage><EndPage>613</EndPage><MedlinePgn>612-3</MedlinePgn></Pagination><Abstract><AbstractText><b>Francis S. Collins and Lawrence A. Tabak</b> discuss initiatives that the US National Institutes of Health is exploring to restore the self-correcting nature of preclinical research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Francis S</ForeName><Initials>FS</Initials></Author><Author ValidYN="Y"><LastName>Tabak</LastName><ForeName>Lawrence A</ForeName><Initials>LA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 OD999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Mar 20;507(7492):306. doi: 10.1038/507306d.</RefSource><PMID Version="1">24646984</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Soc Stud Sci. 2021 Jun;51(3):339-363. doi: 10.1177/0306312720985939.</RefSource><PMID Version="1">33491581</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D022126" MajorTopicYN="N">Access to Information</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D030881" MajorTopicYN="N">Disclosure</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="Y">National Institutes of Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015871" MajorTopicYN="N">Scientific Misconduct</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24482835</ArticleId><ArticleId IdType="mid">NIHMS574872</ArticleId><ArticleId IdType="pmc">PMC4058759</ArticleId><ArticleId IdType="doi">10.1038/505612a</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Prinz F, Schlange T, Asadullah K. Nature Rev. Drug Disc. 2011;10:712&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">21892149</ArticleId></ArticleIdList></Reference><Reference><Citation>The Economist &#x2018;Trouble at the Lab&#x2019;. 2013 Oct 19; available at  http://go.nature.com/dstij3.</Citation></Reference><Reference><Citation>US Department of Health and Human Services. Office of Research Integrity Annual Report 2011. US HHS; 2011.  2011 available at  http://go.nature.com/t7ykcv.</Citation></Reference><Reference><Citation>Carp J. NeuroImage. 2012;63:289&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">22796459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilevsky NA, et al. PeerJ. 2013;1:e148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771067</ArticleId><ArticleId IdType="pubmed">24032093</ArticleId></ArticleIdList></Reference><Reference><Citation>Franzoni C, Scellato G, Stephan P. Science. 2011;333:702&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pubmed">21817035</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Jones A, Lepage L for the CONSORT Group. J. Am. Med. Assoc. 2001;285:1992&#x2013;1995.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013;496:398.</Citation></Reference><Reference><Citation>McNutt M. Science. 2014;343:229.</Citation><ArticleIdList><ArticleId IdType="pubmed">24436391</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis SC, et al. Nature. 2012;490:187&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511845</ArticleId><ArticleId IdType="pubmed">23060188</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24493100</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial.</ArticleTitle><Pagination><StartPage>324</StartPage><EndPage>333</EndPage><MedlinePgn>324-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2013.13656</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Persons with type 2 diabetes mellitus (T2DM) are at increased risk for decline in cognitive function, reduced brain volume, and increased white matter lesions in the brain. Poor control of blood pressure (BP) and lipid levels are risk factors for T2DM-related cognitive decline, but the effect of intensive treatment on brain function and structure is unknown.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether intensive therapy for hypertension and combination therapy with a statin plus a fibrate reduces the risk of decline in cognitive function and total brain volume (TBV) in patients with T2DM.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A North American multicenter clinical trial including 2977 participants without baseline clinical evidence of cognitive impairment or dementia and with hemoglobin A1c (HbA1c) levels less than 7.5% randomized to a systolic BP goal of less than 120 vs less than 140 mm Hg (n = 1439) or to a fibrate vs placebo in patients with low-density lipoprotein cholesterol levels less than 100 mg/dL (n = 1538). Participants were recruited from August 1, 2003, through October 31, 2005, with the final follow-up visit by June 30, 2009.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Cognition was assessed at baseline and 20 and 40 months. A subset of 503 participants underwent baseline and 40-month brain magnetic resonance imaging to assess for change in TBV and other structural measures of brain health.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline mean HbA1c level was 8.3%; mean age, 62 years; and mean duration of T2DM, 10 years. At 40 months, no differences in cognitive function were found in the intensive BP-lowering trial or in the fibrate trial. At 40 months, TBV had declined more in the intensive vs standard BP-lowering group (difference, -4.4 [95% CI, -7.8 to -1.1] cm(3); P =&#x2009;.01). Fibrate therapy had no effect on TBV compared with placebo.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In participants with long-standing T2DM and at high risk for cardiovascular events, intensive BP control and fibrate therapy in the presence of controlled low-density lipoprotein cholesterol levels did not produce a measurable effect on cognitive decline at 40 months of follow-up. Intensive BP control was associated with greater decline in TBV at 40 months relative to standard therapy. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00000620.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Roena B. Kulynych Center for Memory and Cognition Research, Department of Internal Medicine, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Intramural Research Program, National Institute on Aging, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bryan</LastName><ForeName>R Nick</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania Health System, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Social Sciences and Health Policy, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazar</LastName><ForeName>Ronald M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Departments of Neurology and Neurological Surgery, Columbia University College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Hertzel C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Medicine, McMaster University, Hamilton, Ontario, Canada7Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Hennepin County Medical Center and Chronic Disease Research Group, Minneapolis, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Karen R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jingzhong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Roena B. Kulynych Center for Memory and Cognition Research, Department of Internal Medicine, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcovina</LastName><ForeName>Santica</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovato</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovato</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margolis</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>Division of Epidemiology and Community Health, University of Minnesota Medical School, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, University of Pennsylvania Health System, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barzilay</LastName><ForeName>Joshua</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Kaiser Permanente, Crescent Center Medical Office, Tucker, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginsberg</LastName><ForeName>Henry N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linz</LastName><ForeName>Peter E</ForeName><Initials>PE</Initials><AffiliationInfo><Affiliation>Cardiology Division, Naval Medical Center San Diego, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Action to Control Cardiovascular Risk in Diabetes  Memory in Diabetes Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00000620</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>HHSN268201100027C</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2014 Mar;174(3):333-5. doi: 10.1001/jamainternmed.2013.7674.</RefSource><PMID Version="1">24492927</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2014 Feb 03;348:g1302. doi: 10.1136/bmj.g1302.</RefSource><PMID Version="1">24495841</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006937" MajorTopicYN="N">Hypercholesterolemia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>William</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Launer</LastName><ForeName>Lenore J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kramer</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coker</LastName><ForeName>Laura H</ForeName><Initials>LH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovato</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lovato</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hepler</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Felton</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Leanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carter</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woolard</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bryan</LastName><ForeName>R Nick</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Desiderio</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davatzikos</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bilello</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Melhem</LastName><ForeName>Elias R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koka</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parmpi</LastName><ForeName>Evi</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Battapady</LastName><ForeName>Harsha</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erus</LastName><ForeName>Guray</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerstein</LastName><ForeName>Hertzel C</ForeName><Initials>HC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Salim</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capes</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Punthakee</LastName><ForeName>Zubin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cukierman-Yaffe</LastName><ForeName>Tali</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vallis</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mackie</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiding</LastName><ForeName>V</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Rosalie</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tadeson</LastName><ForeName>Beth</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thompson</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capes</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Punthakee</LastName><ForeName>Zubin</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Ada</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valla</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joyce</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsons</LastName><ForeName>Minnie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowe</LastName><ForeName>Bernadette</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hramiak</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gehring</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tereschyn</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lochnan</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maranger</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLean</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sigal</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woo</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berard</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anderlic</LastName><ForeName>Teresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bernard</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mawani</LastName><ForeName>Al-Noor</ForeName><Initials>AN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abbott</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ur</LastName><ForeName>Ehud</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yuille</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murdock</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palmer</LastName><ForeName>Tabitha</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patterson</LastName><ForeName>Anne Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimm</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Kirpach</LastName><ForeName>Brenda</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartkoske</LastName><ForeName>Marian M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyce</LastName><ForeName>Colleen M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Druckman</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gillett</LastName><ForeName>Arlene M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Julie A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Livingston</LastName><ForeName>Gloria J</ForeName><Initials>GJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Margolis</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truwit</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kempainen</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madden</LastName><ForeName>Marcia</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergenstal</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cuddihy</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davick</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>List</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whipple</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashanti</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kendall</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seaquist</LastName><ForeName>Elizabeth R</ForeName><Initials>ER</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mech</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benedict</LastName><ForeName>Luke E</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Demmon</LastName><ForeName>Debra J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Anjali F</ForeName><Initials>AF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinson</LastName><ForeName>Shaina M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Sherry A</ForeName><Initials>SA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pease</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Jyothi P</ForeName><Initials>JP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Redmon</LastName><ForeName>J Bruce</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swanson</LastName><ForeName>Joyce E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wimmer</LastName><ForeName>Julie K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okorocha</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stiles</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kodl</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chadha</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Kevin A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seaquist</LastName><ForeName>Lea A</ForeName><Initials>LA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boese</LastName><ForeName>Christy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mendenhall</LastName><ForeName>Tai J</ForeName><Initials>TJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Andrea M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rudelt</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schrock</LastName><ForeName>Terri M</ForeName><Initials>TM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sperl-Hillen</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Connor</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Busch</LastName><ForeName>Maureeen E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chung</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Becky K</ForeName><Initials>BK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krugen</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bunkers-Lawson</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ekstrom</LastName><ForeName>Heidi L</ForeName><Initials>HL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunderson</LastName><ForeName>Heidi S</ForeName><Initials>HS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Bonnie M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacIndoe</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prewedo</LastName><ForeName>Donna J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rawl</LastName><ForeName>Janet L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roethke</LastName><ForeName>Colleen M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fox</LastName><ForeName>Carol R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bate</LastName><ForeName>Beverly M</ForeName><Initials>BM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cao</LastName><ForeName>Q T</ForeName><Initials>Q</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ohnstad</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meyers</LastName><ForeName>P J</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sivitz</LastName><ForeName>William I</ForeName><Initials>WI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wayson</LastName><ForeName>Sheila M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lower</LastName><ForeName>Theresa A</ForeName><Initials>TA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ochs</LastName><ForeName>Kurt A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wells</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazar</LastName><ForeName>Ronald M</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Slane</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Jimenez</LastName><ForeName>Carlos R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Joy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Truman R</ForeName><Initials>TR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dashnaw</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz-Lobo</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schubart</LastName><ForeName>Ulrich K</ForeName><Initials>UK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russo</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincenty</LastName><ForeName>Nilda</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ibarrando</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alderman</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carroll</LastName><ForeName>Lillian</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanguily</LastName><ForeName>Mary Jo</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>Anna C</ForeName><Initials>AC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramos</LastName><ForeName>Lee</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brillon</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cordero</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiong</LastName><ForeName>Raymond</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyams</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bastien</LastName><ForeName>Arnaud</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grudzinski</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niblack</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Abreu</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casale</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dougherty</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linneman</LastName><ForeName>Dawn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvador</LastName><ForeName>Miriam A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zee</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atabek</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miranda</LastName><ForeName>Jenifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Indira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hill</LastName><ForeName>Cherry</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brautigam</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fischer</LastName><ForeName>Rosemary</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scharf</LastName><ForeName>Deanna M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brautigam</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nunn</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiarot</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flanders</LastName><ForeName>Chris</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goland</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kringas</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montes</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belle</LastName><ForeName>Janiel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berrie</LastName><ForeName>Naomi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Getaneh</LastName><ForeName>Asqual</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramirez</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kranwinkel</LastName><ForeName>G</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vasquez</LastName><ForeName>Erida</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donovan</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Febres</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Clara</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jonaitis</LastName><ForeName>Mary Anne</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez-Jimenez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banerji</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Patel</LastName><ForeName>Priti</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Sondra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genuth</LastName><ForeName>Saul</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail-Beigi</LastName><ForeName>Faramarz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thibonnier</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargo</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelly</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bongorno</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dolish</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavlik</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiktin</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isteitieh</LastName><ForeName>Souzan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bartlett</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yee</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulow</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sunshine</LastName><ForeName>Jeffery</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clampitt</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail-Beigi</LastName><ForeName>Faramarz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krikorian</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>L</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coles-Herman</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frankino</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sood</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hustak</LastName><ForeName>Leighanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julius</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pavlik</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Toni</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Mary K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauss</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Behm</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eskandari</LastName><ForeName>Farideh</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isteitieh</LastName><ForeName>Souzan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Madhun</LastName><ForeName>Zuhayr</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Seeholzer</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shina</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Harris</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schnall</LastName><ForeName>Adrian</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadler</LastName><ForeName>Laurie S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffith</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hornsby</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klyn</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ospelt</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Long</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeSmit</LastName><ForeName>Mariellen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCann</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Nicole Pero</ForeName><Initials>NP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kulow</LastName><ForeName>Tanya</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zaletal</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schnall</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dragmen</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellert</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Jonathon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leksan</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sussman</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail-Beigi</LastName><ForeName>Faramarz</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hustak</LastName><ForeName>Leighanne</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Julius</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwing</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isteitieh</LastName><ForeName>Souzan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kern</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richmond</LastName><ForeName>Mary Ann</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberts</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shina</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suhan</LastName><ForeName>Pam</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Harris</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strauss</LastName><ForeName>G J</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akpunonu</LastName><ForeName>Basil</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Franco-Saenz</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Jenny</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bauer</LastName><ForeName>Becky</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pop-Busui</LastName><ForeName>Rodica</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roman</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blust</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kahkonen</LastName><ForeName>Dorothy M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cushman</LastName><ForeName>Terra</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roman</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stys</LastName><ForeName>Ann M</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>White</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Austin</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chatterton</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Francis</LastName><ForeName>J Kimberly</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kruger</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McLellan</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitehouse</LastName><ForeName>Fred</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgins</LastName><ForeName>E</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Shiri</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schoenherr</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goff</LastName><ForeName>David C</ForeName><Initials>DC</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Summerson</LastName><ForeName>John H</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crago</LastName><ForeName>Lenore</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blackwell</LastName><ForeName>Caroline S</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bertoni</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blaine</LastName><ForeName>Rhonda L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirk</LastName><ForeName>Julienne K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spach</LastName><ForeName>Rhonda L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calles</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katula</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wishnietsky</LastName><ForeName>Dorothy B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordineer</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ding</LastName><ForeName>Jingzhong</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaminsky</LastName><ForeName>Sandy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuller</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feinglos</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jones</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gedon-Lipscomb</LastName><ForeName>Georgianne</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Atkinson</LastName><ForeName>Hal H</ForeName><Initials>HH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanfield</LastName><ForeName>Judy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delvalle-Fagan</LastName><ForeName>Thania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedley</LastName><ForeName>Carolyn F</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauney</LastName><ForeName>Sally</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duclos</LastName><ForeName>Michelle D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kirby</LastName><ForeName>Ruth E</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goley</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vukojicik</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Jerry L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Besterman</LastName><ForeName>W</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Surgener</LastName><ForeName>M</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dulin</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barringer</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Norton</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peace</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stuart</LastName><ForeName>Dennis O</ForeName><Initials>DO</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strickland</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanfield</LastName><ForeName>Judy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peace</LastName><ForeName>Robin</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strickland</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanfield</LastName><ForeName>Judy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crouse</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Suffix>3rd</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Ellis</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fonseca</LastName><ForeName>Vivian</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>John-Kalarickal</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leger</LastName><ForeName>Sharice M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munshi</LastName><ForeName>Kartik</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barzilay</LastName><ForeName>Joshua</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bader</LastName><ForeName>Katrina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eley</LastName><ForeName>Melanie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Probstfield</LastName><ForeName>Jeffery L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kingry</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Janice M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Line</LastName><ForeName>A S</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corson</LastName><ForeName>Marshall A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Knopp</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lipkin</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griswold</LastName><ForeName>C</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liebert</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Ashley</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juliano</LastName><ForeName>Dawn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurashige</LastName><ForeName>Ella Mae</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moberg</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leader</LastName><ForeName>J</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ariani</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Haydee</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Failor</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellsworth</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jackson</LastName><ForeName>Nikki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Capoccia</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Force</LastName><ForeName>Rex</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Mimi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Koester</LastName><ForeName>Shannon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pettingill</LastName><ForeName>Krysti</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linz</LastName><ForeName>Peter E</ForeName><Initials>PE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pepper</LastName><ForeName>Patricia V</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griffin</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kozlowski</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Engle</LastName><ForeName>Marty</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gutierrez</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riddle</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDaniel</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gammell-Matthews</LastName><ForeName>Sarah C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>MacNeil</LastName><ForeName>Brittany</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>DesRochers</LastName><ForeName>Sharlene K</ForeName><Initials>SK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swift</LastName><ForeName>Reyna</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wysham</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weeks</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuntsmann</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dudl</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wu</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murray</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palma</LastName><ForeName>Anton</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevenson</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dailey</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Philas-Tsimikas</LastName><ForeName>Athena</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giannella</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bravo-Medina</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobson</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farro</LastName><ForeName>Estela</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cruz</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juarez</LastName><ForeName>Noemi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dadkhah</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24493100</ArticleId><ArticleId IdType="mid">NIHMS673871</ArticleId><ArticleId IdType="pmc">PMC4423790</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2013.13656</ArticleId><ArticleId IdType="pii">1819574</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>McBean AM, Li S, Gilbertson DT, Collins AJ. Differences in diabetes prevalence, incidence, and mortality among the elderly of four racial/ethnic groups: whites, blacks, Hispanics, and Asians. Diabetes Care. 2004;27(10):2317&#x2013;2324.</Citation><ArticleIdList><ArticleId IdType="pubmed">15451894</ArticleId></ArticleIdList></Reference><Reference><Citation>Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16361024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R, Anstey KJ, Cherbuin N, Wen W, Sachdev PS. Association of type 2 diabetes with depression, brain atrophy, and reduced fine motor speed in a 60- to 64-year-old community sample. Am J Geriatr Psychiatry. 2008;16(12):989&#x2013;998.</Citation><ArticleIdList><ArticleId IdType="pubmed">19038898</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt R, Launer LJ, Nilsson LG, et al. CASCADE Consortium. Magnetic resonance imaging of the brain in diabetes: the Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes. 2004;53(3):687&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">14988253</ArticleId></ArticleIdList></Reference><Reference><Citation>Jongen C, van der Grond J, Kappelle LJ, Biessels GJ, Viergever MA, Pluim JP Utrecht Diabetic Encephalopathy Study Group. Automated measurement of brain and white matter lesion volume in type 2 diabetes mellitus. Diabetologia. 2007;50(7):1509&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1914300</ArticleId><ArticleId IdType="pubmed">17492428</ArticleId></ArticleIdList></Reference><Reference><Citation>Guttmann CR, Benson R, Warfield SK, et al. White matter abnormalities in mobility-impaired older persons. Neurology. 2000;54(6):1277&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">10746598</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Flier WM, van Straaten EC, Barkhof F, et al. LADIS Study Group. Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. J Neurol Neurosurg Psychiatry. 2005;76(11):1497&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1739423</ArticleId><ArticleId IdType="pubmed">16227537</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias PK, Elias MF, D&#x2019;Agostino RB, et al. NIDDM and blood pressure as risk factors for poor cognitive performance: the Framingham Study. Diabetes Care. 1997;20(9):1388&#x2013;1395.</Citation><ArticleIdList><ArticleId IdType="pubmed">9283785</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST. Statin therapy in the treatment of Alzheimer disease: what is the rationale? Am J Med. 2005;118(12A) suppl 12A:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16356808</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson JD, Miller ME, Bryan RN, et al. ACCORD Study Group. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. Am J Cardiol. 2007;99(12A):112i&#x2013;122i.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599421</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse JB, Bigger JT, Byington RP, et al. ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i&#x2013;33i.</Citation><ArticleIdList><ArticleId IdType="pubmed">17599422</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ, Miller ME, Williamson JD, et al. ACCORD MIND Investigators. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10(11):969&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3333485</ArticleId><ArticleId IdType="pubmed">21958949</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545&#x2013;2559.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4551392</ArticleId><ArticleId IdType="pubmed">18539917</ArticleId></ArticleIdList></Reference><Reference><Citation>Cukierman T, Gerstein HC, Williamson JD. Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia. 2005;48(12):2460&#x2013;2469.</Citation><ArticleIdList><ArticleId IdType="pubmed">16283246</ArticleId></ArticleIdList></Reference><Reference><Citation>Coker LH, Shumaker SA. Type 2 diabetes mellitus and cognition: an understudied issue in women&#x2019;s health. J Psychosom Res. 2003;54(2):129&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">12573734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D, editor. Wechsler Adult Intelligence Scale&#x2013;Revised. New York, NY: Psychological Corp; 1988.</Citation></Reference><Reference><Citation>Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.</Citation></Reference><Reference><Citation>Houx PJ, Jolles J, Vreeling FW. Stroop interference: aging effects assessed with the Stroop Color-Word Test. Exp Aging Res. 1993;19(3):209&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pubmed">8223823</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldszal AF, Davatzikos C, Pham DL, Yan MX, Bryan RN, Resnick SM. An image-processing system for qualitative and quantitative volumetric analysis of brain images. J Comput Assist Tomogr. 1998;22(5):827&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">9754125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lao Z, Shen D, Liu D, et al. Computer-assisted segmentation of white matter lesions in 3D MR images using support vector machine. Acad Radiol. 2008;15(3):300&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2528894</ArticleId><ArticleId IdType="pubmed">18280928</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991;1(3):263&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">1669507</ArticleId></ArticleIdList></Reference><Reference><Citation>Molenberghs G, Kenward M, editors. Missing Data in Clinical Studies. Chichester, England: Wiley &amp; Sons; 2007.</Citation></Reference><Reference><Citation>Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine: reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189&#x2013;2194.</Citation><ArticleIdList><ArticleId IdType="pubmed">18032770</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginsberg HN, Elam MB, Lovato LC, et al. ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879499</ArticleId><ArticleId IdType="pubmed">20228404</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman WC, Evans GW, Byington RP, et al. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575&#x2013;1585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4123215</ArticleId><ArticleId IdType="pubmed">20228401</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein HC, Miller ME, Genuth S, et al. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083508</ArticleId><ArticleId IdType="pubmed">21366473</ArticleId></ArticleIdList></Reference><Reference><Citation>Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. Circulation. 2011;123(3):266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220733</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leeuw F-E, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(pt 4):765&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pubmed">11912110</ArticleId></ArticleIdList></Reference><Reference><Citation>Launer LJ. Diabetes and brain aging: epidemiologic evidence. Curr Diab Rep. 2005;5(1):59&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15663919</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24501346</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.</ArticleTitle><Pagination><StartPage>2037</StartPage><EndPage>2050</EndPage><MedlinePgn>2037-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.2581-13.2014</ELocationID><Abstract><AbstractText>Parkinson's disease and dementia with Lewy bodies are associated with abnormal neuronal aggregation of &#x3b1;-synuclein. However, the mechanisms of aggregation and their relationship to disease are poorly understood. We developed an in vivo multiphoton imaging paradigm to study &#x3b1;-synuclein aggregation in mouse cortex with subcellular resolution. We used a green fluorescent protein-tagged human &#x3b1;-synuclein mouse line that has moderate overexpression levels mimicking human disease. Fluorescence recovery after photobleaching (FRAP) of labeled protein demonstrated that somatic &#x3b1;-synuclein existed primarily in an unbound, soluble pool. In contrast, &#x3b1;-synuclein in presynaptic terminals was in at least three different pools: (1) as unbound, soluble protein; (2) bound to presynaptic vesicles; and (3) as microaggregates. Serial imaging of microaggregates over 1 week demonstrated a heterogeneous population with differing &#x3b1;-synuclein exchange rates. The microaggregate species were resistant to proteinase K, phosphorylated at serine-129, oxidized, and associated with a decrease in the presynaptic vesicle protein synapsin and glutamate immunogold labeling. Multiphoton FRAP provided the specific binding constants for &#x3b1;-synuclein's binding to synaptic vesicles and its effective diffusion coefficient in the soma and axon, setting the stage for future studies targeting synuclein modifications and their effects. Our in vivo results suggest that, under moderate overexpression conditions, &#x3b1;-synuclein aggregates are selectively found in presynaptic terminals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spinelli</LastName><ForeName>Kateri J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, Oregon 97239, Research Services, Neurocytology Laboratory, Veterans Affairs Medical Center, Portland, Oregon 97239, Departments of Behavioral Neuroscience and Pathology, Oregon Health and Science University, Portland, Oregon 97239, and Parkinson Center of Oregon, Department of Neurology, Oregon Health and Science University, Portland, Oregon 97239.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Jonathan K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Osterberg</LastName><ForeName>Valerie R</ForeName><Initials>VR</Initials></Author><Author ValidYN="Y"><LastName>Churchill</LastName><ForeName>Madeline J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Eden</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Meshul</LastName><ForeName>Charles K</ForeName><Initials>CK</Initials></Author><Author ValidYN="Y"><LastName>Unni</LastName><ForeName>Vivek K</ForeName><Initials>VK</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NS061800</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG024978</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AT002688</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000128</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS069625</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG024978</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS061800</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AT002688</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS069625</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036681" MajorTopicYN="N">Fluorescence Recovery After Photobleaching</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24501346</ArticleId><ArticleId IdType="pmc">PMC3913861</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.2581-13.2014</ArticleId><ArticleId IdType="pii">34/6/2037</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Adalbert R, Coleman MP. Axon pathology in age-related neurodegenerative disorders. Neuropathol Appl Neurobiol. 2012</Citation><ArticleIdList><ArticleId IdType="pubmed">23046254</ArticleId></ArticleIdList></Reference><Reference><Citation>Arima K, U&#xe9;da K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res. 1998;808:93&#x2013;100. doi: 10.1016/S0006-8993(98)00734-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(98)00734-3</ArticleId><ArticleId IdType="pubmed">9795161</ArticleId></ArticleIdList></Reference><Reference><Citation>Arrio-Dupont M, Foucault G, Vacher M, Devaux PF, Cribier S. Translational diffusion of globular proteins in the cytoplasm of cultured muscle cells. Biophys J. 2000;78:901&#x2013;907. doi: 10.1016/S0006-3495(00)76647-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(00)76647-1</ArticleId><ArticleId IdType="pmc">PMC1300692</ArticleId><ArticleId IdType="pubmed">10653802</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamford NS, Robinson S, Palmiter RD, Joyce JA, Moore C, Meshul CK. Dopamine modulates release from corticostriatal terminals. J Neurosci. 2004;24:9541&#x2013;9552. doi: 10.1523/JNEUROSCI.2891-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2891-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730145</ArticleId><ArticleId IdType="pubmed">15509741</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartels T, Choi JG, Selkoe DJ. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107&#x2013;110. doi: 10.1038/nature10324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10324</ArticleId><ArticleId IdType="pmc">PMC3166366</ArticleId><ArticleId IdType="pubmed">21841800</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci. 2000;3:1301&#x2013;1306. doi: 10.1038/81834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/81834</ArticleId><ArticleId IdType="pubmed">11100151</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodner RA, Housman DE, Kazantsev AG. New directions for neurodegenerative disease therapy: using chemical compounds to boost the formation of mutant protein inclusions. Cell Cycle. 2006;5:1477&#x2013;1480. doi: 10.4161/cc.5.14.2929.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cc.5.14.2929</ArticleId><ArticleId IdType="pubmed">16861893</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown EB, Wu ES, Zipfel W, Webb WW. Measurement of molecular diffusion in solution by multiphoton fluorescence photobleaching recovery. Biophys J. 1999;77:2837&#x2013;2849. doi: 10.1016/S0006-3495(99)77115-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(99)77115-8</ArticleId><ArticleId IdType="pmc">PMC1300555</ArticleId><ArticleId IdType="pubmed">10545381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Dest&#xe9;e A. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004;364:1167&#x2013;1169. doi: 10.1016/S0140-6736(04)17103-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)17103-1</ArticleId><ArticleId IdType="pubmed">15451224</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4:1318&#x2013;1320. doi: 10.1038/3311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3311</ArticleId><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol. 1992;83:525&#x2013;529. doi: 10.1007/BF00310030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00310030</ArticleId><ArticleId IdType="pubmed">1320323</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273:9443&#x2013;9449. doi: 10.1074/jbc.273.16.9443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.16.9443</ArticleId><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Dettmer U, Newman AJ, Luth ES, Bartels T, Selkoe D. In vivo cross-linking reveals principally oligomeric forms of alpha-synuclein and beta-synuclein in neurons and non-neural cells. J Biol Chem. 2013;288:6371&#x2013;6385. doi: 10.1074/jbc.M112.403311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.403311</ArticleId><ArticleId IdType="pmc">PMC3585072</ArticleId><ArticleId IdType="pubmed">23319586</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011;286:35104&#x2013;35118. doi: 10.1074/jbc.M111.247965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.247965</ArticleId><ArticleId IdType="pmc">PMC3186371</ArticleId><ArticleId IdType="pubmed">21846727</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, Langston JW. Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol. 2004;55:174&#x2013;179. doi: 10.1002/ana.10846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10846</ArticleId><ArticleId IdType="pubmed">14755720</ArticleId></ArticleIdList></Reference><Reference><Citation>Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, Lashuel HA. Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer. J Biol Chem. 2012;287:15345&#x2013;15364. doi: 10.1074/jbc.M111.318949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.318949</ArticleId><ArticleId IdType="pmc">PMC3346117</ArticleId><ArticleId IdType="pubmed">22315227</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris AM, Giberson RT, Sanders MA, Day JR. Advanced laboratory techniques for sample processing and immunolabeling using microwave radiation. J Neurosci Methods. 2009;182:157&#x2013;164. doi: 10.1016/j.jneumeth.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneumeth.2009.06.002</ArticleId><ArticleId IdType="pubmed">19520116</ArticleId></ArticleIdList></Reference><Reference><Citation>Flusberg BA, Cocker ED, Piyawattanametha W, Jung JC, Cheung EL, Schnitzer MJ. Fiber-optic fluorescence imaging. Nat Methods. 2005;2:941&#x2013;950. doi: 10.1038/nmeth820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth820</ArticleId><ArticleId IdType="pmc">PMC2849801</ArticleId><ArticleId IdType="pubmed">16299479</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortin DL, Nemani VM, Voglmaier SM, Anthony MD, Ryan TA, Edwards RH. Neural activity controls the synaptic accumulation of alpha-synuclein. J Neurosci. 2005;25:10913&#x2013;10921. doi: 10.1523/JNEUROSCI.2922-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2922-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725870</ArticleId><ArticleId IdType="pubmed">16306404</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164. doi: 10.1038/ncb748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb748</ArticleId><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvin JE, Uryu K, Lee VM, Trojanowski JQ. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A. 1999;96:13450&#x2013;13455. doi: 10.1073/pnas.96.23.13450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.23.13450</ArticleId><ArticleId IdType="pmc">PMC23968</ArticleId><ArticleId IdType="pubmed">10557341</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science. 2000;290:985&#x2013;989. doi: 10.1126/science.290.5493.985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.290.5493.985</ArticleId><ArticleId IdType="pubmed">11062131</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34:521&#x2013;533. doi: 10.1016/S0896-6273(02)00682-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00682-7</ArticleId><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci. 2001;2:492&#x2013;501. doi: 10.1038/35081564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35081564</ArticleId><ArticleId IdType="pubmed">11433374</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Tortosa E, Newell K, Irizarry MC, Sanders JL, Hyman BT. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 2000;99:352&#x2013;357. doi: 10.1007/s004010051135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010051135</ArticleId><ArticleId IdType="pubmed">10787032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport. 1999;10:717&#x2013;721. doi: 10.1097/00001756-199903170-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199903170-00011</ArticleId><ArticleId IdType="pubmed">10208537</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Porat-Shliom Y, Pei Z, Cheng Y, Xiang L, Sommers K, Li Q, Gillardon F, Hengerer B, Berlinicke C, Smith WW, Zack DJ, Poirier MA, Ross CA, Duan W. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem. 2010;114:419&#x2013;429. doi: 10.1111/j.1471-4159.2010.06752.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06752.x</ArticleId><ArticleId IdType="pmc">PMC2910156</ArticleId><ArticleId IdType="pubmed">20412383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci. 2007;27:1405&#x2013;1410. doi: 10.1523/JNEUROSCI.4564-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4564-06.2007</ArticleId><ArticleId IdType="pmc">PMC6673583</ArticleId><ArticleId IdType="pubmed">17287515</ArticleId></ArticleIdList></Reference><Reference><Citation>Kr&#xfc;ger R, Kuhn W, M&#xfc;ller T, Woitalla D, Graeber M, K&#xf6;sel S, Przuntek H, Epplen JT, Sch&#xf6;ls L, Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106&#x2013;108. doi: 10.1038/ng0298-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0298-106</ArticleId><ArticleId IdType="pubmed">9462735</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, Bennett DA, Lesn&#xe9; SE. Soluble alpha-synuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci. 2012;32:10253&#x2013;10266. doi: 10.1523/JNEUROSCI.0581-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0581-12.2012</ArticleId><ArticleId IdType="pmc">PMC3425439</ArticleId><ArticleId IdType="pubmed">22836259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippincott-Schwartz J, Snapp E, Kenworthy A. Studying protein dynamics in living cells. Nat Rev Mol Cell Biol. 2001;2:444&#x2013;456. doi: 10.1038/35073068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35073068</ArticleId><ArticleId IdType="pubmed">11389468</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209:975&#x2013;986. doi: 10.1084/jem.20112457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112457</ArticleId><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949&#x2013;953. doi: 10.1126/science.1227157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroteaux L, Scheller RH. The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res. 1991;11:335&#x2013;343. doi: 10.1016/0169-328X(91)90043-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-328X(91)90043-W</ArticleId><ArticleId IdType="pubmed">1661825</ArticleId></ArticleIdList></Reference><Reference><Citation>Marui W, Iseki E, Nakai T, Miura S, Kato M, U&#xe9;da K, Kosaka K. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci. 2002;195:153&#x2013;159. doi: 10.1016/S0022-510X(02)00006-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(02)00006-0</ArticleId><ArticleId IdType="pubmed">11897247</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science. 2000;287:1265&#x2013;1269. doi: 10.1126/science.287.5456.1265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5456.1265</ArticleId><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013;136:1128&#x2013;1138. doi: 10.1093/brain/awt037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt037</ArticleId><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza D, Braeckmans K, Cella F, Testa I, Vercauteren D, Demeester J, De Smedt SS, Diaspro A. A new FRAP/FRAPa method for three-dimensional diffusion measurements based on multiphoton excitation microscopy. Biophys J. 2008;95:3457&#x2013;3469. doi: 10.1529/biophysj.108.133637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.108.133637</ArticleId><ArticleId IdType="pmc">PMC2547427</ArticleId><ArticleId IdType="pubmed">18621824</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshul CK, McGinty JF. Kappa opioid receptor immunoreactivity in the nucleus accumbens and caudate-putamen is primarily associated with synaptic vesicles in axons. Neuroscience. 2000;96:91&#x2013;99. doi: 10.1016/S0306-4522(99)90481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(99)90481-5</ArticleId><ArticleId IdType="pubmed">10683414</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshul CK, Stallbaumer RK, Taylor B, Janowsky A. Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res. 1994;648:181&#x2013;195. doi: 10.1016/0006-8993(94)91117-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(94)91117-7</ArticleId><ArticleId IdType="pubmed">7922533</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshul CK, Emre N, Nakamura CM, Allen C, Donohue MK, Buckman JF. Time-dependent changes in striatal glutamate synapses following a 6-hydroxydopamine lesion. Neuroscience. 1999;88:1&#x2013;16. doi: 10.1016/S0306-4522(98)00189-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(98)00189-4</ArticleId><ArticleId IdType="pubmed">10051185</ArticleId></ArticleIdList></Reference><Reference><Citation>Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem. 2002;277:19213&#x2013;19219. doi: 10.1074/jbc.M110551200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110551200</ArticleId><ArticleId IdType="pubmed">11893734</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller F, Morisaki T, Mazza D, McNally JG. Minimizing the impact of photoswitching of fluorescent proteins on FRAP analysis. Biophys J. 2012;102:1656&#x2013;1665. doi: 10.1016/j.bpj.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bpj.2012.02.029</ArticleId><ArticleId IdType="pmc">PMC3318116</ArticleId><ArticleId IdType="pubmed">22500766</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray TA, Levene MJ. Singlet gradient index lens for deep in vivo multiphoton microscopy. J Biomed Opt. 2012;17 doi: 10.1117/1.JBO.17.2.021106. 021106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.JBO.17.2.021106</ArticleId><ArticleId IdType="pubmed">22463024</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura K, Nemani VM, Azarbal F, Skibinski G, Levy JM, Egami K, Munishkina L, Zhang J, Gardner B, Wakabayashi J, Sesaki H, Cheng Y, Finkbeiner S, Nussbaum RL, Masliah E, Edwards RH. Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem. 2011;286:20710&#x2013;20726. doi: 10.1074/jbc.M110.213538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.213538</ArticleId><ArticleId IdType="pmc">PMC3121472</ArticleId><ArticleId IdType="pubmed">21489994</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, Lee MK, Chaudhry FA, Nicoll RA, Edwards RH. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79. doi: 10.1016/j.neuron.2009.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.12.023</ArticleId><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, M&#xfc;ller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest. 2002;110:1429&#x2013;1439. doi: 10.1172/JCI15777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI15777</ArticleId><ArticleId IdType="pmc">PMC151810</ArticleId><ArticleId IdType="pubmed">12438441</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris EH, Giasson BI, Lee VM. Alpha-synuclein: Normal function and role in neurodegenerative diseases. Curr Top Dev Biol. 2004;60:17&#x2013;54. doi: 10.1016/S0070-2153(04)60002-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0070-2153(04)60002-0</ArticleId><ArticleId IdType="pubmed">15094295</ArticleId></ArticleIdList></Reference><Reference><Citation>Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A. 2013;110:E3945&#x2013;E3954. doi: 10.1073/pnas.1309991110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1309991110</ArticleId><ArticleId IdType="pmc">PMC3799334</ArticleId><ArticleId IdType="pubmed">23983262</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, Carvalho F, Hyman BT, McLean PJ. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One. 2008;3:e1867. doi: 10.1371/journal.pone.0001867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001867</ArticleId><ArticleId IdType="pmc">PMC2270899</ArticleId><ArticleId IdType="pubmed">18382657</ArticleId></ArticleIdList></Reference><Reference><Citation>Phend KD, Weinberg RJ, Rustioni A. Techniques to optimize post-embedding single and double staining for amino acid neurotransmitters. J Histochem Cytochem. 1992;40:1011&#x2013;1020. doi: 10.1177/40.7.1376741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/40.7.1376741</ArticleId><ArticleId IdType="pubmed">1376741</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045&#x2013;2047. doi: 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, Danner S, Schell H, Boden C, Ruegg MA, Kahle PJ, van der Putten H, Shimshek DR. Neuropathology in mice expressing mouse alpha-synuclein. PLoS One. 2011;6:e24834. doi: 10.1371/journal.pone.0024834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024834</ArticleId><ArticleId IdType="pmc">PMC3180287</ArticleId><ArticleId IdType="pubmed">21966373</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizo J, Sudhof TC. The membrane fusion enigma: SNARES, Sec/Munc18 proteins, and their accomplices&#x2013;guilty as charged? Annu Rev Cell Dev Biol. 2012;28:279&#x2013;303. doi: 10.1146/annurev-cellbio-101011-155818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-cellbio-101011-155818</ArticleId><ArticleId IdType="pubmed">23057743</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberti MJ, Jovin TM, Jares-Erijman E. Confocal fluorescence anisotropy and FRAP imaging of alpha-synuclein amyloid aggregates in living cells. PLoS One. 2011;6:e23338. doi: 10.1371/journal.pone.0023338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023338</ArticleId><ArticleId IdType="pmc">PMC3152574</ArticleId><ArticleId IdType="pubmed">21858077</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E. Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein. J Neurosci Res. 2005;80:247&#x2013;259. doi: 10.1002/jnr.20446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.20446</ArticleId><ArticleId IdType="pubmed">15765523</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Arendt O, Brown EB, Schwaller B, Eilers J. Parvalbumin is freely mobile in axons, somata and nuclei of cerebellar purkinje neurones. J Neurochem. 2007;100:727&#x2013;735. doi: 10.1111/j.1471-4159.2006.04231.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04231.x</ArticleId><ArticleId IdType="pubmed">17263794</ArticleId></ArticleIdList></Reference><Reference><Citation>Schnell EA, Eikenes L, Tufto I, Erikson A, Juthajan A, Lindgren M, de Lange Davies C. Diffusion measured by fluorescence recovery after photobleaching based on multiphoton excitation laser scanning microscopy. J Biomed Opt. 2008;13 doi: 10.1117/1.3042274. 064037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1117/1.3042274</ArticleId><ArticleId IdType="pubmed">19123683</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott D, Roy S. Alpha-synuclein inhibits intersynaptic vesicle mobility and maintains recycling-pool homeostasis. J Neurosci. 2012;32:10129&#x2013;10135. doi: 10.1523/JNEUROSCI.0535-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0535-12.2012</ArticleId><ArticleId IdType="pmc">PMC3426499</ArticleId><ArticleId IdType="pubmed">22836248</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30:8083&#x2013;8095. doi: 10.1523/JNEUROSCI.1091-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1091-10.2010</ArticleId><ArticleId IdType="pmc">PMC2901533</ArticleId><ArticleId IdType="pubmed">20554859</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibayama-Imazu T, Okahashi I, Omata K, Nakajo S, Ochiai H, Nakai Y, Hama T, Nakamura Y, Nakaya K. Cell and tissue distribution and developmental change of neuron specific 14 kDa protein (phosphoneuroprotein 14) Brain Res. 1993;622:17&#x2013;25. doi: 10.1016/0006-8993(93)90796-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(93)90796-P</ArticleId><ArticleId IdType="pubmed">7694766</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841. doi: 10.1126/science.1090278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1090278</ArticleId><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sone M, Yoshida M, Hashizume Y, Hishikawa N, Sobue G. Alpha-synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy. Acta Neuropathol. 2005;110:19&#x2013;26. doi: 10.1007/s00401-005-1013-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1013-9</ArticleId><ArticleId IdType="pubmed">15895299</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague BL, Pego RL, Stavreva DA, McNally JG. Analysis of binding reactions by fluorescence recovery after photobleaching. Biophys J. 2004;86:3473&#x2013;3495. doi: 10.1529/biophysj.103.026765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1529/biophysj.103.026765</ArticleId><ArticleId IdType="pmc">PMC1304253</ArticleId><ArticleId IdType="pubmed">15189848</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan KD, Brown EB. Measuring diffusion coefficients via two-photon fluorescence recovery after photobleaching. J Vis Exp. 2010;36:1636. doi: 10.3791/1636. pii.</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/1636</ArticleId><ArticleId IdType="pmc">PMC3152219</ArticleId><ArticleId IdType="pubmed">20190730</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan R, Hoang CP, Verkman AS. Photobleaching recovery and anisotropy decay of green fluorescent protein GFP-S65T in solution and cells: Cytoplasmic viscosity probed by green fluorescent protein translational and rotational diffusion. Biophys J. 1997;72:1900&#x2013;1907. doi: 10.1016/S0006-3495(97)78835-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-3495(97)78835-0</ArticleId><ArticleId IdType="pmc">PMC1184383</ArticleId><ArticleId IdType="pubmed">9083693</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Abnormal distribution of the non-abeta component of alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest. 1998;78:1169&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9759660</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K, Mori F, Mimura J, Itoh K, Kakita A, Takahashi H, Wakabayashi K. proteinase K-resistant alpha-synuclein is deposited in presynapses in human Lewy body disease and A53T alpha-synuclein transgenic mice. Acta Neuropathol. 2010;120:145&#x2013;154. doi: 10.1007/s00401-010-0676-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0676-z</ArticleId><ArticleId IdType="pubmed">20339856</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofaris GK, Spillantini MG. Alpha-synuclein dysfunction in Lewy body diseases. Mov Disord. 2005;20:S37&#x2013;S44. doi: 10.1002/mds.20538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.20538</ArticleId><ArticleId IdType="pubmed">16092089</ArticleId></ArticleIdList></Reference><Reference><Citation>Unni VK, Weissman TA, Rockenstein E, Masliah E, McLean PJ, Hyman BT. In vivo imaging of alpha-synuclein in mouse cortex demonstrates stable expression and differential subcellular compartment mobility. PLoS One. 2010;5:e10589. doi: 10.1371/journal.pone.0010589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010589</ArticleId><ArticleId IdType="pmc">PMC2868057</ArticleId><ArticleId IdType="pubmed">20485674</ArticleId></ArticleIdList></Reference><Reference><Citation>Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett. 2001;500:105&#x2013;108. doi: 10.1016/S0014-5793(01)02597-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(01)02597-2</ArticleId><ArticleId IdType="pubmed">11445065</ArticleId></ArticleIdList></Reference><Reference><Citation>van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008;4:e1000027. doi: 10.1371/journal.pgen.1000027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000027</ArticleId><ArticleId IdType="pmc">PMC2265412</ArticleId><ArticleId IdType="pubmed">18369446</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker RH, Moore C, Davies G, Dirling LB, Koch RJ, Meshul CK. Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat. PLoS One. 2012;7:e32919. doi: 10.1371/journal.pone.0032919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0032919</ArticleId><ArticleId IdType="pmc">PMC3299711</ArticleId><ArticleId IdType="pubmed">22427909</ArticleId></ArticleIdList></Reference><Reference><Citation>Wislet-Gendebien S, D'Souza C, Kawarai T, St George-Hyslop P, Westaway D, Fraser P, Tandon A. Cytosolic proteins regulate alpha-synuclein dissociation from presynaptic membranes. J Biol Chem. 2006;281:32148&#x2013;32155. doi: 10.1074/jbc.M605965200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M605965200</ArticleId><ArticleId IdType="pubmed">16926154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wislet-Gendebien S, Visanji NP, Whitehead SN, Marsilio D, Hou W, Figeys D, Fraser PE, Bennett SA, Tandon A. Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors. BMC Neurosci. 2008;9:92. doi: 10.1186/1471-2202-9-92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-9-92</ArticleId><ArticleId IdType="pmc">PMC2562387</ArticleId><ArticleId IdType="pubmed">18808659</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda T, Nakata Y, Choong CJ, Mochizuki H. Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener. 2013;2:16. doi: 10.1186/2047-9158-2-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-9158-2-16</ArticleId><ArticleId IdType="pmc">PMC3750287</ArticleId><ArticleId IdType="pubmed">23919415</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoe H, Meyer T. Spatial dynamics of GFP-tagged proteins investigated by local fluorescence enhancement. Nat Biotechnol. 1996;14:1252&#x2013;1256. doi: 10.1038/nbt1096-1252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1096-1252</ArticleId><ArticleId IdType="pubmed">9631088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zach S, Bueler H, Hengerer B, Gillardon F. Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture. Cell Mol Neurobiol. 2007;27:505&#x2013;515. doi: 10.1007/s10571-007-9141-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-007-9141-5</ArticleId><ArticleId IdType="pmc">PMC11517093</ArticleId><ArticleId IdType="pubmed">17380380</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Alegre J, G&#xf3;mez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atar&#xe9;s B, Llorens V, G&#xf3;mez Tortosa E, del Ser T, Mu&#xf1;oz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164&#x2013;173. doi: 10.1002/ana.10795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10795</ArticleId><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24510904</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>111</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>18</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease.</ArticleTitle><Pagination><StartPage>2626</StartPage><EndPage>2631</EndPage><MedlinePgn>2626-31</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1318306111</ELocationID><Abstract><AbstractText>Mutations in leucine-rich repeat kinase 2 (LRRK2) cause inherited Parkinson disease (PD), and common variants around LRRK2 are a risk factor for sporadic PD. Using protein-protein interaction arrays, we identified BCL2-associated athanogene 5, Rab7L1 (RAB7, member RAS oncogene family-like 1), and Cyclin-G-associated kinase as binding partners of LRRK2. The latter two genes are candidate genes for risk for sporadic PD identified by genome-wide association studies. These proteins form a complex that promotes clearance of Golgi-derived vesicles through the autophagy-lysosome system both in vitro and in vivo. We propose that three different genes for PD have a common biological function. More generally, data integration from multiple unbiased screens can provide insight into human disease mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beilina</LastName><ForeName>Alexandria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cell Biology and Gene Expression Section, Computational Biology Core, Laboratory of Neurogenetics, and Molecular Genetics Section, National Institute on Aging/National Institutes of Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudenko</LastName><ForeName>Iakov N</ForeName><Initials>IN</Initials></Author><Author ValidYN="Y"><LastName>Kaganovich</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Civiero</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Chau</LastName><ForeName>Hien</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Kalia</LastName><ForeName>Suneil K</ForeName><Initials>SK</Initials></Author><Author ValidYN="Y"><LastName>Kalia</LastName><ForeName>Lorraine V</ForeName><Initials>LV</Initials></Author><Author ValidYN="Y"><LastName>Lobbestael</LastName><ForeName>Evy</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chia</LastName><ForeName>Ruth</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ndukwe</LastName><ForeName>Kelechi</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Jinhui</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><CollectiveName>International Parkinson&#x2019;s Disease Genomics Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>North American Brain Expression Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Olszewski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>David N</ForeName><Initials>DN</Initials></Author><Author ValidYN="Y"><LastName>Kumaran</LastName><ForeName>Ravindran</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Lozano</LastName><ForeName>Andres M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Baekelandt</LastName><ForeName>Veerle</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>Lois E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Taymans</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Greggio</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GGP12237</GrantID><Acronym>TI_</Acronym><Agency>Telethon</Agency><Country>Italy</Country></Grant><Grant><GrantID>G0701075</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100643</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R01 NS075321</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS041509</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>090532</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L010305/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0700943</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 NS082151</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F-1202</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G-0907</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100479</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496515">BAG5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090802">rab7 GTP-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000716463">rab7 GTP-binding proteins, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C486325">GAK protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.2</RegistryNumber><NameOfSubstance UI="D020691">rab GTP-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2402-3. doi: 10.1073/pnas.1324284111.</RefSource><PMID Version="1">24510898</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056426" MajorTopicYN="N">Genetic Loci</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006056" MajorTopicYN="N">Golgi Apparatus</DescriptorName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018613" MajorTopicYN="N">Microscopy, Confocal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010957" MajorTopicYN="N">Plasmids</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025941" MajorTopicYN="N">Protein Interaction Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022161" MajorTopicYN="N">Transport Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020691" MajorTopicYN="N">rab GTP-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090802" MajorTopicYN="N">rab7 GTP-Binding Proteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BAG5</Keyword><Keyword MajorTopicYN="N">GAK</Keyword><Keyword MajorTopicYN="N">autophagy</Keyword><Keyword MajorTopicYN="N">trans-Golgi</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Mike A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plagnol</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheerin</LastName><ForeName>Una-Marie</ForeName><Initials>UM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saad</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sim&#xf3;n-S&#xe1;nchez</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schulte</LastName><ForeName>Claudia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lesage</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sveinbj&#xf6;rnsd&#xf3;ttir</LastName><ForeName>Sigurlaug</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barker</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ben-Shlomo</LastName><ForeName>Yoav</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berendse</LastName><ForeName>Henk W</ForeName><Initials>HW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bhatia</LastName><ForeName>Kailash</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Bie</LastName><ForeName>Rob M A</ForeName><Initials>RM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biffi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bloem</LastName><ForeName>Bas</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bochdanovits</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bonin</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bras</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brockmann</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Janet</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burn</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Charlesworth</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Honglei</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chinnery</LastName><ForeName>Patrick F</ForeName><Initials>PF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chong</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clarke</LastName><ForeName>Carl E</ForeName><Initials>CE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cooper</LastName><ForeName>J Mark</ForeName><Initials>JM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean Christophe</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Counsell</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dartigues</LastName><ForeName>Jean-Fran&#xe7;ois</ForeName><Initials>JF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deloukas</LastName><ForeName>Panos</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deuschl</LastName><ForeName>G&#xfc;nther</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dexter</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Dijk</LastName><ForeName>Karin D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Durif</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>D&#xfc;rr</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edkins</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foltynie</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>Jianjun</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gardner</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gray</LastName><ForeName>Emma</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guerreiro</LastName><ForeName>Rita</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>G&#xfa;stafsson</LastName><ForeName>&#xd3;mar</ForeName><Initials>&#xd3;</Initials></Investigator><Investigator ValidYN="Y"><LastName>Harris</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Jacobus J</ForeName><Initials>JJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofman</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hollenbeck</LastName><ForeName>Albert</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holton</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hu</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Xuemei</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huber</LastName><ForeName>Heiko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudson</LastName><ForeName>Gavin</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunt</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huttenlocher</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Illig</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>J&#xf3;nsson</LastName><ForeName>P&#xe1;lmi V</ForeName><Initials>PV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lambert</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langford</LastName><ForeName>Cordelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lees</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtner</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Limousin</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lopez</LastName><ForeName>Grisel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lorenz</LastName><ForeName>Delia</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McNeill</LastName><ForeName>Alisdair</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moorby</LastName><ForeName>Catriona</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moore</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>Huw R</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mudanohwo</LastName><ForeName>Ese</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Sullivan</LastName><ForeName>Sean S</ForeName><Initials>SS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pearson</LastName><ForeName>Justin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>P&#xe9;tursson</LastName><ForeName>Hj&#xf6;rvar</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollak</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Post</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Potter</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Revesz</LastName><ForeName>Tamas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riess</LastName><ForeName>Olaf</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivadeneira</LastName><ForeName>Fernando</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rizzu</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryten</LastName><ForeName>Mina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sawcer</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schapira</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scheffer</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaw</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sidransky</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spencer</LastName><ForeName>Chris C A</ForeName><Initials>CC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>Hreinn</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stockton</LastName><ForeName>Joanna D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Strange</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanner</LastName><ForeName>Carlie M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tashakkori-Ghanbaria</LastName><ForeName>Avazeh</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tison</LastName><ForeName>Fran&#xe7;ois</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trabzuni</LastName><ForeName>Daniah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitterlinden</LastName><ForeName>Andr&#xe9; G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velseboer</LastName><ForeName>Daan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Walker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>van de Warrenburg</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wickremaratchi</LastName><ForeName>Mirdhu</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Nigel</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams-Gray</LastName><ForeName>Caroline H</ForeName><Initials>CH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winder-Rhodes</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stef&#xe1;nsson</LastName><ForeName>K&#xe1;ri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martinez</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hardy</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Heutink</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brice</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gasser</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wood</LastName><ForeName>Nicholas W</ForeName><Initials>NW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arepalli</LastName><ForeName>Sampath</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cookson</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dillman</LastName><ForeName>Allissa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gibbs</LastName><ForeName>J Raphael</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hernandez</LastName><ForeName>Dena G</ForeName><Initials>DG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longo</LastName><ForeName>Dan L</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Majounie</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nalls</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Brien</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singleton</LastName><ForeName>Andrew B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traynor</LastName><ForeName>Bryan J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Brug</LastName><ForeName>Marcel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zielke</LastName><ForeName>H Ronald</ForeName><Initials>HR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zonderman</LastName><ForeName>Alan B</ForeName><Initials>AB</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24510904</ArticleId><ArticleId IdType="pmc">PMC3932908</ArticleId><ArticleId IdType="doi">10.1073/pnas.1318306111</ArticleId><ArticleId IdType="pii">1318306111</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cookson MR, Bandmann O. Parkinson&#x2019;s disease: Insights from pathways. Hum Mol Genet. 2010;19(R1):R21&#x2013;R27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2875048</ArticleId><ArticleId IdType="pubmed">20421364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, Bertram L. Towards unveiling the genetics of neurodegenerative diseases. Semin Neurol. 2011;31(5):531&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pubmed">22266890</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton A, Hardy J. A generalizable hypothesis for the genetic architecture of disease: Pleomorphic risk loci. Hum Mol Genet. 2011;20(R2):R158&#x2013;R162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179380</ArticleId><ArticleId IdType="pubmed">21875901</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson&#x2019;s disease. Nat Rev Neurosci. 2010;11(12):791&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662256</ArticleId><ArticleId IdType="pubmed">21088684</ArticleId></ArticleIdList></Reference><Reference><Citation>Satake W, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson&#x2019;s disease. Nat Genet. 2009;41(12):1303&#x2013;1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">19915576</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim&#xf3;n-S&#xe1;nchez J, et al. Genome-wide association study reveals genetic risk underlying Parkinson&#x2019;s disease. Nat Genet. 2009;41(12):1308&#x2013;1312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787725</ArticleId><ArticleId IdType="pubmed">19915575</ArticleId></ArticleIdList></Reference><Reference><Citation>International Parkinson&#x2019;s Disease Genomics Consortium (IPDGC) Wellcome Trust Case Control Consortium 2 (WTCCC2) A two-stage meta-analysis identifies several new loci for Parkinson&#x2019;s disease. PLoS Genet. 2011;7(6):e1002142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128098</ArticleId><ArticleId IdType="pubmed">21738488</ArticleId></ArticleIdList></Reference><Reference><Citation>Do CB, et al. Web-based genome-wide association study identifies two novel loci and a substantial genetic component for Parkinson&#x2019;s disease. PLoS Genet. 2011;7(6):e1002141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3121750</ArticleId><ArticleId IdType="pubmed">21738487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalls MA, et al. Imputation of sequence variants for identification of genetic risks for Parkinson&#x2019;s disease: A meta-analysis of genome-wide association studies. Lancet. 2011;377(9766):641&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3696507</ArticleId><ArticleId IdType="pubmed">21292315</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku CS, Loy EY, Pawitan Y, Chia KS. The pursuit of genome-wide association studies: Where are we now? J Hum Genet. 2010;55(4):195&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">20300123</ArticleId></ArticleIdList></Reference><Reference><Citation>Latourelle JC, Dumitriu A, Hadzi TC, Beach TG, Myers RH. Evaluation of Parkinson disease risk variants as expression-QTLs. PLoS One. 2012;7(10):e46199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465315</ArticleId><ArticleId IdType="pubmed">23071545</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabbage M, Dickman MB. The BAG proteins: A ubiquitous family of chaperone regulators. Cell Mol Life Sci. 2008;65(9):1390&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11131705</ArticleId><ArticleId IdType="pubmed">18264803</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalia SK, et al. BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron. 2004;44(6):931&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzamko N, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J. 2010;430(3):405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631100</ArticleId><ArticleId IdType="pubmed">20659021</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, et al. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson&#x2019;s disease. PLoS One. 2011;6(3):e17153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3046972</ArticleId><ArticleId IdType="pubmed">21390248</ArticleId></ArticleIdList></Reference><Reference><Citation>Civiero L, et al. Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers. PLoS One. 2012;7(8):e43472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3430690</ArticleId><ArticleId IdType="pubmed">22952686</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko HS, et al. CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci USA. 2009;106(8):2897&#x2013;2902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2650345</ArticleId><ArticleId IdType="pubmed">19196961</ArticleId></ArticleIdList></Reference><Reference><Citation>Alegre-Abarrategui J, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet. 2009;18(21):4022&#x2013;4034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758136</ArticleId><ArticleId IdType="pubmed">19640926</ArticleId></ArticleIdList></Reference><Reference><Citation>Stafa K, et al. GTPase activity and neuronal toxicity of Parkinson&#x2019;s disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet. 2012;8(2):e1002526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280333</ArticleId><ArticleId IdType="pubmed">22363216</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Yuan C, Chen R, Dawson TM, Dawson VL. ArfGAP1 is a GTPase activating protein for LRRK2: Reciprocal regulation of ArfGAP1 by LRRK2. J Neurosci. 2012;32(11):3877&#x2013;3886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319331</ArticleId><ArticleId IdType="pubmed">22423108</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod D, et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52(4):587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114044</ArticleId></ArticleIdList></Reference><Reference><Citation>Winner B, et al. Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis. 2011;41(3):706&#x2013;716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059106</ArticleId><ArticleId IdType="pubmed">21168496</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe4;chsel JC, et al. A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord. 2010;16(10):650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3159957</ArticleId><ArticleId IdType="pubmed">20850369</ArticleId></ArticleIdList></Reference><Reference><Citation>Plowey ED, Cherra SJ, 3rd, Liu Y-J, Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem. 2008;105(3):1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2361385</ArticleId><ArticleId IdType="pubmed">18182054</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudenko IN, et al. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson&#x2019;s disease is a partial loss-of-function mutation. Biochem J. 2012;446(1):99&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667980</ArticleId><ArticleId IdType="pubmed">22612223</ArticleId></ArticleIdList></Reference><Reference><Citation>Biskup S, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006;60(5):557&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">17120249</ArticleId></ArticleIdList></Reference><Reference><Citation>Helip-Wooley A, Thoene JG. Sucrose-induced vacuolation results in increased expression of cholesterol biosynthesis and lysosomal genes. Exp Cell Res. 2004;292(1):89&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">14720509</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod DA, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson&#x2019;s disease risk. Neuron. 2013;77(3):425&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646583</ArticleId><ArticleId IdType="pubmed">23395371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D-W, Wu X, Eisenberg E, Greene LE. Recruitment dynamics of GAK and auxilin to clathrin-coated pits during endocytosis. J Cell Sci. 2006;119(Pt 17):3502&#x2013;3512.</Citation><ArticleIdList><ArticleId IdType="pubmed">16895969</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametaka S, et al. Canonical interaction of cyclin G associated kinase with adaptor protein 1 regulates lysosomal enzyme sorting. Mol Biol Cell. 2007;18(8):2991&#x2013;3001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1949374</ArticleId><ArticleId IdType="pubmed">17538018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen PJ, Korswagen HC. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat Cell Biol. 2012;14(1):29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613977</ArticleId><ArticleId IdType="pubmed">22193161</ArticleId></ArticleIdList></Reference><Reference><Citation>Youle RJ, Narendra DP. Mechanisms of mitophagy. Nat Rev Mol Cell Biol. 2011;12(1):9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4780047</ArticleId><ArticleId IdType="pubmed">21179058</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Suaga P, et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2012;21(3):511&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3259011</ArticleId><ArticleId IdType="pubmed">22012985</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong Y, et al. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener. 2012;7:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3296570</ArticleId><ArticleId IdType="pubmed">22230652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nichols RJ, et al. 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson&#x2019;s disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010;430(3):393&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932554</ArticleId><ArticleId IdType="pubmed">20642453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan CJ, et al. High-resolution network biology: Connecting sequence with function. Nat Rev Genet. 2013;14(12):865&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023809</ArticleId><ArticleId IdType="pubmed">24197012</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzoni C, et al. Pathogenic Parkinson&#x2019;s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation. Biochem Biophys Res Commun. 2013;441(4):862&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3858825</ArticleId><ArticleId IdType="pubmed">24211199</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramonet D, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011;6(4):e18568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3071839</ArticleId><ArticleId IdType="pubmed">21494637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee DW, Zhao X, Zhang F, Eisenberg E, Greene LE. Depletion of GAK/auxilin 2 inhibits receptor-mediated endocytosis and recruitment of both clathrin and clathrin adaptors. J Cell Sci. 2005;118(Pt 18):4311&#x2013;4321.</Citation><ArticleIdList><ArticleId IdType="pubmed">16155256</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Chen G. High Ca2+-phosphate transfection efficiency in low-density neuronal cultures. Nat Protoc. 2006;1(2):695&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">17406298</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24508385</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Necroptosis drives motor neuron death in models of both sporadic and familial ALS.</ArticleTitle><Pagination><StartPage>1001</StartPage><EndPage>1008</EndPage><MedlinePgn>1001-1008</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.01.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00016-6</ELocationID><Abstract><AbstractText>Most cases of neurodegenerative diseases are sporadic, hindering the use of genetic mouse models to analyze disease mechanisms. Focusing on the motor neuron (MN) disease amyotrophic lateral sclerosis (ALS), we therefore devised a fully humanized coculture model composed of human adult primary sporadic ALS (sALS) astrocytes and human embryonic stem-cell-derived MNs. The model reproduces the cardinal features of human ALS: sALS astrocytes, but not those from control patients, trigger selective death of MNs. The mechanisms underlying this non-cell-autonomous toxicity were investigated in both astrocytes and MNs. Although causal in familial ALS (fALS), SOD1 does not contribute to the toxicity of sALS astrocytes. Death of MNs triggered by either sALS or fALS astrocytes occurs through necroptosis, a form of programmed necrosis involving receptor-interacting protein 1 and the mixed lineage kinase domain-like protein. The necroptotic pathway therefore constitutes a potential therapeutic target for this&#xa0;incurable disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Re</LastName><ForeName>Diane B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Verche</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Changhao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amoroso</LastName><ForeName>Mackenzie W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, NY 10032, USA; Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Politi</LastName><ForeName>Kristin A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phani</LastName><ForeName>Sudarshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikiz</LastName><ForeName>Burcin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffmann</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koolen</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Academisch Medisch Centrum, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagata</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadimitriou</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kariya</LastName><ForeName>Shingo</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wichterle</LastName><ForeName>Hynek</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Neuroscience, Columbia University, New York, NY 10032, USA; Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA; Department of Neuroscience, Columbia University, New York, NY 10032, USA; Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, NY 10032, USA; Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, New York, NY 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Przedborski</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Motor Neuron Biology and Disease, the Columbia Translational Neuroscience Initiative, and the Columbia Stem Cell Initiative, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA. Electronic address: sp30@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS078614</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS072182-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TL1 TR000082</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS072182</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS062055-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 U42 RR006042</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS064191</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS042269</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U42 RR006042</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS062055</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 ES009089</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01ES160348</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES009089</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS062180</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS042269-05A2</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS078614-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS064191-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS062180</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="C570693">MLKL protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C506249">RIPK1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D053422">Receptor-Interacting Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2014 Mar 5;81(5):961-963. doi: 10.1016/j.neuron.2014.02.024.</RefSource><PMID Version="1">24607221</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002450" MajorTopicYN="N">Cell Communication</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018920" MajorTopicYN="N">Coculture Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053595" MajorTopicYN="N">Embryonic Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055785" MajorTopicYN="N">Gene Knockdown Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009336" MajorTopicYN="N">Necrosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061251" MajorTopicYN="N">Primary Cell Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053422" MajorTopicYN="N">Receptor-Interacting Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24508385</ArticleId><ArticleId IdType="mid">NIHMS555112</ArticleId><ArticleId IdType="pmc">PMC3951532</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.01.011</ArticleId><ArticleId IdType="pii">S0896-6273(14)00016-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amoroso MW, Croft GF, Williams DJ, O&#x2019;Keeffe S, Carrasco MA, Davis AR, Roybon L, Oakley DH, Maniatis T, Henderson CE, et al. Accelerated high-yield generation of limb-innervating motor neurons from human stem cells. J. Neurosci. 2013;33:574&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711539</ArticleId><ArticleId IdType="pubmed">23303937</ArticleId></ArticleIdList></Reference><Reference><Citation>Artus C, Boujrad H, Bouharrour A, Brunelle M-N, Hoos S, Yuste VJ, Lenormand P, Rousselle J-C, Namane A, England P, et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 2010;29:1585&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2876946</ArticleId><ArticleId IdType="pubmed">20360685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates DM, Watts DG. Nonlinear Regression Analysis and Its Applications. Hoboken, NJ, USA: John Wiley &amp; Sons, Inc.; 1988.</Citation></Reference><Reference><Citation>Bosco DA, Morfini G, Karabacak NM, Song Y, Gros-Louis F, Pasinelli P, Goolsby H, Fontaine BA, Lemay N, McKenna-Yasek D, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat. Neurosci. 2010;13:1396&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2967729</ArticleId><ArticleId IdType="pubmed">20953194</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P, Pehar M, Vargas MR, Castellanos R, Barbeito AG, Estevez AG, Thompson JA, Beckman JS, Barbeito L. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: implications for amyotrophic lateral sclerosis. J. Neurochem. 2005;93:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">15773903</ArticleId></ArticleIdList></Reference><Reference><Citation>Degterev A, Hitomi J, Germscheid M, Ch&#x2019;en IL, Korkina O, Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 2008;4:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5434866</ArticleId><ArticleId IdType="pubmed">18408713</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat. Neurosci. 2007;10:608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP, Boulting GL, Bobrowicz S, Eggan KC. Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation. Cell Stem Cell. 2008;3:637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>De Groot CJ, Langeveld CH, Jongenelen CA, Montagne L, Van V D, Dijkstra CD. Establishment of human adult astrocyte cultures derived from postmortem multiple sclerosis and control brain and spinal cord regions: immunophenotypical and functional characterization. J. Neurosci. Res. 1997;49:342&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pubmed">9260745</ArticleId></ArticleIdList></Reference><Reference><Citation>Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, Trotti D, Pasinelli P. An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc. Natl. Acad. Sci. USA. 2012;109:5074&#x2013;5079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324021</ArticleId><ArticleId IdType="pubmed">22416121</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, Murtha MJ, Foust KD, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009;187:761&#x2013;772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806318</ArticleId><ArticleId IdType="pubmed">19951898</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu. Rev. Neurosci. 2010;33:409&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Krysko DV, D&#x2019;Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis. 2006;11:1709&#x2013;1726.</Citation><ArticleIdList><ArticleId IdType="pubmed">16951923</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MC, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. Non-cell-autonomous effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic stem cells. Cell Stem Cell. 2008;3:649&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat. Neurosci. 2007;10:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14:727&#x2013;736.</Citation><ArticleIdList><ArticleId IdType="pubmed">24129419</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadeas ST, Kraig SE, O&#x2019;Banion C, Lepore AC, Maragakis NJ. Astrocytes carrying the superoxide dismutase 1 (SOD1G93A) mutation induce wild-type motor neuron degeneration in vivo. Proc. Natl. Acad. Sci. USA. 2011;108:17803&#x2013;17808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203804</ArticleId><ArticleId IdType="pubmed">21969586</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca FJ, Ramakrishnan L. TNF Dually Mediates Resistance and Susceptibility to Mycobacteria via Mitochondrial Reactive Oxygen Species. Cell. 2013;153:521&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790588</ArticleId><ArticleId IdType="pubmed">23582643</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan C, Delivani P, Cullen SP, Martin SJ. Bax- or Bak-induced mitochondrial fission can be uncoupled from cytochrome C release. Mol. Cell. 2008;31:570&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pubmed">18722181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, et al. Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase. Cell. 2012;148:213&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265413</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Velde C, Miller TM, Cashman NR, Cleveland DW. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. U.S.A. 2008;105:4022&#x2013;4027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268797</ArticleId><ArticleId IdType="pubmed">18296640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Jiang H, Chen S, Du F, Wang X. The Mitochondrial Phosphatase PGAM5 Functions at the Convergence Point of Multiple Necrotic Death Pathways. Cell. 2012;148:228&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">22265414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic stem cells into motor neurons. Cell. 2002;110:385&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">12176325</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332&#x2013;336. (80&#x2212;.).</Citation><ArticleIdList><ArticleId IdType="pubmed">19498109</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24523320</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2014</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>223</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>12</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Lysosomal sorting of amyloid-&#x3b2; by the SORLA receptor is impaired by a familial Alzheimer's disease mutation.</ArticleTitle><Pagination><StartPage>223ra20</StartPage><MedlinePgn>223ra20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3007747</ELocationID><Abstract><AbstractText>SORLA/SORL1 is a unique neuronal sorting receptor for the amyloid precursor protein that has been causally implicated in both sporadic and autosomal dominant familial forms of Alzheimer's disease (AD). Brain concentrations of SORLA are inversely correlated with amyloid-&#x3b2; (A&#x3b2;) in mouse models and AD patients, suggesting that increasing expression of this receptor could be a therapeutic option for decreasing the amount of amyloidogenic products in affected individuals. We characterize a new mouse model in which SORLA is overexpressed, and show a decrease in A&#x3b2; concentrations in mouse brain. We trace the underlying molecular mechanism to the ability of this receptor to direct lysosomal targeting of nascent A&#x3b2; peptides. A&#x3b2; binds to the amino-terminal VPS10P domain of SORLA, and this binding is impaired by a familial AD mutation in SORL1. Thus, loss of SORLA's A&#x3b2; sorting function is a potential cause of AD in patients, and SORLA may be a new therapeutic target for AD drug development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caglayan</LastName><ForeName>Safak</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Max-Delbrueck-Center for Molecular Medicine, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takagi-Niidome</LastName><ForeName>Shizuka</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Carlo</LastName><ForeName>Anne-Sophie</ForeName><Initials>AS</Initials></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Burgert</LastName><ForeName>Tilman</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kitago</LastName><ForeName>Yu</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>F&#xfc;chtbauer</LastName><ForeName>Ernst-Martin</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>F&#xfc;chtbauer</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Takagi</LastName><ForeName>Junichi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Willnow</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026502">LDL-Receptor Related Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C102582">SORL1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2014 Feb 12;6(223):223fs8. doi: 10.1126/scitranslmed.3008562.</RefSource><PMID Version="1">24523319</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026502" MajorTopicYN="N">LDL-Receptor Related Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008247" MajorTopicYN="N">Lysosomes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24523320</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3007747</ArticleId><ArticleId IdType="pii">6/223/223ra20</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24524897</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2083</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>13</Issue><PubDate><Year>2014</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Human molecular genetics</Title><ISOAbbreviation>Hum Mol Genet</ISOAbbreviation></Journal><ArticleTitle>The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.</ArticleTitle><Pagination><StartPage>3523</StartPage><EndPage>3536</EndPage><MedlinePgn>3523-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/hmg/ddu064</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by extracellular plaques containing amyloid &#x3b2; (A&#x3b2;)-protein and intracellular tangles containing hyperphosphorylated Tau protein. Here, we describe the generation of inducible pluripotent stem cell lines from patients harboring the London familial AD (fAD) amyloid precursor protein (APP) mutation (V717I). We examine AD-relevant phenotypes following directed differentiation to forebrain neuronal fates vulnerable in AD. We observe that over differentiation time to mature neuronal fates, APP expression and levels of A&#x3b2; increase dramatically. In both immature and mature neuronal fates, the APPV717I mutation affects both &#x3b2;- and &#x3b3;-secretase cleavage of APP. Although the mutation lies near the &#x3b3;-secretase cleavage site in the transmembrane domain of APP, we find that &#x3b2;-secretase cleavage of APP is elevated leading to generation of increased levels of both APPs&#x3b2; and A&#x3b2;. Furthermore, we find that this mutation alters the initial cleavage site of &#x3b3;-secretase, resulting in an increased generation of both A&#x3b2;42 and A&#x3b2;38. In addition to altered APP processing, an increase in levels of total and phosphorylated Tau is observed in neurons with the APPV717I mutation. We show that treatment with A&#x3b2;-specific antibodies early in culture reverses the phenotype of increased total Tau levels, implicating altered A&#x3b2; production in fAD neurons in this phenotype. These studies use human neurons to reveal previously unrecognized effects of the most common fAD APP mutation and provide a model system for testing therapeutic strategies in the cell types most relevant to disease processes.</AbstractText><CopyrightInformation>&#xa9; The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Muratore</LastName><ForeName>Christina R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Heather C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srikanth</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callahan</LastName><ForeName>Dana G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Taehwan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benjamin</LastName><ForeName>Lawrence N P</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young-Pearse</LastName><ForeName>Tracy L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA tyoung@rics.bwh.harvard.edu tpearse@partners.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG015379</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007753</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG042776</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG006173</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG042776</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Mol Genet</MedlineTA><NlmUniqueID>9208958</NlmUniqueID><ISSNLinking>0964-6906</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24524897</ArticleId><ArticleId IdType="pmc">PMC4049307</ArticleId><ArticleId IdType="doi">10.1093/hmg/ddu064</ArticleId><ArticleId IdType="pii">ddu064</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertram L., Lill C.M., Tanzi R.E. The genetics of Alzheimer disease: back to the future. Neuron. 2010;68:270&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20955934</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398:513&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">10206644</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J., Podlisny M.B. Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 2002;3:67&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">12142353</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L., Tanzi R.E. The genetics of Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 2012;107:79&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482448</ArticleId></ArticleIdList></Reference><Reference><Citation>Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">1671712</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M., Theuns J., Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum. Mutat. 2012;33:1340&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3465795</ArticleId><ArticleId IdType="pubmed">22581678</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Jr, Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336&#x2013;1340.</Citation><ArticleIdList><ArticleId IdType="pubmed">8191290</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe C., Esselens C., Kumar-Singh S., Craessaerts K., Serneels S., Checler F., Annaert W., Van Broeckhoven C., De Strooper B. Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum. Mol. Genet. 2001;10:1665&#x2013;1671.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487570</ArticleId></ArticleIdList></Reference><Reference><Citation>Moechars D., Dewachter I., Lorent K., Revers&#xe9; D., Baekelandt V., Naidu A., Tesseur I., Spittaels K., Haute C.V., Checler F., et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 1999;274:6483&#x2013;6492.</Citation><ArticleIdList><ArticleId IdType="pubmed">10037741</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewachter I., van Dorpe J., Spittaels K., Tesseur I., Van Den Haute C., Moechars D., Van Leuven F. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. 2000;35:831&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">11053674</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A., Odaka A., Ishibashi Y., Usami M., Sahara N., Suzuki N., Nukina N., Mizusawa H., Shoji S., Kanazawa I. APP717 missense mutation affects the ratio of amyloid beta protein species (a beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain. J. Biol. Chem. 1994;269:32721&#x2013;32724.</Citation><ArticleIdList><ArticleId IdType="pubmed">7806491</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D., Eckman C., Jensen M., Song X., Citron M., Suzuki N., Bird T.D., Hardy J., Hutton M., Kukull W., et al. Secreted amyloid &#x3b2;-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi T., Ito D., Okada Y., Akamatsu W., Nihei Y., Yoshizaki T., Yamanaka S., Okano H., Suzuki N. Modeling familial Alzheimer's disease with induced pluripotent stem cells. Hum. Mol. Genet. 2011;20:4530&#x2013;4539.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900357</ArticleId></ArticleIdList></Reference><Reference><Citation>Ooi L., Sidhu K., Poljak A., Sutherland G., O'Connor M.D., Sachdev P., M&#xfc;nch G. Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease. J. Neural Transm. 2013;120:103&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">22695755</ArticleId></ArticleIdList></Reference><Reference><Citation>Malgrange B., Borgs L., Grobarczyk B., Purnelle A., Ernst P., Moonen G., Nguyen L. Using human pluripotent stem cells to untangle neurodegenerative disease mechanisms. Cell. Mol. Life Sci. 2011;68:635&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11115022</ArticleId><ArticleId IdType="pubmed">20976521</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I.-H., Daley G.Q. Human iPS cell derivation/reprogramming. Curr. Protoc. Stem Cell Biol. 2009 Chapter 4, Unit 4A.1.</Citation><ArticleIdList><ArticleId IdType="pubmed">19170021</ArticleId></ArticleIdList></Reference><Reference><Citation>Park I.-H., Arora N., Huo H., Maherali N., Ahfeldt T., Shimamura A., Lensch M.W., Cowan C., Hochedlinger K., Daley G.Q. Disease-specific induced pluripotent stem cells. Cell. 2008;134:877&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633781</ArticleId><ArticleId IdType="pubmed">18691744</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Kirwan P., Smith J., MacLean G., Orkin S.H., Livesey F.J. A human stem cell model of early Alzheimer's disease pathology in Down syndrome. Sci. Transl. Med. 2012;4:124&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4129935</ArticleId><ArticleId IdType="pubmed">22344463</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel M.A., Yuan S.H., Bardy C., Reyna S.M., Mu Y., Herrera C., Hefferan M.P., Van Gorp S., Nazor K.L., Boscolo F.S., et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature. 2012;482:216&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338985</ArticleId><ArticleId IdType="pubmed">22278060</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T., Asai M., Tsukita K., Kutoku Y., Ohsawa Y., Sunada Y., Imamura K., Egawa N., Yahata N., Okita K., et al. Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A&#x3b2; and differential drug responsiveness. Cell Stem Cell. 2013;12:487&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pubmed">23434393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H., Guo M., Martins-Taylor K., Wang X., Zhang Z., Park J.W., Zhan S., Kronenberg M.S., Lichtler A., Liu H.-X., et al. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS ONE. 2010;5:e11853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912324</ArticleId><ArticleId IdType="pubmed">20686615</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulting G.L., Kiskinis E., Croft G.F., Amoroso M.W., Oakley D.H., Wainger B.J., Williams D.J., Kahler D.J., Yamaki M., Davidow L., et al. A functionally characterized test set of human induced pluripotent stem cells. Nat. Biotechnol. 2011;29:279&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3229307</ArticleId><ArticleId IdType="pubmed">21293464</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J., Marjaux E., Vandenbulcke M., Van Laere K., Kumar-Singh S., Bormans G., Brouwers N., Van den Broeck M., Vennekens K., Corsmit E., et al. Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment. Hum. Mutat. 2006;27:888&#x2013;896.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917905</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore B.D., Chakrabarty P., Levites Y., Kukar T.L., Baine A.-M., Moroni T., Ladd T.B., Das P., Dickson D.W., Golde T.E. Overlapping profiles of A&#x3b2; peptides in the Alzheimer's disease and pathological aging brains. Alzheimers Res. Ther. 2012;4:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506932</ArticleId><ArticleId IdType="pubmed">22621179</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Kaether C., Thinakaran G., Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2012;2:a006270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331683</ArticleId><ArticleId IdType="pubmed">22553493</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1997;94:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC19829</ArticleId><ArticleId IdType="pubmed">9037091</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald J.M., Cairns N.J., Taylor-Reinwald L., Holtzman D., Walsh D.M. The levels of water-soluble and triton-soluble A&#x3b2; are increased in Alzheimer's disease brain. Brain Res. 2012;1450:138&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319647</ArticleId><ArticleId IdType="pubmed">22440675</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh Y.-H., Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 2002;54:469&#x2013;525.</Citation><ArticleIdList><ArticleId IdType="pubmed">12223532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenthaler S.F., Wang R., Grimm H., Uljon S.N., Masters C.L., Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease &#x3b3;-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. Proc. Natl. Acad. Sci. 1999;96:3053&#x2013;3058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC15893</ArticleId><ArticleId IdType="pubmed">10077635</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi-Takahara Y., Morishima-Kawashima M., Tanimura Y., Dolios G., Hirotani N., Horikoshi Y., Kametani F., Maeda M., Saido T.C., Wang R., et al. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. J. Neurosci. 2005;25:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725472</ArticleId><ArticleId IdType="pubmed">15647487</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 2010;90:465&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pubmed">20393191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe1;vez-Guti&#xe9;rrez L., Bammens L., Benilova I., Vandersteen A., Benurwar M., Borgers M., Lismont S., Zhou L., Van Cleynenbreugel S., Esselmann H., et al. The mechanism of &#x3b3;-Secretase dysfunction in familial Alzheimer disease. EMBO J. 2012;31:2261&#x2013;2274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3364747</ArticleId><ArticleId IdType="pubmed">22505025</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed R.R., Holler C.J., Webb R.L., Li F., Beckett T.L., Murphy M.P. BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J. Neurochem. 2010;112:1045&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819564</ArticleId><ArticleId IdType="pubmed">19968762</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai H., Wang Y., McCarthy D., Wen H., Borchelt D.R., Price D.L., Wong P.C. BACE1 is the major &#x3b2;-secretase for generation of A&#x3b2; peptides by neurons. Nat. Neurosci. 2001;4:233&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett B.D., Babu-Khan S., Loeloff R., Louis J.-C., Curran E., Citron M., Vassar R. Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. 2000;275:20647&#x2013;20651.</Citation><ArticleIdList><ArticleId IdType="pubmed">10749877</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C., Selkoe D.J. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell. 1993;75:1039&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pubmed">8261505</ArticleId></ArticleIdList></Reference><Reference><Citation>Das U., Scott D.A., Ganguly A., Koo E.H., Tang Y., Roy S. Activity-induced convergence of APP and BACE-1 in acidic microdomains via an endocytosis-dependent pathway. Neuron. 2013;79:447&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3741682</ArticleId><ArticleId IdType="pubmed">23931995</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcinkiewicz M., Seidah N.G. Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J. Neurochem. 2000;75:2133&#x2013;2143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11032903</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Kovacs D.M., Yan R., Wong P.C. The &#x3b2;-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 2009;29:12787&#x2013;12794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879048</ArticleId><ArticleId IdType="pubmed">19828790</ArticleId></ArticleIdList></Reference><Reference><Citation>Knops J., Suomensaari S., Lee M., McConlogue L., Seubert P., Sinha S. Cell-type and amyloid precursor protein-type specific inhibition of A beta release by bafilomycin A1, a selective inhibitor of vacuolar ATPases. J. Biol. Chem. 1995;270:2419&#x2013;2422.</Citation><ArticleIdList><ArticleId IdType="pubmed">7852298</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.-Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid {beta}-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc. Natl. Acad. Sci. USA. 2011 10.1073/pnas.1017033108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3078381</ArticleId><ArticleId IdType="pubmed">21421841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J., Dickson D.W., Lin W.L., Chisholm L., Corral A., Jones G., Yen S.H., Sahara N., Skipper L., Yager D., et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatoon S., Grundke-Iqbal I., Iqbal K. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 1992;59:750&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">1629745</ArticleId></ArticleIdList></Reference><Reference><Citation>Musiek E.S., Holtzman D.M. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr. Opin. Neurol. 2012;25:715&#x2013;720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682920</ArticleId><ArticleId IdType="pubmed">23041958</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24535663</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>449</StartPage><EndPage>453</EndPage><MedlinePgn>449-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.6237</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease in which microglia play a significant and active role. Recently, a rare missense variant (p.R47H) in the microglial activating gene TREM2 was found to increase the risk of several neurodegenerative diseases, including Alzheimer disease. Whether the p.R47H variant is a risk factor for ALS is not known.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether p.R47H (rs75932628) in TREM2 is a risk factor for ALS and assess whether TREM2 expression is dysregulated in disease.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Samples of DNA from 923 individuals with sporadic ALS and 1854 healthy control individuals self-reported as non-Hispanic white were collected from ALS clinics in the United States and genotyped for the p.R47H variant in TREM2. Clinical data were obtained on ALS participants for genotype/phenotype correlations. Expression of TREM2 was measured by quantitative polymerase chain reaction and compared in spinal cord samples from 18 autopsied patients with ALS and 12 neurologically healthy controls, as well as from wild-type and transgenic SOD1G93A mice.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Minor allele frequency of rs75932628 and relative expression of TREM2.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The TREM2 variant p.R47H was more common in patients with ALS than in the controls and is therefore a significant risk factor for ALS (odds ratio, 2.40; 95% CI, 1.29-4.15; P&#x2009;=&#x2009;4.1&#xd7;10-3). Furthermore, TREM2 expression was increased in spinal cord samples from ALS patients and SOD1G93A mice (P&#x2009;=&#x2009;2.8&#xd7;10-4 and P&#x2009;=&#x2009;2.8&#xd7;10-9, respectively), confirming dysregulated TREM2 in disease. Expression of TREM2 in the human spinal cord was negatively correlated with survival (P&#x2009;=&#x2009;.04) but not with other phenotypic aspects of disease.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This study demonstrates that the TREM2 p.R47H variant is a potent risk factor for sporadic ALS. To our knowledge, these findings identify the first genetic influence on neuroinflammation in ALS and highlight the TREM2 signaling pathway as a therapeutic target in ALS and other neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cady</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koval</LastName><ForeName>Erica D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benitez</LastName><ForeName>Bruno A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaidman</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jockel-Balsarotti</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allred</LastName><ForeName>Peggy</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baloh</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Cedars Sinai Medical Center, Los Angeles, California4Department of Neurology, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravits</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simpson</LastName><ForeName>Ericka</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Methodist Neurological Institute, Methodist Research Institute, The Methodist Hospital, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Methodist Neurological Institute, Methodist Research Institute, The Methodist Hospital, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pestronk</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri2Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruchaga</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harms</LastName><ForeName>Matthew B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St Louis, Missouri7Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RC2 HL102926</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL083822</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS075094</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR024992</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-102924</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS069669</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL102924</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-102925</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08-NS075094</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL103010</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-102923</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS078398-02</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL102923</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5 T32 HL 83822-5</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 HL102926</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 HL103010</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL-103010</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS069669</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 HL102923</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000448</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG044546</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 HL102924</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 HL102925</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UC2 HL102925</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C000606291">Sod1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24535663</ArticleId><ArticleId IdType="mid">NIHMS595487</ArticleId><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.6237</ArticleId><ArticleId IdType="pii">1828514</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Engelhardt JI, Appel SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol. 1990 Nov;47(11):1210&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013 Jul 25;4(2):385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp Neurol. 2012 Sep;237(1):147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Prinz M. Factors regulating microglia activation. Front Cell Neurosci. 2013;7:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3632747</ArticleId><ArticleId IdType="pubmed">23630462</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CD, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005 Feb 21;201(4):647&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro RJ, Lohmann E, Bras JM, et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013 Jan;70(1):78&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4001789</ArticleId><ArticleId IdType="pubmed">23318515</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Kestila M, Wu J, et al. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat Genet. 2000 Jul;25(3):357&#x2013;361.</Citation><ArticleIdList><ArticleId IdType="pubmed">10888890</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002 Sep;71(3):656&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med. 2013 Jan 10;368(2):107&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Wallon D, Rousseau S, et al. TREM2 R47H variant as a risk factor for early-onset Alzheimer&#x2019;s disease. J Alzheimers Dis. 2013 Jan 1;35(1):45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">23380991</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer&#x2019;s disease. N Engl J Med. 2013 Jan 10;368(2):117&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of Alzheimer&#x2019;s disease in Spanish population. Neurobiol Aging. 2013 Jun;34(6):1711 e1715&#x2013;1717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3596468</ArticleId><ArticleId IdType="pubmed">23391427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez Murcia JD, Schmutz C, Munger C, et al. Assessment of TREM2 rs75932628 association with Alzheimer&#x2019;s disease in a population-based sample: the Cache County Study. Neurobiol Aging. 2013 Jul 12;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779500</ArticleId><ArticleId IdType="pubmed">23855982</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Mol Neurodegener. 2013;8:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference><Reference><Citation>Benitez Ba, C C. TREM2 and Parkinson&#x2019;s disease. NEJM. 2013 In press.</Citation></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994 Jun 17;264(5166):1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Exome Variant Server. NHLBI GO Exome Sequencing Project (ESP) Seattle, WA: Oct, 2012.  URL:  http://evs.gs.washington.edu/EVS/</Citation></Reference><Reference><Citation>Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998 Jul;23(3):249&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">9633809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6):e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24534188</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1540-9538</ISSN><JournalIssue CitedMedium="Internet"><Volume>211</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of experimental medicine</Title><ISOAbbreviation>J Exp Med</ISOAbbreviation></Journal><ArticleTitle>Neuronal activity regulates extracellular tau in vivo.</ArticleTitle><Pagination><StartPage>387</StartPage><EndPage>393</EndPage><MedlinePgn>387-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1084/jem.20131685</ELocationID><Abstract><AbstractText>Tau is primarily a cytoplasmic protein that stabilizes microtubules. However, it is also found in the extracellular space of the brain at appreciable concentrations. Although its presence there may be relevant to the intercellular spread of tau pathology, the cellular mechanisms regulating tau release into the extracellular space are not well understood. To test this in the context of neuronal networks in vivo, we used in vivo microdialysis. Increasing neuronal activity rapidly increased the steady-state levels of extracellular tau in vivo. Importantly, presynaptic glutamate release is sufficient to drive tau release. Although tau release occurred within hours in response to neuronal activity, the elimination rate of tau from the extracellular compartment and the brain is slow (half-life of &#x223c;11 d). The in vivo results provide one mechanism underlying neuronal tau release and may link trans-synaptic spread of tau pathology with synaptic activity itself.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Kaoru</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holth</LastName><ForeName>Jerrah K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Tirth K</ForeName><Initials>TK</Initials></Author><Author ValidYN="Y"><LastName>Hochgr&#xe4;fe</LastName><ForeName>Katja</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mandelkow</LastName><ForeName>Eva-Maria</ForeName><Initials>EM</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Exp Med</MedlineTA><NlmUniqueID>2985109R</NlmUniqueID><ISSNLinking>0022-1007</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>4368-28-9</RegistryNumber><NameOfSubstance UI="D013779">Tetrodotoxin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.12.-</RegistryNumber><NameOfSubstance UI="D008156">Luciferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005110" MajorTopicYN="N">Extracellular Space</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006207" MajorTopicYN="N">Half-Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008156" MajorTopicYN="N">Luciferases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="N">Synaptic Transmission</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013779" MajorTopicYN="N">Tetrodotoxin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24534188</ArticleId><ArticleId IdType="pmc">PMC3949564</ArticleId><ArticleId IdType="doi">10.1084/jem.20131685</ArticleId><ArticleId IdType="pii">jem.20131685</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arriagada P.V., Growdon J.H., Hedley-Whyte E.T., Hyman B.T. 1992. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer&#x2019;s disease. Neurology. 42:631&#x2013;639 10.1212/WNL.42.3.631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.42.3.631</ArticleId><ArticleId IdType="pubmed">1549228</ArticleId></ArticleIdList></Reference><Reference><Citation>Bancher C., Braak H., Fischer P., Jellinger K.A. 1993. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer&#x2019;s and Parkinson&#x2019;s disease patients. Neurosci. Lett. 162:179&#x2013;182 10.1016/0304-3940(93)90590-H</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0304-3940(93)90590-H</ArticleId><ArticleId IdType="pubmed">8121624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.-M., Holtzman D.M. 2011. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat. Neurosci. 14:750&#x2013;756 10.1038/nn.2801</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H., Braak E. 1995. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol. Aging. 16:271&#x2013;278 10.1016/0197-4580(95)00021-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(95)00021-6</ArticleId><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., et al. 2011. Human apoE isoforms differentially regulate brain amyloid-&#x3b2; peptide clearance. Sci. Transl. Med. 3:89ra57</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X., Dage J.L., Citron M. 2012. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 48:356&#x2013;366 10.1016/j.nbd.2012.05.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.05.021</ArticleId><ArticleId IdType="pubmed">22668776</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. 2005. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 48:913&#x2013;922 10.1016/j.neuron.2005.10.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J.R., Kang J.-E., Lee J., Stewart F.R., Verges D.K., Silverio L.M., Bu G., Mennerick S., Holtzman D.M. 2008. Endocytosis is required for synaptic activity-dependent release of amyloid-&#x3b2; in vivo. Neuron. 58:42&#x2013;51 10.1016/j.neuron.2008.02.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.02.003</ArticleId><ArticleId IdType="pmc">PMC2390913</ArticleId><ArticleId IdType="pubmed">18400162</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F., Bolmont T., Crowther R.A., Abramowski D., Frank S., Probst A., Fraser G., Stalder A.K., Beibel M., Staufenbiel M., et al. 2009. Transmission and spreading of tauopathy in transgenic mouse brain. Nat. Cell Biol. 11:909&#x2013;913 10.1038/ncb1901</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1901</ArticleId><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A., Polydoro M., Su&#xe1;rez-Calvet M., William C., Adamowicz D.H., Kopeikina K.J., Pitstick R., Sahara N., Ashe K.H., Carlson G.A., et al. 2012. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 73:685&#x2013;697 10.1016/j.neuron.2011.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckermann K., Mocanu M.-M., Khlistunova I., Biernat J., Nissen A., Hofmann A., Sch&#xf6;nig K., Bujard H., Haemisch A., Mandelkow E., et al. 2007. The &#x3b2;-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy. J. Biol. Chem. 282:31755&#x2013;31765 10.1074/jbc.M705282200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M705282200</ArticleId><ArticleId IdType="pubmed">17716969</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B., Jacks R.L., Diamond M.I. 2009. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284:12845&#x2013;12852 10.1074/jbc.M808759200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M808759200</ArticleId><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J.L., Lee V.M.-Y. 2011. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J. Biol. Chem. 286:15317&#x2013;15331 10.1074/jbc.M110.209296</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.209296</ArticleId><ArticleId IdType="pmc">PMC3083182</ArticleId><ArticleId IdType="pubmed">21372138</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris J.A., Koyama A., Maeda S., Ho K., Devidze N., Dubal D.B., Yu G.-Q., Masliah E., Mucke L. 2012. Human P301L-mutant tau expression in mouse entorhinal-hippocampal network causes tau aggregation and presynaptic pathology but no cognitive deficits. PLoS ONE. 7:e45881 10.1371/journal.pone.0045881</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045881</ArticleId><ArticleId IdType="pmc">PMC3454317</ArticleId><ArticleId IdType="pubmed">23029293</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochgr&#xe4;fe K., Mandelkow E.-M. 2013. Making the brain glow: in vivo bioluminescence imaging to study neurodegeneration. Mol. Neurobiol. 47:868&#x2013;882 10.1007/s12035-012-8379-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-012-8379-1</ArticleId><ArticleId IdType="pubmed">23192390</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M., Guo J.L., McBride J.D., Zhang B., Trojanowski J.Q., Lee V.M.-Y. 2013. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J. Neurosci. 33:1024&#x2013;1037 10.1523/JNEUROSCI.2642-12.2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2642-12.2013</ArticleId><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C.R., Jr, Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., et al. 2013. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12:207&#x2013;216 10.1016/S1474-4422(12)70291-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Karch C.M., Jeng A.T., Goate A.M. 2012. Extracellular Tau levels are influenced by variability in Tau that is associated with tauopathies. J. Biol. Chem. 287:42751&#x2013;42762 10.1074/jbc.M112.380642</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.380642</ArticleId><ArticleId IdType="pmc">PMC3522274</ArticleId><ArticleId IdType="pubmed">23105105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N., Holmes B.B., Jiang H., Holtzman D.M., Diamond M.I. 2012. Trans-cellular propagation of Tau aggregation by fibrillar species. J. Biol. Chem. 287:19440&#x2013;19451 10.1074/jbc.M112.346072</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.-J., Patel S., Lee S.-J. 2005. Intravesicular localization and exocytosis of &#x3b1;-synuclein and its aggregates. J. Neurosci. 25:6016&#x2013;6024 10.1523/JNEUROSCI.0692-05.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0692-05.2005</ArticleId><ArticleId IdType="pmc">PMC6724798</ArticleId><ArticleId IdType="pubmed">15976091</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Drouet V., Wu J.W., Witter M.P., Small S.A., Clelland C., Duff K. 2012. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 7:e31302 10.1371/journal.pone.0031302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk K.C., Kehm V., Carroll J., Zhang B., O&#x2019;Brien P., Trojanowski J.Q., Lee V.M.-Y. 2012. Pathological &#x3b1;-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 338:949&#x2013;953 10.1126/science.1227157</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227157</ArticleId><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia L.F., Kaeser S.A., Reichwald J., Hruscha M., Martus P., Staufenbiel M., Jucker M. 2013. Changes in amyloid-&#x3b2; and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5:re2</Citation><ArticleIdList><ArticleId IdType="pubmed">23863834</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed N.-V., Herrou T., Plouffe V., Piperno N., Leclerc N. 2013. Spreading of tau pathology in Alzheimer&#x2019;s disease by cell-to-cell transmission. Eur. J. Neurosci. 37:1939&#x2013;1948 10.1111/ejn.12229</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.12229</ArticleId><ArticleId IdType="pubmed">23773063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler A.M., Phillips E.C., Lau D.H.W., Noble W., Hanger D.P. 2013. Physiological release of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14:389&#x2013;394 10.1038/embor.2013.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/embor.2013.15</ArticleId><ArticleId IdType="pmc">PMC3615658</ArticleId><ArticleId IdType="pubmed">23412472</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J.C., Guan S., Burlingame A., Prusiner S.B., Ghaemmaghami S. 2010. Analysis of proteome dynamics in the mouse brain. Proc. Natl. Acad. Sci. USA. 107:14508&#x2013;14513 10.1073/pnas.1006551107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1006551107</ArticleId><ArticleId IdType="pmc">PMC2922600</ArticleId><ArticleId IdType="pubmed">20699386</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Jeugd A., Hochgr&#xe4;fe K., Ahmed T., Decker J.M., Sydow A., Hofmann A., Wu D., Messing L., Balschun D., D&#x2019;Hooge R., Mandelkow E.-M. 2012. Cognitive defects are reversible in inducible mice expressing pro-aggregant full-length human Tau. Acta Neuropathol. 123:787&#x2013;805 10.1007/s00401-012-0987-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-0987-3</ArticleId><ArticleId IdType="pmc">PMC4979687</ArticleId><ArticleId IdType="pubmed">22532069</ArticleId></ArticleIdList></Reference><Reference><Citation>Verges D.K., Restivo J.L., Goebel W.D., Holtzman D.M., Cirrito J.R. 2011. Opposing synaptic regulation of amyloid-&#x3b2; metabolism by NMDA receptors in vivo. J. Neurosci. 31:11328&#x2013;11337 10.1523/JNEUROSCI.0607-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0607-11.2011</ArticleId><ArticleId IdType="pmc">PMC3329800</ArticleId><ArticleId IdType="pubmed">21813692</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K., Cirrito J.R., Stewart F.R., Jiang H., Finn M.B., Holmes B.B., Binder L.I., Mandelkow E.-M., Diamond M.I., Lee V.M.-Y., Holtzman D.M. 2011. In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J. Neurosci. 31:13110&#x2013;13117 10.1523/JNEUROSCI.2569-11.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2569-11.2011</ArticleId><ArticleId IdType="pmc">PMC4299126</ArticleId><ArticleId IdType="pubmed">21917794</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24549548</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>311</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.</ArticleTitle><Pagination><StartPage>682</StartPage><EndPage>691</EndPage><MedlinePgn>682-91</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2014.93</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants (n&#x2009;=&#x2009;186) were randomized to receive a psychosocial intervention plus either citalopram (n&#x2009;=&#x2009;94) or placebo (n&#x2009;=&#x2009;92) for 9 weeks. Dosage began at 10 mg per day with planned titration to 30 mg per day over 3 weeks based on response and tolerability.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Primary outcome measures were based on scores from the 18-point Neurobehavioral Rating Scale agitation subscale (NBRS-A) and the modified Alzheimer Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC). Other outcomes were based on scores from the Cohen-Mansfield Agitation Inventory (CMAI) and the Neuropsychiatric Inventory (NPI), ability to complete activities of daily living (ADLs), caregiver distress, cognitive safety (based on scores from the 30-point Mini Mental State Examination [MMSE]), and adverse events.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants who received citalopram showed significant improvement compared with those who received placebo on both primary outcome measures. The NBRS-A estimated treatment difference at week 9 (citalopram minus placebo) was -0.93 (95% CI, -1.80 to -0.06), P&#x2009;=&#x2009;.04. Results from the mADCS-CGIC showed 40% of citalopram participants having moderate or marked improvement from baseline compared with 26% of placebo recipients, with estimated treatment effect (odds ratio [OR] of being at or better than a given CGIC category) of 2.13 (95% CI, 1.23-3.69), P&#x2009;=&#x2009;.01. Participants who received citalopram showed significant improvement on the CMAI, total NPI, and caregiver distress scores but not on the NPI agitation subscale, ADLs, or in less use of rescue lorazepam. Worsening of cognition (-1.05 points; 95% CI, -1.97 to -0.13; P&#x2009;=&#x2009;.03) and QT interval prolongation (18.1 ms; 95% CI, 6.1-30.1; P&#x2009;=&#x2009;.01) were seen in the citalopram group.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Among patients with probable Alzheimer disease and agitation who were receiving psychosocial intervention, the addition of citalopram compared with placebo significantly reduced agitation and caregiver distress; however, cognitive and cardiac adverse effects of citalopram may limit its practical application at the dosage of 30 mg per day.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00898807.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>University of Rochester School of Medicine and Dentistry, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drye</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Campbell Institute, CAMH, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York5College of Physicians and Surgeons of Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frangakis</LastName><ForeName>Constantine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ismail</LastName><ForeName>Zahinoor</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry and Neurology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marano</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meinert</LastName><ForeName>Curtis L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Clinical Biotechnology Research Institute, Roper St Francis Healthcare, Charleston, South Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munro</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Geriatric Psychiatry, New York State Psychiatric Institute, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabins</LastName><ForeName>Peter V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>University of Southern California Keck School of Medicine, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shade</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Perelman School of Medicine at the University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine, Stanford, California12VA Palo Alto Health Care System, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Johns Hopkins Bayview and Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CitAD Research Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00898807</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI102710</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031348</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG05142</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031348</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2014 Feb 19;311(7):677-8. doi: 10.1001/jama.2014.94.</RefSource><PMID Version="1">24549545</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Med. 2014 Oct;19(5):181. doi: 10.1136/ebmed-2014-110016.</RefSource><PMID Version="1">24824622</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000451" MajorTopicYN="N">nursing</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017028" MajorTopicYN="N">Caregivers</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shade</LastName><ForeName>Dave</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Constantine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avramopoulos</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Munro</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rabins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shade</LastName><ForeName>Dave</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Casper</LastName><ForeName>Anne Shanklin</ForeName><Initials>AS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drye</LastName><ForeName>Lea</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frangakis</LastName><ForeName>Constantine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meinert</LastName><ForeName>Curtis</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pan</LastName><ForeName>Hao-Min</ForeName><Initials>HM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tonascia</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Toepfner</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaidya</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergey</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carlson</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gogel</LastName><ForeName>Carol</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marano</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollutra</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devanand</LastName><ForeName>D P</ForeName><Initials>DP</Initials></Investigator><Investigator ValidYN="Y"><LastName>de la Pena</LastName><ForeName>Corazon</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelton</LastName><ForeName>Gregory H</ForeName><Initials>GH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mintzer</LastName><ForeName>Jacobo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gregory</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brawman-Mintzer</LastName><ForeName>Olga</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moroni</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Amanda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stuckey</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Neill</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weintraub</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czerniakowski</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>DiFilippo</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mamikonyan</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Streim</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porsteinsson</LastName><ForeName>Anton P</ForeName><Initials>AP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldstein</LastName><ForeName>Bonnie</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salem-Spencer</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kowalski</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Kimberly S</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>LaFountain</LastName><ForeName>Jeanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Makino</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stear</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Porter</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Widman</LastName><ForeName>Asa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yesavage</LastName><ForeName>Jerome</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newell</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ashford</LastName><ForeName>Wes</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bratcher</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chao</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fairchild</LastName><ForeName>Jennifer Kaci</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>Leah</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Georgette</LastName><ForeName>Gerald</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gere</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kim</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Periyakoil</LastName><ForeName>Vyjeyanthi</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traum</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vicencio</LastName><ForeName>Alda</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wicks</LastName><ForeName>Deryl</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pollock</LastName><ForeName>Bruce G</ForeName><Initials>BG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miranda</LastName><ForeName>Dielle</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bies</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burhan</LastName><ForeName>Amer</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gerretsen</LastName><ForeName>Phil</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ismail</LastName><ForeName>Zahinoor</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Minh-Quan</ForeName><Initials>MQ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajji</LastName><ForeName>Tarek</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tang-Wai</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Becerra</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dagerman</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pawluczyk</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spann</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teodoro</LastName><ForeName>Liberty</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arndt</LastName><ForeName>Stephan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drye</LastName><ForeName>Lea</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyketsos</LastName><ForeName>Kostas</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryan</LastName><ForeName>Laurie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shade</LastName><ForeName>Dave</ForeName><Initials>D</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24549548</ArticleId><ArticleId IdType="mid">NIHMS582015</ArticleId><ArticleId IdType="pmc">PMC4086818</ArticleId><ArticleId IdType="doi">10.1001/jama.2014.93</ArticleId><ArticleId IdType="pii">1829989</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14):1326&#x2013;1334.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959992</ArticleId><ArticleId IdType="pubmed">23550670</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg M, Shao H, Zandi P, et al. Cache County Investigators Point and five-year period prevalence of neuropsychiatric symptoms in dementia: the Cache county study. Int J Geriatr Psychiatry. 2008;23:170&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2932652</ArticleId><ArticleId IdType="pubmed">17607801</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157(5):708&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">10784462</ArticleId></ArticleIdList></Reference><Reference><Citation>Aalten P, de Vugt ME, Jaspers N, Jolles J, Verhey FR. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry. 2005;20(6):523&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920712</ArticleId></ArticleIdList></Reference><Reference><Citation>Geda YE, Schneider LS, Gitlin LN, et al. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. Alzheimers Dement. 2013 Apr 05; (epub ahead of print)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766403</ArticleId><ArticleId IdType="pubmed">23562430</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman K, Insel P. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:190&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505124</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med. 2006;355(15):1525&#x2013;1538.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7(6):492&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">16715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934&#x2013;1943.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5(5):245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">19488082</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergh S, Selb&#xe6;k G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">22408266</ArticleId></ArticleIdList></Reference><Reference><Citation>Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149102</ArticleId><ArticleId IdType="pubmed">21810886</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">1705151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86(2):138&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">1529737</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragneskog H, Eriksson S, Karlsson I, Gottfries CG. Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram. Int Psychogeriatr. 1996;8(4):659&#x2013;668.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147178</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Vigen CL, Mack WJ, et al. Effectiveness of Citalopram Compared to Atypical Antipsychotics in Alzheimer's Disease Patients Who Discontinued Their Initially Assigned Treatment: CATIE-AD Phase 2 Results. American Journal of Geriatric Psychiatry. 2009;3(Supplement 1):A77.</Citation></Reference><Reference><Citation>Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. Am J Geriatr Psychiatry. 1997;5(1):70&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9169247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002;159(3):460&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">11870012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15(11):942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">17846102</ArticleId></ArticleIdList></Reference><Reference><Citation>Drye LT, Ismail Z, Porsteinsson AP, et al. CitAD Research Group Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012;8(2):121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3333484</ArticleId><ArticleId IdType="pubmed">22301195</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:196&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">7991117</ArticleId></ArticleIdList></Reference><Reference><Citation> [Accessed on June 29, 2013];FDA Drug Safety Communication: Abnormal heart rhythms associated with
high doses of Celexa (citalopram hydrobromide)   at  http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm.</Citation></Reference><Reference><Citation>Levin HS, High WM, Goethe KE, et al. The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. J Neurol Neurosurg Psychiatry. 1987;50(2):183&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1031490</ArticleId><ArticleId IdType="pubmed">3572433</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S22&#x2013;S32.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen-Mansfield J. Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument. Int Psychogeriatr. 1996;8(Suppl 3):309&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">9154580</ArticleId></ArticleIdList></Reference><Reference><Citation>Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33&#x2013;S39.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236950</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurley MV, Scott DL, Rees J, Newham DJ. Sensorimotor changes and functional performance in patients with knee osteoarthritis. Ann Rheum Dis. 1997;56(11):641&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752287</ArticleId><ArticleId IdType="pubmed">9462165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblum M, van der Laan MJ. Simple, efficient estimators of treatment effects in randomized trials using generalized linear models to leverage baseline variables. Int J Biostat. 2010;6(1):Article 13. doi:10.2202/1557-4679.1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2898625</ArticleId><ArticleId IdType="pubmed">20628636</ArticleId></ArticleIdList></Reference><Reference><Citation>Agresti A. Categorical Data Analysis. John Wiley &amp; Sons; New York, N.Y.: 1990.</Citation></Reference><Reference><Citation>Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357:1382&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914039</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox C, Crugel M, Maidment I, et al. Efficacy of Memantine for Agitation in Alzheimer's Dementia: A Randomised Double-Blind Placebo Controlled Trial. PLoS ONE. 2012;7(5):e35185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3342281</ArticleId><ArticleId IdType="pubmed">22567095</ArticleId></ArticleIdList></Reference><Reference><Citation>Culang ME, Sneed JR, Keilp JG, et al. Change in cognitive functioning following acute antidepressant treatment in late-life depression. Am J Geriatr Psychiatry. 2009;17(10):881&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3852681</ArticleId><ArticleId IdType="pubmed">19916207</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg PB, Mielke MM, Han D, et al. The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. Int J Geriatr Psychiatry. 2012;27(12):1248&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3448859</ArticleId><ArticleId IdType="pubmed">22374884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivin K, Pfeiffer PN, Bohnert AS, et al. Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. Am J Psychiatry. 2013;170(6):642&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">23640689</ArticleId></ArticleIdList></Reference><Reference><Citation> [Accessed on June 29, 2013];FDA Drug Safety Communication: Revised recommendations for Celexa
(citalopram hydrobromide) related to a potential risk of abnormal heart
rhythms with high doses.  at  http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm.</Citation></Reference><Reference><Citation>Howard R, Phillips P, Johnson T, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry. 2011;26(8):812&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848576</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro CA, Longmire CF, Drye LT, et al. Cognitive Outcomes after Sertaline Treatment in Patients with Depression of Alzheimer's Disease. Am J Geriatr Psychiatry. 2012;20(12):1036&#x2013;1044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3508666</ArticleId><ArticleId IdType="pubmed">23032478</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24553930</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A sensitive a&#x3b2; oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>2884</StartPage><EndPage>2897</EndPage><MedlinePgn>2884-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.1675-13.2014</ELocationID><Abstract><AbstractText>A hallmark of Alzheimer's disease (AD) brain is the amyloid &#x3b2; (A&#x3b2;) plaque, which is comprised of A&#x3b2; peptides. Multiple lines of evidence suggest that A&#x3b2; oligomers are more toxic than other peptide forms. We sought to develop a robust assay to quantify oligomers from CSF. Antibody 19.3 was compared in one-site and competitive ELISAs for oligomer binding specificity. A two-site ELISA for oligomers was developed using 19.3 coupled to a sensitive, bead-based fluorescent platform able to detect single photons of emitted light. The two-site ELISA was &gt;2500&#xd7; selective for A&#x3b2; oligomers over A&#x3b2; monomers with a limit of detection &#x223c; 0.09 pg/ml in human CSF. The lower limit of reliable quantification of the assay was 0.18 pg/ml and the antibody pairs recognized A&#x3b2; multimers comprised of either synthetic standards, or endogenous oligomers isolated from confirmed human AD and healthy control brain. Using the assay, a significant 3- to 5-fold increase in A&#x3b2; oligomers in human AD CSF compared with comparably aged controls was demonstrated. The increase was seen in three separate human cohorts, totaling 63 AD and 54 controls. CSF oligomers ranged between 0.1 and 10 pg/ml. A&#x3b2; oligomer levels did not strongly associate with age or gender, but had an inverse correlation with MMSE score. The C statistic for the A&#x3b2; oligomer ROC curve was 0.86, with 80% sensitivity and 88% specificity to detect AD, suggesting reasonable discriminatory power for the AD state and the potential for utility as a diagnostic marker.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Mary J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Molecular Biomarkers, Department of Neuroscience, and Department of Pharmacology, Merck &amp; Company, Inc., West Point, Pennsylvania 19486.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinina</LastName><ForeName>Juliya</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wolfe</LastName><ForeName>Abigail</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Tugusheva</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Korn</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cash-Mason</LastName><ForeName>Tanesha</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Maxwell</LastName><ForeName>Jill W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Hatcher</LastName><ForeName>Nathan G</ForeName><Initials>NG</Initials></Author><Author ValidYN="Y"><LastName>Haugabook</LastName><ForeName>Sharie J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guoxin</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Howell</LastName><ForeName>Bonnie J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Renger</LastName><ForeName>John J</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Shughrue</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>McCampbell</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005189" MajorTopicYN="N">False Positive Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012542" MajorTopicYN="N">Scattering, Radiation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abeta oligomer</Keyword><Keyword MajorTopicYN="N">Alzheimer</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>8</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24553930</ArticleId><ArticleId IdType="pmc">PMC6608513</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.1675-13.2014</ArticleId><ArticleId IdType="pii">34/8/2884</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barghorn S, Nimmrich V, Striebinger A, Krantz C, Keller P, Janson B, Bahr M, Schmidt M, Bitner RS, Harlan J, Barlow E, Ebert U, Hillen H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem. 2005;95:834&#x2013;847. doi: 10.1111/j.1471-4159.2005.03407.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03407.x</ArticleId><ArticleId IdType="pubmed">16135089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666&#x2013;669. doi: 10.1212/01.wnl.0000256043.50901.e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000256043.50901.e3</ArticleId><ArticleId IdType="pubmed">17325273</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349&#x2013;357. doi: 10.1038/nn.3028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3028</ArticleId><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein SL, Wyttenbach T, Baumketner A, Shea JE, Bitan G, Teplow DB, Bowers MT. Amyloid beta-protein: monomer structure and early aggregation states of Abeta42 and its Pro19 alloform. J Am Chem Soc. 2005;127:2075&#x2013;2084. doi: 10.1021/ja044531p.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ja044531p</ArticleId><ArticleId IdType="pubmed">15713083</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea JE, Ruotolo BT, Robinson CV, Bowers MT. Amyloid-&#x3b2; protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem. 2009;1:326&#x2013;331. doi: 10.1038/nchem.247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchem.247</ArticleId><ArticleId IdType="pmc">PMC2918915</ArticleId><ArticleId IdType="pubmed">20703363</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Teplow DB. Rapid photochemical cross-linking&#x2013;a new tool for studies of metastable, amyloidogenic protein assemblies. Acc Chem Res. 2004;37:357&#x2013;364. doi: 10.1021/ar000214l.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ar000214l</ArticleId><ArticleId IdType="pubmed">15196045</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Teplow DB. Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays. Methods Mol Biol. 2005;299:3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15980591</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid beta-protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A. 2003;100:330&#x2013;335. doi: 10.1073/pnas.222681699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.222681699</ArticleId><ArticleId IdType="pmc">PMC140968</ArticleId><ArticleId IdType="pubmed">12506200</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, Andreasen N, Zetterberg H, Andreasson U, Blennow K. Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis. 2010;pii:986310. doi: 10.4061/2010/986310.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/986310</ArticleId><ArticleId IdType="pmc">PMC2925386</ArticleId><ArticleId IdType="pubmed">20798852</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruggink KA, Jongbloed W, Biemans EA, Veerhuis R, Claassen JA, Kuiperij HB, Verbeek MM. Amyloid-&#x3b2; oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Anal Biochem. 2013;433:112&#x2013;120. doi: 10.1016/j.ab.2012.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2012.09.014</ArticleId><ArticleId IdType="pubmed">23022042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828. doi: 10.1074/jbc.M701078200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701078200</ArticleId><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry. 2003;42:12749&#x2013;12760. doi: 10.1021/bi030029q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi030029q</ArticleId><ArticleId IdType="pubmed">14596589</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76:908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw L, Trojanowski JQ Alzheimer's Disease Neuroimaging Initiative. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol. 2010;67:949&#x2013;956. doi: 10.1001/archneurol.2010.179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2010.179</ArticleId><ArticleId IdType="pmc">PMC2963067</ArticleId><ArticleId IdType="pubmed">20697045</ArticleId></ArticleIdList></Reference><Reference><Citation>Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL. Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73:104&#x2013;119. doi: 10.1002/ana.23748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23748</ArticleId><ArticleId IdType="pmc">PMC3563737</ArticleId><ArticleId IdType="pubmed">23225543</ArticleId></ArticleIdList></Reference><Reference><Citation>Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, Asante EA, Farrow MA, Sessions RB, Saibil HR, Clarke AR, Rowan MJ, Walsh DM, Collinge J. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011;2:336. doi: 10.1038/ncomms1341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms1341</ArticleId><ArticleId IdType="pmc">PMC3156817</ArticleId><ArticleId IdType="pubmed">21654636</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010;24:2716&#x2013;2726. doi: 10.1096/fj.09-150359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.09-150359</ArticleId><ArticleId IdType="pubmed">20339023</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandy S, Simon AJ, Steele JW, Lublin AL, Lah JJ, Walker LC, Levey AI, Krafft GA, Levy E, Checler F, Glabe C, Bilker WB, Abel T, Schmeidler J, Ehrlich ME. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann Neurol. 2010;68:220&#x2013;230. doi: 10.1002/ana.22052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22052</ArticleId><ArticleId IdType="pmc">PMC3094694</ArticleId><ArticleId IdType="pubmed">20641005</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S. Abeta40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. PLoS One. 2010;5:e15725. doi: 10.1371/journal.pone.0015725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015725</ArticleId><ArticleId IdType="pmc">PMC3012719</ArticleId><ArticleId IdType="pubmed">21209907</ArticleId></ArticleIdList></Reference><Reference><Citation>Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102:2273&#x2013;2276. doi: 10.1073/pnas.0409336102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409336102</ArticleId><ArticleId IdType="pmc">PMC548981</ArticleId><ArticleId IdType="pubmed">15695586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003;100:10417&#x2013;10422. doi: 10.1073/pnas.1834302100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834302100</ArticleId><ArticleId IdType="pmc">PMC193576</ArticleId><ArticleId IdType="pubmed">12925731</ArticleId></ArticleIdList></Reference><Reference><Citation>Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH. Correlation of specific amyloid-&#x3b2; oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol. 2013;70:594&#x2013;599. doi: 10.1001/jamaneurol.2013.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.48</ArticleId><ArticleId IdType="pmc">PMC3725752</ArticleId><ArticleId IdType="pubmed">23479202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P, Kinney G, Joyce JG. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry. 2006;45:15157&#x2013;15167. doi: 10.1021/bi061850f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi061850f</ArticleId><ArticleId IdType="pubmed">17176037</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:2442&#x2013;2453. doi: 10.1523/JNEUROSCI.5038-09.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5038-09.2010</ArticleId><ArticleId IdType="pmc">PMC2947456</ArticleId><ArticleId IdType="pubmed">20164328</ArticleId></ArticleIdList></Reference><Reference><Citation>Herskovits AZ, Locascio JJ, Peskind ER, Li G, Hyman BT. A Luminex assay detects amyloid &#x3b2; oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One. 2013;8:e67898. doi: 10.1371/journal.pone.0067898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0067898</ArticleId><ArticleId IdType="pmc">PMC3699502</ArticleId><ArticleId IdType="pubmed">23844122</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;ltt&#xe4; M, Hansson O, Andreasson U, Hertze J, Minthon L, N&#xe4;gga K, Andreasen N, Zetterberg H, Blennow K. Evaluating amyloid-&#x3b2; oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. PLoS One. 2013;8:e66381. doi: 10.1371/journal.pone.0066381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0066381</ArticleId><ArticleId IdType="pmc">PMC3682966</ArticleId><ArticleId IdType="pubmed">23799095</ArticleId></ArticleIdList></Reference><Reference><Citation>Howlett DR, George AR, Owen DE, Ward RV, Markwell RE. Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation. Biochem J. 1999;343:419&#x2013;423. doi: 10.1042/0264-6021:3430419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/0264-6021:3430419</ArticleId><ArticleId IdType="pmc">PMC1220570</ArticleId><ArticleId IdType="pubmed">10510309</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128. doi: 10.1016/S1474-4422(09)70299-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(09)70299-6</ArticleId><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein WL. Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis. 2013;33:S49&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">22785404</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain. 2012;135:2155&#x2013;2168. doi: 10.1093/brain/aws127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws127</ArticleId><ArticleId IdType="pmc">PMC3381721</ArticleId><ArticleId IdType="pubmed">22637583</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem. 1996;271:4077&#x2013;4081. doi: 10.1074/jbc.271.8.4077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.8.4077</ArticleId><ArticleId IdType="pubmed">8626743</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci. 2004;24:10191&#x2013;10200. doi: 10.1523/JNEUROSCI.3432-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3432-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730194</ArticleId><ArticleId IdType="pubmed">15537891</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Abeta1&#x2013;42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448&#x2013;6453. doi: 10.1073/pnas.95.11.6448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.11.6448</ArticleId><ArticleId IdType="pmc">PMC27787</ArticleId><ArticleId IdType="pubmed">9600986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambert MP, Velasco PT, Viola KL, Klein WL. Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets. 2009;8:65&#x2013;81. doi: 10.2174/187152709787601876.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152709787601876</ArticleId><ArticleId IdType="pubmed">19275637</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357. doi: 10.1038/nature04533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04533</ArticleId><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>LeVine H., 3rd Alzheimer's beta-peptide oligomer formation at physiologic concentrations. Anal Biochem. 2004;335:81&#x2013;90. doi: 10.1016/j.ab.2004.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2004.08.014</ArticleId><ArticleId IdType="pubmed">15519574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF A&#x3b2;42, A&#x3b2;42/A&#x3b2;40 ratio and total tau. Neurobiol Aging. 2004;25:273&#x2013;281. doi: 10.1016/S0197-4580(03)00086-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(03)00086-1</ArticleId><ArticleId IdType="pubmed">15123331</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Beck G, Esselmann H, Bruckmoser R, Zimmermann R, Fiszer M, Bibl M, Maler JM, Kornhuber J, Wiltfang J. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem. 2006;52:332&#x2013;334.</Citation><ArticleIdList><ArticleId IdType="pubmed">16449222</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, Waring JF. Effect of human cerebrospinal fluid sampling frequency on amyloid-beta levels. Alzheimers Dement. 2012;8:295&#x2013;303. doi: 10.1016/j.jalz.2011.05.900.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.05.900</ArticleId><ArticleId IdType="pubmed">22047633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM Medical Research Council Cognitive Function and Ageing Study. The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain. 2010;133:1328&#x2013;1341. doi: 10.1093/brain/awq065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq065</ArticleId><ArticleId IdType="pmc">PMC2859152</ArticleId><ArticleId IdType="pubmed">20403962</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944. doi: 10.1212/WNL.34.7.939.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.34.7.939</ArticleId><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, Darabie AA, Cousins JE, French JE, Lan MF, Chen F, Wong SS, Mount HT, Fraser PE, Westaway D, St George-Hyslop P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med. 2006;12:801&#x2013;808. doi: 10.1038/nm1423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1423</ArticleId><ArticleId IdType="pubmed">16767098</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860&#x2013;866. doi: 10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;860::AID-ANA8&gt;3.0.CO;2-M</ArticleId><ArticleId IdType="pubmed">10589538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D. In-office mental status testing: a practical guide. Geriatrics. 1991;46:54&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">2060803</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, R&#xf6;nicke R, Reymann K, Hutter-Paier B, Alexandru A, Jagla W, Graubner S, Glabe CG, Demuth HU, Bloom GS. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature. 2012;485:651&#x2013;655. doi: 10.1038/nature11060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11060</ArticleId><ArticleId IdType="pmc">PMC3367389</ArticleId><ArticleId IdType="pubmed">22660329</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol. 2008;65:963&#x2013;967. doi: 10.1001/archneur.65.7.963.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.7.963</ArticleId><ArticleId IdType="pmc">PMC2587038</ArticleId><ArticleId IdType="pubmed">18625866</ArticleId></ArticleIdList></Reference><Reference><Citation>Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA. Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:3723&#x2013;3735. doi: 10.1002/rcm.2787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcm.2787</ArticleId><ArticleId IdType="pubmed">17117458</ArticleId></ArticleIdList></Reference><Reference><Citation>Perret-Liaudet A, Pelpel M, Tholance Y, Dumont B, Vanderstichele H, Zorzi W, Elmoualij B, Schraen S, Moreaud O, Gabelle A, Thouvenot E, Thomas-Anterion C, Touchon J, Krolak-Salmon P, Kovacs GG, Coudreuse A, Quadrio I, Lehmann S. Risk of Alzheimer's disease biological misdiagnosis linked to cerebrospinal collection tubes. J Alzheimers Dis. 2012;31:13&#x2013;20. doi: 10.3233/JAD-2012-120361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120361</ArticleId><ArticleId IdType="pubmed">22495345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, Laterza OF. Nonspecific binding of Abeta42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta. 2010;411:1833. doi: 10.1016/j.cca.2010.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2010.07.019</ArticleId><ArticleId IdType="pubmed">20655889</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitschke M, Prior R, Haupt M, Riesner D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med. 1998;4:832&#x2013;834. doi: 10.1038/nm0798-832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0798-832</ArticleId><ArticleId IdType="pubmed">9662376</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel a&#x3b2; isoforms in Alzheimer's disease-their role in diagnosis and treatment. Curr Pharm Des. 2011;17:2594&#x2013;2602. doi: 10.2174/138161211797416039.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161211797416039</ArticleId><ArticleId IdType="pubmed">21728980</ArticleId></ArticleIdList></Reference><Reference><Citation>Sancesario GM, Cencioni MT, Esposito Z, Borsellino G, Nuccetelli M, Martorana A, Battistini L, Sorge R, Spalletta G, Ferrazzoli D, Bernardi G, Bernardini S, Sancesario G. The load of amyloid-&#x3b2; oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients. J Alzheimers Dis. 2012;31:865&#x2013;878. doi: 10.3233/JAD-2012-120211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-120211</ArticleId><ArticleId IdType="pubmed">22717612</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140. doi: 10.1124/jpet.108.143628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.143628</ArticleId><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos AN, Ewers M, Minthon L, Simm A, Silber RE, Blennow K, Prvulovic D, Hansson O, Hampel H. Amyloid-&#x3b2; oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J Alzheimers Dis. 2012;29:171&#x2013;176. doi: 10.3233/JAD-2012-111361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-111361</ArticleId><ArticleId IdType="pubmed">22214781</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarsoza F, Saing T, Kayed R, Dahlin R, Dick M, Broadwater-Hollifield C, Mobley S, Lott I, Doran E, Gillen D, Anderson-Bergman C, Cribbs DH, Glabe C, Head E. A fibril-specific, conformation-dependent antibody recognizes a subset of Ab plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol. 2009;118:505&#x2013;517. doi: 10.1007/s00401-009-0530-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0530-3</ArticleId><ArticleId IdType="pmc">PMC2737113</ArticleId><ArticleId IdType="pubmed">19360426</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat Med. 2008;14:1106&#x2013;1111. doi: 10.1038/nm.1872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.1872</ArticleId><ArticleId IdType="pubmed">18836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Schupf N, Tang MX, Fukuyama H, Manly J, Andrews H, Mehta P, Ravetch J, Mayeux R. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci U S A. 2008;105:14052&#x2013;14057. doi: 10.1073/pnas.0805902105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0805902105</ArticleId><ArticleId IdType="pmc">PMC2544577</ArticleId><ArticleId IdType="pubmed">18779561</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837&#x2013;842. doi: 10.1038/nm1782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1782</ArticleId><ArticleId IdType="pmc">PMC2772133</ArticleId><ArticleId IdType="pubmed">18568035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009;65:403&#x2013;413. doi: 10.1002/ana.21610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21610</ArticleId><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, Hepler RW, Wolfe AL, Matthews M, Heidecker GJ, Joyce JG, Villarreal SA, Kinney GG. Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging. 2010;31:189&#x2013;202. doi: 10.1016/j.neurobiolaging.2008.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2008.04.003</ArticleId><ArticleId IdType="pubmed">18486276</ArticleId></ArticleIdList></Reference><Reference><Citation>Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K. Measurement of Abeta1&#x2013;42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem. 2012;120:325&#x2013;333. doi: 10.1111/j.1471-4159.2011.07553.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07553.x</ArticleId><ArticleId IdType="pubmed">22023354</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;78:709&#x2013;719. doi: 10.1212/WNL.0b013e318248e568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318248e568</ArticleId><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="pubmed">22357717</ArticleId></ArticleIdList></Reference><Reference><Citation>Todd J, Freese B, Lu A, Held D, Morey J, Livingston R, Goix P. Ultrasensitive flow-based immunoassays using single-molecule counting. Clin Chem. 2007;53:1990&#x2013;1995. doi: 10.1373/clinchem.2007.091181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2007.091181</ArticleId><ArticleId IdType="pubmed">17890441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomic JL, Pensalfini A, Head E, Glabe CG. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis. 2009;35:352&#x2013;358. doi: 10.1016/j.nbd.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.05.024</ArticleId><ArticleId IdType="pmc">PMC2725199</ArticleId><ArticleId IdType="pubmed">19523517</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, Walsh DM, Selkoe DJ. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol. 2006;60:668&#x2013;676. doi: 10.1002/ana.21051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21051</ArticleId><ArticleId IdType="pubmed">17192927</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS, Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126:1596&#x2013;1604. doi: 10.1161/CIRCULATIONAHA.112.129437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.129437</ArticleId><ArticleId IdType="pmc">PMC3656719</ArticleId><ArticleId IdType="pubmed">22907935</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Miller RA, Connolly B, Marcus J, Renger J, Savage MJ. Pyroglutamate-modified amyloid-&#x3b2; protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain. Neurodegener Dis. 2013 doi: 10.1159/000353634. doi: 10.1159/000353634. Advance online publication.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000353634</ArticleId><ArticleId IdType="doi">10.1159/000353634</ArticleId><ArticleId IdType="pubmed">24158021</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia W, Yang T, Shankar G, Smith I, Shen Y, Walsh DM, Selkoe DJ. A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol. 2009;66:190&#x2013;199. doi: 10.1001/archneurol.2008.565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.565</ArticleId><ArticleId IdType="pmc">PMC3618974</ArticleId><ArticleId IdType="pubmed">19204155</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto N, Matsubara E, Maeda S, Minagawa H, Takashima A, Maruyama W, Michikawa M, Yanagisawa K. A ganglioside-induced toxic soluble Abeta assembly. Its enhanced formation from Abeta bearing the Arctic mutation. J Biol Chem. 2007;282:2646&#x2013;2655.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135262</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement. 2013;9:99&#x2013;112. doi: 10.1016/j.jalz.2012.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.005</ArticleId><ArticleId IdType="pmc">PMC3604133</ArticleId><ArticleId IdType="pubmed">23375565</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetzsche T, Rujescu D, Hardy J, Hampel H. Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease. Expert Rev Mol Diagn. 2010;10:667&#x2013;690. doi: 10.1586/erm.10.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erm.10.48</ArticleId><ArticleId IdType="pubmed">20629514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24561062</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>156</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Neurogenesis in the striatum of the adult human brain.</ArticleTitle><Pagination><StartPage>1072</StartPage><EndPage>1083</EndPage><MedlinePgn>1072-83</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.01.044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00137-8</ELocationID><Abstract><AbstractText>In most mammals, neurons are added throughout life in the hippocampus and olfactory bulb. One area where neuroblasts that give rise to adult-born neurons are generated is the lateral ventricle wall of the brain. We show, using histological and carbon-14 dating approaches, that in adult humans new neurons integrate in the striatum, which is adjacent to this neurogenic niche. The neuronal turnover in the striatum appears restricted to interneurons, and postnatally generated striatal neurons are preferentially depleted in patients with Huntington's disease. Our findings demonstrate a unique pattern of neurogenesis in the adult human brain.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ernst</LastName><ForeName>Aur&#xe9;lie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alkass</LastName><ForeName>Kanar</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernard</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institut Camille Jordan, CNRS UMR 5208, University of Lyon, 69622 Villeurbanne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salehpour</LastName><ForeName>Mehran</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physics and Astronomy, Ion Physics, Uppsala University, 751 20&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perl</LastName><ForeName>Shira</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>NHLBI, NIH, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisdale</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>NHLBI, NIH, Bethesda, Maryland 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Possnert</LastName><ForeName>G&#xf6;ran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physics and Astronomy, Ion Physics, Uppsala University, 751 20&#xa0;Uppsala, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Druid</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Oncology-Pathology, Karolinska Institute, 171 77 Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fris&#xe9;n</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cell and Molecular Biology, Karolinska Institute, 171 77 Stockholm, Sweden. Electronic address: jonas.frisen@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2014 Feb 27;156(5):870-1. doi: 10.1016/j.cell.2014.02.027.</RefSource><PMID Version="1">24581487</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 Apr;15(4):203. doi: 10.1038/nrn3714.</RefSource><PMID Version="1">24594987</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006816" MajorTopicYN="N">Huntington Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007395" MajorTopicYN="N">Interneurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008954" MajorTopicYN="N">Models, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055495" MajorTopicYN="Y">Neurogenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009830" MajorTopicYN="N">Olfactory Bulb</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24561062</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.01.044</ArticleId><ArticleId IdType="pii">S0092-8674(14)00137-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24598541</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>507</Volume><Issue>7491</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>C9orf72 nucleotide repeat structures initiate molecular cascades of disease.</ArticleTitle><Pagination><StartPage>195</StartPage><EndPage>200</EndPage><MedlinePgn>195-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13124</ELocationID><Abstract><AbstractText>A hexanucleotide repeat expansion (HRE), (GGGGCC)n, in C9orf72 is the most common genetic cause of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here we identify a molecular mechanism by which structural polymorphism of the HRE leads to ALS/FTD pathology and defects. The HRE forms DNA and RNA G-quadruplexes with distinct structures and promotes RNA&#x2022;DNA hybrids (R-loops). The structural polymorphism causes a repeat-length-dependent accumulation of transcripts aborted in the HRE region. These transcribed repeats bind to ribonucleoproteins in a conformation-dependent manner. Specifically, nucleolin, an essential nucleolar protein, preferentially binds the HRE G-quadruplex, and patient cells show evidence of nucleolar stress. Our results demonstrate that distinct C9orf72 HRE structural polymorphism at both DNA and RNA levels initiates molecular cascades leading to ALS/FTD pathologies, and provide the basis for a mechanistic model for repeat-associated neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haeusler</LastName><ForeName>Aaron R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry and Molecular Biology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] Department of Neuroscience, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donnelly</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] The Brain Science Institute, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Periz</LastName><ForeName>Goran</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry and Molecular Biology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] Department of Neuroscience, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simko</LastName><ForeName>Eric A J</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry and Molecular Biology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] Department of Neuroscience, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Patrick G</ForeName><Initials>PG</Initials><AffiliationInfo><Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min-Sik</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maragakis</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Troncoso</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University Baltimore, Maryland, 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Akhilesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattler</LastName><ForeName>Rita</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] The Brain Science Institute, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothstein</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Johns Hopkins University Baltimore, Maryland 21205, USA [2] Department of Neurology, Johns Hopkins University Baltimore, Maryland 21205, USA [3] The Brain Science Institute, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jiou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry and Molecular Biology, Johns Hopkins University Baltimore, Maryland 21205, USA [2] Department of Neuroscience, Johns Hopkins University Baltimore, Maryland 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS074324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS085207</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG05146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32CA009110-36</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS07432</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001079</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005146</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK089502</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 CA009110</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016601">RNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012261">Ribonucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>63231-63-0</RegistryNumber><NameOfSubstance UI="D012313">RNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Mar 13;507(7491):175-7. doi: 10.1038/nature13067.</RefSource><PMID Version="1">24598546</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002466" MajorTopicYN="N">Cell Nucleolus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054856" MajorTopicYN="N">G-Quadruplexes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016366" MajorTopicYN="N">Open Reading Frames</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012313" MajorTopicYN="N">RNA</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016601" MajorTopicYN="N">RNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012261" MajorTopicYN="N">Ribonucleoproteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013312" MajorTopicYN="N">Stress, Physiological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014158" MajorTopicYN="N">Transcription, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097796" MajorTopicYN="N">Nucleolin</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24598541</ArticleId><ArticleId IdType="mid">NIHMS566179</ArticleId><ArticleId IdType="pmc">PMC4046618</ArticleId><ArticleId IdType="doi">10.1038/nature13124</ArticleId><ArticleId IdType="pii">nature13124</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Richard GF, Kerrest A, Dujon B. Comparative Genomics and Molecular Dynamics of DNA Repeats in Eukaryotes. Microbiology and Molecular Biology Reviews. 2008;72:686&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2593564</ArticleId><ArticleId IdType="pubmed">19052325</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9orf72 Causes Chromosome 9p&#x2013;Linked FTD and ALS. Neuron. 2011;72:245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, et al. A Hexanucleotide Repeat Expansion in C9orf72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011;72:257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Amyotrophic lateral sclerosis. The Lancet. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11:323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>van Langenhove T, van der Zee J, van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med. 2012;44:817&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529157</ArticleId><ArticleId IdType="pubmed">22420316</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollinson S, et al. Analysis of the hexanucleotide repeat in C9orf72 in Alzheimer&#x2019;s disease Neurobiol. Aging. 2012;33:e5&#x2013;e6. 1846.</Citation><ArticleIdList><ArticleId IdType="pubmed">22410647</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli MA, et al. Repeat expansions in the C9orf72 gene contribute to Alzheimer&#x2019;s disease in Caucasians Neurobiol. Aging. 2013;34:1519. e5-1519.e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586789</ArticleId><ArticleId IdType="pubmed">23107433</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, et al. Repeat Expansion in C9orf72 in Alzheimer&#x2019;s Disease. N Engl J Med. 2012;366:283&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss DJH, et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neuorology. 2014 Ahead of print.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3929197</ArticleId><ArticleId IdType="pubmed">24363131</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, et al. Length of normal alleles of C9orf72 GGGGCC repeat do not influence disease phenotype Neurobiol. Aging. 2012;33:2950. e5-2950.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617405</ArticleId><ArticleId IdType="pubmed">22840558</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirkin SM. Expandable DNA repeats and human disease. Nature. 2007;447:932&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581576</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Taylor JP. Repeat expansion disease: progress and puzzles in disease pathogenesis. Nature. 2010;11:247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4704680</ArticleId><ArticleId IdType="pubmed">20177426</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P, et al. C9orf72 hexanucleotide repeat associated with amyotrophic lateral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci. Rep. 2012;2:1016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3527825</ArticleId><ArticleId IdType="pubmed">23264878</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, Zamiri B, Stanley SYR, Macgregor RB, Pearson CE. The Disease-associated r(GGGGCC)n Repeat from the C9orf72 Gene Forms Tract Length-dependent Uni- and Multimolecular RNA G-quadruplex Structures. Journal of Biological Chemistry. 2013;288:9860&#x2013;9866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3617286</ArticleId><ArticleId IdType="pubmed">23423380</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, et al. Expanded GGGGCCrepeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc. Natl. Acad Sci U.S.A. 2013;110:7778&#x2013;7783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651485</ArticleId><ArticleId IdType="pubmed">23553836</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, et al. Unconventional Translation of C9orf72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA Toxicity from the ALS/FTD C9orf72 Expansion Is Mitigated by Antisense Intervention. Neuron. 2013;80:415&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense antisense C9orf72 RNA foci as therapy for ALS frontotemporal degeneration. Proc. Natl Acad Sci U.S.A. 2013;110:E4530&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Sareen D, et al. Targeting RNA Foci in iPSC-Derived Motor Neurons from ALS Patients with a C9orf72 Repeat Expansion. Science Translational Medicine. 2013;5 208ra149-208ra149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4090945</ArticleId><ArticleId IdType="pubmed">24154603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T, et al. RAN proteins and RNA foci from antisense transcripts in C9orf72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. U.S.A. 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gellert M, Lipsett MN, Davies DR. Helix Formation By Guanylic Acid. Proc. Natl. Acad. Sci. U.S.A. 1962;48:2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC221115</ArticleId><ArticleId IdType="pubmed">13947099</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert JL. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem. Soc. Rev. 2008;37:1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">18568163</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxam AM, Gilbert W. A new method for sequencing. DNA. Proc. Natl. Acad. Sci. U.S.A. 1977;74:560&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC392330</ArticleId><ArticleId IdType="pubmed">265521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari S, Bugaut A, Huppert JL, Balasubramanian S. An RNA G-quadruplex in the 5&#x2032; UTR of the NRAS proto-oncogene modulates translation. Nature Chemical Biology. 2007;3:218&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2206252</ArticleId><ArticleId IdType="pubmed">17322877</ArticleId></ArticleIdList></Reference><Reference><Citation>Biffi G, Tannahill D, McCafferty J, Balasubramanian S. Quantitative visualization of DNA G-quadruplex structures in human cells. Nature Chemistry. 2013;5:182&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622242</ArticleId><ArticleId IdType="pubmed">23422559</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Ultrasensitive label-free amplified colorimetric detection of p53 based on G-quadruplex MBzymes. Biosensors and Bioelectronic. 2013;50:180&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">23850786</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong S-E, et al. Stable isotope labeling by amino acids in cell culture and SILAC as a simple and accurate approach to expression proteomics. Mol.Cell Proteomics. 2002;1:376&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">12118079</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmohsen K, Gorospe M. RNA-binding protein nucleolin in disease. rnabiology. 2012;9:799&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3495746</ArticleId><ArticleId IdType="pubmed">22617883</ArticleId></ArticleIdList></Reference><Reference><Citation>Eulalio A, Behm-Ansmant I, Izaurralde E. P bodies: at the crossroads of post-transcriptional pathways. Nature reviews Molecular cell biology. 2007;8:9&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17183357</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulon S, Westman BJ, Hutten S, Boisvert F-M, Lamond AI. The nucleolus under stress. Molecular Cell. 2010;40:216&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987465</ArticleId><ArticleId IdType="pubmed">20965417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hetman M, Pietrzak M. Emerging roles of the neuronal nucleolus. Trends in Neurosciences. 2012;35:305&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348388</ArticleId><ArticleId IdType="pubmed">22305768</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazel P, Huppert J, Balasubramanian S, Neidle S. Loop-Length-Dependent Folding of G-Quadruplexes. J.Am.Chem.Soc. 2004;126:16405&#x2013;16415.</Citation><ArticleIdList><ArticleId IdType="pubmed">15600342</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellman LM, Fried MG. Electrophoretic mobility shift assay (EMSA) for detecting protein-nucleic acid interactions. Nat Protoc. 2007;2:1849&#x2013;1861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757439</ArticleId><ArticleId IdType="pubmed">17703195</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D, Hurley LH. Methods in Molecular Biology. Vol. 608. Humana Press; 2009. pp. 65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2797547</ArticleId><ArticleId IdType="pubmed">20012416</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu R-J, et al. Long Tract of Untranslated CAG Repeats Is Deleterious in Transgenic Mice. PLoS ONE. 2011;6:e16417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025035</ArticleId><ArticleId IdType="pubmed">21283659</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy K, et al. Determinants of R-loop formation at convergent bidirectionally transcribed trinucleotide repeats. Nucleic Acids Research. 2011;39:1749&#x2013;1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3061079</ArticleId><ArticleId IdType="pubmed">21051337</ArticleId></ArticleIdList></Reference><Reference><Citation>Iioka H, Loiselle D, Haystead TA, Macara IG. Efficient detection of RNA-protein interactions using tethered RNAs. Nucleic Acids Research. 2011;39:e53&#x2013;e53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082893</ArticleId><ArticleId IdType="pubmed">21300640</ArticleId></ArticleIdList></Reference><Reference><Citation>Wi&#x15b;niewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nature Methods. 2009;6:359&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">19377485</ArticleId></ArticleIdList></Reference><Reference><Citation>Livak KJ, Schmittgen TD. Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2&#x2212;&#x394;&#x394;CT Method. Methods. 2001;25:402&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">11846609</ArticleId></ArticleIdList></Reference><Reference><Citation>Rappsilber J, Ishihama Y, Mann M. Stop go extraction tips for matrix-assisted laser desorption/ionization nanoelectrospray and LC/MS sample pretreatment in proteomics. Anal.Chem. 2003;75:663&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pubmed">12585499</ArticleId></ArticleIdList></Reference><Reference><Citation>Matunis MJ, Xing J, Dreyfuss G. The hnRNP F protein: unique primary structure, nucleic acid-binding properties, and subcellular localization. Nucleic Acids Research. 1994;22:1059&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307930</ArticleId><ArticleId IdType="pubmed">7512260</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsoi H, Lau TC-K, Tsang S-Y, Lau K-F, Chan HYE. CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl.Acad.Sci.U.S.A. 2012;109:13428&#x2013;13433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3421186</ArticleId><ArticleId IdType="pubmed">22847428</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida S, et al. Modeling key pathological features of frontotemporal dementia with C9orf72 repeat expansion in iPSC-derived human neurons. Acta Neuropathol. 2013;126:385&#x2013;399.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3753484</ArticleId><ArticleId IdType="pubmed">23836290</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura M, et al. Overexpression of ribosomal RNA in prostate cancer is common but not linked to rDNA promoter hypomethylation. Oncogene. 2011;31:1254&#x2013;1263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298623</ArticleId><ArticleId IdType="pubmed">21822302</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24599465</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Age-dependent, non-cell-autonomous deposition of amyloid from synthesis of &#x3b2;-amyloid by cells other than excitatory neurons.</ArticleTitle><Pagination><StartPage>3668</StartPage><EndPage>3673</EndPage><MedlinePgn>3668-73</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5079-13.2014</ELocationID><Abstract><AbstractText>Rare, familial, early-onset autosomal dominant forms of familial Alzheimer's disease (FAD) are caused by mutations in genes encoding &#x3b2;-amyloid (A&#x3b2;) precursor protein (APP), presenilin-1 (PS1), and presenilin-2. Each of these genes is expressed ubiquitously throughout the CNS, but a widely held view is that excitatory neurons are the primary (or sole) source of the A&#x3b2; peptides that promote synaptic dysfunction and neurodegeneration. These efforts notwithstanding, APP and the enzymes required for A&#x3b2; production are synthesized by many additional cell types, and the degree to which those cells contribute to the production of A&#x3b2; that drives deposition in the CNS has not been tested. We generated transgenic mice in which expression of an ubiquitously expressed, FAD-linked mutant PSEN1 gene was selectively inactivated within postnatal forebrain excitatory neurons, with continued synthesis in all other cells in the CNS. When combined with an additional transgene encoding an FAD-linked APP "Swedish" variant that is synthesized broadly within the CNS, cerebral A&#x3b2; deposition during aging was found to be unaffected relative to mice with continued mutant PS1 synthesis in excitatory neurons. Thus, A&#x3b2; accumulation is non-cell autonomous, with the primary age-dependent contribution to cerebral A&#x3b2; deposition arising from mutant PS1-dependent cleavage of APP within cells other than excitatory neurons.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Veeraraghavalu</LastName><ForeName>Karthikeyan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurobiology, University of Chicago, Chicago, Illinois 60637, and Department of Neurology, Genetics and Aging Research Unit, Massachusetts General Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129-2060.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Can</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiaoqiong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Tanzi</LastName><ForeName>Rudolph E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Sisodia</LastName><ForeName>Sangram S</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG021494</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG040185</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Neurosci. 2014 Jul 23;34(30):9825-7. doi: 10.1523/JNEUROSCI.1825-14.2014.</RefSource><PMID Version="1">25057186</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">amyloid deposition</Keyword><Keyword MajorTopicYN="N">dementia</Keyword><Keyword MajorTopicYN="N">mouse model</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">presenilin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24599465</ArticleId><ArticleId IdType="pmc">PMC3942582</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5079-13.2014</ArticleId><ArticleId IdType="pii">34/10/3668</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron. 1997;19:939&#x2013;945. doi: 10.1016/S0896-6273(00)80974-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80974-5</ArticleId><ArticleId IdType="pubmed">9354339</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SH, Veeraraghavalu K, Lazarov O, Marler S, Ransohoff RM, Ramirez JM, Sisodia SS. Non-cell-autonomous effects of presenilin 1 variants on enrichment-mediated hippocampal progenitor cell proliferation and differentiation. Neuron. 2008;59:568&#x2013;580. doi: 10.1016/j.neuron.2008.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.07.033</ArticleId><ArticleId IdType="pmc">PMC3489017</ArticleId><ArticleId IdType="pubmed">18760694</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>De Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-secretase complex. Neuron. 2003;38:9&#x2013;12. doi: 10.1016/S0896-6273(03)00205-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00205-8</ArticleId><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res. 1992;16:128&#x2013;134. doi: 10.1016/0169-328X(92)90202-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0169-328X(92)90202-M</ArticleId><ArticleId IdType="pubmed">1334190</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Estus S, Usiak M, Younkin LH, Younkin SG. Expression of beta amyloid protein precursor mRNAs: recognition of a novel alternatively spliced form and quantitation in Alzheimer's disease using PCR. Neuron. 1990;4:253&#x2013;267. doi: 10.1016/0896-6273(90)90100-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(90)90100-T</ArticleId><ArticleId IdType="pubmed">2106330</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Hung AY, Selkoe DJ. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J Neurosci. 1991;11:3783&#x2013;3793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6575298</ArticleId><ArticleId IdType="pubmed">1744690</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937. doi: 10.1016/S0896-6273(03)00124-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00124-7</ArticleId><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lah JJ, Heilman CJ, Nash NR, Rees HD, Yi H, Counts SE, Levey AI. Light and electron microscopic localization of presenilin-1 in primate brain. J Neurosci. 1997;17:1971&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793763</ArticleId><ArticleId IdType="pubmed">9045726</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;nning U, Sandbrink R, Weidemann A, Banati RB, Masters CL, Beyreuther K. Extracellular matrix influences the biogenesis of amyloid precursor protein in microglial cells. J Biol Chem. 1995;270:7104&#x2013;7110. doi: 10.1074/jbc.270.13.7104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.13.7104</ArticleId><ArticleId IdType="pubmed">7706247</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Sisodia SS. Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci. 1998;21:479&#x2013;505. doi: 10.1146/annurev.neuro.21.1.479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.21.1.479</ArticleId><ArticleId IdType="pubmed">9530504</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754&#x2013;760. doi: 10.1038/375754a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/375754a0</ArticleId><ArticleId IdType="pubmed">7596406</ArticleId></ArticleIdList></Reference><Reference><Citation>Thinakaran G, Harris CL, Ratovitski T, Davenport F, Slunt HH, Price DL, Borchelt DR, Sisodia SS. Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors. J Biol Chem. 1997;272:28415&#x2013;28422. doi: 10.1074/jbc.272.45.28415.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.45.28415</ArticleId><ArticleId IdType="pubmed">9353300</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, Mayford M, Kandel ER, Tonegawa S. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996;87:1317&#x2013;1326. doi: 10.1016/S0092-8674(00)81826-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81826-7</ArticleId><ArticleId IdType="pubmed">8980237</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Sisodia SS. Mutant presenilin 1 expression in excitatory neurons impairs enrichment-mediated phenotypes of adult hippocampal progenitor cells. Proc Natl Acad Sci U S A. 2013;110:9148&#x2013;9153. doi: 10.1073/pnas.1302106110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1302106110</ArticleId><ArticleId IdType="pmc">PMC3670351</ArticleId><ArticleId IdType="pubmed">23674689</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on &#x201c;ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models.&#x201d;. Science. 2013;340:924-f. doi: 10.1126/science.1235505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235505</ArticleId><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24598707</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>25</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Contribution of Alzheimer disease to mortality in the United States.</ArticleTitle><Pagination><StartPage>1045</StartPage><EndPage>1050</EndPage><MedlinePgn>1045-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000000240</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the burden of mortality attributable to Alzheimer disease (AD) dementia in the United States.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data came from 2,566 persons aged 65 years and older (mean 78.1 years) without dementia at baseline from 2 cohort studies of aging with identical annual diagnostic assessments of dementia. Because both studies require organ donation, ascertainment of mortality was complete and dates of death accurate. Mortality hazard ratios (HRs) after incident AD dementia were estimated per 10-year age strata from proportional hazards models. Population attributable risk percentage was derived to estimate excess mortality after a diagnosis of AD dementia. The number of excess deaths attributable to AD dementia in the United States was then estimated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over an average of 8 years, 559 participants (21.8%) without dementia at baseline developed AD dementia and 1,090 (42.4%) died. Median time from AD dementia diagnosis to death was 3.8 years. The mortality HR for AD dementia was 4.30 (confidence interval = 3.33, 5.58) for ages 75-84 years and 2.77 (confidence interval = 2.37, 3.23) for ages 85 years and older (too few deaths after AD dementia in ages 65-74 were available to estimate HR). Population attributable risk percentage was 37.0% for ages 75-84 and 35.8% for ages 85 and older. An estimated 503,400 deaths in Americans aged 75 years and older were attributable to AD dementia in 2010.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A larger number of deaths are attributable to AD dementia in the United States each year than the number (&lt;84,000 in 2010) reported on death certificates.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>James</LastName><ForeName>Bryan D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>From the Rush Alzheimer's Disease Center (B.D.J., S.E.L., D.A.B.), Chicago; Departments of Internal Medicine (B.D.J.) and Neurological Sciences (S.E.L., D.A.B.), and Rush Institute on Healthy Aging (L.E.H., P.A.S.), Rush University Medical Center, Chicago, IL; Departments of Psychiatry, Neurology, and Epidemiology (K.Y.), University of California, San Francisco; and San Francisco Veterans Affairs Medical Center (K.Y.), San Francisco, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leurgans</LastName><ForeName>Sue E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Hebert</LastName><ForeName>Liesi E</ForeName><Initials>LE</Initials></Author><Author ValidYN="Y"><LastName>Scherr</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Yaffe</LastName><ForeName>Kristine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01AG014449</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20MD006886</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2AG036547</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS078009</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24AG031155</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NR010211</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG46152</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS028127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AG030346</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK069406</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG05401</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG036650</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG303544</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG033678</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG009466</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026720</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG036042</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH086498</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG009966</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG042210</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG011101</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Sep 30;83(14):1302. doi: 10.1212/01.wnl.0000455099.43083.c6.</RefSource><PMID Version="1">25267987</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Neurology. 2014 Sep 30;83(14):1302.</RefSource><PMID Version="1">25392862</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24598707</ArticleId><ArticleId IdType="pmc">PMC3962992</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000000240</ArticleId><ArticleId IdType="pii">WNL.0000000000000240</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murphy SL, Xu J, Kochanek KD.
Deaths: final data for 2010. In: National Vital Statistics Reports [online]. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_04.pdf. Accessed November 27, 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">24979972</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST. Alzheimer disease and mortality: a 15-year epidemiological study. Arch Neurol 2005;62:779&#x2013;784</Citation><ArticleIdList><ArticleId IdType="pubmed">15883266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010&#x2013;2050) estimated using the 2010 census. Neurology 2013;80:1778&#x2013;1783</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719424</ArticleId><ArticleId IdType="pubmed">23390181</ArticleId></ArticleIdList></Reference><Reference><Citation>Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 2007;29:125&#x2013;132</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2705925</ArticleId><ArticleId IdType="pubmed">17975326</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Corrada MM, Curriero FC, Kawas C. Survival following a diagnosis of Alzheimer disease. Arch Neurol 2002;59:1764&#x2013;1767</Citation><ArticleIdList><ArticleId IdType="pubmed">12433264</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services
National plan to address Alzheimer's disease: 2013 update. Available at: http://aspe.hhs.gov/daltcp/napa/NatlPlan2013.pdf. Accessed November 27, 2013</Citation></Reference><Reference><Citation>Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: cohort study. BMJ 2010;341:c3584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2917003</ArticleId><ArticleId IdType="pubmed">20688840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Aggarwal NT, Barnes LL, Bienias JL, Mendes de Leon CF, Evans DA. Biracial population study of mortality in mild cognitive impairment and Alzheimer disease. Arch Neurol 2009;66:767&#x2013;772</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743243</ArticleId><ArticleId IdType="pubmed">19506138</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol 1999;52:737&#x2013;743</Citation><ArticleIdList><ArticleId IdType="pubmed">10465318</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschanz JT, Corcoran C, Skoog I, et al. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. Neurology 2004;62:1156&#x2013;1162</Citation><ArticleIdList><ArticleId IdType="pubmed">15079016</ArticleId></ArticleIdList></Reference><Reference><Citation>Valcour VG, Masaki KH, Curb JD, Blanchette PL. The detection of dementia in the primary care setting. Arch Intern Med 2000;160:2964&#x2013;2968</Citation><ArticleIdList><ArticleId IdType="pubmed">11041904</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 2001;344:1111&#x2013;1116</Citation><ArticleIdList><ArticleId IdType="pubmed">11297701</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmer C, Joly P, Letenneur L, Commenges D, Dartigues JF. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642&#x2013;648</Citation><ArticleIdList><ArticleId IdType="pubmed">11581098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the Religious Orders Study. Curr Alzheimer Res 2012;9:628&#x2013;645</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012;9:646&#x2013;663</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology 2006;27:169&#x2013;176</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de Leon C, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005;25:163&#x2013;175</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002;59:198&#x2013;205</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol 2009;66:200&#x2013;208</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model, 1st ed New York: Springer-Verlag; 2010</Citation></Reference><Reference><Citation>Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fractions. Am J Epidemiol 1988;128:1185&#x2013;1197</Citation><ArticleIdList><ArticleId IdType="pubmed">3057878</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuto D, Bellocco R, Kivipelto M, Clerici F, Wimo A, Fratiglioni L. Dementia after age 75: survival in different severity stages and years of life lost. Curr Alzheimer Res 2012;9:795&#x2013;800</Citation><ArticleIdList><ArticleId IdType="pubmed">22299618</ArticleId></ArticleIdList></Reference><Reference><Citation>Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y. Survival in Alzheimer disease: a multiethnic, population-based study of incident cases. Neurology 2008;71:1489&#x2013;1495</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2843528</ArticleId><ArticleId IdType="pubmed">18981370</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson EB, Shadlen MF, Wang L, et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med 2004;140:501&#x2013;509</Citation><ArticleIdList><ArticleId IdType="pubmed">15068977</ArticleId></ArticleIdList></Reference><Reference><Citation>Ewbank DC. Deaths attributable to Alzheimer's disease in the United States. Am J Public Health 1999;89:90&#x2013;92</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1508512</ArticleId><ArticleId IdType="pubmed">9987474</ArticleId></ArticleIdList></Reference><Reference><Citation>Ives DG, Samuel P, Psaty BM, Kuller LH. Agreement between nosologist and cardiovascular health study review of deaths: implications of coding differences. J Am Geriatr Soc 2009;57:133&#x2013;139</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631612</ArticleId><ArticleId IdType="pubmed">19016930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganguli M, Rodriguez EG. Reporting of dementia on death certificates: a community study. J Am Geriatr Soc 1999;47:842&#x2013;849</Citation><ArticleIdList><ArticleId IdType="pubmed">10404929</ArticleId></ArticleIdList></Reference><Reference><Citation>Olichney JM, Hofstetter CR, Galasko D, Thal LJ, Katzman R. Death certificate reporting of dementia and mortality in an Alzheimer's disease research center cohort. J Am Geriatr Soc 1995;43:890&#x2013;893</Citation><ArticleIdList><ArticleId IdType="pubmed">7636097</ArticleId></ArticleIdList></Reference><Reference><Citation>Macera CA, Sun RK, Yeager KK, Brandes DA. Sensitivity and specificity of death certificate diagnoses for dementing illnesses, 1988&#x2013;1990. J Am Geriatr Soc 1992;40:479&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pubmed">1634701</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns A, Jacoby R, Luthert P, Levy R. Cause of death in Alzheimer's disease. Age Ageing 1990;19:341&#x2013;344</Citation><ArticleIdList><ArticleId IdType="pubmed">2251969</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunnstrom HR, Englund EM. Cause of death in patients with dementia disorders. Eur J Neurol 2009;16:488&#x2013;492</Citation><ArticleIdList><ArticleId IdType="pubmed">19170740</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197&#x2013;2204</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:270&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassuk SS, Wypij D, Berkman LF. Cognitive impairment and mortality in the community-dwelling elderly. Am J Epidemiol 2000;151:676&#x2013;688</Citation><ArticleIdList><ArticleId IdType="pubmed">10752795</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24598588</PMID><DateCompleted><Year>2014</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>226</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>05</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease.</ArticleTitle><Pagination><StartPage>226ra30</StartPage><MedlinePgn>226ra30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3007901</ELocationID><Abstract><AbstractText>Clinicopathological evidence suggests that the pathology of Alzheimer's disease (AD) begins many years before the appearance of cognitive symptoms. Biomarkers are required to identify affected individuals during this asymptomatic ("preclinical") stage to permit intervention with potential disease-modifying therapies designed to preserve normal brain function. Studies of families with autosomal-dominant AD (ADAD) mutations provide a unique and powerful means to investigate AD biomarker changes during the asymptomatic period. In this biomarker study, we collected cerebrospinal fluid (CSF), plasma, and in vivo amyloid imaging cross-sectional data at baseline in individuals from ADAD families enrolled in the Dominantly Inherited Alzheimer Network. Our study revealed reduced concentrations of CSF amyloid-&#x3b2;1-42 (A&#x3b2;1-42) associated with the presence of A&#x3b2; plaques, and elevated concentrations of CSF tau, ptau181 (phosphorylated tau181), and VILIP-1 (visinin-like protein-1), markers of neurofibrillary tangles and neuronal injury/death, in asymptomatic mutation carriers 10 to 20 years before their estimated age at symptom onset (EAO) and before the detection of cognitive deficits. When compared longitudinally, however, the concentrations of CSF biomarkers of neuronal injury/death within individuals decreased after their EAO, suggesting a slowing of acute neurodegenerative processes with symptomatic disease progression. These results emphasize the importance of longitudinal, within-person assessment when modeling biomarker trajectories across the course of the disease. If corroborated, this pattern may influence the definition of a positive neurodegenerative biomarker outcome in clinical trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagan</LastName><ForeName>Anne M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Jasielec</LastName><ForeName>Mateusz S</ForeName><Initials>MS</Initials></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Goate</LastName><ForeName>Alison M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Benzinger</LastName><ForeName>Tammie L S</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Ghetti</LastName><ForeName>Bernardino</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Martins</LastName><ForeName>Ralph N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Masters</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Mayeux</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ringman</LastName><ForeName>John M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Rossor</LastName><ForeName>Martin N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Schofield</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Cairns</LastName><ForeName>Nigel J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Buckles</LastName><ForeName>Virginia D</ForeName><Initials>VD</Initials></Author><Author ValidYN="Y"><LastName>Ladenson</LastName><ForeName>Jack H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><CollectiveName>Dominantly Inherited Alzheimer Network</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG021886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS048056</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UF1 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG016750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003991</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005681</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EB009352</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS098577</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AR048335</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG016750</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024994</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AG21886</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007118" MajorTopicYN="N">Immunoassay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>3</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24598588</ArticleId><ArticleId IdType="mid">NIHMS587066</ArticleId><ArticleId IdType="pmc">PMC4038930</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3007901</ArticleId><ArticleId IdType="pii">6/226/226ra30</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Beach T, Monsell S, Phillips L, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3331862</ArticleId><ArticleId IdType="pubmed">22437338</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez-Isla T, Price J, McKeel D, Morris J, Growdon J, Hyman B. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in &#x201c;normal&#x201d; aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168&#x2013;1174.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862640</ArticleId></ArticleIdList></Reference><Reference><Citation>Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D. Neuropathologic substrate of Mild Cognitive Impairment. Arch Neurol. 2006;63:38&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401735</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer&#x2019;s disease. J Mol Neurosci. 2001;17:101&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">11816784</ArticleId></ArticleIdList></Reference><Reference><Citation>Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer&#x2019;s disease. Arch Neurol. 2001;58:1395&#x2013;1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">11559310</ArticleId></ArticleIdList></Reference><Reference><Citation>Perrin R, Fagan A, Holtzman D. Multi-modal techniques for diagnosis and prognosis of Alzheimer&#x2019;s disease. Nature. 2009;461:916&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810658</ArticleId><ArticleId IdType="pubmed">19829371</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C, Knopman D, Jagust W, Shaw L, Aisen P, Weiner M, Petersen R, Trojanowski J. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet Neurol. 2010;9:119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, LaRossa G, Spinner M, Klunk W, Mathis C, DeKosky S, Morris J, Holtzman D. Inverse relation between in vivo amyloid imaging load and CSF A&#x3b2;42 in humans. Ann Neurol. 2006;59:512&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pubmed">16372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimmer T, Riemenschneider M, F&#xf6;rstl H, Henriksen G, Klunk W, Mathis C, Shiga T, Wester H, Kurz A, Drzezga A. Beta amyloid in Alzheimer&#x2019;s disease: Increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry. 2009;65:927&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2700302</ArticleId><ArticleId IdType="pubmed">19268916</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolboom N, Van Der Flier W, Yaqub M, Boellaard R, Verwey N, Blankenstein M, Windhorst A, Scheltens P, Lammertsma A, Van Berckel B. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med. 2009;50:1464&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">19690025</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W, Landau S, Shaw L, Trojanowski J, Koeppe R, Reiman E, Foster N, Petersen R, Weiner M, Price J, Mathis C. Alzheimer&#x2019;s Diseaase Neuroimaging Initiative, Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193&#x2013;1199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764726</ArticleId><ArticleId IdType="pubmed">19822868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Alafuzoff I, Herukka S, Parkkinen L, Hartikainen P, Soininen H, Pirttil&#xe4; T. Cerebrospinal fluid &#x3b2;-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol. 2009;66:382&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">19273758</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark C, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris J, McKeel D, Farlow M, Weitlauf S, Quinn J, Kaye J, Knopman D, Arai H, Doody R, DeCarli C, Leight S, Lee V, Trojanowski J. Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol. 2003;60:1696&#x2013;1702.</Citation><ArticleIdList><ArticleId IdType="pubmed">14676043</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White L, Launer L. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampel H, Burger K, Pruessner J, Zinkowski R, DeBernardis J, Kerkman D, Leinsinger G, Evans A, Davies P, Moller H-J, Stefan T. Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol. 2005;62:770&#x2013;773.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann M, Koedam E, Barnes J, Bartlett J, Barkhof F, Wattjes M, Schott J, Scheltens P, Fox N. Alzheimer&#x2019;s Diseaase Neuroimaging Initiative, Visual ratings of atrophy in MCI: Prediction of conversion and relationship with CSF biomarkers. Neurobiol Aging. 2013;34:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22516280</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Overmyer M, Lehtovirta M, Helisalmi S, Ramberg J, Alafuzoff I, Riekkinen P, Soininen H. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer&#x2019;s disease. Neuroreport. 1997;8:3961&#x2013;3963.</Citation><ArticleIdList><ArticleId IdType="pubmed">9462474</ArticleId></ArticleIdList></Reference><Reference><Citation>Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer&#x2019;s disease. Brain. 2006;129:3035&#x2013;3041.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012293</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, Leenheir ED, Martin J, Vanmechelen E, Van Broeckhoven C, De Deyn P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer&#x2019;s disease. Brain. 2007;130:2320&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">17586559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R, Xiong C, Benzinger T, Fagan A, Goate A, Fox N, Marcus D, Cairns N, Xie X, Blazey T, Holtzman D, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen P, Ghetti B, Klunk W, McDade E, Martins R, Masters C, Mayeux R, Ringman J, Rossor M, Schofield P, Sperling R, Salloway S, Morris J, Network DIA. Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Weintraub S, Chui H, Cummings J, Decarli C, Ferris S, Foster N, Galasko D, Graff-Radford N, Peskind E, Beekly D, Ramos E, Kukull W. The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20:210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">17132964</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Shaw L, Xiong C, Vanderstichele H, Mintun M, Trojanowski J, Coart E, Morris J, Holtzman D. Comparison of analytical platforms for cerebrospinal fluid measures of A&#x3b2;1-42, total tau and p-tau181 for identifying Alzheimer&#x2019;s disease amyloid plaque pathology. Arch Neurol. 2011;68:1137&#x2013;1144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154969</ArticleId><ArticleId IdType="pubmed">21555603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, K&#xf6;lsch H, Jessen F, Schr&#xf6;der J, Sch&#xf6;nknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler J, Wiltfang J. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiol Aging. 2008;29:812&#x2013;818.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239996</ArticleId></ArticleIdList></Reference><Reference><Citation>Reijn T, Rikkert M, Van Geel W, De Jong D, Verbeek M. Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid &#x3b2;42 and tau proteins. Clin Chem. 2007;53:859&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pubmed">17395712</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K. Biomarkers in Alzheimer&#x2019;s disease drug development. Nature Med. 2010;16:1218&#x2013;1222.</Citation><ArticleIdList><ArticleId IdType="pubmed">21052077</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, Kimmel L, Bergeson J, Manetti G, Zimmermann M, Tang B, Bartko J, Cohen R. Decreased &#x3b2;-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer&#x2019;s disease. JAMA. 2003;289:2094&#x2013;2103.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709467</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, Arai H, Batish S, Bernardini S, Bocchio-Chiavetto L, Blankenstein M, Carrillo M, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Fagan S. Duller. A., Forlenza O, Frisoni G, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka M, Herskovits A, Herukka S, Holtzman D, Humpel C, Hyman B, Iqbal K, Jucker M, Kaeser S, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen C, Kummer M, Lui J, Llad&#xf3; A, Lewczuk P, Li Q, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo J, Montine T, Nowatzke W, O&#x2019;Brien R, Otto M, Paraskevas G, Parnetti L, Petersen R, Prvulovic D, de Reus H, Rissman R, Scarpini E, Stefani A, Soininen H, Schr&#xf6;der J, Shaw L, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski J, Tumani H, Umek R, Broeck B, Vanderstichele H, Vecsei L, Verbeek M, Windisch M, Zhang J, Zetterberg H, Blennow K. The Alzheimer&#x2019;s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement. 2011;7:386&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710290</ArticleId><ArticleId IdType="pubmed">21784349</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, Carrillo M, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan A, Heegaard H, Robin-Hsiung G, Hyman B, Iqbal K, Lachno D, Lle&#xf3; A, Lewczuk P, Molinuevo J, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schr&#xf6;der J, Shaw L, Teunissen C, Trojanowski J, Vanderstichele H, Vandijck M, Verbeek M, Zetterberg H, Blennow K, K&#xe4;ser S, on behalf of the Alzheimer&#x2019;s Association QC Program Work Group CSF biomarker variability in the Alzheimer&#x2019;s Association quality control program. Alzheimers Dement. 2013;9:251&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707386</ArticleId><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference><Reference><Citation>Teunissen C, Verwey N, Kester M, van Uffelen K, Blankenstein M. Standardization of assay procedures for analysis of the CSF biomarkers amyloid &#x3b2;(1-42), tau, and phosphorylated tau in Alzheimer&#x2019;s disease: Report of an international workshop. Int J Alzheimers Dis doi:pii: 2010;635053 10.4061/2010/635053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948880</ArticleId><ArticleId IdType="pubmed">20936143</ArticleId></ArticleIdList></Reference><Reference><Citation>Laird N, Ware J. Random-effects models for longitudinal data. Biometrics. 1982;38:963&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pubmed">7168798</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Balota D, Aschenbrenner A, Morris J. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN) Neuropsychology. 2014;28:19&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877741</ArticleId><ArticleId IdType="pubmed">24219606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. Manual: Wechsler Memory Scale-Revised. Psychological Corporation; San Antonio: 1987.</Citation></Reference><Reference><Citation>Wechsler D. Manual: Wechsler Adult Intelligence Scale - Revised. Psychological Corporation; New York: 1981.</Citation></Reference><Reference><Citation>Mawuenyega K, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris J, Yarasheski K, Bateman R. Decreased clearance of CNS beta-amyloid in Alzheimer&#x2019;s disease. Science. 2010;330:1774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Rosa-Neto P, Hsiung G, Sadovnick A, Masellis M, Black S, Jia J, Gauthier S. Early-onset familial Alzheimer&#x2019;s disease (EOFAD) Can J Neurol Sci. 2012;39:436&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pubmed">22728850</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Lopera F, Kosik KS, Lendon CL, Ossa J, Saido TC, Yamaguchi H, Ruiz A, Martinez A, Madrigal L, Hincapie L, Arango JC, Anthony DC, Koo EH, Goate AM, Selkoe DJ, Arango JC. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nature Med. 1996;2:1146&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">8837617</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann D, Iwatsubo T, Cairns NJ, Lantos PL, Nochlin D, Sumi SM, Bird TD, Poorkaj P, Hardy J, Hutton M, Prihar G, Crook R, Rossor MN, Haltia M. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer&#x2019;s disease: predominance of Abeta42(43) Ann. Neurol. 1996;40:149&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8773595</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Riordan S, McMonagle P, Janssen J, Fox N, Farrell M, Collinge J, Rossor M, Hutchinson M. Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology. 2002;7:1108&#x2013;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370477</ArticleId></ArticleIdList></Reference><Reference><Citation>Maarouf C, Daugs I, Spina S, Vidal R, Kokjohn T, Patton R, Kalback W, Luehrs D, Walker D, Casta&#xf1;o E, Beach T, Ghetti B, Roher A. Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. Mol Neurodegener. 2008;2008:3&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2600784</ArticleId><ArticleId IdType="pubmed">19021905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippa C, Fujiwara H, Mann D, Giasson B, Baba M, Schmidt M, Nee L, O&#x2019;Connell B, Pollen D, George-Hyslop PS, Ghetti B, Nochlin D, Bird T, Cairns N, Lee V, Iwatsubo T, Trojanowski J. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer&#x2019;s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;5:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1853391</ArticleId><ArticleId IdType="pubmed">9811326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lleo A, Berezovska O, Growdon J, Hyman B. Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry. 2004;12:146&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">15010344</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman E, Quiroz Y, Fleisher A, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan A, Shah A, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling R, Dickerson B, Stern C, Tirado V, Munoz C, Reiman R, Huentelman M, Alexander G, Langbaum J, Kosik K, Tariot P, Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: A case-control study. Lancet Neurol. 2012;11:1048&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, Kaye J, Atack J, Schapiro M, Friedland R, Rapoport S. Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990;40:500&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">2314595</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Mintun M, Shah A, Aldea P, Roe C, Mach R, Marcus D, Morris J, Holtzman D. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer&#x2019;s disease. EMBO Mol Med. 2009;1:371&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Englund H, Anneren G, Gustafsson J, Wester U, Wiltfang J, Lannfelt L, Blennow K, Hoglund K. Increase in &#x3b2;-amyloid levels in cerebrospinal fluid of children with Down syndrome. Dement Geriatr Cogn Disord. 2007;24:369&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">17914261</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Soininen H, Pirttila T. CSF tau and Abeta42 levels in patients with Down&#x2019;s syndrome. Neurology. 2001;56:979&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">11294944</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers for Alzheimer&#x2019;s disease. Nature Rev Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Prvulovic D, Hampel H. Amyloid &#x3b2; (A&#x3b2;) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer&#x2019;s disease. Clin Chem Lab Med. 2011;49:367&#x2013;374.</Citation><ArticleIdList><ArticleId IdType="pubmed">21342022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman J, Younkin S, Pratico D, Seltzer W, Cole G, Geschwind D, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario E, Gylys K, Varpetian A, Medina L, Cummings J. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:85&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">18509095</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Blennow K, Andreasen N, Laterza O, Modur V, Olander J, Gao F, Ohlendorf M, Ladenson J. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients. Clin Chem. 2008;54:1617&#x2013;1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2672199</ArticleId><ArticleId IdType="pubmed">18703769</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, D&#x2019;Angelo G, Macy E, Xiong C, Carter D, Cairns N, Fagan A, Mintun M, Ladenson J, Lee J-M, Morris J, Holtzman D. Visinin-like protein 1: A novel prognostic biomarker in Alzheimer&#x2019;s disease. Ann Neurol. 2011;70:274&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154071</ArticleId><ArticleId IdType="pubmed">21823155</ArticleId></ArticleIdList></Reference><Reference><Citation>Laterza O, Modur V, Crimmins D, Olander J, Landt Y, Lee J, Ladenson J. Identification of novel brain biomarkers. Clin Chem. 2006;52:1713&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pubmed">16858073</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarawneh R, Lee J, Ladenson J, Morris J, Holtzman D. CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology. 2012;10:709&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306162</ArticleId><ArticleId IdType="pubmed">22357717</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Zetterberg H, Minthon L, Lannfelt L, Strid S, Annas P, Basun H, Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer&#x2019;s disease. Neurosci Lett. 2007;419:18&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17482358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstr&#xf6;m C, Syversen S, Mattsson U, Ysander C, Mattsson N, Nordlund A, Vanderstichele H, Vanmechelen E, Jonsson M, Edman A, Blennow K, Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer&#x2019;s disease over two years. J Alzheimers Dis. 2007;12:255&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">18057559</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett L, Harvey D, Gamst A, Donohue M, Kornak J, Zhang H, Kuo J. Alzheimer&#x2019;s Diseaase Neuroimaging Initiative, The Alzheimer&#x2019;s Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010;6:257&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867839</ArticleId><ArticleId IdType="pubmed">20451874</ArticleId></ArticleIdList></Reference><Reference><Citation>Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol. 2010;67:217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">20142530</ArticleId></ArticleIdList></Reference><Reference><Citation>Vemuri P, Wiste H, Weigand S, Knopman D, Trojanowski J, Shaw L, Bernstein M, Aisen P, Weiner M, Petersen R, Jack C. Alzheimer&#x2019;s Diseaase Neuroimaging Initiative, Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 2010;75:143&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905929</ArticleId><ArticleId IdType="pubmed">20625167</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg M, Jensen M, Basun H, Lannfelt L, Wahlund L. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up. Neurosci Lett. 1996;214:163&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">8878109</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Wolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtim&#xe4;ki T, Seubert P. Longitudinal stability of CSF tau levels in Alzheimer patients. Biol Psychiatry. 1999;46:750&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">10494442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, Sasaki H, Abe K, Iwatsubo T, Kosaka T, Watanabe M, Tomidokoro Y, Shizuka M, Mizushima K, Nakamura T, Igeta Y, Ikeda Y, Amari M, Kawarabayashi T, Ishiguro K, Harigaya Y, Wakabayashi K, Okamoto K, Hirai S, Shoji M. Longitudinal study of cerebrospinal fluid levels of tau, A&#x3b2;1-40, and A&#x3b2;1-42(43) in Alzheimer&#x2019;s disease: A study in Japan. Ann. Neurol. 1998;44:17&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">9667589</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapiola T, Pirttil&#xe4; T, Mikkonen M, Mehta P, Alafuzoff I, Koivisto K, Soininen H. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer&#x2019;s disease. Neurosci Lett. 2000;280:119&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">10686392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunderland T, Woolozin B, Galasko D, Levy J, Dukoff R, Bahro M, Lasser R, Motter R, Lehtimaki T, Seubert P. Longitudinal stability of CSF tau levels in Alzheimer&#x2019;s patients. Biol Psychiatry. 1999;46:750&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pubmed">10494442</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo J, Xie S, Trojanowski T, Shaw L. Longitudinal change in CSF tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013 Jun 29;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepp&#xe4;l&#xe4; T, Koivisto A, Hartikainen P, Helisalmi S, Soininen H, Herukka S. Longitudinal changes of CSF biomarkers in Alzheimer&#x2019;s disease. J Alzheimers Dis. 2011;25:583&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pubmed">21460434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringman J, Taylor K, Teng E, Coppola G, Gylys K. Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology. 2011;76:2124&#x2013;2125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111239</ArticleId><ArticleId IdType="pubmed">21562250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, Hashimoto Y, Makioka K, Furuta N, Ishiguro K, Maruki R, Yoshida J, Miyaguchi O, Tsukie T, Kuwano R, Yamazaki T, Yamaguchi H, Amari M, Takatama M, Harigaya Y, Okamoto K. Cerebrospinal fluid levels of phosphorylated tau and A&#x3b2;1-38/A&#x3b2;1-40/A&#x3b2;1-42 in Alzheimer&#x2019;s disease with PS1 mutations. Amyloid. 2013;20:107&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">23638752</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Edland S, Clark C, Galasko D, Koss E, Mohs R, VanBelle G, Fillenbaum G, Heyman A. Consortium to Establish a Registry for Alzheimer&#x2019;s Disease (CERAD). Part IV. Rates of cognitive changes in the longitudinal assessment of Alzheimer&#x2019;s disease. Neurology. 1993;43:2457&#x2013;2465.</Citation><ArticleIdList><ArticleId IdType="pubmed">8255439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito J, May P, O&#x2019;Dell M, Taylor J, Parsadanian M, Cramer J, Audia J, Nissen J, Bales K, Paul S, DeMattos R, Holtzman D. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski B, Podlisny D, Cavanaugh W, Yang T, Holtzman D, Cirrito J, Selkoe D. Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation. J Neurosci. 2011;31:15861&#x2013;15869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird T, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer&#x2019;s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer&#x2019;s disease. Nature Med. 1996;2:864&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pubmed">8705854</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C, Vemuri P, Wiste H, Weigand S, Aisen P, Trojanowski J, Shaw L, Bernstein M, Petersen R, Weiner M, Knopman D. Alzheimer&#x2019;s Diseaase Neuroimaging Initiative, Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68:1526&#x2013;1535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3387980</ArticleId><ArticleId IdType="pubmed">21825215</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Aisen P, Beckett L, Bennett D, Craft S, Fagan A, Iwatsubo T, Jack C, Kaye J, Montine T, Park D, Reiman E, Rowe C, Siemers E, Stern Y, Yaffe K, Carrillo M, Thies W, Morrison-Bogorad M, Wagster M, Phelps C. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan D, Janssen J, Whitwell J, Watt H, Jenkins R, Frost C, Rossor M, Fox N. Change in rates of cerebral atrophy over time in early-onset Alzheimer&#x2019;s disease: Longitudinal MRI study. Lancet. 2003;362:1121&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">14550701</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack C, Weigand S, Shiung M, Przybelski S, O&#x2019;Brien P, Gunter J, Knopman D, Boeve B, Smith G, Petersen R. Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology. 2008;70:1740&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2734477</ArticleId><ArticleId IdType="pubmed">18032747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ridha B, Barnes J, Bartlett J, Godbolt A, Pepple T, Rossor M, Fox N. Tracking atrophy progression in familial Alzheimer&#x2019;s disease: A serial MRI study. Lancet Neurol. 2006;5:828&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">16987729</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight W, Kim L, Douiri A, Frost C, Rossor M, Fox N. Acceleration of cortical thinning in familial Alzheimer&#x2019;s disease. Neurobiol Aging. 2011;32:1765&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">20005601</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman R, Aisen P, Strooper BD, Fox N, Lemere C, Ringman J, Salloway S, Sperling R, Windisch M, Xiong C. Autosomal-dominant Alzheimer&#x2019;s disease: A review and proposal for the prevention of Alzheimer&#x2019;s disease. Alzheimers Res Ther. 2011;3:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3109410</ArticleId><ArticleId IdType="pubmed">21211070</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, McKeel D, Fulling K, Torack R, Berg L. Validation of clinical diagnostic criteria for Alzheimer&#x2019;s disease. Ann Neurol. 1988;24:17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">3415196</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology. 1993;43:2412&#x2013;2414.</Citation><ArticleIdList><ArticleId IdType="pubmed">8232972</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg L, McKeel DW, Miller JP, Storandt M, Rubin EH, Morris JC, Baty J, Coats M, Norton J, Goate AM, Price JL, Gearing M, Mirra SS, Saunders AM. Clinicopathologic studies in cognitively healthy aging and Alzheimer&#x2019;s disease - Relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol. 1998;55:326&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9520006</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer&#x2019;s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopera F, Ardilla A, Mart&#xed;nez A, Madrigal L, Arango-Viana J, Lemere C, Arango-Lasprilla J, Hincap&#xed;e L, Arcos-Burgos M, Ossa J, Behrens I, Norton J, Lendon C, Goate A, Ruiz-Linares A, Rosselli M, Kosik K. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997;277:793&#x2013;799.</Citation><ArticleIdList><ArticleId IdType="pubmed">9052708</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsman E, Daw E, Yu X, Steinbart E, Nochlin D, Bird T, Schellenberg G. APOE and other loci affect age-at-onset in Alzheimer&#x2019;s disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet. 2005;132B:14&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">15389756</ArticleId></ArticleIdList></Reference><Reference><Citation>Kauwe J, Jacquart S, Chakraverty S, Wang J, Mayo K, Mintun M, Fagan A, Holtzman D, Morris J, Goate A. Use of cerebrospinal fluid amyloid-&#x3b2; levels as an endophenotype identifies a PSEN1 mutation causing Alzheimer&#x2019;s disease in a late-onset family. Ann Neurol. 2007;61:446&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pubmed">17366635</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw L, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Seimers E, Potter W, Lee V-Y, Trojanowski J, Initiative T. A. s. D. N. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol. 2011;121:597&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175107</ArticleId><ArticleId IdType="pubmed">21311900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Trenkwalder C, Brechlin P, Ruther E, Kornhuber J, Otto M, Wiltfang J. CSF diagnosis of Alzheimer&#x2019;s disease and dementia with Lewy bodies. J Neural Transm. 2006;113:1771&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">16906356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderstichele H, Vreese KD, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, B&#xfc;rger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bl&#xe4;ser M, Olsson A, Pottel H, Hulstaert F, Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer&#x2019;s disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006;44:1472&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pubmed">17163825</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D. Cerebrospinal fluid tau/A&#x3b2;42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelborghs S, DeVreese K, Van De Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin J, Vanmechelen E, De Deyn P. Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging. 2008;29:1143&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">17428581</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouwman F, Schoonenboom N, Verwey N, Van Elk E, Kok A, Blankenstein M, Scheltens P, Van Der Flier W. CSF biomarker levels in early and late onset Alzheimer&#x2019;s disease. Neurobiol Aging. 2009;30:1895&#x2013;1901.</Citation><ArticleIdList><ArticleId IdType="pubmed">18403055</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka S, Van Der Flier W, Blankenstein M, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Ros&#xe9;n E, Aarsland D, Visser P, Schr&#xf6;der J, Marcusson J, De Leon M, Hampel H, Scheltens P, Pirttil&#xe4; T, Wallin A, J&#xf6;nhagen M, Minthon L, Winblad B, Blennow K. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302:385&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622817</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser P, Verhey F, Knol D, Scheltens P, Wahlund L, Freund-Levi Y, Tsolaki M, Minthon L, Wallin A, Hampel H, B&#xfc;rger K, Pirttila T, Soininen H, Rikkert M, Verbeek M, Spiru L, Blennow K. Prevalence and prognostic value of CSF markers of Alzheimer&#x2019;s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol. 2009;8:619&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">19523877</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, Bergstr&#xf6;m M, Savitcheva I, Huang G-F, Estrada S, Aus&#xe9;n B, Debnath M, Barletta J, Price J, Sandell J, Lopresti B, Wall A, Koivisto P, Antoni G, Mathis C, L&#xe5;ngstr&#xf6;m B. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, Klunk W, Mathis C, DeKosky S, Morris J. [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset O, Ma Y, Evans A. Correction for partial volume effects in PET: Principle and validation. J Nuclear Med. 1998;39:904&#x2013;911.</Citation><ArticleIdList><ArticleId IdType="pubmed">9591599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartigan J, Wong M. Algorithm AS 136: A k-means clustering algorithm. J Royal Stat Society. Series C (Applied Statistics) 1979;28:100&#x2013;108.</Citation></Reference><Reference><Citation>Snijders T, Bosker R. Multilevel analysis. An introduction to basic and advanced multilevel modeling. Sage Publications; London: 1999.</Citation></Reference><Reference><Citation>Hedeker D, editor. Handbook of Multilevel Analysis. Springer; New York: 2008.</Citation></Reference><Reference><Citation>Cleveland W, Grosse E, Shyu W. In: Statistical Models. Chambers S,J, Hastie T, editors. Chapman and Hall; New York: 1992. pp. 309&#x2013;376.</Citation></Reference><Reference><Citation>Kenward M, Roger J. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983&#x2013;997.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24614494</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study.</ArticleTitle><Pagination><StartPage>1044</StartPage><EndPage>1051</EndPage><MedlinePgn>1044-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2014.9</ELocationID><Abstract><AbstractText>This study was designed to evaluate whether subjects with amyloid beta (A&#x3b2;) pathology, detected using florbetapir positron emission tomorgraphy (PET), demonstrated greater cognitive decline than subjects without A&#x3b2; pathology. Sixty-nine cognitively normal (CN) controls, 52 with recently diagnosed mild cognitive impairment (MCI) and 31 with probable Alzheimer's disease (AD) dementia were included in the study. PET images obtained in these subjects were visually rated as positive (A&#x3b2;+) or negative (A&#x3b2;-), blind to diagnosis. Fourteen percent (10/69) of CN, 37% (19/52) of MCI and 68% (21/31) of AD were A&#x3b2;+. The primary outcome was change in ADAS-Cog score in MCI subjects after 36 months; however, additional outcomes included change on measures of cognition, function and diagnostic status. A&#x3b2;+ MCI subjects demonstrated greater worsening compared with A&#x3b2;- subjects on the ADAS-Cog over 36 months (5.66 &#xb1; 1.47 vs -0.71 &#xb1; 1.09, P = 0.0014) as well as on the mini-mental state exam (MMSE), digit symbol substitution (DSS) test, and a verbal fluency test (P &lt; 0.05). Similar to MCI subjects, A&#x3b2;+ CN subjects showed greater decline on the ADAS-Cog, digit-symbol-substitution test and verbal fluency (P&lt;0.05), whereas A&#x3b2;+ AD patients showed greater declines in verbal fluency and the MMSE (P &lt; 0.05). A&#x3b2;+ subjects in all diagnostic groups also showed greater decline on the CDR-SB (P&lt;0.04), a global clinical assessment. A&#x3b2;+ subjects did not show significantly greater declines on the ADCS-ADL or Wechsler Memory Scale. Overall, these findings suggest that in CN, MCI and AD subjects, florbetapir PET A&#x3b2;+ subjects show greater cognitive and global deterioration over a 3-year follow-up than A&#x3b2;- subjects do.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>R A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>E M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>T Z</ForeName><Initials>TZ</Initials><AffiliationInfo><Affiliation>Duke University Medical Center, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>M N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Banner-Sun Health Research Institute, Sun City, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Nova SE University, Ft. Lauderdale, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>1] Banner Alzheimer's Institute, Phoenix, AZ, USA [2] University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carpenter</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>A D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grundman</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] University of California, San Diego, CA, USA [2] Global R&amp;D Partners, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skovronsky</LastName><ForeName>D M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontecorvo</LastName><ForeName>M J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>AV45-A11 Study Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>AV45-A11 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000814">Aniline Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005026">Ethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018697">Nootropic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>6867Q6IKOD</RegistryNumber><NameOfSubstance UI="C545186">florbetapir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000814" MajorTopicYN="N">Aniline Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005026" MajorTopicYN="N">Ethylene Glycols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018697" MajorTopicYN="N">Nootropic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Duara</LastName><ForeName>Ranjan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lawrence Ahern</LastName><ForeName>Geoffrey</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holub</LastName><ForeName>Richard F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farmer</LastName><ForeName>Mildred V</ForeName><Initials>MV</Initials></Investigator><Investigator ValidYN="Y"><LastName>Safirstein</LastName><ForeName>Beth Emmie</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alva</LastName><ForeName>Gustavo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Longmire</LastName><ForeName>Crystal F</ForeName><Initials>CF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jewell</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Korn</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wendt</LastName><ForeName>Jeanette K</ForeName><Initials>JK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wong</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doraiswamy</LastName><ForeName>P Murali</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coleman</LastName><ForeName>R Edward</ForeName><Initials>RE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devous</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>Danna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Cynthia A</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kovnat</LastName><ForeName>Karel D</ForeName><Initials>KD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williamson</LastName><ForeName>Jeff D</ForeName><Initials>JD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadowsky</LastName><ForeName>Carl H</ForeName><Initials>CH</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24614494</ArticleId><ArticleId IdType="pmc">PMC4195975</ArticleId><ArticleId IdType="doi">10.1038/mp.2014.9</ArticleId><ArticleId IdType="pii">mp20149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. Jan. 2011;76:280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="pubmed">21178097</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Aisen PS, Jack CR, Jr., Jagust WJ, Trojanowski JQ, Shaw L, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement. 2010;6:202&#x2013;211 e207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927112</ArticleId><ArticleId IdType="pubmed">20451868</ArticleId></ArticleIdList></Reference><Reference><Citation>Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging. 1997;18 ((4 Suppl:S1&#x2013;S2.</Citation><ArticleIdList><ArticleId IdType="pubmed">9330978</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-beta deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515078</ArticleId><ArticleId IdType="pubmed">23137949</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Rinne JO, Kadir A, Langstrom B. The use of PET in Alzheimer disease. Nat Rev Neurol. 2010;6:78&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">20139997</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66:1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, N&#xe5;gren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 2009;73:754&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830881</ArticleId><ArticleId IdType="pubmed">19587325</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain. 2010;133:3336&#x2013;3348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965425</ArticleId><ArticleId IdType="pubmed">20935035</ArticleId></ArticleIdList></Reference><Reference><Citation>Koivunen J, Scheinin N, Virta JR, Weigand SD, Senjem ML, Zeng G, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology. 2011;76:1085&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pubmed">21325653</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, Bourgeat P, et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol. 2011;69:181&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045039</ArticleId><ArticleId IdType="pubmed">21280088</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Pike KE, Darby D, et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008;46:1688&#x2013;1697.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343463</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66:1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, Zhou Y, An Y, Ye W, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74:807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79:1645&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">23071163</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontecorvo MJ, Mintun MA. PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer's disease. Alzheimers Res Ther. 2011;3:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226273</ArticleId><ArticleId IdType="pubmed">21457498</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50:1887&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3065020</ArticleId><ArticleId IdType="pubmed">19837759</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel H, Gertz HJ, Dresel S, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424&#x2013;435.</Citation><ArticleIdList><ArticleId IdType="pubmed">21481640</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ackerman U, Browne W, Mulligan R, Pike KL, O'Keefe G, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7:129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191617</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Sperling RA, Gidicsin CM, Carmasin JS, Maye JE, Coleman RE, et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9 ((5 Suppl:S72&#x2013;S83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3800236</ArticleId><ArticleId IdType="pubmed">23375563</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013;34:822&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518678</ArticleId><ArticleId IdType="pubmed">22878163</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79:1636&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468774</ArticleId><ArticleId IdType="pubmed">22786606</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">21747008</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A. 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998;50:136&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">9443470</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology. 2000;54:2269&#x2013;2276.</Citation><ArticleIdList><ArticleId IdType="pubmed">10881251</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633&#x2013;638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27767</ArticleId><ArticleId IdType="pubmed">10066203</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement. 2010;6:239&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2867843</ArticleId><ArticleId IdType="pubmed">20451872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study Mol Psychiatryadvance online publication, 19 February 2013; doi:10.1038/mp.2013.19</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.19</ArticleId><ArticleId IdType="pmc">PMC3661739</ArticleId><ArticleId IdType="pubmed">23419831</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's disease neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012;8 ((1 Suppl:S1&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Rowley J, Mohades S, Leuzy A, Dauar MT, Shin M, et al. Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS ONE. 2012;7:e47905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3480449</ArticleId><ArticleId IdType="pubmed">23112868</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009;106:6820&#x2013;6825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665196</ArticleId><ArticleId IdType="pubmed">19346482</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordberg A, Carter SF, Rinne J, Drzezga A, Brooks DJ, Vandenberghe R, et al. A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2013;40:104&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3510420</ArticleId><ArticleId IdType="pubmed">22961445</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24608097</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Plasma phospholipids identify antecedent memory impairment in older adults.</ArticleTitle><Pagination><StartPage>415</StartPage><EndPage>418</EndPage><MedlinePgn>415-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3466</ELocationID><Abstract><AbstractText>Alzheimer's disease causes a progressive dementia that currently affects over 35 million individuals worldwide and is expected to affect 115 million by 2050 (ref. 1). There are no cures or disease-modifying therapies, and this may be due to our inability to detect the disease before it has progressed to produce evident memory loss and functional decline. Biomarkers of preclinical disease will be critical to the development of disease-modifying or even preventative therapies. Unfortunately, current biomarkers for early disease, including cerebrospinal fluid tau and amyloid-&#x3b2; levels, structural and functional magnetic resonance imaging and the recent use of brain amyloid imaging or inflammaging, are limited because they are either invasive, time-consuming or expensive. Blood-based biomarkers may be a more attractive option, but none can currently detect preclinical Alzheimer's disease with the required sensitivity and specificity. Herein, we describe our lipidomic approach to detecting preclinical Alzheimer's disease in a group of cognitively normal older adults. We discovered and validated a set of ten lipids from peripheral blood that predicted phenoconversion to either amnestic mild cognitive impairment or Alzheimer's disease within a 2-3 year timeframe with over 90% accuracy. This biomarker panel, reflecting cell membrane integrity, may be sensitive to early neurodegeneration of preclinical Alzheimer's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mapstone</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester School of Medicine, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheema</LastName><ForeName>Amrita K</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>1] Department of Oncology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Biochemistry, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiandaca</LastName><ForeName>Massimo S</ForeName><Initials>MS</Initials><Identifier Source="ORCID">0000000283761934</Identifier><AffiliationInfo><Affiliation>1] Department of Neurology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Xiaogang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mhyre</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacArthur</LastName><ForeName>Linda H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Rochester School of Medicine, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Susan G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>1] Department of Public Health Sciences, University of Rochester School of Medicine, Rochester, New York, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Derick R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haley</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Medicine, Unity Health System, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazar</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Department of Family Medicine, Unity Health System, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rich</LastName><ForeName>Steven A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Division of Long Term Care and Senior Services, Rochester General Hospital, Rochester, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlau</LastName><ForeName>Dan J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>1] Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peltz</LastName><ForeName>Carrie B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ming T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawas</LastName><ForeName>Claudia H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, University of California, Irvine School of Medicine, Irvine, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Federoff</LastName><ForeName>Howard J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>1] Department of Neurology, Georgetown University Medical Center, Washington, DC, USA. [2] Department of Neuroscience, Georgetown University Medical Center, Washington, DC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG030753</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG030753</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008244">Lysophosphatidylcholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008293">Malates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010713">Phosphatidylcholines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010716">Phosphatidylinositols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013109">Sphingomyelins</NameOfSubstance></Chemical><Chemical><RegistryNumber>64480-66-6</RegistryNumber><NameOfSubstance UI="C024033">glycoursodeoxycholic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>7006-34-0</RegistryNumber><NameOfSubstance UI="D001216">Asparagine</NameOfSubstance></Chemical><Chemical><RegistryNumber>724L30Y2QR</RegistryNumber><NameOfSubstance UI="D014580">Ursodeoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>817L1N4CKP</RegistryNumber><NameOfSubstance UI="C030298">malic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9DLQ4CIU6V</RegistryNumber><NameOfSubstance UI="D011392">Proline</NameOfSubstance></Chemical><Chemical><RegistryNumber>S7UI8SM58A</RegistryNumber><NameOfSubstance UI="D002331">Carnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>BMJ. 2014 Mar 10;348:g2074. doi: 10.1136/bmj.g2074.</RefSource><PMID Version="1">24620352</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Alzheimers Dement. 2017 May;13(5):606-607. doi: 10.1016/j.jalz.2017.01.003.</RefSource><PMID Version="1">28119051</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001216" MajorTopicYN="N">Asparagine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002331" MajorTopicYN="N">Carnitine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008244" MajorTopicYN="N">Lysophosphatidylcholines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008293" MajorTopicYN="N">Malates</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055442" MajorTopicYN="N">Metabolome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010713" MajorTopicYN="N">Phosphatidylcholines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010716" MajorTopicYN="N">Phosphatidylinositols</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011392" MajorTopicYN="N">Proline</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013109" MajorTopicYN="N">Sphingomyelins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014580" MajorTopicYN="N">Ursodeoxycholic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>3</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24608097</ArticleId><ArticleId IdType="mid">NIHMS799554</ArticleId><ArticleId IdType="pmc">PMC5360460</ArticleId><ArticleId IdType="doi">10.1038/nm.3466</ArticleId><ArticleId IdType="pii">nm.3466</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Dementia: a Public Health Priority. Geneva: World Health Organization; 2012.</Citation></Reference><Reference><Citation>Sperling RA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s &amp; Dementia: the Journal of the Alzheimer&#x2019;s Association. 2011;7:280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert F, et al. Improved discrimination of AD patients using &#x3b2;-amyloid(1&#x2013;42) and tau levels in CSF. Neurology. 1999;52:1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331678</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Perera GM, De La Paz R, Mayeux R, Stern Y. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer&#x2019;s disease. Ann. Neurol. 1999;45:466&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">10211471</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging brain amyloid in Alzheimer&#x2019;s disease with Pittsburgh Compound-B. Ann. Neurol. 2004;55:306&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14991808</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. NY Acad. Sci. 2000;908:244&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">10911963</ArticleId></ArticleIdList></Reference><Reference><Citation>Thambisetty M, Lovestone S. Blood-based biomarkers of Alzheimer&#x2019;s disease: challenging but feasible. Biomark. Med. 2010;4:65&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2863057</ArticleId><ArticleId IdType="pubmed">20387303</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Stat. Methodol. 1996;58:267&#x2013;288.</Citation></Reference><Reference><Citation>Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning; Data Mining, Inference, and Prediction. New York: Springer-Verlag; 2008.</Citation></Reference><Reference><Citation>van Meer G, de Kroon AI. Lipid map of the mammalian cell. J. Cell Sci. 2011;124:5&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21172818</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones LL, McDonald DA, Borum PR. Acylcarnitines: role in brain. Prog. Lipid Res. 2010;49:61&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">19720082</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, et al. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA. 1992;89:1671&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48514</ArticleId><ArticleId IdType="pubmed">1311847</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer EJ, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol. 2006;63:1545&#x2013;1550.</Citation><ArticleIdList><ArticleId IdType="pubmed">17101822</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder C, et al. Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer&#x2019;s disease. J. Neural Transm. 2003;110:949&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898349</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter A, et al. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging. 2004;25:1299&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">15465626</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer&#x2019;s disease. Neurochem. Res. 1998;23:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">9482271</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer&#x2019;s disease. Neurochem. Res. 2001;26:771&#x2013;782.</Citation><ArticleIdList><ArticleId IdType="pubmed">11565608</ArticleId></ArticleIdList></Reference><Reference><Citation>Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer&#x2019;s disease neuropathogenesis. Biochim. Biophys. Acta. 2010;1801:878&#x2013;886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907186</ArticleId><ArticleId IdType="pubmed">20452460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Fiandaca MS. Response of the monkey cholinergic septohippocampal system to fornix transection: a histochemical and cytochemical analysis. J. Comp. Neurol. 1990;298:443&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">2172323</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, et al. The aged monkey basal forebrain: rescue and sprouting of axotomized basal forebrain neurons after grafts of encapsulated cells secreting human nerve growth factor. Proc. Natl. Acad. Sci. USA. 1994;91:10898&#x2013;10902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45133</ArticleId><ArticleId IdType="pubmed">7971980</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann. Neurol. 1981;10:122&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">7283399</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, et al. Association between CSF biomarkers and incipient Alzheimer&#x2019;s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">16488378</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010;6:131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx. 2004;1:226&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC534932</ArticleId><ArticleId IdType="pubmed">15717023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray S, et al. Classification and prediction of clinical Alzheimer&#x2019;s diagnosis based on plasma signaling proteins. Nat. Med. 2007;13:1359&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">17934472</ArticleId></ArticleIdList></Reference><Reference><Citation>Doecke JD, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch. Neurol. 2012;69:1318&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6287606</ArticleId><ArticleId IdType="pubmed">22801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, et al. Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology. 2011;76:501&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3053181</ArticleId><ArticleId IdType="pubmed">21228296</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, et al. Cerebrospinal fluid tau/&#x3b2;-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007;64:343&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">17210801</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999;56:303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10190820</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa A, et al. A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved. J. Alzheimers Dis. 2013;34:769&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pubmed">23271318</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Want EJ, et al. Global metabolic profiling procedures for urine using UPLC-MS. Nat. Protoc. 2010;5:1005&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pubmed">20448546</ArticleId></ArticleIdList></Reference><Reference><Citation>Grebe SK, Singh RJ. LC-MS/MS in the clinical laboratory - where to from here? Clin. Biochem. Rev. 2011;32:5&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052391</ArticleId><ArticleId IdType="pubmed">21451775</ArticleId></ArticleIdList></Reference><Reference><Citation>Illig T, et al. A genome-wide perspective of genetic variation in human metabolism. Nat. Genet. 2010;42:137&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3773904</ArticleId><ArticleId IdType="pubmed">20037589</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xf6;misch-Margl WPC, Bogumil R, R&#xf6;hring C, Suhre K. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics. 2011;7:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Huang J. Regularized ROC method for disease classification and biomarker selection with microarray data. Bioinformatics. 2005;21:4356&#x2013;4362.</Citation><ArticleIdList><ArticleId IdType="pubmed">16234316</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Tan M. ROC-based utility function maximization for feature selection and classification with applications to high-dimensional protease data. Biometrics. 2008;64:1155&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18363775</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 2010;33:1&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929880</ArticleId><ArticleId IdType="pubmed">20808728</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24623762</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease.</ArticleTitle><Pagination><StartPage>3826</StartPage><EndPage>3840</EndPage><MedlinePgn>3826-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5171-13.2014</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) is associated with an elevated risk for seizures that may be fundamentally connected to cognitive dysfunction. Supporting this link, many mouse models for AD exhibit abnormal electroencephalogram (EEG) activity in addition to the expected neuropathology and cognitive deficits. Here, we used a controllable transgenic system to investigate how network changes develop and are maintained in a model characterized by amyloid &#x3b2; (A&#x3b2;) overproduction and progressive amyloid pathology. EEG recordings in tet-off mice overexpressing amyloid precursor protein (APP) from birth display frequent sharp wave discharges (SWDs). Unexpectedly, we found that withholding APP overexpression until adulthood substantially delayed the appearance of epileptiform activity. Together, these findings suggest that juvenile APP overexpression altered cortical development to favor synchronized firing. Regardless of the age at which EEG abnormalities appeared, the phenotype was dependent on continued APP overexpression and abated over several weeks once transgene expression was suppressed. Abnormal EEG discharges were independent of plaque load and could be extinguished without altering deposited amyloid. Selective reduction of A&#x3b2; with a &#x3b3;-secretase inhibitor has no effect on the frequency of SWDs, indicating that another APP fragment or the full-length protein was likely responsible for maintaining EEG abnormalities. Moreover, transgene suppression normalized the ratio of excitatory to inhibitory innervation in the cortex, whereas secretase inhibition did not. Our results suggest that APP overexpression, and not A&#x3b2; overproduction, is responsible for EEG abnormalities in our transgenic mice and can be rescued independently of pathology.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Born</LastName><ForeName>Heather A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Department of Neurology, Department of Molecular and Cellular Biology, Department of Human and Molecular Genetics, Department of Neurosurgery, the Jan and Dan Duncan Neurological Research Institute, and the Huffington Center on Aging, Baylor College of Medicine, Houston, Texas 77030, Texas A&amp;M Health Science Center, College Station, Texas 77843, Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, Department of Computational and Applied Mathematics, Rice University, Houston, Texas 77251, Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110, and Department of Neuroscience, University of Florida, Gainesville, Florida 32610.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Yoen</ForeName><Initials>JY</Initials></Author><Author ValidYN="Y"><LastName>Savjani</LastName><ForeName>Ricky R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Das</LastName><ForeName>Pritam</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dabaghian</LastName><ForeName>Yuri A</ForeName><Initials>YA</Initials></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Qinxi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Jong W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Schuler</LastName><ForeName>Dorothy R</ForeName><Initials>DR</Initials></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Noebels</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Jankowsky</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DP2 OD001734</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C545487">APP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019277" MajorTopicYN="N">Entropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009433" MajorTopicYN="N">Neural Inhibition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012640" MajorTopicYN="N">Seizures</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013489" MajorTopicYN="N">Suppression, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019076" MajorTopicYN="N">Transgenes</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EEG</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">seizure</Keyword><Keyword MajorTopicYN="N">sharp wave discharge</Keyword><Keyword MajorTopicYN="N">transgene suppression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24623762</ArticleId><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5171-13.2014</ArticleId><ArticleId IdType="pii">34/11/3826</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amatniek JC, Hauser WA, DelCastillo-Castaneda C, Jacobs DM, Marder K, Bell K, Albert M, Brandt J, Stern Y. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867&#x2013;872. doi: 10.1111/j.1528-1167.2006.00554.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2006.00554.x</ArticleId><ArticleId IdType="pubmed">16686651</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglietto-Vargas D, Moreno-Gonzalez I, Sanchez-Varo R, Jimenez S, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Romero-Acebal M, Ruano D, Vizuete M, Vitorica J, Gutierrez A. Calretinin interneurons are early targets of extracellular amyloid-&#x3b2; pathology in PS1/A&#x3b2;PP Alzheimer mice hippocampus. J Alzheimers Dis. 2010;21:119&#x2013;132. doi: 10.3233/JAD-2010-100066.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100066</ArticleId><ArticleId IdType="pubmed">20413859</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467&#x2013;474. doi: 10.1016/j.neuron.2012.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.023</ArticleId><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-&#x3b2; deposition. Nat Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689. doi: 10.1126/science.1162844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Chen X, Henning HA, Reichwald J, Staufenbiel M, Sakmann B, Konnerth A. Critical role of soluble amyloid-&#x3b2; for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2012;109:8740&#x2013;8745. doi: 10.1073/pnas.1206171109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206171109</ArticleId><ArticleId IdType="pmc">PMC3365221</ArticleId><ArticleId IdType="pubmed">22592800</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrejo L, Guyant-Mar&#xe9;chal L, Laquerri&#xe8;re A, Vercelletto M, De la Fourni&#xe8;re F, Thomas-Ant&#xe9;rion C, Verny C, Letournel F, Pasquier F, Vital A, Checler F, Frebourg T, Campion D, Hannequin D. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966&#x2013;2976. doi: 10.1093/brain/awl237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl237</ArticleId><ArticleId IdType="pubmed">16959815</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah CS, Yu FH, Westenbroek RE, Kalume FK, Oakley JC, Potter GB, Rubenstein JL, Catterall WA. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2012;109:14646&#x2013;14651. doi: 10.1073/pnas.1211591109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1211591109</ArticleId><ArticleId IdType="pmc">PMC3437823</ArticleId><ArticleId IdType="pubmed">22908258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-&#x3b2; levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Serotonin signaling is associated with lower amyloid-&#x3b2; levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968&#x2013;14973. doi: 10.1073/pnas.1107411108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1107411108</ArticleId><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="pubmed">21873225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cobb SR, Buhl EH, Halasy K, Paulsen O, Somogyi P. Synchronization of neuronal activity in hippocampus by individual GABAergic interneurons. Nature. 1995;378:75&#x2013;78. doi: 10.1038/378075a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/378075a0</ArticleId><ArticleId IdType="pubmed">7477292</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbett BF, Leiser SC, Ling HP, Nagy R, Breysse N, Zhang X, Hazra A, Brown JT, Randall AD, Wood A, Pangalos MN, Reinhart PH, Chin J. Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2013;33:7020&#x2013;7026. doi: 10.1523/JNEUROSCI.2325-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2325-12.2013</ArticleId><ArticleId IdType="pmc">PMC6618875</ArticleId><ArticleId IdType="pubmed">23595759</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutsuridis V, Hasselmo M. GABAergic contributions to gating, timing, and phase precession of hippocampal neuronal activity during theta oscillations. Hippocampus. 2012;22:1597&#x2013;1621. doi: 10.1002/hipo.21002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.21002</ArticleId><ArticleId IdType="pubmed">22252986</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Vecchio RA, Gold LH, Novick SJ, Wong G, Hyde LA. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci Lett. 2004;367:164&#x2013;167. doi: 10.1016/j.neulet.2004.05.107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2004.05.107</ArticleId><ArticleId IdType="pubmed">15331144</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraro TN, Golden GT, Smith GG, St Jean P, Schork NJ, Mulholland N, Ballas C, Schill J, Buono RJ, Berrettini WH. Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. J Neurosci. 1999;19:6733&#x2013;6739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782858</ArticleId><ArticleId IdType="pubmed">10436030</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleck D, Garratt AN, Haass C, Willem M. BACE1 dependent neuregulin processing: review. Curr Alzheimer Res. 2012;9:178&#x2013;183. doi: 10.2174/156720512799361637.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512799361637</ArticleId><ArticleId IdType="pubmed">22455478</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999;5:101&#x2013;106. doi: 10.1038/4789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4789</ArticleId><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Zheng H, Justice NJ. Central CRF system perturbation in an Alzheimer's disease knockin mouse model. Neurobiol Aging. 2012;33:2678&#x2013;2691. doi: 10.1016/j.neurobiolaging.2012.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.01.002</ArticleId><ArticleId IdType="pmc">PMC3361634</ArticleId><ArticleId IdType="pubmed">22336193</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Li H, Cole AL, Hur JY, Li Y, Zheng H. Modeling Alzheimer's disease in mouse without mutant protein overexpression: cooperative and independent effects of A&#x3b2; and tau. PLoS One. 2013;8:e80706. doi: 10.1371/journal.pone.0080706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0080706</ArticleId><ArticleId IdType="pmc">PMC3835479</ArticleId><ArticleId IdType="pubmed">24278307</ArticleId></ArticleIdList></Reference><Reference><Citation>Hangya B, Borhegyi Z, Szil&#xe1;gyi N, Freund TF, Varga V. GABAergic neurons of the medial septum lead the hippocampal network during theta activity. J Neurosci. 2009;29:8094&#x2013;8102. doi: 10.1523/JNEUROSCI.5665-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5665-08.2009</ArticleId><ArticleId IdType="pmc">PMC6666051</ArticleId><ArticleId IdType="pubmed">19553449</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiscock JJ, MacKenzie L, Willoughby JO. Fos induction in subtypes of cerebrocortical neurons following single picrotoxin-induced seizures. Brain Res. 1996;738:301&#x2013;312. doi: 10.1016/S0006-8993(96)00806-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(96)00806-2</ArticleId><ArticleId IdType="pubmed">8955526</ArticleId></ArticleIdList></Reference><Reference><Citation>Hitt BD, Jaramillo TC, Chetkovich DM, Vassar R. BACE1&#x2212;/&#x2212; mice exhibit seizure activity that does not correlate with sodium channel level or axonal localization. Mol Neurodegener. 2010;5:31. doi: 10.1186/1750-1326-5-31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-31</ArticleId><ArticleId IdType="pmc">PMC2933677</ArticleId><ArticleId IdType="pubmed">20731874</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoe HS, Lee HK, Pak DT. The upside of APP at synapses. CNS Neurosci Ther. 2012;18:47&#x2013;56. doi: 10.1111/j.1755-5949.2010.00221.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1755-5949.2010.00221.x</ArticleId><ArticleId IdType="pmc">PMC3116065</ArticleId><ArticleId IdType="pubmed">21199446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2; during age-related plaque formation. J Neurosci. 2011;31:15861&#x2013;15869. doi: 10.1523/JNEUROSCI.3272-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3272-11.2011</ArticleId><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R. BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci. 2010;30:8819&#x2013;8829. doi: 10.1523/JNEUROSCI.1334-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1334-10.2010</ArticleId><ArticleId IdType="pmc">PMC2902368</ArticleId><ArticleId IdType="pubmed">20592204</ArticleId></ArticleIdList></Reference><Reference><Citation>Huth T, Alzheimer C. Voltage-dependent Na+ channels as targets of BACE1-implications for neuronal firing and beyond. Curr Alzheimer Res. 2012;9:184&#x2013;188. doi: 10.2174/156720512799361619.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512799361619</ArticleId><ArticleId IdType="pubmed">22455479</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of A&#x3b2; production in a transgenic model of Alzheimer's disease. PLoS Med. 2005;2:e355. doi: 10.1371/journal.pmed.0020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020355</ArticleId><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Younkin LH, Gonzales V, Fadale DJ, Slunt HH, Lester HA, Younkin SG, Borchelt DR. Rodent A&#x3b2; modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007;282:22707&#x2013;22720. doi: 10.1074/jbc.M611050200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M611050200</ArticleId><ArticleId IdType="pmc">PMC4435736</ArticleId><ArticleId IdType="pubmed">17556372</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, Yu CE, Bird TD. Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain. 2010;133:1143&#x2013;1154. doi: 10.1093/brain/awq033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq033</ArticleId><ArticleId IdType="pmc">PMC2850581</ArticleId><ArticleId IdType="pubmed">20375137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937. doi: 10.1016/S0896-6273(03)00124-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00124-7</ArticleId><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Carey BW, Wang H, Ingano LA, Binshtok AM, Wertz MH, Pettingell WH, He P, Lee VM, Woolf CJ, Kovacs DM. BACE1 regulates voltage-gated sodium channels and neuronal activity. Nat Cell Biol. 2007;9:755&#x2013;764. doi: 10.1038/ncb1602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb1602</ArticleId><ArticleId IdType="pmc">PMC2747787</ArticleId><ArticleId IdType="pubmed">17576410</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DY, Gersbacher MT, Inquimbert P, Kovacs DM. Reduced sodium channel NaV1.1 levels in BACE1-null mice. J Biol Chem. 2011;286:8106&#x2013;8116. doi: 10.1074/jbc.M110.134692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.134692</ArticleId><ArticleId IdType="pmc">PMC3048697</ArticleId><ArticleId IdType="pubmed">21190943</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaassen A, Glykys J, Maguire J, Labarca C, Mody I, Boulter J. Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. Proc Natl Acad Sci U S A. 2006;103:19152&#x2013;19157. doi: 10.1073/pnas.0608215103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0608215103</ArticleId><ArticleId IdType="pmc">PMC1681351</ArticleId><ArticleId IdType="pubmed">17146052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi D, Zeller M, Cole T, Buttini M, McConlogue L, Sinha S, Freedman S, Morris RG, Chen KS. BACE1 gene deletion: impact on behavioral function in a model of Alzheimer's disease. Neurobiol Aging. 2008;29:861&#x2013;873. doi: 10.1016/j.neurobiolaging.2007.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.01.002</ArticleId><ArticleId IdType="pubmed">17331621</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler C, Ebert U, Baumann K, Schroder H. Alzheimer's disease-like neuropathology of gene-targeted APP-SLxPS1mut mice expressing the amyloid precursor protein at endogenous levels. Neurobiol Dis. 2005;20:528&#x2013;540. doi: 10.1016/j.nbd.2005.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.04.009</ArticleId><ArticleId IdType="pubmed">15921918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs DM, Gersbacher MT, Kim DY. Alzheimer's secretases regulate voltage-gated sodium channels. Neurosci Lett. 2010;486:68&#x2013;72. doi: 10.1016/j.neulet.2010.08.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.08.048</ArticleId><ArticleId IdType="pmc">PMC2964382</ArticleId><ArticleId IdType="pubmed">20817076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalonde R, Dumont M, Staufenbiel M, Strazielle C. Neurobehavioral characterization of APP23 transgenic mice with the SHIRPA primary screen. Behav Brain Res. 2005;157:91&#x2013;98. doi: 10.1016/j.bbr.2004.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2004.06.020</ArticleId><ArticleId IdType="pubmed">15617775</ArticleId></ArticleIdList></Reference><Reference><Citation>Larner AJ, Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139&#x2013;158. doi: 10.1007/s00415-005-0019-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-005-0019-5</ArticleId><ArticleId IdType="pubmed">16267640</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE. Anti-A&#x3b2;42- and anti-A&#x3b2;40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest. 2006a;116:193&#x2013;201. doi: 10.1172/JCI25410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI25410</ArticleId><ArticleId IdType="pmc">PMC1307561</ArticleId><ArticleId IdType="pubmed">16341263</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-A&#x3b2; antibodies in Alzheimer's disease mouse models. FASEB J. 2006b;20:2576&#x2013;2578. doi: 10.1096/fj.06-6463fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6463fje</ArticleId><ArticleId IdType="pubmed">17068112</ArticleId></ArticleIdList></Reference><Reference><Citation>Loreth D, Ozmen L, Revel FG, Knoflach F, Wetzel P, Frotscher M, Metzger F, Kretz O. Selective degeneration of septal and hippocampal GABAergic neurons in a mouse model of amyloidosis and tauopathy. Neurobiol Dis. 2012;47:1&#x2013;12. doi: 10.1016/j.nbd.2012.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.03.011</ArticleId><ArticleId IdType="pubmed">22426397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683. doi: 10.1126/science.274.5293.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5293.1678</ArticleId><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Men&#xe9;ndez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 2005;27:246&#x2013;252. doi: 10.1016/j.braindev.2004.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.braindev.2004.07.008</ArticleId><ArticleId IdType="pubmed">15862185</ArticleId></ArticleIdList></Reference><Reference><Citation>Minkeviciene R, Rheims S, Dobszay MB, Zilberter M, Hartikainen J, F&#xfc;l&#xf6;p L, Penke B, Zilberter Y, Harkany T, Pitk&#xe4;nen A, Tanila H. Amyloid &#x3b2;-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453&#x2013;3462. doi: 10.1523/JNEUROSCI.5215-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5215-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665248</ArticleId><ArticleId IdType="pubmed">19295151</ArticleId></ArticleIdList></Reference><Reference><Citation>Noebels J. A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia. 2011;52:39&#x2013;46. doi: 10.1111/j.1528-1167.2010.02909.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1528-1167.2010.02909.x</ArticleId><ArticleId IdType="pmc">PMC3058398</ArticleId><ArticleId IdType="pubmed">21214538</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435&#x2013;440. doi: 10.1001/archneurol.2009.15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2009.15</ArticleId><ArticleId IdType="pmc">PMC2812914</ArticleId><ArticleId IdType="pubmed">19204149</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Mucke L. Amyloid-&#x3b2;-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci. 2010;13:812&#x2013;818. doi: 10.1038/nn.2583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2583</ArticleId><ArticleId IdType="pmc">PMC3072750</ArticleId><ArticleId IdType="pubmed">20581818</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697&#x2013;711. doi: 10.1016/j.neuron.2007.07.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.07.025</ArticleId><ArticleId IdType="pmc">PMC8055171</ArticleId><ArticleId IdType="pubmed">17785178</ArticleId></ArticleIdList></Reference><Reference><Citation>Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol. 1972;32:281&#x2013;294. doi: 10.1016/0013-4694(72)90177-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0013-4694(72)90177-0</ArticleId><ArticleId IdType="pubmed">4110397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos B, Baglietto-Vargas D, del Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging. 2006;27:1658&#x2013;1672. doi: 10.1016/j.neurobiolaging.2005.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.09.022</ArticleId><ArticleId IdType="pubmed">16271420</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. Amyloid-&#x3b2;/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700&#x2013;711. doi: 10.1523/JNEUROSCI.4152-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4152-10.2011</ArticleId><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers SP, Born HA, Das P, Jankowsky JL. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012;7:28. doi: 10.1186/1750-1326-7-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-28</ArticleId><ArticleId IdType="pmc">PMC3457908</ArticleId><ArticleId IdType="pubmed">22709352</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachse CC, Kim YH, Agsten M, Huth T, Alzheimer C, Kovacs DM, Kim DY. BACE1 and presenilin/&#x3b3;-secretase regulate proteolytic processing of KCNE1 and 2, auxiliary subunits of voltage-gated potassium channels. FASEB J. 2013;27:2458&#x2013;2467. doi: 10.1096/fj.12-214056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.12-214056</ArticleId><ArticleId IdType="pmc">PMC3659364</ArticleId><ArticleId IdType="pubmed">23504710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez P, Zhu L, Verret L, Vossel K, Orr A, Cirrito J, Devidze N, Ho K, Yu G, Palop J, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109:E2895&#x2013;E2903. doi: 10.1073/pnas.1121081109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121081109</ArticleId><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Snider BJ, Norton J, Coats MA, Chakraverty S, Hou CE, Jervis R, Lendon CL, Goate AM, McKeel DW, Jr, Morris JC. Novel presenilin 1 mutation (S170F) causing Alzheimer disease with Lewy bodies in the third decade of life. Arch Neurol. 2005;62:1821&#x2013;1830. doi: 10.1001/archneur.62.12.1821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.62.12.1821</ArticleId><ArticleId IdType="pubmed">16344340</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Brasnjevic I, Rutten BP, Van Der Kolk N, Perl DP, Bouras C, Steinbusch HW, Schmitz C, Hof PR, Dickstein DL. Hippocampal interneuron loss in an APP/PS1 double mutant mouse and in Alzheimer's disease. Brain Struct Funct. 2010;214:145&#x2013;160. doi: 10.1007/s00429-010-0242-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00429-010-0242-4</ArticleId><ArticleId IdType="pmc">PMC3038332</ArticleId><ArticleId IdType="pubmed">20213270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan GH, Liu YY, Hu XL, Yin DM, Mei L, Xiong ZQ. Neuregulin 1 represses limbic epileptogenesis through ErbB4 in parvalbumin-expressing interneurons. Nat Neurosci. 2012;15:258&#x2013;266. doi: 10.1038/nn.3005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3005</ArticleId><ArticleId IdType="pubmed">22158510</ArticleId></ArticleIdList></Reference><Reference><Citation>Verret L, Mann EO, Hang GB, Barth AM, Cobos I, Ho K, Devidze N, Masliah E, Kreitzer AC, Mody I, Mucke L, Palop JJ. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell. 2012;149:708&#x2013;721. doi: 10.1016/j.cell.2012.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.02.046</ArticleId><ArticleId IdType="pmc">PMC3375906</ArticleId><ArticleId IdType="pubmed">22541439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-&#x3b2; immunotherapy. J Neurosci. 2011;31:4124&#x2013;4136. doi: 10.1523/JNEUROSCI.5077-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5077-10.2011</ArticleId><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Wang B, Yang L, Guo Q, Aithmitti N, Songyang Z, Zheng H. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci. 2009;29:10788&#x2013;10801. doi: 10.1523/JNEUROSCI.2132-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2132-09.2009</ArticleId><ArticleId IdType="pmc">PMC2757256</ArticleId><ArticleId IdType="pubmed">19726636</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen L, Lu YS, Zhu XH, Li XM, Woo RS, Chen YJ, Yin DM, Lai C, Terry AV, Jr, Vazdarjanova A, Xiong WC, Mei L. Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proc Natl Acad Sci U S A. 2010;107:1211&#x2013;1216. doi: 10.1073/pnas.0910302107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0910302107</ArticleId><ArticleId IdType="pmc">PMC2824309</ArticleId><ArticleId IdType="pubmed">20080551</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmark CJ. What's hAPPening at synapses? The role of amyloid &#x3b2;-protein precursor and &#x3b2;-amyloid in neurological disorders. Mol Psychiatry. 2013;18:425&#x2013;434. doi: 10.1038/mp.2012.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.122</ArticleId><ArticleId IdType="pubmed">22925831</ArticleId></ArticleIdList></Reference><Reference><Citation>Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS. Seizure susceptibility and mortality in mice that over-express amyloid precursor protein. Int J Clin Exp Pathol. 2008;1:157&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2480559</ArticleId><ArticleId IdType="pubmed">18784809</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. &#x3b2; Subunits of voltage-gated sodium channels are novel substrates of &#x3b2;-site amyloid precursor protein-cleaving enzyme (BACE1) and &#x3b3;-secretase. J Biol Chem. 2005;280:23009&#x2013;23017. doi: 10.1074/jbc.M414648200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M414648200</ArticleId><ArticleId IdType="pubmed">15824102</ArticleId></ArticleIdList></Reference><Reference><Citation>Young-Pearse TL, Chen AC, Chang R, Marquez C, Selkoe DJ. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin &#x3b2;1. Neural Dev. 2008;3:15. doi: 10.1186/1749-8104-3-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-8104-3-15</ArticleId><ArticleId IdType="pmc">PMC2442059</ArticleId><ArticleId IdType="pubmed">18573216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu FH, Mantegazza M, Westenbroek RE, Robbins CA, Kalume F, Burton KA, Spain WJ, McKnight GS, Scheuer T, Catterall WA. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142&#x2013;1149. doi: 10.1038/nn1754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1754</ArticleId><ArticleId IdType="pubmed">16921370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6:27. doi: 10.1186/1750-1326-6-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-27</ArticleId><ArticleId IdType="pmc">PMC3098799</ArticleId><ArticleId IdType="pubmed">21527012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziyatdinova S, Gurevicius K, Kutchiashvili N, Bolkvadze T, Nissinen J, Tanila H, Pitk&#xe4;nen A. Spontaneous epileptiform discharges in a mouse model of Alzheimer's disease are suppressed by antiepileptic drugs that block sodium channels. Epilepsy Res. 2011;94:75&#x2013;85. doi: 10.1016/j.eplepsyres.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eplepsyres.2011.01.003</ArticleId><ArticleId IdType="pubmed">21300523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24627036</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Blood biomarkers for brain injury in concussed professional ice hockey players.</ArticleTitle><Pagination><StartPage>684</StartPage><EndPage>692</EndPage><MedlinePgn>684-92</MedlinePgn></Pagination><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Lack of objective biomarkers for brain damage hampers acute diagnosis and clinical decision making about return to play after sports-related concussion.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether sports-related concussion is associated with elevated levels of blood biochemical markers of injury to the central nervous system and to assess whether plasma levels of these biomarkers predict return to play in professional ice hockey players with sports-related concussion.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Multicenter prospective cohort study involving all 12 teams of the top professional ice hockey league in Sweden, the Swedish Hockey League. Two hundred eighty-eight professional ice hockey players from 12 teams contesting during the 2012-2013 season consented to participate. All players underwent clinical preseason baseline testing regarding concussion assessment measures. Forty-seven players from 2 of the 12 ice hockey teams underwent blood sampling prior to the start of the season. Thirty-five players had a concussion from September 13, 2012, to January 31, 2013; of these players, 28 underwent repeated blood sampling at 1, 12, 36, and 144 hours and when the players returned to play.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Total tau, S-100 calcium-binding protein B, and neuron-specific enolase concentrations in plasma and serum were measured.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Concussed players had increased levels of the axonal injury biomarker total tau(median, 10.0 pg/mL; range, 2.0-102 pg/mL) compared with preseason values (median, 4.5pg/mL; range, 0.06-22.7 pg/mL) (P &lt; .001). The levels of the astroglial injury biomarker S-100 calcium-binding protein B were also increased in players with sports-related concussion(median, 0.075 &#x3bc;g/L; range, 0.037-0.24 &#x3bc;g/L) compared with preseason values (median,0.045 &#x3bc;g/L; range, 0.005-0.45 &#x3bc;g/L) (P &lt; .001). The highest biomarker concentrations of total tau and S-100 calcium-binding protein B were measured immediately after a concussion, and they decreased during rehabilitation. No significant changes were detected in the levels of neuron-specific enolase from preseason values (median, 6.5 &#x3bc;g/L; range,3.45-18.0 &#x3bc;g/L) to postconcussion values (median, 6.1 &#x3bc;g/L; range, 3.6-12.8 &#x3bc;g/L) (P = .10).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Sports-related concussion in professional ice hockey players is associated with acute axonal and astroglial injury. This can be monitored using blood biomarkers, which may be developed into clinical tools to guide sport physicians in the medical counseling of athletes in return-to-play decisions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shahim</LastName><ForeName>Pashtun</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Tegner</LastName><ForeName>Yelverton</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>David H</ForeName><Initials>DH</Initials></Author><Author ValidYN="Y"><LastName>Randall</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Skillb&#xe4;ck</LastName><ForeName>Tobias</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Pazooki</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kallberg</LastName><ForeName>Birgitta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Jun;71(6):677-8. doi: 10.1001/jamaneurol.2014.443.</RefSource><PMID Version="1">24627000</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Jul 1;71(7):925-6. doi: 10.1001/jamaneurol.2014.1082.</RefSource><PMID Version="1">25023555</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Jul 1;71(7):926-7. doi: 10.1001/jamaneurol.2014.1160.</RefSource><PMID Version="1">25023557</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2016 Sep 1;73(9):1160. doi: 10.1001/jamaneurol.2016.2806.</RefSource><PMID Version="1">27429250</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056352" MajorTopicYN="Y">Athletes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001924" MajorTopicYN="N">Brain Concussion</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006688" MajorTopicYN="N">Hockey</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013548" MajorTopicYN="N" Type="Geographic">Sweden</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24627036</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.367</ArticleId><ArticleId IdType="pii">1846623</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24417410</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5415</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of the American Geriatrics Society</Title><ISOAbbreviation>J Am Geriatr Soc</ISOAbbreviation></Journal><ArticleTitle>Ten-year effects of the advanced cognitive training for independent and vital elderly cognitive training trial on cognition and everyday functioning in older adults.</ArticleTitle><Pagination><StartPage>16</StartPage><EndPage>24</EndPage><MedlinePgn>16-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/jgs.12607</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine the effects of cognitive training on cognitive abilities and everyday function over 10 years.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Ten-year follow-up of a randomized, controlled single-blind trial (Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE)) with three intervention groups and a no-contact control group.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Six U.S. cities.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">A volunteer sample of 2,832 persons (mean baseline age 73.6; 26% African American) living independently.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Ten training sessions for memory, reasoning, or speed of processing; four sessions of booster training 11 and 35 months after initial training.</AbstractText><AbstractText Label="MEASUREMENTS" NlmCategory="METHODS">Objectively measured cognitive abilities and self-reported and performance-based measures of everyday function.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants in each intervention group reported less difficulty with instrumental activities of daily living (IADLs) (memory: effect size = 0.48, 99% confidence interval (CI) = 0.12-0.84; reasoning: effect size = 0.38, 99% CI = 0.02-0.74; speed of processing: effect size = 0.36, 99% CI = 0.01-0.72). At a mean age of 82, approximately 60% of trained participants, versus 50% of controls (P &lt; .05), were at or above their baseline level of self-reported IADL function at 10 years. The reasoning and speed-of-processing interventions maintained their effects on their targeted cognitive abilities at 10 years (reasoning: effect size = 0.23, 99% CI = 0.09-0.38; speed of processing: effect size = 0.66, 99% CI = 0.43-0.88). Memory training effects were no longer maintained for memory performance. Booster training produced additional and durable improvement for the reasoning intervention for reasoning performance (effect size = 0.21, 99% CI = 0.01-0.41) and the speed-of-processing intervention for speed-of-processing performance (effect size = 0.62, 99% CI = 0.31-0.93).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Each Advanced Cognitive Training for Independent and Vital Elderly cognitive intervention resulted in less decline in self-reported IADL compared with the control group. Reasoning and speed, but not memory, training resulted in improved targeted cognitive abilities for 10 years.</AbstractText><CopyrightInformation>&#xa9; 2014, Copyright the Authors Journal compilation &#xa9; 2014, The American Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rebok</LastName><ForeName>George W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Mental Health, Johns Hopkins University, Baltimore, Maryland; Center on Aging and Health, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ball</LastName><ForeName>Karlene</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Guey</LastName><ForeName>Lin T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Richard N</ForeName><Initials>RN</Initials></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hae-Young</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Marsiske</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Tennstedt</LastName><ForeName>Sharon L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Unverzagt</LastName><ForeName>Frederick W</ForeName><Initials>FW</Initials></Author><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Sherry L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><CollectiveName>ACTIVE Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01AG-14260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NR004508</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014260</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NR04508</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 HD042828</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R03 AG023078</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01AG14276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG028740</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014263</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG014289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG14282</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01NR04507</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NR004507</GrantID><Acronym>NR</Acronym><Agency>NINR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Geriatr Soc</MedlineTA><NlmUniqueID>7503062</NlmUniqueID><ISSNLinking>0002-8614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="Y">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057187" MajorTopicYN="N">Independent Living</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008606" MajorTopicYN="N">Mental Processes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cognitive abilities</Keyword><Keyword MajorTopicYN="N">cognitive training</Keyword><Keyword MajorTopicYN="N">elderly</Keyword><Keyword MajorTopicYN="N">everyday function</Keyword><Keyword MajorTopicYN="N">training maintenance</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>Adrienne L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rexroth</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Moser</LastName><ForeName>Lyndsi</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wolinsky</LastName><ForeName>Fredric D</ForeName><Initials>FD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brandt</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cresci</LastName><ForeName>Kay</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gallo</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Talbot</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cannon</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feldman</LastName><ForeName>Henry</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forde</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gee</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartung</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kasten</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kleinman</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Herman</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reed</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoddard</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wright</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hofer</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schaie</LastName><ForeName>K Warner</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Edwards</LastName><ForeName>Jerri</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Owsley</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roenker</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vance</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wadley</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Diehl</LastName><ForeName>Manfred K</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Horgas</LastName><ForeName>Ann L</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lichtenberg</LastName><ForeName>Peter A</ForeName><Initials>PA</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24417410</ArticleId><ArticleId IdType="mid">NIHMS513342</ArticleId><ArticleId IdType="pmc">PMC4055506</ArticleId><ArticleId IdType="doi">10.1111/jgs.12607</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hertzog C, Kramer A, Wilson R, et al. Enrichment effects on adult cognitive development: can the functional capacity of older adults be preserved and enhanced? Psychol Sci. 2008;9(1):1&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">26162004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebok G. State-of-Science Review: SR:E22 UK. Government Foresight Mental Capital and Mental Wellbeing Project. Government Office for Science; 2008. Cognitive training: influence on neuropsychological and brain function in later life.</Citation></Reference><Reference><Citation>Pappa K, Walsh S, Snyder P. Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions. Alzheimers Dement. 2009;5(1):50&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118809</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball K, Berch DB, Helmers KF, et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA. 2002;288(18):2271&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916176</ArticleId><ArticleId IdType="pubmed">12425704</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis SL, Tennstedt SL, Marsiske M, et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA. 2006;296(23):2805&#x2013;2814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2910591</ArticleId><ArticleId IdType="pubmed">17179457</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobe JB, Smith DM, Ball K, et al. ACTIVE: a cognitive intervention trial to promote independence in older adults. Controlled clinical trials. 2001;22(4):453&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2916177</ArticleId><ArticleId IdType="pubmed">11514044</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaridis EN, Rudberg MA, Furner SE, et al. Do activities of daily living have a hierarchical structure? An analysis using the longitudinal study of aging. Journal of gerontology. 1994;49(2):M47&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">8126352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolinsky F, Miller D. Disability concepts and measurement: contributions of the epidemiology of disability to gerontological inquiry. In: Wilmoth J, Ferraro K, editors. Gerontology: Perspectives and issues. Springer Publishing; New York, New York: 2006.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;. a practical method for grading the cognitive state of patients for the clinician. Journal of psychiatric research. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris J, Morris S. ADL Assessment Measures for Use with Frail Elders. In: Teresi J, Lawton M, Holmes D, et al., editors. Measurement in elderly chronic care populations. Springer Publishing Co; New York, NY: 1997.</Citation></Reference><Reference><Citation>Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin Neuropsychol. 1991;5(2):125&#x2013;142.</Citation></Reference><Reference><Citation>Rey A. L&#x2019;examen psychologique dans les cas d&#x2019;enc&#xe9;phalopathie traumatique. (Les problems.). / The psychological examination in cases of traumatic encepholopathy. Problems. Archives de Psychologie. 1941;28:215&#x2013;285.</Citation></Reference><Reference><Citation>Wilson B, Cockburn J, Baddeley A. The Rivermead Behavioural Memory Test. Thames Valley Test Company; 1985. 34 The Square, Titchfield, Fareham, Hampshire PO14 4AF.</Citation></Reference><Reference><Citation>Thurstone L, Thurstone T. Examiner Manual for the SRA Primary Mental Abilities Test (Form 10-14) Science Research Associates; Chicago: 1949.</Citation></Reference><Reference><Citation>Ekstrom R, French J, Harman H, et al. Kit of Factor-Referenced Cognitive Tests (Rev. ed.) Educational Testing Service; Princeton, NJ: 1976.</Citation></Reference><Reference><Citation>Gonda J, Schaie K. Schaie-Thurstone Mental Abilities Test: Word Series Test. Consulting Psychologists Press; Palo Alto, CA: 1985.</Citation></Reference><Reference><Citation>Owsley C, Ball K, Sloane ME, et al. Visual/cognitive correlates of vehicle accidents in older drivers. Psychology and aging. 1991;6(3):403&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">1930757</ArticleId></ArticleIdList></Reference><Reference><Citation>Owsley C, Ball K, McGwin G, Jr., et al. Visual processing impairment and risk of motor vehicle crash among older adults. JAMA. 1998;279(14):1083&#x2013;1088.</Citation><ArticleIdList><ArticleId IdType="pubmed">9546567</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball KK, Beard BL, Roenker DL, et al. Age and visual search: expanding the useful field of view. Journal of the Optical Society of America. 1988;5(12):2210&#x2013;2219.</Citation><ArticleIdList><ArticleId IdType="pubmed">3230491</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JN, Fries BE, Steel K, et al. Comprehensive clinical assessment in community setting: applicability of the MDS-HC. Journal of the American Geriatrics Society. 1997;45(8):1017&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">9256857</ArticleId></ArticleIdList></Reference><Reference><Citation>Landi F, Tua E, Onder G, et al. Minimum data set for home care: a valid instrument to assess frail older people living in the community. Medical care. 2000;38(12):1184&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">11186297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirdes JP, Fries BE, Morris JN, et al. Home care quality indicators (HCQIs) based on the MDS-HC. The Gerontologist. 2004;44(5):665&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">15498842</ArticleId></ArticleIdList></Reference><Reference><Citation>Willis S, Marsiske M. Manual for the Everyday Problems Test. Pennsylvania State University; University Park, PA: 1993.</Citation></Reference><Reference><Citation>Diehl M, Marsiske M, Horgas AL, et al. The Revised Observed Tasks of Daily Living: A performance-based assessment of everyday problem solving in older adults. J Appl Gerontol. 2005;24(3):211&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2153442</ArticleId><ArticleId IdType="pubmed">18160968</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball K. Increased mobility and reducing accidents of older drivers. In: Schaie K, Pietrucha M, editors. Mobility and Transportation in the Elderly. Springer; New York, NY: 2000.</Citation></Reference><Reference><Citation>Owsley C, Sloane M, McGwin G, Jr., et al. Timed instrumental activities of daily living tasks: relationship to cognitive function and everyday performance assessments in older adults. Gerontology. 2002;48(4):254&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">12053117</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown H, Prescott R. Applied Mixed Models in medicine. 2nd Ed. John Wiley; Chichester England; Hoboken NJ: 2006.</Citation></Reference><Reference><Citation>Schafer J. Analysis of Incomplete Multivariate Data. Chapman &amp; Hall; London: 1997.</Citation></Reference><Reference><Citation>van-Buuren S, Oudshoorn C. The mice Package: Multivariate Imputation by Chained Equations. 2007.</Citation></Reference><Reference><Citation>Team RDC . R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2008.</Citation></Reference><Reference><Citation>Abdi H, editor. Bonferroni and Sid&#xe1;k corrections for multiple comparisons. Sage; Thousand Oaks, CA: 2007.</Citation></Reference><Reference><Citation>Dudek F. The continuing misinterpretation of the standard error of measurement. Psychological Bulletin. 1979;86(2):335&#x2013;337.</Citation></Reference><Reference><Citation>Garrett H. Statistics in psychology and education. Longsman; New York: 1937.</Citation></Reference><Reference><Citation>Scogin F, Bienias JL. A three-year follow-up of older adult participants in a memory-skills training program. Psychology and aging. 1988;3(4):334&#x2013;337.</Citation><ArticleIdList><ArticleId IdType="pubmed">3268276</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer T, Lindenberger U, Baltes PB. Plasticity of memory for new learning in very old age: a story of major loss? Psychology and aging. 2003;18(2):306&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">12825778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer&#x2019;s pathological cascade. Lancet neurology. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaie K. Developmental influences on adult intellectual development: The Seattle Longitudinal Study. Oxford University Press; New York: 2005.</Citation></Reference><Reference><Citation>Kelly AM, Garavan H. Human functional neuroimaging of brain changes associated with practice. Cereb Cortex. 2005;15(8):1089&#x2013;1102.</Citation><ArticleIdList><ArticleId IdType="pubmed">15616134</ArticleId></ArticleIdList></Reference><Reference><Citation>May A, Hajak G, Ganssbauer S, et al. Structural brain alterations following 5 days of intervention: dynamic aspects of neuroplasticity. Cereb Cortex. 2007;17(1):205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481564</ArticleId></ArticleIdList></Reference><Reference><Citation>Beland F, Zunzunegui MV. Predictors of functional status in older people living at home. Age and ageing. 1999 Mar;28(2):153&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">10350412</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumgartner RN, Wayne SJ, Waters DL, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obesity research. 2004 Dec;12(12):1995&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">15687401</ArticleId></ArticleIdList></Reference><Reference><Citation>Royall D, Lauterbach E, Kaufer D, et al. The cognitive correlates of functional status: a review from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 2007;19(3):249&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">17827410</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JK, Lui LY, Yaffe K. Executive function, more than global cognition, predicts functional decline and mortality in elderly women. J Gerontol A Biol Sci Med Sci. 2007 Oct;62(10):1134&#x2013;1141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2049089</ArticleId><ArticleId IdType="pubmed">17921427</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowler WC, Fowler SE, Hamman RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374(9702):1677&#x2013;1686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135022</ArticleId><ArticleId IdType="pubmed">19878986</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlson MC, Xue QL, Zhou J, et al. Executive decline and dysfunction precedes declines in memory: the Women&#x2019;s Health and Aging Study II. The journals of gerontology. 2009;64(1):110&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691188</ArticleId><ArticleId IdType="pubmed">19182230</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao S, Thi&#xe9;baut R. Mixed-effect models for truncated longitudinal outcomes with nonignorable missing data. J Data Sci. 2009;7(1):27&#x2013;42.</Citation></Reference><Reference><Citation>Park S, Palta M, Shao J, et al. Bias adjustment in analysing longitudinal data with informative missingness. Statistics in medicine. 2002 Jan 30;21(2):277&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11782065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer&#x2019;s disease, 2000-2050: potential implication of treatment advances. Annual review of public health. 2002;23:213&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">11910061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24648338</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>228</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>The A4 study: stopping AD before symptoms begin?</ArticleTitle><Pagination><StartPage>228fs13</StartPage><MedlinePgn>228fs13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3007941</ELocationID><Abstract><AbstractText>A new secondary prevention trial in older people with amyloid accumulation at high risk for Alzheimer's disease dementia should provide insights into whether anti-amyloid therapy can delay cognitive decline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Karlawish</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000682">Amyloid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000682" MajorTopicYN="N">Amyloid</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24648338</ArticleId><ArticleId IdType="mid">NIHMS589017</ArticleId><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3007941</ArticleId><ArticleId IdType="pii">6/228/228fs13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7:280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N Engl J Med. 2012;367:795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer&#x2019;s disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr., Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3:111cm33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Grill JD, Karlawish J, Elashoff D, Vickrey BG. Risk disclosure and preclinical Alzheimer&#x2019;s disease clinical trial enrollment. Alzheimers Dement. 2013;9:356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572336</ArticleId><ArticleId IdType="pubmed">23141383</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2008;14:266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K, Carmasin J, Maye JE, Johnson KA, Sperling RA. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49:2776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137730</ArticleId><ArticleId IdType="pubmed">21689670</ArticleId></ArticleIdList></Reference><Reference><Citation>Stark SM, Yassa MA, Stark CE. Individual differences in spatial pattern separation performance associated with healthy aging in humans. Learn Mem. 2010;17:284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2884287</ArticleId><ArticleId IdType="pubmed">20495062</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer&#x2019;s disease. N Engl J Med. 2013;368:1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, Ebrahim S. Statins for the primary prevention of cardiovascular disease. The Cochrane database of systematic reviews. 2011:CD004816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4164175</ArticleId><ArticleId IdType="pubmed">21249663</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24647946</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.</ArticleTitle><Pagination><StartPage>4260</StartPage><EndPage>4272</EndPage><MedlinePgn>4260-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3192-13.2014</ELocationID><Abstract><AbstractText>Recent findings suggest that tau oligomers, which form before neurofibrillary tangles (NFTs), are the true neurotoxic tau entities in neurodegenerative tauopathies, including Alzheimer's disease (AD). Studies in animal models of tauopathy suggest that tau oligomers play a key role in eliciting behavioral and cognitive impairments. Here, we used a novel tau oligomer-specific monoclonal antibody (TOMA) for passive immunization in mice expressing mutant human tau. A single dose of TOMA administered either intravenously or intracerebroventricularly was sufficient to reverse both locomotor and memory deficits in a mouse model of tauopathy for 60 d, coincident with rapid reduction of tau oligomers but not phosphorylated NFTs or monomeric tau. Our data demonstrate that antibody protection is mediated by extracellular and rapid peripheral clearance. These findings provide the first direct evidence in support of a critical role for tau oligomers in disease progression and validate tau oligomers as a target for the treatment of AD and other neurodegenerative tauopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Castillo-Carranza</LastName><ForeName>Diana L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Mitchell Center for Neurodegenerative Diseases, Departments of Neurology, Neuroscience, and Cell Biology, Sealy Center for Vaccine Development, University of Texas Medical Branch, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Urmi</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Guerrero-Mu&#xf1;oz</LastName><ForeName>Marcos J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Lasagna-Reeves</LastName><ForeName>Cristian A</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>Gerson</LastName><ForeName>Julia E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Gurpreet</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Estes</LastName><ForeName>D Mark</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Barrett</LastName><ForeName>Alan D T</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Dineley</LastName><ForeName>Kelly T</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>George R</ForeName><Initials>GR</Initials></Author><Author ValidYN="Y"><LastName>Kayed</LastName><ForeName>Rakez</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">immunotherapy</Keyword><Keyword MajorTopicYN="N">tau oligomers</Keyword><Keyword MajorTopicYN="N">tauopathies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24647946</ArticleId><ArticleId IdType="pmc">PMC6608097</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3192-13.2014</ArticleId><ArticleId IdType="pii">34/12/4260</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007;27:9115&#x2013;9129. doi: 10.1523/JNEUROSCI.2361-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2361-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672191</ArticleId><ArticleId IdType="pubmed">17715348</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26&#x2013;35. doi: 10.1007/s004010100423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100423</ArticleId><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, Yang NY, Desplats P, Masliah E, Lee SJ. Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci. 2012;32:13454&#x2013;13469. doi: 10.1523/JNEUROSCI.1292-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1292-12.2012</ArticleId><ArticleId IdType="pmc">PMC3752153</ArticleId><ArticleId IdType="pubmed">23015436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007;8:663&#x2013;672. doi: 10.1038/nrn2194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2194</ArticleId><ArticleId IdType="pubmed">17684513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919. doi: 10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, Wszolek Z, Ashe K, Knight J, Dickson D, Andorfer C, Rosenberry TL, Lewis J, Hutton M, Janus C. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci. 2007;27:3650&#x2013;3662. doi: 10.1523/JNEUROSCI.0587-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0587-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672413</ArticleId><ArticleId IdType="pubmed">17409229</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi M, Ittner A, Ke YD, G&#xf6;tz J, Ittner LM. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One. 2011;6:e26860. doi: 10.1371/journal.pone.0026860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0026860</ArticleId><ArticleId IdType="pmc">PMC3234245</ArticleId><ArticleId IdType="pubmed">22174735</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC, 3rd, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C, Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE, Berchtold N, Dickey CA. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013;123:4158&#x2013;4169. doi: 10.1172/JCI69003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI69003</ArticleId><ArticleId IdType="pmc">PMC3784538</ArticleId><ArticleId IdType="pubmed">23999428</ArticleId></ArticleIdList></Reference><Reference><Citation>Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol. 2010;224:472&#x2013;485. doi: 10.1016/j.expneurol.2010.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.05.010</ArticleId><ArticleId IdType="pubmed">20546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011;118:658&#x2013;667. doi: 10.1111/j.1471-4159.2011.07337.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07337.x</ArticleId><ArticleId IdType="pmc">PMC3366469</ArticleId><ArticleId IdType="pubmed">21644996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: Stability and functional significance. Neurology. 2007;68:1809&#x2013;1814. doi: 10.1212/01.wnl.0000262031.18018.1a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000262031.18018.1a</ArticleId><ArticleId IdType="pmc">PMC2668699</ArticleId><ArticleId IdType="pubmed">17515542</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R. Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) 2013a;5:426&#x2013;438.</Citation><ArticleIdList><ArticleId IdType="pubmed">23277060</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo-Carranza DL, Guerrero-Mu&#xf1;oz MJ, Kayed R. Immunotherapy for the treatment of Alzheimer's disease: amyloid-&#x3b2; or tau, which is the right target? ImmunoTargets and Therapy. 2013b;2014:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918231</ArticleId><ArticleId IdType="pubmed">27471697</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem. 2011;286:34457&#x2013;34467. doi: 10.1074/jbc.M111.229633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.229633</ArticleId><ArticleId IdType="pmc">PMC3190817</ArticleId><ArticleId IdType="pubmed">21841002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res. 2007;85:451&#x2013;463. doi: 10.1002/jnr.21110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21110</ArticleId><ArticleId IdType="pubmed">17086547</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan NB, Siegel GJ. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res. 2003;74:142&#x2013;147. doi: 10.1002/jnr.10721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10721</ArticleId><ArticleId IdType="pubmed">13130516</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowan CM, Quraishe S, Mudher A. What is the pathological significance of tau oligomers? Biochem Soc Trans. 2012;40:693&#x2013;697. doi: 10.1042/BST20120135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20120135</ArticleId><ArticleId IdType="pubmed">22817718</ArticleId></ArticleIdList></Reference><Reference><Citation>d'Abramo C, Acker CM, Jimenez HT, Davies P. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One. 2013;8:e62402. doi: 10.1371/journal.pone.0062402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062402</ArticleId><ArticleId IdType="pmc">PMC3639259</ArticleId><ArticleId IdType="pubmed">23638068</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001;98:8850&#x2013;8855. doi: 10.1073/pnas.151261398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.151261398</ArticleId><ArticleId IdType="pmc">PMC37524</ArticleId><ArticleId IdType="pubmed">11438712</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox LM, William CM, Adamowicz DH, Pitstick R, Carlson GA, Spires-Jones TL, Hyman BT. Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol. 2011;70:588&#x2013;595. doi: 10.1097/NEN.0b013e318220a658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318220a658</ArticleId><ArticleId IdType="pmc">PMC3118928</ArticleId><ArticleId IdType="pubmed">21666499</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159. doi: 10.1038/nrn2786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2786</ArticleId><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallyas F. Physicochemical mechanisms of histological silver staining and their utilization for rendering individual silver methods selective and reliable. Biotech Histochem. 2008;83:221&#x2013;238. doi: 10.1080/10520290802538543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10520290802538543</ArticleId><ArticleId IdType="pubmed">19016367</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerson JE, Kayed R. Formation and propagation of tau oligomeric seeds. Front Neurol. 2013;4:93. doi: 10.3389/fneur.2013.00093.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00093</ArticleId><ArticleId IdType="pmc">PMC3713404</ArticleId><ArticleId IdType="pubmed">23882255</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Das P, Levites Y. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets. 2009;8:31&#x2013;49. doi: 10.2174/187152709787601830.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152709787601830</ArticleId><ArticleId IdType="pubmed">19275635</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17&#x2013;24. doi: 10.1002/ana.410410106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410106</ArticleId><ArticleId IdType="pubmed">9005861</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Sigurdsson EM. Immunotherapy for tauopathies. J Mol Neurosci. 2011;45:690&#x2013;695. doi: 10.1007/s12031-011-9576-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9576-5</ArticleId><ArticleId IdType="pmc">PMC3265133</ArticleId><ArticleId IdType="pubmed">21739165</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzm&#xe1;n-Martinez L, Far&#xed;as GA, Maccioni RB. Tau Oligomers as Potential Targets for Alzheimer's Diagnosis and Novel Drugs. Front Neurol. 2013;4:167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3808896</ArticleId><ArticleId IdType="pubmed">24191153</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroutunian V, Davies P, Vianna C, Buxbaum JD, Purohit DP. Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiol Aging. 2007;28:1&#x2013;7. doi: 10.1016/j.neurobiolaging.2005.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2005.11.001</ArticleId><ArticleId IdType="pubmed">16343696</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins BE, Krishnamurthy S, Castillo-Carranza DL, Sengupta U, Prough DS, Jackson GR, DeWitt DS, Kayed R. Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem. 2013;288:17042&#x2013;17050. doi: 10.1074/jbc.M113.472746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M113.472746</ArticleId><ArticleId IdType="pmc">PMC3675635</ArticleId><ArticleId IdType="pubmed">23632019</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, Saing T, Gylys KH. Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol. 2012;22:826&#x2013;833. doi: 10.1111/j.1750-3639.2012.00598.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1750-3639.2012.00598.x</ArticleId><ArticleId IdType="pmc">PMC3410970</ArticleId><ArticleId IdType="pubmed">22486774</ArticleId></ArticleIdList></Reference><Reference><Citation>Holcomb LA, Gordon MN, Jantzen P, Hsiao K, Duff K, Morgan D. Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet. 1999;29:177&#x2013;185. doi: 10.1023/A:1021691918517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1021691918517</ArticleId><ArticleId IdType="pubmed">10547924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012;287:19440&#x2013;19451. doi: 10.1074/jbc.M112.346072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.346072</ArticleId><ArticleId IdType="pmc">PMC3365982</ArticleId><ArticleId IdType="pubmed">22461630</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnamurthy PK, Deng Y, Sigurdsson EM. Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry. 2011;2:59. doi: 10.3389/fpsyt.2011.00059.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2011.00059</ArticleId><ArticleId IdType="pmc">PMC3198029</ArticleId><ArticleId IdType="pubmed">22025915</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochemistry. 2010;49:10039&#x2013;10041. doi: 10.1021/bi1016233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi1016233</ArticleId><ArticleId IdType="pubmed">21047142</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Glabe CG, Kayed R. Amyloid-{beta} annular protofibrils evade fibrillar fate in Alzheimer's disease brain. J Biol Chem. 2011a;286:22122&#x2013;22130. doi: 10.1074/jbc.M111.236257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.236257</ArticleId><ArticleId IdType="pmc">PMC3121356</ArticleId><ArticleId IdType="pubmed">21507938</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2011b;8:659&#x2013;665. doi: 10.2174/156720511796717177.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720511796717177</ArticleId><ArticleId IdType="pubmed">21605039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed R. Tau Oligomers Impair Memory and Induce Synaptic and Mitochondrial Dysfunction in Wild-type Mice. Mol Neurodegener. 2011c;6:39. doi: 10.1186/1750-1326-6-39.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-39</ArticleId><ArticleId IdType="pmc">PMC3224595</ArticleId><ArticleId IdType="pubmed">21645391</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, Kayed R. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J. 2012a;26:1946&#x2013;1959. doi: 10.1096/fj.11-199851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.11-199851</ArticleId><ArticleId IdType="pmc">PMC4046102</ArticleId><ArticleId IdType="pubmed">22253473</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012b;2:700. doi: 10.1038/srep00700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep00700</ArticleId><ArticleId IdType="pmc">PMC3463004</ArticleId><ArticleId IdType="pubmed">23050084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE. Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. Neurobiol Dis. 2003;14:10&#x2013;18. doi: 10.1016/S0969-9961(03)00044-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00044-5</ArticleId><ArticleId IdType="pubmed">13678662</ArticleId></ArticleIdList></Reference><Reference><Citation>Levites Y, Smithson LA, Price RW, Dakin RS, Yuan B, Sierks MR, Kim J, McGowan E, Reed DK, Rosenberry TL, Das P, Golde TE. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FASEB J. 2006;20:2576&#x2013;2578. doi: 10.1096/fj.06-6463fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6463fje</ArticleId><ArticleId IdType="pubmed">17068112</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW, Davies P, Hutton M. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402&#x2013;405. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA. Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem. 2013;288:4056&#x2013;4065. doi: 10.1074/jbc.M112.393751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.393751</ArticleId><ArticleId IdType="pmc">PMC3567657</ArticleId><ArticleId IdType="pubmed">23264626</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeda S, Sahara N, Saito Y, Murayama S, Ikai A, Takashima A. Increased levels of granular tau oligomers: an early sign of brain aging and Alzheimer's disease. Neurosci Res. 2006;54:197&#x2013;201. doi: 10.1016/j.neures.2005.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2005.11.009</ArticleId><ArticleId IdType="pubmed">16406150</ArticleId></ArticleIdList></Reference><Reference><Citation>Margittai M, Langen R. Template-assisted filament growth by parallel stacking of tau. Proc Natl Acad Sci U S A. 2004;101:10278&#x2013;10283. doi: 10.1073/pnas.0401911101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401911101</ArticleId><ArticleId IdType="pmc">PMC478563</ArticleId><ArticleId IdType="pubmed">15240881</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron. 2005;46:857&#x2013;868. doi: 10.1016/j.neuron.2005.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.05.010</ArticleId><ArticleId IdType="pubmed">15953415</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338. doi: 10.1371/journal.pone.0019338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019338</ArticleId><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D. Immunotherapy for Alzheimer's disease. J Intern Med. 2011;269:54&#x2013;63. doi: 10.1111/j.1365-2796.2010.02315.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2010.02315.x</ArticleId><ArticleId IdType="pmc">PMC3074967</ArticleId><ArticleId IdType="pubmed">21158978</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Munireddy S, Alamed J, DeLeon J, Diamond DM, Bickford P, Hutton M, Lewis J, McGowan E, Gordon MN. Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice. J Alzheimers Dis. 2008;15:605&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3018352</ArticleId><ArticleId IdType="pubmed">19096159</ArticleId></ArticleIdList></Reference><Reference><Citation>Morsch R, Simon W, Coleman PD. Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol. 1999;58:188&#x2013;197. doi: 10.1097/00005072-199902000-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005072-199902000-00008</ArticleId><ArticleId IdType="pubmed">10029101</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321&#x2013;332. doi: 10.1016/j.neuron.2004.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.07.003</ArticleId><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson KR, Remmers C, Fu Y, Brooker S, Kanaan NM, Vana L, Ward S, Reyes JF, Philibert K, Glucksman MJ, Binder LI. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. J Biol Chem. 2011;286:23063&#x2013;23076. doi: 10.1074/jbc.M111.237974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.237974</ArticleId><ArticleId IdType="pmc">PMC3123074</ArticleId><ArticleId IdType="pubmed">21550980</ArticleId></ArticleIdList></Reference><Reference><Citation>Polydoro M, Acker CM, Duff K, Castillo PE, Davies P. Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci. 2009;29:10741&#x2013;10749. doi: 10.1523/JNEUROSCI.1065-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1065-09.2009</ArticleId><ArticleId IdType="pmc">PMC2760256</ArticleId><ArticleId IdType="pubmed">19710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369. doi: 10.1073/pnas.092136199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.092136199</ArticleId><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006;63:1459&#x2013;1467. doi: 10.1001/archneur.63.10.1459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.63.10.1459</ArticleId><ArticleId IdType="pubmed">17030663</ArticleId></ArticleIdList></Reference><Reference><Citation>Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476&#x2013;481. doi: 10.1126/science.1113694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1113694</ArticleId><ArticleId IdType="pmc">PMC1574647</ArticleId><ArticleId IdType="pubmed">16020737</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics. 2008;5:443&#x2013;457. doi: 10.1016/j.nurt.2008.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nurt.2008.05.006</ArticleId><ArticleId IdType="pmc">PMC5084246</ArticleId><ArticleId IdType="pubmed">18625456</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdsson EM. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis. 2008;15:157&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757121</ArticleId><ArticleId IdType="pubmed">18953105</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Kopeikina KJ, Koffie RM, de Calignon A, Hyman BT. Are tangles as toxic as they look? J Mol Neurosci. 2011;45:438&#x2013;444. doi: 10.1007/s12031-011-9566-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9566-7</ArticleId><ArticleId IdType="pmc">PMC3173560</ArticleId><ArticleId IdType="pubmed">21638071</ArticleId></ArticleIdList></Reference><Reference><Citation>Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, Laferla FM. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol. 2011;178:2811&#x2013;2822. doi: 10.1016/j.ajpath.2011.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2011.02.012</ArticleId><ArticleId IdType="pmc">PMC3124234</ArticleId><ArticleId IdType="pubmed">21531375</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426&#x2013;1435. doi: 10.1016/j.ajpath.2012.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.06.033</ArticleId><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD. Do neuronal inclusions kill the cell? J Neural Transm Suppl. 2000;59:91&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961422</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A. 2009;106:4501&#x2013;4506. doi: 10.1073/pnas.0813404106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0813404106</ArticleId><ArticleId IdType="pmc">PMC2647980</ArticleId><ArticleId IdType="pubmed">19246392</ArticleId></ArticleIdList></Reference><Reference><Citation>Troquier L, Caillierez R, Burnouf S, Fernandez-G&#xf3;mez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012;9:397&#x2013;405. doi: 10.2174/156720512800492503.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720512800492503</ArticleId><ArticleId IdType="pmc">PMC3637173</ArticleId><ArticleId IdType="pubmed">22272619</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubhi K, Masliah E. Recent advances in the development of immunotherapies for tauopathies. Exp Neurol. 2011;230:157&#x2013;161. doi: 10.1016/j.expneurol.2010.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2010.10.007</ArticleId><ArticleId IdType="pmc">PMC3125641</ArticleId><ArticleId IdType="pubmed">20970422</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Nes JA, Nafe R, Schlote W. Non-tau based neuronal degeneration in Alzheimer's disease&#x2013;an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex. Brain Res. 2008;1213:152&#x2013;165. doi: 10.1016/j.brainres.2008.03.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2008.03.043</ArticleId><ArticleId IdType="pubmed">18455153</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004;24:6144&#x2013;6151. doi: 10.1523/JNEUROSCI.1090-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1090-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler DT, Abramowski D, Danner S, Zurini M, Paganetti P, Tolnay M, Staufenbiel M. Rapid cerebral amyloid binding by Abeta antibodies infused into beta-amyloid precursor protein transgenic mice. Biol Psychiatry. 2010;68:971&#x2013;974. doi: 10.1016/j.biopsych.2010.01.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2010.01.030</ArticleId><ArticleId IdType="pubmed">20359696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, Feany MB. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711&#x2013;714. doi: 10.1126/science.1062382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062382</ArticleId><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JW, Herman M, Liu L, Simoes S, Acker CM, Figueroa H, Steinberg JI, Margittai M, Kayed R, Zurzolo C, Di Paolo G, Duff KE. Small misfolded tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem. 2013;288:1856&#x2013;1870. doi: 10.1074/jbc.M112.394528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.394528</ArticleId><ArticleId IdType="pmc">PMC3548495</ArticleId><ArticleId IdType="pubmed">23188818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009;29:11393&#x2013;11398. doi: 10.1523/JNEUROSCI.2021-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2021-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665926</ArticleId><ArticleId IdType="pubmed">19741145</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414. doi: 10.1016/j.neuron.2013.07.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.046</ArticleId><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351. doi: 10.1016/j.neuron.2007.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.01.010</ArticleId><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24652937</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>344</Volume><Issue>6180</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>PINK1 loss-of-function mutations affect mitochondrial complex I activity via NdufA10 ubiquinone uncoupling.</ArticleTitle><Pagination><StartPage>203</StartPage><EndPage>207</EndPage><MedlinePgn>203-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1249161</ELocationID><Abstract><AbstractText>Under resting conditions, Pink1 knockout cells and cells derived from patients with PINK1 mutations display a loss of mitochondrial complex I reductive activity, causing a decrease in the mitochondrial membrane potential. Analyzing the phosphoproteome of complex I in liver and brain from Pink1(-/-) mice, we found specific loss of phosphorylation of serine-250 in complex I subunit NdufA10. Phosphorylation of serine-250 was needed for ubiquinone reduction by complex I. Phosphomimetic NdufA10 reversed Pink1 deficits in mouse knockout cells and rescued mitochondrial depolarization and synaptic transmission defects in pink(B9)-null mutant Drosophila. Complex I deficits and adenosine triphosphate synthesis were also rescued in cells derived from PINK1 patients. Thus, this evolutionary conserved pathway may contribute to the pathogenic cascade that eventually leads to Parkinson's disease in patients with PINK1 mutations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morais</LastName><ForeName>Vanessa A</ForeName><Initials>VA</Initials><AffiliationInfo><Affiliation>VIB Center for the Biology of Disease, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Dominik</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Craessaerts</LastName><ForeName>Katleen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>De Bock</LastName><ForeName>Pieter-Jan</ForeName><Initials>PJ</Initials></Author><Author ValidYN="Y"><LastName>Swerts</LastName><ForeName>Jef</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Vilain</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Aerts</LastName><ForeName>Liesbeth</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Overbergh</LastName><ForeName>Lut</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gr&#xfc;newald</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Seibler</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gevaert</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Verstreken</LastName><ForeName>Patrik</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>De Strooper</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029721">Drosophila Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000602554">ND-42 protein, Drosophila</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="D009245">NADH Dehydrogenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.6.99.3</RegistryNumber><NameOfSubstance UI="C588033">NdufA10 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 7.1.1.2</RegistryNumber><NameOfSubstance UI="D042967">Electron Transport Complex I</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029721" MajorTopicYN="N">Drosophila Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042967" MajorTopicYN="N">Electron Transport Complex I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053078" MajorTopicYN="N">Membrane Potential, Mitochondrial</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018345" MajorTopicYN="N">Mice, Knockout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009245" MajorTopicYN="N">NADH Dehydrogenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24652937</ArticleId><ArticleId IdType="doi">10.1126/science.1249161</ArticleId><ArticleId IdType="pii">science.1249161</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24656814</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Detection of misfolded A&#x3b2; oligomers for sensitive biochemical diagnosis of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>268</EndPage><MedlinePgn>261-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.02.031</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)00145-4</ELocationID><Abstract><AbstractText>Alzheimer's disease (AD) diagnosis is hampered by the lack of early, sensitive, and objective laboratory tests. We describe a sensitive method for biochemical diagnosis of AD based on specific detection of misfolded A&#x3b2; oligomers, which play a central role in AD pathogenesis. The protein misfolding cyclic amplification assay (A&#x3b2;-PMCA), exploits the functional property of A&#x3b2; oligomers to seed the polymerization of monomeric A&#x3b2;. A&#x3b2;-PMCA allowed detection of as little as 3 fmol of A&#x3b2; oligomers. Most importantly, using cerebrospinal fluid, we were able to distinguish AD patients from control individuals affected by a variety of other neurodegenerative disorders or nondegenerative neurological diseases with overall sensitivity of 90% and specificity of 92%. These findings provide the proof-of-principle basis for developing a highly sensitive and specific biochemical test for AD diagnosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Salvadores</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Medical School at&#xa0;Houston, 6431 Fannin Street, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahnawaz</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Medical School at&#xa0;Houston, 6431 Fannin Street, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarpini</LastName><ForeName>Elio</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurology Unit, Universit&#xe0; di Milano, Centro Dino Ferrari, Fondazione Ca' Granda, IRCC Ospedale Policlinico, via F. Sforza 35, 20122 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tagliavini</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IRCCS Foundation "Carlo Besta" Neurological Institute, Via Celoria 11, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soto</LastName><ForeName>Claudio</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mitchell Center for Alzheimer's Disease and Related Brain Disorders, Department of Neurology, University of Texas Medical School at&#xa0;Houston, 6431 Fannin Street, Houston, TX 77030, USA. Electronic address: claudio.soto@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017510" MajorTopicYN="N">Protein Folding</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24656814</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.02.031</ArticleId><ArticleId IdType="pii">S2211-1247(14)00145-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24659240</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Amyloidogenic &#x3b1;-synuclein seeds do not invariably induce rapid, widespread pathology in mice.</ArticleTitle><Pagination><StartPage>645</StartPage><EndPage>665</EndPage><MedlinePgn>645-65</MedlinePgn></Pagination><Abstract><AbstractText>In order to further evaluate the parameters whereby intracerebral administration of recombinant &#x3b1;-synuclein (&#x3b1;S) induces pathological phenotypes in mice, we conducted a series of studies where &#x3b1;S fibrils were injected into the brains of M83 (A53T) and M47 (E46K) &#x3b1;S transgenic (Tg) mice, and non-transgenic (nTg) mice. Using multiple markers to assess &#x3b1;S inclusion formation, we find that injected fibrillar human &#x3b1;S induced widespread cerebral &#x3b1;S inclusion formation in the M83 Tg mice, but in both nTg and M47 Tg mice, induced &#x3b1;S inclusion pathology is largely restricted to the site of injection. Furthermore, mouse &#x3b1;S fibrils injected into nTg mice brains also resulted in inclusion pathology restricted to the site of injection with no evidence for spread. We find no compelling evidence for extensive spread of &#x3b1;S pathology within white matter tracts, and we attribute previous reports of white matter tract spreading to cross-reactivity of the &#x3b1;S pSer129/81A antibody with phosphorylated neurofilament subunit L. These studies suggest that, with the exception of the M83 Tg mice which appear to be uniquely susceptible to induction of inclusion pathology by exogenous forms of &#x3b1;S, there are significant barriers in mice to widespread induction of &#x3b1;S pathology following intracerebral administration of amyloidogenic &#x3b1;S.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sacino</LastName><ForeName>Amanda N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Brooks</LastName><ForeName>Mieu</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>McKinney</LastName><ForeName>Alex B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>McGarvey</LastName><ForeName>Nicholas H</ForeName><Initials>NH</Initials></Author><Author ValidYN="Y"><LastName>Rutherford</LastName><ForeName>Nicola J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Ceballos-Diaz</LastName><ForeName>Carolina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>Janice</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Golde</LastName><ForeName>Todd E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Giasson</LastName><ForeName>Benoit I</ForeName><Initials>BI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG047266</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS082672</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497604">SNCA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497605">Snca protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Acta Neuropathol. 2014 Dec;128(6):897-8</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018014" MajorTopicYN="N">Gene Transfer Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009413" MajorTopicYN="N">Nerve Fibers, Myelinated</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009457" MajorTopicYN="N">Neuroglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013045" MajorTopicYN="N">Species Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest</b>. The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24659240</ArticleId><ArticleId IdType="mid">NIHMS578648</ArticleId><ArticleId IdType="pmc">PMC4869357</ArticleId><ArticleId IdType="doi">10.1007/s00401-014-1268-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, Shinsky N, Verdugo JM, Armanini M, Ryan A, Hynes M, Phillips H, Sulzer D, Rosenthal A. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 2000;25 (1):239&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">10707987</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol. 2007;8 (7):552&#x2013;561. doi: 10.1038/nrm2204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2204</ArticleId><ArticleId IdType="pubmed">17585315</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res. 2011;69 (4):337&#x2013;342. doi: 10.1016/j.neures.2010.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2010.12.020</ArticleId><ArticleId IdType="pubmed">21255620</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006;281 (40):29739&#x2013;29752. doi: 10.1074/jbc.M600933200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M600933200</ArticleId><ArticleId IdType="pubmed">16847063</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, Weir D, Thompson C, Szu-Tu C, Trinh J, Aasly JO, Rajput A, Rajput AH, Jon SA, Farrer MJ. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson&#x2019;s disease. Mov Disord. 2013;28:811&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">23457019</ArticleId></ArticleIdList></Reference><Reference><Citation>Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White CL, III, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG Arizona Parkinson&#x2019;s Disease C. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119 (6):689&#x2013;702. doi: 10.1007/s00401-010-0664-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0664-3</ArticleId><ArticleId IdType="pmc">PMC2866090</ArticleId><ArticleId IdType="pubmed">20306269</ArticleId></ArticleIdList></Reference><Reference><Citation>Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA. alpha-Synuclein Alters Toll-Like Receptor Expression. Front Neurosci. 2011;5:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128248</ArticleId><ArticleId IdType="pubmed">21747756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, Bockmann A, Meier BH, Melki R. Structural and functional characterization of two alpha-synuclein strains. Nature Commun. 2013;4:2575. doi: 10.1038/ncomms3575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms3575</ArticleId><ArticleId IdType="pmc">PMC3826637</ArticleId><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson&#x2019;s disease pathology spread. Nat Rev Neurosci. 2008;9 (10):741&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">18769444</ArticleId></ArticleIdList></Reference><Reference><Citation>Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de BM. Triggering of inflammasome by aggregated alpha-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013;8 (1):e55375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3561263</ArticleId><ArticleId IdType="pubmed">23383169</ArticleId></ArticleIdList></Reference><Reference><Citation>Comellas G, Lemkau LR, Nieuwkoop AJ, Kloepper KD, Ladror DT, Ebisu R, Woods WS, Lipton AS, George JM, Rienstra CM. Structured regions of alpha-synuclein fibrils include the early-onset Parkinson&#x2019;s disease mutation sites. J Mol Biol. 2011;411 (4):881&#x2013;895. doi: 10.1016/j.jmb.2011.06.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2011.06.026</ArticleId><ArticleId IdType="pmc">PMC3157309</ArticleId><ArticleId IdType="pubmed">21718702</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway KA, Harper JD, Lansbury PT. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998;4 (11):1318&#x2013;1320.</Citation><ArticleIdList><ArticleId IdType="pubmed">9809558</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. The biochemistry of Parkinson&#x2019;s disease. Annu Rev Biochem. 2005;74:29&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">15952880</ArticleId></ArticleIdList></Reference><Reference><Citation>Couch Y, Alvarez-Erviti L, Sibson NR, Wood MJ, Anthony DC. The acute inflammatory response to intranigral alpha-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation. 2011;8:166. doi: 10.1186/1742-2094-8-166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-8-166</ArticleId><ArticleId IdType="pmc">PMC3239418</ArticleId><ArticleId IdType="pubmed">22122884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremades N, Cohen SI, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TP, Dobson CM, Klenerman D. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell. 2012;149 (5):1048&#x2013;1059. doi: 10.1016/j.cell.2012.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.03.037</ArticleId><ArticleId IdType="pmc">PMC3383996</ArticleId><ArticleId IdType="pubmed">22632969</ArticleId></ArticleIdList></Reference><Reference><Citation>Crystal AS, Giasson BI, Crowe A, Kung MP, Zhuang ZP, Trojanowski JQ, Lee VM. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J Neurochem. 2003;86 (6):1359&#x2013;1368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12950445</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27 (34):9220&#x2013;9232. doi: 10.1523/JNEUROSCI.2617-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2617-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672196</ArticleId><ArticleId IdType="pubmed">17715357</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson WS, Jonas A, Clayton DF, George JM. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273 (16):9443&#x2013;9449.</Citation><ArticleIdList><ArticleId IdType="pubmed">9545270</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryanovski DI, Guzman JN, Xie Z, Galteri DJ, Volpicelli-Daley LA, Lee VM, Miller RJ, Schumacker PT, Surmeier DJ. Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J Neurosci. 2013;33 (24):10154&#x2013;10164. doi: 10.1523/JNEUROSCI.5311-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5311-12.2013</ArticleId><ArticleId IdType="pmc">PMC3682382</ArticleId><ArticleId IdType="pubmed">23761910</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VMY, Trojanowski JQ. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol. 2000;59 (9):830&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">11005264</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanoswki JQ. Novel antibodies to oxidized &#x3b1;-synuclein reveal abundant neuritic pathology in Lewy body disease. Ann Neurol. 2002;52:205&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210791</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, Bianchi E, Pessi A, Neill D, Wallace A. Aggregates from mutant and wild-type alpha-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of beta-sheet and amyloid-like filaments. FEBS letters. 1998;440 (1&#x2013;2):71&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">9862428</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmer KL, Waxman EA, Covy JP, Giasson BI. E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment. J Biol Chem. 2011;286 (40):35104&#x2013;35118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3186371</ArticleId><ArticleId IdType="pubmed">21846727</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyer J, Peterson A. Neurofilament-deficient axons and perikaryal aggregates in viable transgenic mice expressing a neurofilament-beta-galactosidase fusion protein. Neuron. 1994;12 (2):389&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pubmed">8110465</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrer M, Gwinn-Hardy K, Hutton M, Hardy J. The genetics of disorders with synuclein pathology and parkinsonism. Hum Mol Genet. 1999;8 (10):1901&#x2013;1905.</Citation><ArticleIdList><ArticleId IdType="pubmed">10469843</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, Wenning GK, Stefanova N. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia. 2013;61 (3):349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3568908</ArticleId><ArticleId IdType="pubmed">23108585</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. &#x3b1;-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002;4:160&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">11813001</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 2008;28 (30):7687&#x2013;7698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2702093</ArticleId><ArticleId IdType="pubmed">18650345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson&#x2019;s disease. Environ Health Perspect. 2011;119 (6):807&#x2013;814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114815</ArticleId><ArticleId IdType="pubmed">21245015</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler N, Plessmann U, Weber K. The complete amino acid sequence of the major mammalian neurofilament protein (NF-L) FEBS letters. 1985;182 (2):475&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">3920075</ArticleId></ArticleIdList></Reference><Reference><Citation>George JM, Jin H, Woods WS, Clayton DF. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 1995;15 (2):361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">7646890</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Forman MS, Lee VMY, Trojanoswki JQ. Prominent perikaryal expression of &#x3b1;- and &#x3b2;-synuclein in neurons of dorsal root ganglion and in medullary neurons. Exp Neurol. 2001;172:354&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">11716559</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron. 2002;34 (4):521&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">12062037</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, Lee VMY. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson&#x2019;s disease. J Neurosci Res. 2000;59 (4):528&#x2013;533.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679792</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Murray IV, Trojanowski JQ, Lee VMY. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem. 2001;276:2380&#x2013;2386.</Citation><ArticleIdList><ArticleId IdType="pubmed">11060312</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Uryu K, Trojanowski JQ, Lee VMY. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem. 1999;274 (12):7619&#x2013;7622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10075647</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M. Familial Parkinson&#x2019;s disease. The awakening of alpha-synuclein. Nature. 1997;388 (6639):232&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">9230428</ArticleId></ArticleIdList></Reference><Reference><Citation>Golde TE, Borchelt DR, Giasson BI, Lewis J. Thinking laterally about neurodegenerative proteinopathies. J Clin Invest. 2013;123:1847&#x2013;1855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3635732</ArticleId><ArticleId IdType="pubmed">23635781</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, Giasson BI. The E46K mutation in alpha-synuclein increases amyloid fibril formation. JBiolChem. 2005;280 (9):7800&#x2013;7807.</Citation><ArticleIdList><ArticleId IdType="pubmed">15632170</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VM. Distinct alpha-Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell. 2013;154 (1):103&#x2013;117. doi: 10.1016/j.cell.2013.05.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.05.057</ArticleId><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C, Angot E, Bergstrom AL, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li JY, Brundin P. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest. 2011;121 (2):715&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026723</ArticleId><ArticleId IdType="pubmed">21245577</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C. Accumulation of alpha-synuclein in the bowel of patients in the pre-clinical phase of Parkinson&#x2019;s disease. Acta Neuropathol. 2013 doi: 10.1007/s00401-013-1214-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1214-6</ArticleId><ArticleId IdType="pubmed">24240814</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol. 2002;322 (2):383&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">12217698</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Murayama S. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol. 2008;67 (10):945&#x2013;953. doi: 10.1097/NEN.0b013e318186de48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e318186de48</ArticleId><ArticleId IdType="pubmed">18800013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii A, Nonaka T, Taniguchi S, Saito T, Arai T, Mann D, Iwatsubo T, Hisanaga S, Goedert M, Hasegawa M. Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: Implication for alpha-synucleinopathies. FEBS letters. 2007;581 (24):4711&#x2013;4717. doi: 10.1016/j.febslet.2007.08.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2007.08.067</ArticleId><ArticleId IdType="pubmed">17868672</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. The precursor protein of non-A beta component of Alzheimer&#x2019;s disease amyloid is a presynaptic protein of the central nervous system. Neuron. 1995;14 (2):467&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">7857654</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakes R, Spillantini MG, Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994;345 (1):27&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8194594</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature. 2013;501 (7465):45&#x2013;51. doi: 10.1038/nature12481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12481</ArticleId><ArticleId IdType="pmc">PMC3963807</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien JP, Grosveld F, Yazdanbaksh K, Flavell D, Meijer D, Mushynski W. The structure of a human neurofilament gene (NF-L): a unique exon-intron organization in the intermediate filament gene family. Biochim Biophys Acta. 1987;909 (1):10&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">3034332</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien JPMD, Flavel D, Hurst J, Grosveld F. Cloning and developmental expression of the murine neurofilament gene family. Mol Brain Res. 1986;1:243&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">3103856</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300 (5618):486&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL. alpha-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson&#x2019;s disease and multiple system atrophy? Acta Neuropathol. 2013;125:753&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681325</ArticleId><ArticleId IdType="pubmed">23404372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Ho DH, Suk JE, You S, Michael S, Kang J, Joong LS, Masliah E, Hwang D, Lee HJ, Lee SJ. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun. 2013;4:1562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4089961</ArticleId><ArticleId IdType="pubmed">23463005</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL. Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J. 2006;20 (12):2000&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012252</ArticleId></ArticleIdList></Reference><Reference><Citation>Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, McGeer EG, McGeer PL. Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging. 2008;29 (5):739&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">17166628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson&#x2019;s disease. Nat Med. 2008;14 (5):504&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391962</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger R, Muller T, Riess O. Involvement of alpha-synuclein in Parkinson&#x2019;s disease and other neurodegenerative disorders. J Neural Transm. 2000;107 (1):31&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">10809401</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol. 2003;62 (12):1241&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pubmed">14692700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebouvier T, Chaumette T, Damier P, Coron E, Touchefeu Y, Vrignaud S, Naveilhan P, Galmiche JP, Bruley des Varannes S, Derkinderen P, Neunlist M. Pathological lesions in colonic biopsies during Parkinson&#x2019;s disease. Gut. 2008;57 (12):1741&#x2013;1743. doi: 10.1136/gut.2008.162503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2008.162503</ArticleId><ArticleId IdType="pubmed">19022934</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SB, Park SM, Ahn KJ, Chung KC, Paik SR, Kim J. Identification of the amino acid sequence motif of alpha-synuclein responsible for macrophage activation. Biochem Biophys Res Commun. 2009;381 (1):39&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19351591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, Anheim M, Letournel F, Bousset L, Honore A, Rozas N, Pieri L, Madiona K, Durr A, Melki R, Verny C, Brice A. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. AnnNeurol 2013</Citation><ArticleIdList><ArticleId IdType="pubmed">23526723</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Bjorklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson&#x2019;s disease suggest host-to-graft disease propagation. Nat Med. 2008;14 (5):501&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18391963</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JY, Englund E, Widner H, Rehncrona S, Bjorklund A, Lindvall O, Brundin P. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson&#x2019;s disease. Mov Disord. 2010;25 (8):1091&#x2013;1096.</Citation><ArticleIdList><ArticleId IdType="pubmed">20198645</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J Biol Chem. 2005;280 (24):22670&#x2013;22678. doi: 10.1074/jbc.M501508200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M501508200</ArticleId><ArticleId IdType="pubmed">15840579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M, Landon M, Mayer RJ. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson&#x2019;s disease, Pick&#x2019;s disease, and Alzheimer&#x2019;s disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease. J Pathol. 1988;155 (1):9&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">2837558</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm V, Carroll J, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338 (6109):949&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3552321</ArticleId><ArticleId IdType="pubmed">23161999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J Exp Med. 2012;209 (5):975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Song C, O&#x2019;Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl AcadSci USA. 2009;106 (47):20051&#x2013;20056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785290</ArticleId><ArticleId IdType="pubmed">19892735</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, Hasegawa M. Prion-like spreading of pathological alpha-synuclein in brain. Brain. 2013;136 (Pt 4):1128&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613715</ArticleId><ArticleId IdType="pubmed">23466394</ArticleId></ArticleIdList></Reference><Reference><Citation>Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, Lakhdar L, Legastelois S, Baron T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging. 2012;33 (9):2225&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pubmed">21813214</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu L, Sobotka S, Chen J, Su H, Sanders I, Adler CH, Shill HA, Caviness JN, Samanta JE, Beach TG Arizona Parkinson&#x2019;s Disease C. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson disease. J Neuropathol Exp Neurol. 2013;72 (2):119&#x2013;129. doi: 10.1097/NEN.0b013e3182801cde.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3182801cde</ArticleId><ArticleId IdType="pmc">PMC3552335</ArticleId><ArticleId IdType="pubmed">23334595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Y, Hashimoto R, Kashiwagi Y, Wada Y, Sakoda S, Miyamae Y, Kudo T, Takeda M. Casein kinase II is responsible for phosphorylation of NF-L at Ser-473. FEBS letters. 1999;455 (1&#x2013;2):83&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">10428477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ono K, Ikeda T, Takasaki J, Yamada M. Familial Parkinson disease mutations influence alpha-synuclein assembly. Neurobiol Dis. 2011;43 (3):715&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">21684335</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med. 2012;209 (5):889&#x2013;893. doi: 10.1084/jem.20120741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20120741</ArticleId><ArticleId IdType="pmc">PMC3348110</ArticleId><ArticleId IdType="pubmed">22566400</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson&#x2019;s disease. Science. 1997;276 (5321):2045&#x2013;2047.</Citation><ArticleIdList><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Proukakis C, Dudzik CG, Brier T, Mackay DS, Cooper JM, Millhauser GL, Houlden H, Schapira AH. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology. 2013;80 (11):1062&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653201</ArticleId><ArticleId IdType="pubmed">23427326</ArticleId></ArticleIdList></Reference><Reference><Citation>Recasens A, Dehay B, Bove J, Carballo-Carbajal I, Dovero S, Perez A, Fernagut PO, Blesa J, Parent A, Perier C, Farinas I, Obeso JA, Bezard E, Vila M. Lewy body extracts from parkinson&#x2019;s disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2013 doi: 10.1002/ana.24066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24066</ArticleId><ArticleId IdType="pubmed">24243558</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds AD, Glanzer JG, Kadiu I, Ricardo-Dukelow M, Chaudhuri A, Ciborowski P, Cerny R, Gelman B, Thomas MP, Mosley RL, Gendelman HE. Nitrated alpha-synuclein-activated microglial profiling for Parkinson&#x2019;s disease. J Neurochem. 2008;104 (6):1504&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">18036154</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochet JC, Conway KA, Lansbury PT. Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry. 2000;39 (35):10619&#x2013;10626.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978144</ArticleId></ArticleIdList></Reference><Reference><Citation>Roodveldt C, Christodoulou J, Dobson CM. Immunological features of alpha-synuclein in Parkinson&#x2019;s disease. J Cell Mol Med. 2008;12 (5B):1820&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4506153</ArticleId><ArticleId IdType="pubmed">18671754</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubartelli A, Lotze MT. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol. 2007;28 (10):429&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pubmed">17845865</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, Ran Y, Golde TE, Giasson BI. Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein. Acta Neuropathol Commun. 2013;1 (1):38. doi: 10.1186/2051-5960-1-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-38</ArticleId><ArticleId IdType="pmc">PMC3893388</ArticleId><ArticleId IdType="pubmed">24252149</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J, Giasson BI, Golde TE. Conformational templating of alpha-synuclein aggregates in neuronal-glial cultures. Mol Neurodegen. 2013;8:17. doi: 10.1186/1750-1326-8-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-17</ArticleId><ArticleId IdType="pmc">PMC3671973</ArticleId><ArticleId IdType="pubmed">23714769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, Inoue K, Murayama S. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol. 2008;67 (11):1072&#x2013;1083. doi: 10.1097/NEN.0b013e31818b4126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818b4126</ArticleId><ArticleId IdType="pubmed">18957894</ArticleId></ArticleIdList></Reference><Reference><Citation>Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson&#x2019;s disease. Science. 2003;302 (5646):841.</Citation><ArticleIdList><ArticleId IdType="pubmed">14593171</ArticleId></ArticleIdList></Reference><Reference><Citation>Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson&#x2019;s disease. Neurobiol Aging. 2008;29 (11):1690&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2621109</ArticleId><ArticleId IdType="pubmed">17537546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey MG, Goldberg MS. Neuroinflammation in Parkinson&#x2019;s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis. 2010;37 (3):510&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823829</ArticleId><ArticleId IdType="pubmed">19913097</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimpin S, Mixon AE, Stapels MD, Kim MY, Spencer PS, Deinzer ML. Identification of endogenous phosphorylation sites of bovine medium and low molecular weight neurofilament proteins by tandem mass spectrometry. Biochemistry. 2004;43 (7):2091&#x2013;2105. doi: 10.1021/bi030196q.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi030196q</ArticleId><ArticleId IdType="pubmed">14967049</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu PH, Robinson KA, de Snoo F, Eyer J, Peterson A, Lee VM, Trojanowski JQ. Selective degeneration fo Purkinje cells with Lewy body-like inclusions in aged NFHLACZ transgenic mice. J Neurosci. 1997;17 (3):1064&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573175</ArticleId><ArticleId IdType="pubmed">8994061</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, Lee VM. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72 (1):57&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204802</ArticleId><ArticleId IdType="pubmed">21982369</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, Dearmond SJ, Prusiner SB. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl AcadSci USA. 2013;110 (48):19555&#x2013;19560. doi: 10.1073/pnas.1318268110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318268110</ArticleId><ArticleId IdType="pmc">PMC3845125</ArticleId><ArticleId IdType="pubmed">24218576</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol. 2008;116 (1):37&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664556</ArticleId><ArticleId IdType="pubmed">18414880</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta. 2008;1792:616&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756732</ArticleId><ArticleId IdType="pubmed">18955133</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol. 2008;67 (5):402&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2930078</ArticleId><ArticleId IdType="pubmed">18451726</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation. J Neurochem. 2010;113 (2):374&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907888</ArticleId><ArticleId IdType="pubmed">20132485</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Characterization of kinases involved in the phosphorylation of aggregated alpha-synuclein. J Neurosci Res. 2011;89 (2):231&#x2013;247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4484797</ArticleId><ArticleId IdType="pubmed">21162130</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31 (21):7604&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Mazzulli JR, Giasson BI. Characterization of hydrophobic residue requirements for alpha-synuclein fibrillization. Biochemistry. 2009;48 (40):9427&#x2013;9436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758333</ArticleId><ArticleId IdType="pubmed">19722699</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb PH, Zhen W, Poon AW, Conway KA, Lansbury PT. NACP, a protein implicated in Alzheimer&#x2019;s disease and learning, is natively unfolded. Biochemistry. 1996;35 (43):13709&#x2013;13715.</Citation><ArticleIdList><ArticleId IdType="pubmed">8901511</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZS, Liu WS, Willard M. Identification of serine 473 as a major phosphorylation site in the neurofilament polypeptide NF-L. J Neurosci. 1990;10(6):1838&#x2013;1846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6570304</ArticleId><ArticleId IdType="pubmed">2162386</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez TE, del Ser T, Munoz DG, de Yebenes JG. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55 (2):164&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755719</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson&#x2019;s disease. FASEB J. 2005;19 (6):533&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">15791003</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Q, Couillard-Despres S, Julien JP. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Exp Neurol. 1997;148 (1):299&#x2013;316. doi: 10.1006/exnr.1997.6654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/exnr.1997.6654</ArticleId><ArticleId IdType="pubmed">9398473</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24664227</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.</ArticleTitle><Pagination><StartPage>543</StartPage><EndPage>552</EndPage><MedlinePgn>543-52</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.131</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial function, has been shown in preclinical Parkinson disease (PD) models to reduce the loss of dopamine neurons, and was safe and well tolerated in early-phase human studies. A previous phase II study suggested possible clinical benefit.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine whether CoQ10 could slow disease progression in early PD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">A phase III randomized, placebo-controlled, double-blind clinical trial at 67 North American sites consisting of participants 30 years of age or older who received a diagnosis of PD within 5 years and who had the following inclusion criteria: the presence of a rest tremor, bradykinesia, and rigidity; a modified Hoehn and Yahr stage of 2.5 or less; and no anticipated need for dopaminergic therapy within 3 months. Exclusion criteria included the use of any PD medication within 60 days, the use of any symptomatic PD medication for more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale (UPDRS) rest tremor score of 3 or greater for any limb, a Mini-Mental State Examination score of 25 or less, a history of stroke, the use of certain supplements, and substantial recent exposure to CoQ10. Of 696 participants screened, 78 were found to be ineligible, and 18 declined participation.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The remaining 600 participants were randomly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Participants were observed for 16 months or until a disability requiring dopaminergic treatment. The prospectively defined primary outcome measure was the change in total UPDRS score (Parts I-III) from baseline to final visit. The study was powered to detect a 3-point difference between an active treatment and placebo.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The baseline characteristics of the participants were well balanced, the mean age was 62.5 years, 66% of participants were male, and the mean baseline total UPDRS score was 22.7. A total of 267 participants required treatment (94 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely. Treatments were well tolerated with no safety concerns. The study was terminated after a prespecified futility criterion was reached. At study termination, both active treatment groups showed slight adverse trends relative to placebo. Adjusted mean changes (worsening) in total UPDRS scores from baseline to final visit were 6.9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P&#x2009;=&#x2009;.49 relative to placebo), and 8.0 points (2400 mg/d of CoQ10; P&#x2009;=&#x2009;.21 relative to placebo).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Coenzyme Q10 was safe and well tolerated in this population, but showed no evidence of clinical benefit.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT00740714.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><CollectiveName>Parkinson Study Group QE3 Investigators</CollectiveName></Author><Author ValidYN="Y"><LastName>Beal</LastName><ForeName>M Flint</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medical College, New York Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oakes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgetown University, Washington, DC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henchcliffe</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medical College, New York Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galpern</LastName><ForeName>Wendy R</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haas</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juncos</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Wesley Woods Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nutt</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Tiffini Smith</ForeName><Initials>TS</Initials><AffiliationInfo><Affiliation>Merck, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biogen Idec, Cambridge, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shults</LastName><ForeName>Clifford M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla10VA Medical Center, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Helles</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snively</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lew</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griebner</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Arthur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York12Department of Neurology, University of Rochester, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Shan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Rochester Medical Center, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourcher</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Qu&#xe9;bec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bond</LastName><ForeName>Louisette</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Qu&#xe9;bec Memory and Motor Skills Disorders Research Center, Clinique Sainte-Anne, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kompoliti</LastName><ForeName>Katie</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Pinky</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Booth Gardner Parkinson's Care Center, EvergreenHealth, Kirkland, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sia</LastName><ForeName>Cherissa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Booth Gardner Parkinson's Care Center, EvergreenHealth, Kirkland, Washington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jog</LastName><ForeName>Mandar</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Linda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sultana</LastName><ForeName>Munira</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurlan</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Overlook Medical Center, Atlantic Neuroscience Institute, Summit, New Jersey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richard</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deeley</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>Cheryl H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, Neurological Institute, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Angel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, Neurological Institute, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arkun</LastName><ForeName>Ani</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medical College, New York Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Oregon Health and Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ondo</LastName><ForeName>William G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Texas Health Science Center at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunter</LastName><ForeName>Christine B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jimenez-Shahed</LastName><ForeName>Joohi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palao</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>So</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Centre, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tetrud</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Parkinson's Institute and Clinical Center, Sunnyvale, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reys</LastName><ForeName>Liza</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Parkinson's Institute and Clinical Center, Sunnyvale, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Parkinson's Institute and Clinical Center, Sunnyvale, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blenke</LastName><ForeName>Anita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami School of Medicine, Miami, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotto</LastName><ForeName>Candace</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Neurodegenerative Disorders, New Haven, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Butler Hospital, Providence, Rhode Island26Alpert Medical School, Brown University, Providence, Rhode Island.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lannon</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Butler Hospital, Providence, Rhode Island27Port City Neurology, Inc, Scarborough, Maine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Davis, School of Medicine and Sacramento VA Medical Center, Sacramento.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drasby</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Port City Neurology, Inc, Scarborough, Maine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rajeev</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Colorado Neurological Institute, Englewood.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Thyagarajan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Milton S. Hershey Medical Center, Department of Neurology, Pennsylvania State Hershey College of Medicine, Hershey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Donna Stuppy</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Milton S. Hershey Medical Center, Department of Neurology, Pennsylvania State Hershey College of Medicine, Hershey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grimes</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Ottawa Hospital Civic Site, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cote</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ottawa Hospital Civic Site, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conway</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Ottawa Hospital Civic Site, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evatt</LastName><ForeName>Marian Leslie</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Wesley Woods Center, Atlanta, Georgia33Atlanta VA Medical Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sommerfeld</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Emory University School of Medicine, Wesley Woods Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Abraham N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Muhammad Ali Parkinson Center, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Ramon L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merritt</LastName><ForeName>Stacy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swartz</LastName><ForeName>Camille Louise</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>W R Wayne</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Glenrose Rehabilitation Hospital, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Glenrose Rehabilitation Hospital, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stover</LastName><ForeName>Natividad</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guthrie</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watts</LastName><ForeName>Ray L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neurological Restoration, Department of Neurology, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Center for Neurological Restoration, Department of Neurology, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winters</LastName><ForeName>Adrienna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neurological Restoration, Department of Neurology, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mari</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Becky</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feigin</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Feinstein Institute for Medical Research, Center for Neurosciences, Manhasset, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shannon</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Feinstein Institute for Medical Research, Center for Neurosciences, Manhasset, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nirenberg</LastName><ForeName>Melissa Jill</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, New York University Langone Medical Center, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogg</LastName><ForeName>Mattson</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Weill Cornell Medical College, New York Hospital, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellias</LastName><ForeName>Samuel A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Cathi-Ann</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frei</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Parkinson's and Movement Disorder Institute, Fountain Valley, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodis-Wollner</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>State University of New York, Downstate Medical Center, Brooklyn, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glazman</LastName><ForeName>Sofya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>State University of New York, Downstate Medical Center, Brooklyn, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State University of New York, Downstate Medical Center, Brooklyn, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of South Florida, Tampa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langhammer</LastName><ForeName>April</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Kansas Medical Center, Kansas City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranawaya</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derwent</LastName><ForeName>Lorelei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Kapil D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgia Health Science University, Augusta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrow</LastName><ForeName>Buff</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgia Health Science University, Augusta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prakash</LastName><ForeName>Rajan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Georgia Health Science University, Augusta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Louisville, Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sahay</LastName><ForeName>Alok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gartner</LastName><ForeName>Maureen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinson</LastName><ForeName>Vanessa K</ForeName><Initials>VK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of South Carolina, Charleston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markind</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Associated Neurologists, PC, Danbury, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pelikan</LastName><ForeName>Melisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Associated Neurologists, PC, Danbury, Connecticut.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartlein</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molho</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Movement Disorders Center, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evans</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Movement Disorders Center, Albany Medical Center, Albany, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic, Scottsdale, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elmer</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Neurological Health, University of Toledo, Toledo, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kathy</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Ohio at Toledo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spears</LastName><ForeName>Julia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Ohio at Toledo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Ohio at Toledo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Colorado Health Science Center, Denver.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>Neal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine Medical Center, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niswonger</LastName><ForeName>Shari</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, Irvine Medical Center, Irvine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shill</LastName><ForeName>Holly A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obradov</LastName><ForeName>Sanja</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Banner Sun Health Research Institute, Sun City, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Saskatchewan, Royal University Hospital, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowper</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Saskatchewan, Royal University Hospital, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lessig</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zadikoff</LastName><ForeName>Cindy</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blindauer</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergholte</LastName><ForeName>Jo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Propsom</LastName><ForeName>Clara Schindler</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical College of Wisconsin, Milwaukee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stacy</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Field</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihaila</LastName><ForeName>Dragos</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State University of New York Upstate Medical Center and Syracuse VA Medical Center, Syracuse.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chilton</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>State University of New York Upstate Medical Center and Syracuse VA Medical Center, Syracuse.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uc</LastName><ForeName>Ergun Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieren</LastName><ForeName>Jeri</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Iowa, Iowa City.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>David K</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraics</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silver</LastName><ForeName>Althea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyd</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Vermont College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamill</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Vermont College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingvoldstad</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Vermont College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Vermont College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ohio State University, Columbus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostyk</LastName><ForeName>Sandra K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ohio State University, Columbus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojcieszek</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Indiana University School of Medicine, Indianapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Tennessee Health Science Center, Memphis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, CHUM-H&#xf4;pital Notre-Dame, Montr&#xe9;al, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beland</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, CHUM-H&#xf4;pital Notre-Dame, Montr&#xe9;al, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reich</LastName><ForeName>Stephen G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Maryland School of Science, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cines</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Maryland School of Science, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zappala</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Maryland School of Science, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivest</LastName><ForeName>Jean</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Sherbrooke, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zweig</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Louisiana State University Health Science Center, Shreveport.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumina</LastName><ForeName>L Pepper</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Department of Neurology, Louisiana State University Health Science Center, Shreveport.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilliard</LastName><ForeName>Colette Lynn</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Lewis Hall Singletary Oncology Center, Thomasville, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grill</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kellermann</LastName><ForeName>Marye</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Parkinson and Movement Disorders Center of Maryland, Elkridge.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuite</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rolandelli</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Minnesota, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Un Jung</ForeName><Initials>UJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Jayaraman</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ochsner Clinic Foundation, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Maureen M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ochsner Clinic Foundation, New Orleans, Louisiana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Severt</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyar</LastName><ForeName>Karyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Beth Israel Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00740714</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG024040</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS 050324</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS050573</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>1339-63-5</RegistryNumber><NameOfSubstance UI="D014451">Ubiquinone</NameOfSubstance></Chemical><Chemical><RegistryNumber>EJ27X76M46</RegistryNumber><NameOfSubstance UI="C024989">coenzyme Q10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 May;71(5):537-8. doi: 10.1001/jamaneurol.2014.64.</RefSource><PMID Version="1">24664140</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014451" MajorTopicYN="N">Ubiquinone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Oakes</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beal</LastName><ForeName>M Flint</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shoulson</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galpern</LastName><ForeName>Wendy R</ForeName><Initials>WR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haas</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henchcliffe</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juncos</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nutt</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voss</LastName><ForeName>Tiffini</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shults</LastName><ForeName>Clifford</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pourcher</LastName><ForeName>Emmanuelle</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bond</LastName><ForeName>Louisette</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kompoliti</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Pinky</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sia</LastName><ForeName>Cherissa</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jog</LastName><ForeName>Mandar</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cole</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sultana</LastName><ForeName>Munira</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurlan</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richard</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deeley</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Waters</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Figueroa</LastName><ForeName>Angel</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arkun</LastName><ForeName>Ani</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ondo</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jimenez-Shahed</LastName><ForeName>Joohi</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palao</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miyasaki</LastName><ForeName>Janis</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>So</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tetrud</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reys</LastName><ForeName>Liza</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Katharine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blenke</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Russell</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotto</LastName><ForeName>Candace</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannon</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lin</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Drasby</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lannon</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rajeev</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Thyagarajan</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ford</LastName><ForeName>Donna Stuppy</ForeName><Initials>DS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimes</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cote</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Conway</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evatt</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sommerfeld</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lieberman</LastName><ForeName>Abraham</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Okun</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Ramon</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merritt</LastName><ForeName>Stacy</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swartz</LastName><ForeName>Camille</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stover</LastName><ForeName>Natividad</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guthrie</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Ray</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Anwar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winters</LastName><ForeName>Adrienna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mari</LastName><ForeName>Zoltan</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Becky</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feigin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nirenberg</LastName><ForeName>Melissa J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ogg</LastName><ForeName>Mattson</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ellias</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Cathi-Ann</ForeName><Initials>CA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frei</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodis-Wollner</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Glazman</LastName><ForeName>Sofya</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mayer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Langhammer</LastName><ForeName>April</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranawaya</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derwent</LastName><ForeName>Lorelei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sethi</LastName><ForeName>Kapil</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrow</LastName><ForeName>Buff</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prakash</LastName><ForeName>Rajan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Litvan</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sahay</LastName><ForeName>Alok</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gartner</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hinson</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markind</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelikan</LastName><ForeName>Melisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perlmutter</LastName><ForeName>Joel S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartlein</LastName><ForeName>Johanna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Molho</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Evans</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Duffy</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elmer</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davis</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spears</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilson</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hermanowicz</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niswonger</LastName><ForeName>Shari</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shill</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Sanja</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rajput</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowper</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lessig</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Song</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontaine</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zadikoff</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Williams</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blindauer</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bergholte</LastName><ForeName>Jo</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Propsom</LastName><ForeName>Clara Schindler</ForeName><Initials>CS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stacy</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Field</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mihaila</LastName><ForeName>Dragos</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chilton</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uc</LastName><ForeName>Ergun</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sieren</LastName><ForeName>Jeri</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>David K</ForeName><Initials>DK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kraics</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silver</LastName><ForeName>Althea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyd</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamill</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ingvoldstad</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kostyk</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wojcieszek</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pfeiffer</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Panisset</LastName><ForeName>Michel</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beland</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reich</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cines</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zappala</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rivest</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zweig</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lumina</LastName><ForeName>L Pepper</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilliard</LastName><ForeName>Colette</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grill</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kellermann</LastName><ForeName>Marye</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tuite</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rolandelli</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kang</LastName><ForeName>Un Jung</ForeName><Initials>UJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Jayaraman</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Severt</LastName><ForeName>W Lawrence</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boyar</LastName><ForeName>Karyn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oakes</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermott</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gao</LastName><ForeName>Shan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Griebner</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helles</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Plumb</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Snively</LastName><ForeName>Victoria</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lew</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Voss</LastName><ForeName>Tiffini</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gross</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albin</LastName><ForeName>Roger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bell</LastName><ForeName>Karen L</ForeName><Initials>KL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Donna T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beimler</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doolan</LastName><ForeName>Rory</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lang</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lau</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMullen</LastName><ForeName>Nichole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rothenburgh</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCoy</LastName><ForeName>Arita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dorward</LastName><ForeName>Bari J</ForeName><Initials>BJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tran</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sombai</LastName><ForeName>Jassie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quesada</LastName><ForeName>Monica</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hupcey</LastName><ForeName>Roxana</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miracle</LastName><ForeName>Dawn</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Altin</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weeks</LastName><ForeName>Mary Louise</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simpson</LastName><ForeName>Edith</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suelter</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Velcheva</LastName><ForeName>Malinka</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McClain</LastName><ForeName>Theresa</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khavarian</LastName><ForeName>Leyla</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zomok</LastName><ForeName>Marci</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olalde</LastName><ForeName>Heena</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Jared</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Oesterle</LastName><ForeName>Colette</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pancake</LastName><ForeName>Paige</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belden</LastName><ForeName>Joann</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Soucy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnson</LastName><ForeName>Labrillia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kashouty</LastName><ForeName>Rabih</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Niles</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nickels</LastName><ForeName>Breanna</ForeName><Initials>B</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24664227</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.131</ArticleId><ArticleId IdType="pii">1851409</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24660806</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1470-8728</ISSN><JournalIssue CitedMedium="Internet"><Volume>460</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>The Biochemical journal</Title><ISOAbbreviation>Biochem J</ISOAbbreviation></Journal><ArticleTitle>Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.</ArticleTitle><Pagination><StartPage>127</StartPage><EndPage>139</EndPage><MedlinePgn>127-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1042/BJ20140334</ELocationID><Abstract><AbstractText>We have previously reported that the Parkinson's disease-associated kinase PINK1 (PTEN-induced putative kinase 1) is activated by mitochondrial depolarization and stimulates the Parkin E3 ligase by phosphorylating Ser65 within its Ubl (ubiquitin-like) domain. Using phosphoproteomic analysis, we identified a novel ubiquitin phosphopeptide phosphorylated at Ser65 that was enriched 14-fold in HEK (human embryonic kidney)-293 cells overexpressing wild-type PINK1 stimulated with the mitochondrial uncoupling agent CCCP (carbonyl cyanide m-chlorophenylhydrazone), to activate PINK1, compared with cells expressing kinase-inactive PINK1. Ser65 in ubiquitin lies in a similar motif to Ser65 in the Ubl domain of Parkin. Remarkably, PINK1 directly phosphorylates Ser65 of ubiquitin in&#xa0;vitro. We undertook a series of experiments that provide striking evidence that Ser65-phosphorylated ubiquitin (ubiquitinPhospho-Ser65) functions as a critical activator of Parkin. First, we demonstrate that a fragment of Parkin lacking the Ubl domain encompassing Ser65 (&#x394;Ubl-Parkin) is robustly activated by ubiquitinPhospho-Ser65, but not by non-phosphorylated ubiquitin. Secondly, we find that the isolated Parkin Ubl domain phosphorylated at Ser65 (UblPhospho-Ser65) can also activate &#x394;Ubl-Parkin similarly to ubiquitinPhospho-Ser65. Thirdly, we establish that ubiquitinPhospho-Ser65, but not non-phosphorylated ubiquitin or UblPhospho-Ser65, activates full-length wild-type Parkin as well as the non-phosphorylatable S65A Parkin mutant. Fourthly, we provide evidence that optimal activation of full-length Parkin E3 ligase is dependent on PINK1-mediated phosphorylation of both Parkin at Ser65 and ubiquitin at Ser65, since only mutation of both proteins at Ser65 completely abolishes Parkin activation. In conclusion, the findings of the present study reveal that PINK1 controls Parkin E3 ligase activity not only by phosphorylating Parkin at Ser65, but also by phosphorylating ubiquitin at Ser65. We propose that phosphorylation of Parkin at Ser65 serves to prime the E3 ligase enzyme for activation by ubiquitinPhospho-Ser65, suggesting that small molecules that mimic ubiquitinPhospho-Ser65 could hold promise as novel therapies for Parkinson's disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kazlauskaite</LastName><ForeName>Agne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kondapalli</LastName><ForeName>Chandana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gourlay</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Campbell</LastName><ForeName>David G</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ritorto</LastName><ForeName>Maria Stella</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofmann</LastName><ForeName>Kay</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>&#x2020;Institute for Genetics, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alessi</LastName><ForeName>Dario R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knebel</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trost</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>*MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, Dundee, Scotland, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muqit</LastName><ForeName>Miratul M K</ForeName><Initials>MM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>H-1101</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12016/5</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>089698</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UP_A500_1020</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_UU_12016/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100713</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101022/Z/13/Z</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>H-0901</GrantID><Acronym>PUK_</Acronym><Agency>Parkinson's UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>101022</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000735</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Biochem J</MedlineTA><NlmUniqueID>2984726R</NlmUniqueID><ISSNLinking>0264-6021</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>452VLY9402</RegistryNumber><NameOfSubstance UI="D012694">Serine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="C111567">parkin protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D011494">Protein Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C433927">PTEN-induced putative kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Biochem J. 2014 Jun 15;460(3):e1-3. doi: 10.1042/BJ20140459.</RefSource><PMID Version="1">24870025</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011494" MajorTopicYN="N">Protein Kinases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>4</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24660806</ArticleId><ArticleId IdType="pmc">PMC4000136</ArticleId><ArticleId IdType="doi">10.1042/BJ20140334</ArticleId><ArticleId IdType="pii">BJ20140334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392:605&#x2013;608. doi: 10.1038/33416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/33416</ArticleId><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente E. M., Abou-Sleiman P. M., Caputo V., Muqit M. M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A. R., Healy D. G., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158&#x2013;1160. doi: 10.1126/science.1096284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1096284</ArticleId><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucking C. B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B. S., Meco G., Denefle P., Wood N. W., et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 2000;342:1560&#x2013;1567. doi: 10.1056/NEJM200005253422103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200005253422103</ArticleId><ArticleId IdType="pubmed">10824074</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N. L., Graham E., Critchley P., Schrag A. E., Wood N. W., Lees A. J., Bhatia K. P., Quinn N. Parkin disease: a phenotypic study of a large case series. Brain. 2003;126:1279&#x2013;1292. doi: 10.1093/brain/awg142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awg142</ArticleId><ArticleId IdType="pubmed">12764051</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan N. L., Valente E. M., Bentivoglio A. R., Wood N. W., Albanese A., Brooks D. J., Piccini P. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann. Neurol. 2002;52:849&#x2013;853. doi: 10.1002/ana.10417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10417</ArticleId><ArticleId IdType="pubmed">12447943</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark I. E., Dodson M. W., Jiang C., Cao J. H., Huh J. R., Seol J. H., Yoo S. J., Hay B. A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature. 2006;441:1162&#x2013;1166. doi: 10.1038/nature04779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04779</ArticleId><ArticleId IdType="pubmed">16672981</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Lee S. B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J. M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature. 2006;441:1157&#x2013;1161. doi: 10.1038/nature04788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04788</ArticleId><ArticleId IdType="pubmed">16672980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J. W., Yang L., Beal M. F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U.S.A. 2006;103:10793&#x2013;10798. doi: 10.1073/pnas.0602493103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0602493103</ArticleId><ArticleId IdType="pmc">PMC1502310</ArticleId><ArticleId IdType="pubmed">16818890</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda N., Sato S., Shiba K., Okatsu K., Saisho K., Gautier C. A., Sou Y. S., Saiki S., Kawajiri S., Sato F., et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 2010;189:211&#x2013;221. doi: 10.1083/jcb.200910140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.200910140</ArticleId><ArticleId IdType="pmc">PMC2856912</ArticleId><ArticleId IdType="pubmed">20404107</ArticleId></ArticleIdList></Reference><Reference><Citation>Narendra D. P., Jin S. M., Tanaka A., Suen D. F., Gautier C. A., Shen J., Cookson M. R., Youle R. J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010;8:e1000298. doi: 10.1371/journal.pbio.1000298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1000298</ArticleId><ArticleId IdType="pmc">PMC2811155</ArticleId><ArticleId IdType="pubmed">20126261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vives-Bauza C., Zhou C., Huang Y., Cui M., de Vries R. L., Kim J., May J., Tocilescu M. A., Liu W., Ko H. S., et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 2010;107:378&#x2013;383. doi: 10.1073/pnas.0911187107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911187107</ArticleId><ArticleId IdType="pmc">PMC2806779</ArticleId><ArticleId IdType="pubmed">19966284</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S., Holmstrom K. M., Skujat D., Fiesel F. C., Rothfuss O. C., Kahle P. J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010;12:119&#x2013;131. doi: 10.1038/ncb2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncb2012</ArticleId><ArticleId IdType="pubmed">20098416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondapalli C., Kazlauskaite A., Zhang N., Woodroof H. I., Campbell D. G., Gourlay R., Burchell L., Walden H., Macartney T. J., Deak M., et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012;2:120080. doi: 10.1098/rsob.120080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.120080</ArticleId><ArticleId IdType="pmc">PMC3376738</ArticleId><ArticleId IdType="pubmed">22724072</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley B. E., Lougheed J. C., Callaway K., Velasquez M., Brecht E., Nguyen L., Shaler T., Walker D., Yang Y., Regnstrom K., et al. Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat. Commun. 2013;4:1982. doi: 10.1038/ncomms2982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2982</ArticleId><ArticleId IdType="pmc">PMC3709503</ArticleId><ArticleId IdType="pubmed">23770887</ArticleId></ArticleIdList></Reference><Reference><Citation>Wauer T., Komander D. Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J. 2013;32:2099&#x2013;2112. doi: 10.1038/emboj.2013.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2013.125</ArticleId><ArticleId IdType="pmc">PMC3730226</ArticleId><ArticleId IdType="pubmed">23727886</ArticleId></ArticleIdList></Reference><Reference><Citation>Trempe J. F., Sauve V., Grenier K., Seirafi M., Tang M. Y., Menade M., Al-Abdul-Wahid S., Krett J., Wong K., Kozlov G., et al. Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science. 2013;340:1451&#x2013;1455. doi: 10.1126/science.1237908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1237908</ArticleId><ArticleId IdType="pubmed">23661642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamano K., Youle R. J. PINK1 is degraded through the N-end rule pathway. Autophagy. 2013;9:1758&#x2013;1769. doi: 10.4161/auto.24633.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.24633</ArticleId><ArticleId IdType="pmc">PMC4028335</ArticleId><ArticleId IdType="pubmed">24121706</ArticleId></ArticleIdList></Reference><Reference><Citation>Ubersax J. A., Ferrell J. E., Jr Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 2007;8:530&#x2013;541. doi: 10.1038/nrm2203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2203</ArticleId><ArticleId IdType="pubmed">17585314</ArticleId></ArticleIdList></Reference><Reference><Citation>Thingholm T. E., Jorgensen T. J., Jensen O. N., Larsen M. R. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 2006;1:1929&#x2013;1935. doi: 10.1038/nprot.2006.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2006.185</ArticleId><ArticleId IdType="pubmed">17487178</ArticleId></ArticleIdList></Reference><Reference><Citation>Trost M., English L., Lemieux S., Courcelles M., Desjardins M., Thibault P. The phagosomal proteome in interferon-&#x3b3;-activated macrophages. Immunity. 2009;30:143&#x2013;154. doi: 10.1016/j.immuni.2008.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.11.006</ArticleId><ArticleId IdType="pubmed">19144319</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008;26:1367&#x2013;1372. doi: 10.1038/nbt.1511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1511</ArticleId><ArticleId IdType="pubmed">19029910</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodroof H. I., Pogson J. H., Begley M., Cantley L. C., Deak M., Campbell D. G., van Aalten D. M. F., Whitworth A. J., Alessi D. R., Muqit M. M. K. Discovery of catalytically active orthologues of the Parkinson's disease kinase PINK1: analysis of substrate specificity and impact of mutations. Open Biology. 2011;1:110012. doi: 10.1098/rsob.110012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.110012</ArticleId><ArticleId IdType="pmc">PMC3352081</ArticleId><ArticleId IdType="pubmed">22645651</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaugule V. K., Burchell L., Barber K. R., Sidhu A., Leslie S. J., Shaw G. S., Walden H. Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J. 2011;30:2853&#x2013;2867. doi: 10.1038/emboj.2011.204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.204</ArticleId><ArticleId IdType="pmc">PMC3160258</ArticleId><ArticleId IdType="pubmed">21694720</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitby F. G., Xia G., Pickart C. M., Hill C. P. Crystal structure of the human ubiquitin-like protein NEDD8 and interactions with ubiquitin pathway enzymes. J. Biol. Chem. 1998;273:34983&#x2013;34991. doi: 10.1074/jbc.273.52.34983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.52.34983</ArticleId><ArticleId IdType="pubmed">9857030</ArticleId></ArticleIdList></Reference><Reference><Citation>Bain J., Plater L., Elliott M., Shpiro N., Hastie C. J., McLauchlan H., Klevernic I., Arthur J. S., Alessi D. R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007;408:297&#x2013;315. doi: 10.1042/BJ20070797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20070797</ArticleId><ArticleId IdType="pmc">PMC2267365</ArticleId><ArticleId IdType="pubmed">17850214</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell D. G., Morrice N. A. Identification of protein phosphorylation sites by a combination of mass spectrometry and solid phase Edman sequencing. J. Biomol. Tech. 2002;13:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2279855</ArticleId><ArticleId IdType="pubmed">19498976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazlauskaite A., Kelly V., Johnson C., Baillie C., Hastie C. J., Peggie M., Macartney T., Woodroof H. I., Alessi D. R., Pedrioli P. G., Muqit M. M. Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity. Open Biol. 2014;4:130213. doi: 10.1098/rsob.130213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.130213</ArticleId><ArticleId IdType="pmc">PMC3971407</ArticleId><ArticleId IdType="pubmed">24647965</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchell L., Chaugule V. K., Walden H. Small, N-terminal tags activate parkin e3 ubiquitin ligase activity by disrupting its autoinhibited conformation. PLoS ONE. 2012;7:e34748. doi: 10.1371/journal.pone.0034748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0034748</ArticleId><ArticleId IdType="pmc">PMC3319606</ArticleId><ArticleId IdType="pubmed">22496854</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomoo K., Mukai Y., In Y., Miyagawa H., Kitamura K., Yamano A., Shindo H., Ishida T. Crystal structure and molecular dynamics simulation of ubiquitin-like domain of murine parkin. Biochim. Biophys. Acta. 2008;1784:1059&#x2013;1067. doi: 10.1016/j.bbapap.2008.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2008.04.009</ArticleId><ArticleId IdType="pubmed">18485927</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro M., Okubo S., Shimotakahara S., Hatanaka H., Yasuda H., Kainosho M., Yokoyama S., Shindo H. NMR structure of ubiquitin-like domain in PARKIN: gene product of familial Parkinson's disease. J. Biomol. NMR. 2003;25:153&#x2013;156. doi: 10.1023/A:1022254432039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1022254432039</ArticleId><ArticleId IdType="pubmed">12652124</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakata E., Yamaguchi Y., Kurimoto E., Kikuchi J., Yokoyama S., Yamada S., Kawahara H., Yokosawa H., Hattori N., Mizuno Y., et al. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain. EMBO Rep. 2003;4:301&#x2013;306. doi: 10.1038/sj.embor.embor764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.embor764</ArticleId><ArticleId IdType="pmc">PMC1315892</ArticleId><ArticleId IdType="pubmed">12634850</ArticleId></ArticleIdList></Reference><Reference><Citation>Trempe J. F., Chen C. X., Grenier K., Camacho E. M., Kozlov G., McPherson P. S., Gehring K., Fon E. A. SH3 domains from a subset of BAR proteins define a Ubl-binding domain and implicate parkin in synaptic ubiquitination. Mol. Cell. 2009;36:1034&#x2013;1047. doi: 10.1016/j.molcel.2009.11.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2009.11.021</ArticleId><ArticleId IdType="pubmed">20064468</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce L. R., Komander D., Alessi D. R. The nuts and bolts of AGC protein kinases. Nat. Rev. Mol. Cell Biol. 2010;11:9&#x2013;22. doi: 10.1038/nrm2822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm2822</ArticleId><ArticleId IdType="pubmed">20027184</ArticleId></ArticleIdList></Reference><Reference><Citation>Dou H., Buetow L., Sibbet G. J., Cameron K., Huang D. T. Essentiality of a non-RING element in priming donor ubiquitin for catalysis by a monomeric E3. Nat. Struct. Mol. Biol. 2013;20:982&#x2013;986. doi: 10.1038/nsmb.2621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2621</ArticleId><ArticleId IdType="pmc">PMC4471106</ArticleId><ArticleId IdType="pubmed">23851457</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark K., Nanda S., Cohen P. Molecular control of the NEMO family of ubiquitin-binding proteins. Nat. Rev. Mol. Cell Biol. 2013;14:673&#x2013;685. doi: 10.1038/nrm3644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3644</ArticleId><ArticleId IdType="pubmed">23989959</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan G., Tsygankov A. Y. The Cbl family proteins: ring leaders in regulation of cell signaling. J. Cell. Physiol. 2006;209:21&#x2013;43. doi: 10.1002/jcp.20694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcp.20694</ArticleId><ArticleId IdType="pubmed">16741904</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. J., Na K., Kwon M. S., Kim H., Kim K. S., Paik Y. K. Quantitative analysis of phosphopeptides in search of the disease biomarker from the hepatocellular carcinoma specimen. Proteomics. 2009;9:3395&#x2013;3408. doi: 10.1002/pmic.200800943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pmic.200800943</ArticleId><ArticleId IdType="pubmed">19562805</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik R., Lenobel R., Santamaria A., Ries A., Nigg E. A., Korner R. Quantitative analysis of the human spindle phosphoproteome at distinct mitotic stages. J. Proteome Res. 2009;8:4553&#x2013;4563. doi: 10.1021/pr9003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/pr9003773</ArticleId><ArticleId IdType="pubmed">19691289</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennetzen M. V., Larsen D. H., Bunkenborg J., Bartek J., Lukas J., Andersen J. S. Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol. Cell. Proteomics. 2010;9:1314&#x2013;1323. doi: 10.1074/mcp.M900616-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M900616-MCP200</ArticleId><ArticleId IdType="pmc">PMC2877989</ArticleId><ArticleId IdType="pubmed">20164059</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu T. L., Deng X., Huang F., Tucker M., Crosby K., Rimkunas V., Wang Y., Deng G., Zhu L., Tan Z., et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS ONE. 2011;6:e15640. doi: 10.1371/journal.pone.0015640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0015640</ArticleId><ArticleId IdType="pmc">PMC3017127</ArticleId><ArticleId IdType="pubmed">21253578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedford L., Lowe J., Dick L. R., Mayer R. J., Brownell J. E. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat. Rev. Drug Discovery. 2011;10:29&#x2013;46. doi: 10.1038/nrd3321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd3321</ArticleId><ArticleId IdType="pmc">PMC7097807</ArticleId><ArticleId IdType="pubmed">21151032</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24670762</PMID><DateCompleted><Year>2014</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>507</Volume><Issue>7493</Issue><PubDate><Year>2014</Year><Month>Mar</Month><Day>27</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>REST and stress resistance in ageing and Alzheimer's disease.</ArticleTitle><Pagination><StartPage>448</StartPage><EndPage>454</EndPage><MedlinePgn>448-54</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13163</ELocationID><Abstract><AbstractText>Human neurons are functional over an entire lifetime, yet the mechanisms that preserve function and protect against neurodegeneration during ageing are unknown. Here we show that induction of the repressor element 1-silencing transcription factor (REST; also known as neuron-restrictive silencer factor, NRSF) is a universal feature of normal ageing in human cortical and hippocampal neurons. REST is lost, however, in mild cognitive impairment and Alzheimer's disease. Chromatin immunoprecipitation with deep sequencing and expression analysis show that REST represses genes that promote cell death and Alzheimer's disease pathology, and induces the expression of stress response genes. Moreover, REST potently protects neurons from oxidative stress and amyloid &#x3b2;-protein toxicity, and conditional deletion of REST in the mouse brain leads to age-related neurodegeneration. A functional orthologue of REST, Caenorhabditis elegans SPR-4, also protects against oxidative stress and amyloid &#x3b2;-protein toxicity. During normal ageing, REST is induced in part by cell non-autonomous Wnt signalling. However, in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies, REST is lost from the nucleus and appears in autophagosomes together with pathological misfolded proteins. Finally, REST levels during ageing are closely correlated with cognitive preservation and longevity. Thus, the activation state of REST may distinguish neuroprotection from neurodegeneration in the ageing brain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aron</LastName><ForeName>Liviu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zullo</LastName><ForeName>Joseph</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Haeyoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, Dana-Faber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Tun-Hsiang</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyun-Min</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drake</LastName><ForeName>Derek</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X Shirley</ForeName><Initials>XS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, Dana-Faber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colai&#xe1;covo</LastName><ForeName>Monica P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yankner</LastName><ForeName>Bruce A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE53890</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>DP1OD006849</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG26651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000222</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM105853</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM072551</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG027916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 AG044161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG27916</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01GM072551</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP1 OD006849</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026651</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029742">Caenorhabditis elegans Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092779">RE1-silencing transcription factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012097">Repressor Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C474657">SPR-4 protein, C elegans</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Mar 27;507(7493):439-40. doi: 10.1038/nature13214.</RefSource><PMID Version="1">24670758</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 May;15(5):279. doi: 10.1038/nrn3728.</RefSource><PMID Version="1">24675782</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2014 Jun;29(7):869. doi: 10.1002/mds.25910.</RefSource><PMID Version="1">24833024</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2016 Dec 15;540(7633):470. doi: 10.1038/nature20579.</RefSource><PMID Version="1">27851730</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>eNeuro. 2018 Oct 1;5(5):ENEURO.0034-18.2018. doi: 10.1523/ENEURO.0034-18.2018.</RefSource><PMID Version="1">30280122</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001343" MajorTopicYN="N">Autophagy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029742" MajorTopicYN="N">Caenorhabditis elegans Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002467" MajorTopicYN="N">Cell Nucleus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047369" MajorTopicYN="N">Chromatin Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020961" MajorTopicYN="N">Lewy Body Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010588" MajorTopicYN="N">Phagosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012097" MajorTopicYN="N">Repressor Proteins</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015854" MajorTopicYN="N">Up-Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060449" MajorTopicYN="N">Wnt Signaling Pathway</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24670762</ArticleId><ArticleId IdType="mid">NIHMS569698</ArticleId><ArticleId IdType="pmc">PMC4110979</ArticleId><ArticleId IdType="doi">10.1038/nature13163</ArticleId><ArticleId IdType="pii">nature13163</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gomez-Isla T, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer&#x2019;s disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters A, Sethares C, Moss MB. The effects of aging on layer 1 in area 46 of prefrontal cortex in the rhesus monkey. Cereb Cortex. 1998;8:671&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">9863695</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner BA, Lu T, Loerch P. The aging brain. Annu Rev Pathol. 2008;3:41&#x2013;66. doi: 10.1146/annurev.pathmechdis.2.010506.092044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathmechdis.2.010506.092044</ArticleId><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenyon CJ. The genetics of ageing. Nature. 2010;464:504&#x2013;512. doi: 10.1038/nature08980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08980</ArticleId><ArticleId IdType="pubmed">20336132</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisen J. Retrospective birth dating of cells in humans. Cell. 2005;122:133&#x2013;143. doi: 10.1016/j.cell.2005.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.04.028</ArticleId><ArticleId IdType="pubmed">16009139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong JA, et al. REST: a mammalian silencer protein that restricts sodium channel gene expression to neurons. Cell. 1995;80:949&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pubmed">7697725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995;267:1360&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">7871435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G. REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell. 2005;121:645&#x2013;657. doi: 10.1016/j.cell.2005.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.03.013</ArticleId><ArticleId IdType="pubmed">15907476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891.</Citation><ArticleIdList><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS One. 2008;3:e3329. doi: 10.1371/journal.pone.0003329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003329</ArticleId><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr71. doi: 10.1126/scitranslmed.3002369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes JA, et al. The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. J Biol Chem. 2000;275:9461&#x2013;9467.</Citation><ArticleIdList><ArticleId IdType="pubmed">10734093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M. Characterization of the nuclear targeting signal of REST/NRSF. Neurosci Lett. 2006;398:161&#x2013;166. doi: 10.1016/j.neulet.2005.12.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.12.080</ArticleId><ArticleId IdType="pubmed">16442230</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen C, Levitan D, Li X, Greenwald I. spr-2, a suppressor of the egg-laying defect caused by loss of sel-12 presenilin in Caenorhabditis elegans, is a member of the SET protein subfamily. Proc Natl Acad Sci USA. 2000;97:14524&#x2013;14529. doi: 10.1073/pnas.011446498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.011446498</ArticleId><ArticleId IdType="pmc">PMC18952</ArticleId><ArticleId IdType="pubmed">11114162</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakowski B, et al. Two suppressors of sel-12 encode C2H2 zinc-finger proteins that regulate presenilin transcription in Caenorhabditis elegans. Development. 2003;130:2117&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668626</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarriault S, Greenwald I. Suppressors of the egg-laying defective phenotype of sel-12 presenilin mutants implicate the CoREST corepressor complex in LIN-12/Notch signaling in C. elegans. Genes Dev. 2002;16:2713&#x2013;2728. doi: 10.1101/gad.1022402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1022402</ArticleId><ArticleId IdType="pmc">PMC187465</ArticleId><ArticleId IdType="pubmed">12381669</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, et al. Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer&#x2019;s disease risk factors in yeast. Science. 2011;334:1241&#x2013;1245. doi: 10.1126/science.1213210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1213210</ArticleId><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Willert J, Epping M, Pollack JR, Brown PO, Nusse R. A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol. 2002;2:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117803</ArticleId><ArticleId IdType="pubmed">12095419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipinski MM, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2010;107:14164&#x2013;14169. doi: 10.1073/pnas.1009485107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009485107</ArticleId><ArticleId IdType="pmc">PMC2922576</ArticleId><ArticleId IdType="pubmed">20660724</ArticleId></ArticleIdList></Reference><Reference><Citation>Tothova Z, et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell. 2007;128:325&#x2013;339. doi: 10.1016/j.cell.2007.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2007.01.003</ArticleId><ArticleId IdType="pubmed">17254970</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. Hum Mol Genet. 2009;18:4897&#x2013;4904. doi: 10.1093/hmg/ddp459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddp459</ArticleId><ArticleId IdType="pmc">PMC2790334</ArticleId><ArticleId IdType="pubmed">19793722</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballas N, Mandel G. The many faces of REST oversee epigenetic programming of neuronal genes. Curr Opin Neurobiol. 2005;15:500&#x2013;506. doi: 10.1016/j.conb.2005.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2005.08.015</ArticleId><ArticleId IdType="pubmed">16150588</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto SJ, et al. A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J Neurosci. 2007;27:6729&#x2013;6739. doi: 10.1523/jneurosci.0091-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0091-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672685</ArticleId><ArticleId IdType="pubmed">17581960</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrajano JJ, et al. REST and CoREST modulate neuronal subtype specification, maturation and maintenance. PLoS ONE. 2009;4:e7936. doi: 10.1371/journal.pone.0007936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007936</ArticleId><ArticleId IdType="pmc">PMC2782136</ArticleId><ArticleId IdType="pubmed">19997604</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, et al. NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP. Neurobiol Aging. 2013;34:916&#x2013;927. doi: 10.1016/j.neurobiolaging.2012.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.06.002</ArticleId><ArticleId IdType="pubmed">22766071</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature. 2007;447:178&#x2013;182. doi: 10.1038/nature05772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05772</ArticleId><ArticleId IdType="pubmed">17468743</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff J, Tsai LH. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 2013;14:97&#x2013;111. doi: 10.1038/nrn3427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3427</ArticleId><ArticleId IdType="pubmed">23324667</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronan JL, Wu W, Crabtree GR. From neural development to cognition: unexpected roles for chromatin. Nat Rev Genet. 2013;14:347&#x2013;359. doi: 10.1038/nrg3413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg3413</ArticleId><ArticleId IdType="pmc">PMC4010428</ArticleId><ArticleId IdType="pubmed">23568486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce AW, et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci U S A. 2004;101:10458&#x2013;10463. doi: 10.1073/pnas.0401827101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401827101</ArticleId><ArticleId IdType="pmc">PMC478591</ArticleId><ArticleId IdType="pubmed">15240883</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012;9:628&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012;9:646&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Decision rules guiding the clinical diagnosis of Alzheimer&#x2019;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27:169&#x2013;176. doi: 10.1159/000096129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000096129</ArticleId><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, et al. Natural history of mild cognitive impairment in older persons. Neurology. 2002;59:198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200&#x2013;208. doi: 10.1002/ana.21706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21706</ArticleId><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Loerch PM, et al. Evolution of the aging brain transcriptome and synaptic regulation. PLoS One. 2008;3:e3329. doi: 10.1371/journal.pone.0003329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003329</ArticleId><ArticleId IdType="pmc">PMC2553198</ArticleId><ArticleId IdType="pubmed">18830410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">12538238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116&#x2013;5121. doi: 10.1073/pnas.091062498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.091062498</ArticleId><ArticleId IdType="pmc">PMC33173</ArticleId><ArticleId IdType="pubmed">11309499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce AW, et al. Genome-wide analysis of repressor element 1 silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) target genes. Proc Natl Acad Sci USA. 2004;101:10458&#x2013;10463. doi: 10.1073/pnas.0401827101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401827101</ArticleId><ArticleId IdType="pmc">PMC478591</ArticleId><ArticleId IdType="pubmed">15240883</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98:31&#x2013;36. doi: 10.1073/pnas.011404098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.011404098</ArticleId><ArticleId IdType="pmc">PMC14539</ArticleId><ArticleId IdType="pubmed">11134512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, et al. Alteration of NRSF expression exacerbating 1-methyl-4-phenyl-pyridinium ion-induced cell death of SH-SY5Y cells. Neurosci Res. 2009;65:236&#x2013;244. doi: 10.1016/j.neures.2009.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2009.07.006</ArticleId><ArticleId IdType="pubmed">19631241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T, et al. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891. doi: 10.1038/nature02661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02661</ArticleId><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Spalding KL, Bhardwaj RD, Buchholz BA, Druid H, Frisen J. Retrospective birth dating of cells in humans. Cell. 2005;122:133&#x2013;143. doi: 10.1016/j.cell.2005.04.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.04.028</ArticleId><ArticleId IdType="pubmed">16009139</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegmund KD, et al. DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons. PLoS One. 2007;2:e895. doi: 10.1371/journal.pone.0000895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0000895</ArticleId><ArticleId IdType="pmc">PMC1964879</ArticleId><ArticleId IdType="pubmed">17878930</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol. 2008;9:R137. doi: 10.1186/gb-2008-9-9-r137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2008-9-9-r137</ArticleId><ArticleId IdType="pmc">PMC2592715</ArticleId><ArticleId IdType="pubmed">18798982</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenherr CJ, Anderson DJ. The neuron-restrictive silencer factor (NRSF): a coordinate repressor of multiple neuron-specific genes. Science. 1995;267:1360&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">7871435</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DS, Mortazavi A, Myers RM, Wold B. Genome-wide mapping of in vivo protein-DNA interactions. Science. 2007;316:1497&#x2013;1502. doi: 10.1126/science.1141319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141319</ArticleId><ArticleId IdType="pubmed">17540862</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto SJ, et al. A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J Neurosci. 2007;27:6729&#x2013;6739. doi: 10.1523/jneurosci.0091-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/jneurosci.0091-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672685</ArticleId><ArticleId IdType="pubmed">17581960</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao CA, et al. Neuronal transcriptional repressor REST suppresses an Atoh7-independent program for initiating retinal ganglion cell development. Dev Biol. 2011;349:90&#x2013;99. doi: 10.1016/j.ydbio.2010.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ydbio.2010.10.008</ArticleId><ArticleId IdType="pmc">PMC2993882</ArticleId><ArticleId IdType="pubmed">20969844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzo A, et al. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer&#x2019;s disease. Nat Neurosci. 2000;3:460&#x2013;464. doi: 10.1038/74833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/74833</ArticleId><ArticleId IdType="pubmed">10769385</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18. doi: 10.1186/1750-1326-2-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-2-18</ArticleId><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down&#x2019;s syndrome neurons in vitro. Nature. 1995;378:776&#x2013;779. doi: 10.1038/378776a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/378776a0</ArticleId><ArticleId IdType="pubmed">8524410</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S. The genetics of Caenorhabditis elegans. Genetics. 1974;77:71&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1213120</ArticleId><ArticleId IdType="pubmed">4366476</ArticleId></ArticleIdList></Reference><Reference><Citation>Lakowski B, et al. Two suppressors of sel-12 encode C2H2 zinc-finger proteins that regulate presenilin transcription in Caenorhabditis elegans. Development (Cambridge, England) 2003;130:2117&#x2013;2128.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668626</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K, Dorman JB, Rodan A, Kenyon C. daf-16: An HNF-3/forkhead Family Member That Can Function to Double the Life-Span of Caenorhabditis elegans. Science. 1997;278:1319&#x2013;1322. doi: 10.1126/science.278.5341.1319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.278.5341.1319</ArticleId><ArticleId IdType="pubmed">9360933</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Raamsdonk JM, Hekimi S. Deletion of the mitochondrial superoxide dismutase sod-2 extends lifespan in Caenorhabditis elegans. PLoS Genet. 2009;5:e1000361. doi: 10.1371/journal.pgen.1000361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000361</ArticleId><ArticleId IdType="pmc">PMC2628729</ArticleId><ArticleId IdType="pubmed">19197346</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto A, Chelur D, Topalidou I, Chen X, Chalfie M. Enhanced neuronal RNAi in C. elegans using SID-1. Nat Methods. 2010;7:554&#x2013;559. doi: 10.1038/nmeth.1463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1463</ArticleId><ArticleId IdType="pmc">PMC2894993</ArticleId><ArticleId IdType="pubmed">20512143</ArticleId></ArticleIdList></Reference><Reference><Citation>Treusch S, et al. Functional Links Between A&#x3b2; Toxicity, Endocytic Trafficking, and Alzheimer&#x2019;s Disease Risk Factors in Yeast. Science. 2011;334:1241&#x2013;1245. doi: 10.1126/science.1213210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1213210</ArticleId><ArticleId IdType="pmc">PMC3281757</ArticleId><ArticleId IdType="pubmed">22033521</ArticleId></ArticleIdList></Reference><Reference><Citation>Abr&#xe0;moff MD, Magalh&#xe3;es PJ, Ram SJ. Image processing with ImageJ. Biophotonics international. 2004;11:36&#x2013;42.</Citation></Reference><Reference><Citation>Mulligan P, et al. CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol Cell. 2008;32:718&#x2013;726. doi: 10.1016/j.molcel.2008.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2008.10.025</ArticleId><ArticleId IdType="pmc">PMC6595072</ArticleId><ArticleId IdType="pubmed">19061646</ArticleId></ArticleIdList></Reference><Reference><Citation>Westbrook TF, et al. SCFbeta-TRCP controls oncogenic transformation and neural differentiation through REST degradation. Nature. 2008;452:370&#x2013;374. doi: 10.1038/nature06780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06780</ArticleId><ArticleId IdType="pmc">PMC2688689</ArticleId><ArticleId IdType="pubmed">18354483</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M, Hersh LB. Characterization of the REST/NRSF-interacting LIM domain protein (RILP): localization and interaction with REST/NRSF. J Neurochem. 2006;96:1130&#x2013;1138. doi: 10.1111/j.1471-4159.2005.03608.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03608.x</ArticleId><ArticleId IdType="pubmed">16417580</ArticleId></ArticleIdList></Reference><Reference><Citation>Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002;295:868&#x2013;872. doi: 10.1126/science.1067081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067081</ArticleId><ArticleId IdType="pubmed">11786607</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes JA, et al. The co-repressor mSin3A is a functional component of the REST-CoREST repressor complex. J Biol Chem. 2000;275:9461&#x2013;9467.</Citation><ArticleIdList><ArticleId IdType="pubmed">10734093</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimojo M. Characterization of the nuclear targeting signal of REST/NRSF. Neurosci Lett. 2006;398:161&#x2013;166. doi: 10.1016/j.neulet.2005.12.080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.12.080</ArticleId><ArticleId IdType="pubmed">16442230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarov M, et al. A genome-scale resource for in vivo tag-based protein function exploration in C. elegans. Cell. 2012;150:855&#x2013;866. doi: 10.1016/j.cell.2012.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2012.08.001</ArticleId><ArticleId IdType="pmc">PMC3979301</ArticleId><ArticleId IdType="pubmed">22901814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24687165</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Arterial stiffness and &#x3b2;-amyloid progression in nondemented elderly adults.</ArticleTitle><Pagination><StartPage>562</StartPage><EndPage>568</EndPage><MedlinePgn>562-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.186</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Recent studies show that cerebral &#x3b2;-amyloid (A&#x3b2;) deposition is associated with blood pressure and measures of arterial stiffness in nondemented individuals.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the association between measures of arterial stiffness and change in A&#x3b2; deposition over time.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Deposition of A&#x3b2; was determined in a longitudinal observational study of aging by positron emission tomography using the Pittsburgh compound B twice 2 years apart in 81 nondemented individuals 83 years and older. Arterial stiffness was measured with a noninvasive and automated waveform analyzer at the time closest to the second positron emission tomography scan. All measures were performed under standardized conditions. Pulse wave velocity (PWV) was measured in the central (carotid-femoral and heart-femoral PWV), peripheral (femoral-ankle PWV), and mixed (brachial-ankle PWV) vascular beds.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The change in A&#x3b2; deposition over 2 years was calculated from the 81 individuals with repeat A&#x3b2;-positron emission tomography.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The proportion of A&#x3b2;-positive individuals increased from 48% at baseline to 75% at follow-up. Brachial-ankle PWV was significantly higher among A&#x3b2;-positive participants at baseline and follow-up. Femoral-ankle PWV was only higher among A&#x3b2;-positive participants at follow-up. Measures of central stiffness and blood pressure were not associated with A&#x3b2; status at baseline or follow-up, but central stiffness was associated with a change in A&#x3b2; deposition over time. Each standard deviation increase in central stiffness (carotid-femoral PWV, P&#x2009;=&#x2009;.001; heart-femoral PWV, P&#x2009;=&#x2009;.004) was linked with increases in A&#x3b2; deposition over 2 years.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This study showed that A&#x3b2; deposition increases with age in nondemented individuals and that arterial stiffness is strongly associated with the progressive deposition of A&#x3b2; in the brain, especially in this age group. The association between A&#x3b2; deposition changes over time and generalized arterial stiffness indicated a relationship between the severity of subclinical vascular disease and progressive cerebral A&#x3b2; deposition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuller</LastName><ForeName>Lewis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barinas-Mitchell</LastName><ForeName>Emma J M</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klunk</LastName><ForeName>William E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Ann D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Chester A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Virginia, Charlottesville.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Price</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Radiology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lopez</LastName><ForeName>Oscar L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Neurology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R37 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000181</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005133</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG025516</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG025204</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 May;71(5):541-2. doi: 10.1001/jamaneurol.2014.187.</RefSource><PMID Version="1">24687122</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059289" MajorTopicYN="N">Vascular Stiffness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24687165</ArticleId><ArticleId IdType="mid">NIHMS647650</ArticleId><ArticleId IdType="pmc">PMC4267249</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.186</ArticleId><ArticleId IdType="pii">1851478</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sparks DL, Scheff SW, Liu H, Landers TM, Coyne CM, Hunsaker JC., III Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J Neurol Sci. 1995;131(2):162&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C, DeVisser A, Martinez JA, et al. Differential impact of diabetes and hypertension in the brain: adverse effects in white matter. Neurobiol Dis. 2011;42(3):446&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">21324363</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao CW, Seshadri S, Beiser AS, et al. Relations of arterial stiffness and endothelial function to brain aging in the community. Neurology. 2013;81(11):984&#x2013;991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3888200</ArticleId><ArticleId IdType="pubmed">23935179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabkin SW. Arterial stiffness: detection and consequences in cognitive impairment and dementia of the elderly. J Alzheimers Dis. 2012;32(3):541&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pubmed">22886012</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Kuller LH, Klunk WE, et al. In vivo assessment of amyloid-&#x3b2; deposition in nondemented very elderly subjects. Ann Neurol. 2013;73(6):751&#x2013;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725727</ArticleId><ArticleId IdType="pubmed">23596051</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JBS, Chen KW, Launer LJ, et al. Blood pressure is associated with higher brain amyloid burden and lower glucose metabolism in healthy late middle-age persons. Neurobiol Aging. 2012;33(4):e11&#x2013;e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236809</ArticleId><ArticleId IdType="pubmed">21821316</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Toledo E, Weiner MW, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Cardiovascular risk factors, cortisol, and amyloid-&#x3b2; deposition in Alzheimer&#x2019;s Disease Neuroimaging Initiative. Alzheimers Dement. 2012;8(6):483&#x2013;489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3668456</ArticleId><ArticleId IdType="pubmed">23102118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes TM, Kuller LH, Barinas-Mitchell EJM, et al. Pulse wave velocity is associated with &#x3b2;-amyloid deposition in the brains of very elderly adults. Neurology. 2013;81(19):1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3812104</ArticleId><ArticleId IdType="pubmed">24132374</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Fitzpatrick A, Ives DG, et al. GEMS Investigators. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27(3):238&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">16627007</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Mowrey W, Weissfeld LA, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 2013;71:207&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605888</ArticleId><ArticleId IdType="pubmed">23353602</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509&#x2013;1517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, Rosano C, Butters M, et al. A fully automated method for quantifying and localizing white matter hyperintensities on MR images. Psychiatry Res. 2006;148(2-3):133&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1761950</ArticleId><ArticleId IdType="pubmed">17097277</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesielski KC, Udupa JK, Saha PK, Zhuge Y. Iterative relative fuzzy connectedness for multiple objects with multiple seeds. Comput Vis Image Underst. 2007;107(3):160&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442428</ArticleId><ArticleId IdType="pubmed">18769655</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenstein HJ, Butters MA, Clark KA, et al. Prefrontal and striatal activation in elderly subjects during concurrent implicit and explicit sequence learning. Neurobiol Aging. 2006;27(5):741&#x2013;751.</Citation><ArticleIdList><ArticleId IdType="pubmed">15935517</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosano CAH, Aizenstein H, Cochran J, et al. Functional neuroimaging indicators of successful executive control in the oldest old. Neuroimage. 2005;28(4):881&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">16226041</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz BE, Weissfeld LA, Lopez OL, et al. Cognitive trajectories associated with &#x3b2;-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80(15):1378&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662268</ArticleId><ArticleId IdType="pubmed">23516317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuller LH, Ives DG, Fitzpatrick AL, et al. Ginkgo Evaluation of Memory Study Investigators. Does Ginkgo biloba reduce the risk of cardiovascular events? Circ Cardiovasc Qual Outcomes. 2010;3(1):41&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858335</ArticleId><ArticleId IdType="pubmed">20123670</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez-Cooper MY, Supak JA, Tanaka H. A new device for automatic measurements of arterial stiffness and ankle-brachial index. Am J Cardiol. 2003;91(12):1519&#x2013;1522. A9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12804752</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes TM, Althouse AD, Niemczyk NA, Hawkins MS, Kuipers AL, Sutton-Tyrrell K. Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial. Cardiovasc Diabetol. 2012;11:114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468408</ArticleId><ArticleId IdType="pubmed">22998737</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashina A, Tomiyama H, Takeda K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res. 2002;25(3):359&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">12135313</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell GF, Parise H, Benjamin EJ, et al. Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension. 2004;43(6):1239&#x2013;1245.</Citation><ArticleIdList><ArticleId IdType="pubmed">15123572</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol (1985) 2008;105(5):1652&#x2013;1660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2584844</ArticleId><ArticleId IdType="pubmed">18772322</ArticleId></ArticleIdList></Reference><Reference><Citation>Joas E, B&#xe4;ckman K, Gustafson D, et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension. 2012;59(4):796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">22331381</ArticleId></ArticleIdList></Reference><Reference><Citation>Glodzik L, Rusinek H, Pirraglia E, et al. Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly. Neurobiol Aging. 2014;35(1):64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799812</ArticleId><ArticleId IdType="pubmed">23969178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AK, Lawlor DA, Matthews FE, et al. Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts. PLoS Med. 2011;8(6):e1000440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114857</ArticleId><ArticleId IdType="pubmed">21695075</ArticleId></ArticleIdList></Reference><Reference><Citation>Seidlerov&#xe1; J, Filipovsk&#xfd; J, Dolejsov&#xe1; M. Determinants of aortic stiffening in elderly subjects: results of a nine-year follow-up. Blood Press. 2013;22(3):173&#x2013;178.</Citation><ArticleIdList><ArticleId IdType="pubmed">23421614</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group. Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell GF, Vita JA, Larson MG, et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation. 2005;112(24):3722&#x2013;3728.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rom&#xe1;n GC. Brain hypoperfusion: a critical factor in vascular dementia. Neurol Res. 2004;26(5):454&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">15265263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar&#xed;n-Padilla M, Knopman DS. Developmental aspects of the intracerebral microvasculature and perivascular spaces: insights into brain response to late-life diseases. J Neuropathol Exp Neurol. 2011;70(12):1060&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3227674</ArticleId><ArticleId IdType="pubmed">22082663</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid &#x3b2;. Sci Transl Med. 2012;4(147):ra111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551275</ArticleId><ArticleId IdType="pubmed">22896675</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong RA. Classic beta-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer&#x2019;s disease. Curr Neurovasc Res. 2006;3(4):289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17109624</ArticleId></ArticleIdList></Reference><Reference><Citation>Provenzano FA, Muraskin J, Tosto G, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013;70(4):455&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4124641</ArticleId><ArticleId IdType="pubmed">23420027</ArticleId></ArticleIdList></Reference><Reference><Citation>Haight TJ, Landau SM, Carmichael O, Schwarz C, DeCarli C, Jagust WJ. Alzheimer&#x2019;s Disease Neuroimaging Initiative. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. JAMA Neurol. 2013;70(8):1039&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3779687</ArticleId><ArticleId IdType="pubmed">23779022</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24698269</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice.</ArticleTitle><Pagination><StartPage>79</StartPage><EndPage>93</EndPage><MedlinePgn>79-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.02.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00117-2</ELocationID><Abstract><AbstractText>Mushroom dendritic spine structures are essential for memory storage, and the loss of mushroom spines may explain memory defects in Alzheimer's disease (AD). Here we show a significant reduction in the fraction of mushroom spines in hippocampal neurons from the presenilin-1 M146V knockin (KI) mouse model of familial AD (FAD). The stabilization of mushroom spines depends on STIM2-mediated neuronal store-operated calcium influx (nSOC) and continuous activity of Ca(2+)/calmodulin-dependent protein kinase II (CaMKII). We demonstrate that STIM2-nSOC-CaMKII pathway is compromised in KI neurons, in aging neurons, and in sporadic AD brains due to downregulation of STIM2 protein. We further establish that overexpression of STIM2 rescues synaptic nSOC, CaMKII activity, and mushroom spine loss in KI neurons. Our results identify STIM2-nSOC-CaMKII synaptic maintenance pathway as a novel potential therapeutic target for treatment of AD and age-related memory decline.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Suya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popugaeva</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurodegeneration, Saint Petersburg State Polytechnical University, Saint Petersburg, 195251, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Nan-Jie</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai&#xa0;Jiao Tong University School of Medicine, Shanghai 200025, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feske</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, New York University Langone Medical Center, New York, NY 10016, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>Charles L</ForeName><Initials>CL</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Pathology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezprozvanny</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Laboratory of Molecular Neurodegeneration, Saint Petersburg State Polytechnical University, Saint Petersburg, 195251, Russia. Electronic address: Ilya.Bezprozvanny@UTSouthwestern.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI097302</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG012300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS080152</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI097302</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080152</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI066128</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 MH100024</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG12300</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053766">Presenilin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C095101">Psen2 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053766" MajorTopicYN="N">Presenilin-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24698269</ArticleId><ArticleId IdType="mid">NIHMS569119</ArticleId><ArticleId IdType="pmc">PMC4007018</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.02.019</ArticleId><ArticleId IdType="pii">S0896-6273(14)00117-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akbari Y, Hitt BD, Murphy MP, Dagher NN, Tseng BP, Green KN, Golde TE, LaFerla FM. Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochemical and biophysical research communications. 2004;322:1145&#x2013;1152.</Citation><ArticleIdList><ArticleId IdType="pubmed">15336962</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffret A, Gautheron V, Mattson MP, Mariani J, Rovira C. Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice. Journal of Alzheimer's disease : JAD. 2010;19:1021&#x2013;1033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891870</ArticleId><ArticleId IdType="pubmed">20157256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandara S, Malmersjo S, Meyer T. Regulators of Calcium Homeostasis Identified by Inference of Kinetic Model Parameters from Live Single Cells Perturbed by siRNA. Science signaling. 2013;6:ra56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3897207</ArticleId><ArticleId IdType="pubmed">23838183</ArticleId></ArticleIdList></Reference><Reference><Citation>Berna-Erro A, Braun A, Kraft R, Kleinschnitz C, Schuhmann MK, Stegner D, Wultsch T, Eilers J, Meuth SG, Stoll G, et al. STIM2 regulates capacitive Ca2+ entry in neurons and plays a key role in hypoxic neuronal cell death. Sci Signal. 2009;2:ra67.</Citation><ArticleIdList><ArticleId IdType="pubmed">19843959</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Hiesinger PR. The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener. 2013;8:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3708831</ArticleId><ArticleId IdType="pubmed">23829673</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci. 2008;31:454&#x2013;463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566585</ArticleId><ArticleId IdType="pubmed">18675468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojarski L, Pomorski P, Szybinska A, Drab M, Skibinska-Kijek A, Gruszczynska-Biegala J, Kuznicki J. Presenilin-dependent expression of STIM proteins and dysregulation of capacitative Ca2+ entry in familial Alzheimer's disease. Biochim Biophys Acta. 2009;1793:1050&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">19111578</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol. 2007;17:381&#x2013;386.</Citation><ArticleIdList><ArticleId IdType="pubmed">17498943</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci. 2008;31:47&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2561948</ArticleId><ArticleId IdType="pubmed">18284372</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Goussakov I, Miller MB, Stutzmann GE. Deviant ryanodine receptor-mediated calcium release resets synaptic homeostasis in presymptomatic 3xTg-AD mice. J Neurosci. 2009;29:9458&#x2013;9470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6666542</ArticleId><ArticleId IdType="pubmed">19641109</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins SR, Meyer T. Evolutionary origins of STIM1 and STIM2 within ancient Ca(2+) signaling systems. Trends Cell Biol. 2011;21:202&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175768</ArticleId><ArticleId IdType="pubmed">21288721</ArticleId></ArticleIdList></Reference><Reference><Citation>Das HK, Tchedre K, Mueller B. Repression of transcription of presenilin-1 inhibits gamma-secretase independent ER Ca(2)(+) leak that is impaired by FAD mutations. J Neurochem. 2012;122:487&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">22607268</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickstein DL, Weaver CM, Luebke JI, Hof PR. Dendritic spine changes associated with normal aging. Neuroscience. 2013;251:21&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654095</ArticleId><ArticleId IdType="pubmed">23069756</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitriu D, Rodriguez A, Morrison JH. High-throughput, detailed, cell-specific neuroanatomy of dendritic spines using microinjection and confocal microscopy. Nat Protoc. 2011;6:1391&#x2013;1411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3566769</ArticleId><ArticleId IdType="pubmed">21886104</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng B, Raghavachari S, Lisman J. Quantitative estimates of the cytoplasmic, PSD, and NMDAR-bound pools of CaMKII in dendritic spines. Brain Res. 2011;1419:46&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196057</ArticleId><ArticleId IdType="pubmed">21925648</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster TC. Calcium homeostasis and modulation of synaptic plasticity in the aged brain. Aging cell. 2007;6:319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">17517041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gant JC, Sama MM, Landfield PW, Thibault O. Early and simultaneous emergence of multiple hippocampal biomarkers of aging is mediated by Ca2+-induced Ca2+ release. J Neurosci. 2006;26:3482&#x2013;3490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673869</ArticleId><ArticleId IdType="pubmed">16571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Goussakov I, Miller MB, Stutzmann GE. NMDA-mediated Ca(2+) influx drives aberrant ryanodine receptor activation in dendrites of young Alzheimer's disease mice. J Neurosci. 2010;30:12128&#x2013;12137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2944253</ArticleId><ArticleId IdType="pubmed">20826675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruszczynska-Biegala J, Pomorski P, Wisniewska MB, Kuznicki J. Differential Roles for STIM1 and STIM2 in Store-Operated Calcium Entry in Rat Neurons. PloS one. 2011;6:e19285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082561</ArticleId><ArticleId IdType="pubmed">21541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nature medicine. 1999;5:101&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Herms J, Schneider I, Dewachter I, Caluwaerts N, Kretzschmar H, Van Leuven F. Capacitive calcium entry is directly attenuated by mutant presenilin-1, independent of the expression of the amyloid precursor protein. J Biol Chem. 2003;278:2484&#x2013;2489.</Citation><ArticleIdList><ArticleId IdType="pubmed">12431992</ArticleId></ArticleIdList></Reference><Reference><Citation>Higley MJ, Sabatini BL. Calcium signaling in dendritic spines. Cold Spring Harb Perspect Biol. 2012;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312680</ArticleId><ArticleId IdType="pubmed">22338091</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr., Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci. 2003;26:360&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12850432</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus UG, Bamberg A, Bokoch GM. Rac and Rap GTPase activation assays. Methods Mol Biol. 2007;412:59&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18453105</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M, Mansuy IM. Dendritic spine loss and synaptic alterations in Alzheimer's disease. Molecular neurobiology. 2008;37:73&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Hyman BT, Spires-Jones TL. Alzheimer's disease: synapses gone cold. Mol Neurodegener. 2011;6:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178498</ArticleId><ArticleId IdType="pubmed">21871088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Bodhinathan K, Foster TC. Susceptibility to Calcium Dysregulation during Brain Aging. Frontiers in aging neuroscience. 2009;1:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874411</ArticleId><ArticleId IdType="pubmed">20552053</ArticleId></ArticleIdList></Reference><Reference><Citation>Leissring MA, Akbari Y, Fanger CM, Cahalan MD, Mattson MP, LaFerla FM. Capacitative calcium entry deficits and elevated luminal calcium content in mutant presenilin-1 knockin mice. J Cell Biol. 2000;149:793&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2174559</ArticleId><ArticleId IdType="pubmed">10811821</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Dang S, Yan C, Gong X, Wang J, Shi Y. Structure of a presenilin family intramembrane aspartate protease. Nature. 2013;493:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">23254940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisman J, Yasuda R, Raghavachari S. Mechanisms of CaMKII action in long-term potentiation. Nat Rev Neurosci. 2012;13:169&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050655</ArticleId><ArticleId IdType="pubmed">22334212</ArticleId></ArticleIdList></Reference><Reference><Citation>Luebke JI, Weaver CM, Rocher AB, Rodriguez A, Crimins JL, Dickstein DL, Wearne SL, Hof PR. Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models. Brain structure &amp; function. 2010;214:181&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3045830</ArticleId><ArticleId IdType="pubmed">20177698</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakoshi H, Yasuda R. Postsynaptic signaling during plasticity of dendritic spines. Trends Neurosci. 2012;35:135&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306839</ArticleId><ArticleId IdType="pubmed">22222350</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, Supnet C, Liu H, Bezprozvanny I. Familial Alzheimer's disease mutations in presenilins: effects on endoplasmic reticulum calcium homeostasis and correlation with clinical phenotypes. Journal of Alzheimer's disease : JAD. 2010;21:781&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4996666</ArticleId><ArticleId IdType="pubmed">20634584</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson O, Tu H, Lei T, Bentahir M, de Strooper B, Bezprozvanny I. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest. 2007;117:1230&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1847535</ArticleId><ArticleId IdType="pubmed">17431506</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh-Hora M, Yamashita M, Hogan PG, Sharma S, Lamperti E, Chung W, Prakriya M, Feske S, Rao A. Dual functions for the endoplasmic reticulum calcium sensors STIM1 and STIM2 in T cell activation and tolerance. Nature immunology. 2008;9:432&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737533</ArticleId><ArticleId IdType="pubmed">18327260</ArticleId></ArticleIdList></Reference><Reference><Citation>Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3530413</ArticleId><ArticleId IdType="pubmed">21346746</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugaeva E, Bezprozvanny I. Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease. Frontiers in molecular neuroscience. 2013;6:29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3776136</ArticleId><ArticleId IdType="pubmed">24065882</ArticleId></ArticleIdList></Reference><Reference><Citation>Popugaeva E, Supnet C, Bezprozvanny I. Presenilins, deranged calcium homeostasis, synaptic loss and dysfunction in Alzheimer's disease. Messenger. 2012;1:53&#x2013;62.</Citation></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, Wolburg H, Gengler S, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 2006;7:940&#x2013;946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Reese LC, Laezza F, Woltjer R, Taglialatela G. Dysregulated phosphorylation of Ca(2+) /calmodulin-dependent protein kinase II-alpha in the hippocampus of subjects with mild cognitive impairment and Alzheimer's disease. J Neurochem. 2011;119:791&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4021864</ArticleId><ArticleId IdType="pubmed">21883216</ArticleId></ArticleIdList></Reference><Reference><Citation>Riccio A, Medhurst AD, Mattei C, Kelsell RE, Calver AR, Randall AD, Benham CD, Pangalos MN. mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res. 2002;109:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12531519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PloS one. 2008;3:e1997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292261</ArticleId><ArticleId IdType="pubmed">18431482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci. 2011;31:9170&#x2013;9178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3138556</ArticleId><ArticleId IdType="pubmed">21697368</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Alzheimer's disease is a synaptic failure. Science. 2002;298:789&#x2013;791.</Citation><ArticleIdList><ArticleId IdType="pubmed">12399581</ArticleId></ArticleIdList></Reference><Reference><Citation>Skibinska-Kijek A, Wisniewska MB, Gruszczynska-Biegala J, Methner A, Kuznicki J. Immunolocalization of STIM1 in the mouse brain. Acta Neurobiol Exp (Wars) 2009;69:413&#x2013;428.</Citation><ArticleIdList><ArticleId IdType="pubmed">20048759</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, Laferla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007;1097:265&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">17413028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X, Beglopoulos V, Mattson MP, Shen J. Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation. Neuro-degenerative diseases. 2005;2:6&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">16908998</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau. J Neurosci. 2009;29:14439&#x2013;14450.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6665808</ArticleId><ArticleId IdType="pubmed">19923278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tackenberg C, Ghori A, Brandt R. Thin, stubby or mushroom: spine pathology in Alzheimer's disease. Current Alzheimer research. 2009;6:261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pubmed">19519307</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian L, Hires SA, Mao T, Huber D, Chiappe ME, Chalasani SH, Petreanu L, Akerboom J, McKinney SA, Schreiter ER, et al. Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators. Nat Methods. 2009;6:875&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858873</ArticleId><ArticleId IdType="pubmed">19898485</ArticleId></ArticleIdList></Reference><Reference><Citation>Toescu EC, Verkhratsky A. The importance of being subtle: small changes in calcium homeostasis control cognitive decline in normal aging. Aging cell. 2007;6:267&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">17517038</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee S-F, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER calcium leak channels, a function disrupted by mutations linked to familial Alzheimer's disease. Cell. 2006;126:981&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3241869</ArticleId><ArticleId IdType="pubmed">16959576</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Dineley KT, Sweatt JD, Zheng H. Presenilin 1 familial Alzheimer's disease mutation leads to defective associative learning and impaired adult neurogenesis. Neuroscience. 2004;126:305&#x2013;312.</Citation><ArticleIdList><ArticleId IdType="pubmed">15207348</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Lacor PN, Pitt J, Klein WL. Abeta oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol. 2011;31:939&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146579</ArticleId><ArticleId IdType="pubmed">21538118</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ. Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not beta-amyloid in cognitively normal older individuals. J Neurosci. 2013a;33:5553&#x2013;5563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3687777</ArticleId><ArticleId IdType="pubmed">23536070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ. Associations Between Alzheimer Disease Biomarkers, Neurodegeneration, and Cognition in Cognitively Normal Older People. JAMA neurology. 2013b doi: 10.1001/jamaneurol.2013.4013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962545</ArticleId><ArticleId IdType="pubmed">24166579</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh C, Mahoney M, Chesworth R, Shapiro G, Zimina O, et al. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Chemistry &amp; biology. 2011;18:777&#x2013;793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3124661</ArticleId><ArticleId IdType="pubmed">21700213</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda R, Sabatini BL, Svoboda K. Plasticity of calcium channels in dendritic spines. Nat Neurosci. 2003;6:948&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">12937422</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo AS, Cheng I, Chung S, Grenfell TZ, Lee H, Pack-Chung E, Handler M, Shen J, Xia W, Tesco G, et al. Presenilin-mediated modulation of capacitative calcium entry. Neuron. 2000;27:561&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">11055438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I. Role of presenilins in neuronal calcium homeostasis. J Neurosci. 2010;30:8566&#x2013;8580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2906098</ArticleId><ArticleId IdType="pubmed">20573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Du W, Zhou K, Tai Y, Yao H, Jia Y, Ding Y, Wang Y. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat Neurosci. 2008;11:741&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">18516035</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24702820</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1558-1497</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>9</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurobiology of aging</Title><ISOAbbreviation>Neurobiol Aging</ISOAbbreviation></Journal><ArticleTitle>18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.</ArticleTitle><Pagination><StartPage>2096</StartPage><EndPage>2106</EndPage><MedlinePgn>2096-106</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neurobiolaging.2014.03.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0197-4580(14)00240-1</ELocationID><Abstract><AbstractText>Our objective was to examine associations between glucose metabolism, as measured by (18)F-fluorodeoxyglucose positron emission tomography (FDG PET), and age and to evaluate the impact of carriage of an apolipoprotein E (APOE) &#x3b5;4 allele on glucose metabolism and on the associations between glucose metabolism and age. We studied 806 cognitively normal (CN) and 70 amyloid-imaging-positive cognitively impaired participants (35 with mild cognitive impairment and 35 with Alzheimer's disease [AD] dementia) from the Mayo Clinic Study of Aging, Mayo Alzheimer's Disease Research Center and an ancillary study who had undergone structural MRI, FDG PET, and (11)C-Pittsburgh compound B (PiB) PET. Using partial volume corrected and uncorrected FDG PET glucose uptake ratios, we evaluated associations of regional FDG ratios with age and carriage of an APOE &#x3b5;4 allele in CN participants between the ages of 30 and 95 years, and compared those findings with the cognitively impaired participants. In region-of-interest (ROI) analyses, we found modest but statistically significant declines in FDG ratio in most cortical and subcortical regions as a function of age. We also found a main effect of APOE &#x3b5;4 genotype on FDG ratio, with greater uptake in &#x3b5;4 noncarriers compared with carriers but only in the posterior cingulate and/or precuneus, lateral parietal, and AD-signature meta-ROI. The latter consisted of voxels from posterior cingulate and/or precuneus, lateral parietal, and inferior temporal. In age- and sex-matched CN participants the magnitude of the difference in partial volume corrected FDG ratio in the AD-signature meta-ROI for APOE &#x3b5;4 carriers compared with noncarriers was about 4 times smaller than the magnitude of the difference between age- and sex-matched elderly APOE &#x3b5;4 carrier CN compared with AD dementia participants. In an analysis in participants older than 70 years (31.3% of whom had elevated PiB), there was no interaction between PiB status and APOE &#x3b5;4 genotype with respect to glucose metabolism. Glucose metabolism declines with age in many brain regions. Carriage of an APOE &#x3b5;4 allele was associated with reductions in FDG ratio in the posterior cingulate and/or precuneus, lateral parietal, and AD-signature ROIs, and there was no interaction between age and APOE &#x3b5;4 status. The posterior cingulate and/or precuneus and lateral parietal regions have a unique vulnerability to reductions in glucose metabolic rate as a function both of age and carriage of an APOE &#x3b5;4 allele.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Knopman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA; Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA. Electronic address: knopman@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA; Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiste</LastName><ForeName>Heather J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lundt</LastName><ForeName>Emily S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weigand</LastName><ForeName>Stephen D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vemuri</LastName><ForeName>Prashanthi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lowe</LastName><ForeName>Val J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kantarci</LastName><ForeName>Kejal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunter</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senjem</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mielke</LastName><ForeName>Michelle M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Rosebud O</ForeName><Initials>RO</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA; Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic and Foundation, Rochester, MN, USA; Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic and Foundation, Rochester, MN, USA; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG11378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000135</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG06786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurobiol Aging</MedlineTA><NlmUniqueID>8100437</NlmUniqueID><ISSNLinking>0197-4580</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="Y">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="Y">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="Y">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="Y">Radiopharmaceuticals</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Apolipoprotein E</Keyword><Keyword MajorTopicYN="N">FDG positron emission tomography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24702820</ArticleId><ArticleId IdType="mid">NIHMS576132</ArticleId><ArticleId IdType="pmc">PMC4053507</ArticleId><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.03.006</ArticleId><ArticleId IdType="pii">S0197-4580(14)00240-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albert M, DeKosky ST, Dickson D, Dubois B, Feldman H, Fox NC, Gamst A, Holtzman D, Jagust WJ, Petersen RC, Snyder PJ, Phelps CH. The Diagnosis of Mild cognitive impairment due to Alzheimer&#x2019;s disease: Report of the National Institute on Aging and the Alzheimer&#x2019;s Association Workgroup. Alzheimer&#x2019;s Demen J Alzheimer&#x2019;s Assoc. 2011;7:270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour A, Morris JC, Wolk DA, Dickerson BC. The effects of aging and Alzheimer&#x2019;s disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage. 2013;76:332&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4098706</ArticleId><ArticleId IdType="pubmed">23507382</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain&#x2019;s default network: anatomy, function, and relevance to disease. Ann NY Acad Sci. 2008;1124:1&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Cash DM, Ridgway GR, Liang Y, Ryan NS, Kinnunen KM, Yeatman T, Malone IB, Benzinger TL, Jack CR, Jr, Thompson PM, Ghetti BF, Saykin AJ, Masters CL, Ringman JM, Salloway SP, Schofield PR, Sperling RA, Cairns NJ, Marcus DS, Xiong C, Bateman RJ, Morris JC, Rossor MN, Ourselin S, Fox NC. The pattern of atrophy in familial Alzheimer disease: volumetric MRI results from the DIAN study. Neurology. 2013;81:1425&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806583</ArticleId><ArticleId IdType="pubmed">24049139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chetelat G, Desgranges B, Landeau B, Mezenge F, Poline JB, de la Sayette V, Viader F, Eustache F, Baron JC. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer&#x2019;s disease. Brain. 2008;131:60&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">18063588</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, Nebes RD, Saxton JA, Snitz BE, Aizenstein HA, Wolk DA, Dekosky ST, Mathis CA, Klunk WE. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci. 2009;29:14770&#x2013;14778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2810461</ArticleId><ArticleId IdType="pubmed">19940172</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Suarez-Calvet M, William CM, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, Beckmann CF, Mackay CE. Distinct patterns of brain activity in young carriers of the APOE-epsilon4 allele. Proc Natl Acad Sci USA. 2009;106:7209&#x2013;7214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678478</ArticleId><ArticleId IdType="pubmed">19357304</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, McEvoy L, Holland D, Dale AM, Walhovd KB. Brain changes in older adults at very low risk for Alzheimer&#x2019;s disease. J Neurosci. 2013;33:8237&#x2013;8242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4050197</ArticleId><ArticleId IdType="pubmed">23658162</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunter JL, Bernstein MA, Borowski BJ, Ward CP, Britson PJ, Felmlee JP, Schuff N, Weiner M, Jack CR. Measurement of MRI scanner performance with the ADNI phantom. Med Phys. 2009;36:2193&#x2013;2205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2754942</ArticleId><ArticleId IdType="pubmed">19610308</ArticleId></ArticleIdList></Reference><Reference><Citation>Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">12482085</ArticleId></ArticleIdList></Reference><Reference><Citation>Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pubmed">2341813</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez V, Pietrini P, Furey ML, Alexander GE, Millet P, Bokde AL, Teichberg D, Schapiro MB, Horwitz B, Rapoport SI. Resting state brain glucose metabolism is not reduced in normotensive healthy men during aging, after correction for brain atrophy. Brain Res Bull. 2004;63:147&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">15130704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivancevic V, Alavi A, Souder E, Mozley PD, Gur RE, Benard F, Munz DL. Regional cerebral glucose metabolism in healthy volunteers determined by fluordeoxyglucose positron emission tomography: appearance and variance in the transaxial, coronal, and sagittal planes. Clin Nucl Med. 2000;25:596&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">10944013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer&#x2019;s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. An operational approach to National Institute on Aging-Alzheimer&#x2019;s Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586223</ArticleId><ArticleId IdType="pubmed">22488240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer&#x2019;s disease and amnestic mild cognitive impairment. Brain. 2008;131:665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, O&#x2019;Brien PC, Rettman DW, Shiung MM, Xu Y, Muthupillai R, Manduca A, Avula R, Erickson BJ. FLAIR histogram segmentation for measurement of leukoaraiosis volume. J Magn Reson Imaging. 2001;14:668&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2755497</ArticleId><ArticleId IdType="pubmed">11747022</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Landau SM. Apolipoprotein E, not Fibrillar beta-amyloid, Reduces cerebral glucose metabolism in Normal aging. J Neurosci. 2012;32:18227&#x2013;18233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3537830</ArticleId><ArticleId IdType="pubmed">23238736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C, Barre L, Constans JM, Viader F, Eustache F, Desgranges B. Voxel-based mapping of brain gray matter volume and glucose metabolism profiles in normal aging. Neurobiol Aging. 2009;30:112&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pubmed">17630048</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Petersen RC, Przybelski SA, Weigand SD, Shiung MM, Whitwell JL, Negash S, Ivnik RJ, Boeve BF, Knopman DS, Smith GE, Jack CR., Jr Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. Arch Neurol. 2008;65:1621&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2743393</ArticleId><ArticleId IdType="pubmed">19064749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kantarci K, Senjem ML, Lowe VJ, Wiste HJ, Weigand SD, Kemp BJ, Frank AR, Shiung MM, Boeve BF, Knopman DS, Petersen RC, Jack CR., Jr Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol. 2010;31:1247&#x2013;1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2890033</ArticleId><ArticleId IdType="pubmed">20299441</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem M, Ivnik RJ, Roberts RO, Boeve BF, Petersen RC. Short-term Clinical Outcomes for Stages of NIA-AA pre-clinical Alzheimer disease. Neurology. 2012;78:1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. Selective Worsening of brain Injury Biomarker Abnormalities in cognitively Normal elderly with &#x3b2;-amyloidosis. JAMA Neurol. 2013;70:1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884555</ArticleId><ArticleId IdType="pubmed">23797806</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H, Karhunen PJ. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009;65:650&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19557866</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207&#x2013;1218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891865</ArticleId><ArticleId IdType="pubmed">19660834</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302. Epub 2012 Feb 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med. 1995;36:1141&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790936</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959&#x2013;1972.</Citation><ArticleIdList><ArticleId IdType="pubmed">16330558</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L, Jack CR, Jr, Knopman D, Petersen RC. Application of the National Institute on Aging-Alzheimer&#x2019;s Association AD criteria to ADNI. Neurology. 2013;80:2130&#x2013;2137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3716359</ArticleId><ArticleId IdType="pubmed">23645596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O&#x2019;Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci USA. 2003;100:14504&#x2013;14509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CRJ, Kawas CH, Klunk WE. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimer&#x2019;s Demen J Alzheimer&#x2019;s Assoc. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, Dekosky S, Mathis CA. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med. 2009;50:348&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694747</ArticleId><ArticleId IdType="pubmed">19223409</ArticleId></ArticleIdList></Reference><Reference><Citation>Meltzer CC, Cantwell MN, Greer PJ, Ben-Eliezer D, Smith G, Frank G, Kaye WH, Houck PR, Price JC. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med. 2000;41:1842&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079492</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer&#x2019;s disease. Ann Neurol. 1997;42:85&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">9225689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Rabinovici GD, Marks S, Baker SL, Jagust WJ. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 2012;59:1152&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230690</ArticleId><ArticleId IdType="pubmed">21884802</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67:122&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830375</ArticleId><ArticleId IdType="pubmed">20186853</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer&#x2019;s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">15747152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer&#x2019;s disease and mild cognitive impairment. Ann Neurol. 2003;54:343&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">12953266</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp. 2014;35:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600112</ArticleId><ArticleId IdType="pubmed">22965806</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Roberts RO, Knopman DS, Geda YE, Cha RC, Pankratz VS, Boeve BF, Tangalos EG, Ivnik RJ, Rocca WA. Prevalence of mild cognitive impairment is higher in men than in women. The Mayo Clinic Study of Aging. Neurology. 2010;75:889&#x2013;897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2938972</ArticleId><ArticleId IdType="pubmed">20820000</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547.</Citation><ArticleIdList><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD, Furst AJ, Alkalay A, Racine CA, O&#x2019;Neil JP, Janabi M, Baker SL, Agarwal N, Bonasera SJ, Mormino EC, Weiner MW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ. Increased metabolic vulnerability in early-onset Alzheimer&#x2019;s disease is not related to amyloid burden. Brain. 2010;133:512&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2858015</ArticleId><ArticleId IdType="pubmed">20080878</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci USA. 2001;98:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer&#x2019;s disease. Proc Natl Acad Sci USA. 2001;98:3334&#x2013;3339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC30654</ArticleId><ArticleId IdType="pubmed">11248079</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D. Preclinical evidence of Alzheimer&#x2019;s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med. 1996;334:752&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">8592548</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman D, Cha R, Pankratz VS, Boeve B, Ivnik R, Tangalos E, Petersen RC, Rocca WA. The Mayo Clinic study of aging: Design and Sampling, Participation, Baseline measures and Sample Characteristics. Neuroepidemiology. 2008;30:58&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821441</ArticleId><ArticleId IdType="pubmed">18259084</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Tangalos EG, Ivnik RJ, Rocca WA, Petersen RC. The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology. 2012;78:342&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280046</ArticleId><ArticleId IdType="pubmed">22282647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Kennedy KM, Devous MD, Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280058</ArticleId><ArticleId IdType="pubmed">22302550</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O&#x2019;Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O&#x2019;Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology. 2007;68:1718&#x2013;1725.</Citation><ArticleIdList><ArticleId IdType="pubmed">17502554</ArticleId></ArticleIdList></Reference><Reference><Citation>Salat DH, Buckner RL, Snyder AZ, Greve DN, Desikan RS, Busa E, Morris JC, Dale AM, Fischl B. Thinning of the cerebral cortex in aging. Cereb Cortex. 2004;14:721&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">15054051</ArticleId></ArticleIdList></Reference><Reference><Citation>Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. Mapping cortical change across the human life span. Nat Neurosci. 2003;6:309&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548289</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, Mazoyer B, Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771995</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, Aizenstein HJ, Cohen AD, Weissfeld LA, Mathis CA, Klunk WE, Dekoskym ST. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65:557&#x2013;568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828870</ArticleId><ArticleId IdType="pubmed">19475670</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanase D, Matsunari I, Yajima K, Chen W, Fujikawa A, Nishimura S, Matsuda H, Yamada M. Brain FDG PET study of normal aging in Japanese: effect of atrophy correction. Eur J Nucl Med Mol Imaging. 2005;32:794&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">15759148</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24711047</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.</ArticleTitle><Pagination><StartPage>710</StartPage><EndPage>716</EndPage><MedlinePgn>710-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.391</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Optimizing assessments of rate of progression in Parkinson disease (PD) is important in designing clinical trials, especially of potential disease-modifying agents.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the value of measures of impairment, disability, and quality of life in assessing progression in early PD.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Inception cohort analysis of data from 413 patients with early, untreated PD who were enrolled in 2 multicenter, randomized, double-blind clinical trials.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were randomly assigned to 1 of 5 treatments (67 received creatine, 66 received minocycline, 71 received coenzyme Q10, 71 received GPI-1485, and 138 received placebo). We assessed the association between the rates of change in measures of impairment, disability, and quality of life and time to initiation of symptomatic treatment.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Time between baseline assessment and need for the initiation of symptomatic pharmaceutical treatment for PD was the primary indicator of disease progression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">After adjusting for baseline confounding variables with regard to the Unified Parkinson's Disease Rating Scale (UPDRS) Part II score, the UPDRS Part III score, the modified Rankin Scale score, level of education, and treatment group, we assessed the rate of change for the following measurements: the UPDRS Part II score; the UPDRS Part III score; the Schwab and England Independence Scale score (which measures activities of daily living); the Total Functional Capacity scale; the 39-item Parkinson's Disease Questionnaire, summary index, and activities of daily living subscale; and version 2 of the 12-item Short Form Health Survey Physical Summary and Mental Summary. Variables reaching the statistical threshold in univariate analysis were entered into a multivariable Cox proportional hazards model using time to symptomatic treatment as the dependent variable. More rapid change (ie, worsening) in the UPDRS Part II score (hazard ratio, 1.15 [95% CI, 1.08-1.22] for 1 scale unit change per 6 months), the UPDRS Part III score (hazard ratio, 1.09 [95% CI, 1.06-1.13] for 1 scale unit change per 6 months), and the Schwab and England Independence Scale score (hazard ratio, 1.29 [95% CI, 1.12-1.48] for 5 percentage point change per 6 months) was associated with earlier need for symptomatic therapy.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">AND RELEVANCE In early PD, the UPDRS Part II score and Part III score and the Schwab and England Independence Scale score can be used to measure disease progression, whereas the 39-item Parkinson's Disease Questionnaire and summary index, Total Functional Capacity scale, and the 12-item Short Form Health Survey Physical Summary and Mental Summary are not sensitive to change.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifiers: NCT00063193 and NCT00076492.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parashos</LastName><ForeName>Sotirios A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Struthers Parkinson's Center, Golden Valley, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Sheng</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of Texas at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biglan</LastName><ForeName>Kevin M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodis-Wollner</LastName><ForeName>Ivan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>State University of New York, Downstate Medical Center, Brooklyn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of Texas at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Grace S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>The Parkinson's Institute and Clinical Center, Sunnyvale, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>G Webster</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>VA Pacific Islands Health Care System, Honolulu, Hawaii.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tilley</LastName><ForeName>Barbara C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, University of Texas at Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shulman</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Maryland School of Medicine, Baltimore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NET-PD Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00063193</AccessionNumber><AccessionNumber>NCT00076492</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS043127</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 NS043128</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U10 NS044466</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C486238">GPI 1485</NameOfSubstance></Chemical><Chemical><RegistryNumber>WM0HAQ4WNM</RegistryNumber><NameOfSubstance UI="D016559">Tacrolimus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016559" MajorTopicYN="N">Tacrolimus</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Gross</LastName><ForeName>Cynthia R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>T</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodnitzky</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welch</LastName><ForeName>K Michael</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beal</LastName><ForeName>M Flint</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geffen</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fahn</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Russell G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin</LastName><ForeName>Deborah B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDonald</LastName><ForeName>William</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piantadosi</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powers</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wichman</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marler</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odenkirchen</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kieburtz</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilley</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanner</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deppen</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewey</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hayward</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Burton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Field</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manyam</LastName><ForeName>Bala</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whetteckey</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Jayaraman</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aminoff</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christine</LastName><ForeName>Chadwick</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Jessie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parashos</LastName><ForeName>Sotirios</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaglin</LastName><ForeName>Jeana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Singer</LastName><ForeName>Carlos</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Marian A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blenke</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hauser</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Becky</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsons</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pabst</LastName><ForeName>Katharine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elble</LastName><ForeName>Rodger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sethi</LastName><ForeName>Kapil</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>McInnes</LastName><ForeName>Germaine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Vincent P</ForeName><Initials>VP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberge</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamill</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Homan</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodis-Wollner</LastName><ForeName>Ivan G</ForeName><Initials>IG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Webster G</ForeName><Initials>WG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terashita</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Trugman</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Margaret F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sage</LastName><ForeName>Jacob I</ForeName><Initials>JI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caputo</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shearon</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelsey</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feigin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Ray L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stover</LastName><ForeName>Natividad</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reichwein</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarsy</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scollins</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tintner</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>Maryan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shill</LastName><ForeName>Holly</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Danielson</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marlor</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorell</LastName><ForeName>Jay</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krstevska</LastName><ForeName>Shana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schneider</LastName><ForeName>Jay</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gollomp</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lew</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turk</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bower</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Handler</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Greenbaum</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palesch</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamp</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shinaman</LastName><ForeName>Aileen</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Johnsen</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brocht</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gross</LastName><ForeName>Cynthia R</ForeName><Initials>CR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chen</LastName><ForeName>Donna T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>David E</ForeName><Initials>DE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marder</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rodnitzky</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Welch</LastName><ForeName>K Michael</ForeName><Initials>KM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beal</LastName><ForeName>M Flint</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fahn</LastName><ForeName>Stanley</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levin</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Katz</LastName><ForeName>Russell G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marin</LastName><ForeName>Deborah B</ForeName><Initials>DB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Olanow</LastName><ForeName>C Warren</ForeName><Initials>CW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Jeffrey C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murphy</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Powers</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thal</LastName><ForeName>Leon J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wichman</LastName><ForeName>Alison</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marler</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odenkirchen</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shults</LastName><ForeName>Cliff</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kieburtz</LastName><ForeName>Karl</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ravina</LastName><ForeName>Bernard</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Galpern</LastName><ForeName>Wendy R</ForeName><Initials>WR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tilley</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shannon</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tanner</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wooten</LastName><ForeName>G Frederick</ForeName><Initials>GF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sage</LastName><ForeName>Jacob I</ForeName><Initials>JI</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kosa</LastName><ForeName>Emily</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watts</LastName><ForeName>Ray L</ForeName><Initials>RL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stover</LastName><ForeName>Natividad R</ForeName><Initials>NR</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMurray</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lew</LastName><ForeName>Mark F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kawai</LastName><ForeName>Connie</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coffey</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeBlanc</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brodsky</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andrews</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Siderowf</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shulman</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiner</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pabst</LastName><ForeName>Katharine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaglin</LastName><ForeName>Jeana</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Suchowersky</LastName><ForeName>Oksana</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Derwent</LastName><ForeName>Lorelei</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Jayaraman</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cook</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aminoff</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christine</LastName><ForeName>Chad</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roth</LastName><ForeName>Jessie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leehey</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>G Webster</ForeName><Initials>GW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terashita</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perez</LastName><ForeName>Marian A</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blenke</LastName><ForeName>Anita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Racette</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deppen</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Elble</LastName><ForeName>Rodger</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Charlene</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stewart</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sethi</LastName><ForeName>Kapil</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roberge</LastName><ForeName>Peggy</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewey</LastName><ForeName>Richard B</ForeName><Initials>RB</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Hayward</LastName><ForeName>Brigid</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hunter</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keller</LastName><ForeName>Margaret F</ForeName><Initials>MF</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jennings</LastName><ForeName>Danna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelsey</LastName><ForeName>Tammie</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Wayne</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Savitt</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunlop</LastName><ForeName>Becky</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pahwa</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lyons</LastName><ForeName>Kelly E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parsons</LastName><ForeName>Amy</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fang</LastName><ForeName>John</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shearon</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Feigin</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marie</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adler</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lind</LastName><ForeName>Marlene</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scott</LastName><ForeName>Burton</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Field</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nance</LastName><ForeName>Martha</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peterson</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Burns</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marlor</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bodis-Wollner</LastName><ForeName>Ivan</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hayes</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sendek</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gollomp</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vernon</LastName><ForeName>Gwyn</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>LeWitt</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeAngelis</LastName><ForeName>Maryan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paul</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorell</LastName><ForeName>Jay</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krstevska</LastName><ForeName>Shana</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flewellen</LastName><ForeName>Marilyn</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Uitti</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turk</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bower</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabbagh</LastName><ForeName>Marwan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Obradov</LastName><ForeName>Zoran</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juncos</LastName><ForeName>Jorge</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Musante</LastName><ForeName>Mary Louise</ForeName><Initials>ML</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Hubert</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brown</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Peng</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kamp</LastName><ForeName>Cornelia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shinaman</LastName><ForeName>Aileen</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brocht</LastName><ForeName>Alicia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baker</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goetz</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fagan</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mauldin</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24711047</ArticleId><ArticleId IdType="mid">NIHMS630022</ArticleId><ArticleId IdType="pmc">PMC4188544</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.391</ArticleId><ArticleId IdType="pii">1852981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner W. Practice parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology. 2006;66(7):968&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pubmed">16606907</ArticleId></ArticleIdList></Reference><Reference><Citation>Parashos SA, Maraganore DM, O&#x2019;Brien PC, Rocca WA. Medical services utilization and prognosis in Parkinson disease: a population-based study. Mayo Clin Proc. 2002;77(9):918&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">12233925</ArticleId></ArticleIdList></Reference><Reference><Citation>Elm JJ, Goetz CG, Ravina B, et al. A Responsive Outcome for Parkinson&#x2019;s Disease Neuroprotection Futility Studies. Ann Neurol. 2005;57(2):197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">15668964</ArticleId></ArticleIdList></Reference><Reference><Citation>NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481597</ArticleId></ArticleIdList></Reference><Reference><Citation>NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson&#x2019;s disease. Neurology. 2007;68(1):20&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">17200487</ArticleId></ArticleIdList></Reference><Reference><Citation>Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang GS, Ross GW, Tilley BC, Shulman LM NET-PD Investigators. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep;66(9):1099&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839890</ArticleId><ArticleId IdType="pubmed">19597081</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahn S, Elton RL. members of the UPDRS Development Committee. Unified Parkinson&#x2019;s Disease Rating Scale. In: Fahn S, Marsden CO, Calne DB, Goldstein M, editors. Recent development in Parkinson&#x2019;s disease. Florham Park, NJ: Macmillan Health Care Information; 1987. pp. 153&#x2013;164.</Citation></Reference><Reference><Citation>Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap stroke patients. Stroke. 1988;19(5):604&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">3363593</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab RS, England ACJ. Projection technique for evaluating surgery in Parkinson&#x2019;s disease. In: Gillingham FJ, Donaldson IML, editors. Third Symposium on Parkinson&#x2019;s Disease. Edinburgh, Scotland: E &amp; S Livingstone; 1969. pp. 152&#x2013;157.</Citation></Reference><Reference><Citation>Shoulson I, Kurlan, Rubin A, et al. Assessment of functional capacity in neurodegenerative disorders: Huntington&#x2019;s disease as a prototype. In: Munsat TL, editor. Quantification of neurologic deficit. Boston: Butterworth; 1989. pp. 285&#x2013;309.</Citation></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson&#x2019;s Disease Questionnaire (PDQ-39): development and validation of a Parkinson&#x2019;s disease summary index score. Age Ageing. 1997;26(5):353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12&#xae; Health Survey (With a Supplement Documenting Version 1) Lincoln, RI: QualityMetric Incorporated; 2002.</Citation></Reference><Reference><Citation>Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson&#x2019;s disease. N Engl J Med. 1989;321(20):1364&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">2509910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafni UG, Tsiatis AA. Evaluating surrogate markers of clinical outcome when measured with error. Biometrics. 1998;54:1445&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley; New York: 1989.</Citation></Reference><Reference><Citation>Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515&#x2013;526.</Citation></Reference><Reference><Citation>McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson&#x2019;s disease. The Parkinson Study Group. Arch Neurol. 1995;52(6):565&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7763203</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson&#x2019;s disease cohorts. Mov Disord. 2011 Mar;26(4):608&#x2013;13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23581</ArticleId><ArticleId IdType="pubmed">21287602</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman LM, Gruber-Baldini AL, Anderson KE, Vaughan CG, Reich SG, Fishman PS, Weiner WJ. The evolution of disability in Parkinson disease. Mov Disord. 2008 Apr 30;23(6):790&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18361474</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson&#x2019;s Disease Questionnaire (PDQ-39): development and validation of a Parkinson&#x2019;s disease summary index score. Age Ageing. 1997;26(5):353&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">9351479</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12 Health Survey (With a Supplement Documenting Version 1) Lincoln, RI: QualityMetric Incorporated; 2002.</Citation></Reference><Reference><Citation>Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson&#x2019;s disease. N Engl J Med. 1989;321(20):1364&#x2013;1371.</Citation><ArticleIdList><ArticleId IdType="pubmed">2509910</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafni UG, Tsiatis AA. Evaluating surrogate markers of clinical outcome when measured with error. Biometrics. 1998;54:1445&#x2013;1462.</Citation><ArticleIdList><ArticleId IdType="pubmed">9883544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosmer DW, Lemeshow S. Applied Logistic Regression. Wiley; New York: 1989.</Citation></Reference><Reference><Citation>Grambsch P, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515&#x2013;526.</Citation></Reference><Reference><Citation>McDermott MP, Jankovic J, Carter J, et al. Factors predictive of the need for levodopa therapy in early, untreated Parkinson&#x2019;s disease. The Parkinson Study Group. Arch Neurol. 1995;52(6):565&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">7763203</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE Parkinson Study Group DATATOP and PRECEPT investigators. Predictors of time to requiring dopaminergic treatment in 2 Parkinson&#x2019;s disease cohorts. Mov Disord. 2011 Mar;26(4):608&#x2013;13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23581</ArticleId><ArticleId IdType="pubmed">21287602</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman LM, Gruber-Baldini AL, Anderson KE, Vaughan CG, Reich SG, Fishman PS, Weiner WJ. The evolution of disability in Parkinson disease. Mov Disord. 2008 Apr 30;23(6):790&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18361474</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24719099</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>15</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Amyloid deposition is linked to aberrant entorhinal activity among cognitively normal older adults.</ArticleTitle><Pagination><StartPage>5200</StartPage><EndPage>5210</EndPage><MedlinePgn>5200-10</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3579-13.2014</ELocationID><Abstract><AbstractText>Normal aging is often difficult to distinguish from the earliest stages of Alzheimer's disease. Years before clinical memory deficits manifest, amyloid-&#x3b2; deposits in the cortex in many older individuals. Neuroimaging studies indicate that a set of densely connected neocortical regions, referred to as the default network, is especially vulnerable to amyloid-&#x3b2; deposition. Yet, the impact of amyloid-&#x3b2; on age-related changes within the medial temporal lobe (MTL) memory system is less clear. Here we demonstrate that cognitively normal older humans, compared with young adults, show reduced ability to modulate hippocampal activations and entorhinal deactivations during an episodic memory task. Among older adults, amyloid-&#x3b2; deposition was associated with failure to modulate activity in entorhinal cortex, but not hippocampus. Furthermore, we show that entorhinal regions demonstrating amyloid-&#x3b2;-related dysfunction are directly connected to the neocortical regions of the default network. Together these findings link neocortical amyloid-&#x3b2; deposition to neuronal dysfunction specifically in entorhinal cortex, while aging is associated with more widespread functional changes across the MTL.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huijbers</LastName><ForeName>Willem</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts 02129, Harvard Aging Brain Study, Department of Neurology, and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mormino</LastName><ForeName>Elizabeth C</ForeName><Initials>EC</Initials></Author><Author ValidYN="Y"><LastName>Wigman</LastName><ForeName>Sarah E</ForeName><Initials>SE</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Andrew M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Vannini</LastName><ForeName>Patrizia</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>McLaren</LastName><ForeName>Donald G</ForeName><Initials>DG</Initials></Author><Author ValidYN="Y"><LastName>Becker</LastName><ForeName>J Alex</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Aaron P</ForeName><Initials>AP</Initials></Author><Author ValidYN="Y"><LastName>Hedden</LastName><ForeName>Trey</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K24 AG035007</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037497</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM007507</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG036694</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG044054</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG027435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01 AG040197</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 EB015896</GrantID><Acronym>EB</Acronym><Agency>NIBIB NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG042228</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018728" MajorTopicYN="N">Entorhinal Cortex</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">default network</Keyword><Keyword MajorTopicYN="N">entorhinal cortex</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">preclinical Alzheimer's disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24719099</ArticleId><ArticleId IdType="pmc">PMC3983800</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3579-13.2014</ArticleId><ArticleId IdType="pii">34/15/5200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65:1509&#x2013;1517. doi: 10.1001/archneur.65.11.1509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1509</ArticleId><ArticleId IdType="pmc">PMC2636844</ArticleId><ArticleId IdType="pubmed">19001171</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR. The brain's default network and its adaptive role in internal mentation. Neuroscientist. 2012;18:251&#x2013;270. doi: 10.1177/1073858411403316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858411403316</ArticleId><ArticleId IdType="pmc">PMC3553600</ArticleId><ArticleId IdType="pubmed">21677128</ArticleId></ArticleIdList></Reference><Reference><Citation>Anticevic A, Cole MW, Murray JD, Corlett PR, Wang XJ, Krystal JH. The role of default network deactivation in cognition and disease. Trends Cogn Sci. 2012;16:584&#x2013;592. doi: 10.1016/j.tics.2012.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2012.10.008</ArticleId><ArticleId IdType="pmc">PMC3501603</ArticleId><ArticleId IdType="pubmed">23142417</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA. Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69:1032&#x2013;1042. doi: 10.1002/ana.22333.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22333</ArticleId><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-[beta] deposition. Nat Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239&#x2013;259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Brainard DH. The Psychophysics Toolbox. Spat Vis. 1997;10:433&#x2013;436. doi: 10.1163/156856897X00357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1163/156856897X00357</ArticleId><ArticleId IdType="pubmed">9176952</ArticleId></ArticleIdList></Reference><Reference><Citation>Braskie MN, Small GW, Bookheimer SY. Entorhinal cortex structure and functional MRI response during an associative verbal memory task. Hum Brain Mapp. 2009;30:3981&#x2013;3992. doi: 10.1002/hbm.20823.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20823</ArticleId><ArticleId IdType="pmc">PMC2787760</ArticleId><ArticleId IdType="pubmed">19507155</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38. doi: 10.1196/annals.1440.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1440.011</ArticleId><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, Rowe CC, Group AR. Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology. 2012;78:477&#x2013;484. doi: 10.1212/WNL.0b013e318246d67a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318246d67a</ArticleId><ArticleId IdType="pubmed">22302548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Schultz AP, Johnson K, Benzinger TL, Jack C, Jr, Ances BM, Sullivan CA, Salloway SP, Ringman JM, Koeppe RA, Marcus DS, Thompson P, Saykin AJ, Correia S, Schofield PR, Rowe CC, Fox NC, Brickman AM, Mayeux R, McDade E, et al. Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology. 2013;81:736&#x2013;744. doi: 10.1212/WNL.0b013e3182a1aafe.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182a1aafe</ArticleId><ArticleId IdType="pmc">PMC3776464</ArticleId><ArticleId IdType="pubmed">23884042</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275&#x2013;283. doi: 10.1001/jama.2010.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2010.2008</ArticleId><ArticleId IdType="pmc">PMC7041965</ArticleId><ArticleId IdType="pubmed">21245183</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale AM, Greve DN, Burock MA. Optimal stimulus sequences for event-related fMRI. 5th International Conference on Functional Mapping of the Human Brain; June; Duesseldorf, Germany. 1999.</Citation></Reference><Reference><Citation>Daselaar SM, Veltman DJ, Rombouts SA, Raaijmakers JG, Jonker C. Neuroanatomical correlates of episodic encoding and retrieval in young and elderly subjects. Brain. 2003;126:43&#x2013;56. doi: 10.1093/brain/awg005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awg005</ArticleId><ArticleId IdType="pubmed">12477696</ArticleId></ArticleIdList></Reference><Reference><Citation>Daselaar SM, Fleck MS, Cabeza R. Triple dissociation in the medial temporal lobes: recollection, familiarity, and novelty. J Neurophysiol. 2006;96:1902&#x2013;1911. doi: 10.1152/jn.01029.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.01029.2005</ArticleId><ArticleId IdType="pubmed">16738210</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73:685&#x2013;697. doi: 10.1016/j.neuron.2011.11.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.11.033</ArticleId><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM, Alzheimer's Disease Neuroimaging I. Amyloid-beta&#x2013;associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol. 2012;69:709&#x2013;713. doi: 10.1001/archneurol.2011.3354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2011.3354</ArticleId><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Esposito M, Deouell LY, Gazzaley A. Alterations in the BOLD fMRI signal with ageing and disease: a challenge for neuroimaging. Nat Rev Neurosci. 2003;4:863&#x2013;872. doi: 10.1038/nrn1246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1246</ArticleId><ArticleId IdType="pubmed">14595398</ArticleId></ArticleIdList></Reference><Reference><Citation>Du AT, Schuff N, Zhu XP, Jagust WJ, Miller BL, Reed BR, Kramer JH, Mungas D, Yaffe K, Chui HC, Weiner MW. Atrophy rates of entorhinal cortex in AD and normal aging. Neurology. 2003;60:481&#x2013;486. doi: 10.1212/01.WNL.0000044400.11317.EC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000044400.11317.EC</ArticleId><ArticleId IdType="pmc">PMC1851672</ArticleId><ArticleId IdType="pubmed">12578931</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickhoff SB, Paus T, Caspers S, Grosbras MH, Evans AC, Zilles K, Amunts K. Assignment of functional activations to probabilistic cytoarchitectonic areas revisited. Neuroimage. 2007;36:511&#x2013;521. doi: 10.1016/j.neuroimage.2007.03.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2007.03.060</ArticleId><ArticleId IdType="pubmed">17499520</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM. Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009;1:371&#x2013;380. doi: 10.1002/emmm.200900048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.200900048</ArticleId><ArticleId IdType="pmc">PMC2806678</ArticleId><ArticleId IdType="pubmed">20049742</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez G, Brewer JB, Zhao Z, Glover GH, Gabrieli JD. Level of sustained entorhinal activity at study correlates with subsequent cued-recall performance: a functional magnetic resonance imaging study with high acquisition rate. Hippocampus. 1999;9:35&#x2013;44. doi: 10.1002/(SICI)1098-1063(1999)9:1&lt;35::AID-HIPO4&gt;3.0.CO%3B2-Z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-1063(1999)9:1&lt;35::AID-HIPO4&gt;3.0.CO%3B2-Z</ArticleId><ArticleId IdType="pubmed">10088898</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, L&#xe5;ngstr&#xf6;m B, Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging. 2008;29:1456&#x2013;1465. doi: 10.1016/j.neurobiolaging.2007.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.03.029</ArticleId><ArticleId IdType="pubmed">17499392</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotuhi M, Do D, Jack C. Modifiable factors that alter the size of the hippocampus with ageing. Nat Rev Neurol. 2012;8:189&#x2013;202. doi: 10.1038/nrneurol.2012.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2012.27</ArticleId><ArticleId IdType="pubmed">22410582</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678. doi: 10.1073/pnas.0504136102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504136102</ArticleId><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Isla T, Price JL, McKeel DW, Jr, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491&#x2013;4500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578866</ArticleId><ArticleId IdType="pubmed">8699259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusnard DA, Raichle ME. Searching for a baseline: functional imaging and the resting human brain. Nat Rev Neurosci. 2001;2:685&#x2013;694. doi: 10.1038/35094500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35094500</ArticleId><ArticleId IdType="pubmed">11584306</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutchess AH, Welsh RC, Hedden T, Bangert A, Minear M, Liu LL, Park DC. Aging and the neural correlates of successful picture encoding: frontal activations compensate for decreased medial-temporal activity. J Cogn Neurosci. 2005;17:84&#x2013;96. doi: 10.1162/0898929052880048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/0898929052880048</ArticleId><ArticleId IdType="pubmed">15701241</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004;5:87&#x2013;96. doi: 10.1038/nrn1323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1323</ArticleId><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Van Dijk KR, Becker JA, Mehta A, Sperling RA, Johnson KA, Buckner RL. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci. 2009;29:12686&#x2013;12694. doi: 10.1523/JNEUROSCI.3189-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3189-09.2009</ArticleId><ArticleId IdType="pmc">PMC2808119</ArticleId><ArticleId IdType="pubmed">19812343</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Mormino EC, Amariglio RE, Younger AP, Schultz AP, Becker JA, Buckner RL, Johnson KA, Sperling RA, Rentz DM. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J Neurosci. 2012;32:16233&#x2013;16242. doi: 10.1523/JNEUROSCI.2462-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2462-12.2012</ArticleId><ArticleId IdType="pmc">PMC3523110</ArticleId><ArticleId IdType="pubmed">23152607</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology. 2013;80:1341&#x2013;1348. doi: 10.1212/WNL.0b013e31828ab35d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828ab35d</ArticleId><ArticleId IdType="pmc">PMC3656457</ArticleId><ArticleId IdType="pubmed">23547267</ArticleId></ArticleIdList></Reference><Reference><Citation>Huijbers W, Vannini P, Sperling RA, Pennartz CM, Cabeza R, Daselaar SM. Explaining the encoding/retrieval flip: memory-related deactivations and activations in the posteromedial cortex. Neuropsychologia. 2012;50:3764&#x2013;3774. doi: 10.1016/j.neuropsychologia.2012.08.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2012.08.021</ArticleId><ArticleId IdType="pmc">PMC3811140</ArticleId><ArticleId IdType="pubmed">22982484</ArticleId></ArticleIdList></Reference><Reference><Citation>Huijbers W, Schultz AP, Vannini P, McLaren DG, Wigman SE, Ward AM, Hedden T, Sperling RA. The encoding/retrieval flip: interactions between memory performance and memory stage and relationship to intrinsic cortical networks. J Cogn Neurosci. 2013;25:1163&#x2013;1179. doi: 10.1162/jocn_a_00366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1162/jocn_a_00366</ArticleId><ArticleId IdType="pmc">PMC3730829</ArticleId><ArticleId IdType="pubmed">23384193</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630&#x2013;1645. doi: 10.1093/brain/awn016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn016</ArticleId><ArticleId IdType="pmc">PMC2408940</ArticleId><ArticleId IdType="pubmed">18339640</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207&#x2013;216. doi: 10.1016/S1474-4422(12)70291-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70291-0</ArticleId><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013;77:219&#x2013;234. doi: 10.1016/j.neuron.2013.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.01.002</ArticleId><ArticleId IdType="pmc">PMC3558930</ArticleId><ArticleId IdType="pubmed">23352159</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn Sci. 2011;15:520&#x2013;526. doi: 10.1016/j.tics.2011.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tics.2011.09.004</ArticleId><ArticleId IdType="pmc">PMC3206968</ArticleId><ArticleId IdType="pubmed">21983147</ArticleId></ArticleIdList></Reference><Reference><Citation>Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 2010;6:221&#x2013;229. doi: 10.1016/j.jalz.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2010.03.003</ArticleId><ArticleId IdType="pmc">PMC2920531</ArticleId><ArticleId IdType="pubmed">20451870</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK, Smith EE, Rosand J, Rentz DM, Klunk WE, Mathis CA, Price JC, Dekosky ST, Fischman AJ, Greenberg SM. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229&#x2013;234. doi: 10.1002/ana.21164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21164</ArticleId><ArticleId IdType="pubmed">17683091</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn I, Andrews-Hanna JR, Vincent JL, Snyder AZ, Buckner RL. Distinct cortical anatomy linked to subregions of the medial temporal lobe revealed by intrinsic functional connectivity. J Neurophysiol. 2008;100:129&#x2013;139. doi: 10.1152/jn.00077.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00077.2008</ArticleId><ArticleId IdType="pmc">PMC2493488</ArticleId><ArticleId IdType="pubmed">18385483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy KM, Rodrigue KM, Devous MD, Sr, Hebrank AC, Bischof GN, Park DC. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan. Neuroimage. 2012;62:1&#x2013;8. doi: 10.1016/j.neuroimage.2012.03.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2012.03.077</ArticleId><ArticleId IdType="pmc">PMC3381050</ArticleId><ArticleId IdType="pubmed">22569063</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with beta-amyloidosis. JAMA Neurol. 2013a;70:1030&#x2013;1038. doi: 10.1001/jamaneurol.2013.182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.182</ArticleId><ArticleId IdType="pmc">PMC3884555</ArticleId><ArticleId IdType="pubmed">23797806</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. Brain injury biomarkers are not dependent on &#x3b2;-amyloid in normal elderly. Ann Neurol. 2013b;73:472&#x2013;480. doi: 10.1002/ana.23816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23816</ArticleId><ArticleId IdType="pmc">PMC3660408</ArticleId><ArticleId IdType="pubmed">23424032</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy JW, Stark CE. Intrinsic functional connectivity of the human medial temporal lobe suggests a distinction between adjacent MTL cortices and hippocampus. Hippocampus. 2012;22:2290&#x2013;2302. doi: 10.1002/hipo.22047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.22047</ArticleId><ArticleId IdType="pmc">PMC3764462</ArticleId><ArticleId IdType="pubmed">22736526</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby LA, Ekstrom AD, Ragland JD, Ranganath C. Differential connectivity of perirhinal and parahippocampal cortices within human hippocampal subregions revealed by high-resolution functional imaging. J Neurosci. 2012;32:6550&#x2013;6560. doi: 10.1523/JNEUROSCI.3711-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3711-11.2012</ArticleId><ArticleId IdType="pmc">PMC3374643</ArticleId><ArticleId IdType="pubmed">22573677</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Ellis KA, Pietrzak RH, Ames D, Darby D, Harrington K, Martins RN, Masters CL, Rowe C, Savage G, Szoeke C, Villemagne VL, Maruff P, Group AR. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79:1645&#x2013;1652. doi: 10.1212/WNL.0b013e31826e9ae6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826e9ae6</ArticleId><ArticleId IdType="pubmed">23071163</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Pietrzak RH, Ellis KA, Jaeger J, Harrington K, Ashwood T, Szoeke C, Martins RN, Bush AI, Masters CL, Rowe CC, Villemagne VL, Ames D, Darby D, Maruff P. Rapid decline in episodic memory in healthy older adults with high amyloid-beta. J Alzheimer's Dis. 2013;33:675&#x2013;679. doi: 10.3233/JAD-2012-121516.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-121516</ArticleId><ArticleId IdType="pubmed">23001710</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. PLoS One. 2012;7:e31302. doi: 10.1371/journal.pone.0031302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031302</ArticleId><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A. 2003;100:14504&#x2013;14509. doi: 10.1073/pnas.2235925100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2235925100</ArticleId><ArticleId IdType="pmc">PMC283621</ArticleId><ArticleId IdType="pubmed">14608034</ArticleId></ArticleIdList></Reference><Reference><Citation>MacMillan NA, Creelman CD. Detection theory: a user's guide. Ed 2. Mahwah, NJ: Erlbaum; 2005.</Citation></Reference><Reference><Citation>Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19:1233&#x2013;1239. doi: 10.1016/S1053-8119(03)00169-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1053-8119(03)00169-1</ArticleId><ArticleId IdType="pubmed">12880848</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT, Holt DP, Wang Y, Huang GF, Debnath ML, Klunk WE. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett. 2002;12:295&#x2013;298. doi: 10.1016/S0960-894X(01)00734-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-894X(01)00734-X</ArticleId><ArticleId IdType="pubmed">11814781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron. 1999;24:521&#x2013;529. doi: 10.1016/S0896-6273(00)81109-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81109-5</ArticleId><ArticleId IdType="pubmed">10595506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67:446&#x2013;452. doi: 10.1212/01.wnl.0000228230.26044.a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000228230.26044.a4</ArticleId><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Smiljic A, Hayenga AO, Onami SH, Greicius MD, Rabinovici GD, Janabi M, Baker SL, Yen IV, Madison CM, Miller BL, Jagust WJ. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex. 2011;21:2399&#x2013;2407. doi: 10.1093/cercor/bhr025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhr025</ArticleId><ArticleId IdType="pmc">PMC3169663</ArticleId><ArticleId IdType="pubmed">21383234</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Brandel MG, Madison CM, Marks S, Baker SL, Jagust WJ. Abeta deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb Cortex. 2012;22:1813&#x2013;1823. doi: 10.1093/cercor/bhr255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhr255</ArticleId><ArticleId IdType="pmc">PMC3388896</ArticleId><ArticleId IdType="pubmed">21945849</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, K&#xf6;vari E, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362&#x2013;381. doi: 10.1097/NEN.0b013e31825018f7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31825018f7</ArticleId><ArticleId IdType="pmc">PMC3560290</ArticleId><ArticleId IdType="pubmed">22487856</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien JL, O'Keefe KM, LaViolette PS, DeLuca AN, Blacker D, Dickerson BC, Sperling RA. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology. 2010;74:1969&#x2013;1976. doi: 10.1212/WNL.0b013e3181e3966e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181e3966e</ArticleId><ArticleId IdType="pmc">PMC2905893</ArticleId><ArticleId IdType="pubmed">20463288</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Jagust WJ. Frontotemporal network connectivity during memory encoding is increased with aging and disrupted by beta-amyloid. J Neurosci. 2013;33:18425&#x2013;18437. doi: 10.1523/JNEUROSCI.2775-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2775-13.2013</ArticleId><ArticleId IdType="pmc">PMC3834050</ArticleId><ArticleId IdType="pubmed">24259567</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DC, Lautenschlager G, Hedden T, Davidson NS, Smith AD, Smith PK. Models of visuospatial and verbal memory across the adult life span. Psychol Aging. 2002;17:299&#x2013;320. doi: 10.1037/0882-7974.17.2.299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0882-7974.17.2.299</ArticleId><ArticleId IdType="pubmed">12061414</ArticleId></ArticleIdList></Reference><Reference><Citation>Park DC, Polk TA, Hebrank AC, Jenkins LJ. Age differences in default mode activity on easy and difficult spatial judgment tasks. Front Hum Neurosci. 2010;3:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2814559</ArticleId><ArticleId IdType="pubmed">20126437</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Jack CR, Jr, Xu YC, Waring SC, O'Brien PC, Smith GE, Ivnik RJ, Tangalos EG, Boeve BF, Kokmen E. Memory and MRI-based hippocampal volumes in aging and AD. Neurology. 2000;54:581&#x2013;587. doi: 10.1212/WNL.54.3.581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.54.3.581</ArticleId><ArticleId IdType="pubmed">10680786</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, Holt DP, Meltzer CC, DeKosky ST, Mathis CA. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528&#x2013;1547. doi: 10.1038/sj.jcbfm.9600146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600146</ArticleId><ArticleId IdType="pubmed">15944649</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30:1026&#x2013;1036. doi: 10.1016/j.neurobiolaging.2009.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.04.002</ArticleId><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default mode of brain function. Proc Natl Acad Sci U S A. 2001;98:676&#x2013;682. doi: 10.1073/pnas.98.2.676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.676</ArticleId><ArticleId IdType="pmc">PMC14647</ArticleId><ArticleId IdType="pubmed">11209064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci. 2012;13:713&#x2013;726. doi: 10.1038/nrn3338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3338</ArticleId><ArticleId IdType="pubmed">22992647</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentz DM, Amariglio RE, Becker JA, Frey M, Olson LE, Frishe K, Carmasin J, Maye JE, Johnson KA, Sperling RA. Face-name associative memory performance is related to amyloid burden in normal elderly. Neuropsychologia. 2011;49:2776&#x2013;2783. doi: 10.1016/j.neuropsychologia.2011.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropsychologia.2011.06.006</ArticleId><ArticleId IdType="pmc">PMC3137730</ArticleId><ArticleId IdType="pubmed">21689670</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J. Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res Ther. 2011;3:3. doi: 10.1186/alzrt62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/alzrt62</ArticleId><ArticleId IdType="pmc">PMC3109412</ArticleId><ArticleId IdType="pubmed">21345176</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Raz N. Shrinkage of the entorhinal cortex over five years predicts memory performance in healthy adults. J Neurosci. 2004;24:956&#x2013;963. doi: 10.1523/JNEUROSCI.4166-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4166-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729806</ArticleId><ArticleId IdType="pubmed">14749440</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigue KM, Kennedy KM, Devous MD, Sr, Rieck JR, Hebrank AC, Diaz-Arrastia R, Mathews D, Park DC. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78:387&#x2013;395. doi: 10.1212/WNL.0b013e318245d295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318245d295</ArticleId><ArticleId IdType="pmc">PMC3280058</ArticleId><ArticleId IdType="pubmed">22302550</ArticleId></ArticleIdList></Reference><Reference><Citation>Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TLS, Mintun MA, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80:1784&#x2013;1791. doi: 10.1212/WNL.0b013e3182918ca6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3182918ca6</ArticleId><ArticleId IdType="pmc">PMC3719431</ArticleId><ArticleId IdType="pubmed">23576620</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239. doi: 10.1002/hbm.20160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20160</ArticleId><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe G, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 2010;31:1275&#x2013;1283. doi: 10.1016/j.neurobiolaging.2010.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2010.04.007</ArticleId><ArticleId IdType="pubmed">20472326</ArticleId></ArticleIdList></Reference><Reference><Citation>Salthouse TA, Toth J, Daniels K, Parks C, Pak R, Wolbrette M, Hocking KJ. Effects of aging on efficiency of task switching in a variant of the trail making test. Neuropsychology. 2000;14:102&#x2013;111. doi: 10.1037/0894-4105.14.1.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0894-4105.14.1.102</ArticleId><ArticleId IdType="pubmed">10674802</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwindt GC, Chaudhary S, Crane D, Ganda A, Masellis M, Grady CL, Stefanovic B, Black SE. Modulation of the default-mode network between rest and task in Alzheimer's disease. Cereb Cortex. 2013;23:1685&#x2013;1694. doi: 10.1093/cercor/bhs160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhs160</ArticleId><ArticleId IdType="pubmed">22693345</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189. doi: 10.1101/cshperspect.a006189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a006189</ArticleId><ArticleId IdType="pmc">PMC3234452</ArticleId><ArticleId IdType="pubmed">22229116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME. Resting state functional connectivity in preclinical Alzheimer's disease. Biol Psychiatry. 2013;74:340&#x2013;347. doi: 10.1016/j.biopsych.2012.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2012.11.028</ArticleId><ArticleId IdType="pmc">PMC3537262</ArticleId><ArticleId IdType="pubmed">23290495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584&#x2013;587. doi: 10.1016/j.biopsych.2009.08.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2009.08.024</ArticleId><ArticleId IdType="pmc">PMC2829379</ArticleId><ArticleId IdType="pubmed">19833321</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12:585&#x2013;601. doi: 10.1038/nrn3085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3085</ArticleId><ArticleId IdType="pmc">PMC3312472</ArticleId><ArticleId IdType="pubmed">21897434</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R. Potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol Aging. 2011;32(Suppl 1):S37&#x2013;S43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233699</ArticleId><ArticleId IdType="pubmed">22078171</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:280&#x2013;292. doi: 10.1016/j.jalz.2011.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.03.003</ArticleId><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Laviolette PS, O'Keefe K, O'Brien J, Rentz DM, Pihlajamaki M, Marshall G, Hyman BT, Selkoe DJ, Hedden T, Buckner RL, Becker JA, Johnson KA. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63:178&#x2013;188. doi: 10.1016/j.neuron.2009.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.07.003</ArticleId><ArticleId IdType="pmc">PMC2738994</ArticleId><ArticleId IdType="pubmed">19640477</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreng RN, Wojtowicz M, Grady CL. Reliable differences in brain activity between young and old adults: a quantitative meta-analysis across multiple cognitive domains. Neurosci Biobehav Rev. 2010;34:1178&#x2013;1194. doi: 10.1016/j.neubiorev.2010.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2010.01.009</ArticleId><ArticleId IdType="pubmed">20109489</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62:1984&#x2013;1989. doi: 10.1212/01.WNL.0000129697.01779.0A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000129697.01779.0A</ArticleId><ArticleId IdType="pubmed">15184601</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic functional connectivity as a tool for human connectomics: theory, properties, and optimization. J Neurophysiol. 2010;103:297&#x2013;321. doi: 10.1152/jn.00783.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00783.2009</ArticleId><ArticleId IdType="pmc">PMC2807224</ArticleId><ArticleId IdType="pubmed">19889849</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannini P, Hedden T, Becker JA, Sullivan C, Putcha D, Rents D, Johnson KA, Sperling RA. Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging. 2012;33:1237&#x2013;1252. doi: 10.1016/j.neurobiolaging.2011.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.01.003</ArticleId><ArticleId IdType="pmc">PMC3111876</ArticleId><ArticleId IdType="pubmed">21334099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannini P, Hedden T, Huijbers W, Ward A, Johnson KA, Sperling RA. The ups and downs of the posteromedial cortex: age- and amyloid-related functional alterations of the encoding/retrieval flip in cognitively normal older adults. Cereb Cortex. 2013a;23:1317&#x2013;1328. doi: 10.1093/cercor/bhs108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhs108</ArticleId><ArticleId IdType="pmc">PMC3643714</ArticleId><ArticleId IdType="pubmed">22586140</ArticleId></ArticleIdList></Reference><Reference><Citation>Vannini P, Hedden T, Sullivan C, Sperling RA. Differential functional response in the posteromedial cortices and hippocampus to stimulus repetition during successful memory encoding. Hum Brain Mapp. 2013b;34:1568&#x2013;1578. doi: 10.1002/hbm.22011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22011</ArticleId><ArticleId IdType="pmc">PMC3432294</ArticleId><ArticleId IdType="pubmed">22344847</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging B, Lifestyle Research G. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357&#x2013;367. doi: 10.1016/S1474-4422(13)70044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70044-9</ArticleId><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward AM, Schultz AP, Huijbers W, Van Dijk KR, Hedden T, Sperling RA. The parahippocampal gyrus links the default-mode cortical network with the medial temporal lobe memory system. Hum Brain Mapp. 2014;35:1061&#x2013;1073. doi: 10.1002/hbm.22234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.22234</ArticleId><ArticleId IdType="pmc">PMC3773261</ArticleId><ArticleId IdType="pubmed">23404748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24725412</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease.</ArticleTitle><Pagination><StartPage>472</StartPage><EndPage>485</EndPage><MedlinePgn>472-485</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.01.064</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00212-8</ELocationID><Abstract><AbstractText>Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and sporadic Parkinson's disease (PD). Elevated LRRK2 kinase activity and neurodegeneration are linked, but the phosphosubstrate that connects LRRK2 kinase activity to neurodegeneration is not known. Here, we show that ribosomal protein s15 is a key pathogenic LRRK2 substrate in Drosophila and human neuron PD models. Phosphodeficient s15 carrying a threonine 136 to alanine substitution rescues dopamine neuron degeneration and age-related locomotor deficits in G2019S LRRK2 transgenic Drosophila and substantially reduces G2019S LRRK2-mediated neurite loss and cell death in human dopamine and cortical neurons. Remarkably, pathogenic LRRK2 stimulates both cap-dependent and cap-independent mRNA translation and induces a bulk increase in protein synthesis in Drosophila, which can be prevented by phosphodeficient T136A s15. These results reveal a novel mechanism of PD pathogenesis linked to elevated LRRK2 kinase activity and aberrant protein synthesis in vivo.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Ian</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungwoo Wren</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Byoung Dae</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Age-Related and Brain Disease Research Center, Department of Neuroscience, Kyung Hee University, Seoul 130-701, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Ho Chul</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Ajou University School of Medicine, Suwon 443-749, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jin-Chong</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stankowski</LastName><ForeName>Jeannette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min-Sik</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Manoj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrabi</LastName><ForeName>Shaida A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Yulan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wszolek</LastName><ForeName>Zbigniew K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, FL 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Akhilesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; McKusick Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA; Diana Helis Henry Medical Research Foundation, New Orleans, LA 70130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Ted M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA. Electronic address: tdawson@jhmi.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dawson</LastName><ForeName>Valina L</ForeName><Initials>VL</Initials><AffiliationInfo><Affiliation>Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Department of Physiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA; Adrienne Helis Malvin Medical Research Foundation, New Orleans, LA 70130, USA. Electronic address: vdawson@jhmi.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50NS038377</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036004">ribosomal protein S15</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C495280">LRRK2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071158">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D017346">Protein Serine-Threonine Kinases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Cell. 2014 Apr 10;157(2):291-293. doi: 10.1016/j.cell.2014.03.043.</RefSource><PMID Version="1">24725399</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2014 Jul;29(8):990. doi: 10.1002/mds.25932.</RefSource><PMID Version="1">24865568</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004331" MajorTopicYN="N">Drosophila melanogaster</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071158" MajorTopicYN="N">Leucine-Rich Repeat Serine-Threonine Protein Kinase-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017346" MajorTopicYN="N">Protein Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>12</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24725412</ArticleId><ArticleId IdType="mid">NIHMS569050</ArticleId><ArticleId IdType="pmc">PMC4040530</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.01.064</ArticleId><ArticleId IdType="pii">S0092-8674(14)00212-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anand VS, Reichling LJ, Lipinski K, Stochaj W, Duan W, Kelleher K, Pungaliya P, Brown EL, Reinhart PH, Somberg R, et al. Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. FEBS J. 2009;276:466&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pubmed">19076219</ArticleId></ArticleIdList></Reference><Reference><Citation>Belin S, Hacot S, Daudignon L, Therizols G, Pourpe S, Mertani HC, Rosa-Calatrava M, Diaz JJ. Purification of ribosomes from human cell lines. Curr Protoc Cell Biol. 2010;Chapter 3:40. Unit 3.</Citation><ArticleIdList><ArticleId IdType="pubmed">21154551</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhakar AL, Dolen G, Bear MF. The pathophysiology of fragile X (and what it teaches us about synapses) Annu Rev Neurosci. 2012;35:417&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4327822</ArticleId><ArticleId IdType="pubmed">22483044</ArticleId></ArticleIdList></Reference><Reference><Citation>Chartier-Harlin MC, Dachsel JC, Vilarino-Guell C, Lincoln SJ, Lepretre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011;89:398&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169825</ArticleId><ArticleId IdType="pubmed">21907011</ArticleId></ArticleIdList></Reference><Reference><Citation>Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci. 2010;11:791&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4662256</ArticleId><ArticleId IdType="pubmed">21088684</ArticleId></ArticleIdList></Reference><Reference><Citation>Covy JP, Giasson BI. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun. 2009;378:473&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2633649</ArticleId><ArticleId IdType="pubmed">19027715</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol. 2011;7:203&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3287420</ArticleId><ArticleId IdType="pubmed">21378983</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Dzamko N, Prescott A, Davies P, Liu Q, Yang Q, Lee JD, Patricelli MP, Nomanbhoy TK, Alessi DR, et al. Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nature chemical biology. 2011;7:203&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3287420</ArticleId><ArticleId IdType="pubmed">21378983</ArticleId></ArticleIdList></Reference><Reference><Citation>Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010;466:637&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3049892</ArticleId><ArticleId IdType="pubmed">20671708</ArticleId></ArticleIdList></Reference><Reference><Citation>Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis. 2006;23:329&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">16750377</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Gehrke S, Wang HQ, Takahashi R, Hasegawa K, Oota E, Lu B. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008;27:2432&#x2013;2443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2543051</ArticleId><ArticleId IdType="pubmed">18701920</ArticleId></ArticleIdList></Reference><Reference><Citation>Khairulina J, Graifer D, Bulygin K, Ven'yaminova A, Frolova L, Karpova G. Eukaryote-specific motif of ribosomal protein S15 neighbors A site codon during elongation and termination of translation. Biochimie. 2010;92:820&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">20206660</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Greggio E, Beilina A, Kaganovich A, Chan D, Taymans JM, Wolozin B, Cookson MR. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One. 2010;5:e8730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806920</ArticleId><ArticleId IdType="pubmed">20090955</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling SC, Liang TY, Mazur C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci. 2012;15:1488&#x2013;1497.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med. 2010;16:998&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2935926</ArticleId><ArticleId IdType="pubmed">20729864</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Moore DJ, Xiong Y, Dawson TM, Dawson VL. Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2. J Biol Chem. 2010;285:29569&#x2013;29576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937988</ArticleId><ArticleId IdType="pubmed">20595391</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Wang X, Yu Y, Li X, Wang T, Jiang H, Ren Q, Jiao Y, Sawa A, Moran T, et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A. 2008;105:2693&#x2013;2698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2268198</ArticleId><ArticleId IdType="pubmed">18258746</ArticleId></ArticleIdList></Reference><Reference><Citation>Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet. 2007;16:2031&#x2013;2039.</Citation><ArticleIdList><ArticleId IdType="pubmed">17584768</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron. 2006;52:587&#x2013;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">17114044</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin I, Dawson VL, Dawson TM. Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet. 2011;12:301&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4120236</ArticleId><ArticleId IdType="pubmed">21639795</ArticleId></ArticleIdList></Reference><Reference><Citation>Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, De Bock PJ, Morais VA, Vilain S, Haddad D, et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron. 2012;75:1008&#x2013;1021.</Citation><ArticleIdList><ArticleId IdType="pubmed">22998870</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, et al. Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature. 2012;485:507&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3378208</ArticleId><ArticleId IdType="pubmed">22622579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuytemans K, Bademci G, Inchausti V, Dressen A, Kinnamon DD, Mehta A, Wang L, Zuchner S, Beecham GW, Martin ER, et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology. 2013;80:982&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3653206</ArticleId><ArticleId IdType="pubmed">23408866</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisiadou L, Xie C, Cho HJ, Lin X, Gu XL, Long CX, Lobbestael E, Baekelandt V, Taymans JM, Sun L, et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci. 2009;29:13971&#x2013;13980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807632</ArticleId><ArticleId IdType="pubmed">19890007</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisarev AV, Kolupaeva VG, Pisareva VP, Merrick WC, Hellen CU, Pestova TV. Specific functional interactions of nucleotides at key -3 and +4 positions flanking the initiation codon with components of the mammalian 48S translation initiation complex. Genes Dev. 2006;20:624&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1410799</ArticleId><ArticleId IdType="pubmed">16510876</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling SC, Sun E, Wancewicz E, Mazur C, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci. 2011;14:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094729</ArticleId><ArticleId IdType="pubmed">21358643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsden N, Perrin J, Ren Z, Lee BD, Zinn N, Dawson VL, Tam D, Bova M, Lang M, Drewes G, et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011;6:1021&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3688284</ArticleId><ArticleId IdType="pubmed">21812418</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheper GC, van der Knaap MS, Proud CG. Translation matters: protein synthesis defects in inherited disease. Nat Rev Genet. 2007;8:711&#x2013;723.</Citation><ArticleIdList><ArticleId IdType="pubmed">17680008</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci. 2006;9:1231&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Webber PJ, West AB. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization. J Biol Chem. 2009;284:36346&#x2013;36356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2794750</ArticleId><ArticleId IdType="pubmed">19826009</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature neuroscience. 2006;9:1231&#x2013;1233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16980962</ArticleId></ArticleIdList></Reference><Reference><Citation>Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci. 2009;12:1129&#x2013;1135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2745154</ArticleId><ArticleId IdType="pubmed">19684592</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012;485:109&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347774</ArticleId><ArticleId IdType="pubmed">22552098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, Nishimura AL, Zupunski V, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Trancikova A, Mamais A, Webber PJ, Stafa K, Tsika E, Glauser L, West AB, Bandopadhyay R, Moore DJ. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS One. 2012;7:e47784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474772</ArticleId><ArticleId IdType="pubmed">23082216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsika E, Moore DJ. Mechanisms of LRRK2-mediated neurodegeneration. Curr Neurol Neurosci Rep. 2012;12:251&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pubmed">22441981</ArticleId></ArticleIdList></Reference><Reference><Citation>Webber PJ, Smith AD, Sen S, Renfrow MB, Mobley JA, West AB. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities. J Mol Biol. 2011;412:94&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158845</ArticleId><ArticleId IdType="pubmed">21806997</ArticleId></ArticleIdList></Reference><Reference><Citation>West AB, Moore DJ, Choi C, Andrabi SA, Li X, Dikeman D, Biskup S, Zhang Z, Lim KL, Dawson VL, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet. 2007;16:223&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">17200152</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y, Coombes CE, Kilaru A, Li X, Gitler AD, Bowers WJ, Dawson VL, Dawson TM, Moore DJ. GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet. 2010;6:e1000902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2851569</ArticleId><ArticleId IdType="pubmed">20386743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44:601&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24728269</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-1726</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>May</Month></PubDate></JournalIssue><Title>Nature neuroscience</Title><ISOAbbreviation>Nat Neurosci</ISOAbbreviation></Journal><ArticleTitle>Single App knock-in mouse models of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>661</StartPage><EndPage>663</EndPage><MedlinePgn>661-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nn.3697</ELocationID><Abstract><AbstractText>Experimental studies of Alzheimer's disease have largely depended on transgenic mice overexpressing amyloid precursor protein (APP). These mice, however, suffer from artificial phenotypes because, in addition to amyloid &#x3b2; peptide (A&#x3b2;), they overproduce other APP fragments. We generated knock-in mice that harbor Swedish and Beyreuther/Iberian mutations with and without the Arctic mutation in the APP gene. The mice showed typical A&#x3b2; pathology, neuroinflammation and memory impairment in an age-dependent manner.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan. [2] Japan Science and Technology Agency, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuba</LastName><ForeName>Yukio</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihira</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Jiro</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nilsson</LastName><ForeName>Per</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itohara</LastName><ForeName>Shigeyoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Laboratory for Behavioral Genetics, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwata</LastName><ForeName>Nobuhisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>1] Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan. [2] Department of Molecular Medicinal Sciences, Division of Biotechnology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saido</LastName><ForeName>Takaomi C</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Neurosci</MedlineTA><NlmUniqueID>9809671</NlmUniqueID><ISSNLinking>1097-6256</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="Y">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24728269</ArticleId><ArticleId IdType="doi">10.1038/nn.3697</ArticleId><ArticleId IdType="pii">nn.3697</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Neurosci. 2004 Jan 28;24(4):991-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14749444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2005 Apr 22;280(16):16175-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15691848</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropathol Commun. 2013 Sep 10;1:60</Citation><ArticleIdList><ArticleId IdType="pubmed">24252272</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Neurosci. 2011 Jul 03;14(8):1023-32</Citation><ArticleIdList><ArticleId IdType="pubmed">21725313</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 1999 Jan;154(1):271-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9916941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 1995 Feb;14(2):457-66</Citation><ArticleIdList><ArticleId IdType="pubmed">7857653</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Pharmacol Sci. 1991 Oct;12(10):383-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2011 Aug 5;286(31):27081-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21652708</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13287-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9371838</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 Apr;11(4):434-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15778722</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2012 Feb 8;32(6):2037-50</Citation><ArticleIdList><ArticleId IdType="pubmed">22323718</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Aug 2;488(7409):96-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1992 Dec 17;360(6405):672-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1465129</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1997 Dec 19;272(51):32247-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9405428</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Neurol. 2013 Feb;9(2):106-18</Citation><ArticleIdList><ArticleId IdType="pubmed">23296339</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3053-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10077635</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2012 Mar;26(3):1204-17</Citation><ArticleIdList><ArticleId IdType="pubmed">22173972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2004 Nov;10(11):1190-2</Citation><ArticleIdList><ArticleId IdType="pubmed">15502844</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Jun 7;361(9373):1957-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12801742</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1996 Oct 4;274(5284):99-102</Citation><ArticleIdList><ArticleId IdType="pubmed">8810256</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2013 Oct 15;81(16):1425-33</Citation><ArticleIdList><ArticleId IdType="pubmed">24049139</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Rep. 2013 Oct 17;5(1):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24095740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropathol Exp Neurol. 2010 Jan;69(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20010303</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2007 May 4;316(5825):750-4</Citation><ArticleIdList><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14731-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11121072</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24725413</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4172</ISSN><JournalIssue CitedMedium="Internet"><Volume>157</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>10</Day></PubDate></JournalIssue><Title>Cell</Title><ISOAbbreviation>Cell</ISOAbbreviation></Journal><ArticleTitle>Activity-dependent p25 generation regulates synaptic plasticity and A&#x3b2;-induced cognitive impairment.</ArticleTitle><Pagination><StartPage>486</StartPage><EndPage>498</EndPage><MedlinePgn>486-498</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cell.2014.01.065</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0092-8674(14)00213-X</ELocationID><Abstract><AbstractText>Cyclin-dependent kinase 5 regulates numerous neuronal functions with its activator, p35. Under neurotoxic conditions, p35 undergoes proteolytic cleavage to liberate p25, which has been implicated in various neurodegenerative diseases. Here, we show that p25 is generated following neuronal activity under physiological conditions in a GluN2B- and CaMKII&#x3b1;-dependent manner. Moreover, we developed a knockin mouse model in which endogenous p35 is replaced with a calpain-resistant mutant p35 (&#x394;p35KI) to prevent p25 generation. The &#x394;p35KI mice exhibit impaired long-term depression and defective memory extinction, likely mediated through persistent GluA1 phosphorylation at Ser845. Finally, crossing the &#x394;p35KI mice with the 5XFAD mouse model of Alzheimer's disease (AD) resulted in an amelioration of &#x3b2;-amyloid (A&#x3b2;)-induced synaptic depression and cognitive impairment. Together, these results reveal a physiological role of p25 production in synaptic plasticity and memory and provide new insights into the function of p25 in A&#x3b2;-associated neurotoxicity and AD-like pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Jinsoo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giusti-Rodr&#xed;guez</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudenko</LastName><ForeName>Andrii</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sukhee</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ota</LastName><ForeName>Kristie T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patzke</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madabhushi</LastName><ForeName>Ram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mungenast</LastName><ForeName>Alison E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guan</LastName><ForeName>Ji-Song</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delalle</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Li-Huei</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>The Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA. Electronic address: lhtsai@mit.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 GM080055</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS051874</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>F31GM80055-03</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell</MedlineTA><NlmUniqueID>0413066</NlmUniqueID><ISSNLinking>0092-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C500695">CDCA5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492236">Cdk5r1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051937">Dopamine and cAMP-Regulated Phosphoprotein 32</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C497928">PPP1R1B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C118136">TPPP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D051360">Cyclin-Dependent Kinase 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D002154">Calpain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002154" MajorTopicYN="N">Calpain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051360" MajorTopicYN="N">Cyclin-Dependent Kinase 5</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051937" MajorTopicYN="N">Dopamine and cAMP-Regulated Phosphoprotein 32</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004705" MajorTopicYN="N">Endocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055879" MajorTopicYN="N">Gene Knock-In Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036881" MajorTopicYN="N">Long-Term Synaptic Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24725413</ArticleId><ArticleId IdType="mid">NIHMS569069</ArticleId><ArticleId IdType="pmc">PMC4327772</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2014.01.065</ArticleId><ArticleId IdType="pii">S0092-8674(14)00213-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angelo M, Plattner F, Irvine EE, Giese KP. Improved reversal learning and altered fear conditioning in transgenic mice with regionally restricted p25 expression. Eur. J. Neurosci. 2003;18:423&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pubmed">12887424</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibb JA, Snyder GL, Nishi A, Yan Z, Meijer L, Fienberg AA, Tsai LH, Kwon YT, Girault JA, Czernik AJ, et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature. 1999;402:669&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604473</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005;25:7709&#x2013;7717.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin RK, Grab DJ, Cohen RS, Siekevitz P. Isolation and characterization of postsynaptic densities from various brain regions: enrichment of different types of postsynaptic densities. J. Cell Biol. 1980;86:831&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2110694</ArticleId><ArticleId IdType="pubmed">7410481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chae T, Kwon YT, Bronson R, Dikkes P, Li E, Tsai LH. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 1997;18:29&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">9010203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Zhang J, Wu Y, Wang D, Feng G, Tang Y-P, Teng Z, Chen C. Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease. Cell Rep. 2012;2:1329&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513645</ArticleId><ArticleId IdType="pubmed">23122958</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Collingridge GL, Isaac JTR, Wang YT. Receptor trafficking and synaptic plasticity. Nat. Rev. Neurosci. 2004;5:952&#x2013;962.</Citation><ArticleIdList><ArticleId IdType="pubmed">15550950</ArticleId></ArticleIdList></Reference><Reference><Citation>Crews L, Patrick C, Adame A, Rockenstein E, Masliah E. Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death Dis. 2011;2:e120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101702</ArticleId><ArticleId IdType="pubmed">21368891</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Tseng H-C, Goldman JA, Shih H, Tsai L-H. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurode-generation and neurofibrillary tangles. Neuron. 2003;40:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">14642273</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, Tsai L-H. p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. J. Neurosci. 2006;26:10536&#x2013;10541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674706</ArticleId><ArticleId IdType="pubmed">17035538</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, et al. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat. Neurosci. 2011;14:69&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalton GL, Wang YT, Floresco SB, Phillips AG. Disruption of AMPA receptor endocytosis impairs the extinction, but not acquisition of learned fear. Neuropsychopharmacology. 2008;33:2416&#x2013;2426.</Citation><ArticleIdList><ArticleId IdType="pubmed">18046303</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhavan R, Greer PL, Morabito MA, Orlando LR, Tsai L-H. The cyclin-dependent kinase 5 activators p35 and p39 interact with the alpha-subunit of Ca2+/calmodulin-dependent protein kinase II and alpha-actinin-1 in a calcium-dependent manner. J. Neurosci. 2002;22:7879&#x2013;7891.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758084</ArticleId><ArticleId IdType="pubmed">12223541</ArticleId></ArticleIdList></Reference><Reference><Citation>Engmann O, Hortob&#xe1;gyi T, Thompson AJ, Guadagno J, Troakes C, Soriano S, Al-Sarraj S, Kim Y, Giese KP. Cyclin-dependent kinase 5 activator p25 is generated during memory formation and is reduced at an early stage in Alzheimer's disease. Biol. Psychiatry. 2011;70:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">21616478</ArticleId></ArticleIdList></Reference><Reference><Citation>Etkin A, Alarc&#xf3;n JM, Weisberg SP, Touzani K, Huang YY, Nordheim A, Kandel ER. A role in learning for SRF: deletion in the adult fore-brain disrupts LTD and the formation of an immediate memory of a novel context. Neuron. 2006;50:127&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">16600861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu W-Y, Chen Y, Sahin M, Zhao X-S, Shi L, Bikoff JB, Lai K-O, Yung W-H, Fu AKY, Greenberg ME, Ip NY. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat. Neurosci. 2007;10:67&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17143272</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilmore EC, Ohshima T, Goffinet AM, Kulkarni AB, Herrup K. Cyclin-dependent kinase 5-deficient mice demonstrate novel developmental arrest in cerebral cortex. J. Neurosci. 1998;18:6370&#x2013;6377.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6793186</ArticleId><ArticleId IdType="pubmed">9698328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gr&#xe4;ff J, Rei D, Guan J-S, Wang W-Y, Seo J, Hennig KM, Nieland TJF, Fass DM, Kao PF, Kahn M, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature. 2012;483:222&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498952</ArticleId><ArticleId IdType="pubmed">22388814</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan J-S, Haggarty SJ, Giacometti E, Dannenberg J-H, Joseph N, Gao J, Nieland TJF, Zhou Y, Wang X, Mazitschek R, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498958</ArticleId><ArticleId IdType="pubmed">19424149</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan J-S, Su SC, Gao J, Joseph N, Xie Z, Zhou Y, Durak O, Zhang L, Zhu JJ, Clauser KR, et al. Cdk5 is required for memory function and hippocampal plasticity via the cAMP signaling pathway. PLoS ONE. 2011;6:e25735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3184170</ArticleId><ArticleId IdType="pubmed">21984943</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpain S, Girault JA, Greengard P. Activation of NMDA receptors induces dephosphorylation of DARPP-32 in rat striatal slices. Nature. 1990;343:369&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">2153935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemmings HC, Jr., Greengard P, Tung HY, Cohen P. DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984;310:503&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pubmed">6087160</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Ab aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging. 2012;33:196.e29&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">20619937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron. 2003;37:925&#x2013;937.</Citation><ArticleIdList><ArticleId IdType="pubmed">12670422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kesavapany S, Zheng Y-L, Amin N, Pant HC. Peptides derived from Cdk5 activator p35, specifically inhibit deregulated activity of Cdk5. Biotechnol. J. 2007;2:978&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">17526058</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Ryan TA. CDK5 serves as a major control point in neurotransmitter release. Neuron. 2010;67:797&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2939042</ArticleId><ArticleId IdType="pubmed">20826311</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Sung JY, Ceglia I, Lee K-W, Ahn J-H, Halford JM, Kim AM, Kwak SP, Park JB, Ho Ryu S, et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. Nature. 2006;442:814&#x2013;817.</Citation><ArticleIdList><ArticleId IdType="pubmed">16862120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Lee S, Park K, Hong I, Song B, Son G, Park H, Kim WR, Park E, Choe HK, et al. Amygdala depotentiation and fear extinction. Proc. Natl. Acad. Sci. USA. 2007;104:20955&#x2013;20960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2409248</ArticleId><ArticleId IdType="pubmed">18165656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura R, Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol. Dis. 2009;33:229&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2741400</ArticleId><ArticleId IdType="pubmed">19026746</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko J, Humbert S, Bronson RT, Takahashi S, Kulkarni AB, Li E, Tsai LH. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 2001;21:6758&#x2013;6771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763073</ArticleId><ArticleId IdType="pubmed">11517264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu H-Y, Hyman BT, Bacskai BJ. Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Kameyama K, Huganir RL, Bear MF. NMDA induces long-term synaptic depression and dephosphorylation of the GluR1 subunit of AMPA receptors in hippocampus. Neuron. 1998;21:1151&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">9856470</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HK, Barbarosie M, Kameyama K, Bear MF, Huganir RL. Regulation of distinct AMPA receptor phosphorylation sites during bidirectional synaptic plasticity. Nature. 2000a;405:955&#x2013;959.</Citation><ArticleIdList><ArticleId IdType="pubmed">10879537</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 2000b;405:360&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">10830966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S-H, Choi J-H, Lee N, Lee H-R, Kim J-I, Yu N-K, Choi S-L, Lee S-H, Kim H, Kaang B-K. Synaptic protein degradation underlies destabilization of retrieved fear memory. Science. 2008;319:1253&#x2013;1256.</Citation><ArticleIdList><ArticleId IdType="pubmed">18258863</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Jo J, Jia J-M, Lo S-C, Whitcomb DJ, Jiao S, Cho K, Sheng M. Caspase-3 activation via mitochondria is required for long-term depression and AMPA receptor internalization. Cell. 2010;141:859&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909748</ArticleId><ArticleId IdType="pubmed">20510932</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu W, Man H, Ju W, Trimble WS, MacDonald JF, Wang YT. Activation of synaptic NMDA receptors induces membrane insertion of new AMPA receptors and LTP in cultured hippocampal neurons. Neuron. 2001;29:243&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182095</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra A, Mitra SS, Tsien RW. Heterogeneous reallocation of presynaptic efficacy in recurrent excitatory circuits adapting to inactivity. Nat. Neurosci. 2012;15:250&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558750</ArticleId><ArticleId IdType="pubmed">22179109</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukerjee N, McGinnis KM, Park YH, Gnegy ME, Wang KK. Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. Arch. Biochem. Biophys. 2000;379:337&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pubmed">10898953</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Herron CE, Malenka RC. An essential role for protein phosphatases in hippocampal long-term depression. Science. 1993;261:1051&#x2013;1055.</Citation><ArticleIdList><ArticleId IdType="pubmed">8394601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulkey RM, Endo S, Shenolikar S, Malenka RC. Involvement of a calcineurin/inhibitor-1 phosphatase cascade in hippocampal long-term depression. Nature. 1994;369:486&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pubmed">7515479</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 2006;26:10129&#x2013;10140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674618</ArticleId><ArticleId IdType="pubmed">17021169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohshima T, Ogura H, Tomizawa K, Hayashi K, Suzuki H, Saito T, Kamei H, Nishi A, Bibb JA, Hisanaga S-I, et al. Impairment of hippocampal long-term depression and defective spatial learning and memory in p35 mice. J. Neurochem. 2005;94:917&#x2013;925.</Citation><ArticleIdList><ArticleId IdType="pubmed">15992381</ArticleId></ArticleIdList></Reference><Reference><Citation>Otth C, Concha II, Arendt T, Stieler J, Schliebs R, Gonz&#xe1;lez-Billault C, Maccioni RB. AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J. Alzheimers Dis. 2002;4:417&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446973</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604467</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry VH, Nicoll JAR, Holmes C. Microglia in neurodegenerative disease. Nat. Rev. Neurol. 2010;6:193&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234358</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadleir KR, Vassar R. Cdk5 protein inhibition and Ab42 increase BACE1 protein level in primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic target for Alzheimer disease. J. Biol. Chem. 2012;287:7224&#x2013;7235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3293556</ArticleId><ArticleId IdType="pubmed">22223639</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DTS, Sheng M. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron. 2008;58:571&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2488274</ArticleId><ArticleId IdType="pubmed">18498738</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai Y, Lu B, Hu Y, Wang L, Sun K, Zhong Y. Forgetting is regulated through Rac activity in Drosophila. Cell. 2010;140:579&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">20178749</ArticleId></ArticleIdList></Reference><Reference><Citation>Su SC, Tsai L-H. Cyclin-dependent kinases in brain development and disease. Annu. Rev. Cell Dev. Biol. 2011;27:465&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">21740229</ArticleId></ArticleIdList></Reference><Reference><Citation>Swatton JE, Sellers LA, Faull RLM, Holland A, Iritani S, Bahn S. Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 2004;19:2711&#x2013;2719.</Citation><ArticleIdList><ArticleId IdType="pubmed">15147305</ArticleId></ArticleIdList></Reference><Reference><Citation>Szapiro G, Vianna MRM, McGaugh JL, Medina JH, Izquierdo I. The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus. 2003;13:53&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon A, Yu H, Wang L, Rogaeva E, Sato C, Chishti MA, Kawarai T, Hasegawa H, Chen F, Davies P, et al. Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J. Neurochem. 2003;86:572&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859671</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronson NC, Corcoran KA, Jovasevic V, Radulovic J. Fear conditioning and extinction: emotional states encoded by distinct signaling pathways. Trends Neurosci. 2012;35:145&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3290759</ArticleId><ArticleId IdType="pubmed">22118930</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Olabarria M, Noristani HN, Yeh C-Y, Rodriguez JJ. Astrocytes in Alzheimer's disease. Neurotherapeutics. 2010;7:399&#x2013;412.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5084302</ArticleId><ArticleId IdType="pubmed">20880504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y, Yu WH, Maloney B, Bailey J, Ma J, Mari&#xe9; I, Maurin T, Wang L, Figueroa H, Herman M, et al. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008;57:680&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2329816</ArticleId><ArticleId IdType="pubmed">18341989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang T, Knowles JK, Lu Q, Zhang H, Arancio O, Moore LA, Chang T, Wang Q, Andreasson K, Rajadas J, et al. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS ONE. 2008;3:e3604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575383</ArticleId><ArticleId IdType="pubmed">18978948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo BC, Lubec G. p25 protein in neurodegeneration. Nature. 2001;411:763&#x2013;764. discussion 764&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459045</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Storm DR, Wang H. Bidirectional synaptic plasticity and spatial memory flexibility require Ca2+-stimulated adenylyl cyclases. J. Neurosci. 2011;31:10174&#x2013;10183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3145492</ArticleId><ArticleId IdType="pubmed">21752993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Fu Y, Yasvoina M, Shao P, Hitt B, O'Connor T, Logan S, Maus E, Citron M, Berry R, et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. J. Neurosci. 2007;27:3639&#x2013;3649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672403</ArticleId><ArticleId IdType="pubmed">17409228</ArticleId></ArticleIdList></Reference><Reference><Citation>Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van Etten RA, Tsai LH. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron. 2000;26:633&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pubmed">10896159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24733620</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Multiple system atrophy and amyotrophic lateral sclerosis in a family with hexanucleotide repeat expansions in C9orf72.</ArticleTitle><Pagination><StartPage>771</StartPage><EndPage>774</EndPage><MedlinePgn>771-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.5762</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Here we report a family with coexistence of multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS) with hexanucleotide repeat expansions in C9orf72.</AbstractText><AbstractText Label="OBSERVATIONS" NlmCategory="METHODS">A 65-year-old woman had a 2-year history of ataxia with autonomic dysfunction but without motor neuron signs. She was diagnosed as having MSA based on her clinical history and the hot cross bun sign on brain magnetic resonance imaging. Her 62-year-old brother had progressive weakness, fasciculations, hyperreflexia, and active denervation on electromyography without cerebellar ataxia. He was diagnosed as having ALS. Both patients had a greater than 1000/2 hexanucleotide expansion in C9orf72.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Patients with hexanucleotide repeat expansions in C9orf72 can present with MSA as well as ALS or frontotemporal dementia. We report this family with coexisting MSA and ALS, highlighting the phenotypic variability in neurologic presentations with hexanucleotide repeat expansions in C9orf72.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldman</LastName><ForeName>Jill S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinzii</LastName><ForeName>Catarina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunning-Broadbent</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waters</LastName><ForeName>Cheryl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brannagan</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huey</LastName><ForeName>Edward D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York3Department of Psychiatry, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology and Cell Biology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Sheng-Han</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS076837</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-ES016348</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R0103873402</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES016348</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00NS060766</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS076837-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 NS060766</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5R01NS64253-5</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 NS083738</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG041795</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01NS076837</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Sep;71(9):1190-1. doi: 10.1001/jamaneurol.2014.1808.</RefSource><PMID Version="1">25200542</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Sep;71(9):1191-2. doi: 10.1001/jamaneurol.2014.1811.</RefSource><PMID Version="1">25200544</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019578" MajorTopicYN="N">Multiple System Atrophy</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24733620</ArticleId><ArticleId IdType="mid">NIHMS589313</ArticleId><ArticleId IdType="pmc">PMC4051831</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.5762</ArticleId><ArticleId IdType="pii">1859981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>D&#xfc;rr A. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond. Lancet Neurol. 2010;9(9):885&#x2013;894.</Citation><ArticleIdList><ArticleId IdType="pubmed">20723845</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet. 1996;14(3):269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">8896555</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466(7310):1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALSFTD. Neuron. 2011;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3322422</ArticleId><ArticleId IdType="pubmed">22406228</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clin Genet. 2013;83(3):279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel BL, Pribadi M, Pi S, Perlman SL, Geschwind DH, Coppola G. C9ORF72 expansion is not a significant cause of sporadic spinocerebellar ataxia. Mov Disord. 2012;27(14):1832&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536912</ArticleId><ArticleId IdType="pubmed">23080112</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011 Sep;134(Pt 9):2456&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy Neurology. 2008;71(9):670&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676993</ArticleId><ArticleId IdType="pubmed">18725592</ArticleId></ArticleIdList></Reference><Reference><Citation>Tazen S, Figueroa KP, Kwan JY, et al. Amyotrophic lateral sclerosis and spinocerebellar ataxia type 2 in a family with full CAG repeat expansions of ATXN2. JAMA Neurol. Published online August 19, 2013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039635</ArticleId><ArticleId IdType="pubmed">23959108</ArticleId></ArticleIdList></Reference><Reference><Citation>Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013 Jul 18;369(3):233&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">23758206</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet. 2011 Jul 15;89(1):121&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135815</ArticleId><ArticleId IdType="pubmed">21683323</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve BF, Boylan KB, Graff-Radford NR, et al. Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain. 2012;135(Pt 3):765&#x2013;783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286335</ArticleId><ArticleId IdType="pubmed">22366793</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Thompson JC, et al. Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain. 2012;135(Pt 3):693&#x2013;708.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286329</ArticleId><ArticleId IdType="pubmed">22300873</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahoney CJ, Downey LE, Ridgway GR, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther. 2012;4(5):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580398</ArticleId><ArticleId IdType="pubmed">23006986</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135(Pt 3):794&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286334</ArticleId><ArticleId IdType="pubmed">22366795</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339(6125):1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24740065</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>508</Volume><Issue>7496</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Domains of genome-wide gene expression dysregulation in Down's syndrome.</ArticleTitle><Pagination><StartPage>345</StartPage><EndPage>350</EndPage><MedlinePgn>345-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nature13200</ELocationID><Abstract><AbstractText>Trisomy 21 is the most frequent genetic cause of cognitive impairment. To assess the perturbations of gene expression in trisomy 21, and to eliminate the noise of genomic variability, we studied the transcriptome of fetal fibroblasts from a pair of monozygotic twins discordant for trisomy 21. Here we show that the differential expression between the twins is organized in domains along all chromosomes that are either upregulated or downregulated. These gene expression dysregulation domains (GEDDs) can be defined by the expression level of their gene content, and are well conserved in induced pluripotent stem cells derived from the twins' fibroblasts. Comparison of the transcriptome of the Ts65Dn mouse model of Down's syndrome and normal littermate mouse fibroblasts also showed GEDDs along the mouse chromosomes that were syntenic in human. The GEDDs correlate with the lamina-associated (LADs) and replication domains of mammalian cells. The overall position of LADs was not altered in trisomic cells; however, the H3K4me3 profile of the trisomic fibroblasts was modified and accurately followed the GEDD pattern. These results indicate that the nuclear compartments of trisomic cells undergo modifications of the chromatin environment influencing the overall transcriptome, and that GEDDs may therefore contribute to some trisomy 21 phenotypes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Letourneau</LastName><ForeName>Audrey</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santoni</LastName><ForeName>Federico A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>1] Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonilla</LastName><ForeName>Ximena</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sailani</LastName><ForeName>M Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation, University Pompeu Fabra, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kind</LastName><ForeName>Jop</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Gene Regulation, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevalier</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>AneuPath 21, Institut de G&#xe9;n&#xe9;tique Biologie Mol&#xe9;culaire et Cellulaire, Translational medicine and Neuroscience program, IGBMC, ICS, PHENOMIN, CNRS, INSERM, Universit&#xe9; de Strasbourg, UMR7104, UMR964, 1 rue Laurent Fries, 67404 Illkirch, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thurman</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandstrom</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hibaoui</LastName><ForeName>Youssef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Stem Cell Research Laboratory, Department of Obstetrics and Gynecology, Geneva University Hospitals, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garieri</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popadin</LastName><ForeName>Konstantin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconnet</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gagnebin</LastName><ForeName>Maryline</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gehrig</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vannier</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guipponi</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farinelli</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>FASTERIS SA, 1228 Plan-les-Ouates, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robyr</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migliavacca</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1] Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland [2] Swiss Institute of Bioinfomatics, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borel</LastName><ForeName>Christelle</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>DOE Joint Genome Institute, Walnut Creek, California 94598, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feki</LastName><ForeName>Anis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stem Cell Research Laboratory, Department of Obstetrics and Gynecology, Geneva University Hospitals, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamatoyannopoulos</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Genome Sciences, University of Washington, Seattle, Washington 98195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herault</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>AneuPath 21, Institut de G&#xe9;n&#xe9;tique Biologie Mol&#xe9;culaire et Cellulaire, Translational medicine and Neuroscience program, IGBMC, ICS, PHENOMIN, CNRS, INSERM, Universit&#xe9; de Strasbourg, UMR7104, UMR964, 1 rue Laurent Fries, 67404 Illkirch, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Steensel</LastName><ForeName>Bas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gene Regulation, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guigo</LastName><ForeName>Roderic</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Genomic Regulation, University Pompeu Fabra, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonarakis</LastName><ForeName>Stylianos E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>1] Department of Genetic Medicine and Development, University of Geneva Medical School, University Hospitals of Geneva, 1211 Geneva, Switzerland [2] iGE3 Institute of Genetics and Genomics of Geneva, 1211 Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE55426</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U54 HG007010</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54HG007010</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002843">Chromatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006657">Histones</NameOfSubstance></Chemical><Chemical><RegistryNumber>K3Z4F929H6</RegistryNumber><NameOfSubstance UI="D008239">Lysine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Apr 17;508(7496):323-4. doi: 10.1038/508323a.</RefSource><PMID Version="1">24740061</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Nature. 2016 Mar 17;531(7594):400. doi: 10.1038/nature16135.</RefSource><PMID Version="1">26633627</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002843" MajorTopicYN="N">Chromatin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002891" MajorTopicYN="N">Chromosomes, Human, Pair 21</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033481" MajorTopicYN="N">Chromosomes, Mammalian</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042522" MajorTopicYN="N">DNA Replication Timing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004314" MajorTopicYN="N">Down Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005333" MajorTopicYN="N">Fetus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005347" MajorTopicYN="N">Fibroblasts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016678" MajorTopicYN="N">Genome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006657" MajorTopicYN="N">Histones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008239" MajorTopicYN="N">Lysine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24740065</ArticleId><ArticleId IdType="doi">10.1038/nature13200</ArticleId><ArticleId IdType="pii">nature13200</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Biochem Biophys. 2013 Jan 15;529(2):105-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23219734</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):74-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20123070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2009;4(1):44-57</Citation><ArticleIdList><ArticleId IdType="pubmed">19131956</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2004 Oct;5(10):725-38</Citation><ArticleIdList><ArticleId IdType="pubmed">15510164</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet. 1983 Feb;14(2):241-69</Citation><ArticleIdList><ArticleId IdType="pubmed">6220605</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2013 Mar 1;29(5):614-21</Citation><ArticleIdList><ArticleId IdType="pubmed">23329413</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Physiol. 2010 Nov;225(2):569-76</Citation><ArticleIdList><ArticleId IdType="pubmed">20506188</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2008 Oct 31;322(5902):703-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18974345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 Nov 30;131(5):861-72</Citation><ArticleIdList><ArticleId IdType="pubmed">18035408</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2000 Jul 22;9(12):1853-64</Citation><ArticleIdList><ArticleId IdType="pubmed">10915774</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2011 Jun 1;27(11):1571-2</Citation><ArticleIdList><ArticleId IdType="pubmed">21493656</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm Suppl. 1999;57:293-303</Citation><ArticleIdList><ArticleId IdType="pubmed">10666684</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet A. 2008 Aug 15;146A(16):2086-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18627064</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 1995 Oct;11(2):177-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7550346</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):62-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19948260</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2009 Apr;17(4):454-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19002211</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Brain Res. 2012;197:15-28</Citation><ArticleIdList><ArticleId IdType="pubmed">22541286</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Res. 2007 Sep;17(9):1286-95</Citation><ArticleIdList><ArticleId IdType="pubmed">17693573</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Protoc Mol Biol. 2013 Jul;Chapter 27:Unit 21.27</Citation><ArticleIdList><ArticleId IdType="pubmed">23821440</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Biol. 2008 Oct 7;6(10):e245</Citation><ArticleIdList><ArticleId IdType="pubmed">18842067</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Jun 12;453(7197):948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">18463634</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocampus. 2007;17(8):665-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17546680</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2011 Apr;6(4):468-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21412275</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Biochem. 2011 Apr;22(4):328-33</Citation><ArticleIdList><ArticleId IdType="pubmed">20691578</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 May;43(5):491-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21478889</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 May 24;91(11):4997-5001</Citation><ArticleIdList><ArticleId IdType="pubmed">8197171</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Sep 6;489(7414):75-82</Citation><ArticleIdList><ArticleId IdType="pubmed">22955617</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2012 Jun 22;149(7):1474-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22726435</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2011 Apr;164(1):9-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21352207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2004 Jan 1;13(1):15-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14613969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Protoc. 2007;2(6):1467-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17545983</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2010 Jan 1;26(1):139-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19910308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2007 May 18;129(4):823-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17512414</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):139-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19966280</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome. 2008 Jan;51(1):19-29</Citation><ArticleIdList><ArticleId IdType="pubmed">18356936</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Biol. 2012 Oct 03;13(10):R87</Citation><ArticleIdList><ArticleId IdType="pubmed">23034086</ArticleId></ArticleIdList></Reference><Reference><Citation>Genomics. 2007 Dec;90(6):647-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17950572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2005 Dec 1;14(23):3741-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16251198</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2013 Sep 26;501(7468):506-11</Citation><ArticleIdList><ArticleId IdType="pubmed">24037378</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2012 Oct 1;21(19):4162-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22736031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Methods. 2012 Dec;9(12):1185-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23103880</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2008 Feb 1;17(3):440-57</Citation><ArticleIdList><ArticleId IdType="pubmed">17984171</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Clin Biol Res. 1993;384:117-33</Citation><ArticleIdList><ArticleId IdType="pubmed">8115398</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Cell Mater. 2011 Nov 09;22:258-74; discussio 274</Citation><ArticleIdList><ArticleId IdType="pubmed">22071697</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell. 2010 May 28;38(4):603-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20513434</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO Mol Med. 2014 Feb;6(2):259-77</Citation><ArticleIdList><ArticleId IdType="pubmed">24375627</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2008 Sep;83(3):388-400</Citation><ArticleIdList><ArticleId IdType="pubmed">18771760</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Dyn. 2003 Aug;227(4):608-14</Citation><ArticleIdList><ArticleId IdType="pubmed">12889071</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Sep 4;325(5945):1246-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19644074</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011 Apr 20;6(4):e18493</Citation><ArticleIdList><ArticleId IdType="pubmed">21533138</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2001 Feb 16;291(5507):1289-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11181992</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2007 Aug;81(2):252-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17668376</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2014 Feb;15(2):69-81</Citation><ArticleIdList><ArticleId IdType="pubmed">24342920</ArticleId></ArticleIdList></Reference><Reference><Citation>Mamm Genome. 2011 Dec;22(11-12):674-84</Citation><ArticleIdList><ArticleId IdType="pubmed">21953411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Dis. 2006 Jun;22(3):463-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16455265</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Genet. 2007 Jul;8(7):507-17</Citation><ArticleIdList><ArticleId IdType="pubmed">17549064</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Cell Biol. 2002 Jun;14(3):377-83</Citation><ArticleIdList><ArticleId IdType="pubmed">12067662</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24742461</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>16</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain.</ArticleTitle><Pagination><StartPage>380</StartPage><EndPage>397</EndPage><MedlinePgn>380-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.02.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00171-8</ELocationID><Abstract><AbstractText>The colony-stimulating factor 1 receptor (CSF1R) is a key regulator of myeloid lineage cells. Genetic loss of the CSF1R blocks the normal population of resident microglia in the brain that originates from the yolk sac during early development. However, the role of CSF1R signaling in microglial homeostasis in the adult brain is largely unknown. To this end, we tested the effects of selective CSF1R inhibitors on microglia in adult mice. Surprisingly, extensive treatment results in elimination of &#x223c;99% of all microglia brain-wide, showing that microglia in the adult brain are physiologically dependent upon CSF1R signaling. Mice depleted of microglia show no behavioral or cognitive abnormalities, revealing that microglia are not necessary for these tasks. Finally, we discovered that the microglia-depleted brain completely repopulates with new microglia within 1 week of inhibitor cessation. Microglial repopulation throughout the CNS occurs through proliferation of nestin-positive cells that then differentiate into microglia.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elmore</LastName><ForeName>Monica R P</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Najafi</LastName><ForeName>Allison R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Maya A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dagher</LastName><ForeName>Nabil N</ForeName><Initials>NN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spangenberg</LastName><ForeName>Elizabeth E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rice</LastName><ForeName>Rachel A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitazawa</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology, University of California, Merced, Merced, CA 95343, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matusow</LastName><ForeName>Bernice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Plexxikon Inc., Berkeley, CA 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Hoa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Plexxikon Inc., Berkeley, CA 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Brian L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Plexxikon Inc., Berkeley, CA 94710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Kim N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Department of Neurobiology and Behavior, Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA 92697-4545, USA. Electronic address: kngreen@uci.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS083801</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS083801</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00538</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS086409</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31NS086409</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 AG000096</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1TR000153</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008070">Lipopolysaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>81627-83-0</RegistryNumber><NameOfSubstance UI="D016173">Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D016186">Receptor, Macrophage Colony-Stimulating Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2014 Apr 16;82(2):253-5. doi: 10.1016/j.neuron.2014.04.010.</RefSource><PMID Version="1">24742453</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D053687" MajorTopicYN="N">Adult Stem Cells</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008070" MajorTopicYN="N">Lipopolysaccharides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016173" MajorTopicYN="N">Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016186" MajorTopicYN="N">Receptor, Macrophage Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24742461</ArticleId><ArticleId IdType="mid">NIHMS571574</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pii">S0896-6273(14)00171-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abou-Khalil R, Yang F, Mortreux M, Lieu S, Yu YY, Wurmser M, Pereira C, Relaix F, Miclau T, Marcucio RS, et al. Delayed bone regeneration is linked to chronic inflammation in murine muscular dystrophy. J Bone Miner Res 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893315</ArticleId><ArticleId IdType="pubmed">23857747</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci. 2011;14:1142&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804537</ArticleId></ArticleIdList></Reference><Reference><Citation>Artis DR, BR, Gillette S, Hurt CR, Ibrahim PL, Zuckerman RL. U.S. patent, editor. Molecular scaffolds for kinase ligand development. USA: Jul 28, 2005.</Citation></Reference><Reference><Citation>Banisadr G, Gosselin RD, Mechighel P, Rostene W, Kitabgi P, Melik Parsadaniantz S. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. J Comp Neurol. 2005;492:178&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">16196033</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutner C, Roy K, Linnartz B, Napoli I, Neumann H. Generation of microglial cells from mouse embryonic stem cells. Nat Protoc. 2010;5:1481&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">20725065</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin BY, Petrache I, Choi AM, Choi ME. Transforming growth factor beta1 rescues serum deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in macrophages. J Biol Chem. 1999;274:11362&#x2013;11368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10196228</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitu V, Nacu V, Charles JF, Henne WM, McMahon HT, Nandi S, Ketchum H, Harris R, Nakamura MC, Stanley ER. PSTPIP2 deficiency in mice causes osteopenia and increased differentiation of multipotent myeloid precursors into osteoclasts. Blood. 2012;120:3126&#x2013;3135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3471520</ArticleId><ArticleId IdType="pubmed">22923495</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Morimoto ET, Goodarzi H, Liao JT, O&#x2019;Keeffe S, Phatnani HP, Muratet M, Carroll MC, Levy S, Tavazoie S, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep. 2013;4:385&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4272581</ArticleId><ArticleId IdType="pubmed">23850290</ArticleId></ArticleIdList></Reference><Reference><Citation>Coniglio SJ, Eugenin E, Dobrenis K, Stanley ER, West BL, Symons MH, Segall JE. Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling. Mol Med. 2012;18:519&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3356419</ArticleId><ArticleId IdType="pubmed">22294205</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci U S A. 2005;102:16078&#x2013;16083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1276040</ArticleId><ArticleId IdType="pubmed">16249345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornelis S, Bruynooghe Y, Van Loo G, Saelens X, Vandenabeele P, Beyaert R. Apoptosis of hematopoietic cells induced by growth factor withdrawal is associated with caspase-9 mediated cleavage of Raf-1. Oncogene. 2005;24:1552&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15674327</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods. 1993;160:81&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">7680699</ArticleId></ArticleIdList></Reference><Reference><Citation>DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203524</ArticleId><ArticleId IdType="pubmed">22039576</ArticleId></ArticleIdList></Reference><Reference><Citation>Erblich B, Zhu L, Etgen AM, Dobrenis K, Pollard JW. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. PLoS One. 2011;6:e26317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3203114</ArticleId><ArticleId IdType="pubmed">22046273</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol. 2012;13:1118&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3558276</ArticleId><ArticleId IdType="pubmed">23023392</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2010;330:841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Green KN, Khashwji H, Estrada T, Laferla FM. ST101 induces a novel 17 kDa APP cleavage that precludes A beta generation in vivo. Ann Neurol. 2011;69:831&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">21416488</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, Kundig TM, Frei K, Ginhoux F, Merad M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity. 2012;37:1050&#x2013;1060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4291117</ArticleId><ArticleId IdType="pubmed">23177320</ArticleId></ArticleIdList></Reference><Reference><Citation>Greter M, Merad M. Regulation of microglia development and homeostasis. Glia. 2013;61:121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">22927325</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto D, Chow A, Noizat C, Teo P, Beasley MB, Leboeuf M, Becker CD, See P, Price J, Lucas D, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity. 2013;38:792&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3853406</ArticleId><ArticleId IdType="pubmed">23601688</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Rhodes SD, Chen S, Wu X, Yuan J, Yang X, Jiang L, Li X, Takahashi N, Xu M, et al. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One. 2012;7:e46900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492362</ArticleId><ArticleId IdType="pubmed">23144792</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, Riemke P, Holscher C, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">23334579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kueh HY, Champhekhar A, Nutt SL, Elowitz MB, Rothenberg EV. Positive Feedback Between PU.1 and the Cell Cycle Controls Myeloid Differentiation. Science 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3913367</ArticleId><ArticleId IdType="pubmed">23868921</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Chen K, Zhu L, Pollard JW. Conditional deletion of the colony stimulating factor-1 receptor (c-fms proto-oncogene) in mice. Genesis. 2006;44:328&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">16823860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320:807&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pubmed">18467591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M. Microglia in the adult brain arise from Ly-6 ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci. 2007;10:1544&#x2013;1553.</Citation><ArticleIdList><ArticleId IdType="pubmed">18026096</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber T, West BL, Bollag G, Ribas A. Inhibition of CSF1 Receptor Improves the Anti-tumor Efficacy of Adoptive Cell Transfer Immunotherapy. Cancer Res 2013</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947337</ArticleId><ArticleId IdType="pubmed">24247719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi S, Gokhan S, Dai XM, Wei S, Enikolopov G, Lin H, Mehler MF, Richard Stanley E. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol 2012a</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388946</ArticleId><ArticleId IdType="pubmed">22542597</ArticleId></ArticleIdList></Reference><Reference><Citation>Nandi S, Gokhan S, Dai XM, Wei S, Enikolopov G, Lin H, Mehler MF, Stanley ER. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol. 2012b;367:100&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388946</ArticleId><ArticleId IdType="pubmed">22542597</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely KM, Green KN, LaFerla FM. Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a gamma-secretase-independent manner. J Neurosci. 2011;31:2781&#x2013;2791.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3064964</ArticleId><ArticleId IdType="pubmed">21414900</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2640215</ArticleId><ArticleId IdType="pubmed">18567623</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer&#x2019;s disease with plaques and tangles: intracellular A beta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno H, Kubo K, Murooka H, Kobayashi Y, Nishitoba T, Shibuya M, Yoneda T, Isoe T. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006;5:2634&#x2013;2643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17121910</ArticleId></ArticleIdList></Reference><Reference><Citation>Parkhurst CN, Yang G, Ninan I, Savas JN, Yates JR, 3rd, Lafaille JJ, Hempstead BL, Littman DR, Gan WB. Microglia Promote Learning-Dependent Synapse Formation through Brain-Derived Neurotrophic Factor. Cell. 2013;155:1596&#x2013;1609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033691</ArticleId><ArticleId IdType="pubmed">24360280</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem. 2009;9:599&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">19689368</ArticleId></ArticleIdList></Reference><Reference><Citation>Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, et al. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013;125:159&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3547628</ArticleId><ArticleId IdType="pubmed">23099891</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JT, Morganti JM, Bachstetter AD, Hudson CE, Peters MM, Grimmig BA, Weeber EJ, Bickford PC, Gemma C. CX3CR1 deficiency leads to impairment of hippocampal cognitive function and synaptic plasticity. J Neurosci. 2011;31:16241&#x2013;16250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3236509</ArticleId><ArticleId IdType="pubmed">22072675</ArticleId></ArticleIdList></Reference><Reference><Citation>Saederup N, Cardona AE, Croft K, Mizutani M, Cotleur AC, Tsou CL, Ransohoff RM, Charo IF. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One. 2010;5:e13693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965160</ArticleId><ArticleId IdType="pubmed">21060874</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin Kaya S, Mahmood A, Li Y, Yavuz E, Chopp M. Expression of nestin after traumatic brain injury in rat brain. Brain Res. 1999;840:153&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pubmed">10517963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieweke MH, Allen JE. Beyond stem cells: self-renewal of differentiated macrophages. Science. 2013;342:1242974.</Citation><ArticleIdList><ArticleId IdType="pubmed">24264994</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Meer P, Ulrich AM, Gonzalez-Scarano F, Lavi E. Immunohistochemical analysis of CCR2, CCR3, CCR5, and CXCR4 in the human brain: potential mechanisms for HIV dementia. Exp Mol Pathol. 2000;69:192&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">11115360</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Wegiel J, Wisniewski HM, Dziewiatkowski J, Tarnawski M, Kozielski R, Trenkner E, Wiktor-Jedrzejczak W. Reduced number and altered morphology of microglial cells in colony stimulating factor-1-deficient osteopetrotic op/op mice. Brain Res. 1998;804:135&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">9729335</ArticleId></ArticleIdList></Reference><Reference><Citation>Wohl SG, Schmeer CW, Friese T, Witte OW, Isenmann S. In situ dividing and phagocytosing retinal microglia express nestin, vimentin, and NG2 in vivo. PLoS One. 2011;6:e22408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3151247</ArticleId><ArticleId IdType="pubmed">21850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama A, Yang L, Itoh S, Mori K, Tanaka J. Microglia, a potential source of neurons, astrocytes, and oligodendrocytes. Glia. 2004;45:96&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">14648550</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan Y, Paolicelli RC, Sforazzini F, Weinhard L, Bolasco G, Pagani F, Vyssotski AL, Bifone A, Gozzi A, Ragozzino D, et al. Deficient neuron-microglia signaling results in impaired functional brain connectivity and social behavior. Nat Neurosci 2014</Citation><ArticleIdList><ArticleId IdType="pubmed">24487234</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Ibrahim PN, Zhang J, Burton EA, Habets G, Zhang Y, Powell B, West BL, Matusow B, Tsang G, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A. 2013;110:5689&#x2013;5694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619323</ArticleId><ArticleId IdType="pubmed">23493555</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24747528</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4469</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature chemical biology</Title><ISOAbbreviation>Nat Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Pharmacological chaperones stabilize retromer to limit APP processing.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>449</EndPage><MedlinePgn>443-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nchembio.1508</ELocationID><Abstract><AbstractText>Retromer is a multiprotein complex that trafficks cargo out of endosomes. The neuronal retromer traffics the amyloid-precursor protein (APP) away from endosomes, a site where APP is cleaved into pathogenic fragments in Alzheimer's disease. Here we determined whether pharmacological chaperones can enhance retromer stability and function. First, we relied on the crystal structures of retromer proteins to help identify the 'weak link' of the complex and to complete an in silico screen of small molecules predicted to enhance retromer stability. Among the hits, an in vitro assay identified one molecule that stabilized retromer against thermal denaturation. Second, we turned to cultured hippocampal neurons, showing that this small molecule increases the levels of retromer proteins, shifts APP away from the endosome, and decreases the pathogenic processing of APP. These findings show that pharmacological chaperones can enhance the function of a multiprotein complex and may have potential therapeutic implications for neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mecozzi</LastName><ForeName>Vincent J</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Massachusetts, USA. [2] Department of Chemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Masschusetts, USA. [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Diego E</ForeName><Initials>DE</Initials><Identifier Source="ORCID">0000000211313876</Identifier><AffiliationInfo><Affiliation>1] The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simoes</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vetanovetz</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Awal</LastName><ForeName>Mehraj R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Massachusetts, USA. [2] Department of Chemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Masschusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Vivek M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Remy T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petsko</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Massachusetts, USA. [2] Department of Chemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Masschusetts, USA. [3] Helen and Robert Appel Alzheimer's Disease Research Institute, Weill Cornell Medical College, New York, New York, USA. [4] Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York, USA. [5] Department of Neurology, Weill Cornell Medical College, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringe</LastName><ForeName>Dagmar</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>1] Department of Biochemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Massachusetts, USA. [2] Department of Chemistry, Rosenstiel Basic Medical Sciences Research Center, Brandeis University, Waltham, Masschusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>The Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology and Pathology, Columbia University College of Physicians and Surgeons, New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>PubChem-Substance</DataBankName><AccessionNumberList><AccessionNumber>174322461</AccessionNumber><AccessionNumber>174322462</AccessionNumber><AccessionNumber>174322463</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG008702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG08702</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Chem Biol</MedlineTA><NlmUniqueID>101231976</NlmUniqueID><ISSNLinking>1552-4450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C503111">VPS29 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089989">Vps26 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C101274">Vps35 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.-</RegistryNumber><NameOfSubstance UI="D016282">Aspartic Acid Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.23.46</RegistryNumber><NameOfSubstance UI="C509282">Bace1 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016282" MajorTopicYN="N">Aspartic Acid Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011992" MajorTopicYN="N">Endosomes</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing financial interests</b>. The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24747528</ArticleId><ArticleId IdType="mid">NIHMS589062</ArticleId><ArticleId IdType="pmc">PMC4076047</ArticleId><ArticleId IdType="doi">10.1038/nchembio.1508</ArticleId><ArticleId IdType="pii">nchembio.1508</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Seaman MN. The retromer complex&#x2014;endosomal protein recycling and beyond. J Cell Sci. 2012;125:4693&#x2013;4702.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3517092</ArticleId><ArticleId IdType="pubmed">23148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen PJ, Korswagen HC. Sorting nexins provide diversity for retromer-dependent trafficking events. Nat Cell Biol. 2012;14:29&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613977</ArticleId><ArticleId IdType="pubmed">22193161</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Recycle your receptors with retromer. Trends Cell Biol. 2005;15:68&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">15695093</ArticleId></ArticleIdList></Reference><Reference><Citation>Burd C, Cullen PJ. Retromer: a master conductor of endosome sorting. Cold Spring Harb Perspect Biol. 2014;6:a016774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941235</ArticleId><ArticleId IdType="pubmed">24492709</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, et al. Model-guided microarray implicates the retromer complex in Alzheimer&#x2019;s disease. Ann Neurol. 2005;58:909&#x2013;919.</Citation><ArticleIdList><ArticleId IdType="pubmed">16315276</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo Y, et al. Mice deficient in BACE1, the Alzheimer&#x2019;s &#x3b2;-secretase, have normal phenotype and abolished &#x3b2;-amyloid generation. Nat Neurosci. 2001;4:231&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">11224535</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, et al. Alzheimer&#x2019;s-related endosome dysfunction in Down syndrome is A&#x3b2;-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci USA. 2010;107:1630&#x2013;1635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2824382</ArticleId><ArticleId IdType="pubmed">20080541</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O&#x2019;Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, et al. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishitomi K, et al. BACE1 inhibition reduces endogenous A&#x3b2; and alters APP processing in wild-type mice. J Neurochem. 2006;99:1555&#x2013;1563.</Citation><ArticleIdList><ArticleId IdType="pubmed">17083447</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Gandy S. Sorting through the cell biology of Alzheimer&#x2019;s disease: intracellular pathways to pathogenesis. Neuron. 2006;52:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4820242</ArticleId><ArticleId IdType="pubmed">17015224</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla A, et al. The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol Dis. 2012;47:126&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3589992</ArticleId><ArticleId IdType="pubmed">22516235</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieira SI, et al. Retrieval of the Alzheimer&#x2019;s amyloid precursor protein from the endosome to the TGN is S655 phosphorylation state-dependent and retromer-mediated. Mol Neurodegener. 2010;5:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994555</ArticleId><ArticleId IdType="pubmed">20937087</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhammad A, et al. Retromer deficiency observed in Alzheimer&#x2019;s disease causes hippocampal dysfunction, neurodegeneration, and A&#x3b2; accumulation. Proc Natl Acad Sci USA. 2008;105:7327&#x2013;7332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386077</ArticleId><ArticleId IdType="pubmed">18480253</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane RF, et al. Diabetes-associated SorCS1 regulates Alzheimer&#x2019;s amyloid-&#x3b2; metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci. 2010;30:13110&#x2013;13115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3274732</ArticleId><ArticleId IdType="pubmed">20881129</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodson SE, et al. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol. 2006;65:866&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2663339</ArticleId><ArticleId IdType="pubmed">16957580</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen OM, et al. Neuronal sorting protein&#x2013;related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2005;102:13461&#x2013;13466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1224625</ArticleId><ArticleId IdType="pubmed">16174740</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjorback AW, et al. Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. J Neurosci. 2012;32:1467&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6796259</ArticleId><ArticleId IdType="pubmed">22279231</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva E, et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet. 2007;39:168&#x2013;177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2657343</ArticleId><ArticleId IdType="pubmed">17220890</ArticleId></ArticleIdList></Reference><Reference><Citation>Vardarajan BN, et al. Identification of Alzheimer disease-associated variants in genes that regulate retromer function. Neurobiol Aging. 2012;33:2231.e15&#x2013;2231.e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391348</ArticleId><ArticleId IdType="pubmed">22673115</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol. 2004;165:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172094</ArticleId><ArticleId IdType="pubmed">15078903</ArticleId></ArticleIdList></Reference><Reference><Citation>Seaman MN. Cargo-selective endosomal sorting for retrieval to the Golgi requires retromer. J Cell Biol. 2004;165:111&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172078</ArticleId><ArticleId IdType="pubmed">15078902</ArticleId></ArticleIdList></Reference><Reference><Citation>Verg&#xe9;s M, et al. The mammalian retromer regulates transcytosis of the polymeric immunoglobulin receptor. Nat Cell Biol. 2004;6:763&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pubmed">15247922</ArticleId></ArticleIdList></Reference><Reference><Citation>Norwood SJ, et al. Assembly and solution structure of the core retromer protein complex. Traffic. 2011;12:56&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">20875039</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLeod DA, et al. RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson&#x2019;s disease risk. Neuron. 2013;77:425&#x2013;439. erratum 77, 994 (2013)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3646583</ArticleId><ArticleId IdType="pubmed">23395371</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringe D, Petsko GA. What are pharmacological chaperones and why are they interesting? J Biol. 2009;8:80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2776907</ArticleId><ArticleId IdType="pubmed">19833004</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman RL, et al. Structure of acid &#x3b2;-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol. 2007;3:101&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187079</ArticleId></ArticleIdList></Reference><Reference><Citation>Hierro A, et al. Functional architecture of the retromer cargo-recognition complex. Nature. 2007;449:1063&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2377034</ArticleId><ArticleId IdType="pubmed">17891154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattos C, Ringe D. Locating and characterizing binding sites on proteins. Nat Biotechnol. 1996;14:595&#x2013;599.</Citation><ArticleIdList><ArticleId IdType="pubmed">9630949</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins BM, Skinner CF, Watson PJ, Seaman MN, Owen DJ. Vps29 has a phosphoesterase fold that acts as a protein interaction scaffold for retromer assembly. Nat Struct Mol Biol. 2005;12:594&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">15965486</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarbrick JD, et al. VPS29 is not an active metallo-phosphatase but is a rigid scaffold required for retromer interaction with accessory proteins. PLoS ONE. 2011;6:e20420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3101248</ArticleId><ArticleId IdType="pubmed">21629666</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurie AT, Jackson RM. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics. 2005;21:1908&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">15701681</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins BM, et al. Structure of Vps26B and mapping of its interaction with the retromer protein complex. Traffic. 2008;9:366&#x2013;379.</Citation><ArticleIdList><ArticleId IdType="pubmed">18088321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Rojas R, Bonifacino JS, Hurley JH. The retromer subunit Vps26 has an arrestin fold and binds Vps35 through its C-terminal domain. Nat Struct Mol Biol. 2006;13:540&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1584284</ArticleId><ArticleId IdType="pubmed">16732284</ArticleId></ArticleIdList></Reference><Reference><Citation>Landon MR, Lancia DR, Jr, Yu J, Thiel SC, Vajda S. Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. J Med Chem. 2007;50:1231&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pubmed">17305325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mucke L, et al. High-level neuronal expression of A&#x3b2; 1&#x2013;42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000;20:4050&#x2013;4058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772621</ArticleId><ArticleId IdType="pubmed">10818140</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24751827</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-5279</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</Title><ISOAbbreviation>Alzheimers Dement</ISOAbbreviation></Journal><ArticleTitle>An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease.</ArticleTitle><Pagination><StartPage>666</StartPage><EndPage>674</EndPage><MedlinePgn>666-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jalz.2014.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1552-5260(14)00063-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is growing interest in the evaluation of preclinical Alzheimer's disease (AD) treatments. As a result, there is a need to identify a cognitive composite that is sensitive to track preclinical AD decline to be used as a primary endpoint in treatment trials.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Longitudinal data from initially cognitively normal, 70- to 85-year-old participants in three cohort studies of aging and dementia from the Rush Alzheimer's Disease Center were examined to empirically define a composite cognitive endpoint that is sensitive to detect and track cognitive decline before the onset of cognitive impairment. The mean-to-standard deviation ratios (MSDRs) of change over time were calculated in a search for the optimal combination of cognitive tests/subtests drawn from the neuropsychological battery in cognitively normal participants who subsequently progressed to clinical stages of AD during 2- and 5-year periods, using data from those who remained unimpaired during the same period to correct for aging and practice effects. Combinations that performed well were then evaluated for representation of relevant cognitive domains, robustness across individual years before diagnosis, and occurrence of selected items within top performing combinations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The optimal composite cognitive test score comprised seven cognitive tests/subtests with an MSDR&#xa0;=&#xa0;0.964. By comparison, the most sensitive individual test score was Logical Memory Delayed Recall with an MSDR&#xa0;=&#xa0;0.64.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We have identified a composite cognitive test score representing multiple cognitive domains that has improved power compared with the most sensitive single test item to track preclinical AD decline and evaluate preclinical AD treatments. We are confirming the power of the composite in independent cohorts and with other analytical approaches, which may result in refinements, have designated it as the primary endpoint in the Alzheimer's Prevention Initiative's preclinical treatment trials for individuals at high imminent risk for developing symptoms due to late-onset AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Langbaum</LastName><ForeName>Jessica B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA. Electronic address: Jessica.Langbaum@bannerhealth.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendrix</LastName><ForeName>Suzanne B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Pentara Corporation, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayutyanont</LastName><ForeName>Napatkamon</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kewei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Department of Mathematics and Statistics, Arizona State University, Tempe, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleisher</LastName><ForeName>Adam S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Raj C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Family Medicine, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>Lisa L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA; Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tariot</LastName><ForeName>Pierre N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Department of Psychiatry, University of Arizona, Tucson, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiman</LastName><ForeName>Eric M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Banner Alzheimer's Institute, Phoenix, AZ, USA; Arizona Alzheimer's Consortium, Phoenix, AZ, USA; Department of Psychiatry, University of Arizona, Tucson, AZ, USA; Neurogenomics Division, Translational Genomics Research Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG055444</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG19610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG031581</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG22018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG022018</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30AG10161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG019610</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Alzheimers Dement</MedlineTA><NlmUniqueID>101231978</NlmUniqueID><ISSNLinking>1552-5260</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Composite endpoints</Keyword><Keyword MajorTopicYN="N">Power</Keyword><Keyword MajorTopicYN="N">Preclinical Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Sample size</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24751827</ArticleId><ArticleId IdType="mid">NIHMS567714</ArticleId><ArticleId IdType="pmc">PMC4201904</ArticleId><ArticleId IdType="doi">10.1016/j.jalz.2014.02.002</ArticleId><ArticleId IdType="pii">S1552-5260(14)00063-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alzheimer&#x2019;s Association. 2013 Alzheimer&#x2019;s Disease Facts and Figures. 2 Vol. 9. Alzheimer&#x2019;s &amp; Dementia; 2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">23507120</ArticleId></ArticleIdList></Reference><Reference><Citation>Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer&#x2019;s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998 Sep;88(9):1337&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1509089</ArticleId><ArticleId IdType="pubmed">9736873</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS, Tariot PN. Alzheimer&#x2019;s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomarkers in Medicine. 2010 Feb 1;4(1):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850446</ArticleId><ArticleId IdType="pubmed">20383319</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Langbaum JBS, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F, Tariot PN. Alzheimer&#x2019;s Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011;25(Suppl 3):293&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343739</ArticleId><ArticleId IdType="pubmed">21971471</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) 2013 Oct;169(10):737&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880800</ArticleId><ArticleId IdType="pubmed">24016464</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling R, Donohue M, Aisen P. The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer&#x2019;s disease. Alzheimers Dement. 2012 Jul 1;8(4):425&#x2013;6.</Citation></Reference><Reference><Citation>Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer&#x2019;s disease. Pharmacogenomics J. 2010 Oct;10(5):375&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2946560</ArticleId><ArticleId IdType="pubmed">20029386</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbaum JB, Fleisher AS, Chen K, Ayutyanont N, Lopera F, Quiroz YT, Caselli RJ, Tariot PN, Reiman EM. Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol. 2013 Jul;9(7):371&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4084675</ArticleId><ArticleId IdType="pubmed">23752908</ArticleId></ArticleIdList></Reference><Reference><Citation>ADAPT Research Group. Cognitive Function Over Time in the Alzheimer&#x2019;s Disease Anti-inflammatory Prevention Trial (ADAPT): Results of a Randomized, Controlled Trial of Naproxen and Celecoxib. Archives of Neurology. 2008 Jul 1;65(7):896&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925195</ArticleId><ArticleId IdType="pubmed">18474729</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Williamson JD, Fitzpatrick AL, Kronmal RA, Ives DG, Saxton JA, Lopez OL, Burke G, Carlson MC, Fried LP, Kuller LH, Robbins JA, Tracy RP, Woolard NF, Dunn L, Snitz BE, Nahin RL, Furberg CD. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008 Nov 19;300(19):2253&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823569</ArticleId><ArticleId IdType="pubmed">19017911</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverberg NB, Ryan LM, Carrillo MC, Sperling R, Petersen RC, Posner HB, Snyder PJ, Hilsabeck R, Gallagher M, Raber J, Rizzo A, Possin K, King J, Kaye J, Ott BR, Albert MS, Wagster MV, Schinka JA, Cullum CM, Farias ST, Balota D, Rao S, Loewenstein D, Budson AE, Brandt J, et al. Assessment of cognition in early dementia. Alzheimer&#x2019;s and Dementia. 2011 May;7(3):e60&#x2013;e76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613863</ArticleId><ArticleId IdType="pubmed">23559893</ArticleId></ArticleIdList></Reference><Reference><Citation>Cano SJ, Posner HB, Moline ML, Hurt SW, Swartz J, Hsu T, Hobart JC. The ADAS-cog in Alzheimer&#x2019;s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1363&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20881017</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, Potter WZ, Thomas RG, Salmon D, Donohue M, Bednar MM, Touchon J, Vellas B. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011 Jan 18;76(3):280&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="pubmed">21178097</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, Au R, White RF, D&#x2019;Agostino RB. The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000 Jun;57(6):808&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, Newman AB, Kuller L. Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. Neurology. 2004 Dec 28;63(12):2341&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15623697</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease. Archives of Neurology. 2009 Oct 1;66(10):1254&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2795328</ArticleId><ArticleId IdType="pubmed">19822781</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Leurgans SE, Boyle PA, Bennett DA. Cognitive Decline in Prodromal Alzheimer Disease and Mild Cognitive Impairment. Archives of Neurology. 2011 Mar 1;68(3):351&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100533</ArticleId><ArticleId IdType="pubmed">21403020</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Le GM, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, Jacqmin-Gadda H, Dartigues JF. Prodromal Alzheimer&#x2019;s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008 Nov;64(5):492&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067364</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2008 Mar;14(2):266&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Small BJ, Backman L. Longitudinal trajectories of cognitive change in preclinical Alzheimer&#x2019;s disease: a growth mixture modeling analysis. Cortex. 2007 Oct;43(7):826&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17941341</ArticleId></ArticleIdList></Reference><Reference><Citation>Stonnington CM, Chen K, Lee W, Locke DE, Dueck AC, Liu X, Roontiva A, Fleisher AS, Caselli RJ, Reiman EM. Fibrillar amyloid correlates of preclinical cognitive decline. Alzheimers Dement. 2013 Apr 11;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3713087</ArticleId><ArticleId IdType="pubmed">23583233</ArticleId></ArticleIdList></Reference><Reference><Citation>Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, Ames D, Szoeke C, Laws SM, Verdile G, Martins RN, Masters CL, Rowe CC. Cognition and beta-amyloid in preclinical Alzheimer&#x2019;s disease: data from the AIBL study. Neuropsychologia. 2011 Jul;49(9):2384&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21529702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Lim YY, Harrington K, Ames D, Bush AI, Darby D, Martins RN, Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P. Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid-beta. J Alzheimers Dis. 2013 Jan 8;</Citation><ArticleIdList><ArticleId IdType="pubmed">23302660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Maruff P, Pietrzak RH, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer&#x2019;s disease. Brain. 2013 Oct 30;</Citation><ArticleIdList><ArticleId IdType="pubmed">24176981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging. 2013 Mar;34(3):822&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3518678</ArticleId><ArticleId IdType="pubmed">22878163</ArticleId></ArticleIdList></Reference><Reference><Citation>Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DEC, Hoffman-Snyder C, Alexander GE, Rademakers R, Reiman EM. Longitudinal modeling of age-related memory decline and the APOE &#x3b5;4 effect. N Engl J Med. 2009 Jul 16;361(3):255&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2928998</ArticleId><ArticleId IdType="pubmed">19605830</ArticleId></ArticleIdList></Reference><Reference><Citation>Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D. Development and assessment of a composite score for memory in the Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012 Jul 11;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3806057</ArticleId><ArticleId IdType="pubmed">22782295</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbons LE, Carle AC, Mackin RS, Harvey D, Mukherjee S, Insel P, Curtis SM, Mungas D, Crane PK. A composite score for executive functioning, validated in Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav. 2012 May 27;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3684181</ArticleId><ArticleId IdType="pubmed">22644789</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowling NM, Hermann B, La RA, Sager MA. Latent structure and factorial invariance of a neuropsychological test battery for the study of preclinical Alzheimer&#x2019;s disease. Neuropsychology. 2010 Nov;24(6):742&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3057903</ArticleId><ArticleId IdType="pubmed">21038965</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden KM, Kuchibhatla M, Romero HR, Plassman BL, Burke JR, Browndyke JN, Welsh-Bohmer KA. Pre-clinical Cognitive Phenotypes for Alzheimer Disease: A Latent Profile Approach. Am J Geriatr Psychiatry. 2013 Sep 27;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3968245</ArticleId><ArticleId IdType="pubmed">24080384</ArticleId></ArticleIdList></Reference><Reference><Citation>Hendrix SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimers Res Ther. 2012 Jul 13;4(4):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506938</ArticleId><ArticleId IdType="pubmed">22805433</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong C, van Belle G, Chen K, Tian L, Luo J, Gao F, Yan Y, Chen L, Morris JC, Crane P. Combining Multiple Markers to Improve the Longitudinal Rate of Progression: Application to Clinical Trials on the Early Stage of Alzheimer&#x2019;s Disease. Statistics in Biopharmaceutical Research. 2013 Feb 1;5(1):54&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868484</ArticleId><ArticleId IdType="pubmed">24363827</ArticleId></ArticleIdList></Reference><Reference><Citation>Balsis S, Unger AA, Benge JF, Geraci L, Doody RS. Gaining precision on the Alzheimer&#x2019;s Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. Alzheimers Dement. 2012 Jul;8(4):288&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465173</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J. Putting the Alzheimer&#x2019;s cognitive test to the test II: Rasch Measurement Theory. Alzheimers Dement. 2013 Feb;9(1 Suppl):S10&#x2013;S20.</Citation><ArticleIdList><ArticleId IdType="pubmed">23253779</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankle WR, Romney AK, Hara J, Fortier D, Dick MB, Chen JM, Chan T, Sun X. Methods to improve the detection of mild cognitive impairment. Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4919&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC555034</ArticleId><ArticleId IdType="pubmed">15781874</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A. The ADAS-Cog revisited: Novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement. In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3732822</ArticleId><ArticleId IdType="pubmed">23127469</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Shah RC, Aggarwal NT, Bennett DA, Schneider JA. The Minority Aging Research Study: ongoing efforts to obtain brain donation in African Americans without dementia. Curr Alzheimer Res. 2012 Jul;9(6):734&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409294</ArticleId><ArticleId IdType="pubmed">22471868</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res. 2012 Jul;9(6):646&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3439198</ArticleId><ArticleId IdType="pubmed">22471867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res. 2012 Jul;9(6):628&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409291</ArticleId><ArticleId IdType="pubmed">22471860</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Beckett LA, Barnes LL, Schneider JA, Bach J, Evans DA, Bennett DA. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002 Jun;17(2):179&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">12061405</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Barnes LL, Krueger KR, Hoganson G, Bienias JL, Bennett DA. Early and late life cognitive activity and cognitive systems in old age. J Int Neuropsychol Soc. 2005 Jul;11(4):400&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16209420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Buchman AS, Mendes de LC, Bienias JL, Wilson RS. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology. 2005;25(4):163&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103727</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural history of mild cognitive impairment in older persons. Neurology. 2002 Jul 23;59(2):198&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">12136057</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Aggarwal NT, Arvanitakis Z, Shah RC, Kelly JF, Fox JH, Cochran EJ, Arends D, Treinkman AD, Wilson RS. Decision rules guiding the clinical diagnosis of Alzheimer&#x2019;s disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study. Neuroepidemiology. 2006;27(3):169&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">17035694</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer&#x2019;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&#x2019;s Disease. Neurology. 1984 Jul;34(7):939&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology. 2006 Nov 14;67(9):1581&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740723</ArticleId><ArticleId IdType="pubmed">17101887</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009 Aug;66(2):200&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812870</ArticleId><ArticleId IdType="pubmed">19743450</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005 Mar 8;64(5):834&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">15753419</ArticleId></ArticleIdList></Reference><Reference><Citation>McEvoy LK, Edland SD, Holland D, Hagler DJ, Jr, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis Assoc Disord. 2010 Jul;24(3):269&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2929320</ArticleId><ArticleId IdType="pubmed">20683184</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ. The Alzheimer&#x2019;s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2012 Feb;8(1 Suppl):S1&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329969</ArticleId><ArticleId IdType="pubmed">22047634</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Draft guidance. U.S. Department of Health and Human Services, Food and Drug Administratino, Center for Drug Evaluation and Research (CDER); 2013. Guidance for industry Alzheimer&#x2019;s disease: Developing drugs for the treatment of early stage disease.</Citation></Reference><Reference><Citation>Ayutyanont N, Langbaum JBS, Hendrix SB, Chen K, Fleisher AS, Friesenhahn M, Ward M, Aguirre C, Acosta-Baena N, Madrigal L, Munoz C, Tirado V, Moreno S, Tariot PN, Lopera F, Reiman EM. The Alzheimer&#x2019;s Prevention Initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer&#x2019;s disease treatments in presenilin 1 E280A mutation carriers. submitted.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4331113</ArticleId><ArticleId IdType="pubmed">24816373</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley KP, Jicha GA, Davis D, Abner EL, Cooper GE, Stiles N, Smith CD, Kryscio RJ, Nelson PT, Van Eldik LJ, Schmitt FA. Prediction of preclinical Alzheimer&#x2019;s disease: longitudinal rates of change in cognition. J Alzheimers Dis. 2011;25(4):707&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3353267</ArticleId><ArticleId IdType="pubmed">21498903</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenlein M, Kaplan AM. A beginner&#x2019;s guide to partial least squares analysis. Understanding Statistics. 2004;3(4):283&#x2013;97.</Citation></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging and the Alzheimer&#x2019;s Association workgroup. Alzheimers Dement. 2011 May;7(3):280&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24756204</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Expanded C9ORF72 hexanucleotide repeat in depressive pseudodementia.</ArticleTitle><Pagination><StartPage>775</StartPage><EndPage>781</EndPage><MedlinePgn>775-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2013.6368</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Expanded hexanucleotide repeats in C9ORF72 are a common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis. Repeat expansions have also been detected infrequently in other disorders, including Alzheimer disease, dementia with Lewy bodies, and parkinsonian disorders.</AbstractText><AbstractText Label="OBSERVATIONS" NlmCategory="METHODS">A consecutive series of 31 cases from the brain bank for neurodegenerative disorders at Mayo Clinic was screened to assess the incidence of the expanded C9ORF72 repeat in cases of depressive pseudodementia. The presence of the hexanucleotide repeat was established using immunohistochemistry with a highly disease-specific antibody (C9RANT), and was further validated in carriers using repeat-primed polymerase chain reaction and Southern blotting. Two individuals harbored the C9ORF72 repeat expansion. Both patients were men with refractory depression. One patient experienced drug-induced parkinsonism and sudden-onset dementia, while the other patient had a more insidious disease course suspected to be Alzheimer disease.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">This report increases the range of clinicopathologic presentations of C9ORF72 expanded hexanucleotide repeat to include psychiatric disorders such as depressive pseudodementia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bieniek</LastName><ForeName>Kevin F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida2Mayo Graduate School, Mayo Clinic College of Medicine, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Blitterswijk</LastName><ForeName>Marka</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rademakers</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R21 NS84528-01J</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG016574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ES20395-01</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 ES020395</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS080882</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS063964</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-AG16574</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50-NS72187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 NS072187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG003949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS063964-01</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01-AG03949</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG026251</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS077402</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005162" MajorTopicYN="N">Factitious Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Conflict of Interest Disclosure: RR has a pending patent on the identification of the <i>C9ORF72</i> repeat expansion. LP has a patent for the C9RANT antibodies.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24756204</ArticleId><ArticleId IdType="mid">NIHMS627891</ArticleId><ArticleId IdType="pmc">PMC4197801</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2013.6368</ArticleId><ArticleId IdType="pii">1861747</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron. 2011 Oct 20;72(2):245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Majounie E, Abramzon Y, Renton AE, et al. Repeat Expansion in C9ORF72 in Alzheimer&#x2019;s Disease. New England Journal of Medicine. 2012 Jan 19;366(3):283&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3513272</ArticleId><ArticleId IdType="pubmed">22216764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ, et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathologica. 2013 Feb;125(2):289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Rollinson S, Lafon C, et al. Psychosis, C9ORF72 and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):1031&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">22832738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesage S, Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain. 2013 Feb;136(Pt 2):385&#x2013;391.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3984141</ArticleId><ArticleId IdType="pubmed">23413259</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindquist SG, Duno M, Batbayli M, et al. Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease. Clinical Genetics. 2013 Mar;83(3):279&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pubmed">22650353</ArticleId></ArticleIdList></Reference><Reference><Citation>Arighi A, Fumagalli GG, Jacini F, et al. Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis. 2012;31(2):447&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">22571983</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne S, Heverin M, Elamin M, et al. Aggregation of neurologic and neuropsychiatric disease in amyotrophic lateral sclerosis kindreds: A Population-Based Case-Control Cohort Study of Familial and Sporadic Amyotrophic Lateral Sclerosis. Annals of Neurology. 2013 Jul 9;</Citation><ArticleIdList><ArticleId IdType="pubmed">23836460</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Sarraj S, King A, Troakes C, et al. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathologica. 2011 Dec;122(6):691&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">22101323</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K, Weng SM, Arzberger T, et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013 Mar 15;339(6125):1335&#x2013;1338.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash PEA, Bieniek KF, Gendron TF, et al. Unconventional Translation of C9ORF72 GGGGCC Expansion Generates Insoluble Polypeptides Specific to c9FTD/ALS. Neuron. 2013 Feb 20;77(4):639&#x2013;646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, Gijselinck I, Van Langenhove T, van der Zee J, Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends in Neurosciences. 2013 Aug;36(8):450&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pubmed">23746459</ArticleId></ArticleIdList></Reference><Reference><Citation>Caine ED. Pseudodementia. Current concepts and future directions. Arch Gen Psychiatry. 1981 Dec;38(12):1359&#x2013;1364.</Citation><ArticleIdList><ArticleId IdType="pubmed">7316680</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Fonseca JA, Lee L, Walker Z. Long-term outcome of depressive pseudodementia in the elderly. Journal of Affective Disorders. 2007 Aug;101(1&#x2013;3):123&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">17184844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachdev PS, Smith JS, Angus-Lepan H, Rodriguez P. Pseudodementia twelve years on. J Neurol Neurosurg Psychiatry. 1990 Mar;53(3):254&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1014139</ArticleId><ArticleId IdType="pubmed">2324757</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold SJ, Dugger BN, Beach TG. TDP-43 deposition in prospectively followed, cognitively normal elderly individuals: correlation with argyrophilic grains but not other concomitant pathologies. Acta Neuropathologica. 2013 Jul;126(1):51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3691299</ArticleId><ArticleId IdType="pubmed">23604587</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Robinson JL, Malunda JA, et al. Pathological 43-kDa Transactivation Response DNA-Binding Protein in Older Adults With and Without Severe Mental Illness. Archives of Neurology. 2010 Oct;67(10):1238&#x2013;1250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050578</ArticleId><ArticleId IdType="pubmed">20937952</ArticleId></ArticleIdList></Reference><Reference><Citation>Takada LT, Sha SJ. Neuropsychiatric features of C9orf72-associated behavioral variant frontotemporal dementia and frontotemporal dementia with motor neuron disease. Alzheimers Res Ther. 2012 Oct 3;4(5):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580395</ArticleId><ArticleId IdType="pubmed">23034079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, Zeng LL, Shen H, Liu L, Hu D. Altered cerebellar-cerebral resting-state functional connectivity reliably identifies major depressive disorder. Brain Res. 2013 Feb 7;1495:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">23228724</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24760868</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>17</Issue><PubDate><Year>2014</Year><Month>Apr</Month><Day>23</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Activity-dependent tau protein translocation to excitatory synapse is disrupted by exposure to amyloid-beta oligomers.</ArticleTitle><Pagination><StartPage>6084</StartPage><EndPage>6097</EndPage><MedlinePgn>6084-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4261-13.2014</ELocationID><Abstract><AbstractText>Tau is a microtubule-associated protein well known for its stabilization of microtubules in axons. Recently, it has emerged that tau participates in synaptic function as part of the molecular pathway leading to amyloid-beta (A&#x3b2;)-driven synaptotoxicity in the context of Alzheimer's disease. Here, we report the implication of tau in the profound functional synaptic modification associated with synaptic plasticity. By exposing murine cultured cortical neurons to a pharmacological synaptic activation, we induced translocation of endogenous tau from the dendritic to the postsynaptic compartment. We observed similar tau translocation to the postsynaptic fraction in acute hippocampal slices subjected to long-term potentiation. When we performed live confocal microscopy on cortical neurons transfected with human-tau-GFP, we visualized an activity-dependent accumulation of tau in the postsynaptic density. Coprecipitation using phalloidin revealed that tau interacts with the most predominant cytoskeletal component present, filamentous actin. Finally, when we exposed cortical cultures to 100 nm human synthetic A&#x3b2; oligomers (A&#x3b2;o's) for 15 min, we induced mislocalization of tau into the spines under resting conditions and abrogated subsequent activity-dependent synaptic tau translocation. These changes in synaptic tau dynamics may rely on a difference between physiological and pathological phosphorylation of tau. Together, these results suggest that intense synaptic activity drives tau to the postsynaptic density of excitatory synapses and that A&#x3b2;o-driven tau translocation to the spine deserves further investigation as a key event toward synaptotoxicity in neurodegenerative diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frandemiche</LastName><ForeName>Marie Lise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>INSERM, U836, BP 170, and Universit&#xe9; Joseph Fourier, Grenoble Institut des Neurosciences, BP 170, Grenoble Cedex 9, F-38042, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Seranno</LastName><ForeName>Sandrine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Rush</LastName><ForeName>Travis</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Borel</LastName><ForeName>Eve</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Elie</LastName><ForeName>Aur&#xe9;liane</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Arnal</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Lant&#xe9;</LastName><ForeName>Fabien</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Buisson</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003712" MajorTopicYN="N">Dendrites</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LTP</Keyword><Keyword MajorTopicYN="N">amyloid-beta oligomers</Keyword><Keyword MajorTopicYN="N">excitatory synapses</Keyword><Keyword MajorTopicYN="N">phosphorylation</Keyword><Keyword MajorTopicYN="N">synaptic plasticity</Keyword><Keyword MajorTopicYN="N">tau</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24760868</ArticleId><ArticleId IdType="pmc">PMC6608293</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4261-13.2014</ArticleId><ArticleId IdType="pii">34/17/6084</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Allyson J, Dontigny E, Auberson Y, Cyr M, Massicotte G. Blockade of NR2A-containing NMDA receptors induces tau phosphorylation in rat hippocampal slices. Neural Plast. 2010;2010:340168. doi: 10.1155/2010/340168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/340168</ArticleId><ArticleId IdType="pmc">PMC2874924</ArticleId><ArticleId IdType="pubmed">20508838</ArticleId></ArticleIdList></Reference><Reference><Citation>Blard O, Feuillette S, Bou J, Chaumette B, Fr&#xe9;bourg T, Campion D, Lecourtois M. Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila. Hum Mol Genet. 2007;16:555&#x2013;566. doi: 10.1093/hmg/ddm011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm011</ArticleId><ArticleId IdType="pubmed">17309878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Zhou Z, Zhang L, Wang Y, Zhang YW, Zhong M, Xu SC, Chen CH, Li L, Yu ZP. Tau protein is involved in morphological plasticity in hippocampal neurons in response to BDNF. Neurochem Int. 2012;60:233&#x2013;242. doi: 10.1016/j.neuint.2011.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuint.2011.12.013</ArticleId><ArticleId IdType="pubmed">22226842</ArticleId></ArticleIdList></Reference><Reference><Citation>Cou&#xe9; M, Brenner SL, Spector I, Korn ED. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 1987;213:316&#x2013;318. doi: 10.1016/0014-5793(87)81513-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(87)81513-2</ArticleId><ArticleId IdType="pubmed">3556584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlers MD. Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003;6:231&#x2013;242. doi: 10.1038/nn1013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1013</ArticleId><ArticleId IdType="pubmed">12577062</ArticleId></ArticleIdList></Reference><Reference><Citation>Feuillette S, Deramecourt V, Laquerriere A, Duyckaerts C, Delisle MB, Maurage CA, Blum D, Bu&#xe9;e L, Fr&#xe9;bourg T, Campion D, Lecourtois M. Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. Brain Res. 2010;1345:182&#x2013;189. doi: 10.1016/j.brainres.2010.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.05.007</ArticleId><ArticleId IdType="pubmed">20460118</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol. 2006;9:139&#x2013;148.</Citation><ArticleIdList><ArticleId IdType="pubmed">17187063</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tz J, Xia D, Leinenga G, Chew YL, Nicholas H. What renders TAU toxic. Front Neurol. 2013;4:72. doi: 10.3389/fneur.2013.00072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2013.00072</ArticleId><ArticleId IdType="pmc">PMC3677143</ArticleId><ArticleId IdType="pubmed">23772223</ArticleId></ArticleIdList></Reference><Reference><Citation>Grant SG, O'Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER. Impaired long-term potentiation, spatial learning, and hippocampal development in fyn mutant mice. Science. 1992;258:1903&#x2013;1910. doi: 10.1126/science.1361685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1361685</ArticleId><ArticleId IdType="pubmed">1361685</ArticleId></ArticleIdList></Reference><Reference><Citation>He HJ, Wang XS, Pan R, Wang DL, Liu MN, He RQ. The proline-rich domain of tau plays a role in interactions with actin. BMC Cell Biol. 2009;10:81&#x2013;92. doi: 10.1186/1471-2121-10-81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2121-10-81</ArticleId><ArticleId IdType="pmc">PMC2784441</ArticleId><ArticleId IdType="pubmed">19895707</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinrichs MH, Jalal A, Brenner B, Mandelkow E, Kumar S, Scholz T. Tau protein diffuses along the microtubule lattice. J Biol Chem. 2012;287:38559&#x2013;38568. doi: 10.1074/jbc.M112.369785.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.369785</ArticleId><ArticleId IdType="pmc">PMC3493901</ArticleId><ArticleId IdType="pubmed">23019339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson GA, Lanier LM, Yuan LL, Ashe KH, Liao D. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067&#x2013;1081. doi: 10.1016/j.neuron.2010.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.11.030</ArticleId><ArticleId IdType="pmc">PMC3026458</ArticleId><ArticleId IdType="pubmed">21172610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotulainen P, Hoogenraad CC. Actin in dendritic spines: connecting dynamics to function. J Cell Biol. 2010;189:619&#x2013;629. doi: 10.1083/jcb.201003008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201003008</ArticleId><ArticleId IdType="pmc">PMC2872912</ArticleId><ArticleId IdType="pubmed">20457765</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, G&#xf6;tz J. Amyloid-&#x3b2; and tau&#x2013;a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci. 2011;12:65&#x2013;72. doi: 10.1038/nrn2967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2967</ArticleId><ArticleId IdType="pubmed">21193853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, W&#xf6;lfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, G&#xf6;tz J. Dendritic function of tau mediates amyloid-&#x3b2; toxicity in Alzheimer's disease mouse models. Cell. 2010;142:387&#x2013;397. doi: 10.1016/j.cell.2010.06.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.06.036</ArticleId><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, Grigoriev I, Camera P, Spangler SA, Di Stefano P, Demmers J, Krugers H, Defilippi P, Akhmanova A, Hoogenraad CC. Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron. 2009;61:85&#x2013;100. doi: 10.1016/j.neuron.2008.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.11.013</ArticleId><ArticleId IdType="pubmed">19146815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaworski T, K&#xfc;gler S, Leuven F. Modeling of tau-mediated synaptic and neuronal degeneration in Alzheimer's disease. Int J Alzheimers Dis. 2010;2010:573138. doi: 10.4061/2010/573138. pii.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2010/573138</ArticleId><ArticleId IdType="pmc">PMC2938448</ArticleId><ArticleId IdType="pubmed">20862366</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron. 2009;61:340&#x2013;350. doi: 10.1016/j.neuron.2009.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.01.015</ArticleId><ArticleId IdType="pmc">PMC3917551</ArticleId><ArticleId IdType="pubmed">19217372</ArticleId></ArticleIdList></Reference><Reference><Citation>Kneussel M, Wagner W. Myosin motors at neuronal synapses: drivers of membrane transport and actin dynamics. Nat Rev Neurosci. 2013;14:233&#x2013;247. doi: 10.1038/nrn3445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3445</ArticleId><ArticleId IdType="pubmed">23481482</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Wang J, Mansuy IM, Grant SG, Mayford M, Kandel ER. Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. Proc Natl Acad Sci U S A. 1997;94:4761&#x2013;4765. doi: 10.1073/pnas.94.9.4761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.9.4761</ArticleId><ArticleId IdType="pmc">PMC20798</ArticleId><ArticleId IdType="pubmed">9114065</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe1;zaro-Di&#xe9;guez F, Aguado C, Mato E, S&#xe1;nchez-Ru&#xed;z Y, Esteban I, Alberch J, Knecht E, Egea G. Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide. J Cell Sci. 2008;121:1415&#x2013;1425. doi: 10.1242/jcs.017665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.017665</ArticleId><ArticleId IdType="pubmed">18398002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee G, Newman ST, Gard DL, Band H, Panchamoorthy G. Tau interacts with src-family non-receptor tyrosine kinases. J Cell Sci. 1998;111:3167&#x2013;3177.</Citation><ArticleIdList><ArticleId IdType="pubmed">9763511</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe9;veill&#xe9; F, El Gaamouch F, Gouix E, Lecocq M, Lobner D, Nicole O, Buisson A. Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 2008;22:4258&#x2013;4271. doi: 10.1096/fj.08-107268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-107268</ArticleId><ArticleId IdType="pubmed">18711223</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638. doi: 10.1523/JNEUROSCI.0203-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0203-11.2011</ArticleId><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis PA, Howard TH, Castleberry RP, Binder LI. Identification of nuclear tau isoforms in human neuroblastoma cells. Proc Natl Acad Sci U S A. 1990;87:8422&#x2013;8426. doi: 10.1073/pnas.87.21.8422.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.87.21.8422</ArticleId><ArticleId IdType="pmc">PMC54968</ArticleId><ArticleId IdType="pubmed">1700432</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002;25:103&#x2013;126. doi: 10.1146/annurev.neuro.25.112701.142758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.25.112701.142758</ArticleId><ArticleId IdType="pubmed">12052905</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandell JW, Banker GA. A spatial gradient of tau protein phosphorylation in nascent axons. J Neurosci. 1996;16:5727&#x2013;5740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578967</ArticleId><ArticleId IdType="pubmed">8795628</ArticleId></ArticleIdList></Reference><Reference><Citation>Merino-Serrais P, Benavides-Piccione R, Blazquez-Llorca L, Kastanauskaite A, R&#xe1;bano A, Avila J, DeFelipe J. The influence of phospho-tau on dendritic spines of cortical pyramidal neurons in patients with Alzheimer's disease. Brain. 2013;136:1913&#x2013;1928. doi: 10.1093/brain/awt088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt088</ArticleId><ArticleId IdType="pmc">PMC3673457</ArticleId><ArticleId IdType="pubmed">23715095</ArticleId></ArticleIdList></Reference><Reference><Citation>Merriam EB, Millette M, Lumbard DC, Saengsawang W, Fothergill T, Hu X, Ferhat L, Dent EW. Synaptic regulation of microtubule dynamics in dendritic spines by calcium, F-actin, and drebrin. J Neurosci. 2013;33:16471&#x2013;16482. doi: 10.1523/JNEUROSCI.0661-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0661-13.2013</ArticleId><ArticleId IdType="pmc">PMC3797370</ArticleId><ArticleId IdType="pubmed">24133252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mondrag&#xf3;n-Rodr&#xed;guez S, Trillaud-Doppia E, Dudilot A, Bourgeois C, Lauzon M, Leclerc N, Boehm J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation. J Biol Chem. 2012;287:32040&#x2013;32053. doi: 10.1074/jbc.M112.401240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.401240</ArticleId><ArticleId IdType="pmc">PMC3442535</ArticleId><ArticleId IdType="pubmed">22833681</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris M, Maeda S, Vossel K, Mucke L. The many faces of tau. Neuron. 2011;70:410&#x2013;426. doi: 10.1016/j.neuron.2011.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.04.009</ArticleId><ArticleId IdType="pmc">PMC3319390</ArticleId><ArticleId IdType="pubmed">21555069</ArticleId></ArticleIdList></Reference><Reference><Citation>Pooler AM, Usardi A, Evans CJ, Philpott KL, Noble W, Hanger DP. Dynamic association of tau with neuronal membranes is regulated by phosphorylation. Neurobiol Aging. 2012;33:431.e27&#x2013;431.e38. doi: 10.1016/j.neurobiolaging.2011.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.01.005</ArticleId><ArticleId IdType="pubmed">21388709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002;99:6364&#x2013;6369. doi: 10.1073/pnas.092136199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.092136199</ArticleId><ArticleId IdType="pmc">PMC122954</ArticleId><ArticleId IdType="pubmed">11959919</ArticleId></ArticleIdList></Reference><Reference><Citation>Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M, Bradke F, Jenne D, Holak TA, Werb Z, Sixt M, Wedlich-Soldner R. Lifeact: a versatile marker to visualize F-actin. Nat Methods. 2008;5:605&#x2013;607. doi: 10.1038/nmeth.1220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.1220</ArticleId><ArticleId IdType="pmc">PMC2814344</ArticleId><ArticleId IdType="pubmed">18536722</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, Wu T, Hamto P, Devidze N, Yu GQ, Palop JJ, Noebels JL, Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011;31:700&#x2013;711. doi: 10.1523/JNEUROSCI.4152-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4152-10.2011</ArticleId><ArticleId IdType="pmc">PMC3325794</ArticleId><ArticleId IdType="pubmed">21228179</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316:750&#x2013;754. doi: 10.1126/science.1141736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1141736</ArticleId><ArticleId IdType="pubmed">17478722</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Soluble oligomers of the amyloid &#x3b2;-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192:106&#x2013;113. doi: 10.1016/j.bbr.2008.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2008.02.016</ArticleId><ArticleId IdType="pmc">PMC2601528</ArticleId><ArticleId IdType="pubmed">18359102</ArticleId></ArticleIdList></Reference><Reference><Citation>Sergeant N, Delacourte A, Bu&#xe9;e L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta. 2005;1739:179&#x2013;197. doi: 10.1016/j.bbadis.2004.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2004.06.020</ArticleId><ArticleId IdType="pubmed">15615637</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875. doi: 10.1523/JNEUROSCI.4970-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4970-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Star EN, Kwiatkowski DJ, Murthy VN. Rapid turnover of actin in dendritic spines and its regulation by activity. Nat Neurosci. 2002;5:239&#x2013;246. doi: 10.1038/nn811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn811</ArticleId><ArticleId IdType="pubmed">11850630</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner P, Higley MJ, Xu W, Czervionke BL, Malenka RC, Sabatini BL. Destabilization of the postsynaptic density by PSD-95 serine 73 phosphorylation inhibits spine growth and synaptic plasticity. Neuron. 2008;60:788&#x2013;802. doi: 10.1016/j.neuron.2008.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.10.014</ArticleId><ArticleId IdType="pmc">PMC2671083</ArticleId><ArticleId IdType="pubmed">19081375</ArticleId></ArticleIdList></Reference><Reference><Citation>Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem. 2003;278:11612&#x2013;11622. doi: 10.1074/jbc.M210207200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210207200</ArticleId><ArticleId IdType="pubmed">12499373</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultan A, Nesslany F, Violet M, B&#xe9;gard S, Loyens A, Talahari S, Mansuroglu Z, Marzin D, Sergeant N, Humez S, Colin M, Bonnefoy E, Bu&#xe9;e L, Galas MC. Nuclear tau, a key player in neuronal DNA protection. J Biol Chem. 2011;286:4566&#x2013;4575. doi: 10.1074/jbc.M110.199976.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.199976</ArticleId><ArticleId IdType="pmc">PMC3039398</ArticleId><ArticleId IdType="pubmed">21131359</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai HC, Serrano-Pozo A, Hashimoto T, Frosch MP, Spires-Jones TL, Hyman BT. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am J Pathol. 2012;181:1426&#x2013;1435. doi: 10.1016/j.ajpath.2012.06.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2012.06.033</ArticleId><ArticleId IdType="pmc">PMC3463637</ArticleId><ArticleId IdType="pubmed">22867711</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro K, Hasegawa M, Ihara Y, Iwatsubo T. Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex. Neuroreport. 1997;8:2797&#x2013;2801. doi: 10.1097/00001756-199708180-00029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199708180-00029</ArticleId><ArticleId IdType="pubmed">9295120</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem. 1989;37:209&#x2013;215. doi: 10.1177/37.2.2492045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/37.2.2492045</ArticleId><ArticleId IdType="pubmed">2492045</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu JZ, Rasenick MM. Tau associates with actin in differentiating PC12 cells. FASEB J. 2006;20:1452&#x2013;1461. doi: 10.1096/fj.05-5206com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-5206com</ArticleId><ArticleId IdType="pubmed">16816120</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24756323</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.</ArticleTitle><Pagination><StartPage>758</StartPage><EndPage>766</EndPage><MedlinePgn>758-66</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.290</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Currently, diagnosis of Parkinson disease is mainly based on clinical criteria characterized by motor symptoms including bradykinesia, rigidity, resting tremor, and postural instability. Reliable in vivo biomarkers to monitor disease severity and reflect the underlying dopaminergic degeneration are important for future disease-modifying therapy in Parkinson disease.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To use [18F]9-fluoropropyl-(+)-dihydrotetrabenazine (18F-DTBZ; [18F]AV-133) positron emission tomography (PET) to explore the characteristics of vesicular monoamine transporter type 2 imaging in patients with Parkinson disease (PD) with different severity levels as well as to investigate its capability in monitoring clinical severity.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Regional uptakes for 18F-DTBZ PET of different disease stages were measured. Seventeen healthy control participants and 53 patients in 3 groups of mild, moderate, and advanced stages of PD were recruited for 18F-DTBZ PET scans from the Movement Disorders Clinic in the Chang Gung Memorial Hospital, Taiwan.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">The severity of disease in patients with PD was quantified by modified Hoehn-Yahr Scale, Unified Parkinson Disease Rating Scale total scores and subscores of posture instability and gait disturbance, tremor, akinesia, and rigidity while not taking medication. Both voxelwise- and volume of interest-based image analyses were performed. The specific uptake ratio (SUR) of each volume of interest and voxel was calculated as (target uptake&#x2009;-&#x2009;reference uptake)&#x2009;/&#x2009;reference uptake using the occipital reference region from magnetic resonance imaging-based spatially normalized 18F-DTBZ images for each participant. Average SUR images were displayed as 2-dimensional and 3-dimensional to illustrate the image patterns in each group. The nonparametric Kruskal-Wallis test on regional SUR was used for group comparison between healthy control participants and patients with PD at different stages. Quantitative parameters were correlated with severity of disease and disease duration by Spearman correlation. Voxelwise analysis for evaluating dopaminergic neuron decline of different PD stages was performed by SPM5.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 2-dimensional and 3-dimensional 18F-DTBZ PET images demonstrated that the reduction of vesicular monoamine transporter type 2 availability was obviously correlated with the severity of disease in patients with PD. The mean reductions of vesicular monoamine transporter type 2 density for the caudate, putamen,and substantia nigra were 21.50%, 58.20%, and 21.10% for mild PD[Parkinson disease];60.75%, 79.49%,and 39.87%formoderate PD; and63.94%,83.20%, and 44.00% for advanced PD, respectively [corrected]. The SURs of bilateral striatal regions exhibited significantly exponential correlations to stage; disease duration; Unified Parkinson Disease Rating Scale motor score; posture instability and gait disturbance; and akinesia, rigidity, and tremor scores.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In PD, 18F-DTBZ PET is a potential imaging biomarker for measuring dopaminergic degeneration in vivo and monitoring the severity of disease.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hsiao</LastName><ForeName>Ing-Tsung</ForeName><Initials>IT</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan2Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan3Department of Nuclear Medicine and Molecular Imaging Center, Chang G.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Yi-Hsin</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Section of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan5Neuroscience Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan6School of Medicine, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Chia-Ju</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan2Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wey-Yil</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Section of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan5Neuroscience Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wey</LastName><ForeName>Shiaw-Pyng</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan2Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan3Department of Nuclear Medicine and Molecular Imaging Center, Chang G.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Mei-Ping</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan2Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan7Department of Radiology, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Tzu-Chen</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan3Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chin-Song</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan4Section of Movement Disorders, Department of Neurology, Chang Gung Memorial Hospital, Taoyuan, Taiwan5Neuroscience Research Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Kun-Ju</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Medical Imaging and Radiological Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan2Healthy Aging Research Center, Chang Gung University, Taoyuan, Taiwan3Department of Nuclear Medicine and Molecular Imaging Center, Chang G.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005462">Fluorine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>3466-75-9</RegistryNumber><NameOfSubstance UI="C032811">dihydrotetrabenazine</NameOfSubstance></Chemical><Chemical><RegistryNumber>KM31LBX59H</RegistryNumber><NameOfSubstance UI="C549477">florbenazine F 18</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z9O08YRN8O</RegistryNumber><NameOfSubstance UI="D013747">Tetrabenazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2014 Jun;71(6):803</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Jun;10(6):305. doi: 10.1038/nrneurol.2014.81.</RefSource><PMID Version="1">24840973</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005462" MajorTopicYN="N">Fluorine Radioisotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009127" MajorTopicYN="N">Muscle Rigidity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="Y">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013747" MajorTopicYN="N">Tetrabenazine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014202" MajorTopicYN="N">Tremor</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24756323</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.290</ArticleId><ArticleId IdType="pii">1861750</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24781145</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Emerging &#x3b2;-amyloid pathology and accelerated cortical atrophy.</ArticleTitle><Pagination><StartPage>725</StartPage><EndPage>734</EndPage><MedlinePgn>725-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.446</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">The effect of &#x3b2;-amyloid (A&#x3b2;) accumulation on regional structural brain changes in early stages of Alzheimer disease (AD) is not well understood.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To test the hypothesis that the development of A&#x3b2; pathology is related to increased regional atrophy in the brains of cognitively normal (CN) persons.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">Longitudinal clinicobiomarker cohort study involving 47 CN control subjects and 15 patients with AD dementia. All participants underwent repeated cerebrospinal fluid A&#x3b2;42 and structural magnetic resonance imaging measurements for up to 4 years. Cognitively normal controls were classified using the longitudinal cerebrospinal fluid A&#x3b2;42 data and included 13 stable A&#x3b2; negative (normal baseline A&#x3b2;42 levels, with less than the median reduction over time), 13 declining A&#x3b2; negative (normal baseline A&#x3b2;42 levels, with greater than the median reduction over time), and 21 A&#x3b2; positive (pathologic baseline A&#x3b2;42 levels). All 15 patients with AD dementia were A&#x3b2; positive.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Group effects on regional gray matter volumes at baseline and over time, tested by linear mixed-effects models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline gray matter volumes were similar among the CN A&#x3b2; groups, but atrophy rates were increased in frontoparietal regions in the declining A&#x3b2;-negative and A&#x3b2;-positive groups and in amygdala and temporal regions in the A&#x3b2;-positive group. A&#x3b2;-positive patients with AD dementia had further increased atrophy rates in hippocampus and temporal and cingulate regions.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Emerging A&#x3b2; pathology is coupled to increased frontoparietal (but not temporal) atrophy rates. Atrophy rates peak early in frontoparietal regions but accelerate in hippocampus, temporal, and cingulate regions as the disease progresses to dementia. Early-stage A&#x3b2; pathology may have mild effects on local frontoparietal cortical integrity while effects in temporal regions appear later and accelerate, leading to the atrophy pattern typically seen in AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mattsson</LastName><ForeName>Niklas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California2Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, M&#xf6;l.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Insel</LastName><ForeName>Philip S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California3Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nosheny</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tosun</LastName><ForeName>Duygu</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California3Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojanowski</LastName><ForeName>John Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Leslie M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jack</LastName><ForeName>Clifford R</ForeName><Initials>CR</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Radiology, Mayo Clinic, Rochester, Minnesota.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California3Department of Radiology and Biomedical Imaging, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K01 AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG032438</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG024904</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG011378</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K01-AG030514</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG037551</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG041851</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010124</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL096917</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30-AG010129</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001284" MajorTopicYN="N">Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania on which he is coinventor, has received revenue from the sale of Avid to Eli Lilly and Company as coinventor on imaging-related patents submitted by the University of Pennsylvania, and is the William Maul Measey&#x2013;Truman G. Schnabel, Jr, MD, Professor of Geriatric Medicine and Gerontology. Dr Shaw previously was a consultant for Innogenetics, collaborates on quality assessment activities as part of the Alzheimer's Disease Neuroimaging Initiative, and serves as a consultant to Janssen Research &amp; Development LLC on biomarker studies. Dr Jack provides consulting services for Siemens Healthcare and Janssen Research &amp; Development LLC, holds the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation, and is the recipient of research grants R01-AG011378, R01-AG041851, R01-AG037551, U01-HL096917, U01-AG032438, and U01-AG024904 from the National Institutes of Health. Dr Weiner has stock options in Synarc Inc and Elan Corporation; serves as an associate editor of <i>Alzheimer's &amp; Dementia</i>; has served on scientific advisory boards for Pfizer Inc and BOLT International; has received honoraria from Pfizer Inc, Tohoku University, and Danone Trading BV; has research support from Merck &amp; Co Inc, Avid, the Department of Defense, and the Department of Veterans Affairs; has received funding for travel from Pfizer Inc, the International Conference on Alzheimer's and Parkinson's Diseases, Paul Sabatier University, Novartis, Tohoku University, MCI Group, France, Travel eDreams Inc, Neuroscience School of Advanced Studies, Danone Trading BV, and the Clinical Trials on Alzheimer's Disease ANT Congr&#xe8;s; and has been a consultant for Pfizer Inc, Janssen Research &amp; Development LLC, KLJ Associates, Easton Associates, Harvard University, inThought, INC Research LLC, the Alzheimer's Drug Discovery Foundation, Sanofi Groupe, and the University of California, Los Angeles. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24781145</ArticleId><ArticleId IdType="mid">NIHMS677420</ArticleId><ArticleId IdType="pmc">PMC4410966</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.446</ArticleId><ArticleId IdType="pii">1864089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368(9533):387&#x2013;403.</Citation><ArticleIdList><ArticleId IdType="pubmed">16876668</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SR, Schneider JA, Bennett DA, et al. Correlation of amyloid PET ligand florbetapir F 18 (18F-AV-45) binding with &#x3b2;-amyloid aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012;26(1):8&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3286131</ArticleId><ArticleId IdType="pubmed">22354138</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark CM, Pontecorvo MJ, Beach TG, et al. AV-45-A16 Study Group. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-&#x3b2; plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669&#x2013;678. published correction appears in Lancet Neurol. 2012;11(8):658.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749065</ArticleId></ArticleIdList></Reference><Reference><Citation>Strozyk D, Blennow K, White LR, Launer LJ. CSF A&#x3b2; 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60(4):652&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">12601108</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Alzheimer's Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65(4):403&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2696350</ArticleId><ArticleId IdType="pubmed">19296504</ArticleId></ArticleIdList></Reference><Reference><Citation>Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology. 1992;42(9):1681&#x2013;1688.</Citation><ArticleIdList><ArticleId IdType="pubmed">1307688</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Storandt M, McKeel DW, Jr, et al. Cerebral amyloid deposition and diffuse plaques in &#x201c;normal&#x201d; aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 1996;46(3):707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">8618671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819840</ArticleId><ArticleId IdType="pubmed">20083042</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos SJ, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol. 2013;12(10):957&#x2013;965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3904678</ArticleId><ArticleId IdType="pubmed">24012374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging&#x2013;Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1566067</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med. 2011;17(9):1060&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pubmed">21900936</ArticleId></ArticleIdList></Reference><Reference><Citation>Benilova I, Karran E, De Strooper B. The toxic A&#x3b2; oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">22286176</ArticleId></ArticleIdList></Reference><Reference><Citation>de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet. 1989;2(8664):672&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">2570916</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V, Chertkow H, Lerch JP, Evans AC, Dorr AE, Kabani NJ. Spatial patterns of cortical thinning in mild cognitive impairment and Alzheimer's disease. Brain. 2006;129(pt 11):2885&#x2013;2893.</Citation><ArticleIdList><ArticleId IdType="pubmed">17008332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Alzheimer's Disease Neuroimaging Initiative. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci. 2010;30(6):2088&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828879</ArticleId><ArticleId IdType="pubmed">20147537</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. Reply: the early pathological process in sporadic Alzheimer's disease. Acta Neuropathol. 2013;126(4):615&#x2013;618.</Citation><ArticleIdList><ArticleId IdType="pubmed">23982593</ArticleId></ArticleIdList></Reference><Reference><Citation>Attems J, Jellinger KA. Amyloid and tau: neither chicken nor egg but two partners in crime! Acta Neuropathol. 2013;126(4):619&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">23955601</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci. 1970;11(3):205&#x2013;242.</Citation><ArticleIdList><ArticleId IdType="pubmed">5505685</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, R&#xfc;b U, Orantes M, Braak H. Phases of A&#x3b2;-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">12084879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">16894106</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol. 2011;121(2):171&#x2013;181.</Citation><ArticleIdList><ArticleId IdType="pubmed">21170538</ArticleId></ArticleIdList></Reference><Reference><Citation>Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. Neurobiol Aging. 2014;35(2):301&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3977862</ArticleId><ArticleId IdType="pubmed">24080173</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormino EC, Kluth JT, Madison CM, et al. Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated &#x3b2;-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310&#x2013;1323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677792</ArticleId><ArticleId IdType="pubmed">19042931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131(pt 3):665&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730157</ArticleId><ArticleId IdType="pubmed">18263627</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, Sabuncu MR, Schmansky NJ, et al. Alzheimer's Disease Neuroimaging Initiative. Selective disruption of the cerebral neocortex in Alzheimer's disease. PLoS One. 2010;5(9):e12853. doi: 10.1371/journal.pone.0012853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0012853</ArticleId><ArticleId IdType="pmc">PMC2944799</ArticleId><ArticleId IdType="pubmed">20886094</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JA, Hedden T, Carmasin J, et al. Amyloid-&#x3b2; associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032&#x2013;1042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117980</ArticleId><ArticleId IdType="pubmed">21437929</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh H, Habeck C, Madison C, Jagust W. Covarying alterations in A&#x3b2; deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp. 2014;35(1):297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3600112</ArticleId><ArticleId IdType="pubmed">22965806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and &#x3b2;-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20373343</ArticleId></ArticleIdList></Reference><Reference><Citation>Henneman WJ, Vrenken H, Barnes J, et al. Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology. 2009;73(12):935&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839552</ArticleId><ArticleId IdType="pubmed">19770469</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosun D, Schuff N, Shaw LM, Trojanowski JQ, Weiner MW Alzheimer's Disease Neuroimaging Initiative. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data. J Alzheimers Dis. 2011;26(suppl 3):77&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587763</ArticleId><ArticleId IdType="pubmed">21971452</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Villain N, et al. AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high &#x3b2;-amyloid deposition. Neurology. 2012;78(7):477&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pubmed">22302548</ArticleId></ArticleIdList></Reference><Reference><Citation>Schott JM, Bartlett JW, Fox NC, Barnes J. Alzheimer's Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid A&#x3b2;1-42. Ann Neurol. 2010;68(6):825&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">21181717</ArticleId></ArticleIdList></Reference><Reference><Citation>Fjell AM, Walhovd KB, Fennema-Notestine C, et al. Alzheimer's Disease Neuroimaging Initiative. Brain atrophy in healthy aging is related to CSF levels of A&#x3b2;1-42. Cereb Cortex. 2010;20(9):2069&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025722</ArticleId><ArticleId IdType="pubmed">20051356</ArticleId></ArticleIdList></Reference><Reference><Citation>Ch&#xe9;telat G, Villemagne VL, Pike KE, et al. Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain. 2010;133(11):3349&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pubmed">20739349</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF tau and A&#x3b2; biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126(5):659&#x2013;670.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875373</ArticleId><ArticleId IdType="pubmed">23812320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3821718</ArticleId><ArticleId IdType="pubmed">24132377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622225</ArticleId><ArticleId IdType="pubmed">23332364</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27(4):685&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2544629</ArticleId><ArticleId IdType="pubmed">18302232</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14(1):11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">14654453</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33(3):341&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11832223</ArticleId></ArticleIdList></Reference><Reference><Citation>Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for unbiased longitudinal image analysis. Neuroimage. 2012;61(4):1402&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3389460</ArticleId><ArticleId IdType="pubmed">22430496</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. Inf Process Med Imaging. 2009;21:239&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2864489</ArticleId><ArticleId IdType="pubmed">19694267</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson A, Vanderstichele H, Andreasen N, et al. Simultaneous measurement of &#x3b2;-amyloid1-42, total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51(2):336&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pubmed">15563479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Insel P, Nosheny R, et al. Alzheimer's Disease Neuroimaging Initiative. CSF protein biomarkers predicting longitudinal reduction of CSF &#x3b2;-amyloid42 in cognitively healthy elders. Transl Psychiatry. 2013;3:e293. doi: 10.1038/tp.2013.69.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2013.69</ArticleId><ArticleId IdType="pmc">PMC3756294</ArticleId><ArticleId IdType="pubmed">23962923</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Lu M, Joshi AD, et al. Alzheimer's Disease Neuroimaging Initiative. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of &#x3b2;-amyloid. Ann Neurol. 2013;74(6):826&#x2013;836.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3748164</ArticleId><ArticleId IdType="pubmed">23536396</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigand SD, Vemuri P, Wiste HJ, et al. Transforming CSF A&#x3b2;42 measures into calculated Pittsburgh Compound B (PIBcalc) units of brain A&#x3b2; amyloid. Alzheimers Dement. 2011;7(2):133&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060961</ArticleId><ArticleId IdType="pubmed">21282074</ArticleId></ArticleIdList></Reference><Reference><Citation>Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-&#x3b2; peptide deposition identified with Pittsburgh compound B: cognitive decline associated with A&#x3b2; deposition. Arch Neurol. 2009;66(12):1476&#x2013;1481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2796577</ArticleId><ArticleId IdType="pubmed">20008651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeat P, Ch&#xe9;telat G, Villemagne VL, et al. AIBL Research Group. &#x3b2;-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74(2):121&#x2013;127.</Citation><ArticleIdList><ArticleId IdType="pubmed">20065247</ArticleId></ArticleIdList></Reference><Reference><Citation>Desikan RS, McEvoy LK, Thompson WK, et al. Alzheimer's Disease Neuroimaging Initiative. Amyloid-&#x3b2;&#x2013;associated clinical decline occurs only in the presence of elevated p-tau. Arch Neurol. 2012;69(6):709&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3423526</ArticleId><ArticleId IdType="pubmed">22529247</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with &#x3b2;-amyloidosis. JAMA Neurol. 2013;70(8):1030&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884555</ArticleId><ArticleId IdType="pubmed">23797806</ArticleId></ArticleIdList></Reference><Reference><Citation>Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pubmed">20157306</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer's disease. Ann Neurol. 1999;45(3):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RS, Yu L, Trojanowski JQ, et al. TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 2013;70(11):1418&#x2013;1424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3830649</ArticleId><ArticleId IdType="pubmed">24080705</ArticleId></ArticleIdList></Reference><Reference><Citation>Klyubin I, Cullen WK, Hu NW, Rowan MJ. Alzheimer's disease A&#x3b2; assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain. 2012;5:25. doi: 10.1186/1756-6606-5-25.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-5-25</ArticleId><ArticleId IdType="pmc">PMC3502131</ArticleId><ArticleId IdType="pubmed">22805374</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, McKeel DW, Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging. 2009;30(7):1026&#x2013;1036.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737680</ArticleId><ArticleId IdType="pubmed">19376612</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger KA, Attems J. Neuropathology and general autopsy findings in nondemented aged subjects. Clin Neuropathol. 2012;31(2):87&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">22385790</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Andreasson U, Persson S, et al. Alzheimer's Association QC Program Work Group. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013;9(3):251&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3707386</ArticleId><ArticleId IdType="pubmed">23622690</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24786080</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>344</Volume><Issue>6183</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes.</ArticleTitle><Pagination><StartPage>519</StartPage><EndPage>523</EndPage><MedlinePgn>519-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1249547</ELocationID><Abstract><AbstractText>To extend our understanding of the genetic basis of human immune function and dysfunction, we performed an expression quantitative trait locus (eQTL) study of purified CD4(+) T cells and monocytes, representing adaptive and innate immunity, in a multi-ethnic cohort of 461 healthy individuals. Context-specific cis- and trans-eQTLs were identified, and cross-population mapping allowed, in some cases, putative functional assignment of candidate causal regulatory variants for disease-associated loci. We note an over-representation of T cell-specific eQTLs among susceptibility alleles for autoimmune diseases and of monocyte-specific eQTLs among Alzheimer's and Parkinson's disease variants. This polarization implicates specific immune cell types in these diseases and points to the need to identify the cell-autonomous effects of disease susceptibility variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raj</LastName><ForeName>Towfique</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothamel</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mostafavi</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Chun</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Replogle</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Ting</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Asinovski</LastName><ForeName>Natasha</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Frohlich</LastName><ForeName>Irene</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Imboywa</LastName><ForeName>Selina</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Von Korff</LastName><ForeName>Alina</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Yukinori</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Patsopoulos</LastName><ForeName>Nikolaos A</ForeName><Initials>NA</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McCabe</LastName><ForeName>Cristin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Paik</LastName><ForeName>Hyun-il</ForeName><Initials>HI</Initials></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Gyan P</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Raychaudhuri</LastName><ForeName>Soumya</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Hafler</LastName><ForeName>David A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Koller</LastName><ForeName>Daphne</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Regev</LastName><ForeName>Aviv</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hacohen</LastName><ForeName>Nir</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Mathis</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Benoist</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stranger</LastName><ForeName>Barbara E</ForeName><Initials>BE</Initials></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>GEO</DataBankName><AccessionNumberList><AccessionNumber>GSE56035</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Acronym>HHMI</Acronym><Agency>Howard Hughes Medical Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 AG043267</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC2 GM093080</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR063759</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AR055688</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mov Disord. 2014 Sep;29(10):1242. doi: 10.1002/mds.25993.</RefSource><PMID Version="1">25124371</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="N">Adaptive Immunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="N">Ethnicity</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D040641" MajorTopicYN="N">Quantitative Trait Loci</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012213" MajorTopicYN="N">Rheumatic Fever</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24786080</ArticleId><ArticleId IdType="mid">NIHMS788828</ArticleId><ArticleId IdType="pmc">PMC4910825</ArticleId><ArticleId IdType="doi">10.1126/science.1249547</ArticleId><ArticleId IdType="pii">344/6183/519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stranger BE, et al. PLOS Genet. 2012;8:e1002639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330104</ArticleId><ArticleId IdType="pubmed">22532805</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen T, et al. Nature. 2013;501:506&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3918453</ArticleId><ArticleId IdType="pubmed">24037378</ArticleId></ArticleIdList></Reference><Reference><Citation>Battle A, et al. Genome Res. 2014;24:14&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3875855</ArticleId><ArticleId IdType="pubmed">24092820</ArticleId></ArticleIdList></Reference><Reference><Citation>Fairfax BP, et al. Nat Genet. 2012;44:502&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437404</ArticleId><ArticleId IdType="pubmed">22446964</ArticleId></ArticleIdList></Reference><Reference><Citation>Westra HJ, et al. Nat Genet. 2013;45:1238&#x2013;1243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3991562</ArticleId><ArticleId IdType="pubmed">24013639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolae DL, et al. PLOS Genet. 2010;6:e1000888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848547</ArticleId><ArticleId IdType="pubmed">20369019</ArticleId></ArticleIdList></Reference><Reference><Citation>Trynka G, et al. Nat Genet. 2013;45:124&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826950</ArticleId><ArticleId IdType="pubmed">23263488</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurano MT, et al. Science. 2012;337:1190&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771521</ArticleId><ArticleId IdType="pubmed">22955828</ArticleId></ArticleIdList></Reference><Reference><Citation>Abecasis GR, et al. Nature. 2012;491:56&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3498066</ArticleId><ArticleId IdType="pubmed">23128226</ArticleId></ArticleIdList></Reference><Reference><Citation>Flutre T, Wen X, Pritchard J, Stephens M. PLOS Genet. 2013;9:e1003486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3649995</ArticleId><ArticleId IdType="pubmed">23671422</ArticleId></ArticleIdList></Reference><Reference><Citation>Storey JD, Tibshirani R. Proc Natl Acad Sci USA. 2003;100:9440&#x2013;9445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170937</ArticleId><ArticleId IdType="pubmed">12883005</ArticleId></ArticleIdList></Reference><Reference><Citation>Han B, Eskin E. Am J Hum Genet. 2011;88:586&#x2013;598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3146723</ArticleId><ArticleId IdType="pubmed">21565292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein BE, et al. Nature. 2012;489:57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindorff LA, et al. Proc Natl Acad Sci USA. 2009;106:9362&#x2013;9367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687147</ArticleId><ArticleId IdType="pubmed">19474294</ArticleId></ArticleIdList></Reference><Reference><Citation>Nica AC, et al. PLOS Genet. 2010;6:e1000895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848550</ArticleId><ArticleId IdType="pubmed">20369022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, et al. Nat Neurosci. 2013;16:848&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Cell. 2010;140:918&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873093</ArticleId><ArticleId IdType="pubmed">20303880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24793238</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1546-170X</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Nature medicine</Title><ISOAbbreviation>Nat Med</ISOAbbreviation></Journal><ArticleTitle>Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice.</ArticleTitle><Pagination><StartPage>659</StartPage><EndPage>663</EndPage><MedlinePgn>659-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/nm.3569</ELocationID><Abstract><AbstractText>As human lifespan increases, a greater fraction of the population is suffering from age-related cognitive impairments, making it important to elucidate a means to combat the effects of aging. Here we report that exposure of an aged animal to young blood can counteract and reverse pre-existing effects of brain aging at the molecular, structural, functional and cognitive level. Genome-wide microarray analysis of heterochronic parabionts--in which circulatory systems of young and aged animals are connected--identified synaptic plasticity-related transcriptional changes in the hippocampus of aged mice. Dendritic spine density of mature neurons increased and synaptic plasticity improved in the hippocampus of aged heterochronic parabionts. At the cognitive level, systemic administration of young blood plasma into aged mice improved age-related cognitive impairments in both contextual fear conditioning and spatial learning and memory. Structural and cognitive enhancements elicited by exposure to young blood are mediated, in part, by activation of the cyclic AMP response element binding protein (Creb) in the aged hippocampus. Our data indicate that exposure of aged mice to young blood late in life is capable of rejuvenating synaptic plasticity and improving cognitive function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Villeda</LastName><ForeName>Saul A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Neuroscience Graduate Program, University of California San Francisco, San Francisco, California, USA. [4] Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, California, USA. [5] Developmental and Stem Cell Biology Graduate Program, University of California San Francisco, San Francisco, California, USA. [6] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plambeck</LastName><ForeName>Kristopher E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Middeldorp</LastName><ForeName>Jinte</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellano</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosher</LastName><ForeName>Kira I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA. [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Jian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000000220648467</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lucas K</ForeName><Initials>LK</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bieri</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [4] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Karin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Neuroscience Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berdnik</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wabl</LastName><ForeName>Rafael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Udeochu</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Biomedical Sciences Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wheatley</LastName><ForeName>Elizabeth G</ForeName><Initials>EG</Initials><AffiliationInfo><Affiliation>1] Department of Anatomy, University of California San Francisco, San Francisco, California, USA. [2] The Eli and Edythe Broad Center for Regeneration Medicine and Stem Cell Research, San Francisco, California, USA. [3] Developmental and Stem Cell Biology Graduate Program, University of California San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Bende</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000000229073102</Identifier><AffiliationInfo><Affiliation>AfaSci Research Laboratory, Redwood City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Danielle A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Xinmin S</ForeName><Initials>XS</Initials><AffiliationInfo><Affiliation>AfaSci Research Laboratory, Redwood City, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longo</LastName><ForeName>Frank M</ForeName><Initials>FM</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wyss-Coray</LastName><ForeName>Tony</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA. [2] Neuroscience Graduate Program, Stanford University School of Medicine, Stanford, California, USA. [3] Center for Tissue Regeneration, Repair and Restoration, VA Palo Alto Health Care System, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>AG03144</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 MH020016</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31-AG034045-01</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5 OD012178</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025744</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001085</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008568</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HD007470</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1-RR025744</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG045034</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP5-OD1217</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000004</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 AG034045</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Med</MedlineTA><NlmUniqueID>9502015</NlmUniqueID><ISSNLinking>1078-8956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 Jun;15(6):352-3. doi: 10.1038/nrn3763.</RefSource><PMID Version="1">24840795</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurol. 2014 Jun;10(6):307. doi: 10.1038/nrneurol.2014.86.</RefSource><PMID Version="1">24840974</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nat Med. 2014 Jun;20(6):582-3. doi: 10.1038/nm.3597.</RefSource><PMID Version="1">24901563</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Mol Neurodegener. 2024 Jan 7;19(1):3. doi: 10.1186/s13024-023-00681-w.</RefSource><PMID Version="1">38185628</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="N">Blood Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046228" MajorTopicYN="N">Microarray Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009473" MajorTopicYN="N">Neuronal Plasticity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010227" MajorTopicYN="N">Parabiosis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016133" MajorTopicYN="N">Polymerase Chain Reaction</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>COMPETING FINANCIAL INTERESTS</b>. The authors declare competing financial interests: details are available in the online version of the paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24793238</ArticleId><ArticleId IdType="mid">NIHMS632757</ArticleId><ArticleId IdType="pmc">PMC4224436</ArticleId><ArticleId IdType="doi">10.1038/nm.3569</ArticleId><ArticleId IdType="pii">nm.3569</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60:1119&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishop NA, Lu T, Yankner BA. Neural mechanisms of ageing and cognitive decline. Nature. 2010;464:529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2927852</ArticleId><ArticleId IdType="pubmed">20336135</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedden T, Gabrieli JD. Insights into the ageing mind: a view from cognitive neuroscience. Nat Rev Neurosci. 2004;5:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">14735112</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz N, Gunning-Dixon FM, Head D, Dupuis JH, Acker JD. Neuroanatomical correlates of cognitive aging: evidence from structural magnetic resonance imaging. Neuropsychology. 1998;12:95&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9460738</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson MP, Magnus T. Ageing and neuronal vulnerability. Nat Rev Neurosci. 2006;7:278&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3710114</ArticleId><ArticleId IdType="pubmed">16552414</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapp PR, Heindel WC. Memory systems in normal and pathological aging. Curr Opin Neurol. 1994;7:294&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">7952236</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, et al. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheff SW, Price DA, Schmitt FA, DeKosky ST, Mufson EJ. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501&#x2013;1508.</Citation><ArticleIdList><ArticleId IdType="pubmed">17470753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DA, Yoshida R, Berry RW, Gallagher M, Geinisman Y. Reduction in size of perforated postsynaptic densities in hippocampal axospinous synapses and age-related spatial learning impairments. J Neurosci. 2004;24:7648&#x2013;7653.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729620</ArticleId><ArticleId IdType="pubmed">15342731</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith TD, Adams MM, Gallagher M, Morrison JH, Rapp PR. Circuitspecific alterations in hippocampal synaptophysin immunoreactivity predict spatial learning impairment in aged rats. J Neurosci. 2000;20:6587&#x2013;6593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772954</ArticleId><ArticleId IdType="pubmed">10964964</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison JH, Baxter MG. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat Rev Neurosci. 2012;13:240&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592200</ArticleId><ArticleId IdType="pubmed">22395804</ArticleId></ArticleIdList></Reference><Reference><Citation>Villeda SA, et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature. 2011;477:90&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170097</ArticleId><ArticleId IdType="pubmed">21886162</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlopoulos E, et al. Molecular mechanism for age-related memory loss: the histone-binding protein RbAp48. Sci Transl Med. 2013;5:200ra115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4940031</ArticleId><ArticleId IdType="pubmed">23986399</ArticleId></ArticleIdList></Reference><Reference><Citation>Conboy IM, et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005;433:760&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pubmed">15716955</ArticleId></ArticleIdList></Reference><Reference><Citation>Brack AS, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317:807&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruckh JM, et al. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell. 2012;10:96&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3714794</ArticleId><ArticleId IdType="pubmed">22226359</ArticleId></ArticleIdList></Reference><Reference><Citation>Loffredo FS, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell. 2013;153:828&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677132</ArticleId><ArticleId IdType="pubmed">23663781</ArticleId></ArticleIdList></Reference><Reference><Citation>Geinisman Y, de Toledo-Morrell L, Morrell F. Loss of perforated synapses in the dentate gyrus: morphological substrate of memory deficit in aged rats. Proc Natl Acad Sci USA. 1986;83:3027&#x2013;3031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323440</ArticleId><ArticleId IdType="pubmed">3458260</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol. 2003;69:143&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">12758108</ArticleId></ArticleIdList></Reference><Reference><Citation>Small SA, Schobel SA, Buxton RB, Witter MP, Barnes CA. A pathophysiological framework of hippocampal dysfunction in ageing and disease. Nat Rev Neurosci. 2011;12:585&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312472</ArticleId><ArticleId IdType="pubmed">21897434</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberini CM. Transcription factors in long-term memory and synaptic plasticity. Physiol Rev. 2009;89:121&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3883056</ArticleId><ArticleId IdType="pubmed">19126756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">8421494</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey U, Morris RG. Synaptic tagging and long-term potentiation. Nature. 1997;385:533&#x2013;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">9020359</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong H, et al. Sirt1 mediates neuroprotection from mutant huntingtin by activation of the TORC1 and CREB transcriptional pathway. Nat Med. 2012;18:159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3509213</ArticleId><ArticleId IdType="pubmed">22179316</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill DA, Karim R, Darraq M, Chiba AA, Tuszynski MH. Hippocampal cell genesis does not correlate with spatial learning ability in aged rats. J Comp Neurol. 2003;459:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">12640670</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizon JL, Gallagher M. Production of new cells in the rat dentate gyrus over the lifespan: relation to cognitive decline. Eur J Neurosci. 2003;18:215&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12859354</ArticleId></ArticleIdList></Reference><Reference><Citation>Drapeau E, et al. Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis. Proc Natl Acad Sci USA. 2003;100:14385&#x2013;14390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC283601</ArticleId><ArticleId IdType="pubmed">14614143</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolinsky AN, et al. Analysis of grooming behavior and its utility in studying animal stress, anxiety, and depression. In: Gould T, editor. Mouse Models of Mood and Anxiety Disorders. Humana Press; NY: 2009. pp. 21&#x2013;36.</Citation></Reference><Reference><Citation>Gould TD. Mood and Anxiety Related Phenotypes in Mice: Characterization Using Behavioral Tests. Humana Press; New York: 2009.</Citation></Reference><Reference><Citation>Luo J, et al. Glia-dependent TGF-&#x3b2; signaling, acting independently of the TH17 pathway, is critical for initiation of murine autoimmune encephalomyelitis. J Clin Invest. 2007;117:3306&#x2013;3315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040317</ArticleId><ArticleId IdType="pubmed">17965773</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Smart TG. Modulation of long-term potentiation in rat hippocampal pyramidal neurons by zinc. Pflugers Arch. 1994;427:481&#x2013;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">7971146</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimm D, et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82:5887&#x2013;5911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395137</ArticleId><ArticleId IdType="pubmed">18400866</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W, et al. Distinct neuronal coding schemes in memory revealed by selective erasure of fast synchronous synaptic transmission. Neuron. 2012;73:990&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319466</ArticleId><ArticleId IdType="pubmed">22405208</ArticleId></ArticleIdList></Reference><Reference><Citation>Raber J, et al. Irradiation enhances hippocampus-dependent cognition in mice deficient in extracellular superoxide dismutase. Hippocampus. 2011;21:72&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2891276</ArticleId><ArticleId IdType="pubmed">20020436</ArticleId></ArticleIdList></Reference><Reference><Citation>Alamed J, Wilcock DM, Diamond DM, Gordon MN, Morgan D. Two-day radial-arm water maze learning and memory task; robust resolution of amyloidrelated memory deficits in transgenic mice. Nat Protoc. 2006;1:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pubmed">17487150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24798585</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2015</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Deep brain stimulation of the nucleus basalis of Meynert in Alzheimer's dementia.</ArticleTitle><Pagination><StartPage>353</StartPage><EndPage>360</EndPage><MedlinePgn>353-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/mp.2014.32</ELocationID><Abstract><AbstractText>Cholinergic neurons of the medial forebrain are considered important contributors to brain plasticity and neuromodulation. A reduction of cholinergic innervation can lead to pathophysiological changes of neurotransmission and is observed in Alzheimer's disease. Here we report on six patients with mild to moderate Alzheimer's disease (AD) treated with bilateral low-frequency deep brain stimulation (DBS) of the nucleus basalis of Meynert (NBM). During a four-week double-blind sham-controlled phase and a subsequent 11-month follow-up open label period, clinical outcome was assessed by neuropsychological examination using the Alzheimer's Disease Assessment Scale-cognitive subscale as the primary outcome measure. Electroencephalography and [(18)F]-fluoro-desoxyglucose positron emission tomography were, besides others, secondary endpoints. On the basis of stable or improved primary outcome parameters twelve months after surgery, four of the six patients were considered responders. No severe or non-transitional side effects related to the stimulation were observed. Taking into account all limitations of a pilot study, we conclude that DBS of the NBM is both technically feasible and well tolerated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kuhn</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardenacke</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenartz</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Functional Neurosurgery and Stereotaxy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruendler</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>1] Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany [2] Faculty of Economics, Otto-von-Guericke University Magdeburg, Magdeburg, Germany [3] Center for Behavioral Brain Sciences, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullsperger</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1] Center for Behavioral Brain Sciences, Magdeburg, Germany [2] Institute of Psychology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartsch</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mai</LastName><ForeName>J K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neuroanatomy, University of D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zilles</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1] Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany [2] University Hospital of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Aachen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1] Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany [2] Department of Neurology, Medical Faculty, University of D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matusch</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience and Medicine, Research Centre Juelich, Juelich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>R-J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>University of Cologne, Department of Geriatrics and St. Marien-Hospital, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noreik</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Cologne, Department of Geriatrics and St. Marien-Hospital, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B&#xfc;hrle</LastName><ForeName>C P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Functional Neurosurgery and Stereotaxy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maintz</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>University of Cologne, Department for Radiology, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woopen</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Cologne, Research Unit Ethics, Institute for the History of Medicine and Medical Ethics, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe4;ussermann</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>LVR Clinic Cologne, Department of Gerontopsychiatry, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellmich</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Cologne, Institute of Medical Statistics, Informatics and Epidemiology, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klosterk&#xf6;tter</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiltfang</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maarouf</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Stereotaxy and Functional Neurosurgery, Klinikum Merheim, Cologne, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freund</LastName><ForeName>H-J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Neuroanatomy, University of D&#xfc;sseldorf, D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturm</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Functional Neurosurgery and Stereotaxy, University of Cologne, Cologne, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain Stimul. 2015 Jul-Aug;8(4):838-9. doi: 10.1016/j.brs.2015.04.002.</RefSource><PMID Version="1">25991080</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020532" MajorTopicYN="N">Basal Nucleus of Meynert</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="Y">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24798585</ArticleId><ArticleId IdType="doi">10.1038/mp.2014.32</ArticleId><ArticleId IdType="pii">mp201432</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Stat Q. 1988;41(1):32-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3376487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2005 May;11(5):551-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15852017</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1988 Sep 8;275(2):216-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3220975</ArticleId></ArticleIdList></Reference><Reference><Citation>Electroencephalogr Clin Neurophysiol. 1985 Aug;61(2):101-12</Citation><ArticleIdList><ArticleId IdType="pubmed">2410219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychologia. 1999 May;37(5):559-66</Citation><ArticleIdList><ArticleId IdType="pubmed">10340315</ArticleId></ArticleIdList></Reference><Reference><Citation>Appl Neurophysiol. 1985;48(1-6):216-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3915647</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2012 Feb 9;366(6):502-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22316444</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 1988 Nov;8(11):4007-26</Citation><ArticleIdList><ArticleId IdType="pubmed">3183710</ArticleId></ArticleIdList></Reference><Reference><Citation>Alzheimers Dement. 2011 Nov;7(6):579-92</Citation><ArticleIdList><ArticleId IdType="pubmed">22055975</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2002;17 Suppl 3:S73-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11948758</ArticleId></ArticleIdList></Reference><Reference><Citation>World Neurosurg. 2013 Sep-Oct;80(3-4):S27.e35-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23246738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1983 Feb 20;214(2):170-97</Citation><ArticleIdList><ArticleId IdType="pubmed">6841683</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 May 1;71(9):805-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21816388</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Feb 14;368(7):610-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23406026</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2010 Oct;68(4):521-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20687206</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2008 Jan;63(1):119-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18232017</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 2010 Jul;20(7):1685-95</Citation><ArticleIdList><ArticleId IdType="pubmed">19889714</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1273-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23715910</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2003;48(1):19-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12886036</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2011 Oct;68(10):1257-66</Citation><ArticleIdList><ArticleId IdType="pubmed">21670386</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 1983 Dec 19;289(1-2):375-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6362777</ArticleId></ArticleIdList></Reference><Reference><Citation>Mov Disord. 2010 Jul 30;25(10):1519-20</Citation><ArticleIdList><ArticleId IdType="pubmed">20629167</ArticleId></ArticleIdList></Reference><Reference><Citation>J Comp Neurol. 1999 Sep 6;411(4):693-704</Citation><ArticleIdList><ArticleId IdType="pubmed">10421878</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Rev. 1996 Jan;54(1 Pt 2):S59-65</Citation><ArticleIdList><ArticleId IdType="pubmed">8919685</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):171-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22019547</ArticleId></ArticleIdList></Reference><Reference><Citation>Histochem J. 1992 Nov;24(11):902-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1282511</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1998 Mar 13;279(5357):1714-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9497289</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Cogn. 1984 Oct;3(4):426-37</Citation><ArticleIdList><ArticleId IdType="pubmed">6085679</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1997 Nov;48(11):1415-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9355168</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1984 Jul;34(7):939-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Jan 9;449(2):137-41</Citation><ArticleIdList><ArticleId IdType="pubmed">19013218</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Res. 2009 Feb;63(2):122-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19059440</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1989 Dec;106(3):222-36</Citation><ArticleIdList><ArticleId IdType="pubmed">2556292</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 1990 Jan-Feb;11(1):3-13</Citation><ArticleIdList><ArticleId IdType="pubmed">2183081</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 2009 Jun;66(6):781-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19506141</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 1989 Mar 13;98(1):45-50</Citation><ArticleIdList><ArticleId IdType="pubmed">2565563</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24806669</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>19</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models.</ArticleTitle><Pagination><StartPage>6425</StartPage><EndPage>6437</EndPage><MedlinePgn>6425-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.4963-13.2014</ELocationID><Abstract><AbstractText>Recent studies implicate death receptor 6 (DR6) in an amyloid precursor protein (APP)-dependent pathway regulating developmental axon pruning, and in a pruning pathway operating during plastic rearrangements in adult brain. DR6 has also been suggested to mediate toxicity in vitro of A&#x3b2; peptides derived from APP. Given the link between APP, A&#x3b2;, and Alzheimer's disease (AD), these findings have raised the possibility that DR6 contributes to aspects of neurodegeneration in AD. To test this possibility, we have used mouse models to characterize potential function(s) of DR6 in the adult CNS and in AD-related pathophysiology. We show that DR6 is broadly expressed within the adult CNS and regulates the density of excitatory synaptic connections onto pyramidal neurons in a genetic pathway with APP. DR6 knock-out also gives rise to behavioral abnormalities, some of which are similar to those previously documented in APP knock-out animals. However, in two distinct APP transgenic models of AD, we did not observe any alteration in the formation of amyloid plaques, gliosis, synaptic loss, or cognitive behavioral deficits with genetic deletion of DR6, though we did observe a transient reduction in the degree of microglial activation in one model. Our results support the view that DR6 functions with APP to modulate synaptic density in the adult CNS, but do not provide evidence for a role of DR6 in the pathophysiology of AD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kallop</LastName><ForeName>Dara Y</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Imaging, Neuroscience, and Pathology, Genentech Inc., South San Francisco, California 94080, Stanford Behavioral and Functional Neuroscience Laboratory, Stanford University, Stanford, California 94305, and Laboratory of Brain Development and Repair, The Rockefeller University, New York, New York 10065.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meilandt</LastName><ForeName>William J</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Gogineni</LastName><ForeName>Alvin</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Easley-Neal</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Tiffany</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Jubb</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Yaylaoglu</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Shamloo</LastName><ForeName>Mehrdad</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Scearce-Levie</LastName><ForeName>Kimberly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Weimer</LastName><ForeName>Robby M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114109">TNFRSF21 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001362" MajorTopicYN="N">Avoidance Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName><QualifierName UI="Q000254" MajorTopicYN="N">growth &amp; development</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049229" MajorTopicYN="N">Dendritic Spines</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005239" MajorTopicYN="N">Fear</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005911" MajorTopicYN="N">Gliosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017403" MajorTopicYN="N">In Situ Hybridization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009043" MajorTopicYN="N">Motor Activity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">DR6</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24806669</ArticleId><ArticleId IdType="pmc">PMC6608138</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.4963-13.2014</ArticleId><ArticleId IdType="pii">34/19/6425</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, Lee JH, Rondon H, Lantigua RA, Medrano M, Torres M, Arawaka S, Rogaeva E, Song YQ, Sato C, Kawarai T, Fafel KC, Boss MA, Seltzer WK, Stern Y, St George-Hyslop P, et al. A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. JAMA. 2001;286:2257&#x2013;2263. doi: 10.1001/jama.286.18.2257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.18.2257</ArticleId><ArticleId IdType="pubmed">11710891</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ. A therapeutic antibody targeting BACE1 inhibits amyloid-&#x3b2; production in vivo. Sci Transl Med. 2011;3:84ra43. doi: 10.1126/scitranslmed.3002254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002254</ArticleId><ArticleId IdType="pubmed">21613622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevis BJ, Glick BS. Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed) Nat Biotechnol. 2002;20:83&#x2013;87. doi: 10.1038/nbt0102-83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt0102-83</ArticleId><ArticleId IdType="pubmed">11753367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009;29:10405&#x2013;10409. doi: 10.1523/JNEUROSCI.2288-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2288-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665795</ArticleId><ArticleId IdType="pubmed">19692615</ArticleId></ArticleIdList></Reference><Reference><Citation>Brickell KL, Leverenz JB, Steinbart EJ, Rumbaugh M, Schellenberg GD, Nochlin D, Lampe TH, Holm IE, Van Deerlin V, Yuan W, Bird TD. Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatr. 2007;78:1050&#x2013;1055. doi: 10.1136/jnnp.2006.113803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2006.113803</ArticleId><ArticleId IdType="pmc">PMC2117553</ArticleId><ArticleId IdType="pubmed">17615170</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175&#x2013;193. doi: 10.1146/annurev.neuro.31.060407.125529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125529</ArticleId><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St Jean P, Lawson M, Ehm MG, Mayeux R, Goate AM, NIA-LOAD/NCRAD Family Study Consortium Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS ONE. 2012;7:e31039. doi: 10.1371/journal.pone.0031039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031039</ArticleId><ArticleId IdType="pmc">PMC3270040</ArticleId><ArticleId IdType="pubmed">22312439</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet. 1998;7:43&#x2013;51. doi: 10.1093/hmg/7.1.43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/7.1.43</ArticleId><ArticleId IdType="pubmed">9384602</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson GR, Seabrook GR, Zheng H, Smith DW, Graham S, O'Dowd G, Bowery BJ, Boyce S, Trumbauer ME, Chen HY, Van der Ploeg LH, Sirinathsinghji DJ. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90:1&#x2013;13. doi: 10.1016/S0306-4522(98)00410-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(98)00410-2</ArticleId><ArticleId IdType="pubmed">10188929</ArticleId></ArticleIdList></Reference><Reference><Citation>DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457&#x2013;464. doi: 10.1002/ana.410270502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410270502</ArticleId><ArticleId IdType="pubmed">2360787</ArticleId></ArticleIdList></Reference><Reference><Citation>Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, Longo FM, Shamloo M. Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2012;2:142&#x2013;154. doi: 10.1002/brb3.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.41</ArticleId><ArticleId IdType="pmc">PMC3345358</ArticleId><ArticleId IdType="pubmed">22574282</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein M, Keller-Peck C, Nguyen QT, Wallace M, Nerbonne JM, Lichtman JW, Sanes JR. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron. 2000;28:41&#x2013;51. doi: 10.1016/S0896-6273(00)00084-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)00084-2</ArticleId><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Foldi CJ, Eyles DW, McGrath JJ, Burne TH. The effects of breeding protocol in C57BL/6J mice on adult offspring behaviour. PLoS ONE. 2011;6:e18152. doi: 10.1371/journal.pone.0018152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018152</ArticleId><ArticleId IdType="pmc">PMC3063184</ArticleId><ArticleId IdType="pubmed">21448436</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NW, Weimer RM, Bureau I, Svoboda K. Rapid redistribution of synaptic PSD-95 in the neocortex in vivo. PLoS Biol. 2006;4:e370. doi: 10.1371/journal.pbio.0040370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0040370</ArticleId><ArticleId IdType="pmc">PMC1634879</ArticleId><ArticleId IdType="pubmed">17090216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy JC, Crook P. APP mutations table:1&#x2013;2. 2010.  [Accessed October 21, 2013].   http://www.alzforum.org/mutations.</Citation></Reference><Reference><Citation>Holtmaat A, Bonhoeffer T, Chow DK, Chuckowree J, De Paola V, Hofer SB, H&#xfc;bener M, Keck T, Knott G, Lee WC, Mostany R, Mrsic-Flogel TD, Nedivi E, Portera-Cailliau C, Svoboda K, Trachtenberg JT, Wilbrecht L. Long-term, high-resolution imaging in the mouse neocortex through a chronic cranial window. Nat Protoc. 2009;4:1128&#x2013;1144. doi: 10.1038/nprot.2009.89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2009.89</ArticleId><ArticleId IdType="pmc">PMC3072839</ArticleId><ArticleId IdType="pubmed">19617885</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1. doi: 10.1126/scitranslmed.3002369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Lee X, Shao Z, Apicco D, Huang G, Gong BJ, Pepinsky RB, Mi S. complex is responsible for. Cell Death and Disease. 2013;4:e579&#x2013;8. doi: 10.1038/cddis.2013.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2013.110</ArticleId><ArticleId IdType="pmc">PMC3641333</ArticleId><ArticleId IdType="pubmed">23559013</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, Palotie A. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasof GM, Lu JJ, Liu D, Speer B, Mongan KN, Gomes BC, Lorenzi MV. Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB. Oncogene. 2001;20:7965&#x2013;7975. doi: 10.1038/sj.onc.1204985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1204985</ArticleId><ArticleId IdType="pubmed">11753679</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP, Debnath ML, Holt DP, Wang Y, Hyman BT. Imaging AB plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002;61:797&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017. doi: 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, Dominguez SL, Solanoy H, Ngu H, Lewin-Koh N, Chen M, Eastham-Anderson J, Watts R, Scearce-Levie K. EGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALS. PLoS ONE. 2013;8:e62342. doi: 10.1371/journal.pone.0062342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0062342</ArticleId><ArticleId IdType="pmc">PMC3637182</ArticleId><ArticleId IdType="pubmed">23638043</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, O'Leary DD. Axon retraction and degeneration in development and disease. Annu Rev Neurosci. 2005;28:127&#x2013;156. doi: 10.1146/annurev.neuro.28.061604.135632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.28.061604.135632</ArticleId><ArticleId IdType="pubmed">16022592</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik SA, Olsen O, Tessier-Lavigne M, Gilbert CD. Death receptor 6 regulates adult experience-dependent cortical plasticity. J Neurosci. 2013;33:14998&#x2013;15003. doi: 10.1523/JNEUROSCI.2398-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2398-13.2013</ArticleId><ArticleId IdType="pmc">PMC3776054</ArticleId><ArticleId IdType="pubmed">24048829</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller U, Cristina N, Li ZW, Wolfer DP, Lipp HP, R&#xfc;licke T, Brandner S, Aguzzi A, Weissmann C. Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid precursor protein gene. Cell. 1994;79:755&#x2013;765. doi: 10.1016/0092-8674(94)90066-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(94)90066-3</ArticleId><ArticleId IdType="pubmed">8001115</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989. doi: 10.1038/nature07767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07767</ArticleId><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsen O, Kallop DY, McLaughlin T, Huntwork-Rodriguez S, Wu Z, Duggan C, Simon D, Lu Y, Easley-Neal C, Takeda K, Hass PE, Jaworski A, O'Leary DDM, Weimer RM, Tessier-Lavigne M. Genetic analysis reveals that Amyloid Precursor Protein and Death Receptor 6 function to control axonal pruning independent of beta-secretase. J Neurosci. 2014;34:6438&#x2013;6447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4012303</ArticleId><ArticleId IdType="pubmed">24806670</ArticleId></ArticleIdList></Reference><Reference><Citation>Ozmen L, Albientz A, Czech C, Jacobsen H. Expression of transgenic APP mRNA is the key determinant for beta-amyloid deposition in PS2APP transgenic mice. Neurodegener Dis. 2009;6:29&#x2013;36. doi: 10.1159/000170884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000170884</ArticleId><ArticleId IdType="pubmed">19066434</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan G, Bauer JH, Haridas V, Wang S, Liu D, Yu G, Vincenz C, Aggarwal BB, Ni J, Dixit VM. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 1998;431:351&#x2013;356. doi: 10.1016/S0014-5793(98)00791-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(98)00791-1</ArticleId><ArticleId IdType="pubmed">9714541</ArticleId></ArticleIdList></Reference><Reference><Citation>Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci. 2006;26:7212&#x2013;7221. doi: 10.1523/JNEUROSCI.1450-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1450-06.2006</ArticleId><ArticleId IdType="pmc">PMC6673945</ArticleId><ArticleId IdType="pubmed">16822978</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards JG, Higgins GA, Ouagazzal AM, Ozmen L, Kew JN, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA. PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci. 2003;23:8989&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740398</ArticleId><ArticleId IdType="pubmed">14523101</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms J, Buchholz C, Eckman CB, Korte M, Wolfer DP, M&#xfc;ller UC. The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J Neurosci. 2007;27:7817&#x2013;7826. doi: 10.1523/JNEUROSCI.1026-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1026-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672885</ArticleId><ArticleId IdType="pubmed">17634375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockenstein E, Mallory M, Mante M, Sisk A, Masliaha E. Early formation of mature amyloid-beta protein deposits in a mutant APP transgenic model depends on levels of Abeta(1-42) J Neurosci Res. 2001;66:573&#x2013;582. doi: 10.1002/jnr.1247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.1247</ArticleId><ArticleId IdType="pubmed">11746377</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, Liang Y, Richard E, Rogaev EI, Frommelt P, Sadovnick AD, Meschino W, Rockwood K, Boss MA, Mayeux R, St George-Hyslop P. Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology. 2001;57:621&#x2013;625. doi: 10.1212/WNL.57.4.621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.57.4.621</ArticleId><ArticleId IdType="pubmed">11524469</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Nakatsuji N. Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. Dev Biol. 2001;240:237&#x2013;246. doi: 10.1006/dbio.2001.0439.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/dbio.2001.0439</ArticleId><ArticleId IdType="pubmed">11784059</ArticleId></ArticleIdList></Reference><Reference><Citation>Senechal Y, Kelly PH, Dev KK. Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning. Behav Brain Res. 2008;186:126&#x2013;132. doi: 10.1016/j.bbr.2007.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2007.08.003</ArticleId><ArticleId IdType="pubmed">17884188</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan ZX, Lin QX, Yang M, Deng CY, Kuang SJ, Zhou ZL, Xiao DZ, Liu XY, Lin SG, Yu XY. A quick and efficient approach for gene silencing by using triple putative microRNA-based short hairpin RNAs. Mol Cell Biochem. 2009;323:81&#x2013;89. doi: 10.1007/s11010-008-9966-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-008-9966-3</ArticleId><ArticleId IdType="pubmed">19037714</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon DJ, Weimer RM, McLaughlin T, Kallop D, Stanger K, Yang J, O'Leary DD, Hannoush RN, Tessier-Lavigne M. A caspase cascade regulating developmental axon degeneration. J Neurosci. 2012;32:17540&#x2013;17553. doi: 10.1523/JNEUROSCI.3012-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3012-12.2012</ArticleId><ArticleId IdType="pmc">PMC3532512</ArticleId><ArticleId IdType="pubmed">23223278</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam SJ, Richmond DL, Kaminker JS, Modrusan Z, Martin-McNulty B, Cao TC, Weimer RM, Carano RA, van Bruggen N, Watts RJ. Death receptors DR6 and TROY regulate brain vascular development. Dev Cell. 2012;22:403&#x2013;417. doi: 10.1016/j.devcel.2011.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.devcel.2011.11.018</ArticleId><ArticleId IdType="pubmed">22340501</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572&#x2013;580. doi: 10.1002/ana.410300410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410300410</ArticleId><ArticleId IdType="pubmed">1789684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011;31:4124&#x2013;4136. doi: 10.1523/JNEUROSCI.5077-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5077-10.2011</ArticleId><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196. doi: 10.1038/nn.2476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YW, Thompson R, Zhang H, Xu H. APP processing in Alzheimer's disease. Mol Brain. 2011;4:3. doi: 10.1186/1756-6606-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1756-6606-4-3</ArticleId><ArticleId IdType="pmc">PMC3022812</ArticleId><ArticleId IdType="pubmed">21214928</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H, Yan M, Wang H, Erickson S, Grewal IS, Dixit VM. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. J Exp Med. 2001;194:1441&#x2013;1448. doi: 10.1084/jem.194.10.1441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.10.1441</ArticleId><ArticleId IdType="pmc">PMC2193683</ArticleId><ArticleId IdType="pubmed">11714751</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziskin JL, Dunlap D, Yaylaoglu M, Fodor IK, Forrest WF, Patel R, Ge N, Hutchins GG, Pine JK, Quirke P, Koeppen H, Jubb AM. In situ validation of an intestinal stem cell signature in colorectal cancer. Gut. 2013;62:1012&#x2013;1023. doi: 10.1136/gutjnl-2011-301195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2011-301195</ArticleId><ArticleId IdType="pubmed">22637696</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24806670</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>19</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>07</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetic analysis reveals that amyloid precursor protein and death receptor 6 function in the same pathway to control axonal pruning independent of &#x3b2;-secretase.</ArticleTitle><Pagination><StartPage>6438</StartPage><EndPage>6447</EndPage><MedlinePgn>6438-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.3522-13.2014</ELocationID><Abstract><AbstractText>In the developing brain, initial neuronal projections are formed through extensive growth and branching of developing axons, but many branches are later pruned to sculpt the mature pattern of connections. Despite its widespread occurrence, the mechanisms controlling pruning remain incompletely characterized. Based on pharmacological and biochemical analysis in vitro and initial genetic analysis in vivo, prior studies implicated a pathway involving binding of the Amyloid Precursor Protein (APP) to Death Receptor 6 (DR6) and activation of a downstream caspase cascade in axonal pruning. Here, we further test their involvement in pruning in vivo and their mechanism of action through extensive genetic and biochemical analysis. Genetic deletion of DR6 was previously shown to impair pruning of retinal axons in vivo. We show that genetic deletion of APP similarly impairs pruning of retinal axons in vivo and provide evidence that APP and DR6 act cell autonomously and in the same pathway to control pruning. Prior analysis had suggested that &#x3b2;-secretase cleavage of APP and binding of an N-terminal fragment of APP to DR6 is required for their actions, but further genetic and biochemical analysis reveals that &#x3b2;-secretase activity is not required and that high-affinity binding to DR6 requires a more C-terminal portion of the APP ectodomain. These results provide direct support for the model that APP and DR6 function cell autonomously and in the same pathway to control pruning in vivo and raise the possibility of alternate mechanisms for how APP and DR6 control pruning.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsen</LastName><ForeName>Olav</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Laboratory of Brain Development and Repair, The Rockefeller University, New York, New York 10065, Department of Biomedical Imaging, Department of Neuroscience, Department of Biochemical and Cellular Pharmacology, and Department of Protein Chemistry, Genentech Inc., South San Francisco, California 94080, and Molecular Neurobiology Laboratory, The Salk Institute, La Jolla, California 92037.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallop</LastName><ForeName>Dara Y</ForeName><Initials>DY</Initials></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Todd</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Huntwork-Rodriguez</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhuhao</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Duggan</LastName><ForeName>Cynthia D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yanmei</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Easley-Neal</LastName><ForeName>Courtney</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Takeda</LastName><ForeName>Kentaro</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Hass</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Jaworski</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Dennis D M</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Weimer</LastName><ForeName>Robby M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Tessier-Lavigne</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 EY007025</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 EY07025</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018124">Receptors, Tumor Necrosis Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C114109">TNFRSF21 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005727" MajorTopicYN="N">Ganglia, Spinal</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009410" MajorTopicYN="N">Nerve Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018124" MajorTopicYN="N">Receptors, Tumor Necrosis Factor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012165" MajorTopicYN="N">Retinal Ganglion Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011984" MajorTopicYN="N">Sensory Receptor Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">degeneration</Keyword><Keyword MajorTopicYN="N">pruning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24806670</ArticleId><ArticleId IdType="pmc">PMC4012303</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.3522-13.2014</ArticleId><ArticleId IdType="pii">34/19/6438</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J. Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci. 2009;29:10405&#x2013;10409. doi: 10.1523/JNEUROSCI.2288-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2288-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665795</ArticleId><ArticleId IdType="pubmed">19692615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Maloney JA, Kallop DY, Atwal JK, Tam SJ, Baer K, Kissel H, Kaminker JS, Lewcock JW, Weimer RM, Watts RJ. Spatially coordinated kinase signaling regulates local axon degeneration. J Neurosci. 2012;32:13439&#x2013;13453. doi: 10.1523/JNEUROSCI.2039-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2039-12.2012</ArticleId><ArticleId IdType="pmc">PMC6621382</ArticleId><ArticleId IdType="pubmed">23015435</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Frigola C, Carreres MI, Vegar C, Herrera E. Gene delivery into mouse retinal ganglion cells by in utero electroporation. BMC Dev Biol. 2007;7:103. doi: 10.1186/1471-213X-7-103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-213X-7-103</ArticleId><ArticleId IdType="pmc">PMC2080638</ArticleId><ArticleId IdType="pubmed">17875204</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray NW, Weimer RM, Bureau I, Svoboda K. Rapid redistribution of synaptic PSD-95 in the neocortex in vivo. PLoS Biol. 2006;4:e370. doi: 10.1371/journal.pbio.0040370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0040370</ArticleId><ArticleId IdType="pmc">PMC1634879</ArticleId><ArticleId IdType="pubmed">17090216</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Li H, Gaddam SS, Justice NJ, Robertson CS, Zheng H. Amyloid precursor protein revisited: neuron-specific expression and highly stable nature of soluble derivatives. J Biol Chem. 2012;287:2437&#x2013;2445. doi: 10.1074/jbc.M111.315051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.315051</ArticleId><ArticleId IdType="pmc">PMC3268404</ArticleId><ArticleId IdType="pubmed">22144675</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemming ML, Elias JE, Gygi SP, Selkoe DJ. Identification of beta-secretase (BACE1) substrates using quantitative proteomics. PLoS One. 2009;4:e8477. doi: 10.1371/journal.pone.0008477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0008477</ArticleId><ArticleId IdType="pmc">PMC2793532</ArticleId><ArticleId IdType="pubmed">20041192</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallop DY, Meilandt WJ, Gogineni A, Easley-Neal C, Wu T, Jubb AM, Yaylaoglu M, Shamloo M, Tessier Lavigne M, Scearce-Levie K, Weimer RM. A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models. J Neurosci. 2014;34:6425&#x2013;6437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6608138</ArticleId><ArticleId IdType="pubmed">24806669</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L, O'Leary DD. Axon retraction and degeneration in development and disease. Annu Rev Neurosci. 2005;28:127&#x2013;156. doi: 10.1146/annurev.neuro.28.061604.135632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.28.061604.135632</ArticleId><ArticleId IdType="pubmed">16022592</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik SA, Olsen O, Tessier-Lavigne M, Gilbert CD. Death Receptor 6 regulates adult experience-dependent cortical plasticity. J Neurosci. 2013;33:14998&#x2013;15003. doi: 10.1523/JNEUROSCI.2398-13.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2398-13.2013</ArticleId><ArticleId IdType="pmc">PMC3776054</ArticleId><ArticleId IdType="pubmed">24048829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature. 2009;457:981&#x2013;989. doi: 10.1038/nature07767.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07767</ArticleId><ArticleId IdType="pmc">PMC2677572</ArticleId><ArticleId IdType="pubmed">19225519</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaupp A, Sabet O, Dudanova I, Ponserre M, Bastiaens P, Klein R. The composition of EphB2 clusters determines the strength in the cellular repulsion response. J Cell Biol. 2014;204:409&#x2013;422. doi: 10.1083/jcb.201305037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1083/jcb.201305037</ArticleId><ArticleId IdType="pmc">PMC3912530</ArticleId><ArticleId IdType="pubmed">24469634</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenmann Z, Assa-Kunik E, Tiomny S, Minis A, Haklai-Topper L, Arama E, Yaron A. Axonal degeneration is regulated by the apoptotic machinery or a NAD+-sensitive pathway in insects and mammals. J Neurosci. 2010;30:6375&#x2013;6386. doi: 10.1523/JNEUROSCI.0922-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0922-10.2010</ArticleId><ArticleId IdType="pmc">PMC6632718</ArticleId><ArticleId IdType="pubmed">20445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan ZX, Lin QX, Yang M, Deng CY, Kuang SJ, Zhou ZL, Xiao DZ, Liu XY, Lin SG, Yu XY. A quick and efficient approach for gene silencing by using triple putative microRNA-based short hairpin RNAs. Mol Cell Biochem. 2009;323:81&#x2013;89. doi: 10.1007/s11010-008-9966-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-008-9966-3</ArticleId><ArticleId IdType="pubmed">19037714</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22:1567&#x2013;1572. doi: 10.1038/nbt1037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt1037</ArticleId><ArticleId IdType="pubmed">15558047</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon DJ, Weimer RM, McLaughlin T, Kallop D, Stanger K, Yang J, O'Leary DD, Hannoush RN, Tessier-Lavigne M. A caspase cascade regulating developmental axon degeneration. J Neurosci. 2012;32:17540&#x2013;17553. doi: 10.1523/JNEUROSCI.3012-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3012-12.2012</ArticleId><ArticleId IdType="pmc">PMC3532512</ArticleId><ArticleId IdType="pubmed">23223278</ArticleId></ArticleIdList></Reference><Reference><Citation>Vohra BP, Sasaki Y, Miller BR, Chang J, DiAntonio A, Milbrandt J. Amyloid precursor protein cleavage-dependent and -independent axonal degeneration programs share a common nicotinamide mononucleotide adenylyltransferase 1-sensitive pathway. J Neurosci. 2010;30:13729&#x2013;13738. doi: 10.1523/JNEUROSCI.2939-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2939-10.2010</ArticleId><ArticleId IdType="pmc">PMC3104322</ArticleId><ArticleId IdType="pubmed">20943913</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez B, Lee KF, Gan WB, Zheng H. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci. 2005;25:1219&#x2013;1225. doi: 10.1523/JNEUROSCI.4660-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4660-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725967</ArticleId><ArticleId IdType="pubmed">15689559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24813892</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>22</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>Life extension factor klotho enhances cognition.</ArticleTitle><Pagination><StartPage>1065</StartPage><EndPage>1076</EndPage><MedlinePgn>1065-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.03.076</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)00287-3</ELocationID><Abstract><AbstractText>Aging is the primary risk factor for cognitive decline, an emerging health threat to aging societies worldwide. Whether anti-aging factors such as klotho can counteract cognitive decline is unknown. We show that a lifespan-extending variant of the human KLOTHO gene, KL-VS, is associated with enhanced cognition in heterozygous carriers. Because this allele increased klotho levels in serum, we analyzed transgenic mice with systemic overexpression of klotho. They performed better than controls in multiple tests of learning and memory. Elevating klotho in mice also enhanced long-term potentiation, a form of synaptic plasticity, and enriched synaptic GluN2B, an N-methyl-D-aspartate receptor (NMDAR) subunit with key functions in learning and memory. Blockade of GluN2B abolished klotho-mediated effects. Surprisingly, klotho effects were evident also in young mice and did not correlate with age in humans, suggesting independence from the aging process. Augmenting klotho or its effects may enhance cognition and counteract cognitive deficits at different life stages.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubal</LastName><ForeName>Dena B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: dena.dubal@ucsf.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokoyama</LastName><ForeName>Jennifer S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broestl</LastName><ForeName>Lauren</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Worden</LastName><ForeName>Kurtresha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sturm</LastName><ForeName>Virginia E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90024, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Gui-Qiu</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ho</LastName><ForeName>Kaitlyn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eilertson</LastName><ForeName>Kirsten E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Cardiovascular Disease, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuro-o</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA; Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jager</LastName><ForeName>Philip L</ForeName><Initials>PL</Initials><AffiliationInfo><Affiliation>Program in Translational NeuroPsychiatric Genomics, Institute for Neurosciences, Departments of Neurology &amp; Psychiatry, Brigham&#xa0;and&#xa0;Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coppola</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90024, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Small</LastName><ForeName>Gary W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA 90024, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL 60612, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abraham</LastName><ForeName>Carmela R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucke</LastName><ForeName>Lennart</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Gladstone Institute of Neurological Disease, San Francisco, CA 94158, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: lmucke@gladstone.ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG17917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG019712</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG017917</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG00001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG19724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG015819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG025831</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG025831</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR00865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG040127</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG010435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>M01 RR000865</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50AG23501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS065780</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG000001</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG15819</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG010161</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG018440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG019712</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG022074</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG18440</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG032289</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AG034531</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR18938-01</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C121001">NR2B NMDA receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016194">Receptors, N-Methyl-D-Aspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D005966">Glucuronidase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.2.1.31</RegistryNumber><NameOfSubstance UI="D000090265">Klotho Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Rev Neurosci. 2014 Jul;15(7):425. doi: 10.1038/nrn3777.</RefSource><PMID Version="1">24938722</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005966" MajorTopicYN="N">Glucuronidase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090265" MajorTopicYN="N">Klotho Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="N">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016194" MajorTopicYN="N">Receptors, N-Methyl-D-Aspartate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24813892</ArticleId><ArticleId IdType="mid">NIHMS586250</ArticleId><ArticleId IdType="pmc">PMC4176932</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.03.076</ArticleId><ArticleId IdType="pii">S2211-1247(14)00287-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abraham CR, Chen C, Cuny GD, Glicksman MA, Zeldich E. Small-molecule Klotho enhancers as novel treatment of neurodegeneration. Future Med Chem. 2012;4:1671&#x2013;1679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564652</ArticleId><ArticleId IdType="pubmed">22924505</ArticleId></ArticleIdList></Reference><Reference><Citation>Anggono V, Huganir RL. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol. 2012;22:461&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3392447</ArticleId><ArticleId IdType="pubmed">22217700</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res. 2005;96:412&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pubmed">15677572</ArticleId></ArticleIdList></Reference><Reference><Citation>Arking DE, Krebsova A, Macek M, Sr., Macek M, Jr., Arking A, Mian IS, Fried L, Hamosh A, Dey S, McIntosh I, et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA. 2002;99:856&#x2013;861.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC117395</ArticleId><ArticleId IdType="pubmed">11792841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bading H, Ginty DD, Greenberg ME. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways. Science. 1993;260:181&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">8097060</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigman JL, Wright T, Talani G, Prasad-Mulcare S, Jinde S, Seabold GK, Mathur P, Davis MI, Bock R, Gustin RM, et al. Loss of GluN2B-containing NMDA receptors in CA1 hippocampus and cortex impairs long-term depression, reduces dendritic spine density, and disrupts learning. J Neurosci. 2010;30:4590&#x2013;4600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2869199</ArticleId><ArticleId IdType="pubmed">20357110</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JA, Terashima KH, Burggren AC, Ercoli LM, Miller KJ, Small GW, Bookheimer SY. Brain network local interconnectivity loss in aging APOE-4 allele carriers. Proc Natl Acad Sci USA. 2011;108:20760&#x2013;20765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3251140</ArticleId><ArticleId IdType="pubmed">22106308</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao X, Cui Z, Feng R, Tang YP, Qin Z, Mei B, Tsien JZ. Maintenance of superior learning and memory function in NR2B transgenic mice during ageing. Eur J Neurosci. 2007;25:1815&#x2013;1822.</Citation><ArticleIdList><ArticleId IdType="pubmed">17432968</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang PK, Verbich D, McKinney RA. AMPA receptors as drug targets in neurological disease--advantages, caveats, and future outlook. Eur J Neurosci. 2012;35:1908&#x2013;1916.</Citation><ArticleIdList><ArticleId IdType="pubmed">22708602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310:490&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">16239475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chateau MT, Araiz C, Descamps S, Galas S. Klotho interferes with a novel FGF-signalling pathway and insulin/Igf-like signalling to improve longevity and stress resistance in Caenorhabditis elegans. Aging. 2010;2:567&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2984606</ArticleId><ArticleId IdType="pubmed">20844315</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci USA. 2007;104:19796&#x2013;19801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2148378</ArticleId><ArticleId IdType="pubmed">18056631</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CD, Sloane JA, Li H, Aytan N, Giannaris EL, Zeldich E, Hinman JD, Dedeoglu A, Rosene DL, Bansal R, et al. The antiaging protein Klotho enhances oligodendrocyte maturation and myelination of the CNS. J Neurosci. 2013;33:1927&#x2013;1939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3711388</ArticleId><ArticleId IdType="pubmed">23365232</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Halabisky B, Harris JA, Devidze N, Dubal D, Lotz G, Kim DH, Hamto T, Ho K, Yu G-Q, et al. Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature. 2011;469:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3030448</ArticleId><ArticleId IdType="pubmed">21113149</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, Yu L, Leurgans SE, Tran D, Aubin C, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging. 2012;33:1017, e1011&#x2013;1015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3307898</ArticleId><ArticleId IdType="pubmed">22054870</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Harris SE, Fox HC, Hayward C, Wright AF, Starr JM, Whalley LJ. KLOTHO genotype and cognitive ability in childhood and old age in the same individuals. Neurosci Lett. 2005;378:22&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">15763166</ArticleId></ArticleIdList></Reference><Reference><Citation>Deary IJ, Whiteman MC, Pattie A, Starr JM, Hayward C, Wright AF, Carothers A, Whalley LJ. Cognitive change and the APOE epsilon 4 allele. Nature. 2002;418:932.</Citation><ArticleIdList><ArticleId IdType="pubmed">12198535</ArticleId></ArticleIdList></Reference><Reference><Citation>Drag LL, Bieliauskas LA. Contemporary review 2009: Cognitive aging. J Geriatr Psychiatry Neurol. 2010;23:75&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">20101069</ArticleId></ArticleIdList></Reference><Reference><Citation>Duce JA, Podvin S, Hollander W, Kipling D, Rosene DL, Abraham CR. Gene profile analysis implicates Klotho as an important contributor to aging changes in brain white matter of the rhesus monkey. Glia. 2008;56:106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963266</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton M, Sheng M. Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci. 2010;30:2676&#x2013;2685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840640</ArticleId><ArticleId IdType="pubmed">20164351</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankland PW, Bontempi B. The organization of recent and remote memories. Nat Rev Neurosci. 2005:119&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">15685217</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladding CM, Raymond LA. Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function. Mol Cell Neurosci. 2011;48:308&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">21600287</ArticleId></ArticleIdList></Reference><Reference><Citation>Goebel-Goody SM, Davies KD, Alvestad Linger RM, Freund RK, Browning MD. Phospho-regulation of synaptic and extrasynaptic N-methyl-d-aspartate receptors in adult hippocampal slices. Neuroscience. 2009;158:1446&#x2013;1459.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041929</ArticleId></ArticleIdList></Reference><Reference><Citation>Guarente L, Kenyon C. Genetic pathways that regulate ageing in model organisms. Nature. 2000;408:255&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11089983</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris JA, Devidze N, Verret L, Ho K, Hamto T, Lo I, Yu G-Q, Palop JJ, Masliah E, Mucke L. Transsynaptic progression of amyloid-&#x3b2;-induced neuronal dysfunction within the entorhinal-hippocampal network. Neuron. 2010;68:428&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3050043</ArticleId><ArticleId IdType="pubmed">21040845</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley JM, Wilkinson KA. AMPA receptor trafficking and the mechanisms underlying synaptic plasticity and cognitive aging. Dialogues Clin Neurosci. 2013;15:11&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3622464</ArticleId><ArticleId IdType="pubmed">23576886</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y. Secreted Klotho protein in sera and CSF: Implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004;565:143&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">15135068</ArticleId></ArticleIdList></Reference><Reference><Citation>Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, et al. Science. 2007;316:1615&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pubmed">17569864</ArticleId></ArticleIdList></Reference><Reference><Citation>Invidia L, Salvioli S, Altilia S, Pierini M, Panourgia MP, Monti D, De Rango F, Passarino G, Franceschi C. The frequency of Klotho KL-VS polymorphism in a large Italian population, from young subjects to centenarians, suggests the presence of specific time windows for its effect. Biogerontology. 2010;11:67&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">19421891</ArticleId></ArticleIdList></Reference><Reference><Citation>Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer&#x2019;s disease mouse models. Cell. 2010;142:387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pubmed">20655099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerchner GA, Nicoll RA. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat Rev Neurosci. 2008;9:813&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2819160</ArticleId><ArticleId IdType="pubmed">18854855</ArticleId></ArticleIdList></Reference><Reference><Citation>Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron. 2009;61:340&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3917551</ArticleId><ArticleId IdType="pubmed">19217372</ArticleId></ArticleIdList></Reference><Reference><Citation>King GD, Chen C, Huang MM, Zeldich E, Brazee PL, Schuman ER, Robin M, Cuny GD, Glicksman MA, Abraham CR. Identification of novel small molecules that elevate Klotho expression. Biochem J. 2012;441:453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677209</ArticleId><ArticleId IdType="pubmed">21939436</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Sakamoto T, Endo S, Niki H. Impairment of conditioned freezing to tone, but not to context, in Fyn-transgenic mice: relationship to NMDA receptor subunit 2B function. Eur J Neurosci. 2005;21:1359&#x2013;1369.</Citation><ArticleIdList><ArticleId IdType="pubmed">15813945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubik S, Miyashita T, Guzowski JF. Using immediate-early genes to map hippocampal subregional functions. Learn Mem. 2007;14:758&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">18007019</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">9363890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005;309:1829&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536606</ArticleId><ArticleId IdType="pubmed">16123266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YS, Silva AJ. The molecular and cellular biology of enhanced cognition. Nat Rev Neurosci. 2009;10:126&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2664745</ArticleId><ArticleId IdType="pubmed">19153576</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble A&#x3b2; oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci. 2011;31:6627&#x2013;6638.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100898</ArticleId><ArticleId IdType="pubmed">21543591</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, Schimel D, Kuo CJ, et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007;317:803&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pubmed">17690294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wong TP, Pozza MF, Lingenhoehl K, Wang Y, Sheng M, Auberson YP, Wang YT. Role of NMDA receptor subtypes in governing the direction of hippocampal synaptic plasticity. Science. 2004;304:1021&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">15143284</ArticleId></ArticleIdList></Reference><Reference><Citation>Luciano M, Hansell NK, Lahti J, Davies G, Medland SE, Raikkonen K, Tenesa A, Widen E, McGhee KA, Palotie A, et al. Whole genome association scan for genetic polymorphisms influencing information processing speed. Biol Psychol. 2011;86:193&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3319015</ArticleId><ArticleId IdType="pubmed">21130836</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnusson KR, Brim BL, Das SR. Selective vulnerabilities of N-methyl-D-aspartate (NMDA) receptors during brain aging. Front Aging Neurosci. 2010;2:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2874396</ArticleId><ArticleId IdType="pubmed">20552049</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumdar V, Nagaraja D, Christopher R. Association of the functional KL-VS variant of Klotho gene with early-onset ischemic stroke. Biochem Biophys Res Commun. 2010;403:412&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">21093413</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. 2011;6:e19338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3084838</ArticleId><ArticleId IdType="pubmed">21559417</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur P, Graybeal C, Feyder M, Davis MI, Holmes A. Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: Attenuation with ageing. Pharmacol Biochem Behav. 2009;91:453&#x2013;460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2645594</ArticleId><ArticleId IdType="pubmed">18809426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: Molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009;157:1301&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2765303</ArticleId><ArticleId IdType="pubmed">19594762</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 1986;319:774&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">2869411</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai T, Yamada K, Kim HC, Kim YS, Noda Y, Imura A, Nabeshima Y, Nabeshima T. Cognition impairment in the genetic model of aging klotho gene mutant mice: A role of oxidative stress. FASEB J. 2003;17:50&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">12475907</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa K, McHugh TJ, Wilson MA, Tonegawa S. NMDA receptors, place cells and hippocampal spatial memory. Nat Rev Neurosci. 2004;5:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">15100719</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen PV, Kandel ER. A macromolecular synthesis-dependent late phase of long-term potentiation requiring cAMP in the medial perforant pathway of rat hippocampal slices. J Neurosci. 1996;16:3189&#x2013;3198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579127</ArticleId><ArticleId IdType="pubmed">8627357</ArticleId></ArticleIdList></Reference><Reference><Citation>Palop JJ, Jones B, Kekonius L, Chin J, Yu G-Q, Raber J, Masliah E, Mucke L. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer&#x2019;s disease-related cognitive deficits. Proc Natl Acad Sci USA. 2003;100:9572&#x2013;9577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC170959</ArticleId><ArticleId IdType="pubmed">12881482</ArticleId></ArticleIdList></Reference><Reference><Citation>Paoletti P, Neyton J. NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol. 2007;7:39&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">17088105</ArticleId></ArticleIdList></Reference><Reference><Citation>Piggott MA, Perry EK, Perry RH, Court JA. [3H]MK-801 binding to the NMDA receptor complex, and its modulation in human frontal cortex during development and aging. Brain Res. 1992;588:277&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">1393579</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri C. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement. 2013;9:63&#x2013;75 e62.</Citation><ArticleIdList><ArticleId IdType="pubmed">23305823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganath C, Ritchey M. Two cortical systems for memory-guided behaviour. Nat Rev Neurosci. 2012;13:713&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">22992647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray JW, Shadish WR. How interchangeable are different estimators of effect size? J Consult Clin Psychol. 1996;64:1316&#x2013;1325.</Citation><ArticleIdList><ArticleId IdType="pubmed">8991318</ArticleId></ArticleIdList></Reference><Reference><Citation>Razzaque MS. The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009;5:611&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107967</ArticleId><ArticleId IdType="pubmed">19844248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood K. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer&#x2019;s disease. J Neurol Neurosurg Psychiatry. 2004;75:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1763555</ArticleId><ArticleId IdType="pubmed">15090558</ArticleId></ArticleIdList></Reference><Reference><Citation>Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, Guralnik JM, Ferrucci L. Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci. 2011;66:794&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3143348</ArticleId><ArticleId IdType="pubmed">21474560</ArticleId></ArticleIdList></Reference><Reference><Citation>Semba RD, Moghekar AR, Hu J, Sun K, Turner R, Ferrucci L, O&#x2019;Brien R. Klotho in the cerebrospinal fluid of adults with and without Alzheimer&#x2019;s disease. Neuroscience letters. 2014;558:37&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037850</ArticleId><ArticleId IdType="pubmed">24211693</ArticleId></ArticleIdList></Reference><Reference><Citation>Seshadri S, DeStefano AL, Au R, Massaro JM, Beiser AS, Kelly-Hayes M, Kase CS, D&#x2019;Agostino RB, Sr., Decarli C, Atwood LD, et al. Genetic correlates of brain aging on MRI and cognitive test measures: A genome-wide association and linkage analysis in the Framingham Study. BMC Med Genet. 2007;8(Suppl 1):S15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1995608</ArticleId><ArticleId IdType="pubmed">17903297</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiozaki M, Yoshimura K, Shibata M, Koike M, Matsuura N, Uchiyama Y, Gotow T. Morphological and biochemical signs of age-related neurodegenerative changes in klotho mutant mice. Neuroscience. 2008;152:924&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pubmed">18343589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiraki-Iida T, Aizawa H, Matsumura Y, Sekine S, Iida A, Anazawa H, Nagai R, Kuro-o M, Nabeshima Y. Structure of the mouse klotho gene and its two transcripts encoding membrane and secreted protein. FEBS Lett. 1998;424:6&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">9537505</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M, Wells J, Borrie M. Treatment effect size of memantine therapy in Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord. 2006;20:133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sotres-Bayon F, Bush DE, LeDoux JE. Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala. Neuropsychopharmacology. 2007;32:1929&#x2013;1940.</Citation><ArticleIdList><ArticleId IdType="pubmed">17213844</ArticleId></ArticleIdList></Reference><Reference><Citation>Sze C, Bi H, Kleinschmidt-DeMasters BK, Filley CM, Martin LJ. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer&#x2019;s disease. J Neurol Sci. 2001;182:151&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11137521</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ. Genetic enhancement of learning and memory in mice. Nature. 1999;401:63&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">10485705</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucker Zhou TB, King GD, Chen C, Abraham CR. Biochemical and functional characterization of the Klotho-VS polymorphism implicated in aging and disease risk. J Biol Chem. 2013;288:36302&#x2013;36311.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868745</ArticleId><ArticleId IdType="pubmed">24217253</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">17086194</ArticleId></ArticleIdList></Reference><Reference><Citation>Verghese PB, Castellano JM, Holtzman DM. Apolipoprotein E in Alzheimer&#x2019;s disease and other neurological disorders. Lancet Neurol. 2011;10:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132088</ArticleId><ArticleId IdType="pubmed">21349439</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Cui Z, Zeng Q, Kuang H, Wang LP, Tsien JZ, Cao X. Genetic enhancement of memory and long-term potentiation but not CA1 long-term depression in NR2B transgenic rats. PLoS One. 2009;4:e7486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2759522</ArticleId><ArticleId IdType="pubmed">19838302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Stradtman GG, 3rd, Wang XJ, Gao WJ. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci USA. 2008;105:16791&#x2013;16796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575498</ArticleId><ArticleId IdType="pubmed">18922773</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SH, Morris RG. Hippocampal-neocortical interactions in memory formation, consolidation, and reconsolidation. Annu Rev Psychol. 2010;61:49&#x2013;79. C41&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">19575620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">9311354</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Y, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010;398:513&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4130489</ArticleId><ArticleId IdType="pubmed">20599764</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K, Trepanier C, Sidhu B, Xie YF, Li H, Lei G, Salter MW, Orser BA, Nakazawa T, Yamamoto T, et al. Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases. EMBO J. 2012;31:805&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3280552</ArticleId><ArticleId IdType="pubmed">22187052</ArticleId></ArticleIdList></Reference><Reference><Citation>Yashiro K, Philpot BD. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology. 2008;55:1081&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2590778</ArticleId><ArticleId IdType="pubmed">18755202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Rosenke R, Kronemann D, Brim B, Das SR, Dunah AW, Magnusson KR. The effects of aging on N-methyl-D-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory. Neuroscience. 2009;162:933&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2769499</ArticleId><ArticleId IdType="pubmed">19446010</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24819981</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6114</ISSN><JournalIssue CitedMedium="Internet"><Volume>174</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JAMA internal medicine</Title><ISOAbbreviation>JAMA Intern Med</ISOAbbreviation></Journal><ArticleTitle>Resveratrol levels and all-cause mortality in older community-dwelling adults.</ArticleTitle><Pagination><StartPage>1077</StartPage><EndPage>1084</EndPage><MedlinePgn>1077-84</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamainternmed.2014.1582</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Resveratrol, a polyphenol found in grapes, red wine, chocolate, and certain berries and roots, is considered to have antioxidant, anti-inflammatory, and anticancer effects in humans and is related to longevity in some lower organisms.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular disease, and mortality in humans.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study, the Invecchiare in Chianti (InCHIANTI) Study ("Aging in the Chianti Region"), 1998 to 2009 conducted in 2 villages in the Chianti area in a population-based sample of 783 community-dwelling men and women 65 years or older.</AbstractText><AbstractText Label="EXPOSURES" NlmCategory="METHODS">Twenty-four-hour urinary resveratrol metabolites.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Primary outcome measure was all-cause mortality. Secondary outcomes were markers of inflammation (serum C-reactive protein [CRP], interleukin [IL]-6, IL-1&#x3b2;, and tumor necrosis factor [TNF]) and prevalent and incident cancer and cardiovascular disease.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean (95% CI) log total urinary resveratrol metabolite concentrations were 7.08 (6.69-7.48) nmol/g of creatinine. During 9 years of follow-up, 268 (34.3%) of the participants died. From the lowest to the highest quartile of baseline total urinary resveratrol metabolites, the proportion of participants who died from all causes was 34.4%, 31.6%, 33.5%, and 37.4%, respectively (P&#x2009;=&#x2009;.67). Participants in the lowest quartile had a hazards ratio for mortality of 0.80 (95% CI, 0.54-1.17) compared with those in the highest quartile of total urinary resveratrol in a multivariable Cox proportional hazards model that adjusted for potential confounders. Resveratrol levels were not significantly associated with serum CRP, IL-6, IL-1&#x3b2;, TNF, prevalent or incident cardiovascular disease, or cancer.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">In older community-dwelling adults, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease, or cancer or predictive of all-cause mortality. Resveratrol levels achieved with a Western diet did not have a substantial influence on health status and mortality risk of the population in this study.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Semba</LastName><ForeName>Richard D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrucci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Longitudinal Studies Section, National Institute on Aging, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartali</LastName><ForeName>Benedetta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>New England Research Institute, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urp&#xed;-Sarda</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nutrition and Food Science Department, Biomarkers and Nutrimetabolomics Laboratory, Food Technology Reference Net and Nutrition and Food Safety Research Institute (XaRTA and INSA ), Pharmacy School, University of Barcelona, Barcelona, Spain5Unit of Nutrit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamora-Ros</LastName><ForeName>Raul</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nutrition and Food Science Department, Biomarkers and Nutrimetabolomics Laboratory, Food Technology Reference Net and Nutrition and Food Safety Research Institute (XaRTA and INSA ), Pharmacy School, University of Barcelona, Barcelona, Spain5Unit of Nutrit.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cherubini</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Geriatrics and Geriatric Emergency Department, Istituto Nazionale di Riposo e Cura per Anziani V.E.II.-Istituto di Ricovero e Cura a Carattere Scientifico (INRCA-IRCCS), Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandinelli</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Azienda Sanitaria, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres-Lacueva</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Nutrition and Food Science Department, Biomarkers and Nutrimetabolomics Laboratory, Food Technology Reference Net and Nutrition and Food Safety Research Institute (XaRTA and INSA ), Pharmacy School, University of Barcelona, Barcelona, Spain5Unit of Nutrit.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG027012</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>263MD 821336</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MD009164</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-1-2111</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-1-1</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL094507</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>263 MD 9164</GrantID><Acronym>MD</Acronym><Agency>NIMHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01-AG-5-0002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Intern Med</MedlineTA><NlmUniqueID>101589534</NlmUniqueID><ISSNLinking>2168-6106</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q369O8926L</RegistryNumber><NameOfSubstance UI="D000077185">Resveratrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2015 Jan;175(1):140-1. doi: 10.1001/jamainternmed.2014.7000.</RefSource><PMID Version="1">25560944</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2015 Apr;175(4):650. doi: 10.1001/jamainternmed.2014.8068.</RefSource><PMID Version="1">25844739</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Intern Med. 2015 Apr;175(4):651. doi: 10.1001/jamainternmed.2014.8078.</RefSource><PMID Version="1">25844742</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N">Italy</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077185" MajorTopicYN="N">Resveratrol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="Y">urine</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24819981</ArticleId><ArticleId IdType="mid">NIHMS665943</ArticleId><ArticleId IdType="pmc">PMC4346286</ArticleId><ArticleId IdType="doi">10.1001/jamainternmed.2014.1582</ArticleId><ArticleId IdType="pii">1868537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Birrell MA, McCluskie K, Wong S, Donnelly LE, Barnes PJ, Belvisi MG. Resveratrol, an extract of red wine, inhibits lipopolysaccharide induced airway neutrophilia and inflammatory mediators through an NF-kappaB-independent mechanism. FASEB J. 2005;19:840&#x2013;841.</Citation><ArticleIdList><ArticleId IdType="pubmed">15734790</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72:1439&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920072</ArticleId></ArticleIdList></Reference><Reference><Citation>Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4990206</ArticleId><ArticleId IdType="pubmed">17086191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9;-Carneiro J, Gonz&#xe1;lvez M, Larrosa M, et al. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci. 2013;1290:37&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23855464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JM, Hsieh TC. Resveratrol: a cardioprotective substance. Ann N Y Acad Sci. 2011;1215:16&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21261637</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmer S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging. 2012;4:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348475</ArticleId><ArticleId IdType="pubmed">22436213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cant&#xf3; C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD+? Pharmacol Rev. 2012;64:166&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3616312</ArticleId><ArticleId IdType="pubmed">22106091</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Eno Vitic. 1992;43:49&#x2013;52.</Citation></Reference><Reference><Citation>Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;399:1523&#x2013;1526.</Citation><ArticleIdList><ArticleId IdType="pubmed">1351198</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu BL, Zhang X, Zhang W, Zhen HN. New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther. 2007;6:1833&#x2013;1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">18087218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Sia CL, Abauysheh S, et al. An anti-inflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95:E1&#x2013;E8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2936054</ArticleId><ArticleId IdType="pubmed">20534755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Sia CL, Korzeniewski K, et al. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011;96:1409&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3085195</ArticleId><ArticleId IdType="pubmed">21289251</ArticleId></ArticleIdList></Reference><Reference><Citation>Popat R, Plesner T, Davies F, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol. 2013;160:709&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">23205612</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotches-Ribalta M, Andres-Lacueva C, Estruch R, Escribano E, Urpi-Sarda M. Pharmacokinetics of resveratrol metabolic profile in healthy humans after moderate consumption of red wine and grape extract tablets. Pharmacol Res. 2012;66:375&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">22906730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L, Bandinelli S, Benvenuti E, et al. Subsystems contributing to the decline in ability to walk: bridging the gap between epidemiology and geriatric practice in the InCHIANTI study. J Am Geriatr Soc. 2000;48:1618&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">11129752</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisani P, Faggiano F, Krogh V, et al. Relative validity and reproducibility of a food frequency dietary questionnaire for use in the Italian EPIC centres. Int J Epidemiol. 1997;26(suppl 1):S152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">9126543</ArticleId></ArticleIdList></Reference><Reference><Citation>Guralnik JM, Fried LP, Simonsick EM, et al. The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability. Bethesda, MD: National Institute on Aging; 1995. NIH Publication No. 95-4009.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-Mental State&#x201d; A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L, Semba RD, Guralnik JM, et al. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010;115:3810&#x2013;3816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2865871</ArticleId><ArticleId IdType="pubmed">20081092</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrucci L, Corsi A, Lauretani F, et al. The origins of the age-related proinflammatory state. Blood. 2005;105:2294&#x2013;2299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9828256</ArticleId><ArticleId IdType="pubmed">15572589</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparation ultracentrifuge. Clin Chem. 1972;18:499&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">4337382</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(suppl 1):S43&#x2013;S48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16373932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora-Ros R, Urp&#xed;-Sarda M, Lamuela-Revent&#xf3;s RM, et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol Res. 2012;65:615&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465220</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora-Ros R, Urp&#xed;-Sard&#xe0; M, Lamuela-Ravent&#xf3;s RM, et al. Resveratrol metabolites in urine as a biomarker of wine intake in free-living subjects: the PREDIMED Study. Free Radic Biol Med. 2009;46:1562&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pubmed">19167481</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaut M, Clavel T. Metabolic diversity of the intestinal microbiota: implications for health and disease. J Nutr. 2007;137(3 Suppl 2):751S&#x2013;755S.</Citation><ArticleIdList><ArticleId IdType="pubmed">17311972</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;366:1262&#x2013;1267.</Citation><ArticleIdList><ArticleId IdType="pubmed">22674330</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino J, Conte C, Fontana L, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metabolism. 2012;16:658&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3496026</ArticleId><ArticleId IdType="pubmed">23102619</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9;-Carneiro J, Gonz&#xe1;lvez M, Larrosa M, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110:356&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pubmed">22520621</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmer S, Koinings E, Bilet L, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3880862</ArticleId><ArticleId IdType="pubmed">22055504</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott PJ, Walpole S, Morelli L, et al. Resveratrol/SRT-501. Drugs Fut. 2009;34:291&#x2013;295.</Citation></Reference><Reference><Citation>Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">22240353</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9;-Carneiro J, Gonz&#xe1;lvez M, Larrosa M, et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res. 2012;56:810&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">22648627</ArticleId></ArticleIdList></Reference><Reference><Citation>Tom&#xe9;-Carneiro J, Larrosa M, Y&#xe1;&#xf1;ez-Gasc&#xf3;n MJ, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">23557933</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulsen MM, Vestergaard PF, Clasen BF, et al. High-dose resveratrol supplemention in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186&#x2013;1195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3609591</ArticleId><ArticleId IdType="pubmed">23193181</ArticleId></ArticleIdList></Reference><Reference><Citation>Walle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pubmed">15333514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24828079</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1946-6242</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>236</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>Science translational medicine</Title><ISOAbbreviation>Sci Transl Med</ISOAbbreviation></Journal><ArticleTitle>An antidepressant decreases CSF A&#x3b2; production in healthy individuals and in transgenic AD mice.</ArticleTitle><Pagination><StartPage>236re4</StartPage><MedlinePgn>236re4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/scitranslmed.3008169</ELocationID><Abstract><AbstractText>Serotonin signaling suppresses generation of amyloid-&#x3b2; (A&#x3b2;) in vitro and in animal models of Alzheimer's disease (AD). We show that in an aged transgenic AD mouse model (APP/PS1 plaque-bearing mice), the antidepressant citalopram, a selective serotonin reuptake inhibitor, decreased A&#x3b2; in brain interstitial fluid in a dose-dependent manner. Growth of individual amyloid plaques was assessed in plaque-bearing mice that were chronically administered citalopram. Citalopram arrested the growth of preexisting plaques and reduced the appearance of new plaques by 78%. In healthy human volunteers, citalopram's effects on A&#x3b2; production and A&#x3b2; concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram. A&#x3b2; production in CSF was slowed by 37% in the citalopram group compared to placebo. This change was associated with a 38% decrease in total CSF A&#x3b2; concentrations in the drug-treated group. The ability to safely decrease A&#x3b2; concentrations is potentially important as a preventive strategy for AD. This study demonstrates key target engagement for future AD prevention trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheline</LastName><ForeName>Yvette I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Departments of Psychiatry, Radiology, and Neurology, University of Pennsylvania, Philadelphia , PA 19104, USA. sheline@mail.med.upenn.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>West</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>C2N Diagnostics LLC, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swarm</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jasielec</LastName><ForeName>Mateusz S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Jonathan R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ficker</LastName><ForeName>Whitney D</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Chengjie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Washington University, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University Medical Center, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frederiksen</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grzelak</LastName><ForeName>Monica V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chott</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University Medical Center, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>John C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University Medical Center, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mintun</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Avid Radiopharmaceuticals and Eli Lilly Inc., Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jin-Moo</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University Medical Center, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University, St. Louis, MO 63110, USA. Knight Alzheimer's Disease Research Center, Washington University Medical Center, St. Louis, MO 63110, USA. Hope Center for Neurological Disorders, Washington University, St. Louis, MO 63110, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG041502</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG03969002</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH079510</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG042513</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS067905</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 GM136766</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG04150202</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS082529</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG039690</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Transl Med</MedlineTA><NlmUniqueID>101505086</NlmUniqueID><ISSNLinking>1946-6234</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber><NameOfSubstance UI="D015283">Citalopram</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2014 Dec 24;6(268):268le5. doi: 10.1126/scitranslmed.3010053.</RefSource><PMID Version="1">25540322</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Sci Transl Med. 2014 Dec 24;6(268):268lr4. doi: 10.1126/scitranslmed.3010609.</RefSource><PMID Version="1">25540323</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008809" MajorTopicYN="N">Mice, Inbred C3H</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017551" MajorTopicYN="N">Microdialysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Selective Serotonin Reuptake Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing interests:</b> TW is an employee and has stock options in C2N Diagnostics LLC. MAM is an employee of Avid Radiopharmaceuticals. JCM has participated in or is participating in clinical trials of antidementia drugs sponsored by the companies Janssen Alzheimer Immunotherapy Program, Pfizer, and Eli Lilly/Avid Radiopharmaceuticals. JCM has served or is serving as a consultant or has received speaking honoraria for the company Lilly USA. Neither JCM nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company. The other authors declare no competing interests. TW is listed as an inventor on a patent related to this work: Title: Methods for measuring concentrations of biomolecules Publication #: WO2013082307 Application #: PCT/US2012/067110.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24828079</ArticleId><ArticleId IdType="mid">NIHMS648666</ArticleId><ArticleId IdType="pmc">PMC4269372</ArticleId><ArticleId IdType="doi">10.1126/scitranslmed.3008169</ArticleId><ArticleId IdType="pii">scitranslmed.3008169</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003 Aug;60:1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925369</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Science translational medicine. 2011 Apr 6;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JL, Morris JC. Tangles and plaques in nondemented aging and &#x201c;preclinical&#x201d; Alzheimer&#x2019;s disease. Ann Neurol. 1999 Mar;45:358.</Citation><ArticleIdList><ArticleId IdType="pubmed">10072051</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer&#x2019;s disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297:353.</Citation><ArticleIdList><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Clinical and Biomarker Changes in Dominantly Inherited Alzheimer&#x2019;s Disease. N Engl J Med. 2012 Jul 11;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011 Jun;14:750.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A, Teplow DB, Kirschner DA, Benedek GB. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Natl Acad Sci U S A. 1997 Jul 22;94:7942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC21534</ArticleId><ArticleId IdType="pubmed">9223292</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai H, Kosaka K, Iizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem. 1984 Aug;43:388.</Citation><ArticleIdList><ArticleId IdType="pubmed">6204013</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds GP, et al. 5-Hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. British journal of pharmacology. 1995 Mar;114:993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1510307</ArticleId><ArticleId IdType="pubmed">7780656</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjona AA, Pooler AM, Lee RK, Wurtman RJ. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Res. 2002 Sep 27;951:135.</Citation><ArticleIdList><ArticleId IdType="pubmed">12231467</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem. 1996 Feb 23;271:4188.</Citation><ArticleIdList><ArticleId IdType="pubmed">8626761</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert SJ, Zugaza JL, Fischmeister R, Gardier AM, Lezoualc&#x2019;h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J Biol Chem. 2001 Nov 30;276:44881.</Citation><ArticleIdList><ArticleId IdType="pubmed">11584021</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. Serotonin signaling is associated with lower amyloid-beta levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011 Sep 6;108:14968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="pubmed">21873225</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson RL, et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol. 2007 May;205:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1979096</ArticleId><ArticleId IdType="pubmed">17368447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009 Jul;66:48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008 Mar;22:659.</Citation><ArticleIdList><ArticleId IdType="pubmed">17942826</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani A, Furukawa T, Salanti G, Geddes J, Higgins J, Churchill R, Watanabe N, Nakagawa A, Omori I, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373:746&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">19185342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang JE, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009 Nov 13;326:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789838</ArticleId><ArticleId IdType="pubmed">19779148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006 Jul;12:856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007 Jun;18:997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040126</ArticleId><ArticleId IdType="pubmed">17383190</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP protects against Alzheimer&#x2019;s disease and age-related cognitive decline. Nature. 2012 Aug 2;488(7409):96&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15;64(6):527&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2597158</ArticleId><ArticleId IdType="pubmed">18571629</ArticleId></ArticleIdList></Reference><Reference><Citation>Malberg J, Eisch A, Nestler E, Duman R. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000 Dec 15;20(24):9104&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773038</ArticleId><ArticleId IdType="pubmed">11124987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempermann G, Kronenberg G. Depressed new neurons--adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol Psychiatry. 2003 Sep 1;54(5):499&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946878</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisch AJ, Petrik D. Depression and hippocampal neurogenesis: a road to remission? Science. 2012 Oct 5;338:72&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756889</ArticleId><ArticleId IdType="pubmed">23042885</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">23602950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lione A, Errico M, Lin S, Cowen D. Activation of extracellular signal-regulated kinase (ERK) and Akt by human serotonin 5-HT1B receptors in transfected BE(2)-C neuroblastoma cells is inhibited by RGS4. J Neurochem. 2000 Sep;75(3):934&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10936173</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson-Farley N, Kertesy S, Dubyak G, Cowen D. Enhanced activation of Akt and extracellular-regulated kinase pathways by simultaneous occupancy of Gq-coupled 5-HT2A receptors and Gs-coupled 5-HT7A receptors in PC12 cells. J Neurochem. 2005 Jan;92(1):72&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15606897</ArticleId></ArticleIdList></Reference><Reference><Citation>Norum J, Hart K, Levy F. Ras-dependent ERK activation by the human Gs-coupled serotonin receptors 5-HT4(b) and 5-HT7(a) J Biol Chem. 2003 Jan 31;278(5):3098&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446729</ArticleId></ArticleIdList></Reference><Reference><Citation>Cisse M, Duplan E, Guillot-Sestier MV, Rumigny J, Bauer C, Pages G, Orzechowski HD, Slack B, Checler F, Vincent B. The extracellular regulated kinase-1 (ERK1) controls regulated alpha-secretase-mediated processing, promoter transactivation, and mRNA levels of the cellular prion protein. J Biol Chem. 2011 Aug 19;286(33):29192&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3190726</ArticleId><ArticleId IdType="pubmed">21586567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 2006 Jan;20(1):157&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16293708</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan P, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci. 2009 Aug 26;29:10706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2756291</ArticleId><ArticleId IdType="pubmed">19710322</ArticleId></ArticleIdList></Reference><Reference><Citation>McConlogue L, et al. Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem. 2007 Sep 7;282:26326.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616527</ArticleId></ArticleIdList></Reference><Reference><Citation>Savonenko A, et al. Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer&#x2019;s disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis. 2005 Apr;18:602.</Citation><ArticleIdList><ArticleId IdType="pubmed">15755686</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci. 2003 Oct 1;23:8844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Klunk WE, et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol. 2002 Sep;61:797.</Citation><ArticleIdList><ArticleId IdType="pubmed">12230326</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, et al. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci U S A. 2012 Sep 18;109:15502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3458349</ArticleId><ArticleId IdType="pubmed">22927427</ArticleId></ArticleIdList></Reference><Reference><Citation>Diggle P, Heagerty P, Liang K, Zeger S. Analysis of Longitudinal Data. 2. Oxofrd Universal Press; New York: 2002.</Citation></Reference><Reference><Citation>Akaike H. A new look at the statistical model identification. IEEE Transactions on Automatic Control. 1974;19:716.</Citation></Reference><Reference><Citation>Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997 Sep;53:983.</Citation><ArticleIdList><ArticleId IdType="pubmed">9333350</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24828645</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>20</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>14</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Suppression of InsP3 receptor-mediated Ca2+ signaling alleviates mutant presenilin-linked familial Alzheimer's disease pathogenesis.</ArticleTitle><Pagination><StartPage>6910</StartPage><EndPage>6923</EndPage><MedlinePgn>6910-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5441-13.2014</ELocationID><Abstract><AbstractText>Exaggerated intracellular Ca(2+) signaling is a robust proximal phenotype observed in cells expressing familial Alzheimer's disease (FAD)-causing mutant presenilins (PSs). The mechanisms that underlie this phenotype are controversial and their in vivo relevance for AD pathogenesis is unknown. Here, we used a genetic approach to identify the mechanisms involved and to evaluate their role in the etiology of AD in two FAD mouse models. Genetic reduction of the type 1 inositol trisphosphate receptor (InsP3R1) by 50% normalized exaggerated Ca(2+) signaling observed in cortical and hippocampal neurons in both animal models. In PS1M146V knock-in mice, reduced InsP3R1 expression restored normal ryanodine receptor and cAMP response element-binding protein (CREB)-dependent gene expression and rescued aberrant hippocampal long-term potentiation (LTP). In 3xTg mice, reduced InsP3R1 expression profoundly attenuated amyloid &#x3b2; accumulation and tau hyperphosphorylation and rescued hippocampal LTP and memory deficits. These results indicate that exaggerated Ca(2+) signaling, which is associated with FAD PS, is mediated by InsP3R and contributes to disease pathogenesis in vivo. Targeting the InsP3 signaling pathway could be considered a potential therapeutic strategy for patients harboring mutations in PS linked to AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/346910-14$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shilling</LastName><ForeName>Dustin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xfc;ller</LastName><ForeName>Marioly</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics, Neurology, and Neuroscience, Perelman School of Medicine, University of Pennsylvania and the Division of Neurology and the Pediatric Regional Epilepsy Program, the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>Don-On Daniel</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abel</LastName><ForeName>Ted</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulter</LastName><ForeName>Douglas A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Departments of Pediatrics, Neurology, and Neuroscience, Perelman School of Medicine, University of Pennsylvania and the Division of Neurology and the Pediatric Regional Epilepsy Program, the Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foskett</LastName><ForeName>J Kevin</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Physiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104 foskett@mail.med.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 AG038240</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG038240</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH059937</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017362">Cyclic AMP Response Element-Binding Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053496">Inositol 1,4,5-Trisphosphate Receptors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019837">Ryanodine Receptor Calcium Release Channel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020013" MajorTopicYN="N">Calcium Signaling</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017362" MajorTopicYN="N">Cyclic AMP Response Element-Binding Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053496" MajorTopicYN="N">Inositol 1,4,5-Trisphosphate Receptors</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017774" MajorTopicYN="N">Long-Term Potentiation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019837" MajorTopicYN="N">Ryanodine Receptor Calcium Release Channel</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Mouse model</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">calcium</Keyword><Keyword MajorTopicYN="N">ion channel</Keyword><Keyword MajorTopicYN="N">memory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24828645</ArticleId><ArticleId IdType="pmc">PMC4019804</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5441-13.2014</ArticleId><ArticleId IdType="pii">JNEUROSCI.5441-13.2014</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Angehagen M, Margineanu DG, Ben-Menachem E, R&#xf6;nnb&#xe4;ck L, Hansson E, Klitgaard H. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003;14:471&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pubmed">12634506</ArticleId></ArticleIdList></Reference><Reference><Citation>Auffret A, Gautheron V, Mattson MP, Mariani J, Rovira C. Progressive age-related impairment of the late long-term potentiation in Alzheimer's disease presenilin-1 mutant knock-in mice. J Alzheimers Dis. 2010;19:1021&#x2013;1033. doi: 10.3233/JAD-2010-1302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1302</ArticleId><ArticleId IdType="pmc">PMC2891870</ArticleId><ArticleId IdType="pubmed">20157256</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE, Yassa MA, Bassett SS, Shelton AL, Gallagher M. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron. 2012;74:467&#x2013;474. doi: 10.1016/j.neuron.2012.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.03.023</ArticleId><ArticleId IdType="pmc">PMC3351697</ArticleId><ArticleId IdType="pubmed">22578498</ArticleId></ArticleIdList></Reference><Reference><Citation>Barco A, Alarcon JM, Kandel ER. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell. 2002;108:689&#x2013;703. doi: 10.1016/S0092-8674(02)00657-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(02)00657-8</ArticleId><ArticleId IdType="pubmed">11893339</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ. Neuronal calcium signaling. Neuron. 1998;21:13&#x2013;26. doi: 10.1016/S0896-6273(00)80510-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80510-3</ArticleId><ArticleId IdType="pubmed">9697848</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettens K, Sleegers K, Van Broeckhoven C. Genetic insights in Alzheimer's disease. Lancet Neurol. 2013;12:92&#x2013;104. doi: 10.1016/S1474-4422(12)70259-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70259-4</ArticleId><ArticleId IdType="pubmed">23237904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2012;33:1001.e1&#x2013;6. doi: 10.1016/j.neurobiolaging.2011.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.03.011</ArticleId><ArticleId IdType="pmc">PMC3160507</ArticleId><ArticleId IdType="pubmed">21531043</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, Stutzmann GE. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. PLoS One. 2012;7:e52056. doi: 10.1371/journal.pone.0052056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052056</ArticleId><ArticleId IdType="pmc">PMC3528716</ArticleId><ArticleId IdType="pubmed">23284867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Shineman D, M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron. 2008;58:871&#x2013;883. doi: 10.1016/j.neuron.2008.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.04.015</ArticleId><ArticleId IdType="pmc">PMC2495086</ArticleId><ArticleId IdType="pubmed">18579078</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung KH, Mei L, Mak DO, Hayashi I, Iwatsubo T, Kang DE, Foskett JK. Gain-of-function enhancement of IP3 receptor modal gating by familial Alzheimer's disease-linked presenilin mutants in human cells and mouse neurons. Sci Signal. 2010;3:ra22. doi: 10.1126/scisignal.2000818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2000818</ArticleId><ArticleId IdType="pmc">PMC2898196</ArticleId><ArticleId IdType="pubmed">20332427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron. 2005;48:913&#x2013;922. doi: 10.1016/j.neuron.2005.10.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2005.10.028</ArticleId><ArticleId IdType="pubmed">16364896</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis. 2007;28:76&#x2013;82. doi: 10.1016/j.nbd.2007.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2007.06.013</ArticleId><ArticleId IdType="pmc">PMC2756084</ArticleId><ArticleId IdType="pubmed">17659878</ArticleId></ArticleIdList></Reference><Reference><Citation>Demuro A, Parker I. Cytotoxicity of intracellular abeta42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate. J Neurosci. 2013;33:3824&#x2013;3833. doi: 10.1523/JNEUROSCI.4367-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4367-12.2013</ArticleId><ArticleId IdType="pmc">PMC3708452</ArticleId><ArticleId IdType="pubmed">23447594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickerson BC, Salat DH, Greve DN, Chua EF, Rand-Giovannetti E, Rentz DM, Bertram L, Mullin K, Tanzi RE, Blacker D, Albert MS, Sperling RA. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology. 2005;65:404&#x2013;411. doi: 10.1212/01.wnl.0000171450.97464.49.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000171450.97464.49</ArticleId><ArticleId IdType="pmc">PMC4335677</ArticleId><ArticleId IdType="pubmed">16087905</ArticleId></ArticleIdList></Reference><Reference><Citation>Etcheberrigaray R, Hirashima N, Nee L, Prince J, Govoni S, Racchi M, Tanzi RE, Alkon DL. Calcium responses in fibroblasts from asymptomatic members of Alzheimer's disease families. Neurobiol Dis. 1998;5:37&#x2013;45. doi: 10.1006/nbdi.1998.0176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1998.0176</ArticleId><ArticleId IdType="pubmed">9702786</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima H, Maeda R, Suzuki R, Suzuki A, Nomoto M, Toyoda H, Wu LJ, Xu H, Zhao MG, Ueda K, Kitamoto A, Mamiya N, Yoshida T, Homma S, Masushige S, Zhuo M, Kida S. Upregulation of calcium/calmodulin-dependent protein kinase IV improves memory formation and rescues memory loss with aging. J Neurosci. 2008;28:9910&#x2013;9919. doi: 10.1523/JNEUROSCI.2625-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2625-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671266</ArticleId><ArticleId IdType="pubmed">18829949</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuichi T, Simon-Chazottes D, Fujino I, Yamada N, Hasegawa M, Miyawaki A, Yoshikawa S, Gu&#xe9;net JL, Mikoshiba K. Widespread expression of inositol 1,4,5-trisphosphate receptor type 1 gene (Insp3r1) in the mouse central nervous system. Receptors Channels. 1993;1:11&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">8081710</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989;59:675&#x2013;680. doi: 10.1016/0092-8674(89)90013-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(89)90013-5</ArticleId><ArticleId IdType="pubmed">2573431</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Nat Med. 1999;5:101&#x2013;106. doi: 10.1038/4789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4789</ArticleId><ArticleId IdType="pubmed">9883847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartigan JA, Johnson GV. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J Biol Chem. 1999;274:21395&#x2013;21401. doi: 10.1074/jbc.274.30.21395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.30.21395</ArticleId><ArticleId IdType="pubmed">10409701</ArticleId></ArticleIdList></Reference><Reference><Citation>Honarnejad K, Herms J. Presenilins: role in calcium homeostasis. Int J Biochem Cell Biol. 2012;44:1983&#x2013;1986. doi: 10.1016/j.biocel.2012.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2012.07.019</ArticleId><ArticleId IdType="pubmed">22842534</ArticleId></ArticleIdList></Reference><Reference><Citation>Itkin A, Dupres V, Dufr&#xea;ne YF, Bechinger B, Ruysschaert JM, Raussens V. Calcium ions promote formation of amyloid beta-peptide (1&#x2013;40) oligomers causally implicated in neuronal toxicity of Alzheimer's disease. PLoS One. 2011;6:e18250. doi: 10.1371/journal.pone.0018250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018250</ArticleId><ArticleId IdType="pmc">PMC3065491</ArticleId><ArticleId IdType="pubmed">21464905</ArticleId></ArticleIdList></Reference><Reference><Citation>LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci. 2002;3:862&#x2013;872. doi: 10.1038/nrn960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn960</ArticleId><ArticleId IdType="pubmed">12415294</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008;89:312&#x2013;323. doi: 10.1016/j.nlm.2007.08.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nlm.2007.08.018</ArticleId><ArticleId IdType="pmc">PMC2387254</ArticleId><ArticleId IdType="pubmed">17942328</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthews RP, Guthrie CR, Wailes LM, Zhao X, Means AR, McKnight GS. Calcium/calmodulin-dependent protein kinase types II and IV differentially regulate CREB-dependent gene expression. Mol Cell Biol. 1994;14:6107&#x2013;6116. doi: 10.1128/MCB.14.9.6107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.14.9.6107</ArticleId><ArticleId IdType="pmc">PMC359137</ArticleId><ArticleId IdType="pubmed">8065343</ArticleId></ArticleIdList></Reference><Reference><Citation>Meberg PJ, Miller MW. Culturing hippocampal and cortical neurons. Methods in Cell Biol. 2003;71:111&#x2013;127. doi: 10.1016/S0091-679X(03)01007-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-679X(03)01007-0</ArticleId><ArticleId IdType="pubmed">12884689</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullane K, Williams M. Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol. 2013;85:289&#x2013;305. doi: 10.1016/j.bcp.2012.11.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2012.11.014</ArticleId><ArticleId IdType="pubmed">23178653</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, C&#xe1;rdenas C, Mei L, Cheung KH, Foskett JK. Constitutive cAMP response element binding protein (CREB) activation by Alzheimer's disease presenilin-driven inositol trisphosphate receptor (InsP3R) Ca2+ signaling. Proc Natl Acad Sci U S A. 2011;108:13293&#x2013;13298. doi: 10.1073/pnas.1109297108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1109297108</ArticleId><ArticleId IdType="pmc">PMC3156223</ArticleId><ArticleId IdType="pubmed">21784978</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase T, Ito KI, Kato K, Kaneko K, Kohda K, Matsumoto M, Hoshino A, Inoue T, Fujii S, Kato H, Mikoshiba K. Long-term potentiation and long-term depression in hippocampal CA1 neurons of mice lacking the IP(3) type 1 receptor. Neuroscience. 2003;117:821&#x2013;830. doi: 10.1016/S0306-4522(02)00803-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(02)00803-5</ArticleId><ArticleId IdType="pubmed">12654335</ArticleId></ArticleIdList></Reference><Reference><Citation>Namiki S, Sasaki T, Matsuki N, Ikegaya Y. Regional difference in stainability with calcium-sensitive acetoxymethyl-ester probes in mouse brain slices. Int J Neurosci. 2009;119:214&#x2013;226. doi: 10.1080/00207450802330819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207450802330819</ArticleId><ArticleId IdType="pubmed">19125375</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF, Duff K. Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003;38:555&#x2013;565. doi: 10.1016/S0896-6273(03)00259-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00259-9</ArticleId><ArticleId IdType="pubmed">12765608</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409&#x2013;421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira AM, Hawk JD, Abel T, Havekes R. Post-training reversible inactivation of the hippocampus enhances novel object recognition memory. Learn Mem. 2010;17:155&#x2013;160. doi: 10.1101/lm.1625310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.1625310</ArticleId><ArticleId IdType="pmc">PMC2832924</ArticleId><ArticleId IdType="pubmed">20189960</ArticleId></ArticleIdList></Reference><Reference><Citation>Oul&#xe8;s B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Br&#xe9;chot P, Trebak M, Checler F, Benfenati F, Chami M. Ryanodine receptor blockade reduces amyloid-beta load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci. 2012;32:11820&#x2013;11834. doi: 10.1523/JNEUROSCI.0875-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0875-12.2012</ArticleId><ArticleId IdType="pmc">PMC3458216</ArticleId><ArticleId IdType="pubmed">22915123</ArticleId></ArticleIdList></Reference><Reference><Citation>Raymond CR, Redman SJ. Spatial segregation of neuronal calcium signals encodes different forms of LTP in rat hippocampus. J Physiol. 2006;570:97&#x2013;111. doi: 10.1113/jphysiol.2005.098947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2005.098947</ArticleId><ArticleId IdType="pmc">PMC1464297</ArticleId><ArticleId IdType="pubmed">16284072</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, Jimenez-Del-Rio M, Fagan AM, Shah AR, Alvarez S, Arbelaez A, Giraldo M, Acosta-Baena N, Sperling RA, Dickerson B, Stern CE, Tirado V, Munoz C, Reiman RA, Huentelman MJ, Alexander GE, Langbaum JB, Kosik KS, Tariot PN, Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012;11:1048&#x2013;1056. doi: 10.1016/S1474-4422(12)70228-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(12)70228-4</ArticleId><ArticleId IdType="pmc">PMC4181671</ArticleId><ArticleId IdType="pubmed">23137948</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A. 2012;109:E2895&#x2013;2903. doi: 10.1073/pnas.1121081109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1121081109</ArticleId><ArticleId IdType="pmc">PMC3479491</ArticleId><ArticleId IdType="pubmed">22869752</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, Moechars D, Van Leuven F, Herms J. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. J Biol Chem. 2001;276:11539&#x2013;11544. doi: 10.1074/jbc.M010977200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M010977200</ArticleId><ArticleId IdType="pubmed">11278803</ArticleId></ArticleIdList></Reference><Reference><Citation>Selbert MA, Anderson KA, Huang QH, Goldstein EG, Means AR, Edelman AM. Phosphorylation and activation of Ca2+-calmodulin-dependent protein kinase IV by Ca2+-calmodulin-dependent protein kinase Ia kinase. Phosphorylation of threonine 196 is essential for activation. J Biol Chem. 1995;270:17616&#x2013;17621. doi: 10.1074/jbc.270.29.17616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.29.17616</ArticleId><ArticleId IdType="pubmed">7615569</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem. 2005;94:1711&#x2013;1718. doi: 10.1111/j.1471-4159.2005.03332.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03332.x</ArticleId><ArticleId IdType="pubmed">16156741</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist. 2010;16:435&#x2013;452. doi: 10.1177/1073858410366481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858410366481</ArticleId><ArticleId IdType="pubmed">20817920</ArticleId></ArticleIdList></Reference><Reference><Citation>Street VA, Bosma MM, Demas VP, Regan MR, Lin DD, Robinson LC, Agnew WS, Tempel BL. The type 1 inositol 1,4,5-trisphosphate receptor gene is altered in the opisthotonos mouse. J Neurosci. 1997;17:635&#x2013;645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573232</ArticleId><ArticleId IdType="pubmed">8987786</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Caccamo A, LaFerla FM, Parker I. Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci. 2004;24:508&#x2013;513. doi: 10.1523/JNEUROSCI.4386-03.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4386-03.2004</ArticleId><ArticleId IdType="pmc">PMC6729995</ArticleId><ArticleId IdType="pubmed">14724250</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci. 2006;26:5180&#x2013;5189. doi: 10.1523/JNEUROSCI.0739-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0739-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674246</ArticleId><ArticleId IdType="pubmed">16687509</ArticleId></ArticleIdList></Reference><Reference><Citation>Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, Laferla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. Ann N Y Acad Sci. 2007;1097:265&#x2013;277. doi: 10.1196/annals.1379.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1379.025</ArticleId><ArticleId IdType="pubmed">17413028</ArticleId></ArticleIdList></Reference><Reference><Citation>Taufiq AM, Fujii S, Yamazaki Y, Sasaki H, Kaneko K, Li J, Kato H, Mikoshiba K. Involvement of IP3 receptors in LTP and LTD induction in guinea pig hippocampal CA1 neurons. Learn Mem. 2005;12:594&#x2013;600. doi: 10.1101/lm.17405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/lm.17405</ArticleId><ArticleId IdType="pmc">PMC1356177</ArticleId><ArticleId IdType="pubmed">16287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging. 2008;29:1607&#x2013;1618. doi: 10.1016/j.neurobiolaging.2007.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.04.014</ArticleId><ArticleId IdType="pmc">PMC2664168</ArticleId><ArticleId IdType="pubmed">17544172</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BM. Histone acetylation as an epigenetic determinant of long-term transcriptional competence. Cell Mol Life Sci. 1998;54:21&#x2013;31. doi: 10.1007/s000180050122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s000180050122</ArticleId><ArticleId IdType="pmc">PMC11147230</ArticleId><ArticleId IdType="pubmed">9487384</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535&#x2013;539. doi: 10.1038/416535a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416535a</ArticleId><ArticleId IdType="pubmed">11932745</ArticleId></ArticleIdList></Reference><Reference><Citation>Wimmer ME, Hernandez PJ, Blackwell J, Abel T. Aging impairs hippocampus-dependent long-term memory for object location in mice. Neurobiol Aging. 2012;33:2220&#x2013;2224. doi: 10.1016/j.neurobiolaging.2011.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.07.007</ArticleId><ArticleId IdType="pmc">PMC3227775</ArticleId><ArticleId IdType="pubmed">21872364</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Lee EB, Sun E, Wong MM, Leight S, Zhang B, Trojanowski JQ, Lee VM. Intraneuronal APP, not free Abeta peptides in 3xTg-AD mice: implications for tau versus Abeta-mediated Alzheimer neurodegeneration. J Neurosci. 2011;31:7691&#x2013;7699. doi: 10.1523/JNEUROSCI.6637-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.6637-10.2011</ArticleId><ArticleId IdType="pmc">PMC3118598</ArticleId><ArticleId IdType="pubmed">21613482</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods NK, Padmanabhan J. Neuronal calcium signaling and Alzheimer's disease. Adv Exp Med Biol. 2012;740:1193&#x2013;1217. doi: 10.1007/978-94-007-2888-2_54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-94-007-2888-2_54</ArticleId><ArticleId IdType="pubmed">22453989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin JC, Tully T. CREB and the formation of long-term memory. Curr Opin Neurobiol. 1996;6:264&#x2013;268. doi: 10.1016/S0959-4388(96)80082-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0959-4388(96)80082-1</ArticleId><ArticleId IdType="pubmed">8725970</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24835997</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-1247</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>12</Day></PubDate></JournalIssue><Title>Cell reports</Title><ISOAbbreviation>Cell Rep</ISOAbbreviation></Journal><ArticleTitle>APP homodimers transduce an amyloid-&#x3b2;-mediated increase in release probability at excitatory synapses.</ArticleTitle><Pagination><StartPage>1560</StartPage><EndPage>1576</EndPage><MedlinePgn>1560-1576</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.celrep.2014.04.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2211-1247(14)00326-X</ELocationID><Abstract><AbstractText>Accumulation of amyloid-&#x3b2; peptides (A&#x3b2;), the proteolytic products of the amyloid precursor protein (APP), induces a variety of synaptic dysfunctions ranging from hyperactivity to depression that are thought to cause cognitive decline in Alzheimer's disease. While depression of synaptic transmission has been extensively studied, the mechanisms underlying synaptic hyperactivity remain unknown. Here, we show that A&#x3b2;40 monomers and dimers augment release probability through local fine-tuning of APP-APP interactions at excitatory hippocampal boutons. A&#x3b2;40 binds to the APP, increases the APP homodimer fraction at the plasma membrane, and promotes APP-APP interactions. The APP activation induces structural rearrangements in the APP/Gi/o-protein complex, boosting presynaptic calcium flux and vesicle release. The APP growth-factor-like domain (GFLD) mediates APP-APP conformational changes and presynaptic enhancement. Thus, the APP homodimer constitutes a presynaptic receptor that transduces signal from A&#x3b2;40 to glutamate release. Excessive APP activation may initiate a positive feedback loop, contributing to hippocampal hyperactivity in Alzheimer's disease.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fogel</LastName><ForeName>Hilla</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frere</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segev</LastName><ForeName>Oshik</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bharill</LastName><ForeName>Shashank</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shapira</LastName><ForeName>Ilana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gazit</LastName><ForeName>Neta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Tiernan</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin 4, Republic of Ireland; Laboratory for Neurodegenerative Research, Center for Neurologic Diseases, Brigham &amp; Women's Hospital, Harvard Institutes of Medicine, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slomowitz</LastName><ForeName>Edden</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berdichevsky</LastName><ForeName>Yevgeny</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walsh</LastName><ForeName>Dominic M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Laboratory for Neurodegenerative Research, Center for Neurologic Diseases, Brigham &amp; Women's Hospital, Harvard Institutes of Medicine, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isacoff</LastName><ForeName>Ehud Y</ForeName><Initials>EY</Initials><AffiliationInfo><Affiliation>Department of Molecular and Cell Biology and Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA 94720, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirsch</LastName><ForeName>Joel A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences, Tel Aviv University, 69978 Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel; Sagol School of Neuroscience, Tel Aviv University, 69978 Tel Aviv, Israel. Electronic address: islutsky@post.tau.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS35549</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep</MedlineTA><NlmUniqueID>101573691</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.5.1</RegistryNumber><NameOfSubstance UI="D019206">GTP-Binding Protein alpha Subunits, Gi-Go</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019206" MajorTopicYN="N">GTP-Binding Protein alpha Subunits, Gi-Go</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055503" MajorTopicYN="Y">Protein Multimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009435" MajorTopicYN="Y">Synaptic Transmission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24835997</ArticleId><ArticleId IdType="doi">10.1016/j.celrep.2014.04.024</ArticleId><ArticleId IdType="pii">S2211-1247(14)00326-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24842955</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-8561</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical chemistry</Title><ISOAbbreviation>Clin Chem</ISOAbbreviation></Journal><ArticleTitle>Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-&#x3b2; in cerebrospinal fluid.</ArticleTitle><Pagination><StartPage>987</StartPage><EndPage>994</EndPage><MedlinePgn>987-94</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1373/clinchem.2013.220392</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cerebrospinal fluid (CSF) amyloid-&#x3b2; (A&#x3b2;42) is a well-established biomarker for Alzheimer disease. Several immunoassays for A&#x3b2;42 exist but differ in absolute concentrations and may suffer from matrix interference, thereby hampering interlaboratory comparisons and the use of general cutoff levels. Together with the IFCC Working Group on CSF Proteins, we developed a candidate reference measurement procedure (RMP) for A&#x3b2;42.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The antibody-independent candidate RMP was based on solid-phase extraction and isotope-dilution LC-MS/MS. The candidate RMP used 2 differently stable isotope-labeled A&#x3b2;42 peptides for calibration in human CSF, an important aspect since there was no analyte-free matrix available. Because no CSF certified reference material (CRM) exists, we used a nonlabeled A&#x3b2;42 standard, the concentration of which was determined by amino acid analysis. We performed measurements on a high-resolution quadrupole-Orbitrap hybrid instrument. The results were compared with a method run in a second laboratory with triple quadrupole instrumentation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The candidate RMP allowed quantification of CSF A&#x3b2;42 from 150 to 4000 pg/mL. Validation of the method showed a recovery of 100% (15%), intraassay and interassay imprecision of 5.0% and 6.4%, respectively, and an expanded uncertainty of 15.7%. No analytical interferences or carryover were detected.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This method will help set the value of CSF A&#x3b2;42 in a CRM, which could be used to harmonize A&#x3b2;42 assays and facilitate the introduction of general cutoff concentrations for CSF A&#x3b2;42 in clinical trials and practice.</AbstractText><CopyrightInformation>&#xa9; 2014 The American Association for Clinical Chemistry.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leinenbach</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pannee</LastName><ForeName>Josef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;lffer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner</LastName><ForeName>Tobias</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreasson</LastName><ForeName>Ulf</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gobom</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zetterberg</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden; UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobold</LastName><ForeName>Uwe</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Roche Diagnostics GmbH, Penzberg, Germany;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portelius</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden;</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Salgrenska Academy, University of Gothenburg, M&#xf6;lndal, Sweden; kaj.blennow@neuro.gu.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>IFCC Scientific Division Working Group on CSF proteins</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Chem</MedlineTA><NlmUniqueID>9421549</NlmUniqueID><ISSNLinking>0009-9147</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009587">Nitrogen Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002138" MajorTopicYN="N">Calibration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009587" MajorTopicYN="N">Nitrogen Isotopes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012015" MajorTopicYN="N">Reference Standards</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24842955</ArticleId><ArticleId IdType="doi">10.1373/clinchem.2013.220392</ArticleId><ArticleId IdType="pii">clinchem.2013.220392</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24849360</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>21</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Anti-ApoE antibody given after plaque onset decreases A&#x3b2; accumulation and improves brain function in a mouse model of A&#x3b2; amyloidosis.</ArticleTitle><Pagination><StartPage>7281</StartPage><EndPage>7292</EndPage><MedlinePgn>7281-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0646-14.2014</ELocationID><Abstract><AbstractText>Apolipoprotein E (apoE) is the strongest known genetic risk factor for late onset Alzheimer's disease (AD). It influences amyloid-&#x3b2; (A&#x3b2;) clearance and aggregation, which likely contributes in large part to its role in AD pathogenesis. We recently found that HJ6.3, a monoclonal antibody against apoE, significantly reduced A&#x3b2; plaque load when given to APPswe/PS1&#x394;E9 (APP/PS1) mice starting before the onset of plaque deposition. To determine whether the anti-apoE antibody HJ6.3 affects A&#x3b2; plaques, neuronal network function, and behavior in APP/PS1 mice after plaque onset, we administered HJ6.3 (10 mg/kg/week) or PBS intraperitoneally to 7-month-old APP/PS1 mice for 21 weeks. HJ6.3 mildly improved spatial learning performance in the water maze, restored resting-state functional connectivity, and modestly reduced brain A&#x3b2; plaque load. There was no effect of HJ6.3 on total plasma cholesterol or cerebral amyloid angiopathy. To investigate the underlying mechanisms of anti-apoE immunotherapy, HJ6.3 was applied to the brain cortical surface and amyloid deposition was followed over 2 weeks using in vivo imaging. Acute exposure to HJ6.3 affected the course of amyloid deposition in that it prevented the formation of new amyloid deposits, limited their growth, and was associated with occasional clearance of plaques, a process likely associated with direct binding to amyloid aggregates. Topical application of HJ6.3 for only 14 d also decreased the density of amyloid plaques assessed postmortem. Collectively, these studies suggest that anti-apoE antibodies have therapeutic potential when given before or after the onset of A&#x3b2; pathology.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/347281-12$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hori</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudry</LastName><ForeName>Eloise</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Adam Q</ForeName><Initials>AQ</Initials><AffiliationInfo><Affiliation>Department of Radiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lefton</LastName><ForeName>Katheryn B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tony J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dearborn</LastName><ForeName>Joshua T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jungsu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic College of Medicine, Jacksonville, Florida 32224, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Culver</LastName><ForeName>Joseph P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Radiology, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betensky</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Harvard School of Public Health, Boston, Massachusetts 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>David F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Hope Center for Neurological Disorders, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, The Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyman</LastName><ForeName>Bradley T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, holtzman@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AG062421</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG047644</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG13956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078223</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AG013956</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG005134</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508853">PSEN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>97C5T2UQ7J</RegistryNumber><NameOfSubstance UI="D002784">Cholesterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000686" MajorTopicYN="N">Amyloidosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002784" MajorTopicYN="N">Cholesterol</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007794" MajorTopicYN="N">Lameness, Animal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">antibody</Keyword><Keyword MajorTopicYN="N">apolipoprotein E</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24849360</ArticleId><ArticleId IdType="pmc">PMC4028501</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0646-14.2014</ArticleId><ArticleId IdType="pii">34/21/7281</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashford JW. ApoE4: is it the absence of good or the presence of bad? J Alzheimers Dis. 2002;4:141&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226532</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab. 2002;22:1035&#x2013;1041. doi: 10.1097/00004647-200209000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-200209000-00001</ArticleId><ArticleId IdType="pubmed">12218409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 1999;96:15233&#x2013;15238. doi: 10.1073/pnas.96.26.15233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.26.15233</ArticleId><ArticleId IdType="pmc">PMC24803</ArticleId><ArticleId IdType="pubmed">10611368</ArticleId></ArticleIdList></Reference><Reference><Citation>Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916&#x2013;919. doi: 10.1038/78682.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78682</ArticleId><ArticleId IdType="pubmed">10932230</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinson H, Michaelson DM. Pathological synergism between amyloid-beta and apolipoprotein E4&#x2013;the most prevalent yet understudied genetic risk factor for Alzheimer's disease. J Alzheimers Dis. 2009;17:469&#x2013;481. doi: 10.3233/JAD-2009-1065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1065</ArticleId><ArticleId IdType="pubmed">19363257</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, Lee JM, Holtzman DM. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci. 2011;14:750&#x2013;756. doi: 10.1038/nn.2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2801</ArticleId><ArticleId IdType="pmc">PMC3102784</ArticleId><ArticleId IdType="pubmed">21532579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bero AW, Bauer AQ, Stewart FR, White BR, Cirrito JR, Raichle ME, Culver JP, Holtzman DM. Bidirectional relationship between functional connectivity and amyloid-beta deposition in mouse brain. J Neurosci. 2012;32:4334&#x2013;4340. doi: 10.1523/JNEUROSCI.5845-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5845-11.2012</ArticleId><ArticleId IdType="pmc">PMC3326343</ArticleId><ArticleId IdType="pubmed">22457485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bien-Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32:4803&#x2013;4811. doi: 10.1523/JNEUROSCI.0033-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0033-12.2012</ArticleId><ArticleId IdType="pmc">PMC3433173</ArticleId><ArticleId IdType="pubmed">22492035</ArticleId></ArticleIdList></Reference><Reference><Citation>Brody DL, Holtzman DM. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci. 2008;31:175&#x2013;193. doi: 10.1146/annurev.neuro.31.060407.125529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.060407.125529</ArticleId><ArticleId IdType="pmc">PMC2561172</ArticleId><ArticleId IdType="pubmed">18352830</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med. 2011;3:89ra57. doi: 10.1126/scitranslmed.3002156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002156</ArticleId><ArticleId IdType="pmc">PMC3192364</ArticleId><ArticleId IdType="pubmed">21715678</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, West T, Paoletti AC, Kasper TR, DeMattos RB, Zlokovic BV, Holtzman DM. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Abeta clearance in a mouse model of beta-amyloidosis. Proc Natl Acad Sci U S A. 2012;109:15502&#x2013;15507. doi: 10.1073/pnas.1206446109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1206446109</ArticleId><ArticleId IdType="pmc">PMC3458349</ArticleId><ArticleId IdType="pubmed">22927427</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7:180&#x2013;184. doi: 10.1038/ng0694-180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0694-180</ArticleId><ArticleId IdType="pubmed">7920638</ArticleId></ArticleIdList></Reference><Reference><Citation>Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002&#x2013;4013. doi: 10.1172/JCI36663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI36663</ArticleId><ArticleId IdType="pmc">PMC2582453</ArticleId><ArticleId IdType="pubmed">19033669</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264&#x2013;2267. doi: 10.1126/science.1067568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067568</ArticleId><ArticleId IdType="pubmed">11910111</ArticleId></ArticleIdList></Reference><Reference><Citation>Demattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76:908&#x2013;920. doi: 10.1016/j.neuron.2012.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.10.029</ArticleId><ArticleId IdType="pubmed">23217740</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Marr RA, Koistinaho M, Gregersen BM, Malkani S, Verma IM, Paul SM. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2005;102:1211&#x2013;1216. doi: 10.1073/pnas.0409072102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0409072102</ArticleId><ArticleId IdType="pmc">PMC544620</ArticleId><ArticleId IdType="pubmed">15657137</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Cronican A, Pham T, Fogg A, Fauq AH, Chapman R, Lefterov I, Koldamova R. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci. 2010;30:6862&#x2013;6872. doi: 10.1523/JNEUROSCI.1051-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1051-10.2010</ArticleId><ArticleId IdType="pmc">PMC2883862</ArticleId><ArticleId IdType="pubmed">20484628</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, Raichle ME. The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc Natl Acad Sci U S A. 2005;102:9673&#x2013;9678. doi: 10.1073/pnas.0504136102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0504136102</ArticleId><ArticleId IdType="pmc">PMC1157105</ArticleId><ArticleId IdType="pubmed">15976020</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin KB, Paxinos G. The mouse brain in stereotaxic coordinates. Ed 1. San Diego: Academic; 1996.</Citation></Reference><Reference><Citation>Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. J Neurosci. 2003;23:7889&#x2013;7896.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740607</ArticleId><ArticleId IdType="pubmed">12944519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353&#x2013;356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000;47:739&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10852539</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1. doi: 10.1126/scitranslmed.3002369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3002369</ArticleId><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudry E, Dashkoff J, Roe AD, Takeda S, Koffie RM, Hashimoto T, Scheel M, Spires-Jones T, Arbel-Ornath M, Betensky R, Davidson BL, Hyman BT. Gene transfer of human apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5:212ra161. doi: 10.1126/scitranslmed.3007000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3007000</ArticleId><ArticleId IdType="pmc">PMC4334150</ArticleId><ArticleId IdType="pubmed">24259049</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, Younkin LH, Wagner SL, Younkin SG, Borchelt DR. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004;13:159&#x2013;170. doi: 10.1093/hmg/ddh019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693. doi: 10.1016/j.neuron.2008.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.04.010</ArticleId><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron. 2009;64:632&#x2013;644. doi: 10.1016/j.neuron.2009.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.11.013</ArticleId><ArticleId IdType="pmc">PMC2787195</ArticleId><ArticleId IdType="pubmed">20005821</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-beta amyloidosis. J Neurosci. 2011;31:18007&#x2013;18012. doi: 10.1523/JNEUROSCI.3773-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3773-11.2011</ArticleId><ArticleId IdType="pmc">PMC3257514</ArticleId><ArticleId IdType="pubmed">22159114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM, Holtzman DM. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta amyloidosis. J Exp Med. 2012;209:2149&#x2013;2156. doi: 10.1084/jem.20121274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20121274</ArticleId><ArticleId IdType="pmc">PMC3501350</ArticleId><ArticleId IdType="pubmed">23129750</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005;280:4079&#x2013;4088. doi: 10.1074/jbc.M411420200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M411420200</ArticleId><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol. 2010;6:108&#x2013;119. doi: 10.1038/nrneurol.2009.219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2009.219</ArticleId><ArticleId IdType="pmc">PMC2864089</ArticleId><ArticleId IdType="pubmed">20140000</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B, Wang K, Gao HM, Mandavilli B, Wang JY, Hong JS. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J Neurochem. 2001;77:182&#x2013;189. doi: 10.1046/j.1471-4159.2001.t01-1-00216.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.t01-1-00216.x</ArticleId><ArticleId IdType="pubmed">11279274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma J, Yee A, Brewer HB, Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature. 1994;372:92&#x2013;94. doi: 10.1038/372092a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/372092a0</ArticleId><ArticleId IdType="pubmed">7969426</ArticleId></ArticleIdList></Reference><Reference><Citation>Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991;541:163&#x2013;166. doi: 10.1016/0006-8993(91)91092-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(91)91092-F</ArticleId><ArticleId IdType="pubmed">2029618</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science. 2002;298:1379. doi: 10.1126/science.1078259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1078259</ArticleId><ArticleId IdType="pubmed">12434053</ArticleId></ArticleIdList></Reference><Reference><Citation>Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci. 2005;25:629&#x2013;636. doi: 10.1523/JNEUROSCI.4337-04.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4337-04.2005</ArticleId><ArticleId IdType="pmc">PMC6725332</ArticleId><ArticleId IdType="pubmed">15659599</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadowski MJ, Pankiewicz J, Scholtzova H, Mehta PD, Prelli F, Quartermain D, Wisniewski T. Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A. 2006;103:18787&#x2013;18792. doi: 10.1073/pnas.0604011103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0604011103</ArticleId><ArticleId IdType="pmc">PMC1654132</ArticleId><ArticleId IdType="pubmed">17116874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173&#x2013;177. doi: 10.1038/22124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/22124</ArticleId><ArticleId IdType="pubmed">10408445</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287. doi: 10.1523/JNEUROSCI.1879-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1879-05.2005</ArticleId><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993a;90:1977&#x2013;1981. doi: 10.1073/pnas.90.5.1977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.1977</ArticleId><ArticleId IdType="pmc">PMC46003</ArticleId><ArticleId IdType="pubmed">8446617</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993b;90:8098&#x2013;8102. doi: 10.1073/pnas.90.17.8098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.17.8098</ArticleId><ArticleId IdType="pmc">PMC47295</ArticleId><ArticleId IdType="pubmed">8367470</ArticleId></ArticleIdList></Reference><Reference><Citation>Teter B, Raber J, Nathan B, Crutcher KA. The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J Alzheimers Dis. 2002;4:155&#x2013;163.</Citation><ArticleIdList><ArticleId IdType="pubmed">12226534</ArticleId></ArticleIdList></Reference><Reference><Citation>Thal DR, Capetillo-Zarate E, Schultz C, R&#xfc;b U, Saido TC, Yamaguchi H, Haass C, Griffin WS, Del Tredici K, Braak H, Ghebremedhin E. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. Acta Neuropathol. 2005;110:459&#x2013;471. doi: 10.1007/s00401-005-1053-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-005-1053-1</ArticleId><ArticleId IdType="pubmed">16195918</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Bardgett ME, Wong M, Wozniak DF, Lou J, McNeil BD, Chen C, Nardi A, Reid DC, Yamada K, Ornitz DM. Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron. 2002;35:25&#x2013;38. doi: 10.1016/S0896-6273(02)00744-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00744-4</ArticleId><ArticleId IdType="pubmed">12123606</ArticleId></ArticleIdList></Reference><Reference><Citation>White BR, Snyder AZ, Cohen AL, Petersen SE, Raichle ME, Schlaggar BL, Culver JP. Resting-state functional connectivity in the human brain revealed with diffuse optical tomography. Neuroimage. 2009;47:148&#x2013;156. doi: 10.1016/j.neuroimage.2009.03.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2009.03.058</ArticleId><ArticleId IdType="pmc">PMC2699418</ArticleId><ArticleId IdType="pubmed">19344773</ArticleId></ArticleIdList></Reference><Reference><Citation>White BR, Bauer AQ, Snyder AZ, Schlaggar BL, Lee JM, Culver JP. Imaging of functional connectivity in the mouse brain. PLoS One. 2011;6:e16322. doi: 10.1371/journal.pone.0016322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016322</ArticleId><ArticleId IdType="pmc">PMC3024435</ArticleId><ArticleId IdType="pubmed">21283729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci. 2003;23:3745&#x2013;3751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742181</ArticleId><ArticleId IdType="pubmed">12736345</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004a;1:24. doi: 10.1186/1742-2094-1-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-1-24</ArticleId><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN, Morgan D. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci. 2004b;24:6144&#x2013;6151. doi: 10.1523/JNEUROSCI.1090-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1090-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729674</ArticleId><ArticleId IdType="pubmed">15240806</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisniewski T, Casta&#xf1;o EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1887417</ArticleId><ArticleId IdType="pubmed">7977635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wozniak DF, Hartman RE, Boyle MP, Vogt SK, Brooks AR, Tenkova T, Young C, Olney JW, Muglia LJ. Apoptotic neurodegeneration induced by ethanol in neonatal mice is associated with profound learning/memory deficits in juveniles followed by progressive functional recovery in adults. Neurobiol Dis. 2004;17:403&#x2013;414. doi: 10.1016/j.nbd.2004.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.08.006</ArticleId><ArticleId IdType="pubmed">15571976</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada K, Yabuki C, Seubert P, Schenk D, Hori Y, Ohtsuki S, Terasaki T, Hashimoto T, Iwatsubo T. Abeta immunotherapy: intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci. 2009;29:11393&#x2013;11398. doi: 10.1523/JNEUROSCI.2021-09.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2021-09.2009</ArticleId><ArticleId IdType="pmc">PMC6665926</ArticleId><ArticleId IdType="pubmed">19741145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A. 2007;104:10601&#x2013;10606. doi: 10.1073/pnas.0701096104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0701096104</ArticleId><ArticleId IdType="pmc">PMC1890560</ArticleId><ArticleId IdType="pubmed">17563384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24849361</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>21</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Reversal of apoE4-driven brain pathology and behavioral deficits by bexarotene.</ArticleTitle><Pagination><StartPage>7293</StartPage><EndPage>7301</EndPage><MedlinePgn>7293-301</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.5198-13.2014</ELocationID><Abstract><AbstractText>Apolipoprotein E4 (apoE4), the most prevalent genetic risk factor for Alzheimer's disease (AD), is less lipidated than its corresponding AD-benign form, apoE3, and it has been suggested that the pathological effects of apoE4 are mediated by lipid-related mechanisms. ATP-binding cassette transporters A1 and G1 (ABCA1 and ABCG1, respectively) are the most important apoE-lipidating proteins. The expression of these proteins, as well as that of apoE, is controlled by the transcription regulation retinoid X receptor (RXR)-liver X receptor (LXR) system. In the present study, we investigated the effects of the RXR agonist bexarotene on mRNA and protein levels of apoE, ABCA1, and ABCG1 in young, naive apoE3- and apoE4-targeted replacement mice and assessed the extent to which this reverses the apoE4-driven pathological phenotype. This investigation reveled that bexarotene increases the mRNA and protein levels of ABCA1 and ABCG1 in hippocampal neurons, but has no effect on the corresponding levels of apoE. These findings were associated with reversal of the lipidation deficiency of apoE4 and of the cognitive impairments of apoE4 mice in several tests. Furthermore, bexarotene reversed the apoE4-driven accumulation of A&#x3b2;42 and hyperphosphorylated tau in hippocampal neurons, as well as the apoE4-induced reduction in the levels of the presynaptic marker vesicular glutamatergic transporter 1 (VGluT1). In conclusion, the results show that treatment of apoE4 mice with the RXR agonist bexarotene reverses the apoE4-induced cognitive and neuronal impairments in vivo and suggest that this is due to reversal of the lipidation deficiency of apoE4. This puts forward the possibility that RXR activation and increased levels of ABCA1 and ABCG1 could be useful in the treatment of human apoE4 carriers.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/347293-09$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boehm-Cagan</LastName><ForeName>Anat</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of the Neurobiology, The George S. Wise Faculty of Life Sciences, The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 69978, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaelson</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of the Neurobiology, The George S. Wise Faculty of Life Sciences, The Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 69978, Israel dmichael@post.tau.ac.il.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C487540">ABCG1 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064286">ATP Binding Cassette Transporter 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000070998">ATP Binding Cassette Transporter, Subfamily G, Member 1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018528">ATP-Binding Cassette Transporters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016588">Anticarcinogenic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001057">Apolipoproteins E</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008074">Lipoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013764">Tetrahydronaphthalenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical><Chemical><RegistryNumber>A61RXM4375</RegistryNumber><NameOfSubstance UI="D000077610">Bexarotene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D064286" MajorTopicYN="N">ATP Binding Cassette Transporter 1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000070998" MajorTopicYN="N">ATP Binding Cassette Transporter, Subfamily G, Member 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018528" MajorTopicYN="N">ATP-Binding Cassette Transporters</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016588" MajorTopicYN="N">Anticarcinogenic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001057" MajorTopicYN="N">Apolipoproteins E</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077610" MajorTopicYN="N">Bexarotene</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008074" MajorTopicYN="N">Lipoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021641" MajorTopicYN="N">Recognition, Psychology</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013764" MajorTopicYN="N">Tetrahydronaphthalenes</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ABCA1</Keyword><Keyword MajorTopicYN="N">ABCG1</Keyword><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">ApoE4</Keyword><Keyword MajorTopicYN="N">apoE-targeted mice</Keyword><Keyword MajorTopicYN="N">bexarotene</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>11</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24849361</ArticleId><ArticleId IdType="pmc">PMC6608187</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.5198-13.2014</ArticleId><ArticleId IdType="pii">34/21/7293</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bachmeier C, Beaulieu-Abdelahad D, Crawford F, Mullan M, Paris D. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier. J Mol Neurosci. 2013;49:270&#x2013;276. doi: 10.1007/s12031-012-9866-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-012-9866-6</ArticleId><ArticleId IdType="pubmed">22890420</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinson H, Michaelson DM. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. J Neural Transm. 2009;116:1427&#x2013;1434. doi: 10.1007/s00702-009-0218-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-009-0218-9</ArticleId><ArticleId IdType="pubmed">19370389</ArticleId></ArticleIdList></Reference><Reference><Citation>Belinson H, Lev D, Masliah E, Michaelson DM. Activation of the amyloid cascade in apolipoprotein E4 transgenic mice induces lysosomal activation and neurodegeneration resulting in marked cognitive deficits. J Neurosci. 2008;28:4690&#x2013;4701. doi: 10.1523/JNEUROSCI.5633-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5633-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844816</ArticleId><ArticleId IdType="pubmed">18448646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedazo-M&#xed;nguez A, Popescu BO, Blanco-Mill&#xe1;n JM, Akterin S, Pei JJ, Winblad B, Cowburn RF. Apolipoprotein E and beta-amyloid (1&#x2013;42) regulation of glycogen synthase kinase-3beta. J Neurochem. 2003;87:1152&#x2013;1164. doi: 10.1046/j.1471-4159.2003.02088.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02088.x</ArticleId><ArticleId IdType="pubmed">14622095</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci U S A. 2005;102:18694&#x2013;18699. doi: 10.1073/pnas.0508254102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508254102</ArticleId><ArticleId IdType="pmc">PMC1311737</ArticleId><ArticleId IdType="pubmed">16344479</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161&#x2013;171. doi: 10.1016/S1097-2765(01)00164-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00164-2</ArticleId><ArticleId IdType="pubmed">11172721</ArticleId></ArticleIdList></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012;335:1503&#x2013;1506. doi: 10.1126/science.1217697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1217697</ArticleId><ArticleId IdType="pmc">PMC3651582</ArticleId><ArticleId IdType="pubmed">22323736</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans TA, Barkauskas DS, Myers JT, Hare EG, You JQ, Ransohoff RM, Huang AY, Silver J. High-resolution intravital imaging reveals that blood-derived macrophages but not resident microglia facilitate secondary axonal dieback in traumatic spinal cord injury. Exp Neurol. 2014;254:109&#x2013;120. doi: 10.1016/j.expneurol.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3954731</ArticleId><ArticleId IdType="pubmed">24468477</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitz NF, Cronican AA, Lefterov I, Koldamova R. Comment on &#x201c;ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models&#x201d;. Science. 2013;340:924-c. doi: 10.1126/science.1235809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235809</ArticleId><ArticleId IdType="pmc">PMC4086452</ArticleId><ArticleId IdType="pubmed">23704552</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilat-Frenkel M, Boehm-Cagan A, Liraz O, Xian X, Herz J, Michaelson DM. Involvement of the Apoer2 and Lrp1 receptors in mediating the pathological effects of ApoE4 in vivo. Curr Alzheimer Res. 2013 doi: 10.2174/1567205010666131119232444. doi: 10.2174/1567205010666131119232444. Advance online publication.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1567205010666131119232444</ArticleId><ArticleId IdType="doi">10.2174/1567205010666131119232444</ArticleId><ArticleId IdType="pmc">PMC4065855</ArticleId><ArticleId IdType="pubmed">24251389</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong JS, Kobayashi M, Hayashi H, Zou K, Sawamura N, Fujita SC, Yanagisawa K, Michikawa M. Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. J Biol Chem. 2002;277:29919&#x2013;29926. doi: 10.1074/jbc.M203934200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M203934200</ArticleId><ArticleId IdType="pubmed">12042316</ArticleId></ArticleIdList></Reference><Reference><Citation>Haas A, Liraz O, Michaelson DM. The effects of apolipoproteins E3 and E4 on the transforming growth factor-beta system in targeted replacement mice. Neurodegener Dis. 2012;10:41&#x2013;45. doi: 10.1159/000334902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000334902</ArticleId><ArticleId IdType="pubmed">22301441</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S. Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial. JAMA Neurol. 2013;70:972&#x2013;980. doi: 10.1001/jamaneurol.2013.396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.396</ArticleId><ArticleId IdType="pmc">PMC3859238</ArticleId><ArticleId IdType="pubmed">23779114</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris FM, Brecht WJ, Xu Q, Mahley RW, Huang Y. Increased tau phosphorylation in apolipoprotein E4 transgenic mice is associated with activation of extracellular signal-regulated kinase: modulation by zinc. J Biol Chem. 2004;279:44795&#x2013;44801. doi: 10.1074/jbc.M408127200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M408127200</ArticleId><ArticleId IdType="pubmed">15322121</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Cooley K, Chung CH, Dashti N, Tang J. Apolipoprotein receptor 2 and X11 alpha/beta mediate apolipoprotein E-induced endocytosis of amyloid-beta precursor protein and beta-secretase, leading to amyloid-beta production. J Neurosci. 2007;27:4052&#x2013;4060. doi: 10.1523/JNEUROSCI.3993-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3993-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672528</ArticleId><ArticleId IdType="pubmed">17428983</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem. 2004;279:41197&#x2013;41207. doi: 10.1074/jbc.M407962200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407962200</ArticleId><ArticleId IdType="pubmed">15269218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008;58:681&#x2013;693. doi: 10.1016/j.neuron.2008.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.04.010</ArticleId><ArticleId IdType="pmc">PMC2493297</ArticleId><ArticleId IdType="pubmed">18549781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariv-Inbal Z, Yacobson S, Berkecz R, Peter M, Janaky T, L&#xfc;tjohann D, Broersen LM, Hartmann T, Michaelson DM. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28:667&#x2013;683. doi: 10.3233/JAD-2011-111265.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-111265</ArticleId><ArticleId IdType="pubmed">22057027</ArticleId></ArticleIdList></Reference><Reference><Citation>Karten B, Campenot RB, Vance DE, Vance JE. Expression of ABCG1, but not ABCA1, correlates with cholesterol release by cerebellar astroglia. J Biol Chem. 2006;281:4049&#x2013;4057. doi: 10.1074/jbc.M508915200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M508915200</ArticleId><ArticleId IdType="pubmed">16352604</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WS, Weickert CS, Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem. 2008;104:1145&#x2013;1166. doi: 10.1111/j.1471-4159.2007.05099.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05099.x</ArticleId><ArticleId IdType="pubmed">17973979</ArticleId></ArticleIdList></Reference><Reference><Citation>Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005;280:4079&#x2013;4088. doi: 10.1074/jbc.M411420200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M411420200</ArticleId><ArticleId IdType="pubmed">15557325</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci U S A. 2001;98:507&#x2013;512. doi: 10.1073/pnas.98.2.507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.507</ArticleId><ArticleId IdType="pmc">PMC14617</ArticleId><ArticleId IdType="pubmed">11149950</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fi&#xe9;vet C, Staels B, Tailleux A. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler Thromb Vasc Biol. 2009;29:1488&#x2013;1495. doi: 10.1161/ATVBAHA.109.189506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.109.189506</ArticleId><ArticleId IdType="pmc">PMC2824837</ArticleId><ArticleId IdType="pubmed">19592467</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi O, Michaelson DM. Environmental enrichment stimulates neurogenesis in apolipoprotein E3 and neuronal apoptosis in apolipoprotein E4 transgenic mice. J Neurochem. 2007;100:202&#x2013;210. doi: 10.1111/j.1471-4159.2006.04189.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04189.x</ArticleId><ArticleId IdType="pubmed">17074063</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi O, Jongen-Relo AL, Feldon J, Roses AD, Michaelson DM. ApoE4 impairs hippocampal plasticity isoform-specifically and blocks the environmental stimulation of synaptogenesis and memory. Neurobiol Dis. 2003;13:273&#x2013;282. doi: 10.1016/S0969-9961(03)00045-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-9961(03)00045-7</ArticleId><ArticleId IdType="pubmed">12901842</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem. 2004;88:623&#x2013;634. doi: 10.1111/j.1471-4159.2004.02183.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02183.x</ArticleId><ArticleId IdType="pubmed">14720212</ArticleId></ArticleIdList></Reference><Reference><Citation>Liraz O, Boehm-Cagan A, Michaelson DM. ApoE4 induces Abeta42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice. Mol Neurodegener. 2013;8:16. doi: 10.1186/1750-1326-8-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-16</ArticleId><ArticleId IdType="pmc">PMC3659080</ArticleId><ArticleId IdType="pubmed">23684315</ArticleId></ArticleIdList></Reference><Reference><Citation>Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 2000;74:1008&#x2013;1016. doi: 10.1046/j.1471-4159.2000.0741008.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0741008.x</ArticleId><ArticleId IdType="pubmed">10693931</ArticleId></ArticleIdList></Reference><Reference><Citation>Minagawa H, Gong JS, Jung CG, Watanabe A, Lund-Katz S, Phillips MC, Saito H, Michikawa M. Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J Neurosci Res. 2009;87:2498&#x2013;2508. doi: 10.1002/jnr.22073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22073</ArticleId><ArticleId IdType="pmc">PMC3065888</ArticleId><ArticleId IdType="pubmed">19326444</ArticleId></ArticleIdList></Reference><Reference><Citation>Price AR, Xu G, Siemienski ZB, Smithson LA, Borchelt DR, Golde TE, Felsenstein KM. Comment on &#x201c;ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models.&#x201d;. Science. 2013;340:924-d. doi: 10.1126/science.1234089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1234089</ArticleId><ArticleId IdType="pubmed">23704553</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglielli L, Tanzi RE, Kovacs DM. Alzheimer's disease: the cholesterol connection. Nat Neurosci. 2003;6:345&#x2013;351. doi: 10.1038/nn0403-345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn0403-345</ArticleId><ArticleId IdType="pubmed">12658281</ArticleId></ArticleIdList></Reference><Reference><Citation>Riddell DR, Zhou H, Atchison K, Warwick HK, Atkinson PJ, Jefferson J, Xu L, Aschmies S, Kirksey Y, Hu Y, Wagner E, Parratt A, Xu J, Li Z, Zaleska MM, Jacobsen JS, Pangalos MN, Reinhart PH. Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels. J Neurosci. 2008;28:11445&#x2013;11453. doi: 10.1523/JNEUROSCI.1972-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1972-08.2008</ArticleId><ArticleId IdType="pmc">PMC6671315</ArticleId><ArticleId IdType="pubmed">18987181</ArticleId></ArticleIdList></Reference><Reference><Citation>Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 1996;47:387&#x2013;400. doi: 10.1146/annurev.med.47.1.387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.med.47.1.387</ArticleId><ArticleId IdType="pubmed">8712790</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon-Zimri S, Boehm-Cagan A, Liraz O, Michaelson DM. Hippocampus-related cognitive impairments in young apoE4 targeted replacement mice. Neurodegener Dis. 2014;13:86&#x2013;92. doi: 10.1159/000354777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000354777</ArticleId><ArticleId IdType="pubmed">24080852</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467&#x2013;1472. doi: 10.1212/WNL.43.8.1467.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.43.8.1467</ArticleId><ArticleId IdType="pubmed">8350998</ArticleId></ArticleIdList></Reference><Reference><Citation>Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:11183&#x2013;11186. doi: 10.1073/pnas.91.23.11183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.23.11183</ArticleId><ArticleId IdType="pmc">PMC45191</ArticleId><ArticleId IdType="pubmed">7972031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem. 1997;272:17972&#x2013;17980. doi: 10.1074/jbc.272.29.17972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.29.17972</ArticleId><ArticleId IdType="pubmed">9218423</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ. Levels of soluble apolipoprotein E/amyloid-beta (Abeta) complex are reduced and oligomeric Abeta increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J Biol Chem. 2013;288:5914&#x2013;5926. doi: 10.1074/jbc.M112.442103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.442103</ArticleId><ArticleId IdType="pmc">PMC3581407</ArticleId><ArticleId IdType="pubmed">23293020</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesseur I, Lo AC, Roberfroid A, Dietvorst S, Van Broeck B, Borgers M, Gijsen H, Moechars D, Mercken M, Kemp J, D'Hooge R, De Strooper B. Comment on &#x201c;ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models.&#x201d;. Science. 2013;340:924-e. doi: 10.1126/science.1233937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1233937</ArticleId><ArticleId IdType="pubmed">23704554</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem J. 2000;348:359&#x2013;365. doi: 10.1042/0264-6021:3480359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/0264-6021:3480359</ArticleId><ArticleId IdType="pmc">PMC1221074</ArticleId><ArticleId IdType="pubmed">10816430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulrich JD, Burchett JM, Restivo JL, Schuler DR, Verghese PB, Mahan TE, Landreth GE, Castellano JM, Jiang H, Cirrito JR, Holtzman DM. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol Neurodegener. 2013;8:13. doi: 10.1186/1750-1326-8-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-13</ArticleId><ArticleId IdType="pmc">PMC3640999</ArticleId><ArticleId IdType="pubmed">23601557</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010;1801:806&#x2013;818. doi: 10.1016/j.bbalip.2010.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbalip.2010.02.007</ArticleId><ArticleId IdType="pubmed">20170744</ArticleId></ArticleIdList></Reference><Reference><Citation>Veeraraghavalu K, Zhang C, Miller S, Hefendehl JK, Rajapaksha TW, Ulrich J, Jucker M, Holtzman DM, Tanzi RE, Vassar R, Sisodia SS. Comment on &#x201c;ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models.&#x201d;. Science. 2013;340:924-f. doi: 10.1126/science.1235505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1235505</ArticleId><ArticleId IdType="pubmed">23704555</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem. 2004;279:40987&#x2013;40993. doi: 10.1074/jbc.M407963200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M407963200</ArticleId><ArticleId IdType="pubmed">15269217</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol. 2002;16:1378&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pubmed">12040022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Huang Y, M&#xfc;llendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Proc Natl Acad Sci U S A. 2005;102:18700&#x2013;18705. doi: 10.1073/pnas.0508693102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0508693102</ArticleId><ArticleId IdType="pmc">PMC1311738</ArticleId><ArticleId IdType="pubmed">16344478</ArticleId></ArticleIdList></Reference><Reference><Citation>Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, Kim J, Eimer WA, Estus S, Rebeck GW, Weeber EJ, Bu G, Yu C, Ladu MJ. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287:41774&#x2013;41786. doi: 10.1074/jbc.M112.407957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.407957</ArticleId><ArticleId IdType="pmc">PMC3516726</ArticleId><ArticleId IdType="pubmed">23060451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zepa L, Frenkel M, Belinson H, Kariv-Inbal Z, Kayed R, Masliah E, Michaelson DM. ApoE4-driven accumulation of intraneuronal oligomerized Abeta42 following activation of the amyloid cascade in vivo is mediated by a gain of function. Int J Alzheimers Dis. 2011;2011:792070. doi: 10.4061/2011/792070.</Citation><ArticleIdList><ArticleId IdType="doi">10.4061/2011/792070</ArticleId><ArticleId IdType="pmc">PMC3042644</ArticleId><ArticleId IdType="pubmed">21350674</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24849862</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-4465</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Lancet. Neurology</Title><ISOAbbreviation>Lancet Neurol</ISOAbbreviation></Journal><ArticleTitle>Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.</ArticleTitle><Pagination><StartPage>614</StartPage><EndPage>629</EndPage><MedlinePgn>614-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1474-4422(14)70090-0</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1474-4422(14)70090-0</ELocationID><Abstract><AbstractText>In the past 8 years, both the International Working Group (IWG) and the US National Institute on Aging-Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's disease (AD) that better define clinical phenotypes and integrate biomarkers into the diagnostic process, covering the full staging of the disease. This Position Paper considers the strengths and limitations of the IWG research diagnostic criteria and proposes advances to improve the diagnostic framework. On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of Alzheimer's pathology. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the preclinical states of AD.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubois</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Centre des Maladies Cognitives et Comportementales, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris, France; Universit&#xe9; Pierre et Marie Curie-Paris 6, AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France. Electronic address: bruno.dubois@psl.aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Howard H</ForeName><Initials>HH</Initials><AffiliationInfo><Affiliation>Division of Neurology, University of British Columbia and Vancouver Coastal Health, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacova</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UBC Division of Neurology, S152 UBC Hospital, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampel</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre des Maladies Cognitives et Comportementales, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris, France; Universit&#xe9; Pierre et Marie Curie-Paris 6, AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molinuevo</LastName><ForeName>Jos&#xe9; Luis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, IDIBAPS Hospital Clinici Universitari, Barcelona, Spain; BarcelonaBeta Brain Research Centre, Fundaci&#xf3; Pasqual Maragall, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blennow</LastName><ForeName>Kaj</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, M&#xf6;lndal, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeKosky</LastName><ForeName>Steven T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Virginia, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gauthier</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>McGill Center for Studies in Aging, Douglas Hospital, Montreal, Quebec, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selkoe</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Harvard Medical School Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Washington University School of Medicine, St Louis, Missouri, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cappa</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milan, Italy; Department of Clinical Neurosciences, Cognitive Neurorehabilitation, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crutch</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegeneration, Institute of Neurology, University College London, London, UK; Dementia Research Centre, National Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engelborghs</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA), Middelheim and Hoge Beuken, Antwerp, Belgium; Reference Centre for Biological Markers of Dementia, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisoni</LastName><ForeName>Giovanni B</ForeName><Initials>GB</Initials><AffiliationInfo><Affiliation>Hopitaux Universitaires et Universit&#xe9; de Gen&#xe8;ve, Geneva, Switzerland; IRCCS Fatebenefratelli, Brescia, Italy; HUG Belle-Id&#xe9;e, b&#xe2;timent les Voirons, Ch&#xea;ne-Bourg, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fox</LastName><ForeName>Nick C</ForeName><Initials>NC</Initials><AffiliationInfo><Affiliation>Dementia Research Centre, Department of Neurodegeneration, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galasko</LastName><ForeName>Douglas</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, -University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habert</LastName><ForeName>Marie-Odile</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>INSERM UMR, Paris, France; AP-HP, Groupe Hospitalier Piti&#xe9;-Salp&#xea;tri&#xe8;re, Service de M&#xe9;decine Nucl&#xe9;aire, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jicha</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>University of Kentucky Alzheimer's Disease Center, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordberg</LastName><ForeName>Agneta</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Karolinska Institutet, Karolinska University Hospital Huddinge, Alzheimer Neurobiology Center, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquier</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Lille Nord de France, Lille, France; CHRU, Clinique Neurologique, H&#xf4;pital Roger Salengro, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rabinovici</LastName><ForeName>Gil</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>UCSF Memory &amp; Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>EA CoBTeK and Memory Center, CHU University of Nice, UNSA, H&#xf4;pital de Cimiez 4 av Victoria, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>FRACP, Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salloway</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Neurology and the Memory and Aging Program, Butler Hospital, Department of Neurology and Psychiatry, The Warren Alpert Medical School of Brown University, Providence, RI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarazin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurologie de la M&#xe9;moire et du Langage, Centre Hospitalier Sainte-Anne, Paris Cedex, France; Universit&#xe9; Paris 5, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Epelbaum</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre des Maladies Cognitives et Comportementales, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris, France; Universit&#xe9; Pierre et Marie Curie-Paris 6, AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Leonardo C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Centre des Maladies Cognitives et Comportementales, Institut du Cerveau et de la Moelle &#xe9;pini&#xe8;re, Paris, France; Universit&#xe9; Pierre et Marie Curie-Paris 6, AP-HP, H&#xf4;pital de la Salp&#xea;tri&#xe8;re, Paris, France; Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vellas</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Gerontopole, Pavillon Junod, University Toulouse 3, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Pieter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School of Mental Health and Neuroscience, Maastricht University Medical Centre, Maastricht, Netherlands; Department of Neurology and Alzheimer Center, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schneider</LastName><ForeName>Lon</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Neurology, and Gerontology, Keck School of Medicine of USC, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stern</LastName><ForeName>Yaakov</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Cognitive Neuroscience Division of the Taub Institute, Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scheltens</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer Centrum Vrije Universiteit Medical Center, VU University, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummings</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Neurol</MedlineTA><NlmUniqueID>101139309</NlmUniqueID><ISSNLinking>1474-4422</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Neurol. 2014 Aug;13(8):757</RefSource></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Neurol. 2014 Jun;13(6):532-4. doi: 10.1016/S1474-4422(14)70098-5.</RefSource><PMID Version="1">24849852</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007391" MajorTopicYN="N">International Cooperation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24849862</ArticleId><ArticleId IdType="doi">10.1016/S1474-4422(14)70090-0</ArticleId><ArticleId IdType="pii">S1474-4422(14)70090-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24857020</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4199</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>18</Day></PubDate></JournalIssue><Title>Neuron</Title><ISOAbbreviation>Neuron</ISOAbbreviation></Journal><ArticleTitle>Distinct tau prion strains propagate in cells and mice and define different tauopathies.</ArticleTitle><Pagination><StartPage>1271</StartPage><EndPage>1288</EndPage><MedlinePgn>1271-88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuron.2014.04.047</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-6273(14)00362-6</ELocationID><Abstract><AbstractText>Prion-like propagation of tau aggregation might underlie the stereotyped progression of neurodegenerative tauopathies. True prions stably maintain unique conformations ("strains") in vivo that link structure to patterns of pathology. We now find that tau meets this criterion. Stably expressed tau repeat domain indefinitely propagates distinct amyloid conformations in a clonal fashion in culture. Reintroduction of tau from these lines into naive cells reestablishes identical clones. We produced two strains in vitro that induce distinct pathologies in vivo as determined by successive inoculations into three generations of transgenic mice. Immunopurified tau from these mice recreates the original strains in culture. We used the cell system to isolate tau strains from 29 patients with 5 different tauopathies, finding that different diseases are associated with different sets of strains. Tau thus demonstrates essential characteristics of a prion. This might explain the phenotypic diversity of tauopathies and could enable more effective diagnosis and therapy.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>David W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Sarah K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeVos</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Apurwa M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirbaha</LastName><ForeName>Hilda</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Scarlett J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Foley</LastName><ForeName>Alex C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thorpe</LastName><ForeName>Julian R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serpell</LastName><ForeName>Louise C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>School of Life Sciences, University of Sussex, Falmer BN1 9QG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Timothy M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Department of Neurology and Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology and Pathology, University of California, San Francisco, San Francisco, CA 94143, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamond</LastName><ForeName>Marc I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University in St. Louis, St. Louis, MO 63105, USA. Electronic address: diamondm@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01NS071835</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS078398</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P50 AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1F31NS086251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 NS086251</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM008151</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/K022105/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P50AG023501</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30NS057105</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F30 AG048653</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neuron</MedlineTA><NlmUniqueID>8809320</NlmUniqueID><ISSNLinking>0896-6273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Neuron. 2014 Jun 18;82(6):1189-90. doi: 10.1016/j.neuron.2014.06.004.</RefSource><PMID Version="1">24945760</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="N">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="N">Prions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024801" MajorTopicYN="N">Tauopathies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b><u>Conflict of Interest</u></b>: M.I.D. acknowledges a potential conflict of interest in that he is a co-inventor of antibodies used in this study (HJ9.3 and HJ8.5) that have been licensed by C2N Diagnostics through an agreement with Washington University in St. Louis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>6</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24857020</ArticleId><ArticleId IdType="mid">NIHMS600493</ArticleId><ArticleId IdType="pmc">PMC4171396</ArticleId><ArticleId IdType="doi">10.1016/j.neuron.2014.04.047</ArticleId><ArticleId IdType="pii">S0896-6273(14)00362-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron. 2009;64:783&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20064386</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P. The Hippocampus Book. Oxford University Press; 2007.</Citation></Reference><Reference><Citation>Aoyagi H, Hasegawa M, Tamaoka A. Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau. J Biol Chem. 2007;282:20309&#x2013;20318.</Citation><ArticleIdList><ArticleId IdType="pubmed">17526496</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghorn S, Zheng-Fischh&#xf6;fer Q, Ackmann M, Biernat J, Bergen von M, Mandelkow EM, Mandelkow E. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11714&#x2013;11721.</Citation><ArticleIdList><ArticleId IdType="pubmed">10995239</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergen von M, Barghorn S, Li L, Marx A, Biernat J, Mandelkow EM, Mandelkow E. Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem. 2001;276:48165&#x2013;48174.</Citation><ArticleIdList><ArticleId IdType="pubmed">11606569</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessen RA, Marsh RF. Distinct PrP properties suggest the molecular basis of strain variation in transmissible mink encephalopathy. J Virol. 1994;68:7859&#x2013;7868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237248</ArticleId><ArticleId IdType="pubmed">7966576</ArticleId></ArticleIdList></Reference><Reference><Citation>Birkett CR, Hennion RM, Bembridge DA, Clarke MC, Chree A, Bruce ME, Bostock CJ. Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. Embo J. 2001;20:3351&#x2013;3358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC125505</ArticleId><ArticleId IdType="pubmed">11432823</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonar L, Cohen AS, Skinner MM. Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med. 1969;131:1373&#x2013;1375.</Citation><ArticleIdList><ArticleId IdType="pubmed">5812002</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, Madiona K, Olieric V, B&#xf6;ckmann A, Meier BH, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013;4:2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826637</ArticleId><ArticleId IdType="pubmed">24108358</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Staging of Alzheimer&#x2019;s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271&#x2013;8. discussion278&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">7566337</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce M, Chree A, McConnell I, Foster J, Pearson G, Fraser H. Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. Philos Trans R Soc Lond, B, Biol Sci. 1994;343:405&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">7913758</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald J, Staufenbiel M, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S a 2013a</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677441</ArticleId><ArticleId IdType="pubmed">23690619</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11:909&#x2013;913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2726961</ArticleId><ArticleId IdType="pubmed">19503072</ArticleId></ArticleIdList></Reference><Reference><Citation>Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. &#x201c;Prionlike&#x201d; templated misfolding in tauopathies. Brain Pathol. 2013b;23:342&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8028860</ArticleId><ArticleId IdType="pubmed">23587140</ArticleId></ArticleIdList></Reference><Reference><Citation>Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318:930&#x2013;936.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991853</ArticleId></ArticleIdList></Reference><Reference><Citation>de Calignon A, Polydoro M, Su&#xe1;rez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, et al. Propagation of tau pathology in a model of early Alzheimer&#x2019;s disease. Neuron. 2012;73:685&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3292759</ArticleId><ArticleId IdType="pubmed">22365544</ArticleId></ArticleIdList></Reference><Reference><Citation>Derkatch IL, Chernoff YO, Kushnirov VV, Inge-Vechtomov SG, Liebman SW. Genesis and variability of [PSI] prion factors in Saccharomyces cerevisiae. Genetics. 1996;144:1375&#x2013;1386.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1207691</ArticleId><ArticleId IdType="pubmed">8978027</ArticleId></ArticleIdList></Reference><Reference><Citation>Desplats P, Lee H-J, Bae E-J, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S-J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S a. 2009;106:13010&#x2013;13015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2722313</ArticleId><ArticleId IdType="pubmed">19651612</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos SL, Miller TM. Direct intraventricular delivery of drugs to the rodent central nervous system. J Vis Exp. 2013:75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679837</ArticleId><ArticleId IdType="pubmed">23712122</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkel PD, Siddiqua A, Huynh H, Shah M, Margittai M. Variations in filament conformation dictate seeding barrier between three- and four-repeat tau. Biochemistry. 2011;50:4330&#x2013;4336.</Citation><ArticleIdList><ArticleId IdType="pubmed">21510682</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyckaerts C, Delatour B, Potier M-C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118:5&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">19381658</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, Mattiace LA, Dickson DW. Neuropathologic overlap of progressive supranuclear palsy, Pick&#x2019;s disease and corticobasal degeneration. J Neuropathol Exp Neurol. 1996;55:53&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">8558172</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155&#x2013;159.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3648341</ArticleId><ArticleId IdType="pubmed">20029438</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009a;284:12845&#x2013;12852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2676015</ArticleId><ArticleId IdType="pubmed">19282288</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost B, Ollesch J, Wille H, Diamond MI. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J Biol Chem. 2009b;284:3546&#x2013;3551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2635036</ArticleId><ArticleId IdType="pubmed">19010781</ArticleId></ArticleIdList></Reference><Reference><Citation>Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM-Y. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300:636&#x2013;640.</Citation><ArticleIdList><ArticleId IdType="pubmed">12714745</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Kimmel DL. Neuroimaging insights into network-based neurodegeneration. Curr Opin Neurol. 2012;25:727&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">23108250</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, et al. Distinct &#x3b1;-Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell. 2013;154:103&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820001</ArticleId><ArticleId IdType="pubmed">23827677</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 2011;122:187&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">21720849</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Diamond MI. Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol. 2012;25:721&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564233</ArticleId><ArticleId IdType="pubmed">23108252</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes BB, Devos SL, Kfoury N, Li M, Jacks R, Yanamandra K, Ouidja MO, Brodsky FM, Marasa J, Bagchi DP, et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc Natl Acad Sci U S a. 2013;110:E3138&#x2013;E3147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3746848</ArticleId><ArticleId IdType="pubmed">23898162</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzman DM, Morris JC, Goate AM. Alzheimer&#x2019;s disease: the challenge of the second century. Sci Transl Med. 2011;3:77sr1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3130546</ArticleId><ArticleId IdType="pubmed">21471435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, et al. Association of missense and 5&#x2019;-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM-Y. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer&#x2019;s-like tauopathy. J Neurosci. 2013;33:1024&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3575082</ArticleId><ArticleId IdType="pubmed">23325240</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Bowser R, Kazam IG, Davies P. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res. 1997;48:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">9130141</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim C, Haldiman T, Surewicz K, Cohen Y, Chen W, Blevins J, Sy M-S, Cohen M, Kong Q, Telling GC, et al. Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrP(C) PLoS Pathog. 2012;8:e1002835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3410855</ArticleId><ArticleId IdType="pubmed">22876179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Lee S, Jung C, Ahmed A, Lee G, Hall GF. Interneuronal transfer of human tau between Lamprey central neurons in situ. J Alzheimers Dis. 2010;19:647&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">20110609</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer C, Kryndushkin D, Suhre MH, Kremmer E, Hofmann A, Pfeifer A, Scheibel T, Wickner RB, Sch&#xe4;tzl HM, Vorberg I. The yeast Sup35NM domain propagates as a prion in mammalian cells. Proc Natl Acad Sci U S a. 2009;106:462&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2626725</ArticleId><ArticleId IdType="pubmed">19114662</ArticleId></ArticleIdList></Reference><Reference><Citation>Kryndushkin DS, Alexandrov IM, Ter-Avanesyan MD, Kushnirov VV. Yeast [PSI+] prion aggregates are formed by small Sup35 polymers fragmented by Hsp104. J Biol Chem. 2003;278:49636&#x2013;49643.</Citation><ArticleIdList><ArticleId IdType="pubmed">14507919</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121&#x2013;1159.</Citation><ArticleIdList><ArticleId IdType="pubmed">11520930</ArticleId></ArticleIdList></Reference><Reference><Citation>Legname G, Nguyen H-OB, Peretz D, Cohen FE, DeArmond SJ, Prusiner SB. Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. Proc Natl Acad Sci U S a. 2006;103:19105&#x2013;19110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1748184</ArticleId><ArticleId IdType="pubmed">17142317</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C. Darwinian evolution of prions in cell culture. Science. 2010;327:869&#x2013;872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848070</ArticleId><ArticleId IdType="pubmed">20044542</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Transsynaptic spread of tau pathology in vivo. PLoS ONE. 2012;7:e31302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3270029</ArticleId><ArticleId IdType="pubmed">22312444</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu J-X, Qiang W, Yau W-M, Schwieters CD, Meredith SC, Tycko R. Molecular structure of &#x3b2;-amyloid fibrils in Alzheimer&#x2019;s disease brain tissue. Cell. 2013;154:1257&#x2013;1268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3814033</ArticleId><ArticleId IdType="pubmed">24034249</ArticleId></ArticleIdList></Reference><Reference><Citation>Luk KC, Kehm VM, Zhang B, O&#x2019;Brien P, Trojanowski JQ, Lee VM-Y. Intracerebral inoculation of pathological &#x3b1;-synuclein initiates a rapidly progressive neurodegenerative &#x3b1;-synucleinopathy in mice. J Exp Med. 2012;209:975&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348112</ArticleId><ArticleId IdType="pubmed">22508839</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science. 2006;313:1781&#x2013;1784.</Citation><ArticleIdList><ArticleId IdType="pubmed">16990547</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyasaka T, Morishima-Kawashima M, Ravid R, Kamphorst W, Nagashima K, Ihara Y. Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. J Neuropathol Exp Neurol. 2001;60:872&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">11556544</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C, O&#x2019;Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci U S a. 2011;108:3548&#x2013;3553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048161</ArticleId><ArticleId IdType="pubmed">21321227</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik S, Piwnica-Worms D. Real-time imaging of beta-catenin dynamics in cells and living mice. Proc Natl Acad Sci U S a. 2007;104:17465&#x2013;17470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2077279</ArticleId><ArticleId IdType="pubmed">17954915</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Some speculations about prions, amyloid, and Alzheimer&#x2019;s disease. N Engl J Med. 1984;310:661&#x2013;663.</Citation><ArticleIdList><ArticleId IdType="pubmed">6363926</ArticleId></ArticleIdList></Reference><Reference><Citation>Prusiner SB. Prions. Proc Natl Acad Sci U S a. 1998;95:13363&#x2013;13383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33918</ArticleId><ArticleId IdType="pubmed">9811807</ArticleId></ArticleIdList></Reference><Reference><Citation>Raj A, Kuceyeski A, Weiner M. A network diffusion model of disease progression in dementia. Neuron. 2012;73:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3623298</ArticleId><ArticleId IdType="pubmed">22445347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P-H, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol. 2009;11:219&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2757079</ArticleId><ArticleId IdType="pubmed">19151706</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacino AN, Thomas MA, Ceballos-Diaz C, Cruz PE, Rosario AM, Lewis J, Giasson BI, Golde TE. Conformational templating of &#x3b1;-synuclein aggregates in neuronalglial cultures. Mol Neurodegener. 2013;8:17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3671973</ArticleId><ArticleId IdType="pubmed">23714769</ArticleId></ArticleIdList></Reference><Reference><Citation>Safar J, Wille H, Itri V, Groth D, Serban H, Torchia M, Cohen FE, Prusiner SB. Eight prion strains have PrP(Sc) molecules with different conformations. Nat Med. 1998;4:1157&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9771749</ArticleId></ArticleIdList></Reference><Reference><Citation>Santa-Maria I, Varghese M, Ksiezak-Reding H, Dzhun A, Wang J, Pasinetti GM. Paired helical filaments from Alzheimer disease brain induce intracellular accumulation of Tau protein in aggresomes. J Biol Chem. 2012;287:20522&#x2013;20533.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3370237</ArticleId><ArticleId IdType="pubmed">22496370</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2691647</ArticleId><ArticleId IdType="pubmed">19376066</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqua A, Margittai M. Three- and four-repeat Tau coassemble into heterogeneous filaments: an implication for Alzheimer disease. J Biol Chem. 2010;285:37920&#x2013;37926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988394</ArticleId><ArticleId IdType="pubmed">20921227</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Collins SR, Toyama BH, Weissman JS. The physical basis of how prion conformations determine strain phenotypes. Nature. 2006;442:585&#x2013;589.</Citation><ArticleIdList><ArticleId IdType="pubmed">16810177</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama BH, Kelly MJS, Gross JD, Weissman JS. The structural basis of yeast prion strain variants. Nature. 2007;449:233&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">17767153</ArticleId></ArticleIdList></Reference><Reference><Citation>True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature. 2000;407:477&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">11028992</ArticleId></ArticleIdList></Reference><Reference><Citation>van Groen T, Miettinen P, Kadish I. The entorhinal cortex of the mouse: organization of the projection to the hippocampal formation. Hippocampus. 2003;13:133&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">12625464</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Langenhove T, van der Zee J, Van Broeckhoven C. The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum. Ann Med. 2012;44:817&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3529157</ArticleId><ArticleId IdType="pubmed">22420316</ArticleId></ArticleIdList></Reference><Reference><Citation>Waxman EA, Giasson BI. Induction of intracellular tau aggregation is promoted by &#x3b1;-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci. 2011;31:7604&#x2013;7618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122484</ArticleId><ArticleId IdType="pubmed">21613474</ArticleId></ArticleIdList></Reference><Reference><Citation>Wischik CM, Novak M, Th&#xf8;gersen HC, Edwards PC, Runswick MJ, Jakes R, Walker JE, Milstein C, Roth M, Klug A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S a. 1988;85:4506&#x2013;4510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280459</ArticleId><ArticleId IdType="pubmed">3132715</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, Diamond MI, Holtzman DM. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80:402&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924573</ArticleId><ArticleId IdType="pubmed">24075978</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshiyama Y, Higuchi M, Zhang B, Huang S-M, Iwata N, Saido TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM-Y. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53:337&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17270732</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73:1216&#x2013;1227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3361461</ArticleId><ArticleId IdType="pubmed">22445348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziebell JM, Taylor SE, Cao T, Harrison JL, Lifshitz J. Rod microglia: elongation, alignment, and coupling to form trains across the somatosensory cortex after experimental diffuse brain injury. J Neuroinflammation. 2012;9:247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3526458</ArticleId><ArticleId IdType="pubmed">23111107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24856820</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1301</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>19</Day></PubDate></JournalIssue><Title>Chemistry &amp; biology</Title><ISOAbbreviation>Chem Biol</ISOAbbreviation></Journal><ArticleTitle>Direct observations of amyloid &#x3b2; self-assembly in live cells provide insights into differences in the kinetics of A&#x3b2;(1-40) and A&#x3b2;(1-42) aggregation.</ArticleTitle><Pagination><StartPage>732</StartPage><EndPage>742</EndPage><MedlinePgn>732-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chembiol.2014.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1074-5521(14)00148-3</ELocationID><Abstract><AbstractText>Insight into how amyloid &#x3b2; (A&#x3b2;) aggregation occurs in&#xa0;vivo is vital for understanding the molecular pathways that underlie Alzheimer's disease and requires new techniques that provide detailed kinetic and mechanistic information. Using noninvasive fluorescence lifetime recordings, we imaged the formation of A&#x3b2;(1-40) and A&#x3b2;(1-42) aggregates in live cells. For both peptides, the cellular uptake via endocytosis is rapid and spontaneous. They are then retained in lysosomes, where their accumulation leads to aggregation. The kinetics of A&#x3b2;(1-42) aggregation are considerably faster than those of A&#x3b2;(1-40) and, unlike those of the latter peptide, show no detectable lag phase. We used superresolution fluorescence imaging to examine the resulting aggregates and could observe compact amyloid structures, likely because of spatial confinement within cellular compartments. Taken together, these findings provide clues as to how A&#x3b2; aggregation may occur within neurons.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Esbj&#xf6;rner</LastName><ForeName>Elin K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK; Department of Chemical and Biological Engineering, Division of Chemistry and Biochemistry, Chalmers University of Technology, Kemiv&#xe4;gen 10, 41296 Gothenburg, Sweden. Electronic address: eline@chalmers.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdelyi</LastName><ForeName>Miklos</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luheshi</LastName><ForeName>Leila M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertoncini</LastName><ForeName>Carlos W</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Biophysics, Institute for Research in Biomedicine, Baldiri Reixac 10-12, 08028 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski</LastName><ForeName>Clemens F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dobson</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski Schierle</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Department of Chemical Engineering and Biotechnology, University of Cambridge, New Museums Site, Pembroke Street, Cambridge CB2 3RA, UK. Electronic address: gsk20@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_G1000734</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Chem Biol</MedlineTA><NlmUniqueID>9500160</NlmUniqueID><ISSNLinking>1074-5521</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C078592">amyloid beta-protein (1-40)</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Chem Biol. 2014 Jun 19;21(6):703-4. doi: 10.1016/j.chembiol.2014.06.001.</RefSource><PMID Version="1">24950101</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="Y">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="Y">Protein Aggregation, Pathological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014407" MajorTopicYN="N">Tumor Cells, Cultured</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24856820</ArticleId><ArticleId IdType="pmc">PMC4067742</ArticleId><ArticleId IdType="doi">10.1016/j.chembiol.2014.03.014</ArticleId><ArticleId IdType="pii">S1074-5521(14)00148-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal A&#x3b2; causes the onset of early Alzheimer&#x2019;s disease-related cognitive deficits in transgenic mice. Neuron. 2005;45:675&#x2013;688.</Citation><ArticleIdList><ArticleId IdType="pubmed">15748844</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D., Soreghan B., Kwon M., Kosmoski J., Knauer M., Henschen A., Yates J., Cotman C., Glabe C. Assembly and aggregation properties of synthetic Alzheimer&#x2019;s A4/&#x3b2; amyloid peptide analogs. J.&#xa0;Biol. Chem. 1992;267:546&#x2013;554.</Citation><ArticleIdList><ArticleId IdType="pubmed">1730616</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick D., Kosmoski J., Knauer M.F., Glabe C.G. Preferential adsorption, internalization and resistance to degradation of the major isoform of the Alzheimer&#x2019;s amyloid peptide, A &#x3b2; 1-42, in differentiated PC12 cells. Brain Res. 1997;746:275&#x2013;284.</Citation><ArticleIdList><ArticleId IdType="pubmed">9037507</ArticleId></ArticleIdList></Reference><Reference><Citation>Campioni S., Mannini B., Zampagni M., Pensalfini A., Parrini C., Evangelisti E., Relini A., Stefani M., Dobson C.M., Cecchi C., Chiti F. A causative link between the structure of aberrant protein oligomers and their toxicity. Nat. Chem. Biol. 2010;6:140&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">20081829</ArticleId></ArticleIdList></Reference><Reference><Citation>Capetillo-Zarate E., Gracia L., Yu F., Banfelder J.R., Lin M.T., Tampellini D., Gouras G.K. High-resolution 3D reconstruction reveals intra-synaptic amyloid fibrils. Am. J. Pathol. 2011;179:2551&#x2013;2558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204026</ArticleId><ArticleId IdType="pubmed">21925470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan F.T., Kaminski Schierle G.S., Kumita J.R., Bertoncini C.W., Dobson C.M., Kaminski C.F. Protein amyloids develop an intrinsic fluorescence signature during aggregation. Analyst (Lond.) 2013;138:2156&#x2013;2162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360231</ArticleId><ArticleId IdType="pubmed">23420088</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H., Ahsan S.S., Santiago-Berrios M.B., Abru&#xf1;a H.D., Webb W.W. Mechanisms of quenching of Alexa fluorophores by natural amino acids. J.&#xa0;Am. Chem. Soc. 2010;132:7244&#x2013;7245.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892418</ArticleId><ArticleId IdType="pubmed">20446733</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiti F., Dobson C.M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006;75:333&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756495</ArticleId></ArticleIdList></Reference><Reference><Citation>Clifford P.M., Zarrabi S., Siu G., Kinsler K.J., Kosciuk M.C., Venkataraman V., D&#x2019;Andrea M.R., Dinsmore S., Nagele R.G. A&#x3b2; peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res. 2007;1142:223&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">17306234</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S.I., Vendruscolo M., Dobson C.M., Knowles T.P. From macroscopic measurements to microscopic mechanisms of protein aggregation. J.&#xa0;Mol. Biol. 2012;421:160&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">22406275</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen S.I., Linse S., Luheshi L.M., Hellstrand E., White D.A., Rajah L., Otzen D.E., Vendruscolo M., Dobson C.M., Knowles T.P. Proliferation of amyloid-&#x3b2;42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. USA. 2013;110:9758&#x2013;9763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3683769</ArticleId><ArticleId IdType="pubmed">23703910</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich R.P., Tepper K., R&#xf6;nicke R., Soom M., Westermann M., Reymann K., Kaether C., F&#xe4;ndrich M. Mechanism of amyloid plaque formation suggests an intracellular basis of A&#x3b2; pathogenicity. Proc. Natl. Acad. Sci. USA. 2010;107:1942&#x2013;1947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2836607</ArticleId><ArticleId IdType="pubmed">20133839</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghukasyan V., Hsu C.C., Liu C.R., Kao F.J., Cheng T.H. Fluorescence lifetime dynamics of enhanced green fluorescent protein in protein aggregates with expanded polyglutamine. J.&#xa0;Biomed. Opt. 2010;15:016008.</Citation><ArticleIdList><ArticleId IdType="pubmed">20210454</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenner G.G., Wong C.W. Alzheimer&#x2019;s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984;120:885&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">6375662</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G.K., Tsai J., N&#xe4;slund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H. Intraneuronal A&#x3b2;42 accumulation in human brain. Am. J. Pathol. 2000;156:15&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer&#x2019;s disease. Trends Pharmacol. Sci. 1991;12:383&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pubmed">1763432</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Crick S.L., Bu G., Frieden C., Pappu R.V., Lee J.-M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-&#x3b2; peptide. Proc. Natl. Acad. Sci. USA. 2009;106:20324&#x2013;20329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2787156</ArticleId><ArticleId IdType="pubmed">19910533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrett J.T., Berger E.P., Lansbury P.T., Jr. The carboxy terminus of the &#x3b2; amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer&#x2019;s disease. Biochemistry. 1993;32:4693&#x2013;4697.</Citation><ArticleIdList><ArticleId IdType="pubmed">8490014</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaganovich D., Kopito R., Frydman J. Misfolded proteins partition between two distinct quality control compartments. Nature. 2008;454:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746971</ArticleId><ArticleId IdType="pubmed">18756251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski Schierle G.S., Bertoncini C.W., Chan F.T., van der Goot A.T., Schwedler S., Skepper J., Schlachter S., van Ham T., Esposito A., Kumita J.R. A FRET sensor for non-invasive imaging of amyloid formation in&#xa0;vivo. ChemPhysChem. 2011;12:673&#x2013;680.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5402868</ArticleId><ArticleId IdType="pubmed">21308945</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski Schierle G.S., van de Linde S., Erdelyi M., Esbj&#xf6;rner E.K., Klein T., Rees E., Bertoncini C.W., Dobson C.M., Sauer M., Kaminski C.F. In situ measurements of the formation and morphology of intracellular &#x3b2;-amyloid fibrils by super-resolution fluorescence imaging. J.&#xa0;Am. Chem. Soc. 2011;133:12902&#x2013;12905.</Citation><ArticleIdList><ArticleId IdType="pubmed">21793568</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R., Head E., Sarsoza F., Saing T., Cotman C.W., Necula M., Margol L., Wu J., Breydo L., Thompson J.L. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol. Neurodegener. 2007;2:18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2100048</ArticleId><ArticleId IdType="pubmed">17897471</ArticleId></ArticleIdList></Reference><Reference><Citation>Klucken J., Outeiro T.F., Nguyen P., McLean P.J., Hyman B.T. Detection of novel intracellular &#x3b1;-synuclein oligomeric species by fluorescence lifetime imaging. FASEB J. 2006;20:2050&#x2013;2057.</Citation><ArticleIdList><ArticleId IdType="pubmed">17012257</ArticleId></ArticleIdList></Reference><Reference><Citation>Knauer M.F., Soreghan B., Burdick D., Kosmoski J., Glabe C.G. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/&#x3b2; protein. Proc. Natl. Acad. Sci. USA. 1992;89:7437&#x2013;7441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC49725</ArticleId><ArticleId IdType="pubmed">1502155</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Culyba E.K., Powers E.T., Kelly J.W. Amyloid-&#x3b2; forms fibrils by nucleated conformational conversion of oligomers. Nat. Chem. Biol. 2011;7:602&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3158298</ArticleId><ArticleId IdType="pubmed">21804535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomakin A., Chung D.S., Benedek G.B., Kirschner D.A., Teplow D.B. On the nucleation and growth of amyloid &#x3b2;-protein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA. 1996;93:1125&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC40042</ArticleId><ArticleId IdType="pubmed">8577726</ArticleId></ArticleIdList></Reference><Reference><Citation>Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. USA. 1985;82:4245&#x2013;4249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC397973</ArticleId><ArticleId IdType="pubmed">3159021</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire E.K., Motskin M., Bolognesi B., Bergin S.D., Knowles T.P., Skepper J., Luheshi L.M., McComb D.W., Dobson C.M., Porter A.E. Selenium-enhanced electron microscopic imaging of different aggregate forms of a segment of the amyloid &#x3b2; peptide in cells. ACS Nano. 2012;6:4740&#x2013;4747.</Citation><ArticleIdList><ArticleId IdType="pubmed">22631869</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel C.H., Kumar S., Pinotsi D., Tunnacliffe A., St George-Hyslop P., Mandelkow E., Mandelkow E.M., Kaminski C.F., Kaminski Schierle G.S. Extracellular monomeric tau protein is sufficient to initiate the spread of tau protein pathology. J.&#xa0;Biol. Chem. 2014;289:956&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3887218</ArticleId><ArticleId IdType="pubmed">24235150</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayan P., Orte A., Clarke R.W., Bolognesi B., Hook S., Ganzinger K.A., Meehan S., Wilson M.R., Dobson C.M., Klenerman D. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-&#x3b2;(1-40) peptide. Nat. Struct. Mol. Biol. 2012;19:79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4979993</ArticleId><ArticleId IdType="pubmed">22179788</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinotsi D., Buell A.K., Dobson C.M., Kaminski Schierle G.S., Kaminski C.F. A label-free, quantitative assay of amyloid fibril growth based on intrinsic fluorescence. ChemBioChem. 2013;14:846&#x2013;850.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790954</ArticleId><ArticleId IdType="pubmed">23592254</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinotsi D., Buell A.K., Galvagnion C., Dobson C.M., Kaminski Schierle G.S., Kaminski C.F. Direct observation of heterogeneous amyloid fibril growth kinetics via two-color super-resolution microscopy. Nano Lett. 2014;14:339&#x2013;345.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3901574</ArticleId><ArticleId IdType="pubmed">24303845</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees E., Erdelyi M., Pinotsi D., Knight A., Metcalf D., Kaminski C. Blind assessment of localisation microscope image resolution. Optical Nanoscopy. 2012;1:12.</Citation></Reference><Reference><Citation>Roberti M.J., Bertoncini C.W., Klement R., Jares-Erijman E.A., Jovin T.M. Fluorescence imaging of amyloid formation in living cells by a functional, tetracysteine-tagged &#x3b1;-synuclein. Nat. Methods. 2007;4:345&#x2013;351.</Citation><ArticleIdList><ArticleId IdType="pubmed">17351621</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider C.A., Rasband W.S., Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Chang P.-T. Acidic pH promotes the formation of toxic fibrils from &#x3b2;-amyloid peptide. Brain Res. 2001;893:287&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11223020</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi R.H., Almeida C.G., Kearney P.F., Yu F., Lin M.T., Milner T.A., Gouras G.K. Oligomerization of Alzheimer&#x2019;s &#x3b2;-amyloid within processes and synapses of cultured neurons and brain. J.&#xa0;Neurosci. 2004;24:3592&#x2013;3599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729733</ArticleId><ArticleId IdType="pubmed">15071107</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson R.E., Larson D.R., Webb W.W. Precise nanometer localization analysis for individual fluorescent probes. Biophys. J. 2002;82:2775&#x2013;2783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1302065</ArticleId><ArticleId IdType="pubmed">11964263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tokunaga M., Imamoto N., Sakata-Sogawa K. Highly inclined thin illumination enables clear single-molecule imaging in cells. Nat. Methods. 2008;5:159&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pubmed">18176568</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh D.M., Tseng B.P., Rydel R.E., Podlisny M.B., Selkoe D.J. The oligomerization of amyloid &#x3b2;-protein begins intracellularly in cells derived from human brain. Biochemistry. 2000;39:10831&#x2013;10839.</Citation><ArticleIdList><ArticleId IdType="pubmed">10978169</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter S., Sch&#xfc;ttpelz M., Tscherepanow M., van de Linde S., Heilemann M., Sauer M. Real-time computation of subdiffraction-resolution fluorescence images. J.&#xa0;Microsc. 2010;237:12&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">20055915</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood S.J., Maleeff B., Hart T., Wetzel R. Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer&#x2019;s amyloid peptide A&#x3b2;. J.&#xa0;Mol. Biol. 1996;256:870&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pubmed">8601838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24876496</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1095-9203</ISSN><JournalIssue CitedMedium="Internet"><Volume>344</Volume><Issue>6187</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>30</Day></PubDate></JournalIssue><Title>Science (New York, N.Y.)</Title><ISOAbbreviation>Science</ISOAbbreviation></Journal><ArticleTitle>Composition of isolated synaptic boutons reveals the amounts of vesicle trafficking proteins.</ArticleTitle><Pagination><StartPage>1023</StartPage><EndPage>1028</EndPage><MedlinePgn>1023-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1126/science.1252884</ELocationID><Abstract><AbstractText>Synaptic vesicle recycling has long served as a model for the general mechanisms of cellular trafficking. We used an integrative approach, combining quantitative immunoblotting and mass spectrometry to determine protein numbers; electron microscopy to measure organelle numbers, sizes, and positions; and super-resolution fluorescence microscopy to localize the proteins. Using these data, we generated a three-dimensional model of an "average" synapse, displaying 300,000 proteins in atomic detail. The copy numbers of proteins involved in the same step of synaptic vesicle recycling correlated closely. In contrast, copy numbers varied over more than three orders of magnitude between steps, from about 150 copies for the endosomal fusion proteins to more than 20,000 for the exocytotic ones.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Association for the Advancement of Science.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilhelm</LastName><ForeName>Benjamin G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany. International Max Planck Research School Neurosciences, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandad</LastName><ForeName>Sunit</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Group, Max-Planck-Institute for Biophysical Chemistry, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truckenbrodt</LastName><ForeName>Sven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany. International Max Planck Research School Molecular Biology, 37077 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kr&#xf6;hnert</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sch&#xe4;fer</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rammner</LastName><ForeName>Burkhard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koo</LastName><ForeName>Seong Joo</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Leibniz Institut f&#xfc;r Molekulare Pharmakologie, Department of Molecular Pharmacology and Cell Biology, Robert-R&#xf6;ssle-Strasse 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cla&#xdf;en</LastName><ForeName>Gala A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Leibniz Institut f&#xfc;r Molekulare Pharmakologie, Department of Molecular Pharmacology and Cell Biology, Robert-R&#xf6;ssle-Strasse 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krauss</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Leibniz Institut f&#xfc;r Molekulare Pharmakologie, Department of Molecular Pharmacology and Cell Biology, Robert-R&#xf6;ssle-Strasse 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haucke</LastName><ForeName>Volker</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Leibniz Institut f&#xfc;r Molekulare Pharmakologie, Department of Molecular Pharmacology and Cell Biology, Robert-R&#xf6;ssle-Strasse 10, 13125 Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urlaub</LastName><ForeName>Henning</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Group, Max-Planck-Institute for Biophysical Chemistry, 37077 G&#xf6;ttingen, Germany. Bioanalytics, Department of Clinical Chemistry, University Medical Center G&#xf6;ttingen, 37075 G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzoli</LastName><ForeName>Silvio O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Neuro- and Sensory Physiology, University of G&#xf6;ttingen Medical Center, European Neuroscience Institute, Cluster of Excellence Nanoscale Microscopy and Molecular Physiology of the Brain, G&#xf6;ttingen, Germany. srizzol@gwdg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Science</MedlineTA><NlmUniqueID>0404511</NlmUniqueID><ISSNLinking>0036-8075</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nat Methods. 2014 Aug;11(8):788-9. doi: 10.1038/nmeth.3057.</RefSource><PMID Version="1">25229096</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005089" MajorTopicYN="N">Exocytosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015151" MajorTopicYN="N">Immunoblotting</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008854" MajorTopicYN="N">Microscopy, Electron</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008959" MajorTopicYN="N">Models, Neurological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017729" MajorTopicYN="N">Presynaptic Terminals</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021381" MajorTopicYN="N">Protein Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013572" MajorTopicYN="N">Synaptic Vesicles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013574" MajorTopicYN="N">Synaptosomes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24876496</ArticleId><ArticleId IdType="doi">10.1126/science.1252884</ArticleId><ArticleId IdType="pii">344/6187/1023</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24887018</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Effect of 1 night of total sleep deprivation on cerebrospinal fluid &#x3b2;-amyloid 42 in healthy middle-aged men: a randomized clinical trial.</ArticleTitle><Pagination><StartPage>971</StartPage><EndPage>977</EndPage><MedlinePgn>971-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.1173</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Increasing evidence suggests a relationship between poor sleep and the risk of developing Alzheimer disease. A previous study found an effect of sleep on &#x3b2;-amyloid (A&#x3b2;), which is a key protein in Alzheimer disease pathology.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the effect of 1 night of total sleep deprivation on cerebrospinal fluid A&#x3b2;42 protein levels in healthy middle-aged men.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">The Alzheimer, Wakefulness, and Amyloid Kinetics (AWAKE) study at the Radboud Alzheimer Center, a randomized clinical trial that took place between June 1, 2012, and October 1, 2012. Participants were cognitively normal middle-aged men (40-60 years of age) with normal sleep (n&#x2009;=&#x2009;26) recruited from the local population.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">Participants were randomized to 1 night with unrestricted sleep (n&#x2009;=&#x2009;13) or 1 night of total sleep deprivation (24 hours of wakefulness) (n&#x2009;=&#x2009;13).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Sleep was monitored using continuous polysomnographic recording from 3 pm until 10 am. Cerebrospinal fluid samples were collected using an intrathecal catheter at defined times to compare cerebral A&#x3b2;42 concentrations between evening and morning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A night of unrestricted sleep led to a 6% decrease in A&#x3b2;42 levels of 25.3 pg/mL (95% CI [0.94, 49.6], P&#x2009;=&#x2009;.04), whereas sleep deprivation counteracted this decrease. When accounting for the individual trajectories of A&#x3b2;42 over time, a difference of 75.8 pg/mL of A&#x3b2;42 was shown between the unrestricted sleep and sleep deprivation group (95% CI [3.4, 148.4], P&#x2009;=&#x2009;.04). The individual trajectories of evening and morning A&#x3b2;42 concentrations differed between the unrestricted sleep and sleep deprivation groups (P&#x2009;=&#x2009;.04) in contrast to stable A&#x3b2;40, tau, and total protein levels.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Sleep deprivation, or prolonged wakefulness, interferes with a physiological morning decrease in A&#x3b2;42. We hypothesize that chronic sleep deprivation increases cerebral A&#x3b2;42 levels, which elevates the risk of Alzheimer disease.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">clinicaltrials.gov Identifier: NCT01194713.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ooms</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands2Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands3Department of Geriatric Medicine, Radboud University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Overeem</LastName><ForeName>Sebastiaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands4Department of Neurology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besse</LastName><ForeName>Kees</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Anaesthesiology, Radboud University Medical Center, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rikkert</LastName><ForeName>Marcel Olde</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands2Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands3Department of Geriatric Medicine, Radboud University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verbeek</LastName><ForeName>Marcel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands2Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands4Department of Neurology, Radboud University Medical.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claassen</LastName><ForeName>Jurgen A H R</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands2Radboud Alzheimer Center, Radboud University Medical Center, Nijmegen, the Netherlands3Department of Geriatric Medicine, Radboud University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01194713</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C075222">amyloid beta-protein (1-42)</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24887018</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.1173</ArticleId><ArticleId IdType="pii">1875833</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24886908</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>8</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.</ArticleTitle><Pagination><StartPage>961</StartPage><EndPage>970</EndPage><MedlinePgn>961-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2014.803</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To demonstrate the feasibility of a cognitive composite outcome for clinically normal elderly participants with evidence of AD pathology using the ADCS Preclinical Alzheimer Cognitive Composite (ADCS-PACC). The ADCS-PACC combines tests that assess episodic memory, timed executive function, and global cognition. The ADCS-PACC is the primary outcome measure for the first clinical trial in preclinical AD (ie, the Anti-Amyloid Treatment in Asymptomatic Alzheimer's study).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">With the ADCS-PACC, we derive pilot estimates of amyloid-related decline using data from 2 observational studies conducted in North America and another conducted in Australia. The participants analyzed had normal cognition and mean ages of 75.81, 71.37, and 79.42 years across the 3 studies.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">For the 2 studies that collected data on A&#x3b2; levels (ADNI and AIBL), we estimate decline in a preclinical AD "A&#x3b2;-positive" placebo group and compare them with an "A&#x3b2;-negative" group. For the study that did not include data on A&#x3b2; levels (the ADCS Prevention Instrument [ADCS-PI] study), we grouped participants by the presence of APOE-&#x3b5;4 and by clinical progression.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In ADNI, A&#x3b2;-positive participants showed more decline than did A&#x3b2;-negative participants with regard to the ADCS-PACC score at 24 months (mean [SE] difference, -1.239 [0.522] [95% CI, -2.263 to -0.215]; P&#x2009;=&#x2009;.02). In AIBL, the mean (SE) difference is significant at both 18 months (-1.009 [0.406] [95% CI, -1.805 to -0.213]; P&#x2009;=&#x2009;.01) and 36 months (-1.404 [0.452] [95% CI, -2.290 to -0.519]; P&#x2009;=&#x2009;.002). In the ADCS-PI study, APOE-&#x3b5;4 allele carriers performed significantly worse on the ADCS-PACC at 24 months (mean [SE] score, -0.742 [0.294] [95% CI, -1.318 to -0.165]; P&#x2009;=&#x2009;.01) and 36 months (-1.531 [0.469] [95% CI, -2.450 to -0.612]; P&#x2009;=&#x2009;.001). In the ADCS-PI study, cognitively normal participants who progress from a global Clinical Dementia Rating score of 0 are significantly worse on the ADCS-PACC than cognitively normal participants who are stable with a global Clinical Dementia Rating score of 0 at months 12, 24, and 36 (mean [SE] ADCS-PACC score, -4.471 [0.702] [95% CI, -5.848 to -3.094]; P&#x2009;&lt;&#x2009;.001). Using pilot estimates of variance and assuming 500 participants per group with 30% attrition and a 5% &#x3b1; level, we project 80% power to detect effects in the range of &#x394;&#x2009;=&#x2009;0.467 to 0.733 on the ADCS-PACC.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Analyses of at-risk cognitively normal populations suggest that we can reliably measure the first signs of cognitive decline with the ADCS-PACC. These analyses also suggest the feasibility of secondary prevention trials.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donohue</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla2Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperling</LastName><ForeName>Reisa A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salmon</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rentz</LastName><ForeName>Dorene M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raman</LastName><ForeName>Rema</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla2Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California5Department of Radiology, University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aisen</LastName><ForeName>Paul S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Alzheimer's Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Ageing</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Cooperative Study</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 AG005131</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01-AG10483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AG010483</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR031978</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1KL2RR031978</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053327">Apolipoprotein E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>5D6PWO0333</RegistryNumber><NameOfSubstance UI="C550616">solanezumab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2014 Aug;71(8):947-9. doi: 10.1001/jamaneurol.2014.1120.</RefSource><PMID Version="1">24886838</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053327" MajorTopicYN="N">Apolipoprotein E4</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="N">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062706" MajorTopicYN="N">Prodromal Symptoms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Drs Donohue and Salmon are consultants for Bristol-Myers Squibb. Dr Aisen serves on a scientific advisory board for NeuroPhage; has served as a consultant to Elan, Wyeth, Eisai, Schering-Plough, Bristol-Myers Squibb, Eli Lilly, NeuroPhage, Merck, Roche, Amgen, Genentech, Abbott, Pfizer, Novartis, Bayer, Astellas, Dainippon, Biomarin, Solvay, Otsuka, Daiichi, AstraZeneca, Janssen, Medivation, Ichor, Toyama, Lundbeck, Biogen Idec, iPerian, Probiodrug, Somaxon, Biotie, Cardeus, Anavex, Kyowa Hakko Kirin Pharma, and Medtronic; and receives research support from Eli Lilly. Dr Sperling is funded by Boehringer-Ingelheim, Bristol-Myers Squibb, Eisai, Genentech, Janssen, Lundbeck, Merck, and Roche.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2015</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24886908</ArticleId><ArticleId IdType="mid">NIHMS688836</ArticleId><ArticleId IdType="pmc">PMC4439182</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2014.803</ArticleId><ArticleId IdType="pii">1875831</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):280&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3220946</ArticleId><ArticleId IdType="pubmed">21514248</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly Inherited Alzheimer Network Clinical and biomarker changes in dominantly inherited Alzheimer&#x2019;s disease. N Engl J Med. 2012;367(9):795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3474597</ArticleId><ArticleId IdType="pubmed">22784036</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemagne VL, Burnham S, Bourgeat P, et al. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group Amyloid &#x3b2; deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer&#x2019;s disease: a prospective cohort study. Lancet Neurol. 2013;12(4):357&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">23477989</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Jacqmin-Gadda H, Le Goff M, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative Estimating long-term multivariate progression from short-term data [published online March 24, 2014] Alzheimers Dement. doi: 10.1016/j.jalz.2013.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.10.003</ArticleId><ArticleId IdType="pmc">PMC4169767</ArticleId><ArticleId IdType="pubmed">24656849</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer&#x2019;s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">17616482</ArticleId></ArticleIdList></Reference><Reference><Citation>Aisen PS, Andrieu S, Sampaio C, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 2011;76(3):280&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034393</ArticleId><ArticleId IdType="pubmed">21178097</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer&#x2019;s disease: recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(3):270&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Jack CR, Jr, Aisen PS. Testing the right target and right drug at the right stage. Sci Transl Med. 2011;3(111):111cm33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3752906</ArticleId><ArticleId IdType="pubmed">22133718</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR, Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer&#x2019;s disease. Alzheimers Dement. 2011;7(4):474&#x2013;485e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396131</ArticleId><ArticleId IdType="pubmed">21784356</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiman EM, Alzheimer&#x2019;s Disease Biomarkers Working Group for the Alliance for Aging Research Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer&#x2019;s disease-modifying treatments. Neurobiol Aging. 2011;32(suppl 1):S44&#x2013;S47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3343736</ArticleId><ArticleId IdType="pubmed">21983241</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-&#x3b2; load in patients with Alzheimer&#x2019;s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pubmed">20189881</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">21987394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings JL. Biomarkers in Alzheimer&#x2019;s disease drug development. Alzheimers Dement. 2011;7(3):e13&#x2013;e44.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550318</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox NC, Black RS, Gilman S, et al. AN1792(QS-21)-201 Study Effects of A&#x3b2; immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64(9):1563&#x2013;1572.</Citation><ArticleIdList><ArticleId IdType="pubmed">15883317</ArticleId></ArticleIdList></Reference><Reference><Citation>Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer&#x2019;s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">19067364</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon DP, Ferris SH, Thomas RG, et al. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 2013;27(4):391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3831285</ArticleId><ArticleId IdType="pubmed">23876113</ArticleId></ArticleIdList></Reference><Reference><Citation>US Dept of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry: Alzheimer&#x2019;s disease: developing drugs for the treatment of early stage disease (draft guidance)   http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338287.pdf. Published February 2013. Accessed April 28, 2014.</Citation></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: Stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):28fs13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Elias MF, Beiser A, Wolf PA, Au R, White RF, D&#x2019;Agostino RB. The preclinical phase of Alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">10867777</ArticleId></ArticleIdList></Reference><Reference><Citation>Grober E, Hall CB, Lipton RB, Zonderman AB, Resnick SM, Kawas C. Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer&#x2019;s disease. J Int Neuropsychol Soc. 2008;14(2):266&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2763488</ArticleId><ArticleId IdType="pubmed">18282324</ArticleId></ArticleIdList></Reference><Reference><Citation>Derby CA, Burns LC, Wang C, et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology. 2013;80(14):1307&#x2013;1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656458</ArticleId><ArticleId IdType="pubmed">23468542</ArticleId></ArticleIdList></Reference><Reference><Citation>Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology. 2010;74(10):807&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839197</ArticleId><ArticleId IdType="pubmed">20147655</ArticleId></ArticleIdList></Reference><Reference><Citation>Landau SM, Mintun MA, Joshi AD, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72(4):578&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786871</ArticleId><ArticleId IdType="pubmed">23109153</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitz BE, Weissfeld LA, Lopez OL, et al. Cognitive trajectories associated with &#x3b2;-amyloid deposition in the oldest-old without dementia. Neurology. 2013;80(15):1378&#x2013;1384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3662268</ArticleId><ArticleId IdType="pubmed">23516317</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469&#x2013;1475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2798814</ArticleId><ArticleId IdType="pubmed">20008650</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim YY, Ellis KA, Pietrzak RH, et al. AIBL Research Group Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology. 2012;79(16):1645&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">23071163</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman DS, Jack CR, Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78(20):1576&#x2013;1582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3348848</ArticleId><ArticleId IdType="pubmed">22551733</ArticleId></ArticleIdList></Reference><Reference><Citation>Doraiswamy PM, Sperling RA, Coleman RE, et al. AV45-A11 Study Group Amyloid-&#x3b2; assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology. 2012;79(16):1636&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468774</ArticleId><ArticleId IdType="pubmed">22786606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawas CH, Greenia DE, Bullain SS, et al. Amyloid imaging and cognitive decline in nondemented oldest-old: the 90+ Study. Alzheimers Dement. 2013;9(2):199&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3604036</ArticleId><ArticleId IdType="pubmed">23164550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris SH, Aisen PS, Cummings J, et al. Alzheimer&#x2019;s Disease Cooperative Study Group ADCS Prevention Instrument Project: overview and initial results. Alzheimer Dis Assoc Disord. 2006;20(4 suppl 3):S109&#x2013;S123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17135805</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler D. WMS-R: Wechsler Memory Scale&#x2013;Revised: Manual. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Adult Intelligence Scale&#x2013;Revised. San Antonio, TX: Psychological Corporation; 1981.</Citation></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189&#x2013;198.</Citation><ArticleIdList><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5):871&#x2013;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">10355672</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer&#x2019;s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2809036</ArticleId><ArticleId IdType="pubmed">20042704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer&#x2019;s Disease Assessment Scale that broaden its scope: the Alzheimer&#x2019;s Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S13&#x2013;S21.</Citation><ArticleIdList><ArticleId IdType="pubmed">9236948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis KA, Bush AI, Darby D, et al. AIBL Research Group The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer&#x2019;s disease. Int Psychogeriatr. 2009;21(4):672&#x2013;687.</Citation><ArticleIdList><ArticleId IdType="pubmed">19470201</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. The California Verbal Learning Test. San Antonio, TX: Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Kluger A, Ferris SH, Golomb J, Mittelman MS, Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol. 1999;12(4):168&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">10616864</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry. 1987;48(8):314&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">3611032</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaike H. Information theory as an extension of the maximum likelihood principle. In: Petrov BN, Csaki F, editors. Second International Symposium on Information Theory. Budapest, Hungary: Akad&#xe9;miai Kiad&#xf3;; 1973. pp. 267&#x2013;281.</Citation></Reference><Reference><Citation>Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50(3):346&#x2013;363. doi: 10.1002/bimj.200810425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bimj.200810425</ArticleId><ArticleId IdType="pubmed">18481363</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilding GE, Chandrasekhar R, Hutson AD. A new linear model-based approach for inferences about the mean area under the curve. Stat Med. 2012;31(28):3563&#x2013;3578. doi: 10.1002/sim.5387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5387</ArticleId><ArticleId IdType="pubmed">23175104</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu K, Luo X, Chen PY. Sample size estimation for repeated measures analysis in randomized clinical trials with missing data. Int J Biostat. 2008;4(1):9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22462117</ArticleId></ArticleIdList></Reference><Reference><Citation>Donohue MC, Gamst AC, Edland SD. longpower: sample size calculation for longitudinal data.   http://www.cran.r-project.org/web/packages/longpower/index.html. Published September 21, 2013. Accessed May 1, 2014.</Citation></Reference><Reference><Citation>The Comprehensive R Archive Network.   http://www.cran.r-project.org/. Accessed May 1, 2014.</Citation></Reference><Reference><Citation>Pinheiro J, Bates D, DebRoy S, Sarkar D, editors. nlme: linear and nonlinear mixed effects models.   http://www.cran.r-project.org/web/packages/nlme/index.html. Published March 31, 2014. Accessed May 1, 2014.</Citation></Reference><Reference><Citation>Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer; 2009.</Citation></Reference><Reference><Citation>Rizopoulos D. ltm: an R package for latent variable modeling and item response analyses. J Stat Softw. 2006;17(5):1&#x2013;25.  http://www.jstatsoft.org/v17/i05/. Accessed May 1, 2014.</Citation></Reference><Reference><Citation>Nelder JA, Mead R. A simplex method for function minimization. Comput J. 1965;7(4):308&#x2013;313. doi: 10.1093/comjnl/7.4.308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/comjnl/7.4.308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozauer N, Katz R. Regulatory innovation and drug development for early-stage Alzheimer&#x2019;s disease. N Engl J Med. 2013;368(13):1169&#x2013;1171.</Citation><ArticleIdList><ArticleId IdType="pubmed">23484795</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24834516</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-4687</ISSN><JournalIssue CitedMedium="Internet"><Volume>509</Volume><Issue>7500</Issue><PubDate><Year>2014</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Nature</Title><ISOAbbreviation>Nature</ISOAbbreviation></Journal><ArticleTitle>Policy: NIH to balance sex in cell and animal studies.</ArticleTitle><Pagination><StartPage>282</StartPage><EndPage>283</EndPage><MedlinePgn>282-3</MedlinePgn></Pagination><Abstract><AbstractText><b>Janine A. Clayton</b> and <b>Francis S. Collins</b> unveil policies to ensure that preclinical research funded by the US National Institutes of Health considers females and males.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Janine A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Francis S</ForeName><Initials>FS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nature</MedlineTA><NlmUniqueID>0410462</NlmUniqueID><ISSNLinking>0028-0836</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Jun 19;510(7505):340. doi: 10.1038/510340b.</RefSource><PMID Version="1">24943945</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Nature. 2014 Jun 19;510(7505):340. doi: 10.1038/510340a.</RefSource><PMID Version="1">24943947</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D032761" MajorTopicYN="Y">Animal Experimentation</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000830" MajorTopicYN="N">Animals, Laboratory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004681" MajorTopicYN="N">Encephalomyelitis, Autoimmune, Experimental</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005381" MajorTopicYN="N">Financing, Organized</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="Y">National Institutes of Health (U.S.)</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017712" MajorTopicYN="N">Peer Review, Research</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="Y">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="Y">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012744" MajorTopicYN="Y">Sex Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>11</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24834516</ArticleId><ArticleId IdType="pmc">PMC5101948</ArticleId><ArticleId IdType="doi">10.1038/509282a</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zucker I, Beery AK. Nature. 2010;465:690.</Citation><ArticleIdList><ArticleId IdType="pubmed">20535186</ArticleId></ArticleIdList></Reference><Reference><Citation>Beery AK, Zucker I. Neurosci Biobehav Rev. 2011;35:565&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3008499</ArticleId><ArticleId IdType="pubmed">20620164</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogil JS, Chanda ML. Pain. 2005;117:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">16098670</ArticleId></ArticleIdList></Reference><Reference><Citation>Franconi F, Brunelleschi S, Steardo L, Cuomo V. Pharmacol Res. 2007;55:81&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17129734</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins FS, Tabak LA. Nature. 2014;505:612&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4058759</ArticleId><ArticleId IdType="pubmed">24482835</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis SC, et al. Nature. 2012;490:187&#x2013;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511845</ArticleId><ArticleId IdType="pubmed">23060188</ArticleId></ArticleIdList></Reference><Reference><Citation>Voskuhl RR, Palaszynski K. Neuroscientist. 2001;7:258&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pubmed">11499404</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisdom AJ, Cao Y, Itoh N, Spence RD, Voskuhl RR. J Neurosci Res. 2013;91:901&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4376676</ArticleId><ArticleId IdType="pubmed">23633287</ArticleId></ArticleIdList></Reference><Reference><Citation>Du S, et al. Proc Natl Acad Sci USA. 2014;111:2806&#x2013;2811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932937</ArticleId><ArticleId IdType="pubmed">24550311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebers GC, et al. Lancet. 2004;363:1773&#x2013;1774.</Citation><ArticleIdList><ArticleId IdType="pubmed">15172777</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox HC, Morgan PT, Sinha R. Neuropsychopharmacol. 2014;39:1527&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3988558</ArticleId><ArticleId IdType="pubmed">24395021</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendergast BJ, Onishi KG, Zucker I. Neurosci Biobehav Rev. 2014;40:1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24456941</ArticleId></ArticleIdList></Reference><Reference><Citation>Du L, Bayir H, Lai Y, et al. J Biol Chem. 2004;279:38563&#x2013;38570.</Citation><ArticleIdList><ArticleId IdType="pubmed">15234982</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker JB, et al. Endocrinology. 2005;146:1650&#x2013;1673.</Citation><ArticleIdList><ArticleId IdType="pubmed">15618360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, et al. PLoS Genet. 2012;8:e1002709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3349739</ArticleId><ArticleId IdType="pubmed">22589744</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24893131</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><PubDate><Year>2014</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43.</ArticleTitle><Pagination><StartPage>3996</StartPage><MedlinePgn>3996</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3996</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/ncomms4996</ELocationID><Abstract><AbstractText>Mitochondria and the endoplasmic reticulum (ER) form tight structural associations and these facilitate a number of cellular functions. However, the mechanisms by which regions of the ER become tethered to mitochondria are not properly known. Understanding these mechanisms is not just important for comprehending fundamental physiological processes but also for understanding pathogenic processes in some disease states. In particular, disruption to ER-mitochondria associations is linked to some neurodegenerative diseases. Here we show that the ER-resident protein VAPB interacts with the mitochondrial protein tyrosine phosphatase-interacting protein-51 (PTPIP51) to regulate ER-mitochondria associations. Moreover, we demonstrate that TDP-43, a protein pathologically linked to amyotrophic lateral sclerosis and fronto-temporal dementia perturbs ER-mitochondria interactions and that this is associated with disruption to the VAPB-PTPIP51 interaction and cellular Ca(2+) homeostasis. Finally, we show that overexpression of TDP-43 leads to activation of glycogen synthase kinase-3&#x3b2; (GSK-3&#x3b2;) and that GSK-3&#x3b2; regulates the VAPB-PTPIP51 interaction. Our results describe a new pathogenic mechanism for TDP-43.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stoica</LastName><ForeName>Radu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Vos</LastName><ForeName>Kurt J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [3] [4].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paillusson</LastName><ForeName>S&#xe9;bastien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sancho</LastName><ForeName>Rosa M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [3].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Kwok-Fai</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2].</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizcay-Barrena</LastName><ForeName>Gema</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Ultrastructural Imaging, King's College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wen-Lang</ForeName><Initials>WL</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Ya-Fei</ForeName><Initials>YF</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Jada</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucelli</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, Jacksonville, Florida 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Jacqueline C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Christopher C J</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>1] Department of Neuroscience, Institute of Psychiatry, Kings College London, London SE5 8AF, UK [2] Clinical Neurosciences, Institute of Psychiatry, Kings College London, London SE5 8AF, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>089701</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900635</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_G1000733</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G1100695</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0900688</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MILLER/OCT08/6247</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>078662</GrantID><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K005146/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0501573</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0500289</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024101">Mitochondrial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578077">TDP-43 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496748">VAPB protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C529892">VAPB protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D033921">Vesicular Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605506">GSK3B protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="D000071679">Glycogen Synthase Kinase 3 beta</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.1</RegistryNumber><NameOfSubstance UI="C000605507">Gsk3b protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.26</RegistryNumber><NameOfSubstance UI="D038362">Glycogen Synthase Kinase 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C534801">PTPIP51 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D017027">Protein Tyrosine Phosphatases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C515449">RMDN3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038362" MajorTopicYN="N">Glycogen Synthase Kinase 3</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071679" MajorTopicYN="N">Glycogen Synthase Kinase 3 beta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024101" MajorTopicYN="N">Mitochondrial Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017027" MajorTopicYN="N">Protein Tyrosine Phosphatases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D033921" MajorTopicYN="N">Vesicular Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">EMS58329</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24893131</ArticleId><ArticleId IdType="mid">EMS58329</ArticleId><ArticleId IdType="pmc">PMC4046113</ArticleId><ArticleId IdType="doi">10.1038/ncomms4996</ArticleId><ArticleId IdType="pii">ncomms4996</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rizzuto R. et al.. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. Science 280, 1763&#x2013;1766 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9624056</ArticleId></ArticleIdList></Reference><Reference><Citation>Csordas G. et al.. Structural and functional features and significance of the physical linkage between ER and mitochondria. J. Cell Biol. 174, 915&#x2013;921 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2064383</ArticleId><ArticleId IdType="pubmed">16982799</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi T., Rizzuto R., Hajnoczky G. &amp; Su T. P. MAM: more than just a housekeeper. Trends Cell Biol. 19, 81&#x2013;88 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750097</ArticleId><ArticleId IdType="pubmed">19144519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland A. A. &amp; Voeltz G. K. Endoplasmic reticulum-mitochondria contacts: function of the junction. Nat. Rev. Mol. Cell Biol. 13, 607&#x2013;625 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5111635</ArticleId><ArticleId IdType="pubmed">22992592</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornmann B. The molecular hug between the ER and the mitochondria. Curr. Opin. Cell Biol. 25, 443&#x2013;448 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23478213</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmen T., Lynes E. M., Gesson K. &amp; Thomas G. Oxidative protein folding in the endoplasmic reticulum: Tight links to the mitochondria-associated membrane (MAM). Biochim. Biophys. Acta 1798, 1465&#x2013;1473 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2885528</ArticleId><ArticleId IdType="pubmed">20430008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamasaki M. et al.. Autophagosomes form at ER-mitochondria contact sites. Nature 495, 389&#x2013;393 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23455425</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobova F., Ramabhadran V. &amp; Higgs H. N. An actin-dependent step in mitochondrial fission mediated by the ER-associated formin INF2. Science 339, 464&#x2013;467 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843506</ArticleId><ArticleId IdType="pubmed">23349293</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornmann B. et al.. An ER-mitochondria tethering complex revealed by a synthetic biology screen. Science 325, 477&#x2013;481 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2933203</ArticleId><ArticleId IdType="pubmed">19556461</ArticleId></ArticleIdList></Reference><Reference><Citation>de Brito O. M. &amp; Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456, 605&#x2013;610 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">19052620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cali T., Ottolini D., Negro A. &amp; Brini M. Alpha-synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 287, 17914&#x2013;17929 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3365710</ArticleId><ArticleId IdType="pubmed">22453917</ArticleId></ArticleIdList></Reference><Reference><Citation>Area-Gomez E. et al.. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. EMBO J. 31, 4106&#x2013;4123 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3492725</ArticleId><ArticleId IdType="pubmed">22892566</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampese E. et al.. Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc. Natl Acad. Sci. USA 108, 2777&#x2013;2782 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041131</ArticleId><ArticleId IdType="pubmed">21285369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedskog L. et al.. Modulation of the endoplasmic reticulum-mitochondria interface in Alzheimer&#x2019;s disease and related models. Proc. Natl Acad. Sci. USA 110, 7916&#x2013;7921 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3651455</ArticleId><ArticleId IdType="pubmed">23620518</ArticleId></ArticleIdList></Reference><Reference><Citation>Guardia-Laguarta C. et al.. alpha-Synuclein is localized to mitochondria-associated ER membranes. J. Neurosci. 34, 249&#x2013;259 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3866487</ArticleId><ArticleId IdType="pubmed">24381286</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M. et al.. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130&#x2013;113 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R., Neumann M. &amp; Mackenzie I. R. Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8, 423&#x2013;434 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. &amp; Baralle F. E. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem. Sci. 37, 237&#x2013;247 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen T. J., Lee V. M. &amp; Trojanowski J. Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 17, 659&#x2013;667 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos K. J. et al.. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Hum. Mol. Genet. 21, 1299&#x2013;1311 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284118</ArticleId><ArticleId IdType="pubmed">22131369</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosson P., Marchetti A., Ravazzola M. &amp; Orci L. Mitofusin-2 independent juxtaposition of endoplasmic reticulum and mitochondria: an ultrastructural study. PLoS ONE 7, e46293 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460865</ArticleId><ArticleId IdType="pubmed">23029466</ArticleId></ArticleIdList></Reference><Reference><Citation>Csordas G. et al.. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol. Cell 39, 121&#x2013;132 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3178184</ArticleId><ArticleId IdType="pubmed">20603080</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q. et al.. A syntaxin 1, Galpha(o), and N-type calcium channel complex at a presynaptic nerve terminal: analysis by quantitative immunocolocalization. J. Neurosci. 24, 4070&#x2013;4081 (2004).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6729428</ArticleId><ArticleId IdType="pubmed">15102922</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallings N. R., Puttaparthi K., Luther C. M., Burns D. K. &amp; Elliott J. L. Progressive motor weakness in transgenic mice expressing human TDP-43. Neurobiol. Dis. 40, 404&#x2013;414 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20621187</ArticleId></ArticleIdList></Reference><Reference><Citation>Wils H. et al.. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc. Natl Acad. Sci. USA 107, 3858&#x2013;3863 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2840518</ArticleId><ArticleId IdType="pubmed">20133711</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y. F. et al.. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J. Neurosci. 30, 10851&#x2013;10859 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056148</ArticleId><ArticleId IdType="pubmed">20702714</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V. et al.. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 134, 2610&#x2013;2626 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan X., Chiang P. M., Price D. L. &amp; Wong P. C. Altered distributions of Gemini of coiled bodies and mitochondria in motor neurons of TDP-43 transgenic mice. Proc. Natl Acad. Sci. USA 107, 16325&#x2013;16330 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2941282</ArticleId><ArticleId IdType="pubmed">20736350</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H. &amp; Matsuoka M. ALS-linked mutant VAPB enhances TDP-43-induced motor neuronal toxicity. J. Neurochem. 119, 1099&#x2013;1107 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21933185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambegaokar S. S. &amp; Jackson G. R. Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum. Mol. Genet. 20, 4947&#x2013;4977 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221533</ArticleId><ArticleId IdType="pubmed">21949350</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S. et al.. Alzheimer&#x2019;s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077&#x2013;1086 (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7704571</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H. et al.. Transgenic rat model of neurodegeneration caused by mutation in the TDP Gene. PLoS Genet. 6, e1000887 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845661</ArticleId><ArticleId IdType="pubmed">20361056</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura A. L. et al.. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain 133, 1763&#x2013;1771 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C., Bassell G. J. &amp; Rossoll W. The ALS disease protein TDP-43 is actively transported in motor neuron axons and regulates axon outgrowth. Hum. Mol. Genet. 21, 3703&#x2013;3718 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406762</ArticleId><ArticleId IdType="pubmed">22641816</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W. et al.. The ALS disease associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Hum. Mol. Genet. 22, 4706&#x2013;4719 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3820133</ArticleId><ArticleId IdType="pubmed">23827948</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A. K. et al.. ALS-associated TDP-43 Induces endoplasmic reticulum stress, which drives cytoplasmic TDP-43 accumulation and stress granule formation. PLoS ONE 8, e81170 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843686</ArticleId><ArticleId IdType="pubmed">24312274</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong J. et al.. XBP1 depletion precedes ubiquitin aggregation and Golgi fragmentation in TDP-43 transgenic rats. J. Neurochem. 123, 406&#x2013;416 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534861</ArticleId><ArticleId IdType="pubmed">22970712</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H. &amp; Matsuoka M. TDP-43 toxicity is mediated by the unfolded protein response-unrelated induction of C/EBP homologous protein expression. J. Neurosci. Res. 90, 641&#x2013;647 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22057717</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccaro A. et al.. TDP-1/TDP-43 regulates stress signaling and age-dependent proteotoxicity in Caenorhabditis elegans. PLoS Genet. 8, e1002806 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3390363</ArticleId><ArticleId IdType="pubmed">22792076</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun R. J. et al.. Neurotoxic 43-kDa TAR DNA-binding protein (TDP-43) triggers mitochondrion-dependent programmed cell death in yeast. J. Biol. Chem. 286, 19958&#x2013;19972 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3103370</ArticleId><ArticleId IdType="pubmed">21471218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao W. et al.. Rodent models of TDP-43: recent advances. Brain Res. 1462, 26&#x2013;39 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3613131</ArticleId><ArticleId IdType="pubmed">22608070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper C., Killick R. &amp; Lovestone S. The GSK3 hypothesis of Alzheimer&#x2019;s disease. J. Neurochem. 104, 1433&#x2013;1439 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073119</ArticleId><ArticleId IdType="pubmed">18088381</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Perez D. I., Gil C. &amp; Martinez A. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy. Curr. Med. Chem. 18, 3028&#x2013;3034 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21651477</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L., Kirby J., Grierson A. J., Sendtner M. &amp; Shaw P. J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7, 616&#x2013;630 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths E. J. &amp; Rutter G. A. Mitochondrial calcium as a key regulator of mitochondrial ATP production in mammalian cells. Biochim. Biophys. Acta 1787, 1324&#x2013;1333 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19366607</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolome F. et al.. Pathogenic VCP mutations induce mitochondrial uncoupling and reduced ATP levels. Neuron 78, 57&#x2013;64 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3843114</ArticleId><ArticleId IdType="pubmed">23498975</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxton W. M. &amp; Hollenbeck P. J. The axonal transport of mitochondria. J. Cell Sci. 125, 2095&#x2013;2104 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656622</ArticleId><ArticleId IdType="pubmed">22619228</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman J. R., Webster B. M., Mastronarde D. N., Verhey K. J. &amp; Voeltz G. K. ER sliding dynamics and ER-mitochondrial contacts occur on acetylated microtubules. J. Cell Biol. 190, 363&#x2013;375 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2922647</ArticleId><ArticleId IdType="pubmed">20696706</ArticleId></ArticleIdList></Reference><Reference><Citation>Kornmann B., Osman C. &amp; Walter P. The conserved GTPase Gem1 regulates endoplasmic reticulum-mitochondria connections. Proc. Natl Acad. Sci. USA 108, 14151&#x2013;14156 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3161550</ArticleId><ArticleId IdType="pubmed">21825164</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Zhang X., Song L. &amp; Le W. Autophagy dysregulation in amyotrophic lateral sclerosis. Brain Pathol. 22, 110&#x2013;116 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029048</ArticleId><ArticleId IdType="pubmed">22150926</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang I. F. et al.. Autophagy activators rescue and alleviate pathogenesis of a mouse model with proteinopathies of the TAR DNA-binding protein 43. Proc. Natl Acad. Sci. USA 109, 15024&#x2013;15029 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3443184</ArticleId><ArticleId IdType="pubmed">22932872</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmen T. et al.. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. EMBO J. 24, 717&#x2013;729 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC549619</ArticleId><ArticleId IdType="pubmed">15692567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekura K., Suzuki H., Aiso S. &amp; Matsuoka M. ER Stress and unfolded protein response in amyotrophic lateral sclerosis. Mol. Neurobiol. 39, 81&#x2013;89 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19184563</ArticleId></ArticleIdList></Reference><Reference><Citation>Sepulveda-Falla D. et al.. Familial Alzheimer&#x2019;s disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. J. Clin. Invest. 124, 1552&#x2013;1567 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3973081</ArticleId><ArticleId IdType="pubmed">24569455</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J. et al.. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1688&#x2013;1672 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Morotz G. M. et al.. Amyotrophic lateral sclerosis-associated mutant VAPBP56S perturbs calcium homeostasis to disrupt axonal transport of mitochondria. Hum. Mol. Genet. 21, 1979&#x2013;1988 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3315205</ArticleId><ArticleId IdType="pubmed">22258555</ArticleId></ArticleIdList></Reference><Reference><Citation>Vagnoni A., Rodriguez L., Manser C., De Vos K. J. &amp; Miller C. C. J. Phosphorylation of kinesin light chain-1 at serine-460 modulates binding and trafficking of calsyntenin-1. J. Cell Sci. 124, 1032&#x2013;1042 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056604</ArticleId><ArticleId IdType="pubmed">21385839</ArticleId></ArticleIdList></Reference><Reference><Citation>Perkinton M. S. et al.. The c-Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to stimulate Fe65/amyloid precursor protein nuclear signalling. J. Biol. Chem. 279, 22084&#x2013;22091 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15031292</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerley S. et al.. Glutamate slows axonal transport of neurofilaments in transfected neurons. J. Cell Biol. 150, 165&#x2013;175 (2000).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2185569</ArticleId><ArticleId IdType="pubmed">10893265</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24893973</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2014</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Altered microglial response to A&#x3b2; plaques in APPPS1-21 mice heterozygous for TREM2.</ArticleTitle><Pagination><StartPage>20</StartPage><MedlinePgn>20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1750-1326-9-20</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent genome-wide association studies linked variants in TREM2 to a strong increase in the odds of developing Alzheimer's disease. The mechanism by which TREM2 influences the susceptibility to Alzheimer's disease is currently unknown. TREM2 is expressed by microglia and is thought to regulate phagocytic and inflammatory microglial responses to brain pathology. Given that a single allele of variant TREM2, likely resulting in a loss of function, conferred an increased risk of developing Alzheimer's disease, we tested whether loss of one functional trem2 allele would affect A&#x3b2; plaque deposition or the microglial response to A&#x3b2; pathology in APPPS1-21 mice.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was no significant difference in A&#x3b2; deposition in 3-month old or 7-month old APPPS1-21 mice expressing one or two copies of trem2. However, 3-month old mice with one copy of trem2 exhibited a marked decrease in the number and size of plaque-associated microglia. While there were no statistically significant differences in cytokine levels or markers of microglial activation in 3- or 7-month old animals, there were trends towards decreased expression of NOS2, C1qa, and IL1a in 3-month old TREM2+/- vs. TREM2+/+ mice.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Loss of a single copy of trem2 had no effect on A&#x3b2; pathology, but altered the morphological phenotype of plaque-associated microglia. These data suggest that TREM2 is important for the microglial response to A&#x3b2; deposition but that a 50% decrease inTREM2 expression does not affect A&#x3b2; plaque burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ulrich</LastName><ForeName>Jason D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Finn</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yaming</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Alice</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mahan</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hong</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>Floy R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Piccio</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Colonna</LastName><ForeName>Marco</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri 63110, USA. holtzman@neuro.wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32 NS083187</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32-NS083187-01A1</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053764">Presenilin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498716">Trem2 protein, mouse</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006579" MajorTopicYN="N">Heterozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053764" MajorTopicYN="N">Presenilin-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24893973</ArticleId><ArticleId IdType="pmc">PMC4049806</ArticleId><ArticleId IdType="doi">10.1186/1750-1326-9-20</ArticleId><ArticleId IdType="pii">#N/A</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tanzi RE. In: The Biology of Alzheimer Disease. Selkoe DJ, Mandelkow E, Holtzman DM, editor. New York: Cold Spring Harbor Press; 2011. The Genetics of Alzheimer Disease; pp. 249&#x2013;258.</Citation></Reference><Reference><Citation>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer&#x2019;s disease in late onset families. Science. 1993;261:921&#x2013;923. doi: 10.1126/science.8346443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8346443</ArticleId><ArticleId IdType="pubmed">8346443</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JSK, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J. TREM2 variants in Alzheimer&#x2019;s disease. New Engl J Med. 2013;368:117&#x2013;127. doi: 10.1056/NEJMoa1211851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211851</ArticleId><ArticleId IdType="pmc">PMC3631573</ArticleId><ArticleId IdType="pubmed">23150934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. New Engl J Med. 2013;368:107&#x2013;116. doi: 10.1056/NEJMoa1211103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pmc">PMC3677583</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchon A, Hern&#xe1;ndez-Munain C, Cella M, Colonna M. A Dap12-mediated pathway regulates expression of Cc chemokine receptor 7 and maturation of human dendritic cells. J Exp Med. 2001;194:1111&#x2013;1122. doi: 10.1084/jem.194.8.1111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.194.8.1111</ArticleId><ArticleId IdType="pmc">PMC2193511</ArticleId><ArticleId IdType="pubmed">11602640</ArticleId></ArticleIdList></Reference><Reference><Citation>Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y, Peltonen L. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet. 2002;71:656&#x2013;662. doi: 10.1086/342259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342259</ArticleId><ArticleId IdType="pmc">PMC379202</ArticleId><ArticleId IdType="pubmed">12080485</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid CD, Sautkulis LN, Danielson PE, Cooper J, Hasel KW, Hilbush BS, Sutcliffe JG, Carson MJ. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem. 2002;83:1309&#x2013;1320. doi: 10.1046/j.1471-4159.2002.01243.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01243.x</ArticleId><ArticleId IdType="pmc">PMC2637869</ArticleId><ArticleId IdType="pubmed">12472885</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Rochford CDP, Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 2005;201:647&#x2013;657. doi: 10.1084/jem.20041611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041611</ArticleId><ArticleId IdType="pmc">PMC2213053</ArticleId><ArticleId IdType="pubmed">15728241</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M, Panina-Bordignon P. Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol. 2007;37:1290&#x2013;1301. doi: 10.1002/eji.200636837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200636837</ArticleId><ArticleId IdType="pubmed">17407101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieber MW, Jaenisch N, Brehm M, Guenther M, Linnartz-Gerlach B, Neumann H, Witte OW, Frahm C. Attenuated inflammatory response in triggering receptor expressed on myeloid cells 2 (TREM2) knock-out mice following stroke. PLoS One. 2013;8:e52982. doi: 10.1371/journal.pone.0052982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052982</ArticleId><ArticleId IdType="pmc">PMC3536811</ArticleId><ArticleId IdType="pubmed">23301011</ArticleId></ArticleIdList></Reference><Reference><Citation>Melchior B, Garcia AE, Hsiung BK, Lo KM, Doose JM, Thrash JC, Stalder AK, Staufenbiel M, Neumann H, Carson MJ. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer&#x2019;s disease. ASN Neuro. 2010;2:e00037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905103</ArticleId><ArticleId IdType="pubmed">20640189</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank S, Burbach GJ, Bonin M, Walter M, Streit W, Bechmann I, Deller T. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia. 2008;56:1438&#x2013;1447. doi: 10.1002/glia.20710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.20710</ArticleId><ArticleId IdType="pubmed">18551625</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer&#x2019;s disease. Nature. 2008;451:720&#x2013;724. doi: 10.1038/nature06616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature06616</ArticleId><ArticleId IdType="pmc">PMC3264491</ArticleId><ArticleId IdType="pubmed">18256671</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME. Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci. 2008;28:4283&#x2013;4292. doi: 10.1523/JNEUROSCI.4814-07.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4814-07.2008</ArticleId><ArticleId IdType="pmc">PMC3844768</ArticleId><ArticleId IdType="pubmed">18417708</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339:156&#x2013;161. doi: 10.1126/science.1227901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1227901</ArticleId><ArticleId IdType="pmc">PMC4431634</ArticleId><ArticleId IdType="pubmed">23307732</ArticleId></ArticleIdList></Reference><Reference><Citation>Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, J&#xe4;ggi F, Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, H&#xf6;lscher C, Mathews PM, Jucker M. A&#x3b2;42&#x2012;driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Reports. 2006;7:940&#x2013;946. doi: 10.1038/sj.embor.7400784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400784</ArticleId><ArticleId IdType="pmc">PMC1559665</ArticleId><ArticleId IdType="pubmed">16906128</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR. Analysis of fractalkine receptor CX3CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20:4106&#x2013;4114. doi: 10.1128/MCB.20.11.4106-4114.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.20.11.4106-4114.2000</ArticleId><ArticleId IdType="pmc">PMC85780</ArticleId><ArticleId IdType="pubmed">10805752</ArticleId></ArticleIdList></Reference><Reference><Citation>Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer&#x2019;s disease pathology. J Histochem Cytochem. 2000;48:1223&#x2013;1232. doi: 10.1177/002215540004800906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/002215540004800906</ArticleId><ArticleId IdType="pubmed">10950879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaikwad S, Heneka M. In: Microglia. Volume 1041. Joseph B, Venero JL, editor. New York: Humana Press; 2013. Studying M1 and M2 States in Adult Microglia; pp. 185&#x2013;197. Methods in Molecular Biology]</Citation><ArticleIdList><ArticleId IdType="pubmed">23813380</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher KI, Wyss-Coray T. Microglial dysfunction in brain aging and Alzheimer&#x2019;s disease. Biochem Pharmacol. 2014;88:594&#x2013;604.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3972294</ArticleId><ArticleId IdType="pubmed">24445162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63&#x2013;73. doi: 10.1016/S0002-9440(10)63945-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63945-4</ArticleId><ArticleId IdType="pmc">PMC1850262</ArticleId><ArticleId IdType="pubmed">11141480</ArticleId></ArticleIdList></Reference><Reference><Citation>Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, Levine AP, Hardy J, Pocock JM, Guerreiro R, Weale ME, Ryten M. Insights into TREM2 biology by network analysis of human brain gene expression data. Neurobiol Aging. 2013;34:2699&#x2013;2714. doi: 10.1016/j.neurobiolaging.2013.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.05.001</ArticleId><ArticleId IdType="pmc">PMC3988951</ArticleId><ArticleId IdType="pubmed">23855984</ArticleId></ArticleIdList></Reference><Reference><Citation>Koth LL, Cambier CJ, Ellwanger A, Solon M, Hou L, Lanier LL, Abram CL, Hamerman JA, Woodruff PG. DAP12 is required for macrophage recruitment to the lung in response to cigarette smoke and chemotaxis toward CCL2. J Immunol. 2010;184:6522&#x2013;6528. doi: 10.4049/jimmunol.0901171.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0901171</ArticleId><ArticleId IdType="pmc">PMC4091814</ArticleId><ArticleId IdType="pubmed">20421649</ArticleId></ArticleIdList></Reference><Reference><Citation>Bondolfi L, Calhoun M, Ermini F, Kuhn HG, Wiederhold K-H, Walker L, Staufenbiel M, Jucker M. Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758656</ArticleId><ArticleId IdType="pubmed">11784797</ArticleId></ArticleIdList></Reference><Reference><Citation>Otero K, Shinohara M, Zhao H, Cella M, Gilfillan S, Colucci A, Faccio R, Ross FP, Teitelbaum SL, Takayanagi H, Colonna M. TREM2 and &#x3b2;-catenin regulate bone homeostasis by controlling the rate of osteoclastogenesis. J Immunol. 2012;188:2612&#x2013;2621. doi: 10.4049/jimmunol.1102836.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1102836</ArticleId><ArticleId IdType="pmc">PMC3732181</ArticleId><ArticleId IdType="pubmed">22312126</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore Monica RP, Najafi Allison R, Koike Maya A, Dagher Nabil N, Spangenberg Elizabeth E, Rice Rachel A, Kitazawa M, Matusow B, Nguyen H, West Brian L, Green Kim N. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron. 2014;82:380&#x2013;397. doi: 10.1016/j.neuron.2014.02.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.02.040</ArticleId><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Nicola D, Fransen NL, Suzzi S, Perry VH. Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci. 2013;33:2481&#x2013;2493. doi: 10.1523/JNEUROSCI.4440-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4440-12.2013</ArticleId><ArticleId IdType="pmc">PMC6619184</ArticleId><ArticleId IdType="pubmed">23392676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, Barrow AD, Diamond MS, Colonna M. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941469</ArticleId><ArticleId IdType="pubmed">22729249</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol. 2006;177:3520&#x2013;3524. doi: 10.4049/jimmunol.177.6.3520.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.6.3520</ArticleId><ArticleId IdType="pubmed">16951310</ArticleId></ArticleIdList></Reference><Reference><Citation>Griciuc A, Serrano-Pozo A, Parrado Antonio R, Lesinski Andrea N, Asselin Caroline N, Mullin K, Hooli B, Choi Se H, Hyman Bradley T, Tanzi Rudolph E. Alzheimer&#x2019;s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta. Neuron. 2013;78:631&#x2013;643. doi: 10.1016/j.neuron.2013.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.04.014</ArticleId><ArticleId IdType="pmc">PMC3706457</ArticleId><ArticleId IdType="pubmed">23623698</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BMM, Hooli B, DiVito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE. Genome-wide association analysis reveals putative Alzheimer&#x2019;s disease susceptibility loci in addition to APOE. Am J Hum Genet. 2008;83:623&#x2013;632. doi: 10.1016/j.ajhg.2008.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.10.008</ArticleId><ArticleId IdType="pmc">PMC2668052</ArticleId><ArticleId IdType="pubmed">18976728</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D. et al.Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer&#x2019;s disease. Nat Genet. 2011;43:429&#x2013;435. doi: 10.1038/ng.803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.803</ArticleId><ArticleId IdType="pmc">PMC3084173</ArticleId><ArticleId IdType="pubmed">21460840</ArticleId></ArticleIdList></Reference><Reference><Citation>Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT. et al.Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer&#x2019;s disease. Nat Genet. 2011;43:436&#x2013;441. doi: 10.1038/ng.801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.801</ArticleId><ArticleId IdType="pmc">PMC3090745</ArticleId><ArticleId IdType="pubmed">21460841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Alzheimer Disease Neuroimaging I, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL. CD33 Alzheimer&#x2019;s disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848&#x2013;850. doi: 10.1038/nn.3435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3435</ArticleId><ArticleId IdType="pmc">PMC3703870</ArticleId><ArticleId IdType="pubmed">23708142</ArticleId></ArticleIdList></Reference><Reference><Citation>Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M. Formation and maintenance of Alzheimer&#x2019;s disease beta-amyloid plaques in the absence of microglia. Nat Neurosci. 2009;12:1361&#x2013;1363. doi: 10.1038/nn.2432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2432</ArticleId><ArticleId IdType="pmc">PMC4721582</ArticleId><ArticleId IdType="pubmed">19838177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB. TREM2 variant p.r47h as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurology. 2014;71:449&#x2013;453. doi: 10.1001/jamaneurol.2013.6237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6237</ArticleId><ArticleId IdType="pmc">PMC4087113</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley W, Hatanpaa K, Lomen-Hoerth C, Kertesz A, Bigio E, Lippa C, Josephs KA, Knopman DS, White CL 3rd, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK. et al.TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Mol Neurodegeneration. 2013;8:19. doi: 10.1186/1750-1326-8-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-19</ArticleId><ArticleId IdType="pmc">PMC3691612</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24899709</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>23</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults.</ArticleTitle><Pagination><StartPage>7862</StartPage><EndPage>7870</EndPage><MedlinePgn>7862-70</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0385-14.2014</ELocationID><Abstract><AbstractText>Dietary habits such as caloric restriction or nutrients that mimic these effects may exert beneficial effects on brain aging. The plant-derived polyphenol resveratrol has been shown to increase memory performance in primates; however, interventional studies in older humans are lacking. Here, we tested whether supplementation of resveratrol would enhance memory performance in older adults and addressed potential mechanisms underlying this effect. Twenty-three healthy overweight older individuals that successfully completed 26 weeks of resveratrol intake (200 mg/d) were pairwise matched to 23 participants that received placebo (total n = 46, 18 females, 50-75 years). Before and after the intervention/control period, subjects underwent memory tasks and neuroimaging to assess volume, microstructure, and functional connectivity (FC) of the hippocampus, a key region implicated in memory functions. In addition, anthropometry, glucose and lipid metabolism, inflammation, neurotrophic factors, and vascular parameters were assayed. We observed a significant effect of resveratrol on retention of words over 30 min compared with placebo (p = 0.038). In addition, resveratrol led to significant increases in hippocampal FC, decreases in glycated hemoglobin (HbA1c) and body fat, and increases in leptin compared with placebo (all p &lt; 0.05). Increases in FC between the left posterior hippocampus and the medial prefrontal cortex correlated with increases in retention scores and with decreases in HbA1c (all p &lt; 0.05). This study provides initial evidence that supplementary resveratrol improves memory performance in association with improved glucose metabolism and increased hippocampal FC in older adults. Our findings offer the basis for novel strategies to maintain brain health during aging.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/347862-09$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Witte</LastName><ForeName>A Veronica</ForeName><Initials>AV</Initials><AffiliationInfo><Affiliation>Department of Neurology, NeuroCure Cluster of Excellence, and veronica.witte@charite.de agnes.floeel@charite.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kerti</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margulies</LastName><ForeName>Daniel S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Max Planck Research Group: Neuroanatomy and Connectivity, Max Planck Institute for Human Cognitive and Brain Sciences, 04103 Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fl&#xf6;el</LastName><ForeName>Agnes</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, NeuroCure Cluster of Excellence, and Center for Stroke Research Berlin, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, 10117 Berlin, Germany; and veronica.witte@charite.de agnes.floeel@charite.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006442">Glycated Hemoglobin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020738">Leptin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013267">Stilbenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q369O8926L</RegistryNumber><NameOfSubstance UI="D000077185">Resveratrol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="N">Antioxidants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006442" MajorTopicYN="N">Glycated Hemoglobin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006624" MajorTopicYN="N">Hippocampus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020738" MajorTopicYN="N">Leptin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077185" MajorTopicYN="N">Resveratrol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013267" MajorTopicYN="N">Stilbenes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Aging</Keyword><Keyword MajorTopicYN="N">CR-mimetic</Keyword><Keyword MajorTopicYN="N">HbA1c</Keyword><Keyword MajorTopicYN="N">microstructure</Keyword><Keyword MajorTopicYN="N">resting-state fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24899709</ArticleId><ArticleId IdType="pmc">PMC6608268</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0385-14.2014</ArticleId><ArticleId IdType="pii">34/23/7862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andrews-Hanna JR, Snyder AZ, Vincent JL, Lustig C, Head D, Raichle ME, Buckner RL. Disruption of large-scale brain systems in advanced aging. Neuron. 2007;56:924&#x2013;935. doi: 10.1016/j.neuron.2007.10.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2007.10.038</ArticleId><ArticleId IdType="pmc">PMC2709284</ArticleId><ArticleId IdType="pubmed">18054866</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews-Hanna JR, Reidler JS, Sepulcre J, Poulin R, Buckner RL. Functional-anatomic fractionation of the brain's default network. Neuron. 2010;65:550&#x2013;562. doi: 10.1016/j.neuron.2010.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.02.005</ArticleId><ArticleId IdType="pmc">PMC2848443</ArticleId><ArticleId IdType="pubmed">20188659</ArticleId></ArticleIdList></Reference><Reference><Citation>Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337&#x2013;342. doi: 10.1038/nature05354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05354</ArticleId><ArticleId IdType="pmc">PMC4990206</ArticleId><ArticleId IdType="pubmed">17086191</ArticleId></ArticleIdList></Reference><Reference><Citation>Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493&#x2013;506. doi: 10.1038/nrd2060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd2060</ArticleId><ArticleId IdType="pubmed">16732220</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL, Colcombe S, Dogonowski AM, Ernst M, Fair D, Hampson M, Hoptman MJ, Hyde JS, Kiviniemi VJ, K&#xf6;tter R, Li SJ, Lin CP, et al. Toward discovery science of human brain function. Proc Natl Acad Sci U S A. 2010;107:4734&#x2013;4739. doi: 10.1073/pnas.0911855107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911855107</ArticleId><ArticleId IdType="pmc">PMC2842060</ArticleId><ArticleId IdType="pubmed">20176931</ArticleId></ArticleIdList></Reference><Reference><Citation>Brasny&#xf3; P, Moln&#xe1;r GA, Moh&#xe1;s M, Mark&#xf3; L, Laczy B, Cseh J, Mikol&#xe1;s E, Szij&#xe1;rt&#xf3; IA, M&#xe9;rei A, Halmai R, M&#xe9;sz&#xe1;ros LG, S&#xfc;megi B, Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383&#x2013;389. doi: 10.1017/S0007114511000316.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0007114511000316</ArticleId><ArticleId IdType="pubmed">21385509</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813&#x2013;820. doi: 10.1038/414813a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/414813a</ArticleId><ArticleId IdType="pubmed">11742414</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25:7709&#x2013;7717. doi: 10.1523/JNEUROSCI.2177-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2177-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725245</ArticleId><ArticleId IdType="pubmed">16120771</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckner RL, Andrews-Hanna JR, Schacter DL. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci. 2008;1124:1&#x2013;38. doi: 10.1196/annals.1440.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1440.011</ArticleId><ArticleId IdType="pubmed">18400922</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron. 2002;35:625&#x2013;641. doi: 10.1016/S0896-6273(02)00830-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00830-9</ArticleId><ArticleId IdType="pubmed">12194864</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH Study. Neurology. 2012;79:1019&#x2013;1026. doi: 10.1212/WNL.0b013e31826846de.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826846de</ArticleId><ArticleId IdType="pubmed">22946113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chhatwal JP, Sperling RA. Functional MRI of mnemonic networks across the spectrum of normal aging, mild cognitive impairment, and Alzheimer's disease. J Alzheimers Dis. 2012;31:S155&#x2013;S167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3736339</ArticleId><ArticleId IdType="pubmed">22890098</ArticleId></ArticleIdList></Reference><Reference><Citation>Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012;67:1307&#x2013;1312. doi: 10.1093/gerona/glr235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glr235</ArticleId><ArticleId IdType="pmc">PMC3670158</ArticleId><ArticleId IdType="pubmed">22219517</ArticleId></ArticleIdList></Reference><Reference><Citation>Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, Hu F, Ballabh P, Podlutsky A, Losonczy G, de Cabo R, Mathew R, Wolin MS, Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 2009;54:668&#x2013;675. doi: 10.1161/HYPERTENSIONAHA.109.133397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.133397</ArticleId><ArticleId IdType="pmc">PMC2745434</ArticleId><ArticleId IdType="pubmed">19597040</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal-Pan A, Pifferi F, Marchal J, Picq JL, Aujard F, RESTRIKAL Consortium Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS One. 2011;6:e16581. doi: 10.1371/journal.pone.0016581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0016581</ArticleId><ArticleId IdType="pmc">PMC3031601</ArticleId><ArticleId IdType="pubmed">21304942</ArticleId></ArticleIdList></Reference><Reference><Citation>De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 2000;30:857&#x2013;866. doi: 10.1080/004982500433282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/004982500433282</ArticleId><ArticleId IdType="pubmed">11055264</ArticleId></ArticleIdList></Reference><Reference><Citation>Do GM, Kwon EY, Kim HJ, Jeon SM, Ha TY, Park T, Choi MS. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun. 2008;374:55&#x2013;59. doi: 10.1016/j.bbrc.2008.06.113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.06.113</ArticleId><ArticleId IdType="pubmed">18611391</ArticleId></ArticleIdList></Reference><Reference><Citation>Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddock L, Kim JS, Heo S, Alves H, White SM, Wojcicki TR, Mailey E, Vieira VJ, Martin SA, Pence BD, Woods JA, McAuley E, Kramer AF. Exercise training increases size of hippocampus and improves memory. Proc Natl Acad Sci U S A. 2011;108:3017&#x2013;3022. doi: 10.1073/pnas.1015950108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1015950108</ArticleId><ArticleId IdType="pmc">PMC3041121</ArticleId><ArticleId IdType="pubmed">21282661</ArticleId></ArticleIdList></Reference><Reference><Citation>Fl&#xf6;el A, Witte AV, Lohmann H, Wersching H, Ringelstein EB, Berger K, Knecht S. Lifestyle and memory in the elderly. Neuroepidemiology. 2008;31:39&#x2013;47. doi: 10.1159/000137378.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000137378</ArticleId><ArticleId IdType="pubmed">18535399</ArticleId></ArticleIdList></Reference><Reference><Citation>Folstein MF, Folstein SE, McHugh PR. &#x201c;Mini-mental state&#x201d;: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189&#x2013;198. doi: 10.1016/0022-3956(75)90026-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-3956(75)90026-6</ArticleId><ArticleId IdType="pubmed">1202204</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey I, Berg A, Grathwohl D, Keul J. [Freiburg Questionnaire of physical activity-development, evaluation and application] Soz Praventivmed. 1999;44:55&#x2013;64. doi: 10.1007/BF01667127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01667127</ArticleId><ArticleId IdType="pubmed">10407953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, Chaudhuri A, Dandona P. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95:E1&#x2013;E8. doi: 10.1210/jc.2010-0482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-0482</ArticleId><ArticleId IdType="pmc">PMC2936054</ArticleId><ArticleId IdType="pubmed">20534755</ArticleId></ArticleIdList></Reference><Reference><Citation>Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637&#x2013;4642. doi: 10.1073/pnas.0308627101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0308627101</ArticleId><ArticleId IdType="pmc">PMC384799</ArticleId><ArticleId IdType="pubmed">15070770</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Carmichael O, Fletcher E, Singh B, Iosif AM, Martinez O, Reed B, Yonelinas A, Decarli C. Influence of functional connectivity and structural MRI measures on episodic memory. Neurobiol Aging. 2012;33:2612&#x2013;2620. doi: 10.1016/j.neurobiolaging.2011.12.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.12.029</ArticleId><ArticleId IdType="pmc">PMC3353006</ArticleId><ArticleId IdType="pubmed">22285758</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram DK, Zhu M, Mamczarz J, Zou S, Lane MA, Roth GS, deCabo R. Calorie restriction mimetics: an emerging research field. Aging Cell. 2006;5:97&#x2013;108. doi: 10.1111/j.1474-9726.2006.00202.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1474-9726.2006.00202.x</ArticleId><ArticleId IdType="pubmed">16626389</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingram DK, Young J, Mattison JA. Calorie restriction in nonhuman primates: assessing effects on brain and behavioral aging. Neuroscience. 2007;145:1359&#x2013;1364. doi: 10.1016/j.neuroscience.2006.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2006.10.031</ArticleId><ArticleId IdType="pubmed">17223278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamogawa K, Kohara K, Tabara Y, Uetani E, Nagai T, Yamamoto M, Igase M, Miki T. Abdominal fat, adipose-derived hormones and mild cognitive impairment: the J-SHIPP study. Dement Geriatr Cogn Disord. 2010;30:432&#x2013;439. doi: 10.1159/000321985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000321985</ArticleId><ArticleId IdType="pubmed">21088422</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91:1590&#x2013;1597. doi: 10.3945/ajcn.2009.28641.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/ajcn.2009.28641</ArticleId><ArticleId IdType="pubmed">20357044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Fl&#xf6;el A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology. 2013;81:1746&#x2013;1752. doi: 10.1212/01.wnl.0000435561.00234.ee.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000435561.00234.ee</ArticleId><ArticleId IdType="pubmed">24153444</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007;26:3169&#x2013;3179. doi: 10.1038/sj.emboj.7601758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601758</ArticleId><ArticleId IdType="pmc">PMC1914106</ArticleId><ArticleId IdType="pubmed">17581637</ArticleId></ArticleIdList></Reference><Reference><Citation>Krohne H, Egloff B, Kohlmann C, Tausch A. Untersuchungen mit einer deutschen Version der &#x201c;Positive and Negative Affective Schedule&#x201d; (PANAS) Diagnostica. 1996;42:139&#x2013;156.</Citation></Reference><Reference><Citation>Kuhner C, Burger C, Keller F, Hautzinger M. Reliability and validity of the Revised Beck Depression Inventory (BDI-II). Results from German samples [article in German] Nervenarzt. 2007;78:651&#x2013;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">16832698</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell. 2006;127:1109&#x2013;1122. doi: 10.1016/j.cell.2006.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2006.11.013</ArticleId><ArticleId IdType="pubmed">17112576</ArticleId></ArticleIdList></Reference><Reference><Citation>Lezak MD. Neuropsychological assessment, Ed 4. New York, Oxford: OUP; 2004.</Citation></Reference><Reference><Citation>Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302:2565&#x2013;2572. doi: 10.1001/jama.2009.1836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2009.1836</ArticleId><ArticleId IdType="pmc">PMC2838501</ArticleId><ArticleId IdType="pubmed">20009056</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu GS, Zhang ZS, Yang B, He W. Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence-accelerated mice. Life Sci. 2012;91:872&#x2013;877. doi: 10.1016/j.lfs.2012.08.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2012.08.033</ArticleId><ArticleId IdType="pubmed">22982350</ArticleId></ArticleIdList></Reference><Reference><Citation>McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A. 2000;97:2881&#x2013;2885. doi: 10.1073/pnas.050583697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.050583697</ArticleId><ArticleId IdType="pmc">PMC16024</ArticleId><ArticleId IdType="pubmed">10706633</ArticleId></ArticleIdList></Reference><Reference><Citation>Miatello R, V&#xe1;zquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens. 2005;18:864&#x2013;870. doi: 10.1016/j.amjhyper.2004.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2004.12.012</ArticleId><ArticleId IdType="pubmed">15925749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizutani K, Ikeda K, Nishikata T, Yamori Y. Phytoestrogens attenuate oxidative DNA damage in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Hypertens. 2000;18:1833&#x2013;1840. doi: 10.1097/00004872-200018120-00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004872-200018120-00018</ArticleId><ArticleId IdType="pubmed">11132608</ArticleId></ArticleIdList></Reference><Reference><Citation>Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523&#x2013;1529. doi: 10.1001/jama.282.16.1523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.282.16.1523</ArticleId><ArticleId IdType="pubmed">10546691</ArticleId></ArticleIdList></Reference><Reference><Citation>Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56:907&#x2013;922. doi: 10.1016/j.neuroimage.2011.02.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroimage.2011.02.046</ArticleId><ArticleId IdType="pmc">PMC3417233</ArticleId><ArticleId IdType="pubmed">21352927</ArticleId></ArticleIdList></Reference><Reference><Citation>Paz-Filho G, Wong ML, Licinio J. The procognitive effects of leptin in the brain and their clinical implications. Int J Clin Pract. 2010;64:1808&#x2013;1812. doi: 10.1111/j.1742-1241.2010.02536.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1742-1241.2010.02536.x</ArticleId><ArticleId IdType="pmc">PMC2998704</ArticleId><ArticleId IdType="pubmed">21070531</ArticleId></ArticleIdList></Reference><Reference><Citation>Poppenk J, Moscovitch M. A hippocampal marker of recollection memory ability among healthy young adults: contributions of posterior and anterior segments. Neuron. 2011;72:931&#x2013;937. doi: 10.1016/j.neuron.2011.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.10.014</ArticleId><ArticleId IdType="pubmed">22196329</ArticleId></ArticleIdList></Reference><Reference><Citation>Prvulovic D, Bokde AL, Faltraco F, Hampel H. Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer's disease. Prog Neurobiol. 2011;95:557&#x2013;569. doi: 10.1016/j.pneurobio.2011.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2011.05.008</ArticleId><ArticleId IdType="pubmed">21722703</ArticleId></ArticleIdList></Reference><Reference><Citation>Rombouts SA, Barkhof F, Goekoop R, Stam CJ, Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp. 2005;26:231&#x2013;239. doi: 10.1002/hbm.20160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.20160</ArticleId><ArticleId IdType="pmc">PMC6871685</ArticleId><ArticleId IdType="pubmed">15954139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma M, Gupta YK. Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. 2002;71:2489&#x2013;2498. doi: 10.1016/S0024-3205(02)02083-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(02)02083-0</ArticleId><ArticleId IdType="pubmed">12270754</ArticleId></ArticleIdList></Reference><Reference><Citation>Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol Pharm Bull. 2008;31:897&#x2013;902. doi: 10.1248/bpb.31.897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.31.897</ArticleId><ArticleId IdType="pubmed">18451515</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorg C, Riedl V, M&#xfc;hlau M, Calhoun VD, Eichele T, L&#xe4;er L, Drzezga A, F&#xf6;rstl H, Kurz A, Zimmer C, Wohlschl&#xe4;ger AM. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760&#x2013;18765. doi: 10.1073/pnas.0708803104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0708803104</ArticleId><ArticleId IdType="pmc">PMC2141850</ArticleId><ArticleId IdType="pubmed">18003904</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranahan AM, Mattson MP. Impact of energy intake and expenditure on neuronal plasticity. Neuromolecular Med. 2008;10:209&#x2013;218. doi: 10.1007/s12017-008-8043-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-008-8043-0</ArticleId><ArticleId IdType="pmc">PMC2635925</ArticleId><ArticleId IdType="pubmed">18543119</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and neurodegeneration. In: Benzie IFF, Wachtel-Galor S, editors. Herbal medicine: biomolecular and clinical aspects. Ed 2. Boca Raton, FL: CRC; 2011.</Citation></Reference><Reference><Citation>Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612&#x2013;622. doi: 10.1016/j.cmet.2011.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2011.10.002</ArticleId><ArticleId IdType="pmc">PMC3880862</ArticleId><ArticleId IdType="pubmed">22055504</ArticleId></ArticleIdList></Reference><Reference><Citation>Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Fatar M, Hernandez Hernandez R, Jaff M, Kownator S, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaut E, et al. Mannheim carotid intima-media thickness consensus (2004&#x2013;2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007;23:75&#x2013;80. doi: 10.1159/000097034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000097034</ArticleId><ArticleId IdType="pubmed">17108679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006;20:2313&#x2013;2320. doi: 10.1096/fj.06-6281com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.06-6281com</ArticleId><ArticleId IdType="pubmed">17077308</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Negreira A, LaViolette P, Bakkour A, Sperling RA, Dickerson BC. Intrinsic interhemispheric hippocampal functional connectivity predicts individual differences in memory performance ability. Hippocampus. 2010;20:345&#x2013;351. doi: 10.1002/hipo.20771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20771</ArticleId><ArticleId IdType="pmc">PMC2872925</ArticleId><ArticleId IdType="pubmed">20087893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047&#x2013;1053. doi: 10.2337/diacare.27.5.1047.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diacare.27.5.1047</ArticleId><ArticleId IdType="pubmed">15111519</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011;21:851&#x2013;856. doi: 10.1016/j.numecd.2010.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2010.03.003</ArticleId><ArticleId IdType="pubmed">20674311</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24899710</PMID><DateCompleted><Year>2014</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>23</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>Genetic modulation of soluble A&#x3b2; rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease.</ArticleTitle><Pagination><StartPage>7871</StartPage><EndPage>7885</EndPage><MedlinePgn>7871-85</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0572-14.2014</ELocationID><Abstract><AbstractText>An unresolved debate in Alzheimer's disease (AD) is whether amyloid plaques are pathogenic, causing overt physical disruption of neural circuits, or protective, sequestering soluble forms of amyloid-&#x3b2; (A&#x3b2;) that initiate synaptic damage and cognitive decline. Few animal models of AD have been capable of isolating the relative contribution made by soluble and insoluble forms of A&#x3b2; to the behavioral symptoms and biochemical consequences of the disease. Here we use a controllable transgenic mouse model expressing a mutant form of amyloid precursor protein (APP) to distinguish the impact of soluble A&#x3b2; from that of deposited amyloid on cognitive function and synaptic structure. Rapid inhibition of transgenic APP modulated the production of A&#x3b2; without affecting pre-existing amyloid deposits and restored cognitive performance to the level of healthy controls in Morris water maze, radial arm water maze, and fear conditioning. Selective reduction of A&#x3b2; with a &#x3b3;-secretase inhibitor provided similar improvement, suggesting that transgene suppression restored cognition, at least in part by lowering A&#x3b2;. Cognitive improvement coincided with reduced levels of synaptotoxic A&#x3b2; oligomers, greater synaptic density surrounding amyloid plaques, and increased expression of presynaptic and postsynaptic markers. Together these findings indicate that transient A&#x3b2; species underlie much of the cognitive and synaptic deficits observed in this model and demonstrate that significant functional and structural recovery can be attained without removing deposited amyloid.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/347871-15$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Stephanie W</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Angie C A</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savjani</LastName><ForeName>Ricky R</ForeName><Initials>RR</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience and Texas A&amp;M Health Science Center, College Station, Texas 77843.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Megan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55454, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sherman</LastName><ForeName>Mathew A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55454, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuler</LastName><ForeName>Dorothy R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cirrito</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Department of Neurology, Washington University School of Medicine, St. Louis, Missouri 63110.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lesn&#xe9;</LastName><ForeName>Sylvain E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, N. Bud Grossman Center for Memory Research and Care, and Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota 55454, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankowsky</LastName><ForeName>Joanna L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Departments of Neuroscience and Neurology and Neurosurgery, Huffington Center on Aging, Baylor College of Medicine, Houston, Texas 77030, jankowsk@bcm.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 AG000183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DP2 OD001734</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-NS033249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG031293</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00-AG031293</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS033249</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001381">Azepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C484278">N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical><Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber><NameOfSubstance UI="D000409">Alanine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurosci. 2014 Dec 10;34(50):16917</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001381" MajorTopicYN="N">Azepines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005106" MajorTopicYN="N">Exploratory Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018782" MajorTopicYN="N">Maze Learning</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058225" MajorTopicYN="N">Plaque, Amyloid</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013569" MajorTopicYN="N">Synapses</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APP</Keyword><Keyword MajorTopicYN="N">TTA</Keyword><Keyword MajorTopicYN="N">amyloid</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">oligomer</Keyword><Keyword MajorTopicYN="N">tetracycline transactivator</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24899710</ArticleId><ArticleId IdType="pmc">PMC4044248</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0572-14.2014</ArticleId><ArticleId IdType="pii">34/23/7871</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, Gouras GK. &#x3b2;-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis. 2005;20:187&#x2013;198. doi: 10.1016/j.nbd.2005.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.02.008</ArticleId><ArticleId IdType="pubmed">16242627</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoine-Bertrand J, Villemure JF, Lamarche-Vane N. Implication of rho GTPases in neurodegenerative diseases. Curr Drug Targets. 2011;12:1202&#x2013;1215. doi: 10.2174/138945011795906543.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138945011795906543</ArticleId><ArticleId IdType="pubmed">21561415</ArticleId></ArticleIdList></Reference><Reference><Citation>Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, Sivilia S, Giardino L, Calz&#xe0; L, Lanzillotta A, Sarnico I, Pizzi M, Usiello A, Viscomi AR, Ottonello S, Villetti G, Imbimbo BP, Nistic&#xf2; G, Forloni G, Nistic&#xf2; R. The &#x3b3;-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis. 2011;24:799&#x2013;816. doi: 10.3233/JAD-2011-101839.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2011-101839</ArticleId><ArticleId IdType="pubmed">21321397</ArticleId></ArticleIdList></Reference><Reference><Citation>Born HA, Kim JY, Savjani RR, Das P, Dabaghian YA, Guo Q, Yoo JW, Schuler DR, Cirrito JR, Zheng H, Golde TE, Noebels JL, Jankowsky JL. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzheimer's disease. J Neurosci. 2014;34:3826&#x2013;3840. doi: 10.1523/JNEUROSCI.5171-13.2014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5171-13.2014</ArticleId><ArticleId IdType="pmc">PMC3951689</ArticleId><ArticleId IdType="pubmed">24623762</ArticleId></ArticleIdList></Reference><Reference><Citation>Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science. 2008;321:1686&#x2013;1689. doi: 10.1126/science.1162844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1162844</ArticleId><ArticleId IdType="pubmed">18802001</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D. &#x3b2;-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096&#x2013;9101. doi: 10.1523/JNEUROSCI.1697-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1697-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725749</ArticleId><ArticleId IdType="pubmed">16207868</ArticleId></ArticleIdList></Reference><Reference><Citation>Calon F, Lim GP, Yang F, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Jr, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004;43:633&#x2013;645. doi: 10.1016/j.neuron.2004.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.08.013</ArticleId><ArticleId IdType="pmc">PMC2442162</ArticleId><ArticleId IdType="pubmed">15339646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang WP, Huang X, Downs D, Cirrito JR, Koelsch G, Holtzman DM, Ghosh AK, Tang J. &#x3b2;-secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice. FASEB J. 2011;25:775&#x2013;784. doi: 10.1096/fj.10-167213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.10-167213</ArticleId><ArticleId IdType="pmc">PMC3023390</ArticleId><ArticleId IdType="pubmed">21059748</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng IH, Scearce-Levie K, Legleiter J, Palop JJ, Gerstein H, Bien-Ly N, Puoliv&#xe4;li J, Lesn&#xe9; S, Ashe KH, Muchowski PJ, Mucke L. Accelerating amyloid-&#x3b2; fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem. 2007;282:23818&#x2013;23828. doi: 10.1074/jbc.M701078200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M701078200</ArticleId><ArticleId IdType="pubmed">17548355</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-&#x3b2; metabolism and half-life. J Neurosci. 2003;23:8844&#x2013;8853.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6740389</ArticleId><ArticleId IdType="pubmed">14523085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirrito JR, Disabato BM, Restivo JL, Verges DK, Goebel WD, Sathyan A, Hayreh D, D'Angelo G, Benzinger T, Yoon H, Kim J, Morris JC, Mintun MA, Sheline YI. Serotonin signaling is associated with lower amyloid-&#x3b2; levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A. 2011;108:14968&#x2013;14973. doi: 10.1073/pnas.1107411108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1107411108</ArticleId><ArticleId IdType="pmc">PMC3169155</ArticleId><ArticleId IdType="pubmed">21873225</ArticleId></ArticleIdList></Reference><Reference><Citation>Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL. Acute &#x3b3;-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2005;25:8898&#x2013;8902. doi: 10.1523/JNEUROSCI.2693-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2693-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725598</ArticleId><ArticleId IdType="pubmed">16192379</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F. Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci. 2011;14:69&#x2013;76. doi: 10.1038/nn.2709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2709</ArticleId><ArticleId IdType="pubmed">21151119</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Amore JD, Kajdasz ST, McLellan ME, Bacskai BJ, Stern EA, Hyman BT. In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories. J Neuropathol Exp Neurol. 2003;62:137&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">12578223</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis RC, Marsden IT, Maloney MT, Minamide LS, Podlisny M, Selkoe DJ, Bamburg JR. Amyloid &#x3b2; dimers/trimers potently induce cofilin-actin rods that are inhibited by maintaining cofilin-phosphorylation. Mol Neurodegener. 2011;6:10. doi: 10.1186/1750-1326-6-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-6-10</ArticleId><ArticleId IdType="pmc">PMC3037337</ArticleId><ArticleId IdType="pubmed">21261978</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. Immunization reverses memory deficits without reducing brain A&#x3b2; burden in Alzheimer's disease model. Nat Neurosci. 2002;5:452&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">11941374</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H, Martin MV, Chambers S, Csernansky JG. Spatial relationship between synapse loss and &#x3b2;-amyloid deposition in Tg2576 mice. J Comp Neurol. 2007;500:311&#x2013;321. doi: 10.1002/cne.21176.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.21176</ArticleId><ArticleId IdType="pmc">PMC1661843</ArticleId><ArticleId IdType="pubmed">17111375</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates A&#x3b2; pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:11157&#x2013;11166. doi: 10.1523/JNEUROSCI.2884-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2884-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-&#x3b2; antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:6213&#x2013;6220. doi: 10.1523/JNEUROSCI.0664-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0664-05.2005</ArticleId><ArticleId IdType="pmc">PMC6725066</ArticleId><ArticleId IdType="pubmed">15987951</ArticleId></ArticleIdList></Reference><Reference><Citation>Heredia L, Helguera P, de Olmos S, Kedikian G, Sol&#xe1; Vigo F, LaFerla F, Staufenbiel M, de Olmos J, Busciglio J, C&#xe1;ceres A, Lorenzo A. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid &#x3b2;-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci. 2006;26:6533&#x2013;6542. doi: 10.1523/JNEUROSCI.5567-05.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5567-05.2006</ArticleId><ArticleId IdType="pmc">PMC6674046</ArticleId><ArticleId IdType="pubmed">16775141</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, Holtzman DM, Cirrito JR, Selkoe DJ. Dynamic analysis of amyloid &#x3b2;-protein in behaving mice reveals opposing changes in ISF versus parenchymal A&#x3b2;a during age-related plaque formation. J Neurosci. 2011;31:15861&#x2013;15869. doi: 10.1523/JNEUROSCI.3272-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3272-11.2011</ArticleId><ArticleId IdType="pmc">PMC3227224</ArticleId><ArticleId IdType="pubmed">22049429</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky JL, Slunt HH, Gonzales V, Savonenko AV, Wen JC, Jenkins NA, Copeland NG, Younkin LH, Lester HA, Younkin SG, Borchelt DR. Persistent amyloidosis following suppression of A&#x3b2; production in a transgenic model of Alzheimer's disease. PLoS Med. 2005;2:e355. doi: 10.1371/journal.pmed.0020355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0020355</ArticleId><ArticleId IdType="pmc">PMC1283364</ArticleId><ArticleId IdType="pubmed">16279840</ArticleId></ArticleIdList></Reference><Reference><Citation>Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D. A&#x3b2; peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979&#x2013;982. doi: 10.1038/35050110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35050110</ArticleId><ArticleId IdType="pubmed">11140685</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid &#x3b2; protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci. 2001;21:372&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763819</ArticleId><ArticleId IdType="pubmed">11160418</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486&#x2013;489. doi: 10.1126/science.1079469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1079469</ArticleId><ArticleId IdType="pubmed">12702875</ArticleId></ArticleIdList></Reference><Reference><Citation>Knafo S, Alonso-Nanclares L, Gonzalez-Soriano J, Merino-Serrais P, Fernaud-Espinosa I, Ferrer I, DeFelipe J. Widespread changes in dendritic spines in a model of Alzheimer's disease. Cereb Cortex. 2009;19:586&#x2013;592. doi: 10.1093/cercor/bhn111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cercor/bhn111</ArticleId><ArticleId IdType="pubmed">18632740</ArticleId></ArticleIdList></Reference><Reference><Citation>Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, Hyman BT, Spires-Jones TL. Oligomeric amyloid &#x3b2; associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009;106:4012&#x2013;4017. doi: 10.1073/pnas.0811698106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0811698106</ArticleId><ArticleId IdType="pmc">PMC2656196</ArticleId><ArticleId IdType="pubmed">19228947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci. 2002;22:6331&#x2013;6335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758140</ArticleId><ArticleId IdType="pubmed">12151510</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ. A&#x3b2; plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron. 2008;59:214&#x2013;225. doi: 10.1016/j.neuron.2008.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.06.008</ArticleId><ArticleId IdType="pmc">PMC2578820</ArticleId><ArticleId IdType="pubmed">18667150</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchibhotla KV, Lattarulo CR, Hyman BT, Bacskai BJ. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science. 2009;323:1211&#x2013;1215. doi: 10.1126/science.1169096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1169096</ArticleId><ArticleId IdType="pmc">PMC2884172</ArticleId><ArticleId IdType="pubmed">19251629</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson ME, Lesne SE. Soluble A&#x3b2; oligomer production and toxicity. J Neurochem. 2012;120(Suppl 1):125&#x2013;139. doi: 10.1111/j.1471-4159.2011.07478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07478.x</ArticleId><ArticleId IdType="pmc">PMC3254782</ArticleId><ArticleId IdType="pubmed">22121920</ArticleId></ArticleIdList></Reference><Reference><Citation>Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesn&#xe9; SE. The complex PrP(c)-Fyn couples human oligomeric A&#x3b2; with pathological tau changes in Alzheimer's disease. J Neurosci. 2012;32:16857&#x2013;16871a. doi: 10.1523/JNEUROSCI.1858-12.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1858-12.2012</ArticleId><ArticleId IdType="pmc">PMC3568961</ArticleId><ArticleId IdType="pubmed">23175838</ArticleId></ArticleIdList></Reference><Reference><Citation>Le R, Cruz L, Urbanc B, Knowles RB, Hsiao-Ashe K, Duff K, Irizarry MC, Stanley HE, Hyman BT. Plaque-induced abnormalities in neurite geometry in transgenic models of Alzheimer disease: implications for neural system disruption. J Neuropathol Exp Neurol. 2001;60:753&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">11487049</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, Lee VM. Targeting amyloid-&#x3b2; peptide (A&#x3b2;) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A&#x3b2; precursor protein (APP) transgenic mice. J Biol Chem. 2006;281:4292&#x2013;4299. doi: 10.1074/jbc.M511018200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M511018200</ArticleId><ArticleId IdType="pubmed">16361260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-&#x3b2; protein assembly in the brain impairs memory. Nature. 2006;440:352&#x2013;357. doi: 10.1038/nature04533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04533</ArticleId><ArticleId IdType="pubmed">16541076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lesn&#xe9; S, Kotilinek L, Ashe KH. Plaque-bearing mice with reduced levels of oligomeric amyloid-&#x3b2; assemblies have intact memory function. Neuroscience. 2008;151:745&#x2013;749. doi: 10.1016/j.neuroscience.2007.10.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2007.10.054</ArticleId><ArticleId IdType="pmc">PMC2677385</ArticleId><ArticleId IdType="pubmed">18155846</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Yang F, Calon F, Ubeda OJ, Hansen JE, Weisbart RH, Beech W, Frautschy SA, Cole GM. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem. 2008;283:14132&#x2013;14143. doi: 10.1074/jbc.M708034200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M708034200</ArticleId><ArticleId IdType="pmc">PMC2376243</ArticleId><ArticleId IdType="pubmed">18347024</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma QL, Yang F, Frautschy SA, Cole GM. PAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell Logist. 2012;2:117&#x2013;125. doi: 10.4161/cl.21602.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/cl.21602</ArticleId><ArticleId IdType="pmc">PMC3490962</ArticleId><ArticleId IdType="pubmed">23162743</ArticleId></ArticleIdList></Reference><Reference><Citation>Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, et al. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein &#x3b3;-secretase for the treatment of Alzheimer's disease. J Pharmacol Exp Ther. 2009;331:598&#x2013;608. doi: 10.1124/jpet.109.152975.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.152975</ArticleId><ArticleId IdType="pubmed">19671883</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER. Control of memory formation through regulated expression of a CaMKII transgene. Science. 1996;274:1678&#x2013;1683. doi: 10.1126/science.274.5293.1678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.274.5293.1678</ArticleId><ArticleId IdType="pubmed">8939850</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, Moore BD, Golde TE, Felsenstein KM, Savonenko A, Borchelt DR. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci. 2013;33:3765&#x2013;3779. doi: 10.1523/JNEUROSCI.4251-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4251-12.2013</ArticleId><ArticleId IdType="pmc">PMC3711622</ArticleId><ArticleId IdType="pubmed">23447589</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendoza-Naranjo A, Contreras-Vallejos E, Henriquez DR, Otth C, Bamburg JR, Maccioni RB, Gonzalez-Billault C. Fibrillar amyloid-&#x3b2; 1&#x2013;42 modifies actin organization affecting the cofilin phosphorylation state: a role for Rac1/cdc42 effector proteins and the slingshot phosphatase. J Alzheimers Dis. 2012;29:63&#x2013;77. doi: 10.3233/JAD-2012-101575.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2012-101575</ArticleId><ArticleId IdType="pubmed">22204905</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, Bennett CF, Bishop KM, Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12:435&#x2013;442. doi: 10.1016/S1474-4422(13)70061-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70061-9</ArticleId><ArticleId IdType="pmc">PMC3712285</ArticleId><ArticleId IdType="pubmed">23541756</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y, Yarimizu J, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble A&#x3b2;42 without affecting other A&#x3b2; pools. J Neurochem. 2013;125:465&#x2013;472. doi: 10.1111/jnc.12125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.12125</ArticleId><ArticleId IdType="pubmed">23240999</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N. Differential effects between &#x3b3;-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci. 2012;32:2037&#x2013;2050. doi: 10.1523/JNEUROSCI.4264-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4264-11.2012</ArticleId><ArticleId IdType="pmc">PMC6621706</ArticleId><ArticleId IdType="pubmed">22323718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno K. Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation. Cell Signal. 2013;25:457&#x2013;469. doi: 10.1016/j.cellsig.2012.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2012.11.001</ArticleId><ArticleId IdType="pubmed">23153585</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW. A&#x3b2; peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 2000;408:982&#x2013;985. doi: 10.1038/35050116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35050116</ArticleId><ArticleId IdType="pubmed">11140686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgers SP, Born HA, Das P, Jankowsky JL. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012;7:28. doi: 10.1186/1750-1326-7-28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-28</ArticleId><ArticleId IdType="pmc">PMC3457908</ArticleId><ArticleId IdType="pubmed">22709352</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers K, Felsenstein KM, Hrdlicka L, Tu Z, Albayya F, Lee W, Hopp S, Miller MJ, Spaulding D, Yang Z, Hodgdon H, Nolan S, Wen M, Costa D, Blain JF, Freeman E, De Strooper B, Vulsteke V, Scrocchi L, Zetterberg H, et al. Modulation of &#x3b3;-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice. Mol Neurodegener. 2012;7:61. doi: 10.1186/1750-1326-7-61.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-61</ArticleId><ArticleId IdType="pmc">PMC3573960</ArticleId><ArticleId IdType="pubmed">23249765</ArticleId></ArticleIdList></Reference><Reference><Citation>Rozkalne A, Spires-Jones TL, Stern EA, Hyman BT. A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model. Brain Res. 2009;1280:178&#x2013;185. doi: 10.1016/j.brainres.2009.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.05.045</ArticleId><ArticleId IdType="pmc">PMC2709805</ArticleId><ArticleId IdType="pubmed">19465012</ArticleId></ArticleIdList></Reference><Reference><Citation>Rust MB, Gurniak CB, Renner M, Vara H, Morando L, G&#xf6;rlich A, Sasso&#xe8;-Pognetto M, Banchaabouchi MA, Giustetto M, Triller A, Choquet D, Witke W. Learning, AMPA receptor mobility and synaptic plasticity depend on n-cofilin-mediated actin dynamics. EMBO J. 2010;29:1889&#x2013;1902. doi: 10.1038/emboj.2010.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2010.72</ArticleId><ArticleId IdType="pmc">PMC2885936</ArticleId><ArticleId IdType="pubmed">20407421</ArticleId></ArticleIdList></Reference><Reference><Citation>Saneyoshi T, Hayashi Y. The Ca2+ and Rho GTPase signaling pathways underlying activity-dependent actin remodeling at dendritic spines. Cytoskeleton. 2012;69:545&#x2013;554. doi: 10.1002/cm.21037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cm.21037</ArticleId><ArticleId IdType="pubmed">22566410</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-&#x3b2; protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007;27:2866&#x2013;2875. doi: 10.1523/JNEUROSCI.4970-06.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4970-06.2007</ArticleId><ArticleId IdType="pmc">PMC6672572</ArticleId><ArticleId IdType="pubmed">17360908</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman MA, Lesn&#xe9; SE. Detecting A&#x3b2;*56 oligomers in brain tissues. Methods Mol Biol. 2011;670:45&#x2013;56. doi: 10.1007/978-1-60761-744-0_4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-60761-744-0_4</ArticleId><ArticleId IdType="pubmed">20967582</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci. 2005;25:7278&#x2013;7287. doi: 10.1523/JNEUROSCI.1879-05.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1879-05.2005</ArticleId><ArticleId IdType="pmc">PMC1820616</ArticleId><ArticleId IdType="pubmed">16079410</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones T, Knafo S. Spines, plasticity, and cognition in Alzheimer's model mice. Neural Plast. 2012;2012:319836. doi: 10.1155/2012/319836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/319836</ArticleId><ArticleId IdType="pmc">PMC3238410</ArticleId><ArticleId IdType="pubmed">22203915</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, Bacskai BJ, Hyman BT. Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol. 2007;171:1304&#x2013;1311. doi: 10.2353/ajpath.2007.070055.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070055</ArticleId><ArticleId IdType="pmc">PMC1988879</ArticleId><ArticleId IdType="pubmed">17717139</ArticleId></ArticleIdList></Reference><Reference><Citation>Spires-Jones TL, Mielke ML, Rozkalne A, Meyer-Luehmann M, de Calignon A, Bacskai BJ, Schenk D, Hyman BT. Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease. Neurobiol Dis. 2009;33:213&#x2013;220. doi: 10.1016/j.nbd.2008.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2008.10.011</ArticleId><ArticleId IdType="pmc">PMC2672591</ArticleId><ArticleId IdType="pubmed">19028582</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern EA, Bacskai BJ, Hickey GA, Attenello FJ, Lombardo JA, Hyman BT. Cortical synaptic integration in vivo is disrupted by amyloid-&#x3b2; plaques. J Neurosci. 2004;24:4535&#x2013;4540. doi: 10.1523/JNEUROSCI.0462-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0462-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729398</ArticleId><ArticleId IdType="pubmed">15140924</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokin GB, Lillo C, Falzone TL, Brusch RG, Rockenstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LS. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 2005;307:1282&#x2013;1288. doi: 10.1126/science.1105681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1105681</ArticleId><ArticleId IdType="pubmed">15731448</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda S, Hashimoto T, Roe AD, Hori Y, Spires-Jones TL, Hyman BT. Brain interstitial oligomeric amyloid &#x3b2; increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J. 2013;27:3239&#x2013;3248. doi: 10.1096/fj.13-229666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.13-229666</ArticleId><ArticleId IdType="pmc">PMC3714573</ArticleId><ArticleId IdType="pubmed">23640054</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol. 2004;55:801&#x2013;814. doi: 10.1002/ana.20101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20101</ArticleId><ArticleId IdType="pubmed">15174014</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, Das P, Switzer RC, 3rd, Golde TE, Jankowsky JL. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-&#x3b2; immunotherapy. J Neurosci. 2011;31:4124&#x2013;4136. doi: 10.1523/JNEUROSCI.5077-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5077-10.2011</ArticleId><ArticleId IdType="pmc">PMC3074951</ArticleId><ArticleId IdType="pubmed">21411653</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Dong Q, Xu XF, Feng X, Xin J, Wang DD, Yu H, Tian T, Chen ZY. Phosphorylation of cofilin regulates extinction of conditioned aversive memory via AMPAR trafficking. J Neurosci. 2013;33:6423&#x2013;6433. doi: 10.1523/JNEUROSCI.5107-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5107-12.2013</ArticleId><ArticleId IdType="pmc">PMC6619091</ArticleId><ArticleId IdType="pubmed">23575840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei W, Nguyen LN, Kessels HW, Hagiwara H, Sisodia S, Malinow R. Amyloid &#x3b2; from axons and dendrites reduces local spine number and plasticity. Nat Neurosci. 2010;13:190&#x2013;196. doi: 10.1038/nn.2476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.2476</ArticleId><ArticleId IdType="pmc">PMC3310198</ArticleId><ArticleId IdType="pubmed">20037574</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerman MA, Cooper-Blacketer D, Mariash A, Kotilinek L, Kawarabayashi T, Younkin LH, Carlson GA, Younkin SG, Ashe KH. The relationship between A&#x3b2; and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci. 2002;22:1858&#x2013;1867.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6758862</ArticleId><ArticleId IdType="pubmed">11880515</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against A&#x3b2; in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation. 2004;1:24. doi: 10.1186/1742-2094-1-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-1-24</ArticleId><ArticleId IdType="pmc">PMC539292</ArticleId><ArticleId IdType="pubmed">15588287</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D. Deglycosylated anti-amyloid-&#x3b2; antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci. 2006;26:5340&#x2013;5346. doi: 10.1523/JNEUROSCI.0695-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0695-06.2006</ArticleId><ArticleId IdType="pmc">PMC6675288</ArticleId><ArticleId IdType="pubmed">16707786</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Lacor PN, Pitt J, Klein WL. A&#x3b2; oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol. 2011;31:939&#x2013;948. doi: 10.1007/s10571-011-9691-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-011-9691-4</ArticleId><ArticleId IdType="pmc">PMC3146579</ArticleId><ArticleId IdType="pubmed">21538118</ArticleId></ArticleIdList></Reference><Reference><Citation>Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG. Neutralization of soluble, synaptotoxic amyloid &#x3b2; species by antibodies is epitope specific. J Neurosci. 2012;32:2696&#x2013;2702. doi: 10.1523/JNEUROSCI.1676-11.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1676-11.2012</ArticleId><ArticleId IdType="pmc">PMC6621896</ArticleId><ArticleId IdType="pubmed">22357853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat Neurosci. 2006;9:234&#x2013;242. doi: 10.1038/nn1630.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1630</ArticleId><ArticleId IdType="pubmed">16415866</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24920637</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1529-2401</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>24</Issue><PubDate><Year>2014</Year><Month>Jun</Month><Day>11</Day></PubDate></JournalIssue><Title>The Journal of neuroscience : the official journal of the Society for Neuroscience</Title><ISOAbbreviation>J Neurosci</ISOAbbreviation></Journal><ArticleTitle>CNS amyloid-&#x3b2;, soluble APP-&#x3b1; and -&#x3b2; kinetics during BACE inhibition.</ArticleTitle><Pagination><StartPage>8336</StartPage><EndPage>8346</EndPage><MedlinePgn>8336-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1523/JNEUROSCI.0540-14.2014</ELocationID><Abstract><AbstractText>BACE, a &#x3b2;-secretase, is an attractive potential disease-modifying therapeutic strategy for Alzheimer's disease (AD) as it results directly in the decrease of amyloid precursor protein (APP) processing through the &#x3b2;-secretase pathway and a lowering of CNS amyloid-&#x3b2; (A&#x3b2;) levels. The interaction of the &#x3b2;-secretase and &#x3b1;-secretase pathway-mediated processing of APP in the rhesus monkey (nonhuman primate; NHP) CNS is not understood. We hypothesized that CNS inhibition of BACE would result in decreased newly generated A&#x3b2; and soluble APP&#x3b2; (sAPP&#x3b2;), with increased newly generated sAPP&#x3b1;. A stable isotope labeling kinetics experiment in NHPs was performed with a (13)C6-leucine infusion protocol to evaluate effects of BACE inhibition on CNS APP processing by measuring the kinetics of sAPP&#x3b1;, sAPP&#x3b2;, and A&#x3b2; in CSF. Each NHP received a low, medium, or high dose of MBI-5 (BACE inhibitor) or vehicle in a four-way crossover design. CSF sAPP&#x3b1;, sAPP&#x3b2;, and A&#x3b2; were measured by ELISA and newly incorporated label following immunoprecipitation and liquid chromatography-mass spectrometry. Concentrations, kinetics, and amount of newly generated APP fragments were calculated. sAPP&#x3b2; and sAPP&#x3b1; kinetics were similar, but both significantly slower than A&#x3b2;. BACE inhibition resulted in decreased labeled sAPP&#x3b2; and A&#x3b2; in CSF, without observable changes in labeled CSF sAPP&#x3b1;. ELISA concentrations of sAPP&#x3b2; and A&#x3b2; both decreased and sAPP&#x3b1; increased. sAPP&#x3b1; increased by ELISA, with no difference by labeled sAPP&#x3b1; kinetics indicating increases in product may be due to APP shunting from the &#x3b2;-secretase to the &#x3b1;-secretase pathway. These results provide a quantitative understanding of pharmacodynamic effects of BACE inhibition on NHP CNS, which can inform about target development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 the authors 0270-6474/14/348336-11$15.00/0.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dobrowolska</LastName><ForeName>Justyna A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-1718-147X</Identifier><AffiliationInfo><Affiliation>Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michener</LastName><ForeName>Maria S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Guoxin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Molecular Biomarkers.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patterson</LastName><ForeName>Bruce W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chott</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ovod</LastName><ForeName>Vitaliy</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pyatkivskyy</LastName><ForeName>Yuriy</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildsmith</LastName><ForeName>Kristin R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasten</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Departments of Neurology and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathers</LastName><ForeName>Parker</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dancho</LastName><ForeName>Mandy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lennox</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Brad E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilberto</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Safety and Laboratory Animal Resources.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLoughlin</LastName><ForeName>Debra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Preclinical Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania 19486 and Kenilworth, New Jersey 07033.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holder</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Early Development Statistics, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamford</LastName><ForeName>Andrew W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Medicinal Chemistry.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yarasheski</LastName><ForeName>Kevin E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Medicine, Washington University School of Medicine, St. Louis, Missouri 63110 and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennedy</LastName><ForeName>Matthew E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Neuroscience.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Mary J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Molecular Biomarkers.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Departments of Neurology and batemanr@wustl.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS065667</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK056341</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103422</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK020579</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neurosci</MedlineTA><NlmUniqueID>8102140</NlmUniqueID><ISSNLinking>0270-6474</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016229">Amyloid beta-Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016564">Amyloid beta-Protein Precursor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002247">Carbon Isotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.-</RegistryNumber><NameOfSubstance UI="D053829">Amyloid Precursor Protein Secretases</NameOfSubstance></Chemical><Chemical><RegistryNumber>GMW67QNF9C</RegistryNumber><NameOfSubstance UI="D007930">Leucine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D053829" MajorTopicYN="N">Amyloid Precursor Protein Secretases</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016229" MajorTopicYN="N">Amyloid beta-Peptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016564" MajorTopicYN="N">Amyloid beta-Protein Precursor</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002247" MajorTopicYN="N">Carbon Isotopes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002490" MajorTopicYN="N">Central Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047468" MajorTopicYN="N">Immunoprecipitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007930" MajorTopicYN="N">Leucine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="N">Peptide Fragments</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014162" MajorTopicYN="N">Transfection</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BACE inhibitor</Keyword><Keyword MajorTopicYN="N">SILK</Keyword><Keyword MajorTopicYN="N">amyloid beta</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">sAPP&#x3b1;</Keyword><Keyword MajorTopicYN="N">sAPP&#x3b2;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>12</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24920637</ArticleId><ArticleId IdType="pmc">PMC4051982</ArticleId><ArticleId IdType="doi">10.1523/JNEUROSCI.0540-14.2014</ArticleId><ArticleId IdType="pii">34/24/8336</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, Westerteicher C, Leante MR, F&#xf6;rstl H, Livrea P, Kurz A, Perneczky R. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement. 2012;8:304&#x2013;311. doi: 10.1016/j.jalz.2011.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2011.04.009</ArticleId><ArticleId IdType="pubmed">22055653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-&#x3b2; synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856&#x2013;861. doi: 10.1038/nm1438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1438</ArticleId><ArticleId IdType="pmc">PMC2983090</ArticleId><ArticleId IdType="pubmed">16799555</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007;18:997&#x2013;1006. doi: 10.1016/j.jasms.2007.02.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jasms.2007.02.009</ArticleId><ArticleId IdType="pmc">PMC2040126</ArticleId><ArticleId IdType="pubmed">17383190</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. A gamma-secretase inhibitor decreases amyloid-&#x3b2; production in the central nervous system. Ann Neurol. 2009;66:48&#x2013;54. doi: 10.1002/ana.21623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21623</ArticleId><ArticleId IdType="pmc">PMC2730994</ArticleId><ArticleId IdType="pubmed">19360898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernier F, Sato Y, Matijevic M, Desmond H, McGrath S, Burns L, Kaplow JM, Albala B. Clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF. Alzheimers Dement. 2013;9:P886. doi: 10.1016/j.jalz.2013.08.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.08.244</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M. Soluble amyloid precursor protein &#x3b1; and &#x3b2; in CSF in Alzheimer's disease. Brain Res. 2013;1513:117&#x2013;126. doi: 10.1016/j.brainres.2013.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.03.019</ArticleId><ArticleId IdType="pubmed">23541617</ArticleId></ArticleIdList></Reference><Reference><Citation>Busciglio J, Gabuzda DH, Matsudaira P, Yankner BA. Generation of beta-amyloid in the secretory pathway in neuronal and nonneuronal cells. Proc Natl Acad Sci U S A. 1993;90:2092&#x2013;2096. doi: 10.1073/pnas.90.5.2092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.5.2092</ArticleId><ArticleId IdType="pmc">PMC46027</ArticleId><ArticleId IdType="pubmed">8446635</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook JJ, Wildsmith KR, Gilberto DB, Holahan MA, Kinney GG, Mathers PD, Michener MS, Price EA, Shearman MS, Simon AJ, Wang JX, Wu G, Yarasheski KE, Bateman RJ. Acute gamma-secretase inhibition of nonhuman primate CNS shifts Amyloid Precursor Protein (APP) metabolism from amyloid-&#x3b2; production to alternative APP fragments without Amyloid-&#x3b2; rebound. J Neurosci. 2010;30:6743&#x2013;6750. doi: 10.1523/JNEUROSCI.1381-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.1381-10.2010</ArticleId><ArticleId IdType="pmc">PMC2913973</ArticleId><ArticleId IdType="pubmed">20463236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumming JN, Smith EM, Wang L, Misiaszek J, Durkin J, Pan J, Iserloh U, Wu Y, Zhu Z, Strickland C, Voigt J, Chen X, Kennedy ME, Kuvelkar R, Hyde LA, Cox K, Favreau L, Czarniecki MF, Greenlee WJ, McKittrick BA, et al. Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor. Bioorg Med Chem Lett. 2012;22:2444&#x2013;2449. doi: 10.1016/j.bmcl.2012.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2012.02.013</ArticleId><ArticleId IdType="pubmed">22390835</ArticleId></ArticleIdList></Reference><Reference><Citation>Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modeling-a new classification of biomarkers. Pharm Res. 2005;22:1432&#x2013;1437. doi: 10.1007/s11095-005-5882-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11095-005-5882-3</ArticleId><ArticleId IdType="pubmed">16132354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska J, Mawuenyega KG, Bateman RJ. The metabolism of amyloid precursor protein as measured in human cerebrospinal fluid. Soc Neurosci Abstr. 2008;34:138.2.</Citation></Reference><Reference><Citation>Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, Morris JC, Bateman RJ. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One. 2014;9:e89998. doi: 10.1371/journal.pone.0089998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089998</ArticleId><ArticleId IdType="pmc">PMC3960093</ArticleId><ArticleId IdType="pubmed">24646516</ArticleId></ArticleIdList></Reference><Reference><Citation>Egan MF, Forman MS, Palcza J, Tseng J, Leempoels J, Ramael S, Han D, Jhee S, Ereshefsky L, Tanen M, Laterza O, Dockendorf M, Krishna G, Ma L, Wagner JA, Troyer MD. The novel BACE inhibitor MK-8931 dramatically lowers CSF A&#x3b2; peptides in healthy subjects following single and multiple dose administration. 5th conference clinical trials on Alzheimer's disease: October 29&#x2013;31, 2012, Grimaldi Forum, Convention Center, Monte Carlo. J Nutr Health Aging. 2012;16:797. doi: 10.1007/s12603-012-0393-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-012-0393-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Palcza J, Tseng J, Dockendorf M, Canales C, Apter J, Backonja M, Bryan E, Ereshefsky L, Gevorkyan H, Jhee S, Ostler R, Zari A, Kleijn HJ, Laterza O, Ma L, Stone J, Tanen M, Wagner JA, Troyer MD. The novel BACE inhibitor MK-8931 dramatically lowers CSF A&#x3b2; peptide in patients with mild to moderate Alzheimer's disease. AD/PDTM 2013, the 11th International Conference on Alzheimer's and Parkinson's Diseases; Florence, Italy. 2013.</Citation></Reference><Reference><Citation>Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. &#x3b2;-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59:1381&#x2013;1389. doi: 10.1001/archneur.59.9.1381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.59.9.1381</ArticleId><ArticleId IdType="pubmed">12223024</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M. A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci. 2010;30:11157&#x2013;11166. doi: 10.1523/JNEUROSCI.2884-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2884-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633483</ArticleId><ArticleId IdType="pubmed">20720123</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabelle A, Roche S, G&#xe9;ny C, Bennys K, Labauge P, Tholance Y, Quadrio I, Tiers L, Gor B, Chaulet C, Vighetto A, Croisile B, Krolak-Salmon P, Touchon J, Perret-Liaudet A, Lehmann S. Correlations between soluble &#x3b1;/&#x3b2; forms of amyloid precursor protein and A&#x3b2;38, 40, and 42 in human cerebrospinal fluid. Brain Res. 2010;1357:175&#x2013;183. doi: 10.1016/j.brainres.2010.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.08.022</ArticleId><ArticleId IdType="pubmed">20713025</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilberto DB, Zeoli AH, Szczerba PJ, Gehret JR, Holahan MA, Sitko GR, Johnson CA, Cook JJ, Motzel SL. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp Top Lab Anim Sci. 2003;42:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">12906404</ArticleId></ArticleIdList></Reference><Reference><Citation>Holsinger RM, Lee JS, Boyd A, Masters CL, Collins SJ. CSF BACE1 activity is increased in CJD and Alzheimer disease versus other dementias. Neurology. 2006;67:710&#x2013;712. doi: 10.1212/01.wnl.0000229925.52203.4c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000229925.52203.4c</ArticleId><ArticleId IdType="pubmed">16924032</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain I, Hawkins J, Harrison D, Hille C, Wayne G, Cutler L, Buck T, Walter D, Demont E, Howes C, Naylor A, Jeffrey P, Gonzalez MI, Dingwall C, Michel A, Redshaw S, Davis JB. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem. 2007;100:802&#x2013;809. doi: 10.1111/j.1471-4159.2006.04260.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04260.x</ArticleId><ArticleId IdType="pubmed">17156133</ArticleId></ArticleIdList></Reference><Reference><Citation>Irizarry MC, Locascio JJ, Hyman BT. &#x3b2;-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol. 2001;158:173&#x2013;177. doi: 10.1016/S0002-9440(10)63955-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63955-7</ArticleId><ArticleId IdType="pmc">PMC1850271</ArticleId><ArticleId IdType="pubmed">11141490</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, J&#xf6;nsson EG, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012;488:96&#x2013;99. doi: 10.1038/nature11283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11283</ArticleId><ArticleId IdType="pubmed">22801501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ML, Zhang B, Mills IP, Milla ME, Brunden KR, Lee VM. Effects of TNF&#x3b1;-converting enzyme inhibition on amyloid &#x3b2; production and APP processing in vitro and in vivo. J Neurosci. 2008;28:12052&#x2013;12061. doi: 10.1523/JNEUROSCI.2913-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2913-08.2008</ArticleId><ArticleId IdType="pmc">PMC2646261</ArticleId><ArticleId IdType="pubmed">19005070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, B&#xfc;rger K, Hampel H, Fr&#xf6;lich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, H&#xfc;ll M, Schr&#xf6;der J, Kessler H, Pantel J, Gertz HJ, Klafki HW, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry. 2010;15:138&#x2013;145. doi: 10.1038/mp.2008.84.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2008.84</ArticleId><ArticleId IdType="pubmed">18663368</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y. Amyloid &#x3b2; peptide load is correlated with increased &#x3b2;-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A. 2004;101:3632&#x2013;3637. doi: 10.1073/pnas.0205689101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0205689101</ArticleId><ArticleId IdType="pmc">PMC373514</ArticleId><ArticleId IdType="pubmed">14978286</ArticleId></ArticleIdList></Reference><Reference><Citation>Malamas MS, Robichaud A, Erdei J, Quagliato D, Solvibile W, Zhou P, Morris K, Turner J, Wagner E, Fan K, Olland A, Jacobsen S, Reinhart P, Riddell D, Pangalos M. Design and synthesis of aminohydantoins as potent and selective human &#x3b2;-secretase (BACE1) inhibitors with enhanced brain permeability. Bioorg Med Chem Lett. 2010;20:6597&#x2013;6605. doi: 10.1016/j.bmcl.2010.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2010.09.029</ArticleId><ArticleId IdType="pubmed">20880704</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal M, Zhu Z, Cumming JN, Liu X, Strickland C, Mazzola RD, Caldwell JP, Leach P, Grzelak M, Hyde L, Zhang Q, Terracina G, Zhang L, Chen X, Kuvelkar R, Kennedy ME, Favreau L, Cox K, Orth P, Buevich A, et al. Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation. J Med Chem. 2012;55:9331&#x2013;9345. doi: 10.1021/jm301039c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm301039c</ArticleId><ArticleId IdType="pubmed">22989333</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E. BACE1 inhibition induces a specific cerebrospinal fluid &#x3b2;-amyloid pattern that identifies drug effects in the central nervous system. PLoS One. 2012;7:e31084. doi: 10.1371/journal.pone.0031084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0031084</ArticleId><ArticleId IdType="pmc">PMC3273469</ArticleId><ArticleId IdType="pubmed">22328928</ArticleId></ArticleIdList></Reference><Reference><Citation>May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, et al. Robust central reduction of Amyloid-&#x3b2; in humans with an orally available, non-peptidic &#x3b2;-secretase inhibitor. J Neurosci. 2011;31:16507&#x2013;16516. doi: 10.1523/JNEUROSCI.3647-11.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3647-11.2011</ArticleId><ArticleId IdType="pmc">PMC6633289</ArticleId><ArticleId IdType="pubmed">22090477</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science. 2010;330:1774. doi: 10.1126/science.1197623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1197623</ArticleId><ArticleId IdType="pmc">PMC3073454</ArticleId><ArticleId IdType="pubmed">21148344</ArticleId></ArticleIdList></Reference><Reference><Citation>Oltersdorf T, Ward PJ, Henriksson T, Beattie EC, Neve R, Lieberburg I, Fritz LC. The Alzheimer amyloid precursor protein. Identification of a stable intermediate in the biosynthetic/degradative pathway. J Biol Chem. 1990;265:4492&#x2013;4497.</Citation><ArticleIdList><ArticleId IdType="pubmed">1968460</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega F, Stott J, Visser SA, Bendtsen C. Interplay between &#x3b1;-, &#x3b2;-, and &#x3b3;-secretases determines biphasic amyloid-&#x3b2; protein level in the presence of a &#x3b3;-secretase inhibitor. J Biol Chem. 2013;288:785&#x2013;792. doi: 10.1074/jbc.M112.419135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.419135</ArticleId><ArticleId IdType="pmc">PMC3543028</ArticleId><ArticleId IdType="pubmed">23152503</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez RG, Squazzo SL, Koo EH. Enhanced release of amyloid &#x3b2;-protein from codon 670/671 &#x201c;Swedish&#x201d; mutant &#x3b2;-amyloid precursor protein occurs in both secretory and endocytic pathways. J Biol Chem. 1996;271:9100&#x2013;9107. doi: 10.1074/jbc.271.15.9100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.15.9100</ArticleId><ArticleId IdType="pubmed">8621560</ArticleId></ArticleIdList></Reference><Reference><Citation>Portelius E, Price E, Brinkmalm G, Stiteler M, Olsson M, Persson R, Westman-Brinkmalm A, Zetterberg H, Simon AJ, Blennow K. A novel pathway for amyloid precursor protein processing. Neurobiol Aging. 2011;32:1090&#x2013;1098. doi: 10.1016/j.neurobiolaging.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.06.002</ArticleId><ArticleId IdType="pubmed">19604603</ArticleId></ArticleIdList></Reference><Reference><Citation>Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ. Increased in vivo amyloid-&#x3b2;42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med. 2013;5:189ra77. doi: 10.1126/scitranslmed.3005615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3005615</ArticleId><ArticleId IdType="pmc">PMC3838868</ArticleId><ArticleId IdType="pubmed">23761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H. Cerebrospinal fluid profiles of amyloid &#x3b2;-related biomarkers in Alzheimer's disease. Neuromolecular Med. 2012;14:65&#x2013;73. doi: 10.1007/s12017-012-8171-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-012-8171-4</ArticleId><ArticleId IdType="pubmed">22350541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, et al. First demonstration of cerebrospinal fluid and plasma A&#x3b2; lowering with oral administration of a &#x3b2;-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J Pharmacol Exp Ther. 2009;328:131&#x2013;140. doi: 10.1124/jpet.108.143628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.108.143628</ArticleId><ArticleId IdType="pubmed">18854490</ArticleId></ArticleIdList></Reference><Reference><Citation>Savage M, Holder D, Wu G, Kaplow JM, Siuciak J, Potter W Alzheimer's Disease Neuroimaging Initiative (ADNI), Foundation for NIH Biomarkers Consortium CSF Proteomics Project Team. Soluble BACE activity and sAPP&#x3b2; levels do not differentiate Alzheimer's disease and age-matched control cerebrospinal fluid in the ADNI-1 cohort. Alzheimers Dement. 2013;9:P201. doi: 10.1016/j.jalz.2013.05.362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2013.05.362</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamford AW, Scott JD, Li SW, Babu S, Tadesse D, Hunter R, Wu Y, Misiaszek J, Cumming JN, Gilbert EJ, Huang C, McKittrick BA, Hong L, Guo T, Zhu Z, Strickland C, Orth P, Voigt JH, Kennedy ME, Chen X, et al. Discovery of an orally available, brain penetrant BACE1 inhibitor that affords robust CNS A&#x3b2; reduction. ACS Med Chem Lett. 2012;3:897&#x2013;902. doi: 10.1021/ml3001165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ml3001165</ArticleId><ArticleId IdType="pmc">PMC3568987</ArticleId><ArticleId IdType="pubmed">23412139</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi H, Fukumoto H, Maeda R, Terauchi J, Kato K, Miyamoto M. Ameliorative effects of a non-competitive BACE1 inhibitor TAK-070 on A&#x3b2; peptide levels and impaired learning behavior in aged rats. Brain Res. 2010;1361:146&#x2013;156. doi: 10.1016/j.brainres.2010.09.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2010.09.032</ArticleId><ArticleId IdType="pubmed">20849831</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong AP, T&#xf3;th G, Probst GD, Sealy JM, Bowers S, Wone DW, Dressen D, Hom RK, Konradi AW, Sham HL, Wu J, Peterson BT, Ruslim L, Bova MP, Kholodenko D, Motter RN, Bard F, Santiago P, Ni H, Chian D, et al. Design of an orally efficacious hydroxyethylamine (HEA) BACE-1 inhibitor in a preclinical animal model. Bioorg Med Chem Lett. 2010;20:6231&#x2013;6236. doi: 10.1016/j.bmcl.2010.08.102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2010.08.102</ArticleId><ArticleId IdType="pubmed">20833041</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Maanen E, van Steeg T, Ahsman M, Savage MJ, Michener MS, Kleijn HJ, Danhof M, Stone J. A systems pharmacology model of the APP processing pathway in Alzheimer's Disease. American Conference on Pharmacometrics, Ft; Lauderdale, FL. 2013.</Citation></Reference><Reference><Citation>Verheijen JH, Huisman LG, van Lent N, Neumann U, Paganetti P, Hack CE, Bouwman F, Lindeman J, Bollen EL, Hanemaaijer R. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin Chem. 2006;52:1168&#x2013;1174. doi: 10.1373/clinchem.2006.066720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1373/clinchem.2006.066720</ArticleId><ArticleId IdType="pubmed">16614000</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidemann A, K&#xf6;nig G, Bunke D, Fischer P, Salbaum JM, Masters CL, Beyreuther K. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989;57:115&#x2013;126. doi: 10.1016/0092-8674(89)90177-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(89)90177-3</ArticleId><ArticleId IdType="pubmed">2649245</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe RR, Chinkes DL. Isotope tracers in metabolic research: principles and practice of kinetic analysis. Ed 2. Hoboken, NJ: Wiley; 2005.</Citation></Reference><Reference><Citation>Wu G, Sankaranarayanan S, Hsieh SH, Simon AJ, Savage MJ. Decrease in brain soluble amyloid precursor protein &#x3b2; (sAPP&#x3b2;) in Alzheimer's disease cortex. J Neurosci Res. 2011;89:822&#x2013;832. doi: 10.1002/jnr.22618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.22618</ArticleId><ArticleId IdType="pubmed">21433051</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Sankaranarayanan S, Wong J, Tugusheva K, Michener MS, Shi X, Cook JJ, Simon AJ, Savage MJ. Characterization of plasma &#x3b2;-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J Neurosci Res. 2012;90:2247&#x2013;2258. doi: 10.1007/s12017-012-8171-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-012-8171-4</ArticleId><ArticleId IdType="pubmed">22987781</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang LB, Lindholm K, Yan R, Citron M, Xia W, Yang XL, Beach T, Sue L, Wong P, Price D, Li R, Shen Y. Elevated &#x3b2;-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med. 2003;9:3&#x2013;4. doi: 10.1038/nm0103-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0103-3</ArticleId><ArticleId IdType="pubmed">12514700</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarasheski KE, Smith K, Rennie MJ, Bier DM. Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol Mass Spectrom. 1992;21:486&#x2013;490. doi: 10.1002/bms.1200211004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bms.1200211004</ArticleId><ArticleId IdType="pmc">PMC4003887</ArticleId><ArticleId IdType="pubmed">1420371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L, Simon AJ, Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol. 2008;65:1102&#x2013;1107. doi: 10.1001/archneur.65.8.1102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.8.1102</ArticleId><ArticleId IdType="pubmed">18695061</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>